-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Q2e8Sumxl/0dVnx0X3qHFKARATgLxu3rFMFfxMiQ03b4jQRhbzqkhMRJp/ZH/JsD
 Bnq3Ml6v8Jh7vCYLgQYSfw==

<SEC-DOCUMENT>0001047469-10-003299.txt : 20100405
<SEC-HEADER>0001047469-10-003299.hdr.sgml : 20100405
<ACCEPTANCE-DATETIME>20100405154230
ACCESSION NUMBER:		0001047469-10-003299
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20100405
DATE AS OF CHANGE:		20100405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-165899
		FILM NUMBER:		10731047

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>a2197644zs-3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg18801_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As filed with the Securities and Exchange Commission on April&nbsp;5, 2010  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>Registration Statement No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-3<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of Registrant as Specified in Its Charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State of Incorporation)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 13-3191702</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>119 Fourth Avenue<BR>
Needham, Massachusetts 02494<BR>
(781)&nbsp;433-0771<BR>  </B></FONT><FONT SIZE=1>(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Avery W. Catlin<BR>
Chief Financial Officer<BR>
CELLDEX THERAPEUTICS,&nbsp;INC.<BR>
119 Fourth Avenue<BR>
Needham, Massachusetts 02494<BR>
(781)&nbsp;433-0771<BR>  </B></FONT><FONT SIZE=1>(Name, address, including zip code and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copy to:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> Anthony O. Pergola, Esq.<BR>
Ethan A. Skerry, Esq.<BR>
Lowenstein Sandler PC<BR>
65 Livingston Avenue<BR>
Roseland, New Jersey 07068<BR>
(973)&nbsp;597-2500  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1><B>Approximate Date of Commencement of Proposed Sale to the Public: From time to time after this Registration Statement becomes
effective, as
determined by the Registrant.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act
of
1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is used to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and
list the Securities Act Registration Statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the
Securities Act Registration Statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a registration statement pursuant to General Instruction&nbsp;I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D. filed to register additional
securities or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether each registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=1>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a smaller<BR>
reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered(1)(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price<BR>
Per Unit(1)(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(1)(2)(3)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee(4)</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, par value $0.001 per share (with associated stock purchase rights)(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Preferred Stock(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Warrants(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Depositary Shares(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Units(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$150,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$10,695</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amount to be registered and the proposed maximum aggregate offering price per unit are not specified as to each class of securities to be registered
pursuant to General Instruction&nbsp;II.D. of Form&nbsp;S-3 under the Securities Act of 1933, as amended (the "Securities Act"). The securities covered by this registration statement
may be sold or otherwise distributed separately or together with any other securities covered by this registration statement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
no event will the aggregate offering price of all securities issued from time to time by the registrant under this registration statement exceed
$150,000,000 or its equivalent in any other currency, currency units, or composite currency or currencies. The securities covered by this registration statement may be sold separately, together or as
units with other securities registered under this registration statement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
solely for purposes of calculating the registration fee under Rule&nbsp;457 under the Securities Act.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Calculated
pursuant to Rule&nbsp;457(o) under the Securities Act.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Subject
to note&nbsp;(2), this registration statement covers such an indeterminate amount of common stock (with accompanying purchase rights, if any), as
may be sold, from time to time, at indeterminate prices, by the registrant and such indeterminate number of shares of common stock as may, from time to time, be issued upon conversion or exchange of
other securities registered hereunder, to the extent any such securities are, by their terms, convertible or exchangeable for common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Subject
to note&nbsp;(2), this registration statement covers such an indeterminate number of shares of preferred stock (with accompanying purchase rights,
if any) as may be sold from time to time at indeterminate prices by the registrant. Also covered is such an indeterminate amount of common stock (with accompanying purchase rights, if any,)
(i)&nbsp;as may be issuable or deliverable upon conversion of shares of preferred stock, and (ii)&nbsp;as may be required for delivery upon conversion of shares of preferred stock as a result of
anti-dilution provisions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Subject
to note&nbsp;(2), this registration statement covers such an indeterminate amount and number of warrants, representing rights to purchase common
stock and preferred stock registered under this registration statement as may be sold from time to time at indeterminate prices by the registrant. Also covered is such an indeterminate amount of
common stock and preferred stock (in each case, with accompanying purchase rights, if any) (i)&nbsp;as may be issuable or deliverable upon exercise of warrants, and (ii)&nbsp;as may be required
for delivery upon exercise of any warrants as a result of anti-dilution provisions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
the event that Celldex Therapeutics,&nbsp;Inc. elects to offer to the public fractional or multiple shares of common stock or preferred stock, rather
than single shares of common stock or preferred stock registered hereunder, depositary shares, evidenced by depositary receipts issued pursuant to a deposit agreement, will be distributed to those
persons purchasing such fractional interests, and the shares of preferred stock will be issued to the depositary under any such agreement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
the event that Celldex Therapeutics,&nbsp;Inc. elects to offer to the public units, each unit will be issued under a unit agreement and will represent
an interest in two or more securities, which may or may not be separable from one another. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as
amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may
determine.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=61795,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]BA18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_TXTHEX,"" -->


</FONT> <FONT COLOR="#FF4040" SIZE=2><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not
soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TXTHEX,"" -->


 </B></FONT><FONT COLOR="#FF4040" SIZE=2><B>Subject to Completion, dated April&nbsp;5, 2010  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=5><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$150,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Depositary Shares<BR>
Units  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination
of (i)&nbsp;our common stock, (ii)&nbsp;our preferred stock, which we may issue in one or more series, (iii)&nbsp;warrants, (iv)&nbsp;depositary shares and (v)&nbsp;units, up to a maximum
aggregate offering price of $150,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer and sell these securities in amounts, at prices and on terms determined at the time of the offering. We will provide the specific terms of these securities in supplements to
this prospectus. You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully
before you make your investment decision. Our common stock is traded on the NASDAQ Global Select Market System under the symbol "CLDX." On March&nbsp;31, 2010, the last reported sale price of our
common stock on the NASDAQ Global Select Market System was $6.14 per share. You are urged to obtain current market
quotations of the common stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus may not be used to sell securities unless accompanied by a prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable prospectus
supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the
applicable prospectus supplement. For general information about the distribution of securities offered, please see "Plan of Distribution" in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Investing in our securities involves risks. You should carefully review the information contained in this prospectus under the heading "Risk Factors" beginning on
page&nbsp;9 of this prospectus.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2010. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=543208,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]BC18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg18801_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="BG18801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg18801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG18801_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi18801_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi18801_prospectus_summary"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi18801_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi18801_special_note_regarding_forward-looking_statements"><FONT SIZE=2><BR>
7</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de18801_risk_factors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de18801_risk_factors"><FONT SIZE=2><BR>
9</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIOS OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_use_of_proceeds"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_use_of_proceeds"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTIONS OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_descriptions_of_securities_we_may_offer"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_description_of_common_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_description_of_common_stock"><FONT SIZE=2><BR>
23</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_description_of_preferred_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_description_of_preferred_stock"><FONT SIZE=2><BR>
24</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_description_of_warrants"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_description_of_warrants"><FONT SIZE=2><BR>
26</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg18801_description_of_depositary_shares"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg18801_description_of_depositary_shares"><FONT SIZE=2><BR>
28</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_description_of_units"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_description_of_units"><FONT SIZE=2><BR>
29</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_plan_of_distribution"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_plan_of_distribution"><FONT SIZE=2><BR>
29</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_incorporation_of_certain_documents_by_reference"><FONT SIZE=2><BR>
31</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_legal_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_legal_matters"><FONT SIZE=2><BR>
32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_experts"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_experts"><FONT SIZE=2><BR>
32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di18801_where_you_can_find_more_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di18801_where_you_can_find_more_information"><FONT SIZE=2><BR>
33</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <BR>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We have not authorized any person to give any information or make any statement that differs from what is in this prospectus. If any person does make a statement
that differs from what is in this prospectus, you should not rely on it. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any state in which
the offer or sale is not permitted. The information in this prospectus is complete and accurate as of its date, but the information may change after that date. You should not assume that the
information in this prospectus is accurate as of any date after its date.</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=72207,FOLIO='2',FILE='DISK105:[10ZAU1.10ZAU18801]BG18801A.;11',USER='LPALLES',CD=';5-APR-2010;12:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi18801_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi18801_prospectus_summary"> </A>
<A NAME="toc_bi18801_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>PROSPECTUS SUMMARY    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing
a "shelf" registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under
this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement, including the exhibits and the documents incorporated or
deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2> as
described under the heading "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
time we sell securities pursuant to this prospectus, we will provide a prospectus supplement containing specific information about the terms of a particular offering by us. That
prospectus supplement may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may add, update or change information in
this prospectus.
If the information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if
applicable, any prospectus supplement. See "Where You Can Find More Information" for more information. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this
prospectus or any prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any prospectus supplement. This
prospectus and any prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this
prospectus and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the
front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus
and any prospectus supplement is delivered or securities are sold on a later date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Unless this prospectus indicates otherwise or the context otherwise requires, the terms "we," "our," "us," "Celldex" or the "Company" as used in this prospectus
refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics,&nbsp;Inc. and not its subsidiaries in the sections entitled "Description
of Common Stock," "Description of Preferred Stock," "Description of Warrants," "Description of Depositary Shares," and "Description of Units."</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Company Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an integrated biopharmaceutical company that applies our comprehensive Precision Targeted Immunotherapy Platform to generate a
pipeline of candidates to treat cancer and other difficult-to-treat diseases. Our immunotherapy platform includes a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create novel disease-specific drug candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
strategy is to develop and demonstrate proof-of-concept for our product candidates before leveraging their value through partnerships or, in appropriate
situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a product candidate generally involves bringing it through
Phase&nbsp;1 clinical trials and one or more Phase&nbsp;2 clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=916902,FOLIO='3',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_bi18801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>trials
so that we are able to demonstrate, based on human trials, good safety data for the product candidate and some data indicating its effectiveness. We thus leverage the value of our technology
portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best
ensuring the expeditious development of each individual product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;7, 2008, a wholly-owned subsidiary of Celldex (formerly named AVANT Immunotherapeutics,&nbsp;Inc.) merged into Celldex Research Corporation (formerly named Celldex
Therapeutics,&nbsp;Inc.), which was then a privately-held company. Through that merger, Celldex acquired a therapeutic cancer vaccine candidate, known as CDX-110, which is
currently in Phase&nbsp;2 development for the treatment of glioblastoma multiforme. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex (which we refer to as the Merger Sub), merged with and into CuraGen Corporation ("CuraGen"), which we refer to as the
CuraGen Merger, in accordance with the Agreement and Plan of Merger, dated May&nbsp;28, 2009, among CuraGen, Merger Sub and Celldex, which we refer to as the Merger Agreement. As a result of the
Merger, CuraGen became a wholly-owned subsidiary of Celldex. Through the CuraGen Merger, Celldex acquired over $70&nbsp;million in cash, cash equivalents and marketable securities and an antibody
drug candidate, known as CDX-011, which is currently in Phase&nbsp;2 development for treatment of metastatic melanoma and breast cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;31, 2009, CuraGen merged into Celldex and, as a result of the merger, Celldex succeeded to all of CuraGen's assets and liabilities and the separate existence of
CuraGen ceased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Current Programs and Partnerships  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading developer of innovative products that we call Precision Targeted Immunotherapeutics which are designed
to address major unmet health care needs. Most of our products are derived from a broad set of complementary technologies (collectively known as our Precision Targeted Immunotherapy Platform). This
platform includes monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create novel disease-specific drugs. We are using our Precision
Targeted Immunotherapy Platform to
develop targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders and disease caused by infectious organisms. We expect that a large percentage of our research and
development expenses will be incurred in support of our current and future clinical trial programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=76539,FOLIO='4',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_bi18801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are material to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10pt" style="font-family:times;"></TD>
<TD WIDTH="21%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2 VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CLINICAL</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110 (rindopepimut)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Glioblastoma multiforme</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>Pfizer (PF-4948568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-011 (glembatumumab vedotin)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Metastatic melanoma and breast cancer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Colorectal, bladder, pancreas, ovarian and breast tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2 VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PRECLINICAL</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cancer, autoimmune disease and transplant</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Immuno-modulation, multiple tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal and ovarian cancer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1189</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>MARKETED PRODUCTS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rotarix&reg;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Rotavirus infection</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>GlaxoSmithKline</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Marketed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-110  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead clinical development program, CDX-110, is a peptide-based immunotherapy that targets the tumor specific molecule
called EGFRvIII, a functional variant of the naturally expressed epidermal growth factor receptor ("EGFR"), a protein which has been well validated as a target for cancer therapy. Unlike EGFR,
EGFRvIII is not present in normal tissues, and has been shown to be a transforming oncogene that can directly contribute to the cancer cell growth. EGFRvIII is commonly present in glioblastoma
multiforme, or GBM, the most common and aggressive form of brain cancer, and has also been observed in various other cancers such as breast, ovarian, prostate, colorectal, and head&nbsp;&amp; neck
cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2008, we and Pfizer&nbsp;Inc. ("Pfizer") entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide
license to CDX-110. The Pfizer Agreement also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other potential indications. Pfizer funds all development costs for these
programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-011  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-011 (formerly CR011-vcMMAE) is an antibody-drug conjugate (ADC) that consists of a fully-human
monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB or (GPNMB) that is expressed in a
variety of human cancers including breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle
Genetics,&nbsp;Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CDX-011 targets and binds to&nbsp;GPNMB and upon internalization into the
targeted cell, CDX-011 is designed to release MMAE from CR011 to produce a cell-killing effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=769256,FOLIO='5',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_bi18801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1307  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead APC Targeting Technology&#153; product candidate, CDX-1307, is in development for the treatment of
epithelial tumors such as colorectal, pancreatic, bladder, ovarian and breast cancers. CDX-1307 targets the beta chain of human chorionic gonadotropin, known as hCG-Beta, which
is an antigen often found in epithelial tumors. The presence of hCG-Beta in these cancers correlates with a poor clinical outcome, suggesting that this molecule may contribute to tumor
growth. Normal adult tissues have minimal expression of hCG-Beta; therefore, targeted immune responses are not expected to generate significant side effects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell
receptor, DEC-205, linked to the NY-ESO-1 tumor antigen. In humans, NY-ESO-1 has been detected in 20&nbsp;-&nbsp;30% of
cancers, thus representing a broad opportunity. This product is intended to selectively deliver the NY-ESO-1 antigen to APCs for generating robust immune responses against
cancer cells expressing NY-ESO-1. Unlike CDX-1307, which targets the mannose receptor expressing dendritic cells, CDX-1401 is the first APC product
targeting DEC-205 expressing dendritic cells. We are developing CDX-1401 for the treatment of malignant melanoma and a variety of solid tumors which express the proprietary
cancer antigen NY-ESO-1, which we licensed from the Ludwig Institute for Cancer Research in 2006. We believe that preclinical studies have shown that CDX-1401 is
effective for activation of human T-cell responses against NY-ESO-1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1135  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135 is a molecule that inhibits a part of the immune system called the complement system. The complement system is a
series of proteins that are important initiators of the body's acute inflammatory response against disease, infection and injury. Excessive complement activation also plays a role in some persistent
inflammatory conditions. CDX-1135 is a soluble form of naturally occurring Complement Receptor 1 that inhibits the activation of the complement cascade in animal models and in human
clinical trials. We believe that regulating the complement system could have therapeutic and prophylactic applications in several acute and chronic conditions, including organ transplantation,
multiple sclerosis, rheumatoid arthritis, age-related macular degeneration ("AMD"), atypical Hemolytic Uremic Syndrome ("aHUS"), Paroxysmal Nocturnal Hemaglobinuria ("PNH"), Dense Deposit
Disease ("DDD") in kidneys, and myasthenia gravis. We are currently defining the most appropriate clinical development path for CDX-1135 and are focusing on rare disease conditions of
unregulated complement activation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Preclinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301 is a FMS-like tyrosine kinase 3 ligand (Flt3L) that we licensed from Amgen in March 2009.
CDX-301 is a growth factor for stem cells and immune cells called dendritic cells. Based on previous experience with this molecule, we believe that CDX-301 has considerable
opportunity in various transplant settings as a stem cell mobilizing agent. In addition, CDX-301 is an immune modulating molecule that increases the numbers and activity of specific types
of immune cells. We believe CDX-301 has significant opportunity for synergistic development in combination with proprietary molecules in our portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1127  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a License Agreement with the University of Southampton, UK, to develop human antibodies to CD27, a potentially
important target for immunotherapy of various cancers. In </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=518192,FOLIO='6',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_bi18801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>preclinical
models, antibodies to CD27 alone have been shown to mediate anti-tumor effects, and may be particularly effective in combination with other immunotherapies. CD27 is a critical
molecule in the activation pathway of lymphocytes. It is downstream from CD40, and may provide a novel way to regulate the immune responses. Engaging CD27 with the appropriate monoclonal antibody has
proven highly effective at promoting anti-cancer immunity in mouse models. We are evaluating new human monoclonal antibodies in preclinical models. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 (formerly CR014-vcMMAE) is a fully-human monoclonal ADC that targets TIM-1, an
immunomudulatory protein that appears to down regulate immune response to tumors. The antibody, CDX-014, is linked to a potent chemotherapeutic, monomethyl auristatin E (MMAE), using
Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells,
resulting in a targeted cell-killing effect. CDX-014 has shown potent activity in preclinical models of ovarian and renal cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> CDX-1189  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing therapeutic human antibodies to a signaling molecule known as CD89 or Fc<FONT FACE="SYMBOL">a</FONT>
receptor type&nbsp;I (Fc<FONT FACE="SYMBOL">a</FONT>RI). CD89 is expressed by some white blood cells and leukemic cell lines, and has been shown to be important in controlling
inflammation and tumor growth in animal models. We have proprietary, fully human antibodies to CD89 in preclinical development. Depending upon the specific antibody used, anti-CD89
antibodies can either be activating and thus stimulate immune responses, or down-regulating and act as an anti-inflammatory agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Marketed Products  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rotavirus Vaccine  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rotavirus is a major cause of diarrhea and vomiting in infants and children. In 1997, we licensed our oral rotavirus strain to
GlaxoSmithKline, or Glaxo, and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. Glaxo gained approval for its rotavirus vaccine,
Rotarix&reg;, in Mexico in July 2004, which represented the first in a series of worldwide approvals and commercial launches for the product leading up to the approval in Europe in 2006 and in
the U.S. in 2008. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Corporate Information  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. The principal executive offices of Celldex are located at 119 Fourth Avenue, Needham,
Massachusetts 02494 and its telephone number is (781)&nbsp;433-0771. Our corporate website is </FONT><FONT SIZE=2><I>www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. The information
on our website is not incorporated by reference into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi18801_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_bi18801_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Any statements about our expectations, beliefs, plans, objectives, assumptions or future
events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as "anticipate," "estimate,"
"plans," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar words or phrases. Accordingly, these statements involve estimates, assumptions and
uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=10608,FOLIO='7',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_bi18801_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>risk
factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the
statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including
the factors described in the section entitled "Risk Factors" in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise
any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and
risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in
this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=913082,FOLIO='8',FILE='DISK105:[10ZAU1.10ZAU18801]BI18801A.;6',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de18801_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de18801_risk_factors"> </A>
<A NAME="toc_de18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>An investment in our securities involves risks. Before making an investment decision, you should carefully
consider the risks described under "Risk Factors" in this prospectus as well as the applicable prospectus supplement and in our most recent Annual Report on Form&nbsp;10-K, and in our
updates to those Risk Factors in our Quarterly Reports on Form&nbsp;10-Q following the most recent Form&nbsp;10-K, and in all other information appearing in this prospectus
or incorporated by reference into this prospectus and any applicable prospectus supplement. The material risks and uncertainties that management believes affect us will be described in those
documents. In addition to those risk factors, there may be additional risks and uncertainties of which management is not aware or focused on or that management deems immaterial. Our business,
financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose
all or part of your investment. This prospectus is qualified in its entirety by these risk factors.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to Our Business  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our products and product candidates are subject to extensive regulatory scrutiny.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our products and product candidates are at various stages of development and commercialization and our activities, products and
product candidates are significantly regulated by a number of governmental entities, including the Food and Drug Administration in the United States, which we refer to as the FDA, and by comparable
authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of our products and product
candidates. We or our partners must obtain regulatory approval for a product candidate in all of these areas before we can commercialize a product candidate. Product development within this regulatory
framework takes a number of years and involves the expenditure of substantial resources. This process typically requires extensive preclinical and clinical testing, which may take longer or cost more
than we anticipate, and may prove unsuccessful due to numerous factors. Many product candidates that initially appear promising ultimately do not reach the market because they are found to be unsafe
or ineffective when tested. Companies in the pharmaceutical, biotechnology and vaccines industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising
results in earlier trials. Our inability to commercialize a product or product candidate would impair our ability to earn future revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If our products do not pass required tests for safety and effectiveness, we will not be able to derive commercial revenue from them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to succeed, we will need to derive commercial revenue from the products we have under development. The FDA has not approved
our CDX-110 or CDX-011 product candidates or any of our other lead products for sale to date. Products in our vaccine programs are in various stages of preclinical and clinical
testing. Preclinical tests are performed at an early stage of a product's development and provide information about a product's safety and effectiveness on laboratory animals. Preclinical tests can
last years. If a product passes its preclinical tests satisfactorily, and we determine that further development is warranted, we would file an investigational new drug application for the product with
the FDA, and if the FDA gives its approval we would begin Phase&nbsp;1 clinical tests. Phase&nbsp;1 testing generally lasts between 6 and 24&nbsp;months. If Phase&nbsp;1 test results are
satisfactory and the FDA gives its approval, we can begin Phase&nbsp;2 clinical tests. Phase&nbsp;2 testing generally lasts between 6 and 36&nbsp;months. If Phase&nbsp;2 test results are
satisfactory and the FDA gives its approval, we can begin Phase&nbsp;3 pivotal studies. Phase&nbsp;3 studies generally last between 12 and 48&nbsp;months. Once clinical testing is completed and
a new drug application is filed with the FDA, it may take more than a year to receive FDA approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=509648,FOLIO='9',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases we must show that a pharmaceutical product is both safe and effective before the FDA, or drug approval agencies of other countries where we intend to sell the product, will
approve it for sale. Our research and testing programs must comply with drug approval requirements both in the United States and in other countries, since we are developing our lead products with
companies, including Glaxo and Pfizer, which intend to or could later decide to commercialize them both in the U.S. and abroad. A product may fail for safety or effectiveness at any stage of the
testing process. A major risk we face is the possibility that none of our products under development will come through the testing process to final approval for sale, with the result that we cannot
derive any commercial revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Product testing is critical to the success of our products but subject to delay or cancellation if we have difficulty enrolling patients.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our portfolio of potential products moves from preclinical testing to clinical testing, and then through progressively larger and
more complex clinical trials, we will need to enroll an increasing number of patients with the appropriate characteristics. At times we have experienced difficulty enrolling patients and we may
experience more difficulty as the scale of our clinical testing program increases. The factors that affect our ability to enroll patients are largely uncontrollable and include principally the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the nature of the clinical test;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the size of the patient population;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>patients' willingness to receive a placebo or less effective treatment on the control arm of a clinical study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the distance between patients and clinical test sites; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the eligibility criteria for the trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot enroll patients as needed, our costs may increase or it could force us to delay or terminate testing for a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn future revenues.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that none of the products or product candidates that we develop will obtain the regulatory approvals necessary for us to
begin commercializing them. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the nature of
the product candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory
approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular product candidate. Furthermore, if we, or
our partners, do not reach the market with our products before our competitors offer products for the same or similar uses, or if we, or our partners, are not effective in marketing our products, our
revenues from product sales, if any, will be reduced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies,
firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research institutions. These competitors
include Alexion, Anadys, Antigenics, Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent, Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck, NeoPharm, Northwest </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=972540,FOLIO='10',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>Biotherapeutics,
Novavax, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Vical. Most of our competitors have substantially greater resources, more extensive experience in conducting preclinical
studies and clinical testing and obtaining regulatory approvals for their products, greater operating experience, greater research and development and marketing capabilities and greater production
capabilities than those of ours. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products, especially if we experience any
delay in obtaining required regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Failure to comply with applicable regulatory requirements would adversely impact our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even after receiving regulatory approval, our products would be subject to extensive regulatory requirements, and our failure to comply
with applicable regulatory requirements will adversely impact our operations. In the United States, the FDA requires that the manufacturing facility that produces a product meet specified standards,
undergo an inspection and obtain an establishment license prior to commercial marketing. Subsequent discovery of previously unknown problems with a product or its manufacturing process may result in
restrictions on the product or the manufacturer, including withdrawal of the product from the market. Failure to comply with the applicable regulatory requirements can result in fines, suspensions of
regulatory approvals, product recalls, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We depend greatly on the intellectual capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our
products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of Anthony S. Marucci, our President and Chief Executive Officer, or other key members of our staff, including Avery W.
Catlin, our Chief Financial Officer, Dr.&nbsp;Thomas Davis, our Chief Medical Officer, or Dr.&nbsp;Tibor Keler, our Chief Scientific Officer, could harm us. We entered into employment agreements
with Messrs.&nbsp;Marucci, Catlin, Davis and Keler. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability
to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial and marketing personnel, particularly as
we expand our activities in clinical trials, the regulatory approval process and sales and manufacturing. We routinely enter into consulting agreements with our scientific and clinical collaborators
and advisors, opinion leaders and heads of academic departments in the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who recruit patients
into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for this type of personnel from other companies,
research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on contract manufacturers. Should the cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers vary to our
disadvantage, our business operations could suffer significant harm.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have small-lot manufacturing capability at our Fall River facility, we rely on sourcing from third-party
manufacturers for suitable quantities of some of our clinical and commercial grade materials essential to preclinical and clinical studies currently underway and to planned clinical trials in addition
to those currently being conducted by third parties
or us. The inability to have suitable quality and quantities of these essential materials produced in a timely manner would result in significant delays in the clinical development and
commercialization of products, which could adversely affect our business, financial condition and results of operations. We also rely on collaborators and contract manufacturers to manufacture
proposed products in both clinical and commercial quantities in the future. Our leading vaccine candidates require specialized manufacturing capabilities and processes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=271053,FOLIO='11',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may face difficulty in securing commitments from U.S. and foreign contract manufacturers as these manufacturers could be unwilling or unable to accommodate our needs. Relying on
foreign manufacturers involves peculiar and increased risks, including the risk relating to the difficulty foreign manufacturers may face in complying with the FDA's Good Manufacturing Practices
("GMP") as a result of language barriers, lack of familiarity with GMP or the FDA regulatory process or other causes, economic or political instability in or affecting the home countries of our
foreign manufacturers, shipping delays, potential changes in foreign regulatory laws governing the sales of our product supplies, fluctuations in foreign currency exchange rates and the imposition or
application of trade restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurances that we will be able to enter into long-term arrangements with third party manufacturers on acceptable terms, or at all. Further, contract
manufacturers must also be able to meet our timetable and requirements, and must operate in compliance with GMP; failure to do so could result in, among other things, the disruption of product
supplies. As noted above, non-U.S. contract manufacturers may face special challenges in complying with the FDA's GMP requirements, and although we are not currently dependent on
non-U.S. collaborators or contract manufacturers, we may choose or be required to rely on non-U.S. sources in the future as we seek to develop stable supplies of increasing
quantities of materials for ongoing clinical trials of larger scale. Our dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to
develop and deliver products on a timely and competitive basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third-parties who we currently rely on for sourcing of suitable quantities of some of our clinical and commercial grade materials include: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pfizer, Bayer, and Genzyme for the CDX-110 drug product;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dalton for Hiltonol which is an integral part of several of our drug products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>3M for Resiquimod which is an integral part of several of our drug products; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Piramal for the CDX-011 drug product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or our third-party manufacturers are unable to produce drug material in suitable quantities of appropriate quality, in a timely manner, and at a feasible cost, our clinical tests
will face delays. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product development.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. Our significant third-party clinical development providers
include Pfizer for the development of our CDX-110 drug product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these third parties fails to perform as we expect or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We depend greatly on third party collaborators to license, develop and commercialize some of our products, and they may not meet our expectations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreements with companies, including Glaxo, Pfizer and VTI for the licensing, development and ultimate commercialization of
some of our products. Some of those agreements give substantial responsibility over the products to the collaborator. Some collaborators may be unable or unwilling to devote sufficient resources to
develop our products as their agreements require. They often face business risks similar to ours, and this could interfere with their efforts. Also, collaborators may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=588120,FOLIO='12',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>choose
to devote their resources to products that compete with ours. If a collaborator does not successfully develop any one of our products, we will need to find another collaborator to do so. The
success of our search for a new collaborator will depend on our legal right to do so at the time and whether the product remains commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
success of our products depends in great part upon our and our collaborators' success in promoting them as superior to other treatment alternatives. We believe that our products can
be proven to offer disease prevention and treatment with notable advantages over drugs in terms of patient compliance and effectiveness. However, there can be no assurance that we will be able to
prove these advantages or that the advantages will be sufficient to support the successful commercialization of our products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> We may face delays, difficulties or unanticipated costs in establishing sales, distribution and manufacturing capabilities for our commercially ready products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have chosen to retain, rather than license, all rights to some of our lead products, such as CDX-011 and our
APC Targeting Technology programs. If we proceed with this strategy, we will have full responsibility for commercialization of these products if and when they are approved for sale. We currently lack
the marketing, sales and distribution capabilities that we will need to carry out this strategy. To market any of our products directly, we must develop a substantial marketing and sales force with
technical expertise and a supporting distribution capability. We have little expertise in this area, and we may not succeed. We may find it necessary to enter into strategic partnerships on uncertain
but potentially unfavorable terms to sell, market and distribute our products when they are approved for sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our products are difficult to manufacture, especially in large quantities, and we have not yet developed commercial scale manufacturing processes for any of our products. We do
not currently plan to develop internal manufacturing capabilities to produce any of our products at commercial scale if
they are approved for sale. To the extent that we choose to market and distribute these products ourselves, this strategy will make us dependent on other companies to produce our products in adequate
quantities, in compliance with regulatory requirements, and at a competitive cost. We may not find third parties capable of meeting those manufacturing needs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Certain factors could negatively affect the demand for and sales and profitability of Rotarix&reg;, which would have a material adverse affect on our revenues.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Both the demand and ultimately the profitability of Rotarix&reg; are components to our success. We have licensed a rotavirus
strain to Glaxo for the purposes of Glaxo developing and commercializing their Rotarix&reg; vaccine worldwide. Glaxo gained approval for Rotarix&reg; in Mexico in July 2004, in the
European Union in February 2006 and in the United States in April 2008. In May 2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund, or PRF, purchased an interest in the net
royalties we will receive on worldwide sales of Rotarix&reg;. In addition, we retain upside participation in the worldwide net royalties from Rotarix&reg; once, and if, PRF receives an
agreed upon return on capital invested (2.45 times PRF's aggregate cash payments to us of $60&nbsp;million). The following are potential factors, among others, that may negatively affect the demand
for Rotarix&reg;: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Competitors in the pharmaceuticals, biotechnology and vaccines market have greater financial and management resources, and
significantly more experience in bringing products to market, and may develop, manufacture and market products that are more effective or less expensive than Rotarix&reg;; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Rotarix&reg; could be replaced by a novel product and may become obsolete; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=309260,FOLIO='13',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Glaxo may be unable to prevent third parties from infringing upon their proprietary rights related to
Rotarix&reg;;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Users may not accept such a recently approved product without years of proven history; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We are dependent on Glaxo for the manufacturing, testing, acquisition of regulatory approvals, marketing, distribution and
commercialization of Rotarix&reg;. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on the sales of Rotarix&reg; and our results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Other factors could affect the demand for and sales and profitability of Rotarix&reg; and any other of our current or future products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, other factors that could affect the demand for and sales and profitability of our products include, but are not limited
to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The timing of regulatory approval, if any, of competitive products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our, Glaxo's, Pfizer's or any other of our partners' pricing decisions, as applicable, including a decision to increase or
decrease the price of a product, and the pricing decisions of our competitors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Government and third-party payer reimbursement and coverage decisions that affect the utilization of our products and
competing products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Negative safety or efficacy data from new clinical studies conducted either in the U.S. or internationally by any party
could cause the sales of our products to decrease or a product to be recalled;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The degree of patent protection afforded our products by patents granted to or licensed by us and by the outcome of
litigation involving our or any of our licensor's patents;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The outcome of litigation involving patents of other companies concerning our products or processes related to production
and formulation of those products or uses of those products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The increasing use and development of alternate therapies;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The rate of market penetration by competing products; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The termination of, or change in, existing arrangements with our partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on Glaxo's sales of Rotarix&reg; and on any other of our current or future products and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may be unable to manage multiple late stage clinical trials for a variety of product candidates simultaneously.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue
developing all of our current products. The management of late stage clinical trials is more complex and time consuming than early stage trials. Typically early stage trials involve several hundred
patients in no more than 10-30 clinical sites. Late stage (Phase&nbsp;3) trials may involve up to several thousand patients in up to several hundred clinical sites and may require
facilities in several countries. Therefore, the project management required to supervise and control such an extensive program is substantially larger than early stage programs. As the need for these
resources is not known until some months before the trials begin it is necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this
team to be recruited quickly the sponsor is faced with a decision to delay the program or to initiate it </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=82977,FOLIO='14',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>with
inadequate management resources. This may result in recruitment of inappropriate patients, inadequate monitoring of clinical investigators and inappropriate handling of data or data analysis.
Consequently it is possible that conclusions of efficacy or safety may not be acceptable to permit filing of a Biologic License Application ("BLA") or New Drug Application ("NDA") for any one of the
above reasons or a combination of several. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We face the risk of product liability claims, which could exceed our insurance coverage, and produce recalls, each of which could deplete our cash resources.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a participant in the pharmaceutical, biotechnology and vaccines industries, we are exposed to the risk of product liability claims
alleging that use of our products or product candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our products or
product candidates and may be made directly by patients involved in clinical trials of our products, by consumers or healthcare providers or by individuals, organizations or companies selling our
products. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
covering product liability claims becomes increasingly expensive as a product candidate moves through the development pipeline to commercialization. Under our license
agreements, we are required to maintain clinical trial liability insurance coverage up to $14&nbsp;million. However, there can be no assurance that such insurance coverage is or will continue to be
adequate or available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be
able to secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any
liability for damages resulting from a product liability claim could exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material
adverse effect on our business, financial condition and results of operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business
and inhibit or prevent commercialization of other products and product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If we cannot maintain acceptable amounts
of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material
adverse impact on our operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements will typically restrict the ability of our
collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are
notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are typically
controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets
under the terms of research and development partnership or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach
of these agreements, independent development or publication of information including our trade secrets in cases </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=16,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=368546,FOLIO='15',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>where
we do not have proprietary or otherwise protected rights at the time of publication. A competitor's discovery of our trade secrets would impair our competitive position. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> We may not be able to successfully integrate newly-acquired technology with our existing technology or to modify our technologies to create new vaccines.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our acquisition of technology assets from entities such as 3M Company and Amgen, we have acquired access to
Resiquimod&#153; (a TLR 7/8 agonist) and Flt3L, which may improve the immunogenicity of our vaccines. If we are able to integrate these licensed assets with our vaccine technologies, we believe
these assets will give our vaccines a competitive advantage. However, if we are unable to successfully integrate licensed assets, or other technologies which we have acquired or may acquire in the
future, with our existing technologies and potential products currently under development, we may be unable to realize any benefit from our acquisition of these assets, or other technologies which we
have acquired or may acquire in the future and may face the loss of our investment of financial resources and time in the integration process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our vaccine technology portfolio may offer opportunities to develop vaccines that treat a variety of oncology, inflammatory and infectious diseases by stimulating a
patient's immune system against those disease organisms. If our vaccine technology portfolio cannot be used to create effective vaccines against a variety of disease organisms, we may lose all or
portions of our investment in development efforts for new vaccine candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We license technology from other companies to develop products, and those companies could influence research and development or restrict our use of it.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Companies that license technologies to us that we use in our research and development programs may require us to achieve milestones or
devote minimum amounts of resources to develop products using those technologies. They may also require us to make significant royalty and milestone payments, including a percentage of any
sublicensing income, as well as payments to reimburse them for patent costs. The number and variety of our research and development programs require us to establish priorities and to allocate
available resources among competing programs. From time to time we may choose to slow down or cease our efforts on particular products. If in doing so we fail to fully perform our obligations under a
license, the licensor can terminate the licenses or permit our competitors to use the technology. Moreover, we may lose our right to market and sell any products based on the licensed technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have many competitors in our field and they may develop technologies that make ours obsolete.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology, pharmaceuticals and therapeutics are rapidly evolving fields in which scientific and technological developments are
expected to continue at a rapid pace. We have many competitors in the U.S. and abroad. These competitors include Alexion, Anadys, Antigenics,
Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent, Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck, NeoPharm, Northwest Biotherapeutics, Novavax, Pfizer, Roche,
Sanofi-Aventis, Seattle Genetics, and Vical. Our success depends upon our ability to develop and maintain a competitive position in the product categories and technologies on which we focus. Many of
our competitors have greater capabilities, experience and financial resources than we do. Competition is intense and is expected to increase as new products enter the market and new technologies
become available. Our competitors may: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>develop technologies and products that are more effective than ours, making ours obsolete or otherwise noncompetitive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain regulatory approval for products more rapidly or effectively than us; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=17,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=831550,FOLIO='16',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain patent protection or other intellectual property rights that would block our ability to develop competitive
products. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on patents, patent applications and other intellectual property protections to protect our technology and trade secrets; which are expensive and may not provide
sufficient protection.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to obtain and maintain patent protection for technologies that we use. Biotechnology patents
involve complex legal, scientific and factual questions and are highly uncertain. To date, there is no consistent policy regarding the breadth of claims allowed in biotechnology patents, particularly
in regard to patents for technologies for human uses like those we use in our business. We cannot predict whether the patents we seek will issue. If they do issue, a competitor may challenge them and
limit their scope. Moreover, our patents may not afford effective protection against competitors with similar technology. A successful challenge to any one of our patents could result in a third
party's ability to use the technology covered by the patent. We also face the risk that others will infringe, avoid or circumvent our patents. Technology that we license from others is subject to
similar risks and this could harm our ability to use that technology. If
we, or a company that licenses technology to us, were not the first creator of an invention that we use, our use of the underlying product or technology will face restrictions, including elimination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we must defend against suits brought against us or prosecute suits against others involving intellectual property rights, we will incur substantial costs. In addition to any potential
liability for significant monetary damages, a decision against us may require us to obtain licenses to patents or other intellectual property rights of others on potentially unfavorable terms. If
those licenses from third parties are necessary but we cannot acquire them, we would attempt to design around the relevant technology, which would cause higher development costs and delays, and may
ultimately prove impracticable </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our business requires us to use hazardous materials, which increases our exposure to dangerous and costly accidents.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development activities involve the use of hazardous chemicals, biological materials and radioactive compounds.
Although we believe that our safety procedures for handling and disposing of hazardous materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate
the risk of accidental contamination or injury from these materials. In the event of an accident, an injured party will likely sue us for any resulting damages with potentially significant liability.
The ongoing cost of complying with environmental laws and regulations is significant and may increase in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Health care reform and restrictions on reimbursement may limit our returns on potential products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our strategy ultimately depends on the commercial success of our products, we assume, among other things, that end users of our
products will be able to pay for them. In the United States and other countries, in most cases, the volume of sales of products like those we are developing depends on the availability of
reimbursement from third-party payors, including national health care agencies, private health insurance plans and health maintenance organizations. Third-party payors increasingly challenge the
prices charged for medical products and services. Accordingly, if we succeed in bringing products to market, and reimbursement is not available or is insufficient, we could be prevented from
successfully commercializing our potential products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
health care industry in the United States and in Europe is undergoing fundamental changes as a result of political, economic and regulatory influences. Reforms proposed from time to
time include mandated basic health care benefits, controls on health care spending, the establishment of governmental controls over the cost of therapies, creation of large medical services and
products </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=18,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=79679,FOLIO='17',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>purchasing
groups and fundamental changes to the health care delivery system. We anticipate ongoing review and assessment of health care delivery systems and methods of payment in the United States
and other countries. We cannot predict whether any particular reform initiatives will result or, if adopted, what their impact on us will be. However, we expect that adoption of any reform proposed
will impair our ability to market products at acceptable prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Changes in laws affecting the health care industry could adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., there have been numerous proposals considered at the federal and state levels for comprehensive reforms of health care and
its cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. In March 2010, the U.S. passed legislation to reform the
U.S. health care system by expanding health insurance coverage, reducing certain health care costs and making other changes. While this and continued health care reform may increase the number of
patients who have insurance coverage for our products, it may also include cost containment measures that adversely affect reimbursement for our products, including:  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>change the Medicare reimbursement system for outpatient drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>increase the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>facilitate the importation of lower-cost prescription drugs that are marketed outside the U.S. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and
requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some
cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may
result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our collaborators and partners operate in a highly regulated industry. As a result, governmental actions may adversely affect our business, operations or financial condition,
including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to
health care availability, method of delivery and payment for health care products and services;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and
result in lost market opportunity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on
product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of
approved products, or otherwise adversely affect the market for our products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations and judicial decisions affecting pricing or marketing practices; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the tax laws relating to our operations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment in the U.S. of health care reform, possible legislation which could ease the entry of competing follow-on biologics in the marketplace, new legislation or
implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of
previously enacted and possible future changes in laws that could adversely affect our business. In addition, the Food and Drug Administration </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=19,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=173526,FOLIO='18',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Amendments
Act of 2007 included new authorization for the FDA to require post-market safety monitoring, along with an expanded clinical trials registry and clinical trials results
database, and expanded authority for the FDA to impose civil monetary penalties on companies that fail to meet certain commitments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If physicians, patients and third-party payors do not accept any future drugs that we may develop, we may be unable to generate significant revenue, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if our drug candidates as well as any drug candidates that we may develop or acquire in the future obtain regulatory approval,
they may not gain market acceptance among physicians, patients and health care payors. Physicians may elect not to recommend these drugs for a variety of reasons including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>timing of market introduction of competitive drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lower demonstrated clinical safety and efficacy compared to other drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of cost-effectiveness;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of availability of reimbursement from third-party payors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>convenience and ease of administration;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>prevalence and severity of adverse side effects;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>other potential advantages of alternative treatment methods; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ineffective marketing and distribution support. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our approved drugs fail to achieve market acceptance, we would not be able to generate sufficient revenue from product sales to maintain or grow our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are not successful in integrating CuraGen's drug development programs, we may not be able to operate efficiently after the CuraGen Merger, which may have a material
adverse effect on our results of operations and financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Achieving the benefits of the CuraGen Merger will depend in part on the successful integration of CuraGen's clinical and preclinical
programs and personnel in a timely and efficient manner. The integration process requires coordination of different development, regulatory, and manufacturing teams, and involves the integration of
systems, applications, policies, procedures, business processes and operations. This may be difficult and unpredictable because of possible cultural conflicts and different opinions on scientific and
regulatory matters. If we cannot successfully integrate CuraGen's programs and personnel, we may not realize the expected benefits of the CuraGen Merger. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Integrating CuraGen's programs may divert management's attention away from our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful integration of CuraGen's programs and personnel may place a significant burden on our management and internal resources,
including time that will be spent on winding down CuraGen's facility in Connecticut and transitioning certain CuraGen employees to our facilities. The diversion of management's attention and any
difficulties encountered in the transition and integration process could result in delays in our clinical trial programs and could otherwise harm our business, financial condition and operating
results. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=20,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=633799,FOLIO='19',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to Our Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our history of losses and uncertainty of future profitability make our securities a highly speculative investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have had no commercial revenues to date from sales of our human therapeutic or vaccine products and cannot predict when we will. We
have an accumulated deficit of $157.7&nbsp;million as of December&nbsp;31, 2009. We expect to spend substantial funds to continue the research and development testing of our products that we have
in the preclinical and clinical testing stages of development that have not been partnered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities.
These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the regulatory approval process. As a
result, we may continue to lose money for several years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
securities, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we cannot sell securities to raise necessary funds, we may be forced to limit our research, development and testing programs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will need to raise more capital from investors to advance our clinical and preclinical products and to fund our operations until we
receive final FDA approval and our products begin to generate revenues for us. However, based on our history of losses and the on-going uncertainty of the U.S. capital markets, we may have
difficulty raising sufficient capital on terms that are acceptable to us, or at all. As of December&nbsp;31, 2009, we had cash, cash equivalents and marketable securities of $82.5&nbsp;million,
which, at that time, we believed would support expected operations for more than 12&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continue to seek partnerships with pharmaceutical and biotech companies and with other organizations to support the clinical development of our programs, in addition to funded
research grants. This kind of funding is at the discretion of other organizations and companies which have limited funds and many companies compete with us for those funds. As a result, we may not
receive any research grants or funds from collaborators. If we are unable to raise the necessary funds, we may have to delay or discontinue the clinical development of programs, license out programs
earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or evaluate a sale of all or part of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
we begin generating revenue, we may seek funding through the sale of equity, or securities convertible into equity, and further dilution to the then existing stockholders may
result. If we raise additional capital through the incurrence of debt, our business may be affected by the amount of leverage it incurs, and its borrowings may subject it to restrictive covenants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> The market price of our common stock has been and could remain volatile.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January
2009 through December 2009, the market price of our common stock has fluctuated from a high of $14.19 per share in the second quarter of 2009, to a low of $4.16 per share in the fourth quarter of
2009. Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=21,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=701960,FOLIO='20',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_de18801_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>competitors
could cause the market price of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock,
especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock. In addition, in recent years, the stock market has
experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and
may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in
substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=22,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=972589,FOLIO='21',FILE='DISK105:[10ZAU1.10ZAU18801]DE18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg18801_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_dg18801_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our consolidated ratio of earnings to fixed charges for the years ended December&nbsp;31, 2009, 2008,
2007, 2006 and 2005. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Ratio of Earnings to Fixed Charges  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="30%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2006 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2005 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Due
to our loss from continuing operations for the years ended December&nbsp;31, 2009, 2008, 2007, 2006 and 2005 earnings were insufficient to cover fixed
charges by $36.9&nbsp;million, $48.8&nbsp;million, $15.5&nbsp;million, $18.8&nbsp;million, and $17.4&nbsp;million, respectively. For this reason, no ratios are provided. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_use_of_proceeds"> </A>
<A NAME="toc_dg18801_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>USE OF PROCEEDS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to
use the net proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, and the repayment, redemption or
refinancing of all or a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations until we receive FDA approval of our products and are able to
commercialize our products and to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products.
Pending the application of the net proceeds, we expect to invest the proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase
and consist primarily of investments in money market mutual funds with commercial banks and financial institutions or other investment-grade securities. Such investments may include depositing such
net proceeds into, and maintaining cash balances with, financial institutions in excess of insured limits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_descriptions_of_securities_we_may_offer"> </A>
<A NAME="toc_dg18801_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTIONS OF SECURITIES WE MAY OFFER    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we may
offer and sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more of these
securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These summary descriptions
and any summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in their entirety by
reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions and
from which such summary descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the terms
described herein will be deemed superseded by the terms set forth in that prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable
prospectus supplement. Each sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the
securities only in registered form, without coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or
quoted on a securities exchange or quotation system, the applicable prospectus supplement will say so. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=325763,FOLIO='22',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_description_of_common_stock"> </A>
<A NAME="toc_dg18801_4"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF COMMON STOCK    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2010 we are authorized to issue up to 297,000,000 shares of common stock, $.001 par value per share. As of
March&nbsp;31, 2010, approximately 31,759,718 shares of common stock were outstanding. All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is
listed on the NASDAQ Global Select Market System under the symbol "CLDX". </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Dividends  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of
shares of our common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Voting  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including
the election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Rights Upon Liquidation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled
to share equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Miscellaneous  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any
class, whether now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be
issued, sold or offered for sale by Celldex. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Anti-Takeover Provisions  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate, as well as our
shareholder rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders
receiving a substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring
control of our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a
single director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to our shareholder rights agreement (referred to in this prospectus as the rights agreement) a dividend of one Preferred Stock Purchase Right (referred to in this prospectus as
a right) for each share of common stock of Celldex was declared for each outstanding share of common stock of Celldex on November&nbsp;11, 2004. Each share of common stock of Celldex issued after
such date is also issued with a right. Each right entitles the registered holder to purchase from Celldex a unit consisting of one one-ten thousandth of a share of Celldex
Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock, at a cash exercise price of $35 per unit, subject to adjustment as specified in the rights agreement. We describe
the rights more completely in the rights agreement itself, which is contained in Exhibit&nbsp;4.1 to our Registration Statement on Form&nbsp;8-A filed on November&nbsp;8, 2004. The
summary of the provisions of the rights agreement is qualified in its entirety by reference to that agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare
Trust Company, N.A. is presently the transfer agent and registrar for our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=322759,FOLIO='23',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_description_of_preferred_stock"> </A>
<A NAME="toc_dg18801_5"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF PREFERRED STOCK    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2009, the Company had authorized preferred stock comprised of 3,000,000 shares of Class&nbsp;C Preferred Stock
of which 350,000 shares has been designated as Class&nbsp;C-1&nbsp;Junior Participating Cumulative, the terms of which are to be determined by our Board of Directors. As of
March&nbsp;31, 2010, there was no preferred stock outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Class&nbsp;C Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the general terms and provisions of our Class&nbsp;C Preferred Stock. The applicable prospectus supplement
will describe the specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares
of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class&nbsp;C Preferred Stock In general, our third
restated certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there
are sufficient authorized shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each series of our Class&nbsp;C Preferred Stock, our board of directors has the authority to fix the following terms: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation of the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of shares within the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below
under "Description of Depositary Shares";  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the shares are redeemable, the redemption price and the terms of redemption;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amount payable to you for each share you own if we dissolve or liquidate;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms
and conditions;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any restrictions on issuance of shares in the same series or any other series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>voting rights applicable to the series of preferred stock; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other rights, priorities, preferences, restrictions or limitations of such series. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rights with respect to any shares of our Class&nbsp;C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class&nbsp;C Preferred Stock that
we issue in accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by
issuing a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate
a business combination transaction by issuing a series of preferred stock having sufficient voting rights to provide </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=613043,FOLIO='24',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>a
required percentage vote of the stockholders. Additionally, under certain circumstances, our issuance of preferred stock could adversely affect the voting power of the holders of our common stock.
Although our board of directors is required to make any determination to issue any preferred stock based on its judgment as to the best interests of our stockholders, our board of directors could act
in a manner that would discourage an acquisition attempt or other transaction that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might
receive a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek stockholder approval prior to any issuance of currently
authorized stock, unless otherwise required by law or applicable stock exchange requirements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Terms of the Preferred Stock That We May Offer and Sell to You  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable
prospectus supplement provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement, which will contain additional information
and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock, we will further
amend our third restated certificate of incorporation, as amended, designating the stock of that series and the terms of that series. We will file&nbsp;a copy of the certificate of designation that
contains the terms of each new series of preferred stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number of shares included
in a designated series and fix the designation, powers, privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions. You
should refer to the applicable certificate of designation as well as our third restated certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in
the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights,
conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred
stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of
directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate action. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where
applicable: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation, stated value and liquidation preference of such preferred stock;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of shares within the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the offering price;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether
such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by depository shares as more fully described below
under "Description of Depositary Shares");  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any redemption or sinking fund provisions;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or
winding-up; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=495654,FOLIO='25',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our
stock of any other class or classes, or other series of the same class;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series
redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the
purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon
liquidation;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of
any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges,
limitations and restrictions of such preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our
third restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus
supplement, each series of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the
holders of our preferred stock will be subordinate to that of our general creditors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_description_of_warrants"> </A>
<A NAME="toc_dg18801_6"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF WARRANTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides
otherwise. This summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement.
These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the
warrant agreement. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We
may issue the warrants under warrant
agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act solely as our agent in
connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being delivered: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the title of the warrants; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=230998,FOLIO='26',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and
conditions relating to the exercise of such warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of
warrants issued with each such security;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the price or prices at which the warrants will be issued;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the aggregate number of warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the
exercise price of the warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the price or prices at which the securities purchasable upon exercise of the warrants may be purchased; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will
be separately transferable;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the
warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the date on which the right to exercise the warrants shall commence and the date on which the right shall expire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, the maximum or minimum number of warrants which may be exercised at any time;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the identity of the warrant agent;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any mandatory or optional redemption provision;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the warrants are to be issued in registered or bearer form;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the warrants are extendible and the period or periods of such extendibility;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>information with respect to book-entry procedures, if any; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other terms of the warrants. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive
dividends, if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Exercise of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities
at the exercise price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business
on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set
forth in the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust
office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants
represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=697485,FOLIO='27',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_dg18801_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Enforceability of Rights of Holders of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or
responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive
the securities purchasable upon exercise of, that holder's warrant(s). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Modification of the Warrant Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the
agreement in the following circumstances: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to cure any ambiguity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to correct or supplement any provision which may be defective or inconsistent with any other provisions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and
which do not adversely affect the interests of the warrant holders. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg18801_description_of_depositary_shares"> </A>
<A NAME="toc_dg18801_7"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF DEPOSITARY SHARES    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides
otherwise. This summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt
applicable to any depositary shares. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should
read the depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the
information below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of
common stock or preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will
be issued to the public. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us,
and the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least
$50&nbsp;million. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred
stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the depositary share, including dividend, voting,
redemption and liquidation rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the
fractional shares of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=29,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=613861,FOLIO='28',FILE='DISK105:[10ZAU1.10ZAU18801]DG18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di18801_1_29"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_description_of_units"> </A>
<A NAME="toc_di18801_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF UNITS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security.
The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The
applicable prospectus supplement may describe: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation and terms of the units and of the securities comprising the units, including whether and under what
circumstances those securities may be held or transferred separately;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising
the units;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the terms of the unit agreement governing the units;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>United States federal income tax considerations relevant to the units; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the units will be issued in fully registered global form. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their
entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. The forms of the unit
agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to
you. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_plan_of_distribution"> </A>
<A NAME="toc_di18801_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>PLAN OF DISTRIBUTION    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public,
negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities,
including without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
securities from time to time in one or more transactions: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at a fixed price or prices, which may be changed;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at market prices prevailing at the time of sale;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at prices related to such prevailing market prices;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at varying prices determined at the time of sale; or  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus supplement or supplements will describe the terms of the offering of the securities, including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the name or names of the underwriters, dealers or agents participating in the offering, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive
from the offering;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any over-allotment options under which underwriters may purchase additional securities from us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any agency fees or underwriting discounts or commissions and other items constituting agents' or underwriters'
compensation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=928337,FOLIO='29',FILE='DISK105:[10ZAU1.10ZAU18801]DI18801A.;11',USER='MSULLIV',CD=';5-APR-2010;11:49' -->
<A NAME="page_di18801_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any public offering price;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any discounts or concessions allowed or reallowed or paid to dealers; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any securities exchange or market on which the securities may be listed. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any
public offering price and any discounts or commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material
relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any
commissions and other compensation we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the
period of its appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with
respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary
course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is
currently no market for any of the offered securities, other than our common stock which is listed on the on the NASDAQ Capital Market. We have no current plans for listing of the debt securities,
preferred stock, warrants or subscription rights on any securities exchange or quotation system; any such listing with respect to any particular debt securities, preferred stock, warrants or
subscription rights will be described in the applicable prospectus supplement or other offering materials, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act.
Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those
activities may cause the price of the securities to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=100391,FOLIO='30',FILE='DISK105:[10ZAU1.10ZAU18801]DI18801A.;11',USER='MSULLIV',CD=';5-APR-2010;11:49' -->
<A NAME="page_di18801_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>be
higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
agents and underwriters who are qualified market makers on the NASDAQ Capital Market may engage in passive market making transactions in the securities on the NASDAQ Capital Market
in accordance with Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits
are exceeded. Passive market
making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum compensation to be received by any FINRA member or independent broker dealer may not
exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_di18801_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" into this prospectus the information we have filed with the SEC, which means that we
can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by
reference into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009, filed on March&nbsp;12,
2010, as amended by Amendment No.&nbsp;1 to our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009 filed on March&nbsp;31, 2010.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Current Reports on Form&nbsp;8-K filed with the Commission on January&nbsp;8, 2010, January&nbsp;25,
2010, February&nbsp;16, 2010, March&nbsp;4, 2010 and March&nbsp;30, 2010 (in each case except to the extent furnished but not filed).  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The description of our Common Stock contained in our registration statement on Form&nbsp;8-A, filed with the
Commission on September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended, and any amendments or reports filed for the purpose of updating such description. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The description of the rights to purchase our Series&nbsp;C-1&nbsp;Junior Participating Cumulative
Preferred Stock contained in our registration statement on Form&nbsp;S-4, filed with the SEC on December&nbsp;21, 2007, our registration statement on Form&nbsp;8-A filed
with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on October&nbsp;22, 2007, our registration statement on
Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such descriptions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (a)&nbsp;after the initial filing date of the registration
statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a
post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold.
The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this
prospectus, commencing on the date on which the document is filed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=388263,FOLIO='31',FILE='DISK105:[10ZAU1.10ZAU18801]DI18801A.;11',USER='MSULLIV',CD=';5-APR-2010;11:49' -->
<A NAME="page_di18801_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we incorporate by reference the documents listed below made by CuraGen with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CuraGen's Annual Report on Form&nbsp;10-K for the year Fiscal year ended December&nbsp;31, 2008, filed on
March&nbsp;10, 2009 as amended by Amendment No.&nbsp;1 to CuraGen's Annual Report on Form&nbsp;10-K for the Fiscal Year ended December&nbsp;31, 2008 filed on April&nbsp;30, 2009
and Amendment No.&nbsp;2 to CuraGen's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2008 filed on June&nbsp;19, 2009.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CuraGen's Quarterly Report on Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2009, filed
November&nbsp;6, 2009. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by
reference other than exhibits to those documents. Requests should be addressed to: 119 Fourth Avenue, Needham, Massachusetts 02494, Attention: Corporate Secretary (telephone number
(781)&nbsp;433-0771). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone to provide you with different information. You should not
assume that the information in this prospectus or the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Celldex Therapeutics,&nbsp;Inc.</B></FONT><FONT SIZE=2><BR>
Attention: Investor Relations<BR>
119 Fourth Avenue<BR>
Needham, Massachusetts 02494<BR>
telephone number (781)&nbsp;433-0771 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_legal_matters"> </A>
<A NAME="toc_di18801_4"> </A>
<BR></FONT><FONT SIZE=2><B><I>LEGAL MATTERS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon
for us by Lowenstein Sandler PC, Roseland, New Jersey. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the
underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_experts"> </A>
<A NAME="toc_di18801_5"> </A>
<BR></FONT><FONT SIZE=2><B><I>EXPERTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of Celldex Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2009 and 2008 and for the years ended
December&nbsp;31, 2009 and 2008 and management's assessment of the effectiveness of internal control over financial reporting (which is included in Management's Report on Internal Control over
Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc. for the year ended December&nbsp;31, 2009
have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst
&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Celldex Therapeutics,&nbsp;Inc. included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2007, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements as of
December&nbsp;31, 2007 are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=138798,FOLIO='32',FILE='DISK105:[10ZAU1.10ZAU18801]DI18801A.;11',USER='MSULLIV',CD=';5-APR-2010;11:49' -->
<A NAME="page_di18801_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements of CuraGen Corporation, incorporated in this prospectus by reference from CuraGen Corporation's Annual Report on Form&nbsp;10-K for
the year ended December&nbsp;31, 2008, as amended by Amendments No.&nbsp;1 and 2 to CuraGen's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008 and the
effectiveness of CuraGen Corporation's internal control over financial reporting, have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, an independent registered public accounting firm, as stated
in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in
accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di18801_where_you_can_find_more_information"> </A>
<A NAME="toc_di18801_6"> </A>
<BR></FONT><FONT SIZE=2><B><I>WHERE YOU CAN FIND MORE INFORMATION    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act with
respect to the securities being offered under this prospectus. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of
certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete,
and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated
by reference in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and special reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at </FONT> <FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex
Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room, located at 100&nbsp;F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. We make available free of
charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports
on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or
furnished to the SEC. Our website address is </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. Please note that our website address is provided as an inactive textual
reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such
information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained or incorporated by reference in this prospectus. No one has been authorized to provide you with different information. If anyone
provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus, as well as information we filed with the SEC and incorporated by reference, is accurate as of the date of those documents only. Our
business, financial condition and results of operations described in those documents may have changed since those dates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>
PROSPECTUS<BR>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


&nbsp;, 2010</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=34,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=146545,FOLIO='33',FILE='DISK105:[10ZAU1.10ZAU18801]DI18801A.;11',USER='MSULLIV',CD=';5-APR-2010;11:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja18801_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja18801_part_ii_information_not_required_in_the_prospectus"> </A>
<A NAME="toc_ja18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  <BR>    INFORMATION NOT REQUIRED IN THE PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja18801_item_14._other_expense__ja101992"> </A>
<A NAME="toc_ja18801_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the estimated costs and expenses payable by the Registrant in connection with the registration of the
securities being registered under this Registration Statement. All amounts shown are estimates except the Securities and Exchange Commission registration statement filing fee: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:60%;margin-left:20%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Registration Statement filing fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:20%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Estimated
</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja18801_item_15._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja18801_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex is a Delaware corporation. In accordance with the Delaware General Corporation Law (the "DGCL"), Article Six of
the Registrant's Third Restated Certificate of Incorporation, as amended, provides that no director of the Registrant shall be personally liable to the Registrant or its stockholders for breach of
fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director's duty of loyalty to Celldex or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL, or (iv)&nbsp;for any transaction from which the director derived an improper
personal benefit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
DGCL permits, but does not require, a corporation to indemnify its directors, officers, employees or agents and expressly provides that the indemnification provided for under the
DGCL shall not be deemed exclusive of any indemnification right under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The DGCL permits indemnification against
expenses and certain other liabilities arising out of legal actions brought or threatened against such persons for their conduct on behalf of the corporation, provided that each such person acted in
good faith and in a manner that he or she reasonably believed was in or not opposed to the corporation's best interests and in the case of a criminal proceeding, had no reasonable cause to believe his
or her conduct was unlawful. The DGCL does not allow indemnification of directors in the case of an action by or in the right of the corporation (including stockholder derivative suits) unless the
directors successfully defend the action or indemnification is ordered by the court. The Amended and Restated Bylaws of Celldex (the "Bylaws") provide for indemnification to the directors, officers,
employees and agents of Celldex consistent with that authorized by the DGCL. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to
directors and officers of Celldex pursuant to the foregoing provision or otherwise, Celldex has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is
against public policy as expressed in the Securities Exchange Act of 1934, as amended, and is therefore, unenforceable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex
currently carries a directors' and officers' liability insurance policy which provides for payment of expenses of Celldex's directors and officers in connection with threatened,
pending or completed actions, suits or proceedings against them in their capacities as directors and officers, in accordance with the Bylaws and the DGCL. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=785555,FOLIO='II-1',FILE='DISK105:[10ZAU1.10ZAU18801]JA18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_ja18801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja18801_item_16._exhibits."> </A>
<A NAME="toc_ja18801_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex, Cottrell Merger Sub,&nbsp;Inc. and CuraGen Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;2.1 Celldex's Registration Statement on Form&nbsp;S-4 (Reg. N. 333-160257), filed June&nbsp;26, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.2 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Quarterly Report on Form&nbsp;10-Q, filed May&nbsp;10, 2002</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated By-Laws of Celldex as of March&nbsp;14, 2007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.5 of Celldex's Annual Report on Form&nbsp;10-K, filed March&nbsp;18, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Celldex classifying and designating the Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Elimination of Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.6 of Celldex's Annual Report on Form&nbsp;10-K, filed March&nbsp;16, 2005</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fourth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fifth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.2 of Celldex's Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Shareholder Rights Agreement dated November&nbsp;5, 2004 between Celldex and EquiServe Trust Company, N.A. as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;1 to Shareholder Rights Agreement dated October&nbsp;19, 2007 between Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.) as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;10.1 of Celldex's Registration Statement on Form&nbsp;8-A/A filed October&nbsp;22, 2007</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=73709,FOLIO='II-2',FILE='DISK105:[10ZAU1.10ZAU18801]JA18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_ja18801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;2 to Shareholder Rights Agreement dated March&nbsp;7, 2008, between Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;10.1 of Celldex's Registration Statement on Form&nbsp;8-A12G/A filed on March&nbsp;7, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Indenture, dated February&nbsp;17, 2004, between CuraGen Corporation and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.5 of Celldex's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009 filed on March&nbsp;12, 2010</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Supplemental Indenture, dated September&nbsp;30, 2009, by and among Celldex, CuraGen, Merger Sub and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Current Report on Form&nbsp;8-K filed on October&nbsp;2, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Supplemental Indenture, dated December&nbsp;31, 2009, by and among Celldex, CuraGen and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Current Report on Form&nbsp;8-K filed on December&nbsp;31, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen of Common Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(included in Exhibit&nbsp;4.15)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen of Preferred Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Depository Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Depository Receipt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(included in Exhibit&nbsp;4.18)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Unit Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Opinion of Lowenstein Sandler PC as to the legality of the securities being registered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Computation of Ratio of Earnings to Fixed Charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of PricewaterhouseCoopers&nbsp;LLP, Registered Independent Public Accounting Firm of Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=308705,FOLIO='II-3',FILE='DISK105:[10ZAU1.10ZAU18801]JA18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_ja18801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, Registered Independent Public Accounting Firm of Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Deloitte&nbsp;&amp; Touche&nbsp;LLP, Registered Independent Public Accounting Firm of CuraGen Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Lowenstein Sandler PC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Included in Exhibit 5.1 hereto</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Powers of Attorney</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Included on signature pages to this Registration Statement</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja18801_item_17._undertakings."> </A>
<A NAME="toc_ja18801_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;To
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, Paragraphs&nbsp;(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on
Form&nbsp;S-3 or Form&nbsp;F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
or furnished to the Commission by the registrant pursuant to section&nbsp;13 or section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration
Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2>
offering thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability under the Securities Act to any purchaser, (A)&nbsp;each prospectus filed by the registrant pursuant to
Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and (B)&nbsp;each
prospectus required to be filed pursuant to </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=545363,FOLIO='II-4',FILE='DISK105:[10ZAU1.10ZAU18801]JA18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<A NAME="page_ja18801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<BR>

<P style="font-family:times;"><FONT SIZE=2>Rule&nbsp;424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for
the purpose of providing the information required by section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of
the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that
no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was
made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a
seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report
pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that
is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Act and will be governed by the final adjudication of such issue. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=593557,FOLIO='II-5',FILE='DISK105:[10ZAU1.10ZAU18801]JA18801A.;11',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc18801_signatures"> </A>
<A NAME="toc_jc18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form&nbsp;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town
of Needham, Commonwealth of Massachusetts, on April&nbsp;5, 2010. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Anthony S. Marucci<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc18801_power_of_attorney"> </A>
<A NAME="toc_jc18801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  POWER OF ATTORNEY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Anthony S. Marucci and
Avery W. Catlin, or any one of them, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue
hereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Anthony S. Marucci</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Director, Chief Executive Officer and President<BR>
(Principal Executive Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Avery W. Catlin</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Senior Vice President, Treasurer and Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LARRY ELLBERGER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Larry Ellberger</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director, Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=518349,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]JC18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;HERBERT J. CONRAD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Herbert J. Conrad</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;GEORGE O. ELSTON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> George O. Elston</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;KAREN SHOOS LIPTON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Karen Shoos Lipton</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DR.&nbsp;RAJESH B. PAREKH<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dr.&nbsp;Rajesh B. Parekh</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HARRY H. PENNER, JR.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Harry H. Penner, Jr.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;CHARLES R. SCHALLER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Charles R. Schaller</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;TIMOTHY M. SHANNON, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Timothy M. Shannon, M.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;5, 2010</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=756038,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]JC18801A.;7',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg18801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je18801_exhibit_index"> </A>
<A NAME="toc_je18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex, Cottrell Merger Sub,&nbsp;Inc. and CuraGen Corporatio.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;2.1 Celldex's Registration Statement on Form&nbsp;S-4 (Reg. N. 333-160257), filed June&nbsp;26, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.2 of Celldex's Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Quarterly Report on Form&nbsp;10-Q, filed May&nbsp;10, 2002</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amended and Restated By-Laws of Celldex as of March&nbsp;14, 2007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.5 of Celldex's Annual Report on Form&nbsp;10-K, filed March&nbsp;18, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of Celldex classifying and designating the Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Elimination of Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.6 of Celldex's Annual Report on Form&nbsp;10-K, filed March&nbsp;16, 2005</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fourth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.1 of Celldex's Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fifth Certificate of Amendment of Third Restated Certificate of Incorporation of Celldex</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;3.2 of Celldex's Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Shareholder Rights Agreement dated November&nbsp;5, 2004 between Celldex and EquiServe Trust Company, N.A. as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment No.&nbsp;1 to Shareholder Rights Agreement dated October&nbsp;19, 2007 between Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.) as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;10.1 of Celldex's Registration Statement on Form&nbsp;8-A/A filed October&nbsp;22, 2007</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=42,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=609641,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]JE18801A.;12',USER='LPALLES',CD=';5-APR-2010;13:13' -->

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;2 to Shareholder Rights Agreement dated March&nbsp;7, 2008, between Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as Rights Agent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;10.1 of Celldex's Registration Statement on Form&nbsp;8-A12G/A filed on March&nbsp;7, 2008</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Indenture, dated February&nbsp;17, 2004, between CuraGen Corporation and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.5 of Celldex's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009 filed on March&nbsp;12, 2010</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Supplemental Indenture, dated September&nbsp;30, 2009, by and among Celldex, CuraGen, Merger Sub and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Current Report on Form&nbsp;8-K filed on October&nbsp;2, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Supplemental Indenture, dated December&nbsp;31, 2009, by and among Celldex, CuraGen and Trustee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Incorporated by reference to Exhibit&nbsp;4.1 of Celldex's Current Report on Form&nbsp;8-K filed on December&nbsp;31, 2009</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Specimen of Common Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Warrant Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Warrant Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(included in Exhibit&nbsp;4.15)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Specimen of Preferred Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Depository Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Depository Receipt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(included in Exhibit&nbsp;4.18)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Unit Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>To be filed subsequently by an amendment to the Registration Statement or by a Current Report of the Registrant on a Current Report on Form&nbsp;8-K and incorporated by reference therein</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Opinion of Lowenstein Sandler PC as to the legality of the securities being registered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>12.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Computation of Ratio of Earnings to Fixed Charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of PricewaterhouseCoopers&nbsp;LLP, Registered Independent Public Accounting Firm of Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=43,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=902238,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]JE18801A.;12',USER='LPALLES',CD=';5-APR-2010;13:13' -->

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg18801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Location </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, Registered Independent Public Accounting Firm of Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of Deloitte&nbsp;&amp; Touche&nbsp;LLP, Registered Independent Public Accounting Firm of CuraGen Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of Lowenstein Sandler PC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Included in Exhibit 5.1 hereto</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Powers of Attorney</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Included on signature pages to this Registration Statement</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=44,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=54865,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]JE18801A.;12',USER='LPALLES',CD=';5-APR-2010;13:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>2
<FILENAME>a2197644zex-4_17.htm
<DESCRIPTION>EXHIBIT 4.17
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.17</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="93%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:93.04%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="681" height="880" src="g70882kgi001.gif"></font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:6.96%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ZQ|00000187|AVAN|C02|CUS|C0000022632|CAPIN|00453000|1051
  </font><font size="1" color="white" style="color:white;font-size:1.0pt;">COMMON STOCK </font><font size="1" color="white" style="color:white;font-size:1.0pt;">PAR VALUE $0,001 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">Certificate
  Number </font><font size="1" color="white" style="color:white;font-size:1.0pt;">ZQ00000187 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">THIS
  CERTIFIES THAT is the owner of Celldex </font><font size="1" color="white" style="color:white;font-size:1.0pt;">INCORPORATED
  UNDER THE LAWS OF THE STATE OF DELAWARE </font><font size="1" color="white" style="color:white;font-size:1.0pt;">therapeutics
  COMPUTERSHARE SHAREHOLDER SERVICES INC SPECIMEN </font><font size="1" color="white" style="color:white;font-size:1.0pt;">CERTIFICATE</font><font size="1" color="white" style="color:white;font-size:1.0pt;"> **ONE** </font><font size="1" color="white" style="color:white;font-size:1.0pt;">COMMON STOCK </font><font size="1" color="white" style="color:white;font-size:1.0pt;">THIS CERTIFICATE
  IS TRANSFERABLE IN CANTON, MA AND JERSEY CITY, NJ </font><font size="1" color="white" style="color:white;font-size:1.0pt;">CUSIP
  15117B 10 3 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">SEE REVERSE FOR CERTAIN
  DEFINITIONS </font><font size="1" color="white" style="color:white;font-size:1.0pt;">Shares FULLY PAID AND
  NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF CELLDEX THERAPEUTICS, INC. transferable
  on the books of the Corporation by the holder hereof in person or by duly
  authorized attorney, upon surrender of this Certificate properly endorsed.
  This Certificate is not valid unless countersigned by the Transfer Agent and
  registered by the Registrar. WITNESS the
  facsimile seal of the Corporation and the facsimile signatures of its duly
  authorized officers. </font><font size="1" color="white" style="color:white;font-size:1.0pt;">President and
  Chief Executive Officer Senior </font><font size="1" color="white" style="color:white;font-size:1.0pt;">vice</font><font size="1" color="white" style="color:white;font-size:1.0pt;"> president</font><font size="1" color="white" style="color:white;font-size:1.0pt;">
  and Chief Financial Officer DATED 25-MAR-2010 COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER
  AGENT AND REGISTRAR. </font><font size="1" color="white" style="color:white;font-size:1.0pt;">229682 SPECIMEN
  1 1 1 1 1</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=816097,FOLIO='',FILE="DISK106:[10ZAU2.10ZAU18802]7088-2-KG_ZAU18802.CHC",USER="CDESORM",CD='Mar 26 23:12 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="80%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:80.92%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="667" height="863" src="g70882kgi002.gif"></font></p>
  </td>
  <td width="19%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:19.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">This
  certificate also evidences and entitles the holder hereof to certain Rights
  as set forth in a Shareholder Rights Agreement between Celldex Therapeutics,
  Inc. and Computershare Trust Company, N.A. (or any successor thereto), as
  Rights Agent, dated as of November 5, 2004 as amended, restated, renewed,
  supplemented or extended from time to time (the &#147;Rights Agreement&#148;), the
  terms of which are hereby incorporated herein by reference and a copy of
  which is on file at the principal offices of Celldex Therapeutics, Inc. and
  the stock transfer administration office of the Rights Agent. Under certain
  circumstances, as set forth in the Rights Agreement, such Rights will be
  evidenced by separate certificates and will no longer be evidenced by this
  certificate. Celldex Therapeutics, Inc. may redeem the Rights at a redemption
  price of $0.01 per Right, subject to adjustment, under the terms of the
  Rights Agreement. Celldex Therapeutics, Inc. will mail to the holder of this
  certificate a copy of the Rights Agreement, as in effect on the date of
  mailing, without charge promptly after receipt of a written request therefor.
  Under certain circumstances, Rights issued to or held by Acquiring Persons or
  any Affiliates or Associates thereof (as defined in the Rights Agreement),
  and any subsequent holder of such Rights, may become null and void. The
  Rights shall not be exercisable, and shall be void so long as held, by a
  holder in any jurisdiction, where the requisite qualification, if any, to the
  issuance to such holder, or the exercise by such holder, of the Rights in
  such jurisdiction shall not have been obtained or be obtainable. The
  following abbreviations, when used in the inscription on the face of this
  certificate, shall be construed as though they were written out in full
  according to applicable laws or regulations: TEN COM - as tenants in common
  UNIF GIFT MIN ACT- Custodian (Cust) (Minor) TEN ENT - as tenants by the
  entireties under Uniform Gifts to Minors Act (State) JT TEN- as joint tenants
  with right of survivorship UNIF TRF MIN ACT Custodian (until age) and not as
  tenants in common (Cust) (Minor) under Uniform Transfers to Minors Act
  (State) Additional abbreviations may also be used though not in the above
  list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE
  For value received, hereby sell, assign and transfer unto (PLEASE PRINT OR
  TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE)
  represented by the within Certificate, and do hereby irrevocably constitute
  and appoint to transfer the said shares on the books of the within-named
  Corporation with full power of substitution in the premises. Shares Attorney
  Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S)
  SHOULD BE GUARANTEED BY AN ELIGIBLE. GUARANTOR INSTITUTION (Banks,
  Stockbroker, Savings and Loan Association and Credit Unions) WITH MEMBERSHIP
  IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM. PURSUANT TO S.E.C RULE
  17Ad-15. SPECIMEN Signature: Signature: Notice: The signature to this
  assignment must correspond with the name as written upon the face of the
  certificate, in every particular, without alteration or enlargement, or any
  change whatever. SECURITY INSTRUCTIONS THIS IS WATERMARKED PAPER. DO NOT
  ACCEPT WITHOUT NOTING WATERMARK. HOLD TO LIGHT TO VERIFY WATERMARK</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=843564,FOLIO='',FILE="DISK106:[10ZAU2.10ZAU18802]7088-2-KG_ZAU18802.CHC",USER="CDESORM",CD='Mar 26 23:12 2010' -->


<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>a2197644zex-5_1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;5.1</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Lowenstein
Letterhead]</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;5, 2010</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119 Fourth Avenue</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham, Massachusetts
02494</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Re:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><u style="font-weight:bold;">Shelf Registration
Statement on Form&nbsp;S-3</u></b></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This opinion is being furnished to you in connection
with the Registration Statement on Form&nbsp;S-3 (the &#147;Registration Statement&#148;),
including the prospectus that is part of the Registration Statement (the &#147;Prospectus&#148;),
filed by Celldex Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;Company&#148;),
with the Securities and Exchange Commission (the &#147;Commission&#148;) on April&nbsp;5,
2010 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Prospectus provides that it will be supplemented
in the future by one or more prospectus supplements (each, a &#147;Prospectus Supplement&#148;).
The Prospectus, as supplemented by the various Prospectus Supplements, will
provide for the issuance and sale by the Company from time to time of (i)&nbsp;&nbsp;shares
of the Company&#146;s preferred stock, par value $0.001 per share (the &#147;Preferred
Stock&#148;) in one or more series or classes, (ii)&nbsp;shares of the Company&#146;s common
stock, par value $0.001 per share (the &#147;Common Stock&#148;), (iii)&nbsp;warrants to
purchase Common Stock or Preferred Stock (the &#147;Warrants&#148;), (iv)&nbsp;depositary
shares (evidenced by depositary receipts) representing a fractional interest in
a share, or multiple shares, of Common Stock or Preferred Stock (the &#147;Depositary
Shares&#148;), or (v)&nbsp;units comprised of the foregoing (the &#147;Units&#148;). &#160;The Preferred Stock, Common Stock, Warrants,
Depositary Shares and Units are collectively referred to herein as the &#147;Securities.&#148;
&#160;The Securities are being registered for
offering and sale from time to time pursuant to Rule&nbsp;415 under the
Securities Act.&#160; The shares of Common
Stock or Preferred Stock represented by Depositary Shares will be deposited
pursuant to a Depositary Agreement (the &#147;Depositary Agreement&#148;) between the
Company and a bank or trust company as depositary.&#160; The Units may be issued pursuant to a Unit
Agreement (the &#147;Unit Agreement&#148;) between the Company and a bank or trust
company as unit agent.&#160; The Warrants may
be issued pursuant to a warrant agreement (the &#147;Warrant Agreement&#148;) between the
Company and a bank or trust company as warrant agent.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In rendering our opinions set forth below, we have
reviewed the Registration Statement and the exhibits thereto. We have also
reviewed such corporate documents and records of the Company, such certificates
of public officials and officers of the Company and such other matters as we
have deemed necessary or appropriate for purposes of this opinion. &#160;In our examination, we have assumed: (i)&nbsp;the
authenticity of original documents and the genuineness of all signatures; (ii)&nbsp;the
conformity to the originals of all documents submitted to us as copies; (iii)&nbsp;the
truth, accuracy and completeness of the information, representations and
warranties contained in the instruments, documents, certificates and records we
have reviewed; and (iv)&nbsp;the legal capacity for all purposes relevant
hereto of all natural persons and, with respect to all parties to agreements or
instruments relevant hereto other than the Company, that such parties had the
requisite power and authority (corporate or otherwise) to execute, deliver and
perform such agreements or instruments, that such agreements or instruments
have been duly authorized by all requisite action (corporate or otherwise),
executed and delivered by such parties and that such agreements or instruments
are the valid, binding and enforceable obligations of such parties. As to any
facts material to the opinions expressed herein that were not independently
established or verified, we have relied upon oral or written statements and
representations of officers and other representatives of the Company.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on the foregoing, and subject to the assumptions,
limitations and qualifications set forth herein, we are of the opinion that:</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With
respect to any particular series of shares of Preferred Stock, when (a)&nbsp;the
issuance and the terms of the sale of the shares of Preferred Stock have been
duly authorized by the Board of Directors of the Company in conformity with its
certificate of incorporation; (b)&nbsp;an appropriate certificate of
designation relating to a series of the Preferred Stock to be sold under the
Registration Statement has been duly authorized and adopted and filed with the
Secretary of State of Delaware; (c)&nbsp;the terms of issuance and sale of
shares of such series of Preferred Stock have been duly established in
conformity with the Company&#146;s certificate of incorporation and bylaws so as not
to violate any applicable law or result in a default under or breach of any
agreement or instrument binding upon</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=879189,FOLIO='',FILE="DISK106:[10ZAU2.10ZAU18802]7088-2-KM_ZAU18802.CHC",USER="CDESORM",CD='Apr  3 16:39 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Company and comply with any requirement or
restriction imposed by any court or governmental body having jurisdiction over
the Company or any of its property; (d)&nbsp;such shares have been issued and
delivered against payment of the purchase price therefor in an amount in excess
of the par value thereof, in accordance with the applicable definitive
purchase, underwriting or similar agreement, and as contemplated by the
Registration Statement, the Prospectus and the related Prospectus Supplement;
and (e)&nbsp;to the extent such shares of Preferred Stock are to be issued upon
the conversion, exchange or exercise of any Units or Warrants, when such shares
have been duly issued and delivered as contemplated by the terms of the
applicable agreement relating to such Units or Warrants, the shares of
Preferred Stock will be validly issued, fully paid and nonassessable.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With
respect to shares of Common Stock, when (a)&nbsp;the issuance and the terms of
the sale of the shares of Common Stock have been duly authorized by the Board
of Directors of the Company in conformity with its certificate of
incorporation; (b)&nbsp;such shares have been issued and delivered against
payment of the purchase price therefor in an amount in excess of the par value
thereof, in accordance with the applicable definitive purchase, underwriting or
similar agreement, and as contemplated by the Registration Statement, the
Prospectus and the related Prospectus Supplement; and (c)&nbsp;to the extent
such shares of Common Stock are to be issued upon the conversion, exchange or
exercise of any Units, Preferred Stock or Warrants, when such shares have been
duly issued and delivered as contemplated by the terms of the applicable
Preferred Stock or agreement relating to such Units or Warrants, the shares of
Common Stock will be validly issued, fully paid and nonassessable.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With
respect to Warrants, when (a)&nbsp;the issuance and the terms of the sale of the
Warrants have been duly authorized by the Board of Directors of the Company; (b)&nbsp;the
terms of the Warrants and of their issuance and sale have been duly established
so as not to violate any applicable law or result in a default under or breach
of any agreement or instrument binding upon the Company and comply with any
requirement or restriction imposed by any court or governmental body having
jurisdiction over the Company or any of its property; (c)&nbsp;the Warrants and
the applicable Warrant Agreement relating to the Warrants have been duly
executed and countersigned and the Warrants have been issued and sold in
accordance with the applicable definitive purchase, underwriting or similar
agreement, as contemplated by the Registration Statement, the Prospectus and
the related Prospectus Supplement; and (d)&nbsp;the Company has received the
applicable consideration provided for the Warrants, the Warrants will
constitute valid and binding obligations of the Company enforceable against the
Company in accordance with their terms.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With
respect to Depositary Shares, when (a)&nbsp;the issuance and the terms of the
sale of the Depositary Shares (and the Common Stock or Preferred Stock
underlying such Depositary Shares) have been duly authorized by the Board of
Directors of the Company; (b)&nbsp;the terms of the Depositary Shares (and the
Common Stock or Preferred Stock underlying such Depositary Shares) and of the
issuance and sale of the foregoing have been duly established so as not to
violate any applicable law or result in a default under or breach of any
agreement or instrument binding upon the Company and comply with any
requirement or restriction imposed by any court or governmental body having
jurisdiction over the Company or any of its property; (c)&nbsp;the Deposit
Agreement and the related Depositary Receipts (the &#147;Depository Receipts&#148;) have
been duly authorized and validly executed and delivered by the Company and the
depositary appointed by the Company; (d)&nbsp;the shares of Common Stock or
Preferred Stock underlying such Depositary Shares have been deposited with a
bank or trust company (which meets the requirements for the depositary set
forth in the Registration Statement) under the applicable Deposit Agreement; (e)&nbsp;the
Depositary Receipts representing the Depositary Shares have been duly executed,
countersigned, registered and delivered in accordance with the appropriate
Deposit Agreement, the applicable definitive purchase, underwriting or similar
agreement, and as contemplated by the Registration Statement, the Prospectus and
the related Prospectus Supplement; and (f)&nbsp;the Company has received the
applicable consideration provided for in respect of the Depositary Shares, the
Depositary Shares will be validly issued, fully paid and nonassessable.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With
respect to Units, when (a)&nbsp;the issuance and the terms of the sale of the
Units have been duly authorized by the Board of Directors of the Company; (b)&nbsp;the
terms of the Units and of their issuance and sale have been duly established so
as not to violate any applicable law or result in a default under or breach of
any agreement or instrument binding upon the Company and comply with any
requirement or restriction imposed by any court or governmental body having
jurisdiction over the Company or any of its property; (c)&nbsp;the Unit Agreement
and the</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="7088-2-KM_PB_2_163613_5335"></a></font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=933700,FOLIO='2',FILE="DISK106:[10ZAU2.10ZAU18802]7088-2-KM_ZAU18802.CHC",USER="CDESORM",CD='Apr  3 16:39 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Units have been duly executed and countersigned and
the Units have been issued and sold in accordance with the applicable Unit
Agreement, as contemplated by the Registration Statement, the Prospectus and
the related Prospectus Supplement; and (d)&nbsp;the Company has received the
applicable consideration for the Units provided for in the Unit Agreement, the
Units will constitute valid and binding obligations of the Company enforceable
against the Company in accordance with their terms.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In rendering the opinions set forth above, we have
assumed that (i)&nbsp;the Registration Statement (and any applicable
post-effective amendment thereto) will have become effective under the
Securities Act, a Prospectus Supplement will have been prepared and filed with
the Commission describing the Securities offered thereby and such Securities
will have been issued and sold in accordance with the terms of such Prospectus
Supplement and in compliance with all applicable laws; (ii)&nbsp;a definitive
purchase, underwriting or similar agreement with respect to such Securities (if
applicable) will have been duly authorized, executed and delivered by the
Company and the other parties thereto; (iii)&nbsp;the Securities will be duly
authorized by all necessary corporate action by the Company and any agreement
pursuant to which such Securities may be issued will be duly authorized,
executed and delivered by the Company and the other parties thereto; (iv)&nbsp;the
Company is and will remain duly organized, validly existing and in good
standing under applicable state law; and (v)&nbsp;the Company has reserved a
sufficient number of shares of its duly authorized, but unissued, Common Stock
and Preferred Stock as is necessary to provide for the issuance of the shares
of Common Stock and Preferred Stock pursuant to the Registration Statement.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The opinions set forth above are subject to the
following exceptions, limitations and qualifications: (i)&nbsp;the effect of
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or
other similar laws now or hereafter in effect relating to or affecting the
rights and remedies of creditors; (ii)&nbsp;the effect of general principles of
equity, including without limitation, concepts of materiality, reasonableness,
good faith and fair dealing and the possible unavailability of specific
performance or injunctive relief, regardless of whether enforcement is
considered in a proceeding in equity or at law, and the discretion of the court
before which any proceeding therefore may be brought; (iii)&nbsp;the
unenforceability under certain circumstances under law or court decisions of
provision providing for the indemnification of, or contribution to, a party
with respect to at liability where such indemnification or contribution is
contrary to public policy.&#160; We express no
opinion concerning the enforceability of any waiver of rights or defenses with
respect to stay, extension or usury laws.&#160;
Our opinion expressed herein is also subject to the qualification that
no term or provision shall be included in any Warrant, any Deposit Agreement or
any other agreement or instrument pursuant to which any of the Securities are
to be issued that would affect the validity of such opinion.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our opinion is limited to the federal laws of the
United States and to the Delaware General Corporation Law.&#160; We express no opinion as to the effect of the
law of any other jurisdiction. Our opinion is rendered as of the date hereof,
and we assume no obligation to advise you of changes in law or fact (or the
effect thereof on the opinions expressed herein) that hereafter may come to our
attention.</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1
to the Registration Statement and to the references to our firm therein and in
the Prospectus and in any Prospectus Supplement under the caption &#147;Legal
Matters&#148;. In giving our consent, we do not admit that we are in the category of
persons whose consent is required under Section&nbsp;7 of the Securities Act or
the rules&nbsp;and regulations thereunder.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 3.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 3.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>

<p style="margin:0in 0in .0001pt 3.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 3.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Lowenstein Sandler PC</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="7088-2-KM_PB_3_163702_5796"></a></font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- ZEQ.=1,SEQ=3,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=23074,FOLIO='3',FILE="DISK106:[10ZAU2.10ZAU18802]7088-2-KM_ZAU18802.CHC",USER="CDESORM",CD='Apr  3 16:39 2010' -->


<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>a2197644zex-12_1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#10ZAU18801_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kb18801_exhibit_12.1"> </A>
<A NAME="toc_kb18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;12.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CELLDEX PHARMACEUTICALS,&nbsp;INC.<BR>
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2006 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2005 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from continuing operations before taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,508</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,795</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,369</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fixed Charges:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expensed and amortization of debt discount</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>156</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Estimate of interest within rental expense(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>726</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=2 VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total fixed charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>882</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=2 VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss as defined for ratio to fixed charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,874</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,409</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,729</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,336</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=2 VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of earnings to fixed charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Due
to the Company's loss from continuing operations for the years ended December&nbsp;31, 2009, 2008, 2007, 2006, and 2005 earnings were insufficient to
cover fixed charges by $36.9&nbsp;million, $48.8&nbsp;million, $15.5&nbsp;million, $18.8&nbsp;million, and $17.4&nbsp;million, respectively.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Interest
component on rentals estimated to be one-third of rentals. </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="4",CHK=785543,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]KB18801A.;5',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="10ZAU18801_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kb18801_1">Exhibit 12.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a2197644zex-23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#10ZAU18801_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kc18801_exhibit_23.1"> </A>
<A NAME="toc_kc18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kc18801_consent_of_independent__kc102316"> </A>
<A NAME="toc_kc18801_2"> </A>
<BR></FONT><FONT SIZE=2><I>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3 of our report dated
March&nbsp;12, 2010 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Celldex Therapeutics,&nbsp;Inc.'s Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2009. We also consent to the reference to us under the heading "Experts" in such Registration Statement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Boston,
MA<BR>
April&nbsp;5, 2010 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="5",CHK=124722,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]KC18801A.;5',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="10ZAU18801_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc18801_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc18801_2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>a2197644zex-23_2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#10ZAU18801_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kd18801_exhibit_23.2"> </A>
<A NAME="toc_kd18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kd18801_consent_of_independent__kd102317"> </A>
<A NAME="toc_kd18801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form&nbsp;S-3
No.&nbsp;333-00000) and related Prospectus of Celldex Therapeutics,&nbsp;Inc. for the registration of shares of its common stock and to the incorporation by reference therein of our
report dated May&nbsp;7, 2008, with respect to the consolidated financial statements of Celldex Therapeutics,&nbsp;Inc. and Subsidiary, included in the 2009 Annual Report to Shareholders of
Celldex Therapeutics,&nbsp;Inc., filed with the Securities and Exchange Commission. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young,&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Metro
Park, New Jersey<BR>
April&nbsp;5, 2010 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="6",CHK=1034532,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]KD18801A.;5',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="10ZAU18801_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kd18801_1">Exhibit 23.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kd18801_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>7
<FILENAME>a2197644zex-23_3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#10ZAU18801_7">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ke18801_exhibit_23.3"> </A>
<A NAME="toc_ke18801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.3    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3 of our report dated March&nbsp;9, 2009, relating to the consolidated
financial statements of CuraGen Corporation and subsidiary, and the effectiveness of CuraGen Corporation's internal control over financial reporting, appearing in&nbsp;the Annual Report on
Form&nbsp;10-K, as amended by Amendment No.&nbsp;2 filed on June&nbsp;19, 2009 of CuraGen Corporation for the year ended December&nbsp;31, 2008 and to the reference to us under the
heading "Experts" in the Prospectus, which is part of this Registration Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Deloitte&nbsp;&amp; Touche&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Hartford,
CT<BR>
April&nbsp;5, 2010 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="7",CHK=382152,FOLIO='blank',FILE='DISK105:[10ZAU1.10ZAU18801]KE18801A.;5',USER='PJAMES',CD=';3-APR-2010;06:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="10ZAU18801_7">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke18801_1">Exhibit 23.3</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=CDESORM,SEQ=,EFW="2197644",CP="CELLDEX THERAPEUTICS, INC.",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g70882kgi001.gif
<DESCRIPTION>G70882KGI001.GIF
<TEXT>
begin 644 g70882kgi001.gif
M1TE&.#EAJ`)P`_<```($!Q<9&@@0%A(;)1HD)Q4I-"<H*2@L-"LS-SL\/#0U
M-BTP,!HB'A`M=S@\1"DY22HV>0\D83Q$1S1(5C-*=A=$=D-$1$M+3$1(2TA,
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M_?GV]O/R[=[BW<'`OH*!?2'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````*@"<`,`"/\`]0D<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8
M,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`
M@PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-H
MTZI=R[:MV[=PX\J=2[>NW;MX\^K=R[>OW[^``PL>3+BPX<.($RM>S+BQX\>0
M(TN>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX
M<^O>S;NW[]_`@PL?3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@
MPXO_'T^^O/GSZ-.K7\^^O?OW\./+GT^_OOW[^//KW\^_O___``8HX(`$%FC@
M@0@FJ.""##;HX(,01BCA0<'L,^&%?V%"#X8<ZG4//QV&*.*())9HXHDHIJCB
MBBRVZ.*+,,8HXXPTUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGD
MDU!&*>645%9IY9589JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGG
MG'36:>>=>.:IYYY\]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKI
MI9AFJNFFG';JZ:>@ABKJJ*26:NJIJ*:JZJJLMNKJ=/B\_RKKK+36:NNMN.:J
MZZZ\]NKKK\`&*^RPQ!9K[+'()JOLLLPVZ^RST$8K[;345FOMM=AFJ^VVW';K
M[;?@ABONN.26:^ZYZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_C<4*
M\,`$%VSPP0@GK/#"##?L\,,01RSQQ!17;/'%&&>L\<8<=^SQQ^L*#/+())=L
M\LDHIZSRCODP)+*%%H;4LD`Q"S3S0;'>7-`^L>Y3,\T+Q2HP/C'G0_30,>,C
M\LM&"Y0S04+KD[34!2D]4,M%$VUA/C/CH_-`^]PLLCY-ZW.TV3R#7?/+8],L
M]D!C?YVJ,L$TT\PX^M`3C#\;XO\SB3GZT#U0,,[0#,PY9)\3#-7C-$/0.!OJ
MX\R&YIQC#CW[].-XWAOZ?'7D<!-$#S[*@*A//X`[;6&LF$N=.ME.+[2/.7*'
M=$]#]""^<SU@C]WSZOG$#'I)2\O^ZC\CJ&``(OIL0$(*%_BCCP?T3$+""('H
M$P@*'$RB#PHJ<-!,/R24KT\P'JP`B$"87"`U"B-PX(P_&ZA@@2&49*]/!_^<
MSD'D*\B$/BCA`1!E8@,6RD0*],&!<YR#!!S@@"$"!T%@Z*,2&Y`?^O31#.YQ
M0!G:0QP]_D&/9D0P>\H@@3[,\0\.K,!QP<#>AC8Q@@GJ`Q`<D!X__J$"O/F#
M`X58(?+_)L@/0(R`$OHX!_PP<<$-V-`0)&!>)OHWCA3\`Q"Z"T8@6N:,%`!"
M!9O01R:8:(@-G8,2YE`!/OJ1@D`X+A,HL&'@O$</0P2"A/WXA_<D]X]*"`08
M@%C</B9A",`A8G'ZT,2&Z$$)3%@H&).HQ.:",;Q5`<,"]`#$`L6(21*,8P,.
M[$`S+*`/3&P`$QRXX1V#N`%@H(")H-S$!1(0./==42#!2,`Y#"'%#5C`<1L0
M8#-TJ8\1*`")F0#``@TQ`@;R8P3,XX<%7`D,]#G#`^;0Q`:4L0$&!H(>FU#`
M.2ZP.'XDH!D;V`0^1@`(9Z3R`H9P!B`\L(\-^",0A6C&!93!_P%@4$(%&_0B
M)48PRF!<H!*!($$,_3&"0N12&2E`1#-(<,")-G(#S<!>)E2@#PND(!B%^)\^
M2&``$!)PC!;`!"!0H`\!3#`8F$RE!`VQ@7%8((4VO(`"SG>!213"'#U50?8L
M0`D6&$(9*;W`.1!!`F8RT(*!6("%&AI%?5Q`!21@(B9*RJJ6Y=*"^Z2:!9RA
MT!&`B`23Z.8X2!"(!4Y"!2D(8Q3%-U(F*N,"((+?!OHA$!($,1#9&T$F`+&^
M37A`'_\(HB]2<,U2C@"M/QRI.T&$#WJ8@P.`DQ^(3)E1@PZ.'MO,VP7,,0(4
M'*X9P5!H-__H66=@;X&%^$<@+(B"3/^0H'#8XR@E_G$.O*$@G_.PZB0XL(E_
M!(,?R!T!)L91N+9J,1BK%>,^4CC0`:ZOF(6@!"`N^TOH\H,$H\3<!@JQ@E)V
M,Q`C:*8AN@?"P@$B$)[%1%,7F`(H%FZ?**#;/Q#8#_>Y<QSDQ)LR`K$!1*J*
M:#T5"#FEM@\%D!5]@",!!@/'@2_JPQ`H2`$2)4A0!MJ5ELKH0##^P3QG(%`?
M/M7'`JZW`,Q98!P=`.$(+A"(`"B#$ASHQ_T6R`'HUJP?'`"1!PHWB00P5[5Y
MBUF,]2'-<>SC'Q[H9VHWD<K+\32)&0[B)E``"`$"`HJ(*Q\*5QL(O/85!?Q@
M`#[==^$$,!'_Q0G8!R8"@8D%IDT?B$B!,A1`#TPL@`,62"4^QZ%'^8&RQPG8
M$`H"4=[4^N(?_6@F)31L@<4IPP"8\$<'!@A/)*:@C8!KY0@LN`\6[,,9[AO'
MJ"7HQ+X:6%4US-L-1X`/1*"`I7OM<3]`:8%]_)!^^FCC':WJ6B;^4G*DQ'$I
M25D(ENJC$).8Q`B"H0P/D+&T^@!P)D9,@LA.`@`<O8!K]WC*VYH3'SAVG#)&
M4$^^TN.#K5SA!9H11'W03Y\P!=$^4@`,]ZV[$-F;A!4%J%P4+(X#MAY@>;$J
MD.]F+QR8]/#B3/GL$0!NSOP<R`J@FX))=&`2_B"!.9JQH4(8XAS-_T2!\\;!
M`9MB3H(JA",*/$#235A.'RL(A(4`+%_'MC78VP-K"J6WCQ&4L)OG\(`#KSS2
M5Z,J&`9@P082L#X")^`"#62!X@+-Q$ULX`),5#D)>FN!$2R0K.,5")"36+X>
MZT,%2'RV(5(@0!0W<QP!L."D!4+:0'!TI"SM`#_NNH+XB?'6@*"'`4@@6W=>
M&)X;4.\%J%S>ZT&1L:GDGM>;R6%#C",!P-B`,'!,"5K^H[XDV,<%".@/0Q@`
MDOS<IR'V<6MFYC*&A<!$`/RNB2GBG`2N7$'[<'D_9PL$$8A8^SX6<`%Z]%JH
MZ^4'V"5XZM(_F035!@8'*)'6=P,#K<`@:/\!KWC)IN?M?_00-R6`OP%^;$\@
M_605/LRAN6:D;AQXRT32'7<WJHUO<*FC.&:31"`D$/10.'D##'B##^<0.8`0
M1)%#.GEC#A9"@623#^>`.C0C7H7##YD`0K$"#!;$#\4`#)A0-\TD.88@/0*1
M"88P"9$S"8"`1-`E-9E`9Y2#/W]4"-*##X90"(53/8'`5\!`=_9&"784#)A`
M2(5D#G94.(`T>\WP@P:G4F8S"8"%#\%@05Y#"9G`A0)!-^9@08&#";N6;7F&
M.,%07P+##V'DA*]T/G#%5YE081O"3'YD#BM08`RT./2`"!L"72)71,\3.4!8
M*SJ##V,7$;73$('_L$<500\=@#<.D4(#^!">51/:!3L7H4\_(Q(Y]!!M\RI<
M<S/[X`ZC"!+F8#J1V`RIB!#G4(`(T386<@Y^=#6S"#6Z>(FQ,S7%8S.X&"O.
M0(8M\XI!LT*(8(P&\8F[R(FZZ$8*H8PK,XW4&"726(U]0338:!CTX`[;.!C;
M0`[UP#O?&!CUP`Q;6(Z"<8Z9P%?D@@_DN`[M,`_U,`_KL`[GL`ZKLP[TN"'K
M,#KF,`\P8Q#:V#;7^#6-&!CW<`_V4`_,>!,):101.1X3.17.\`5^\`R*L`5?
M\`5_X`=A\`<?^06@H`B/X`>*L`J@\`A7\`6/\)*JD`BJ\)(R:9(OZ0B/_Z`*
M?D"2H.`+?N`(L1`+EN`(CK`(H("3C+"2<?`(_.`,_$`/[#".\&`VXPB55K,/
M]S`/HQ,Z5+,S9H,/\P"6];`TO,,[17,1,_.0$'$S,V.*&8$UC,@2C=B6N*@0
M.M,R"8F7=4D1%8D1:FDS7",5@=F770&76",WI8B7@1F-%[B8,\$-1C`$U^`(
M1[`%8!`&7.`%81`'70`*I6`$7$`$8J`$8=`)&\D%2L`%9E`&7F`$7F`&4Z`$
M8,`%8[`$1J`$6]`)99`$4\`%2\`%1Q`*OCD&9#`%90`%2H`$90`&[>`(UT`.
MV9`-[3"=ZI`-W^`-V2`.\\`.W-D.WM`.]7"/_/_(#NW`G?0`E=M)GM<0G=I@
MG=-)GM'I#>Q@#JQ3#_!0E?5P#_DYCO,07.,(C_UYGN>IGZ-3H/LPCOJP#OJ0
ME?3PG[=C,_3PH#:S#_0XEIPSH+>C-`O9-P/QH/<0H?7P#IASC1+ZE0NIH<=8
MHG\I$"7JF`8AH?<0,Q[J$25:$(3)$0EYC5-QHUF!-?O`#UP3-D":#T#*,_F`
M.<$3-F$C-4IC-/!XI%9#-F%C-/G@D%[3I"QA#4NP!.'@"5)@F5Q0!IP)!KY@
M#%^P!5-P!)T`!D/0!-+`"*7`"%\`G$B@")<9!U[0!%0P!680I[:P"Q3`!"VY
M!7BP!:Q`#'&PG*\)!F#_(`5X\`7;L`K6X`W><)V5J@[82:G?T`[P``_J@*G?
MP`[ID`[P\`WI4)[JT*GDF:KJT)[5J0W?$*OB\`W9H`VP^JGKP`Z?J@[WP`[P
M$`_J,*JG^@WK\*OJ(`Z?2JG>@`[)FJRD"@_>\*GHP`W<N0[IP)WW$`_WD`[Q
ML`[Q8)_Q``_KH`[,V@Z?F@[H\`WPD`ZIB@[K2JKE$`_/6@_I$*WHL)[>4`ZZ
MVJW>ZJV_JI_ED`X+J9^CZJD!^P[K\)_ZH)6=.H[LD*[L<#OU"`_P6`\->I_V
M>0_K2JWPL)#UT*WO$`_Q\`[KNJS1J@[=P*S>4*R>&J[P(*HLRYWU@*GJX*O?
M_]JQV2J5]]FI-=NQG1H/#;F?"RFN(NNQ/-NQ_/BOXSB60Z,T^)"A7ZDT]9`/
M"PFTG7H[6"LP3,NB7(FU!P&U>\F(#QDW)Y&(8#&8"]HU!*D/]G`U>HD07!,U
M7E,V.KH1QT`$1*`,>&`$1X";6Q`&JP`-H/`%0Z`$1[`(].`(9J`(1Q`#CA`)
MH``+78`';X`#MQD*81`&K@`'K-`$$!`&7A`'L-`-5Q`#2C`$K0`+K(`'7="Z
M9J`$24`%VW`)W$"KZJ"NL7J[MLL.(OL-\<`-W1`/O/NKHUJL\KJNW\`-Z5`-
MU5"[U8`-J$JKX)`-E,JLN=NPGKJMJ=JIWQ"LNWJ=N_\JK9_:O93ZJ\0;#]VK
M#N$:O.NZKOKYK>B[J][@J;MZ#]NKONK+K9[ZJ]?IJ>A@G=<)#J:JOA]+JN$J
MLC]+O-^KKN.J#[[:H.%Z#[[[J1WKJQ2K-%$ILO6`N_)*P9UZGR*+OMT*#NB`
M#LU+O=60#=QPN[OJJ>F0OICJJ=1;J?#0#>JKL<8:OM3[O^;[PBT;PLK+K=Q:
M#K1JJ=@IP.P:#^5PG@O+#F$YCO,HM?7`G?!0N\`;KPRL#OG9J>4YEO3`CPN[
M#K?##KFZ#WT#CV!LQE8C-+<3@4T;-KRSE08X.K_(Q%##.E!*CD[*.:(CH*PC
M,`+*E0A12051HY4E-W<V$_3_\`[@D`S,`+SIT`WK4`[C(*KGF0^`PX#TL,0B
MB@_V<,@;8K&>_*/W4%E@?!#",SHU&A+$4`,X4`Q=(`5>,`5=<`6*P`Z,8`,]
ML`2Y\+Q%"095``,R4`40D)JQ,`M/4`9,8`9?H`U7``8N4`-E\`(UL)2O4`SJ
M$`VC$`-'0`380`Q2P`52D`2S'`;L8`G`&ZNQF@VI"L.?.K/82;VUFL+/&PTI
M;*NV&@W$H`W$D`O1L`NPH`W24`W1H`W52;WCF[[L;)^Z&J_O4,"^R[W9\,'=
M"ZPON\Z?^KX4?+/Z2ZK?8)_WJ;T?K*H>S-#ST+#Z.;,(#*SJ4+N46KLMRYW/
MNI#Z_]"I25P.K-J]*$W3^\L.ZEH.(ZV?'INJ40G2M>NN[/`.Y:"Q13NT]*NI
MUED-KNK!W/FINDK![&"=-,RS+KNN-3NSUJD.X*"^P.JK+`R^/,NJV)F\M`K`
MG^J=VTO%.YO1&WS6[!R?\JFJ"\F[S^K!1&W!+US4STJJ]M"Q^0F_^KF@"[JT
M([VS+YNJX=G86$NO\XNSOQJNQONQ^WFQF?V^XDJR,]NI."VP!/P.`ZNM&ARB
M4<G4MQ/2_SJPHJJO^9D.^PD/2\VB)>JU'8HS=GD/?1DKW8`+IO`$>_`&4?`&
M71`'<T`':B`*I"`'HE`%IR`*J#`'5/`&GC`'DA`'?)`'GO\`!Z0P!Z(P!XR0
M!WCP"7'P!J=@"YMK"JOP"JW@"8PPW^4M"IY`"G%@"?J@"[UP"2"1#%6P!>OP
M!D_@!>$,!KEP!42@`U5P!*M``7>0!$8`!J%0"E]@!#DP!3;@FSG`J$N0X420
M`ST``3B`X*3P!3B0FR`P"C;0"42P!8G@"5U0!5ZP!4D`!N0`"^4@U5I]T.S,
MJE+]S=#@S\S[G2ELJ;O*G>B`G;":#00-#02]S_P,#=$@#=$0G=%9L\FJP?@;
MK=W[#6,-K=V+K#7K#=5@NQ],JCX=K?:YP>W[JS.;OM_)JC6;P=U*VUI\CZ6J
ML00KO-_`O!:]KO2JKBZ[H#\[Q>C_^M>B^K(I?;0^?;6\,[`\.XZD>@\G>[O[
MV["'3;^8BIVS6@V:NJ^EFJHG.[^QJJFW^ZT?&]>!S@W,.]$@[:D/F];=FPW,
M>M9G_N<&K>56K:O[&Z[L7*J_2JFW6ZG*^J\?O+V>&JTN>[RCJK'JF\#U.JHB
MFPXDB[$8:X\1F^RQ'JV\>SL?K;'A>=@&+.Z-#<+R.L78;NKKBMH:"Z\O3-L&
MK*T#RPW?V@[IH`\J3=&T;;Y%2[(^G:KRRJ[<(*Z\L]J^R@XCFK$+^K1F(Z%5
M6LKZWJ$T':.\75D/R@VXD`M5<`=[4-QZD`=N,`6,\`U6$`4_\`-CX`/J/0I6
M``5WP)IV_P`%>)`'>Z`&)Q\%46`%;Q`'GG`'5F`'3R`%92`%NS`'1+^G'>\&
M>!`'I)`/;M`#C.`1+9,,3T`$QI`'?"L%2A`*NB`%>C#T%+`+H_`&1I`$ITL!
MTU`*\MT%G2`%3M`*Y!`'3$`%<7`%K3`'R0`+0V`$4-`#1W`*D4`'+C`%3<#,
MW2`%1C`%$KX%U'`)UL#CZURKM0H-E/J\E'H-]SD-WE`/YNJI?\ZIWL`-2\X-
MMFJ=6/Z_E(KEV"D-NP`-NZ`-QA`-UR"?6ES%M>OD*ZP.TE#LU?D-UZ`-JU^=
M[.`-^LL.0'W9/$OM[3N_"1VJ-`O4-7O2]4BO(=JP\VO`H&[#E?_ZL>'ZK!A+
MKVFNKB?[K3G;L+PJKE4,V0E;M>%*QN]`VYZ?OOO[SL9OO[K[J0#<UMY`YK3M
MK@`!CYTZ;]Z^%?P&SAL\>.KBJ:N7[EN]=>K8P3L(#]RW;^H8UE,7$F3'ANHZ
MAGR8[9NV;-D(#@QI45VY;P+CM8M9DF,V;]FTA40',MXWB>E`8A2(KB9$@?"\
M&:T'+YU%>/>^O7O';=TZ>%NYLKO'[MV]>O>&LHN7+AY->/'6331;MJI3>'+3
M,?08-5Y4LVF_E6,8CR&\=^7NW2MY,1YBC]_BI1U\^-Z\=?5&KKL6[UU;D!XA
M%VS8%F]@AAV-FJVZV>34=O4>UZ,WMNS_8<OW])'55R\?/GWT]/T&CH\W/GJ\
MN]UJ5:7*GCU4WNSY%"N9*#M1HN2Y8X7"*5MT>HUZ8P6*GE-/[J2J0J7*FU.F
M;/&Z\>1-G#=Z[IC:9>J-ESME](!_8PYW]N@!%.`.1#!!!16DI@8<C/'BB2>D
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M1M[808TF%G%ZCE'LJ.$)3YJP!15/3/'A!AVJ$(4.7NCPY(X;JM`C#EBV82,)
M*:0X)992O)C"BBKPN`,/4>[)(PA&],EG0=EG!RZ9'8@@AQ$CP`##B"ETZ`26
M2(@Q9H@EEIA"B1R,F..)!JZX8I=50/$C%[WA<(25,,*`H`$PRM#!##"X(&+[
M;N280Q$OC.#BB$ZZ>**3=5I)IQMM%,I&FFBXN8N@D)S*!CRZ@8W!J.,:WD"&
M,;`Q#6A48QC(>(4PC!&-7<!"&])(1BYVL8O_!A)#&MO0F3KLEXY:#85_:=*&
M-J)1#750`V4M\08S[B*F`];/).I05#V"YD*CQ",W-[M'.OB'LGNH@RQW64<W
M=&:8=82%'5-)!V#JHBQ?03&*Z>#*/8)6E;+\9E26*8=6#C477AWF-NR("%>X
M(99ZZ,.']WB'44K5QG4(YAM8`HQ'XAB1F!Q$'9[Z%JY&AJK!I"4>[4I'N[B!
M*W)()1WC8(=6#O-$--+$&X(ABUO@@2JBL*-=H:')0V`VC1M^RR(D$T@]T$$.
M=K1C'I_T!DX<XDE"40MH:(RB1Y12J-`8<I/S0%E4[B)%(M*F+$TLX\_HT124
ML:,<@AG,$RU#K+K,_P.8:JG)1<A2#G0\4367M&%5//FQ2PG$((X9%C7TT9#'
M$`5E=RE79U8CDD.:I"8-V8A3=H*HL,EK:AR!S%TJ)IC:H#&(6*2($+$XMG)T
M`XOT:&-N]/$.R_QF'UNQA]=:884[W"$*5;@#+W3Q!#+4@!7WTX0;7#$*)M3`
M#D#H@15^T`LG5,<./TC%'7[`@Q[LX09.B$,I&'&)=$0#%3HHW3=V0;<]T,$^
MC+B'&EX0A]O0SJH*(H8-B#"-3APA%%TPPAAJ``I'M&&D/#C"$WC0@"_LXCVD
M2$(2N.`'6(#A"U\PPBE(L84>$,$)TC"%*#Q1`QE,P0A&2((CFG$%8U!!0O\Q
M*,,;G@`&:Y!"B!N$QMB\$:F:7:24U8A&0;#1P$_"+)BU4M0WQ.$3:O2D:KA(
MQ@>+H0MI\$1LY:@C.<JA#Q&"=AII(@9+T,$_>$0#(BCK1C)8F`YMN#`M$-7'
M.MYAT$=-$RV(:6)9KLB5=5J#'+:AZ%[*00[IWJ.)(4R'E=*!E764@R)AL8Q8
M)$,FADBRC16=S1$M0XZ,4=2]PWK46,+8D&X@IL!!J\=TZP<3!N_K*>5HAWN5
M8C24K<,;U-"7`0O"#6[PI2LD9`<YZ$$6<HRK+J.:QX>98:DH8N0::L15-^S9
M+HNDV!ZH:@=93ODH:@P&)(52AYC@H124/=,O(#'_F3?:>\QTT&,=^C!,5!),
MT=S`D2M;F>24(1J6=;2C'0]!,CN[`IMCQA&>BXF*1:#"CA!ZHRS>P,<\"@4.
ME1`$'BZI!C;L:9BNN24D\A+(,[EAD-)<+22KZL;8L(@.<(!#&GRZ(#B:"RBP
MO,.A\-A&19^,&+G,-[_WS<VH>#4/?#249.6U37',JP][W",9MP#'$Z"P'"^<
MH@YJC0(/7.&$-^3A!S_@@RU.H88&/($&.OB!#IY0"CC0``A`H,$3;!"%.?`"
M%59(0ASF@`57Z.`..J!"*5PA!3VHX0Y4.(4]\A`%4ES5W0B*AH.FT;M02.$)
M24`"-$@!"U%`P`A;(,(4_TCQ#5"$`0[)V`4.N-"$(TC!"$J80A*4H`0;'&$=
MI)#"%9XA#37L@`D.AX`NX."*./S`!CSP0AQT`(9UO"(9RN5&-N[!C=6VY&8A
MJ08QVL3A(-;$U8,8!#E<LPU"9"$9ZXA&*RZ!#7"\XA9P:T4RCG,):W`C%VS0
M@I1>\0IBE&,<N"!(-NHQ#4)8`E&NB,4M;C&,>AP#$I;H!J!?T8@><Z,8'7Z'
M,-KQSG6.HRO&VBU$*T.;*VU%Z&)A,T;0&`\GNQ$U(Q/B.KAQF*9$I3*62187
M>?8-)_.%-K:)J(C-R/@FHC$WRBK,OMBQ3$IIK#6;-:)`"D64J*##*(D?3%NB
MV/\-'WJR:F([_5C6X??3U..)B"',.@^3+,L\A2@>N4<WKO'.=-CI5NMRY6PB
MTHXX&S^ZDQ^,L[Y5KFU<,HBYK\NCVE)'$M-&++W2ASML<P][;$;*TO5F@L>Q
MWGI\=Y-"%"&&<*A2N3VY8+.H8`@AJHH1.YC%Z`USX(MVR@NU:*ATV(B(X`9W
MR)21(`JMB(=NB(B&^`92.J2:``=JX(8JH09DL)[:HA..T**U"!JMJ(=K2"@V
M,R2WH(@GJXVH``Z*6*?L`@ZR2+`RN3QX2)M[`(=DL`4JN(,I:((NX`4G<*HH
M>`))T(544(-?LP,:$(5OL(5E<`17R(,XB`,F=`,GF(7_1X"%5LBY"D`#,G@"
M)QB%_""",MB#,L@#<*`"**@/-YB#?N`#/HB$=WNWV.F&.^B$::`"*<"#))@"
M+I@@..B"(^""$-F":!"%+N`",P@#,,@%1NB"2`P#+I`"3X"X(9"#6(`%'`B#
M+?@#.,"%4]B!B?N#+NB$5:@&L$J"E4L"W'D%J`F)=GBRAC@7;\"&:&`30'&,
MO;`P>+B$`\@"#"``9K@%`IB`#QB`2X`'!P``9)`&`1B`8/!&3>"&`A@`:["$
M`M"`#'B`5R`'`OB`>Q`$#5`':?@&8GB`##"`#A`&!S@`!RB`+(`$!)@`!W``
M9N"&$T``@;R%36"`=2@&!="`_ZW`A[)8%JGH&2RJC+1HJ'>@!R62#.V2BK#@
MAFV`A_I+"ZJI"27*KFDBBU;"(OBJ%(O!2!^DC=MC(]-+L%@ABWF0E8Z8OHA0
MB[IXAQ+3F2:2B8L@"F\8!VH`R7<XB<.(HZ;AAH[@!F9(RN^[/(I:%LJKH[H`
M"RWJBKU@F<'0&3-S#$"!%W4H#&+$!N/[B!K<.TP"B9:(!K>8/(<H!ZDD)=>X
M&`LS";%X*%1IHMP8O%C!BM^P,CB"*./SKS:2"L@(-#HZP/FB"9I)"Z'C"WQX
M&5Q@!CA*"UVP!<](03C:AF:(!W#8!6O8I&V8O&M(!L<@AG=8"Q(:KYGAAKP$
MATCYKO]N8(9QP(;86A1XB!J+F<$P2K1NV(9E8(9MV`9RF(;V6J\P6H??L@8,
MFXJ+("$B3+#;@*[>0"ZH`;U[H(9;L(0GJ!LJ2`5?VX$?V`%7D`8XJ``Z,!T@
M"((?H``^<(=+:`5&0(5CP((YL`5&<(1+B`9=L((HN($HN(,G<`,=8(1N,(4<
M>((;J`$ZD`4IH((]P`-&L`>I>AU#?+=D^($A6`91:``\P`,HC(4KH`(><`$=
M2`(<>`5HF(*4^X).Z(1$T(=H\`0>>((OZ`(K4`(I,`9]L!T\`(,N>`,B.()J
M2(08V((8P('=8015D((I``,IT($MN(9(*!..J`8L(1E<`1C_<:B(@^BF]*L,
M?3B`$]"'8Q@!7-"`#:`'>C"!`#B&#!"`18"$`4``:9@``5B#5QB``^"&!YC'
M>\``"5@'!!"`6S@$#2B'*<F"`E@'82B!%1.$`Q@O!,B","$`%="%`"@&?>B`
M%-`$!*`&!_@`8LRB7LD\LR0S-WHF`&NCD5RG5!H5BJJ+08,'2HN5NA"(*DN'
M>2B+$4LE8_4--@,]P1A+Q)`,LP`]HRP+$"(($JH?4[D-L^F_PSL*J>`?=+`&
M;W@'*+N981F(!#O7BXB*K(C6_'I3HJ0HA(J(46$SH_@(ZAO!/FF)0UL(R;N'
M<?`[R[`(RV@Q55D(<+&(,+J+$$,B_]PRRW4`AZXPFW;H,/,B!WN(B.FJ!X\M
MBYB1#'U0UEBQ#(HR!U/)I&YXIKF0"ZS`(M_+BP1D!NM\IFV8``1@Q[^0`&Q$
M`*D+R'2XA`#H@'X@`"?0!T@0`#:`!T(@``)`@$BXAS60@*Z0`$S0I$$H``(`
M`6E0`0*0``E`@&&XQ@=X`%TH(A,H@`,H@65``1"(AU9``&[D'ZP@PL4HV6'!
MBF&1O7=B3L`@H;+(!WO(!SC"V+7@,-Z;N6$8*3S\`2`@@RAPA5-HA6G0`9B"
M`NO0`37(`QUP@2>8@U,HA3R8`VN`!3DXA5/@`VBC@3R($#NX`R_@`2EP`G=@
M!%-`A2?XJ/\IB(,\*(-2B`<U"`)1(-$2I8$:F`80(8)8&`4(``,E8`4N@`(C
MC8-O\`(O`(,MV()2"`582`=EJ(=>>(1YT`=8<`0.,X=HB`-/`(,CF`(F!05I
M0*H>X`(WT(,M"(4(4(504((8"(-U6`1RN`8Z.S1V4,9$F1BCD(BYC(ID((!-
ML(9DT(=SI(1YL`9?$`!A^(`)$($0"`$'Z-,)``$V.$AA*(!&T#E)&(!7T``1
MT``V*(%[8"%Q<``!>(!:D+%!0(`*/H!@_(80F(`TD(!WX#Y]T(0"F(`!2%5E
MH92RH(B]<`U]P(?!*XN&,H@G&B]@RI_ZN89I*%/-VBQ$<9B/T+'_JC@O?#`F
M4S$,DK&-VWBOVN@-P]`8<Z`\,THEOX4HB*J_W#BQM.@?.UJ6RAB8MBB,>&6]
M)I(5C-!;T.L560&OL?C64:E6DKF9B^RAK1$((;*238:'V&`6-!*G$TLP5(F(
M#!NBNZ`H+<(B$MH&BEJRQXA8@=@*X1N'L6@UB!(ZE"69<J&RDD$F1]+;H4"^
M67X(9X$(LV"*5+Z'#I"`>]B$`&`&%4"`;;`'#9B`82```9"&$P"`#E`&`2B`
M82A42-`%`3B$>6`#`7B%$@"`1L"'`9@$?4"'<&Z$;C@`1&`&2"``$[`$95B`
M0+`&+1@`:F!;9;`$=D8!#0"'`3"!*F/,_ZJ:/_DCPO1CM1&C!V`>,"%ZH_F[
MAWPHC.6CAKCKAF*PA1_0`S>X@1Z`*6C0@6&P`C3X`2N8@F-CA?98!SGX-2M@
M!%>(`CN@@CEP!2;H@1M0`VZ8Q5+8`1X8`_%0`T_0!0K@!2:`@L;YA%$P`SB(
M!SZX@78[WJL:!AJ0`G*0+"+X`EFP`C,P@RW@@A[(@2TX!5;8`CS@@BZ(`U#(
M`T9@AGDPAV6H!%50!4L0AF1)!U!@!%+`@\_A`C!0A%V8@R(@`B;P!"DP`RB]
MAB9X:S&P!D9H!V\`!XBH!T2).8]HAY)10&5I!P(>:0)8@PHF@6V0``[XC4`(
M@&W`@$;@64N0`/]F<`!(<(`':`0%Z`<$T(*Z8(,#8(8'&`800``5F(?/%@9A
M.(83"(!E4(<5<("U((!7:(L.&`%#0("LJ05EN`4`6`01<`#S*A?0V\$\8HAK
MP(9K6,'DXKUE&)MM*(=KV`;A1)/?(H=MF`9DD)=HL`9HP(:J^2-LP`9Q:#)8
M7I8N2K`ETE>((L;NO(C$^PU[V+3YFX=&PC\VPS+SHLDGBH=(P1F!`"&0,(BA
M&;P10XR+E`J=T8R^A&-*5CXTNC^SF5;O(Q6!$`ZLD*):(0BEV!>=.2/M:H?>
M^*)8<;*T>(HXDF)T,"_VT@<T,INX<*,O2M>@@2,ZQ@J>_#SO\R$_OKS_Q:#,
M]$O<B"CD_[$]1U&+#XR'`X"$M?"A!""$F;.$%GZ``H`$#6#'8#B``G"$"9B`
M0C`$!="'=K@&`6B$+#@`"1"&`["$>4`&<\B``@@!2+#F=R"`2]`'04B`>JB&
MAB8$$&@#??B&9=`'(7Z`#F`6='B()WHD%T('='!9^9H-K*B-K4BQ786C=-@[
M7Z=DE9&(:!`&4J`!/?`UMU8$74`%6R!J()@04NB&77"#+I@#?7`"6?L!)F`"
M*P""*-AI"OB&1<`;8AB'.8@0>RL"8F"$I=(!'EB"_X""4K@'*Z"!$?UJV;$-
M7:"!)+"&-^"!*9"")I`&.H"!H!H1P;H;+^`"_SSH`CQH!0%RA":0@1F8@09P
M`1A``C\PAGJ`!NSHTB[8WCA@!2_`@2,H!2F(@5#(!238`BD0@S`8!T<X!W)8
ME&PXDVAJC3.FAFJP!F1`!H(E!#D'@0`PAT@0@$&X!`'0@F\X@%8-@$Q@@&,P
M@$9X@`'8!`$X!T'@\TH0@$#@!SXM;PY8!VCX!A,P@&T8!`:XA:IE``[3@`,8
M!J:%A'%@;5L8@!1HA`&@AVT@`$)@ELF\ANQ$AFI`06^8OJJPDB*"XJZ@*(J@
M!\J@8I!L<LL\"=&X(W9`A_9ZAW'`+=N#3'S(B@V?R;#P3NVK#=M(3*HDA]3^
MY"[2F-KH'\!8Y+:!L/]]B:/+NX?)OQ)9=3)Y<0>\?>39X,%3XQ_I`E>#,9M3
MJC3)"XR&'302/S$W[K^MP'%2D2;B6B28X9E\-2]K@&*-8995MN(JBRCIBAV*
M$.6R\%A'-B_+`*8@\HB[X.0J289H&&EF4"YMP(8_`0AOS)(EX\8MVK)DU+@5
M6'2OV[![$];`N\=HP*L'(B90`!%"%X80$T1D$63(@KYV[`P<ZJ#BQ(0"ENJU
MXS=LD(8!:^S=&D!H'2$$]]*E*X#H`IMZT;RU,S%`A(16ZKQEJV8M'3ENTZYQ
M\]8MVKA[[,J-6U?O[#I][][5TW>OK;ZX]=YA-7M/[=U[;^^54W8*R!,K0.S_
MS.DFR0>/*&2F-+&5JTN5.'F>.#+VZDF5**.DX,$318>G7:28W,G3Y8LK:5N\
M5+'C(X^I>&[R6(ER9XJ3>*CXK(KK^S?PX,)]WQT&9`JY/%"@2%'"2H>-'*5D
MN5BU:\F4)U[R>/ETL(@.&2Y<&*$"P04,&S@>+9/D!0^8)TV4A$EFQ8BV,$(@
M*&*$0TES88SC2#O6?/,--M[4<X\Z\+3CC8/KB)7.0NO`<Q8[];BCB003"!//
M-Z]\,`$ATFBS!B:0!%*,(,RH<`DE@O23`C#EK/'``XB<,TX*S.@S""+M5%,-
M-B<X\``AZ=1C20?I=+.-D21:4P^'$H`PCB8="$-._R,3W$(.-<Q@TXTWZ5P3
M3SWPI"/A/?:L\\U4:<)SX3WPT&7..OC<@\\[ZZP3#YKO<`,/A';JE0X[[;0U
M%SSLS%-.,M&0D]4ZB-YCUEEQZ>5G6Q+ZN=8]?69Z3SQZU4G/HFC6R=:<2K*C
MIJIBT4,..V72@VH]I=;##CH7XD-/.N5D6$\^BRZ*CUOZV%F/G_.D\]8[R:XS
MSZQS,CM/FNI8J*8W"I[UC9)G;<I6J._D0^H]])2SSCMPI@//.MRL>19=[^BE
M:#D*IA//L_HL2`^H=S'[3CSZX+E.-TJ::DY>9@E;SE4'71/I-]-@0Q0\():3
M*\?P?D,H.FBF@TXWW<!C@O\#U!P2P#!9''!+-`]H<$L!D`@@`DRW7)`)`&R8
MX$<F`D!2CR,`O(*!">5,`$`K<2ES@"[W2"!!/,L,`,D]MPB@23V1#'","`^,
MT\H`K:C@@#XG%%".LNS<I<\\L;Y%CUMG(4O--5<![*]><?V:#SWVV)-./P77
M0^W;?`G#2P,_G$)'!7DXH<8-/=!@1PV%9:9&%9WDP40W^T33A1%@M,(($SZT
M4HX]3NR1QQUWV/'&-I'$4(8--_"`!QR3O:''$U!XLLX;49`R'/+)`Y?,'F",
M8\<31N2`PQVH4&'#%[F\@$0SI:CQQ!UN?`)-)#+D8,L=/#`!BS56)"&%+%5$
M\(7_-G%(`0;I8+P"RPLX)$/$&<(0BBD080E'H`\S2%&K740#'O.8!SRNH0YU
MI.-6#J+5G)3E+W+4R5_\(L92Z&(/=42#*&_Y1ITJ110E$24?[CA'.[!1D&Y4
MPT)A80>BQK&,@51#'752!S?N<8UN("@7;E,2-X05#5P08QC6P%5;\.0ONV!J
M'>4@2C72D42MH(,<Z2C0-M9A#:Y4`QK6H$8YN%$-=&0#&]4X$+_J@0][A(H<
M?JJ(G]8!#6]@(QK5,%E%YK*@@;F-7G-YASUN]0ZZB8LM\^"&A.A!I[4,4EQH
M*D<\UO$J<JCC&NT0HY+TL:ZS6(H=['A'HUZU-]_L@VYQ_V&+H.9QRG=@2U-N
M*0<ZY)(.MJ!#D^SP4[[J(<E`UNDM:(D'N1;$)GB(PY2*XE0AQS$XMU!#DQ<Z
M"ZHTB4QZF(,>>JG'QO)AL$2:PUBZX@97O#'$:$1#'>TX1X;F<:E*2>A"^3!7
ML<QBKWEH$E-LJ<8]MA&"#A$"'MQP``(.@`%F*$,!MU@`)%2P@6!LP!H,P$0*
M_I$/%`Q@`@\(A#Y&L`)]7"(`F^B&,L:Q@0$DE!+Z&`<!N)8.0@C@`0580SFV
M(8$#/``#];B1/K@A@#6\E)%*LHM;Z#(W?>Q#'_CXU3S&T0UFH)`X;7$'LN[Q
M#6YTXUS$NL<\]E&-6Y#B!U#8`?\X:O"#-]"A$V3H@Q5\H!L[T(8*I[!%'DC1
M#W[8(Q+)$*<IHO$.<@S#$Z'@`Q6H,(8Q,"(;/O#"$\C0G3@\P079J$(5:L"(
M>SSA!<=3'FB'DXP:%($;5OC!%)K#A5+$(`E&*(<H9,">9.3"?KS@10P@$`=7
MX*$7TNA&,;JQ"T8\`A0[@,`C>'&'+83"$MV`QA%R``M3Q(`(5Y"%$I*0!"70
MIQR1((<Q=N&-1)E#)::L(#O(T0YT@#64IN*+-;C!C#!Z@UWO8$:WID$-;ZC#
ME(1JAS:RT0TOQNL=['"G"M.Q#&I<A1S>6",NU^$-9#!#7MZPQANI(8TE&N,8
MQK"&LY3_!`]U6.,8T[#067K%EG6,8QOD*`<YML&,:M1W759<RSJ\"<$_Y6HH
M6HP'F;I5C6APXQO4H+$IL34MN.3#A*VZAIFZP0UL*NM";C'FX30U#TV)BY0+
M,F:\L#4P>#V+*-^0I3CJD8VY7!$>:JED1:!U(710"WE[8@<],F2G"F)K3_I`
MU2CK\2Q-3J@;Y:`EHK*BCTA^BED+8LNAIU@IMA!EP)5JBYTXB(]K%/(NQ6)6
M-O7DU'K8HT\5<5OBP&F.<E"C+(?+V!4O19-OS@62U$`'#A>I+J),BQS6F'2.
MM?B-@LU7'^!Z1S&&<>-UD(,>F=2O$\EQ#6P4`RS*N,4X6AD._VN0@QG=.,8P
MW(')9%S"'?%05T*0D0QZ!`,2R7C(.\IQB5OPBQK"J.`MA"'C:XS#3%@A1Z`$
M#1??X`,NI+)CO*/EEE_YJRVD&H<=E=4.?50#%Z:(0A2>P`A3.,$+72B%$6[P
MA%'4]@YQP,,=2J$*42P"GK`@Q1S@P`A2P((9]X@$*T`1BC=0079S@,9FDN"#
M3[C!$TGP!#&,4(;2T$,-/7!$:*,.'%U4@`C<N,,3CB"%K*NB$V4P`C1,D0,9
M0&`:D9`"*^)1A!QX@A5=2`4H%)&+::PB$:S8`AA2D00(X,(59=B"-4@!`QD<
M`1ISD`(7.J&(_W"7/MU@!+4/-*=U4/^P6^P81WW?G(Y:W@4>VS`(/>Y9CDO%
MHQPT[!8U2!B-:0Q)&]J(1C>0,8V2?04;T]@7J?SEXB%'0QO=4I.:R)0-8T2#
M&L,@QI"^(49D7&,=[=`+P8+O1V9$@QDGWL:ZN,$60>^+)FT19S[L<:YOVJO4
MI>*7A<KT*CUKLDSM*(>W^R1+.7T9+O1H,1H71;"\(+)O;[NR6\#+@@B@/V&(
MF]7#QS3(O.!:AER:_[W%-:F%O0B2/N0#/A1+<!2<./E+HYB%WZ!*HBA3AJS8
MG_V2GXR#H*3%+UU((;F%%86*PP',(L&-]IU%G*&*7%Q1P[E%)C'+I>"#!X(3
MZQ@+C*6#-<3_0S?%VQ0ADCWHRCBLEQ>1PS)\'C4@1#3(WC0H`X-]WE9,PS18
MPS04PS$L!(8=630<@Y-0P[[`P\>02J5<R`1U@S400R[0H3,T`S><`S_0!84P
M0U84#,$`"C4D@QB6@WZEPSB0FI297O5M0S1L`S*,PS1PPSR\`Y3-Q2E-VEN4
M18R1`[+XS2<"!U^00SWL@QSYB\)5H+3ETC[L`S6T0BL`P6(9`2/P@@OPP"A@
MP0_D02[`P1N`@11XP7N`0N&`@@[0`#*^0#+>@"BXPSHH0B=X`AYTP1V\P1>P
M`M;!02H\00WPPBKH0!7<011X@C[@#B-('3KJ@R[00!+$@QI`@1),_X$5$`$H
M?`(%Z``K=(,:U,`02($TP`%9P0`M@,(5<,$K4,,TM`,^+$,WR,(>$`$8S((4
MB($XP`$IE`(.Z``1^,(N<$$."`$KA`$13($2'%`8K`,I/!^<H`6A=$LT8$-%
M))(,M@403L,V.-R?T8T[L(60'5DW3"(WQ$-79&+(I(,Z?(,V0`,T2%LR&!H\
MT!$;94,V0`,VO$,8O4H?Y4(V$`,L^)ZUX$,[M,/L15\W2(,T_%$U$`0E2IK`
MB%A_30J,J0.N61$YH"$Z?<,UK-Y4=8,$98/A+(I:Q`4]_$EZO9A\J8J_T,U=
M.`LZ]1LX,9*?E-KW"0RTQ!L$,<NZB`6A0?^@*/%7@ZB##:*#-[Q%AH#5WH"F
M6M"17!0,/K3B)X9BCH6?,662O:2+LE"2OSS+(F'*P!P.NUC+;YJ%FYE*6T3:
M6]C#Z+D)L"R(OYP2!*9+;1H364@(!RT(/LB3J/Q2.R`#.<S)+[G2_S5*D5G%
M-50#-XS#6#C?G+`@O!B3O\C3>*$%)JWG%Y'#-'C1'PU#64K#-V21A1R864J#
M.G0#B$P5.'2#,-R"0CQ+190*F$@#-.1"-=P:&S9*-9@E.`Q)\@5E.:@#!\[%
ME:5:/-`1]%G1M$R+/,B#4X7BJ/4)VS@5<%@@.V!#6N@#0;@"#P!!%/3`&^0!
M#=P`$Y3#$^A`.WC_PA1XP1MP#AV80C9,P8_2P`N\`!Y`090&P0WX`#BXPAN\
M@3A6`<]U@Q44`3A0P0V\0![$P0V\P1A$!CUX00^<8SI&G2[P(S>\P1-,P?L@
M'B]000R`0B2<@A7PP!"L`BS8PA/$P'MT02C`03/D@Z.^`S\(PQPP01C,00U`
M@"\T`B_`@0X4@2(4%Q4H@1G@07,HP1*(@12$`3DL0CET:)K,&J%$P^B1VEO,
MRZ[$"RG&1;$@RNAQ`SGT'CK`WJYD#*F`T[`U2L8T2*O4@QTE##,@0U7T2EEV
M`R[@`C1HPS4(6EFL0U[VT(CY"1&992Y00SPT2*C@4%CVEZ"]B>D]6#9P_T6+
M80,V7(,G?=$VM(.O846+?<.&88,A0D,_V`D_?5F;Y$.-"I/IT9"A">9=W$I<
MF,.O;0,*75(]_5FTQ-DZ]-)>9-(ZG`LI@MF%K,FS>)->7%/!`:`+MH6YY$4%
M.E6-`L=3\4V5/=J?20@V,><(VJP781(XS8M:Y)AM^M^L_(E>D$.\'5K/$M&<
M*$C#/EJIA4H%`LJ5L8EO],GGC=>T-&>%V@E74<-"E(,X-(H/S@VB/)]**!.G
M_(N?5*".O:I;V$./;0I7;<,XP%@UY*4VG"7NQ0,\Q%X\1,.&J9&&@8,T9.C=
M=D4W@`-H3@6]FEXR5`.@U(,/I<DN#9N@=06A*?]FP]4HJ6P@$$Y*K@Y'/L"8
M=5ZGIA2<H#T?1)@":B'&#?1"'MQ`#<0"'31`'M!#*SC!EN9!*^A"$+S`*,B"
M&WB!)&"#*[C!&XS"*;P`$'A#*[R!E_Y`*P1>`V#!+MP`$(C"+OR`#51!\#""
M/83"*$!=G(96,;Q!)\S#*$!!:BD!$<`!++@6(TC"*I1"$N``#L1",MP`##0!
M+[0"-*C)()!#/C@"&E;#*+!")[P`<K&#%^"`$2#!+SQ"*VR!$)@!+1"!$4S!
MJ=+'.:S"@?C0L+P),\SJ@HC34*P#-BB*P/A&G@`+,WB;9Z+#H)4*J4A2.GA#
M-&0#X+YK5TQ#%XVF%H'_)3L1PROHPH0>B%3*(3O\V3<$*S$@PS)<15CLZC8L
MA,"@2CMDPS0@`S)L0S:4B<C:<)K,`_C]QJYH"L!(;CP<&!!]@SU,RA<2A3"9
M4K(HX:*QPWW>GEST#;+0PR`&I9Q9$ELDU9K$&2+9RZ+-2UZD29^D"QW=DZDD
MBV^,K;]LC`TC2Q2Q*%-ABJ8DCK_P8!..2[C<YI1PJSQ-LEYXDQS-`XDR9V*J
MRP9MK3>@R;D\2ZCLA0M&Y^&8"CDT0ZNRRUP$H2-SPWX9A+QD<88P;)Z1@WDN
MPY#EYQD9L^QMPS5(,3=\WA^!2"U#D@"F0\$U[#<00S*HPY"<I4'T0S)<Q;M0
M_RZIE&4NH',.7PI>^A$V@,N%D)F3<%4R8,7II</=^IHZD$.+]4E9:,HZV`,E
MHX4U9(@K^<8&WH-Z.=7_E2)3<=HW+(,H\,`49!P0W$$3_"@I@(,._(`;&$,R
MY$$2N`$X_``$E,$L?-PLJ(,E$`-7>L$HO`$-4$$W>`(4?`(L)(,D1,$/5`,I
MT`#V,,(-_`!F]<`<V$,7\,!GE:_R"$,5A,$T0*\20`$]X@(7+$$,1$(NN,$7
M3,$4[$`CV`)Z:$'=30,]2((,@($J#,$@6$,W;($BY$$#R(`?^`(.+,$3)$$B
M+`)T$0%>?X(2&`$7',%5EX,C[(NNG$4]J.''9-"G9?_L-'S9EH7R7;##-?"L
MFF4#!>7*%1D$,OA1I5@#]1U8MUS,O,;>,4BB#$T#-#!#.B`#HK@9.0C#,`S#
M:4<#.'C#-\0P.-/#)QJ40FR#-A/T)WUQ+>L#+L?%M.19GIF2@241NZR)&(V8
M.F3#QU054VV*67"#.&1#.[#*.&Q9WUQ>BP'<8,+HK3B+-7";,I&:69237LQ#
M?>F%FPR6=M>?(+F-`_G37;#)]S'*-]VP(KOL_\'HKU@3*I(:QSSL@IN*M4@V
M'EG*7KSJGCP5<WY3W93*E4FNE"5,QM!1(;]%6H0*W%X*<8ZA#B:+_UW>YWU*
MG@E3FBS:H5G#-ES%-2P#Q+7_@Q:APQ7MRV"NQ6XRBQ5]'JNE`^N9B!M%PY^(
MK!IM@SS-":!T0[Y9S$)DS(5X0ZO"B<AT0YA,`R[L%W^=!3*E0S0D`S+<+0N!
M9I'A;%N@R9S$6UU>TZ@@R\G6[&837"7W"8R"HF*N@S3<@BGH`/L^`0]0@2M`
M00]HP3#`P0T$@2=T@^O8`A\$02?\0A=TP2Y$@B5<82*4`AX8@2OD01#0P2Z8
MQC7,`0VLU3>XP0^4P?$"01)$015(]3W$00WT!E4KSYS&P#+0@124P124P2@$
M3PZ$POP2`Q/DP!28@CZXP@M003JL0BB(`]R@PJ4^`K*D0QPH`B^\00-<P3Y(
M0Q4D_P$1?($ZN,%H/($8X$$GC*0P@@$Y.$*:M*&;O8E;/%_?;-"OM:@M#<55
MU(D-=[?;I%$Y]&W"U$-0ZD.Y/I\ZF+$PT8-Y'L,YZ!<:B=)<'$,U'-H[5(,N
MX$(R2`,Q;(O%8IB948.)?</GJ9?*YMB(5<,VO(OI>5M\89Z0"_FLV!B/3]4U
M2.@U\!<W])>#:THB61&]-HK,>C(2IH,Y1,O)_A^W9G9<E*:FH!*G!."CX63=
MH&*T'-);?#*?GXN%2#QI?]GIPFRRZ(E8?+B$/*UDZHJH5`0JT4FVX.2TI,,&
MRBST_1DY7%FII!^XO,N(-C(K?[*]Z.9Y=D.T)+@XV<,Y%/_AR_YQ:PY%]IT1
MC&W?7-!:15Q3!75*$]<-JA23J?#++JD#-=R"+=C"XP+<76S5D$`^WX*+,9.Y
M&H;+R!P$F0?9-$A#5?Q1R31(KC1()A&%O.P?)4,?@/,+-Y0^32KFIYW#P!%'
M7,R#.?QYP]Y*/4C#,;!NKD/!#5B!)_A`$+Q!,MC"#Z#!#92"*\!!-5!`'O3"
M$_@`'A"#.YA#/O"#.VP#0$CBL>34GAW0/)EJU>/,CV3%Z-`P4LH'D"E/GD")
M<^^.#4;Z0(84.9)D29#X]!&KH<.;%RA5I'BQ]:1,E2^M5MDR`F6*HGRV)+;2
M!BM:,W-S:MAH$B[8+5*Q>*F9<67_GS0=2I:`&8>%51<H1/"<.J*$RQ0PUU:M
M2P>/[;UR[>I]4P=/7[UU(-]1:W?O)#V1[-:AJU=/7S!!BW#I>R5L&Z1#E^Y:
MT[1NW:UFD-H)>\6M&29EQ6[5<GRK'#=<;+:9R[1M&BYCE:3=2S9,+2YT\`:3
MZR9-VJYN\_CZU;<N&[9T:M]QL^:-6[5HWKS1VW=7']_JA`>/7`?O6W=KZLJE
M^WZ-W3V^YM?9NU[.V[5UA.D1KL[WW;MS[P;OTZ<?9#ERY>JAYYUXZ+GG'7O>
M>\<\D,[+IQ[SK.-K'';JL:>><>I1L!UV]$%)07KL*<>Z?*J;[T'J0,H')9#J
MV0L_\^*[_\>>^NXQ1\%[[**'POK\,N^==MZC\!YZB`P)'R+306D='-\+D,5[
MOHGGGK6:Y"O`(U.4\IYUN.'F/9%PK"N\<LQ9L2Y\\+D'GW(H"V^P]WPDS,:Z
MXI&K&FZR:<<Y=9CA9AIDTK&/&W7FF0<>MY9\,)YNJ.&F''7BV<::<GB#!IIN
MXLGGG7'2&;2;:OIT-)UJZKFS&VSH62<><L9)!I=HB`&'FW3N@4<=:J9)!IIJ
MIJ'F&F:J22:::!KM9LDA!;00)'/&F?50?>C!)Q_K\$(Q).OF.8>D-._IAAA7
M>*C"BA^@>$(25&BH8I4Y2+GA!C)Z<>J%&^YX@Y%(AMG''6B[)/\D#B_RN.$%
M5Z;9Y0X>:I`CDE;>"((51WZ(XHDJWN"!D77>H.$CDSCN6"1<;#"BFSRBJ$()
M)3SQ)(\DCF@%%C<8*6.*(2S)A087D&#%C5?.606'4GC1(9%;4&%"D3D:F"$1
M99P(]PA%VH`&C!RFD.*3.)2X2(DNP%EEP'H``VR>>G!CQ\PM%S02I'W(67([
MOE0HP9(/D''@!'TR&&00%?1Q9@1]A"%!DP>P@82%;K:Q(!AD`CEAC4(H*:>;
M+"9@`Y(.5EA&'T$^6.,2#22PQI`2LL%%&"\#K=4;:P*E)Q]^ZHG&F&6F66?`
M>`[-T)MTZ"D4'[LX7<97<MI9BTUN<+O_AQUVUCH41W+8(0>==NBRYSS\](%G
M'6^P69+$#D$2\)UU.`0_I.3\PQ$W>_*))YWJXGEOQNLBW+(>;BITQ\"ZMDSG
MP>K>$2ASX(@PYLG070I8$C2IPQP.D@^TV&>]^E3''@7B7X$@9+_Q_0\E:0J)
M788C#_!ML"YNX])@W%>.$A').K:+1SFJL9;]7$M&RID0M4B4)G6PHQO66(<%
M\9>H-X6'&;<PXC"8T8UA;(,9[7B%,=ZA#FO$PQK"<,<R-(,,;AA#%]TH(BYP
M,8UTB.<8[Q`1-;IH#5U\(QG'V$8RDJ$+7%`#'O&HSCJ&(0UH&,,:WRB'/;JA
MBUXA@VS?"-8K_VY1#76HB1M^[`8[N*.J>\0C'MSH!C>001=]D.@=(Y%<)\TG
MDGB8XUG4"HD\4)0/51(F&K@PQ0^J\(,;\(`)J/B!#:Q@C#KPP@<]N`$5[E&'
M%]"@%+)P13KB80I1Z(,9;.C&.VR!BE[0X`5OL(<;;O`#*T0C#K#PP@L4`0H=
M2.P);YB"*-R1!R"0HD0><Z=(2)2+'1B!&U5X@A>FP`4E=$(:^K1$(G(ABAPH
MX0C8B$<-&G"%4VS!%=6(AR6T!0MX6,,45.B$'EPP@U7HPPU&0$(1H.$%5GPA
M":%(Q1*(@!5]AJ$<D:C'6@ASCG5`KT/3D4]XM'<2,\GC03)Z!SDVA_\(380@
M"XLHP3D^<(E!"((OA*A$%B!1B"P(8A,L*,<X..`.9S1"!2M8@S#8P0TM:.`5
M'R"'(##QC@]L0Q`B>,4:!`&)$EB#&_&@!C4R925U#.N9X8$+M,HQ1;:,,1W=
M6,8RAF&-'(W1&N0@QS7&N(YQS-22PVK4-^JA2A+=8VSIV`:GW@>A+QEH'-NP
M%IKZPPQR8"=\:^$&,TQ+MAI%BI+Z:%N&)NFED`BH'N6`1XS&B)L,P6,>^+D1
M#7'421>:DB3U.!(DW\&AP6CO//*)!WX&,[XE<8A39!/)/$)9).&@R7[AB^Y+
MO\&\<G32>I2Q3F^'@;\226L^YJ"&B``82N+_O2<^G:16JK@4#7%<PQO&0($#
M#'$(3.B#!9,`!"92L`)(D(T0)E@!("CQ`4$THA(:R,()(&$!!W!U$R8(P1H0
M`8E(F$`$B]#'"2[QB@E43@0B*($F:@6(8@SB!(,@'^4V@(@0]%@3^C#!(>`!
MXW28`!>#^,`F;O$!$52"QR?0!1M,L(9AZ(/#^B!$""3Q#40P0Q^W.$$)`K')
M0PCC$/EH1B;X5Y>Z/.B!(G%2A^23CVL0@Q03BP*Y>&$%']B`"=*(A!-N8`<H
M.*$<:J`!#6PQ!T^L(QE?J($=DO`$4]1C#E8PQ:.!T`TG,$$-/MB")++!A'05
M,PIOJ,(=RN`)=_"!_PZ.>.>MKZ4/:=R!#N5X@\2XP(4S?,$67N`",1;!BB8D
M00K:F)0;7-")*;S!$XE083[X8XE'O$$*;TA"#+"!#&^X(0E%4(0H6J$(,;`"
M%$;0YQ&XL`4PM,,1O55'7=JVH.NBEA[6,%">':0/!`F\@)T$A`H@H0L15'@2
M'*C%!C`QI$UH8!"9"(&3(<$W>GB`'IA8`PE40(E7*.,6B]"`%M;`C$"\@AX?
M&(<*-,`,01RB'!_83G7&N(UN&+)XY"-'H$`RCU1-(QK'Z$<W1#3)22+=/(=*
M$X4>B*.U1*-XU-`BG+++H'I<HQCB$,>A>C>D\1&(,FA:$0$OB4S7U2IYZ_^@
MQCK400]DLH4[N)$A>N23)NS@R!OJ$(<Z>BN<$IT'0J#T2SQZRK%:.8@=.RS;
M.LK!(;[`P[_Z,&Z&$`\<TV)73=#"QSX\>&>U4>M$\.A4_"@?IG;NXQW)>)]?
MS+2/<FP#M]5Q1][)@8UV@,CRV8'?[%GWHGL`U1DET$<A2K")"TS"#X`8`288
MPPP-#&,<D!!$%BH!#$04XA88R`<E!*$/#DQB!(T81AK6X(1N"`,2Y`A!".QA
M"!+H(P1MT(0<J5$"0V3A%9#PXCU$P!#X(0&2(0LTH!LZ(`WB00,TX!8Z`!(H
M#A-4(`1J@1E8@!)J(1G6(!D.(03*H0,Z8!U4X!;_0N`02.`8].$0VN`6,D$_
M2.`2%N`2E"'-TH8O;(=CR$$_OH<OL&$83N$)[B`*["`/WF"6WH`7*``<U.D'
MNN`;[L$*@H`7JB$.;&&3.*H!:``<5.D4P(`;IND'X*$;WN`)C*`3N*$)9H*6
M\B`47(T.JL`3[H$*;B`2K!#7;LT6:L`(K$$-GD`*I*`+SHD4>N`(A*$;XH`'
ME$`2>,$1S,$J0@$/N*`+(D$<PF$=YN$:L*$4N,`(X(`5O,`/],$2(L$5HD`)
MQ,`72($1D.`(=D$*@NUDE``,SL$1B$1*K&$;($3@KF52$BA\T@2\,LN4!*'(
MAF$-XN$82``%SJ$?3J!+_]ZA!`H!$HH,$0!A!1KA$M)`!3[`XT[`$""A4[+@
M`1H!$E+@$!KA'$M@$#9A#4)@&^B!$.A*';XA&F*(Z*I!\+9D&:S!&O3A..C,
M&2LI/)J#6(1G'\7!&QQKIMZ!'IPG';XA4+2G'=2A>'AKLR@$'M#A&O:"?WRO
M'JSA'.H!O.HB/@8C2@@#-R#O4*P!&\3!/"*K';BA;<JC'__G)':$+BR1'<0A
M&@BC'W`A$A:!$"0!%[:AA.RG'A#OUFQG^++!4:(DLJ:%+NJC@/C"'MYG.\B&
M\LIA;'JJ\[Z'058D3:Q'3;9!>]!!+2AO@TCDA]"$3;#'+U`DL/SB>U0$3<1A
M'O^`1$T,Z$1*HQS<04'L[!WV01@\@,M*(!,R`!,&01E*K!'TH1@X`%J4005(
M(!`R@1!4``36X/A,@,$PX0(>$!%20`2ZX3@&8<;Z@1+20!]6X/UN01JX@01N
MP1),(`V"81OR(:[XP0+60`*V`1%.(`0L00NX:@7B`1)&0!,0(0-$X!9*(`1D
M\P380`*881-.X`2`X1]&(`0H`06VK!)`,,WT004P(00"`1(F`5J8Q$K((4)"
M21_<X4CX0Q^J(1=F8@SL:13VX`;&0`<D011L00[M@`E@01^L@`:L`!I.011<
M81D^#0AZ``R0H1E0H12&P=&LX!YR00K&X`G@@!CDH&C_@"`'0*$4JJ!DIF`.
M[D$-;,`5[-`.6X$&E(`<QK`*J.`*P&`6G*`,PF`?),$(9L8<?C`1TF$.("`,
M:,$+N@`4'"$2(H$1.B$,)H(5(``)U"$7;M0>L*`&I"`,H"$1IF`+0*$3N$`*
MD@`0O\`<(J%0V$(:,&A!$H4>R,%,S*>W<(A!+*\8`.1`[N$<S,$<]($7<*$;
MNJ%V*F1+UJ$?AB$9Z@&19J\9BN$8O.$=F*$0X($;+@$;7N$2B*$2HB$=;B$8
MTH$:F$,;H.$6^N&W^C$AX\>/*&D<S$$>0"]22H,>JT$PP`9'M@0=1!)'V"&`
MRJ$?N@,ZX&)!?F>F_D.!\%+P_T8"+Q\(*3O)03COWT#"&Z+A&I+#'=R''M9K
M'D3$O^KG@O@"AC34"1Y@``1``-!5`!Y`"W`!1[`D;3Q&@^!!!`C@$`@##@;@
M;L@&E+IR,``6``]@$RPO*BW/'72P]T1"!PD/'MAD22XI];(#/\KA&A:)1!QD
M;.H">5ADLTJH;59D+EED&[@!,&7D'KX'\M)A'#0A,@V!$O3A^09A#:C,!-SB
M!`2A$%2@$%`@$UZ!$%K!&3H@!><O`PC!`\9!'U+`$`9!$AHA!$0@&`QA!82,
M_@C!B,RC!-;@!&Y!`6YA+=*@$.AA`^YA#=9@!2X!`C6@'$Q``2`!$H*A!+I1
MX$(`$_^0:`7*80TT(0T.@1"R$1@J@0-4(!C>X1`@H1F4P2](@!)(H!DLP!"@
M!3Y*)!^L920"93!41-=TH15X``JB``K(H`KBX$#C@!K40!2H(`J"H`^8@1$>
M;12J0`VZ`1?D@`GNH16<P!74P0WH0!0>;0_Z@0IJ@`R@@!'@(!D<[0V\X!.B
MP`>J``J\P`WN80XTYD5QS15J0`FLX0W&`)^DP!.DH0ARH`C$(0\HP!*RX1G"
M8`_R8!72X0L@X`M``0P>)A=TP11<P1/`(`]@``*<`1E`H0R^8!6^P16>0`G:
M815L(`84(17\T!6E(`[6P1$HHTZHH7?^QT`L!.X^STC\0D#_KB-%"@CR4L4>
MKBM\IH$8,,4O7H221B7GDBLDV(%7<'$:.*4<%H4;B.$5=J4:J*$;7B$9ML,=
MW`$3[:(]NB$:<-B`V"$<L&$9D.DXU*%+AH$8],(:(.LLI^$6R$&36&2]9J0:
MC&$<_&TD6H3`1!+V3N*G0*DO\.Q-:^5&*`-.2B0=Y%&%N4$7=.$57H$9L,<N
M_*<7*2]R'T4=V*``!*``.D`+"&$-5$`$$$!=LZ`;UFZ]F*LDB`2$0````H%"
MV@``C,]VA"2#WD$PQL@='D``'),RY"-,2.1!%O(D.N2X[&*ZUJ$T$>\\+(\<
M%"OQM&XKZT(_,@LD[.&SPA(E7MF,_PSO'7;P'+;AO@:CF/6A',X!'PX+&<[A
M$`K!&EYA&;:A$`ZA&V[A$":!$J8!%F:7&8Y!$Y)!&)BA&2)E&(:A&M:`$-;/
M'MS!G2$!&1R#$%[A'C"5&BYA#5Z!&HQAAW$A&1R!&HZ!#2X!2BZA$H3A%@@A
M&1KAJS+A%F2D$I@6$BIA',H!$2#7'BAA$PPA!91A$E1`$"@:$`S!+PQ!&"`W
M$RH!6NY"\(AD/D>"<OGB>Y+A%5Q!!SKT1'7`%$J!!Q2A%19!&F3)!U!!'URA
M`6Z@%ZA`#5J!&MQ!&:#E&-SA%=1`#8#B!99)$FP`")(`&Q;!%*H@!TJ!<T'7
M"L;`"$S!'O\<;6.LMV-(!!=H@`BN(0ZF0`GDS188X25(`1L:H`FL`0X2@15&
M(0\6`1/@P0DHP`N(X`B$X!%\Q@B*0`IJ``>@H?JZH!-*@1&PH!?X``(`B@C*
M``Q@80OZD`N\(`RN81&<BSNH`;SJ8UHF:>OJ3)9YKZ?M3$12Q4#&J!JJ@1B\
M01_,`8%`J1R@81K(@4B.I(!&11U^CAMPDR]>:!O>"!9>(1(N(3S6X5-!8AN*
MP1@H(W=TN!JZP1O*`QZN(1H&Y1NPX9(H#1FN`:@6)$/2X1B.8?:.Y5HH@QJL
M@5E#8J;4>"0H=1U>.:=!PAV*,F"OXQU,RSR8AQS<)Q)$8`(&H,/_!Z``$&#*
M`,11,IE%DA9'(`4+V!4U1@(?T@$2$'D"F"$?0@0PS4=CM>.W`!``#@$E%@&4
M;4OR",@\$&1[MN,!``!FQX?V7'D?,I>#CM6_ZF$;P@,_F`/PM*0ZL+N-O[)%
M&FBWY,,>5FMA?P<]+*CI`$0MR&$9!D@]/H@=F`$9NL$]GL1`]L4<NBA"P$%*
MI`%4D@&[O\&2!N4:"*,9WL&+P($:V&=<X8@9L*-3RM(;<@%6I$&^ZZ)/0()6
M)@F'!:,<_/B#QN<X;MG-281]^N-]FLOR.LGLC`0?`-4D^#0DE,@5DF`*[`DF
M&($*R.`4<*(*@&`'YN`8JX$"V%<'U"`/_R)!/>Q('Y(A#JI`!T#!#FQ`&XKA
M&^B@!G@@#G#"1#U!$J#`<^^@"KP@#NS!$^R@%>[ZG6P!"I0`&?#`%6-1&IQ`
M!HP@&5IA"ER!%/2`%$ZA%.8`%6"!'+X!#GA@!F9`!E9"!FP`!F`@#K*A&VRA
M%!0A$?(]#B1!%YB@$YA!$7*`"%:!$:K&#+P`#,@A$8YD46@E<K,#D#D&@ZJ#
M62U1[I:D/<L!A[W!]UBD'IA!&[PA'B0/'P!S')BACQRR?0AC'9JA-+A[&UX(
M&7`AB',!%H8!%ZK![JZ!4RS)BV9E5,!!&XB!&'`!&_+[>-H!&8H!&[AA'$Q)
MLAQE&Z[A*QFD/O]6ZTCL@1],W2XZ+]?<(EJP+91*`X$XLE;&`2Z01QT6(9([
MG`$*(/'350`08`U^Q)+GXQT.!7?D0``<X!KV0^_8CB^.80(`(`3BQY?W(57:
M`96B^WQZ2@0``!'X8@U`F3+$I!8?1.Z8ATLF0``L89HE!8$J*%HRA##>`3C8
MP5L1+]39A!W<Y\%CY*K<@D'Z7A_"P4P*1#BTB[GPX1++A[FXY%BFQ1[4`Y#O
MZAOHHARR8`VH01^`H1'(@0UN@1O.402TX`2H@1!$H!4,#1Z2X1;608\CNAX`
M8EHA?<!J2<O5[98N>)"8E;O%;!"A8=RX=>MFR9(@-BJ2(4)T:YTN0J__]&F"
M!.E6,FNWE*5[9XW2.'?,@F6Z9$N7-&[C[N7;MDT?MW+=K)G3AQ1IOGOUQNFC
MAP]?4J10I^K#=T_?O759D5:+UHI'%2]EHE#9925('5NF;D!11"V2+GV*JI3:
M`Z6**$G:M%4;=NI-E#N]?KC1)VQ5L2Y`=.3:%(?&FUU5H$2)4J7*G'Q\JL2R
M"CJT:-"XS(2QUF6*$BF>I,7)$>I2`S#:7,7A0\H3*5>\P;D#1^='#QLW>$BA
MH\L>.-Z@2'62Y<D3HUFEEA2!ED2*KUQ2MGA1\@5;HG7UX'FK=X_<.GWUD-8C
MQPYTOJOOHEZ=>B^=/7I9KU'+6L\UZ&EU3W[L_V1CC#?TU&.//?G,=P\UR%!#
MCE1:/57/-NN04\XZZ91#SSK5=-,*))?@PDPRKPQS#3&M#$,,,>H`!18LQ.1"
M3#3I6$/.-,E\`V1[Z2'#33SJI(,44^E<]$TY[Z`'3WM(L3,->4G-AY0YYA18
MH#[OW!-/AO24@Y^7`G;)E#U>5O--/-),(,``<C+`@)QR%D!``0,(X(`U^O#3
M'GKI?`./.KH<(,`M^K#S3E5)W4.//MM((,`E7JY'SY?MX1-I>??,\RDY[8D`
MP"&1$@)`"?>TLTX\W6S)8'OQY!,/./!\```D7I8S3SGE9$7//H^RDPX]],!S
M#U;PS%-///K!$X]ZD?_JD\\X/2%EX7SXG*,4:.E8F&12`:X'VCWF/`EL@TB5
MPPU7]43ZCCXE'%*((-MXH$$Y*K!P3PC#K*%!(R<`TD@(D@R@2R1K5$/,/804
MH(X)!;PS00CZE)..!OE*P$8^@1BB`20?L-7*+0&3<`@DFVP`R0JO:$#(":^$
ML,8:DYRP3PFOE`.,!B:$0$D:FR00`ALB?+-&)4@!8K$*F^@CB#"@=?K./M-.
MM0ZY2>V#53WK+:4/-6!-,08894`QAQM!6,%*/'5`844D]L#QQBG?//%"*K)(
M,8H>KI"RBRB@7!$*'S3LT,TN=WA1#R,YE+''.:081PHJ4-Q1Q1Y<,$(/'C?_
MD#):Z*)+U0H,1UCCQ11''*%-$66`TDH<2B31!3;0=&)&)Z6`4@HKL`03S)/$
M?)A,4,$`T\HIH'32R?**E%+-*E(D@80KGW@R1"R3<Z$$&-]$,L\Z[%33'E20
M4JO/-?%.A:6CWH)J#C+>4,,.5^FX6R`YX_"*C8#UU/.DIQ!E&ET*%SV8`10G
MH<M#QYB&-;:Q#%AH@QC0@,8K;.0->!##$J]HQ8J:L0UL1*,;Z1@0/KK!C6I\
M14CK0"$\?/6D9KUC&^[82C?@@4/TH.<=ZU@?^I1BCFV@Z4M(F:&4K`(/;GR)
M2_RAQS>D80H]#4!/="H`G>RTIP+HZ0"'>)*QTA&/_R;!`P0`.,%6>F4U3EWE
M5VI:`P`Z\+]WP$,?(B&$"#(P`1"<8!#%>`HYBG4/4AT"*8,`P`B0<HYWV",=
MR9#$"4```BU<XH;T<```,,&>#:VG&Y(0`23;L`A<K(,>R"CA/;8QC&[$@U@8
MBP<W!I6.:0AC&MO`"K.,Q2Q]M.,HR7K2@^CQ$FPM:%/G4$>DNM*5>%AC?>.8
M!W_N80]V9>4>[S@*.\:A*F-A(@MI:(8A/D")$Y2C%B'H%YGLJ(6:L0$LW6C$
M!,!A@@\$XP0?2,8Z,E&"$"3C!`]8Q!H(L89`KL$AP>!`)DZ`B$M`(@O,4,$Q
M3A`"2`@C!(<XA#DRL0%-L/\'$)#XQC&$D0:H94(?D!!!%M9QC'L4H@":$`0F
M44")JX`K*4<1C3F$99]N9>T^T2"&*7B@ACM$P0JZX,,/7+"(7-Q`"M*0!BGR
M@(HYZ((9.IC!*>C`!SY(@AI%Y8,;4O&"&F1#&IX8A2<DP0UM2$$'TIB#"W10
M"E=PP0MXH$(91'&/._P`=*+KJVA*IP1LA`$'6W!$+G;0B40P8@M;,`,1_#`/
M4("!%IYPP]]\@8]PA",6B6C&.>#P"'$T8Q_8`(4JX@`&3X`B#KO0!0C`P(4P
M7"$W1O`#=J0P!$6@@Q6<6@<VH)F5?4@)'^WH"OOTP:W0X&,:XN"&.XK%E2>5
MT$O_Y+B&A]C3#7=@B8Z^VA]HMC6,;<3+N.DX1C'&L8YY(,4;EL!%*V!1#6X8
MXQ4XFB\QO-&NI;@2'>F`SS33X0T/C<-37D/O-;B14W.4`Q[O@(8WV,$4`E&3
M7-M%I%,`I+5WD.FX^H`',\3W/WW$0RO<B`2B"$``!@B`3BNF$XNUN*<U.,MK
MY`AC/)A1``$$(S_O>(=Z\W&4>LC#/OY(``:XP9Y[]",$`HA3`0[P@"8/8`W6
M:&:D0@``0Q#RC?JP!PWC(8(]"0#&<8J$/B0``*4Q:!W<6,,``-!D/35Y`I%(
MQ_DJ,>9;C(\8W+B'*I,Q@2F^`D#R&&6PUC%@F>9T*_8P_RX]^(&4=9RC0!7F
M[HBQA14Z;H,_^4`/L=YCC1",XQ8I4`$B3K`&%?CC!!*@AR%6H(\0`,,>;,C"
M"2ZA`$MP8QC@6(,G11`"08A``VM(QPE,D($UG$`2&@A!&_0Y`4N=HQ\CH(0A
MEB&,3:C@$((PQR:&@>HV9"0>]B!!`$]`B7Q<HA(GT(<*)H%<"2B*'/H(!"((
MH0&-KN$6!60/3:]F%6-)12K&7<<<LT*-89CB"7>X@Q6ZX`HK1&$*S*!#`USD
M!E*4(@]U*(4XK($#*P`A"$&@02FL\((@``$*."#&.$@1AU&<XA2*>`4I&N`&
M7E3!#G&`!1:F0(<W3$$.][!"#?],X=>D/TH?K9#!$:`ANR^((PY46`4K5@.!
M+4S!"+[@QASP$(I0>"(4J]#',O!`!,9V(0Q;4(0O]C$,.(!"$7/OQ"JZ004>
M=.((6[B"U:EP!5788@=@2`0WD$Z/:V0C2=-42CON<Z5(*_<<UYBC>Y[IJ7)8
MXU=)X2&6UH&Q+ZUC/EC:"CF*08ZLJ"D?T2S&A[M"CW%,(^$`%@8LHO$*7+R"
M&.7I1C6P,5UZ;*,=[[!NDGF4CG:,XVJ^K=_C2_^-BD0C:ZM/2H=$`_H"T8,=
M`Z*C#ZF%I6M<8U%S_-\]V"4,!(Q9Q2YN?_L%@`A7Q2-*]X!'-^[1"#Z1HU%T
M5*YZJ17_(DZR#G!R`(%`0YF2#&Q````0`@8G1Z0R$/=02.TV*.```F-6"<M0
M#D"Q"90""1,``)8@%`>$9@1P",)P#!&D"1T0)XW085J1!@+P`*)4#386#TPV
M`:T0#\("&N*@-3)%+>P0'Q4F+.9`;Y2V7?.07#XQ7.FP#99G7/6`#M95"1WP
M`9LP2.-P`H?0#,50`OG@#X&@#YC@`2N`",(@AB&`"2K`;X-P"%D`"2&0!K@@
M,N1P",-P"3]S"RUC"7F4!MWP#:T0`BH@#&MP""E@"(.@#VGPAHB0!;4@`FUP
M`I%0#RI`)O9@#343`HT@"/JP!IBD#RO`#)6@#)Z("/T@`8>P_P9I,`SN\$-7
M0P\UA2U)00__]T-4D7I(T0VYT`I)4`5T0`5R00,VP`JM\`:BD`QU(`JAH`=\
MP`BNL`O9P`YP8`,T0'(W4'+6^`;-!`VN4%:G(`NE$`?7P`BM(0<TH`/0(`D\
M-P=>T`;K4`6?HW3SJ`^P(`-($`U&(`6O8`E)T`3%0`QQ$`=><`5F,`5;``LD
M$@>G8'?IX`A7L`5@@`>,]0=@T`5-$`K`8`I@4`J*0`K0D`VD8`1>\`5AL#F.
M,#=<<`7"$`=2@`3<L`KWL`_?H`X^$1KQ@7U6@0_V8`[H%2Y@TAX]<@WT%GF1
M$H#3Q1X;IA4>4@X`I!0%`A/'<&D%4O]>PQ`/!=(--H(+N%`-[(!*&Y9$V:`.
MX@)@2N1OM3@/[?!\VE(/E#<@8`,/[9`-T#"$W:(/[O"#4R$JLS@5_"$:3J(/
M^]!HY?`*W9`,R3`-)4@G>>)^!A```5`+\?`CK\`,]:,.\>%&&K`.#Y8L20$N
M-KD/]0<.U0`/:R``",`,[`%`6$(-E"((YQ=(N9(5J&(QWV`/:0``&+`-[])#
M^F6:ZE<)]5`D('@!I4B+PG((*'8)\6!PL=DG3V(.8#9FQ[`-^X$4PA5I2FF7
MZE$N&"(:])!<6[->6O,@`!)?WH`,4,$M^1!?Y_=`718BU#`/H\8U'<8-V]`*
MR\`-]H`>12'_2\2`#<9P"Q11#KY0,K=P#!<1#_V@0L+P#M52#,[@#LV0(B!B
M";_"#,(@#,$P#)O79?HP#I4`%..`B<O0$T&Q"<<`HJG)#,I@"5*)9)DV%3GU
M73/5+?B@-=2`"Z8`!7M`!D]@#%ZU!;I``3HP"L1`"DE:"J+@":<`C<R0#](@
M"6I@!49@!6JP"`MQ#;!0"J?`"$E:.9X`#:6@`TRP#2"P![Q@"U5P!\#X"?IP
M"GQ0=O28=*YP!EO`#9[P!;$`!CHP!6*0#*3`"))0`TM@!JOS".20#(S@"-L0
M#470"42@!'^@!$=P!5_0!&5@!(N`#ZL`!ZZ@#M:@"$P`!EN`!$<`_PM?4`Z)
M``9+<`2[(P6DL`V1D"Q$89-/$2ZC00]$:7U(5@^V2%/%9PTX>27"V4)[J17"
MV1X,YEV_ZB!:,0[MDHOL,0[8,#Q9H:C<X`W1T`[4@`U(L0W&("[6H".,-P_3
M<`Q"$FGD8`WK$87T4"7HDQ7X@`[&\%M6,1_75R[6,%SX`2J@`4`E]"#Z\`H/
M@`47@0OE0"GN9T4L9@":X`[N$`^7<`"0<`_L4`Z/AV7M5I-]R9?"TBSIH`W>
MT`WJ)PP;4D+_<S\$,0`!H`SM,0(`T`A9$0@`@`):@0EC%@P78W#L$0]"]`%-
MYH+I``D"(`'G4"O%PBD?H@^&```9,"9SQ/\-N((!G(>;"$`)[J`I%M(@7F-<
M4^$U%88E_!<:^U`.-CH?Y!`-[K,4]<<-_E$/`U</WP`-Y3`AY9,/[_!'U]`,
MO_H_WB`-ZH`-5G(/XE=Y]=`-N&`)Q"`-K[`*T1`-`RH,OP)<7D-`M(@4U#`-
MY'!,VZ5$`-1H$+(>`/0>W,`?]M`,TY(5\_$.%C$:9#*P5K$EV-<5T;"C4;`'
M-F`+JV`#LB`+ID`%/\H(^K`+>B`*IR!SLM`*N&`-WQH,3K$/P+"BQN`*L\`+
M>5`*2YH+WT`*4V`'1`4+G_`"ND`*-J`':N`)ZT`'.S"\E4:GH=$*4_`%%:<(
MG:`$16`&,M`*K9#_",%P!S>0!$:0!$3P!=#@"^FP"E_0/3W'"(PP=[!`"EW`
M!&;`"=>P"LNP"HS5!%[`=Y;@"DH`<GG0!4L`!IV`!XJP#9+@'M[PH?OP?\PB
MBP$7#H'2*DE"N-;7KL6"++68%..0#'Y)(.RQ(!O8>/NWKIQK9^RA84L2+XQD
M#-Q`#M5`#M2`,<L`+U6R?>TA#,M00!&R#.4A+N?P89`'KO]!+5TAA-&`9+G*
M'GT6&FUY(0$'<)*G85WF,!/P`!00#P,:#VCF?@/```"`FF`"#G50``\P`7WF
M-?+"9=_0?63,'E+1#BKD#>J`*AT@+O[*R")X#[@2G%##@%KA1JHB7IE2_P_W
MTQ/!$"=*DPYDA`@BABSQ<)5,43^4HF8+,BD"\`'Q<`AQ<@C=4`Y@8UQ;<42,
MEQ^W^(KNRQ[A8*-GW)2?J17;8`W\VF_K,`WE<"T70@_>P"$'YQ4J]`VPUPWC
MD,3P@`MJ7`ZXQXNY0)4HN#Y0R0S<$&)@LYGW26E9\4):<0[;T)0+(L^6IV'G
M`IC=D@\[.<:A,2WNBP_*K$OW\7NN<`,[8`K)0`5>\`9QX`16\`2:J@O0@`>B
MP*0@S0AV%@\1+`K@8`IP,-+V<`Z.<`K145:>L!)/\`E24`540`J@``7(X05/
ML`-RL`YO0`-F]KZADQ6FX'3,T`5=``:F,04\\/\(CZ`(L:`+3I`$2<`%7/`$
M1]`)2=``3Y!SC+`(B:![DB`'<2`+7M`%$(`#B7"152`%4J`$6X`%[;`*L1`+
M3.`%4D`$G="2CM`-D9`/^Q`/U7`/[N!,@5F$VCD5YD`>%C%B7<&Y[B%^V0`/
M].`G_!DB!:(.W;`^K,=Z&4(.VS"M;;P.!\8.8?)'6U%-34E-U9`,T$`,U"G+
M]9`,PE`,RY!Z]3`-S!!`[.`+T4"L88,,XQ<L6<%(P0)^5$$-ZJ!(Y8$/Y<%<
M41'=Z!-B5O&K0\;&D09PF39#]N`J(D`!$X``$R`-:FP/6-9B=`(`+,`NJM0&
M$R#?`G`(!;(>*O"T'0;_85/!->_"#^'#?>R005H``&EP"YH@#*^`";=P"QH*
M#,6`WUF@%3'K@OIPR1UF22ZH0/7`#O3`#1#&#0@``#&U#7*B"<W0#=)`#=0`
M%&+3#>M`*H3@)>D@L25;X&Y$"9+9;YV7ETG10W&L4\#:E\7\*$*T7>^B#^1`
M#%8RH\L@#E("-O"*#>8G)-8P#)2;%>L0#0*"%#?&#.UAF-4@V]S`XDC!$OJ!
M)17Q#=5P'A<B7O6@8$O$%#[A$SNR'J:TW(MD#4B"K_K0).L0PY$F+`PM&I.M
M#]+@"XRP!TS05G3`"-(@"E50`W95!6H0#[N0!WDP"JA0"EU`#N1`!VHP&%1P
M_P=E8`5S``[FT`::'@>>\`G0D`ZI@79)\`:JP`QW\`:\,`PUL`>'(=1\5=2A
MXPH](`;$\`9B(`9<$`J=@`5#L-5A<`G<8`1O$,!C0`1#L`5X\`WXN:?0\`58
M``VKD`AW?0]XL'4Y4`5/D`1F4`2PP`VA,`1'D`,;_`E@``86S0CE0(D&%V#[
M<4STD`]C@GW\_"O(<B%<L4:[F15ZFZR?D@[L@`];4I[:-P[.P'GU@"7D@`S,
M`$CL42SET`Q;<B[;8!':``W&@"Q@4P\I`MLU.2;?8"SW@`[8`'Q:@234<`WF
M$"D!3T?]52;<T`[W\ZLXZ2'M:A^#3I[S$2(_/J_AHO^$5M$5XQ`4K3`!XST!
M!3`!N0`.V44(3<;>+"!_X"`"#P`"5U\``>4K%@X`!S`.\##<U&T.G+(/'J(%
M(I`,^L""`@``>\_W?:_W`'`!7Y(!`.`'2"$(J2(4448)C>*44<(?;(9F2G,,
M<A(`<"9E37;YE4\"5]%"W6`/QT```J`%S'`/4CF[5O$K380?H^=OV\F#=HD/
M9POU^N#S7[LJR("340&RSW`.QK+<]4`1JQMAW.#;;;LHR6!G3%$/+D%'R7`-
MU2`_5&R[I`DIR4`-0X'/\BST[B$J3$$.#N$E7)(4Z8`.G;VZ1UY*4G*K`60.
MX0!IXD)ZH/&OH7$-TQ(-QN#_"!2`"L2P`S=`!;8`$+A<C;)3A8Z5.=1TN1(U
M"D^U17&JE'ES<,P>-5.Z+`*7AQ6H7;R\,9*2A\J=.::(>:/R!$PR3SRH[+-2
M8Y6^>_IT[N39T^=/G:M@(%'W28F8,$04)6M""PF3&+$DN3)BA$F<3N(8L?GR
M)<P1"HQD%3ER)$R81UA&<GGRA`@H7+JP$&GRR8LC:4VD@*'"I1.U2/?PP:NV
M3E\]<_CTX:M7CUS.G8S?61N'SW#/=>7*K<M)3R>[=#KK79M7CQX]<_EPZDMG
M[MWFG?5RL@OV>-_E<=[([=.7KQRW9/&Z$8/EK7%CGLAR=?O6[5XY>.4>TTL7
MKYJW_W7FZJUK7>Z=9WSOZN$[9XZGZ7K<RM7#>:]>.7WFK%WVS`ZR3M[ZYI%C
MCS\G/GG(X0F?>U2C1YEU()E@`@H>>*"`!RZ)IY][(!'@PD#`T26>840H8,$'
M&@PA'6ZZT4>7`01`AAW.5CL-'\7TTP<2``AP!IX.`"@!$4(:$:012"`A))!%
M+&FDD4K*N2<#``K1:1``0M!GFP,`T$2?=[(TC9QTUO%&'0T`H$2?8P8H8`5`
MUE"!#4G66&.10;)P<P5(]%EG'76\B0<21PH08`WUZ'FM/YS4TX>>>W*"C$#\
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M*10AI0N?O2""E!V2^4(*6!)1)`P<;G@#ARER,.*+*Y)(0@H9N,AAB"T8$444
MHF]Q(HXXDNC$""I46:4),I+P(FC_;R2A9QUXK,GU/LA0/>^UT$Z+=QIF-H6L
MGM`RV[:>?.IY%B=SF$D'44L/78?+9CX5<,IEWH%LFU>XT>>;6Y))IYYVMGV\
MMWO&(:::>]))YYKWK'DG'6G6B8<<>_23=<I('1?]4')BO&>=9]]AYMF<UI$'
MGWW(.6<Q??:9YQ[>T%5-GW&&]RG&Q<#G_IY%0F1P@@<+D.2;=/)9`X`4]$DF
M%UU`6!#$!0M0)IYX9)-`@!/`HW^KN1Z\<O(!`9B@728``"`<]1-+'>\>(0!`
M(W1""`"8`"<?`,`A]%$.U]A#,-S@3SH08*4/%F``S*A9O,IQCGIT`QZ1$,`#
M(%$``+#A_Q[N<$=C[M,-P_R')^$`7SZ,=XUU&%$GD'G'ILZ5$W.0XVZR>0ZO
MO(6<<F!C'>BXACW640][U,,:UN@63L2SF?GH@QWDF,PUN`$/Q)'#&M'`1S6(
M00UBF"Y1!DI&-*+AC6M@HQLF(M%ZTK$W>*3C'>0PT6KT(9QCM.@PBKD'-IKH
M$SC:R3N*`F-O=/(=>N0C'I7KR6F`0H\8)>,5T'A#*4:A@R?8@0FZ>`,O^M&$
M*3PA"E&``AULH8M>``$((>/%+:C`"T<PPA9QL`(4DL`+:.+!"E7PPAV>$`=B
MX((-X-C!':(`A$[(XA.+L`<J[D"SFZ73)SE9Q1C^@(P=*.%G5/_H@B+8,0<E
M,&$+K\C%."X!AT<P`0(XJ`($NM`%6LS!"TDP`KY&X84Y4&`*2X#`$?`0AU!L
M@QNX@`,.XC`$:<#B"UV00A6Z@`-2I,,1]9@':%B:J]C<HW,[X<^YQB&:U31Q
M')[;5J*:1PUJP(=U[N$&XEK#N,-8"A_F@.$XUB&XWR`C'CMAQBW@2`Q1M>,P
MH*)'?G:2CFD<`Q[JP,8UH%6X:$PU'M:`SC1@F@YWN,<[.SF53C3S+--L0S'F
M:,<Z%"./U.FD>#K9GDZB2,I'F6<?7E4,.=H!"?LQR$$54.$BRD$Z`&3B'O'`
M1631]]D)("`9\/"6)@8P`$A,*WR$2I?_/BYQ(6"PYQ8`4(`]4*F8[-W-'H'0
M@#!T,H$F/0D`)S@,&W2D27-0*AW6N$<Q4F0(^U"0$)H\!X#,D9WX`"(-Q=B.
M[B[A)Q2X]D)IN(=M$:4:Q,UC0(JAAU9]D@]Z=-$>7E7-.MK5D^;1`XSZ1=ZA
MRN$.5\%C';"C!SH*1%3;O4,<AYM//9@!1\<P5QW;ZD<YV-&.V64#&[!`!I;L
MP8_MT8,:QC"&.KZQC60(U1WDP`8+5W,/<@@C'?=I##.FD<3>-,Y.GI&'/,HE
M&\?IPQU92NHDJ[>8<LBP4>!#Y4^.MY-JM,(5;[B#-ST1AR@\X0T4T,4K(KH'
M.MP!"$_XP0NL_\`(8>C""770Q2)X(0DJM,(7BK#!"Z;``R!@I`I2P`,DA@$'
M4M"A"FIPPQA20652\,,*#5B$.AW=$U9`80O&D`(7Q,`%K&S!$;#8A1NV0)9%
M2`,,?Y#"$VI0"D?D`AJ,4$0IC/`$6"1S%[O(@RRJP@4\8($8K\!"$1B!!%+8
M`A==P$,GXH!I(SQB'8N@!SLN;#O(",8P3[7K33^7CWN8!UWE:/9Z$L4.>,"C
M'=.8AF?X!F-N6#L>G4G4.&XJ&VYX+AWL(U%.QO$-9#2&&'><1XS2@V.?F`,7
MH<G&-!*U&6,<\D[E(/=]PH@\]^J$.DU\APA[LQWP@`\?CCW>B_"K2/^@)$9\
M$A\')"APO@=\=@`G`$<W:@$`2TB#&KTH0`$J@#X1H*\""'CP4W$U`0$<8!A8
M`J7']7$+'`[B4/%P!P($$`E]P+&\B2+M;`G0#)V$"1*J@9(*MG4+,_FV'`^_
M6_M`<*%*Y.02`+@`K]X1C[>78Q^*:01MSWB/841``"'`1SOBL0@!H%:-F<%)
M-T(3+W/08QR)@2`[QN.3;2!6-)R133P.?YB*'Z9:.KE<;_#!#6NP)S>](4=A
M]$%&G5##&J4I:CFH\0YLB.,ZVH`&-J::#]P7UDZJ["(WF!$IG*Q#]3W9QBV6
M4:[8/88?T]N)*0]E.\['PQZ3RM0VTB'4>WC_QE+IV,8VV(,/W?O$AX2*!BY:
M$04U6$$*GK"%&H!P$#643A)\\`$9QF`#-PR#&O%8R![X<`I).(51N(-32`9Z
MD`9;J((*<!@?$(4YF`9BR`,EJ((=<`-3<`4\J`*)8`1]H`,:$(5'"T%]B(2A
M"`=/6`(E`(-.^(0XP`-/8`56P(,ID((BZ(0N,`)%X`:.P0534`1%V`)7:(55
M,(8K\`,P6`58R`52Z`9)R`$P4`0IV((NZ`0\`(=6V`*T\80NT`LOZ()H<`3!
MV([*T"\#ZKMV&(?P2SS5L`P8H8>YZ@]XN(8;6P^+ZXSNP11MT8=VF(?-.(U0
MLB\24J\>T@<Y,@UO_\"&6W".WL@/=(D7GE"':I"5="`&^]B&87"K<+,3_5L-
MU?@-K0(?P&$5W%L,>4"BYP&??6B&B7N6&,&V>Z`=GM@>?`B'[).'GH">2-"`
M\Z&`FJN``5@#7;@$20"`2&B%5S"%!YF`F[N?#_F&3_FB=^`&#1"``E`!X",L
M?:`&-WB``1`!:.0,L!L`0G!$?>B&!\BL#X*'LV,#X5H#:+F'$Z"M8CB4'?*,
M=-""`7@``<`$HML``-B`=X.CKM('6"B``+B2[QB'`Q@`#>",>8@'9F@#,TFM
M=>`-X?B.R.`\9#`/GLB/X@D_T1@YG>"&T'B/+Y*X92`M=+"&RF$&^"@'VO_I
MMPO3I*=B#VYK(L>9E@&S#W+0(VYXA=\).$O9AW!8!N?`NVU(E$-)!AEBC^V@
M!@Q3AW:QATRT$W)H$6_A%.CXE,)"+VYHAG()'YSP#>^8E'/IB1##L7R0AM?1
M@3O``R_0`5Z0@Q[H@2FX`5-@!$D0A2CP`3IP!5[0A1NH`AVP@QL`@AXX!2K0
M@1_HRS?P`5Y@"#R0&T;(A4B@`QYH@CO8@E;X!AV(@C<8&4:PAS>X@580P4<S
M!1D(@W0@"R[H`BSL@CA0A"*`@SDP@AW@@3'0`2H@!4N0A#F(`U#``S"`@T1@
M!%*`@RX8*5)@!#B0!$DP!2IPPB;8@2;`@U+H`B__8`0WR#22,H(Y@(96X(9M
M\(9QP`7$B0?K6X=K*0=HN(8>2KS$.Y[_^CU,09?'2!1J($EX>`>LDXU/D@[L
M0PR=B`;2TH?>P;S+Z8]X0!YJ08=HD+%/@AZ<`(_OV8?1*(9BN`=DH(89NX=D
MV)#56(=E$!"EQ!)D\*J=Z(9AZ(]]0!36L`9\F`?&(E'X("5LRX;[\HESF+O'
M*ZQZP(6<NY\%H:PU:`4Y:`,`$(%%8`-D?(`*2,;\^0#$08?M>)9QP,<:^H`U
M8(-%6`,1T,=?K`?KN9N<:(04Z8!&:(5;:`5(.`$!(`!"<`Q$"9-&R`D,4H&H
M2P=[$`%J7`-<Z#Y=D$@!_[@$X*J%PX!(!Z#&1G"&<3@&9G@%-L`A2_B@>P`'
MX,H`17H'=G`]>*3&2]`'?MB'=.B&<<#1/04*RU"B[QDYU>@?>-BIU=D')+H6
M]?JJR9@QG"`0<B"'?DB>G)"=>`NR8K"&2)D'9HB&Y\`%9I"-U5F,@>2)<1`&
MM[H'8FBP*=D_;K`MQ#DX8WV6S5F,UQ"/=Q"?>A@'TR.L`CD4]6">)^(V>\,^
MZQDYFTQ*G2"&-M6R-W@#.\B#5I`$'M"#&F@%-L6%15@%4<@#'U"#P^P!'[`#
M']B#)-@#*:`")N`!.^"!*JB"3R`%4@`#8P`%2\B#'R@%'@"#7#"%,IB"*K,"
M4__0!S6@`5/`-M2T&<40BB:8!A_P`2O@@89J`BQ8!$(@!#9H`SDX6CE@!#E)
M!#AH!*%E6C@8!#;0@D20`^,D!*'M3JL=!#>0@T6`@T7X@CCXVCF``SF8`S?X
M`CC0RR.!A$APVTBP!+>5VTN`A$:(A$VP6TBP!+F-A+:-!&)@*<UCCVVPAL9Q
M5@!=AVN`UQV%'&XPJUE)%&8H%:4LAV;XHF%Y(V1@OA>5.'2!$4(Y%U>D!F%8
M#V;8O^>PANLZC.B8AFWH'=RKAV8X!^:K'FR;AF_8":\B!X[,2'JPAO8!/YY`
M!R?RI/A@C^+5AVM(!A,0@<AR$'T\`4L0@340`"=HTEK_*-)E_)`"&,=Q0`Y1
M6H=Y&`80X,;`$P``"#HGN(3LPP?'HR)]$`8)"(`+.:T+D0#?F@SHZ``!,(0+
MRB#N,;![D`,_`0#ZO1`'N(5[.,<Z<8]X^`812)$X/:WTG8!;X)X)`3H$Z(</
M>HQO2(9$,:X"H`3U4@=I>-:=@`?ON44`]8EY2%Z=X!;D6*+X"(=#VHG2.+UH
MN0\8$14\M)/"88_&H89FQ0EG8(;CR2-,X0>><#[=_2!8((9DZ51984\LT:A[
M:(=&JH=CF(:<9)3#@!2A(BS5L`9E<(=+B3K#*(=39:EM\Y;G&#LC6R<IVHED
MP`5)J`([B`,W>`,JF(-NH`)/_Z"!/&`$5T@&4Z"#/;B!!K`#-[""7O"$7NB%
M+I")4^"%42B%@M$#%T`(1K"$?D!D/>@!.*"";^!.-3`(D2$&?=@#,D"GFKT9
M4K`!)+"&55B%:(`#)<`#4&@#5W"%7[(%^LD%5\@%7!`(6[B$2]`%2Q#"2WB%
M2[`%:2;85A!&4U#F5ZB$2[B%6]`$6Z#F:%9F:1;G2V@%7*`?-N7F-HV+81@&
M8M`%=7Z%5[B%2\"%6\"%5;"$RH&4+]*6G!"/X[E*`\$6!6TB3'&/Z)B^J1LC
M,Q(0OVH4'*;AGQC%WUT'=^"&/*FX<HB']9"-H((KA;X':U@^SW"51^J6W=@)
MU>@W<_]04??($F[;'GN#83MA#\'HB7-@AT80@2&%D`DH@#60!/L!@`EH`Q-X
MT@]).:4NAGRX))_*DMYYAV"@!$%8`TCP!^;C!WYP#S@V-V:P!#5!A$L(AJ1*
ME&U)AF88:7KHAELX!LNIC@_:!#_P`!8`!$LP#WM@AK$V:SIDAD/(@A,(@4$X
M!-]JC#!2AC4P!&?(C`&R!FC@AGF@!T-(@4!P!WOX!FI`R\/@/J"PGB/K":;R
MB5!"AM#X#O`)!ZQ;HNPCQ&+XHM!E!B3*B7C`AW(HAFO\76-0E'(8AD/"A6@P
M;'N8OI'C#=48Q6XP!FVXL/?8!F[)79.\AOS$E.YQ8IT8!Y;_C,7XR+9R4(P8
MN1;1*%>)*U['H6V1/)1KU`<[BH0J>P-/J+(O(`5P2(9I^@$H$`54&(4XF(,\
M>(,/-@97<`-4L`4WD`1=B(-(,&9H<`,UH(,\*`58:(4NT#(KL(9DL(0WJ*8[
MH+(RD`1]((B;B.6;D84]Z(1<V`$=D((D&`(N:((OR(5=L(60T(9=R`5IB`8[
MR@4<5S7ZT85=T`5>2`9SEH9A@(6X"$Q>D`9=D&8<GW%>$&8>UX5D@`8DUP5P
MD(9JB`8KMW*F5(?]_(8O20>@FK=J$(YJZ`9UD.<IRN+,=@]"D1T9]K</W0_S
M>#*=L#A0<1R8%`U9B3RQ;+[R?B\[_Z&&*\\&>.B&]V"/:#QTQ_E>SC,L5/EG
M_2!>\#E5426E.\$)>%7*_NI(Q>`']1))V[$%"G`"$:@`4Z<L+5B$'2B"`:``
M'YB`&[HY*)UU$8BKTWB//4*/FH$>\]"Q5CRE[Z.'=3L70;DO-\R)[MN)#\-A
MBQ,/Q^F=T(T71#F>3<%/1.F&HJJN<_$<ZPNEQ;!IH@,*/@2*=8@XB;M)B1L/
M:K^&2%E7.)*CZ6F,ZZ&.97CH8/T-2TD/P\N5=,`&</"&/#H=*L)(E98\G>B&
M7&"':$@&UDB'8U`2]KC*T",M;]D&9A`=G[*3=[@N4!QCIFH1>%"-=]@&:K@&
M8U@Q:[B&:_\8!^OKAG*@<)(DS]\`\VK9##=2)6)HIFG2@S?8`SS8@SGH!8+0
M`2M@V%GJ!EX@!4_(`U'8@V-:&#?P!$^@`VBRA6[0A2>`@CU0OSUPA0MDA$_X
MA#L80"^@@U'@0#MX`0X'<:#("5"(`3%PABE0@C#@`K_8@B\@AAE'\EW8-V*`
M!FCH>VCXA5>8AE\P!EO@IX4Y9UT8?%PP!E]`AE>@A'/&<5N`AEQ(PAR'AK]7
MM7V#ABCW!BP7_6J8AFK`ACS!,&[@!F\H50OS!G'P!H)EXKM2$FP#=W*`AIR8
MAUMEC<SP*W.SE,R#A\=@SUYM%YSL'FA]Z+.LGC_'QM,3_<#EABO_GRK$Z2O[
M"-9G@:GJ(8>]X0;%B.S*6(QV8"^F@@SG.7>`UO@!H:M/GY>=J)9[!(&38Q`(
M&(`V:(.;$P`&D8!+N#F`H#!!((4'N/3MTZ?OWCMX^?2MPV<.GSY\\^@I5'@/
M(46%^#IF3)B/'LEZ&>NE4_AN7;UU].XQ7+<.7CV8]^R]XV:2WCI[Z=;%O%>/
M7KER]>J5@T?Q8[Y[[KAMK#A/7[U\W+K=6W>1WE%[Y<A5U3<RH\N,]/`EK&@2
MW\.,^LB)"XET'4234=>EJS>OG-MZU(RBTT<3:=YU[>J]TU?N'=*-\)@E[0:O
M'-YTW8AY$UJ3<;Y]:16.=?NR6[1XR.C6_^-&C=W"=_>P<8NWT.0Z<OU<+]2\
MD!Q0E5$ADG/\D!RA18L((6=$2-(B2(L.08)TJ-&AYM*-'Y=#B(TD.8O@.&G3
MIPUY-^;).U'#I(X;)W7DE)\S!XL;1HSDX._B1LY].'!,Q6'%''0XX<1^6-"!
MQQM5W'%'''14(8D^>P0ABEL78IBAA@HI`H,8X<2AA!A'>-')%EK`HHLTQ$@3
M#331:`--,KE$4PD"!K10B3&O$!,-C]$0`PX;G.1"`"?`!$""!EDD@TN/K^0B
M#2PT-A(),<)<DPTRN!A333?51)---=-4PTTUZ7CC#3?JJ)-..O%PXXTZWW#3
MRB7FE*.3/N/8H_]//%&]<PXV%+&3F$+<Y$457?=05DX^#[E9SSAYM4,58^U,
M8Q=&)FV8X:,E39,.-(QQ0PQ?&UUCS#BYZ6,.0YQ210Y8Y]`S#T4D*9366?2<
MHY`YG^G#C5'Z)'I21K1Z=&%1]"0C`@@B3"`!!`^DD<8#$PCPP+60:#O!!`>`
M,,$@&(F%3TU4W?,2N14!BQ!&]UB$SV^W@F1N/<-LP],FA615#DPFU6,/.O`P
M]%)7,AGU*CWON!;/.MNDLQ%)'^GC&D/E$-7(,VZ^8P\SW.A#$F/Q!)P.:WVU
M1E?(Z^HSSU2@N7581OA@K!!7(:\CCS4TU;:0/M1LHQ!20A\3M&(MK5/_#CLX
M39,5-^NP4\XUT43\S32Y8,50QS"M+!H_0J-U,SF2(?.-0M$D(_,]ZJP3#3?P
M+%1..NIT@PS(C,X3U;`M+:703TI3E`XDE^BB2S*&%RX-+LDPWLWAQ"1#3"NW
MX**B+I,7;HLNE1-NRR6FU**)+79*<HLNGMLR>BN1F)++):W`XLHMK=ABBBNM
M6&*[)*V0THKOMN2B"RQV,D+%'%3H\$0><TA!RCU2N$!*I]-/[XD+8B3C@Q12
M4-'%%D>P\8HTU,C(#=K(Q!A-*P*8\(T&"$P#31:#C#.,)8>P(<`'KX"@B08!
MW&(0D4!&);)@"6T8(PO[@P7[IC&,0C1"'-B8_T:8U"2F:L`&'ME(4SJ^$0]X
M=+`;ZU`'.JIAB5:,(V$0L<=(^H61>:1E*7G"",7$0@V@1.4>Y/@).]8Q#70@
M1C6_R5`--<26?%`L'L=(AS!(MHYAS,8;U[C&1FQRCWQ59"'TN(8U^-*6AYA#
M')QJ"SXBTIN3K$,GZ5@76LSB$9`LY!SXP,@E/N`M"3Q@`&DX00$J,(`"%&`"
MF4!`("<``@>88!SKV@<]V$%##,&*B!&9V:W<4D9]2*`0"L%`"?3AE9[<XR'W
M<)-9<G@/8:TK*YYLBU`>0A1TO2,!Q]"'/#:@B6`I!![5>`?+0ID.=`Q1;A4S
ME+SVT99:A<22+YN'.?_<4C-\C(,QC'E85MJQ#7N$4E)OX09OV`$/<M#L:<22
M%#G&<11X4,-M.J3&-W2ACGO$PQT^T^*%\,'"8X+F'MTXAC=,!4*YH8,NU>`+
M.9B1F&W@D!O,@)LU;M:1<AQ#95G<R#:,]HY&X.(;WTA'G+B!#G3`B6[QT.@W
MNM&-<I@4$IJ(QS:H<3A=@",:QR#&-9(AC<,=(W+#8`8S#B>-:D@#&<GP$E`U
MFHTOW50:TJ!@-$B#06MT@QG3H,8RMA&-XIWB#E%XP^%.H0M]5($&D9@G]<KJ
MLU)$P`C)*,(4I'"$+73A"W"@T8O&!"8P#342`[";,*9A#`=\P`&#T(0`)"#_
M@@%((!($&,0$!@")#&3A%00(00`.@8@,9,`!B`"``UZ!R`,(8AVWN$8UP*&.
M:WRI&M7P1EYH,@Z6S`,>U_`&.^JACE>\(BT;:<A&UC&.4-8E9"`L2237D1.?
M]98<(=/A+5BSC6,T,R,PK&=9][$1M!2CG\,@6#>V41.A6&,;552(,OBB$9-L
M8U5BD:XQKH$08,V#&FX9"3V\$HT+D5&B182(.^KA#GM`PEL:N$0;3"$"0/ZQ
M``^X120LT09`8L!H;ID'2WPFD8RT14-E*:LE#H"`3>CC!!DPP02&@1'/:@`3
M]YA'%@ZQ`6'HPQ`2P``E*/**09S``Y0XRST.D8`U_V!$&2-8518RH8]`$*`#
MRSBR,%I2B!"LH6/K:$0'",$;I'1CO1O!B<WF>Y*O25(?YXBNSXQ+CV4HEVOX
M&-@URF&/>^[#'?!8!D;RX0YST`-,]F!D/N+1#=F$<AW)(`<[XD$,<N!I(?%(
MQBY<D0R2=2P?]9!';-51#T;ZUQ[Q(!D]A*&-:"`#'-+813:B48UX]`.FW\@%
M+T3-"VFT.A[>F(8MI`&->+3Q'BY5!SSD4<,U$F4=B&A%.;;!#&R<]AJ6V6B;
MMG&.J\0&%Q)@@0,&$`Q?2``FS!C&-]H$-'"@U+3?Z!%);VKJ,$7CIQ>\!@5=
M&HUS)V.VV(C&%+F1#68<8_\138B#%*HPA2U8(0F,R(<>]M`*LR(\(Z#`@12X
M(04O)&$+25!$*[2P"Z6V2$RD65$U(B$`9EC#&M/P.&,U0-@_#V`3]1#`+4Z`
M`$RN(002T(<FAK$)+61``+5@P.``D`4)2"`=UK#@-\8D<F^L`XB29DRA!H./
M=J3C%;?(L$+,V9+?,),JJC$)PS)B#G,<Y3=IA!M,^I'E>D#F0O6H%QP13@]<
M9&,;BZD&4KC.DG&P,F?CZ(A0,,:/MF=#'+[&L#WP88V4N.4F[(B&1*F2D'I4
MZHT9$<HZXL'">MQB`AUXQ0,`V?D_1@"0`EB#'`J@`F9L:/!EQ8>O^S:]II!#
M`FO_6)4(`D"-%21`'\%P@"8@$8!BZ,,!"IC$.,9A@5I`@@'-T$<6!/"*2Q#`
M$OH@A`2.X8$/Z&,3`K"&/@A@"'U0@@`K(`<]`G!+#7B@$@3@0/87<(D0=*!E
M7L*O0AQ&W8JPS))H68HH0T;H=SQ$GT6#*7B")Y""!SF$6-R"+8A)E(`#4&G#
M9+`%-Y`"*?!"+MC"+C#"*>1"*YR"-#C#\NT#!;K!';P!([A"-J1#QW@%*.0!
M'>R"0GA#'GA"'N"!+.0#.1!#+JB#*SQ()X3"+%R#.J0"'7C")S3('>C!*'P"
M'MB"/7`#'BP/+\2#**5#-=@"+_Q*1TS%/M3#-A#"+7`4_S>4%*]]0SG0"3QP
MPQI>Q3;$PR4(0#!T0QIH@B88P`F$P"U0@XB)@#D`0QNLP"U(@@80`C(@PR"8
M0!N8VS=`0S60%IB8FIA,`S9\FE)!@YJ\&S5XB12AC23$P1UXP2CH01RH@1U(
MR!O\P%@E',*5PA1T`3>\`<.!`1',PB:<`#3,FYE4@S;LXEU%`P&L@3>8@`+<
M@@`T0A80@B4`P#'`@P$,PC0``":(``'H`P(0P@D00#<,PB%(``ADP0`<`P$<
M0BT,0".DP1JLH4:9E)>D`SEX`P@QS&:D`X6U##OLT"U80F=4D0[E2Q&]TC:D
M&5685SLHEV)<%\<8RCIP'SQ8`_]8T-\JTA\]O%L\O`.<_$EPO%(\(%ZZ0,2I
M'$5BS!&8=48[?,3+),0<N4;C/<H(C8,Y!*!9],H0>=U"/`I,O`('7,(!3(""
M`5)/%L``K$$:#$)K8(AU-=Y#6I(9F8,\=`I,T(4$5()"?,`(Z`,D+(`^V,@:
MK,`!0`(F78(^\`,]'$(;G(`!.(,^J`#VZ<,%D(`^9``&'$('&``^O((!<-^'
M5<P!!(-B&$`PT(,!P-@Q1"4P2(`*$,(EY$4W2`.L\)A0@)/0=(9&?`W5981#
M9I%&6`,U#$6ZU`,K>`$9>($)TH$M?`,\5"0=V($GJ$$5J,$+[L$H=,-1Z$,N
M*,$>W$'_%>#F&^B!'JC!&P15Q+Q#\>SF)Q"G)_#"1O##/<P!&=@!*<`-,3S!
M'NQ!&7A".N!#->2"-J`"*.9!'NQ"/9!#=XZ";7K!&R3A&[A"/MC#&T`!'9B"
M0[0$&H)"*7#?0\B#1&W#(N@"&J:1W)`,.<"#P[A)GFQ#5+G#&A"`!*3!.V@"
M`1""`93`,&B`%@"E[P'"&B"`(!``)*S!Z&G`+71#(W+#`Z:).HB#:D4#-D"B
M:JU6-JB#-_P%-Y"6^3!"'NQ!*'J"@NS!'.Q#%+R`]$!D6;$"!%#`+3A!]X"!
M)X#!$"P"-'P:+P+5:G6#2W7<`3C``2Q"-YR`!"``)+P"`C#C_P@00"0@P"1H
M@0380P9D:08@``+H@LQ-XS&L`,NQ``8XP"&DP\?(B3J<R1E:&DJ<4U8(JEZ`
MU"5<`CU(FDK<T$NX7COVR>0EADQTQ,UL0V+PTEOXQ!<N`^*AS(:T7:>,VS"@
M1#3TR3MXUZ/2@WCQQ,JX1+J8%S[(D4>XA!>R`\7D@[^T!IA1Q#RH@SYL`YDE
MQ,OD"CVD!11Z'2_EPSDT0D^&7H(A6!I@TX9-'B/-$ZZX1;M4Q$;8RO3`A&MD
M0%?J0PBT)23DWB0X`#<(PPH`7P:`F#XTP@/H0H>M"HEM4B#H@P:H*R2@@#YD
M`@'TB@+<$C<H`/#1@P+XPSL@P%D6`_\D7%'O:8`$U,27P$I5/$1+<$J[G`6&
MX)FT:L1*$%JZT$,O[($:D$&#?*(3HA,\O`$0?$(51('+-H@=P`$\K`,UY((4
M)"%N*J$)Y@$J\%H]K((4[$$>O$%WYL$=2$(\D$0\S,$8[$$JD$PT=('1Y@$X
MM`,[4(,TU.C(>D(N\$,YR,<I%)P:]&8>C$(>N,(]?(,72"<>),.CO`,Y9$,I
MR,(TA(-)K%%&<,,B9%0'!:@W?!!KJ6&EPI.I@H,NW(([0((`3,(MO%P:L``Y
ML($6%,`*;,+,$4(!<&,69-X$G,!/\>)/5<,&?8.:J)8ZM`,WB*XCJI::J`8W
M8$,Y),,BE$+_]QBM&HR!*,1#%00!D`;I])1"`Q1!,E`!&,2!%Q2!%!`!'"3#
M4?7BE\A)-4`#,:2#-%R"1B7#-YC.HGV)XYC.NR4#OCC.4.D"-9CO)425+AS#
M)>3))7!;,D0#/+!).K09FAS%VBT75?1)5-1#/+3"*\"$*V&,.<V169!#?8H2
M0SC#5%#,8M0=501,?UW#/'"#.7T&97H*PMU#345M2G@%,[#$3H`3R":$<KV#
M>:T,1IR#>E5$,[D*HJI$S=A0K8;,1"@$/6H(99C%KF2?!FB`(3VLMWA+`:3!
M3;S#?K6*=7F$#4_/'%'$/H#9?%6L;I@``5""/HP`"U3E`N##.Y3`_QJ4``=@
MA`1<L3Y@@C6>0&7I@R`$0""0``$`'R5X`"2$`"'H0S,0``H,0@!<\3@LP`<H
MT@'<`A9[P"88P+Y"`@#<`H8*13HPWA#91(5ER,W,UU3D'S[T5[#`PTN`0QZL
MYAU0P1X@X1UX@C3PQ1OP@!Y4`10\@12\@154@13D`J+80@TLB!1``154P8(H
MR"FP`SNT`A68@1X<[1WL00U202M,S/&J`1^HPQ8IB!?@`1V``T^D`R^XP2B@
M0A2,P2Z\0SI(X2<47!78`8/8P1O(@CY(@WGJP1N4PCM=DS>4`C0XTE$TGN*^
M`DL\3674`SNL(`C]A)O\5_)=0C((`"3X0_\`Z$,)J$`E!(`N$(`*'`(!Y`,B
M((`PG,#S'>8`L,&XK58TJ`,9FBYI>8,V9$.<>`,XP(9JL8,WY`EE1,,<@`.`
M2&<<5,$3Y,(]6$$0F,+O4@\HT,`62&TG@`(5)`$>#$$;)(,W2`,OFEHUT,TW
M7`,U3(.<F-1/B=J[\2E0O5NZ@2XV8`,Q0$,W>(.I,;6,:,/BE<-(F90WH,1,
MY`FB;,08%65%L(,E1()FE$,SC80WU01/0`4WP-$7%J2YS)&>]$D\\`E59,IK
MK1<&@\8E(]PX3`/(<%-6"`PR@$0Y<-]T55VO7*LYN6&&T2.E76OD?<6Y5`R8
M[<-1>@2O((19I`7_QFS:1'P$25C#.80E:+1=G9D%9%M2LE!K<"=+&YT#)C0#
M/9C#JC2#,,`0/DP",%Q7,)PE1FC"Z44'6GK`*Z!`,U%$,13"*_@,,ZC`+0C#
M\N'#,Q0"."&W/9`#)-`A-7!#/V@"E!6#$4_#47(--Y`+95IK1;C#9WP&-)&+
MF[R$+7A!&92!%1RI>9:!%,2@/GC"#XQ!%$`!%#CM'4"!$<0!W+@"#8"B#E0!
M%3S!$TS!%%B!*R`&%5C!)^P!%$R!%\3!)Y1"'G3X1C!"%1QSKT:#%^@L%4B#
M1-R#-%2!'GC";9Z"/K`#')2!>=YF%WC!&$S!$\B"GQWO\7["+J@#.5B%_RNP
M1BA9`UVTA3LT0C0P#`@A!L-D1<18["A]\SM0'R&Z@R90Y2$$0CEXP`FL`2#4
M]SLDPPIHGC-<K@1D@4@_-3;0UC=TT1J*29JDR4FA@P>Q0SM0>K%APR(P`09&
MP6V^010\X4[[KD]K""@T`!(<0Q.(P2[$XA04`1RLUAI6`S6X"5ZDD9DX;TF-
M3_>FM#>LZ)=$0SH1P[P-E3<D`VET@_E$BMRD@SN4IE`0C$;2!(;-RQ-KA*$*
M)/EY!#.`!4Z00ZFN"SP@%%U03!F=RFX`DV+0&37DD$;4TZ<BG*0Q`RZ0S#18
M0Z!9`VN0RPTE"T2$^7SI4#_`BR6U]J>>Q6'`$?^NY(R&T(-(8L0^[.\U61Y7
M4(0]G!FG?L12[$,!UQ.VJMV^7V:7.?R^4PRGH,6L-CQ0D`NQD@M,],D*=))"
MG$.%#05%P$K!9"Q5A`Q(+@2B1(S-<,TZN)>Q=*MZ428^1#$_1%+&*K>PZA,\
M>4)Y>D$D?(,TN,$4W($4L()"O($-W/2"Q`$53`&,-X'9N,(-X,$=@,$<@$(7
M%&`<P$$,IL,38/@28'TRN`(>G+T72$-6@,(8D/(W#/D3Z*P5V,);!/X;O($=
MJ,$I>%<Q>T$IY((KP`(KE((K8$TZ=((Q[R8OQ#H4WM=:5+"\5-T@0)%0(.J_
ML$;'-`17..4VF,N?<!/_3E3D-EQ%.HQ#.YBJ&R*4F[V#+HP4-*A&J)A4!^4)
M//"Z-VR0FZ!)-]3O-4RZ[5,#(^R`*T0#$XP!T59!)/"#)^Q!(HAZIX""$H2!
M*PS!'ZP"*>A`'+C"(D0#2<U$Y7W09+C)BW[#-A1#@:93-=`)BYJ:-H!#-P!$
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MJ>'@(>]9PQ<MSR<NK#ZF`R>E2A5/H;_02.+EWKJXGIZ,>6)+GRT;4_"`T]>.
M6OADW^"-D\8#"I0GVD"NPO[$E7OP800*+SZ!YYYNK(@""BN@"-"B:*8P+PHU
M=K%F'%+&>,.4;[2IAJY\^+%G&W#FN.,-//+@)1YO!B,)1IWJF8D?2&ZYQYYZ
M[-F+,WTB4BV>D79K1Z)RUEG'R'K,(B@=;*SAAAQNPO];AQMNNMFFFBS!N::;
M<N"QIIQORD'GFVJPR:;+(Z'DIIQXZFF''7+0J8<<.)B@0A%4[I@##R\ZR:<+
M&QQAC-!"20*%BRN&\0("1WB1HHM$V*CF&W2Z^8:;P=*!AU-UONFF&G4N(>"6
M=SA8Y!YO5+7RFXU\BH>;1C"()YXL.4U'&F[BV:L<>_!Q1Y_@Z`G21R7?\:U0
M?2*Q!)CA]'$VHW+>"<VW\/39IYVPWB'GN*$RTJF<<NCA"9]EYN&-L*7R03;9
MI4A:AQBDQ"LGGW0,XZFQQ58R3!_2F%KMG;!`DF<=M98J)U-V"#/'FM<@8RPP
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M#R>J_Y@E#R]`T4>-%TC1F'Z06&D`"6:8,`()1UJ!(`Z)0$=XU%$/>$Q$/.%Y
M1SR^`0YX+`(`'[C'!`JQ#DR,XQ6W8(8E-J$"8*QA#=U(@P$BH05E[.,6)[#$
M.8"1"4'<XB99D8E(**.Q35SB*NZ:!C8(0X]MK,PI\TA05O!"CGO`(S#V*`<Y
MQJ&/I84$:?5CRC&LT0V>!&\YP<('1HXC(*VP!%@LD8O(O.*4F(V$)^1(QU+(
MT8ZN0.8Q-.286-(A%RDFBQZ/61?*"B4>E,4LBE%!UCT<!A*P,&<B)+')2XPF
MFWB\2!_6J`:"]$*2B9`#6F_)"%JBB(]S1(4?XT#,(I-1#O]IO.$.7MB%)Z^!
MCE@8H0I=R(H7@!"%.]@N>\&0PA2D((MZ,((&/7@#-Z:1CF]X`Q?3@,<Y[.&)
MNCW!&_D@HCX<H0,HY&%G<P!"%4:A#WY(XP=`N$$/;G`'<+@#'IZ(W#9]@)YU
MN*$,91@%/*21#6U\0W7JX(8^%($^.N2A%-1`2SJJ(:,UAD1YD$"&NO)A.R=>
M*R/ZB(=#%Z,:P.C()SNJCWC,D95R/"0=[JA&.KR1J7=,:R+<8P?SI)4.-G$O
M'MVPGEXXU3AJ.$(:.]##':30"5+D00[ZX`,-WG='0^GC?F)@AA2X<`0D$.,(
M3F!$IM+!CM(H32;L0%T\K@&/0QS_@`"$"$$A;D&`=$A``ML00`@D,(`0"$`3
MA!"`"0B`@FT0(`0'R(0?!)`!3>BC5Q+AHU'UT0I+Z$.4B%G'/,BQ,X3>XF<?
M&<<T?K:/-LY(2>2@!S'W6:@X@B20A2*'$D/SK&ULC!QM`DDYY#$/?-G$+CL!
M"6\VAA>4!<^)8(+B4\CQF,.<XXE3(^QP@P71X]3O,AO#&*'XE3*QS(@I$5G*
M/C*#59)L(QJZ>Z@3[Y%)3LUHAI`Y4E04@YQQ"24:=X#:+I8YCW)$8Q6MN,4W
MXA$''E@A#Q_)%#W*<`<RH*(>KJ"!?G:Q#GAX`QW&,*(TXT`#'GSB)P^%11.L
M``>2S*%N_WJXG2YL<(-M_H`.\;`+*:IP!QT`X0=E:X<G\%,*6+$C(22)4C[P
M$`4'[>$.MGB7;;X5,F9(HA_'W=@GL7H3LJ"%&^[8XD5(0J]X;",?Y7"'`?42
MFL#<9%CW<-,CT>)0V85EHA-#S41GQ(Z]O,,<^>C'(I91B2[<H`K0$$422)$/
M-[R`$<0E%"A@``9B)($+8$""(KZ!!388!:LZT5W.4JJ/0X1`$P=``"0PH0!]
MD$`#Z0C`,2*M#PS<XA"6AL0"`!%6!)P@"QO(R+16\\3ZW>,2K]`*/XJ[CW&$
MQDABN8H1\7(-:XC%*#,9QUZ8<8WF1F6+>MY81!I[CW<H@R0KV?]&Q8`6CFO$
M<1^D:<?(WIC)>XPC*;B)5AB->RUR8":R(Q-E5.:Q7&1_)+33G6/]!+8/G?BV
M71XIV6<C^A$N"I)CNDMD1"=2CJ?<@QWZL.I$'/N7CVD2+TYQ^''&2P]B=$$/
M;XA#+DSKDX\D(QZAJ"4>-`+E>&0G"I[0ARYNL`<J=.,FP:@',W0'CR[0P`:G
MR`=BWA$-:=CF'HP(P@WRFP]IW`#.M&`"-'U%AQMXX@WA/,5MYO"$)\R!@0OD
MA3;4D0URQ,,38XC"$[R@!UGLC"%"<:Q(F+$(9BP%$QMHQAH.<8]-E$`?D"B!
M,B90B5MD0!B&.,$V0E")8&"@&91003G_5("(8'!`&(4@`3E,<(ECA(`9B%@!
M,U0`B6!L?A.(V$86-+&,-23#$)L(!B+&$0E(4.LW]HC&(EI!#SE4@0ZYN,,3
MG*`/-SQA%<J.2B@:<`1<*$$*7TA4+HH`!W38PXBV"XL0PR-8?0Q"`OH0`0`H
M(0P#K",#&NB'`)@!"4LKX!:0"$`YV&`!2A#`$BF`A`DZL&H9"K\DEUB)/$#2
MCT\RS8OP@1E>8C`V1B,H"2B<XR5V`S"0P24*I8:&ZR*8@4300C.RZ#,XB26P
M82Z>`=\\B=9"QAJ"9YI\Q%^V*([6@?\B,"3<(9-$XAS<C3&2K5#\PB-D\&*@
M8EQ`ZRGF89'X_VUD_,W>V(4>V.7K&,,W]*@;N($>UDC+.`,?SDTG/&)'AF*`
MA(L>PH$'$\..\,%9OF(R]*OLO*`*&"$7T"$?P*&@DL$M\J!"O(`=*"O*GL`*
MD@`5]`$6;F`,X@P;HH$7=,$4<F$7(H()>H`'2D'(:(@L[.L'1D$SN@'IJ``4
M>&!R$*X/@H`/J""83H$:ID&=H.`'[H`.[L`3\N`.5D1'"`0*]"!M2B$;]($<
MM.$>F.&@1.(8W&XI,F$$BF$%%D\%UD`?UJ`#R"$$#D$9.N`6"($%MB$%!.$8
M.J`6&H$%E&$%!$$8)$`8`H$$F$$##B$9).`2!$$#F*$#7L@!A"$-//\@&!1`
M$("!`"ZA`T1`$@;@$D2@`ZC%=F:(&1S!$OA`#=2`%VRA!U!$'SQ!%((/_T0B
M%*;@#9(A"8Y`";@`"5S!$;3`JEX"'_!-XEZB$3Q`'ZB!`"9A'Q9``CK@`[8!
M`9AA$SK@'C#@$BP!`32``#@!'TI@`10@&%1`U>@B+.*M?C3A$B!J.+Y"*U9"
M'(#+FYP%9>@AX4YJN\S!'%;BV^H%&KP!!Q/R8HYA'=IAV\CA*U9B'L1!26CH
M_T)B'%[P6IH(*MKA6)!F+^RHB%H#+D5B'.;-W]`2*_--D-8B(WO#*78.`O-H
MN?AA'Y`E8##&-]XA6R9"-J:A&W['B0ZCW2+_J2LB8R*,)8A\RUGHH2P!PQHF
M`AOX#][HX0O:YP[*P`OF(!?B(1F@@1I>`@]XP`Z>P%QV9A=J8`J28)5,@0;(
MX`>>0`=DP`9LH`9@(`[RX1R8@!+1X[B>XC7HPK[21AWH(1MT@`:`(!9PH`=.
M`1[200IN@`_>@`9N@!?>JQ-H(`IX8`:@8`EL+`JD`!<F*@ZVR17@8`KV`#VL
M01O8(1SPP5Y"8AY:KQCFPF@X,U@"X27"@I%X4C&*$,WHPB[>@1^4HUCZI1QH
MC2<#AB?!(@;Y81OXH1R:H3E4(P:=Z"]THAD800Y.P09$X1:>0`J>@!'R@0I>
M0.6NTJ@>X0BVX!F>_^`(CH`+MD`1*M(NB69CQJ4?7"4TSD$9ZN'6S`$I:.4=
MMN%KMJ$9KL4<@"'(QF'=G,+5ZF<?8@TO:"L'O9`&4R:\N`L?Y$%F,/)-]B$>
M="'=\E(D/`)4WH0=C.)9@D4+(Z,UC@/;@F4N.\,N,V6[X.TF.HN&*A/9YFTM
MBI1.(3!=,*8>"E.+B`M'G6(DM,K?MJ(;U$$F8N:-"F8EQLO`)J++,`8C*?4=
MR+0Q5N$)=BH.=LH-5F'KXH$GXL`&@(`+HB<>K&$.HL`+J&`7]`&8>,`+3O$.
M[*`,=JIL^*$*/(P7KB4KZ,+>@,(BNB`*\.`3E*0=;B`(@``6I"`*3N$>H/_!
M"FX`%?*@!ZJ`%=(A&E2!!\A@#XS@#NX`QTY1INJK!ZA`%G;A#9X&'JI!&[CA
MDRK"MNK!$I(A69I!!8"0,=;"-YYB.7SC!HO0-S!B+8SF*59"8BT6,)TA$?(@
M#[!`&MQ`<*9`$O)!#6@@S_)R)4`A`HH@&I+`"([`"Z9`">`@$>8T6>HA"24C
M38%F58LF4C_B%OX*)+`!8ZSBL_+AC8C#2(CRN++B**I!&GSV:#_"9D+#USYB
ML2)#,:YEC,3"(\9+C("&AIJ'B)0":C<"*M9!"^_H6K=6+!(1+XS&:((%4DU&
M^!!#N(Y#8,(B1VQG71H*5`X(8Z+R8SYK=Z+BV)C_@PG511J,``]2@13PH`SP
M``RZ0!9VY1ZB-0HZ(17F(`^ZX`UVJ@ND`:E<P`;>0!;X8!3RX)_R0!3HX@W&
M"1QD!U#7Y3B`I0N>``\\@2>NX09>X`>J80[V@`_J81=\``AX@1&`8`\"A!H(
M9%OW`)7P5;WB@1G@H1-^@`I<(1U.80^K`1P\87?OTM]NHA'>#@F]"1#FZ$LU
M9B9(ABG@36(S!BJ04Q)T@`FZX7%.L0SF(!_R(`A$X6A+`0*D(!F,@`B0@`N4
M0$@;H;2DR`:!HJ%@A$#'5E/M5A\N06E]T),@(QP&2Q_Z$T"M8=N<@B^Q01O`
M0<Q`^&1&,)+4\EH>`V8\_P8H?!"-.A:(H2@H6A@D8@*PS.L<)N*.?#(O)U20
M@")F<#!3C6JYMF@S(D;?)DJFR(M<-#4XUL%<0`EI/$(UB'B10(,4CN`34F$/
MHJ`,4B0/ND0?[`L(\$`/[E-[JP`/Z*`:\+`'=*`*\L`-]"`*KD8*/,$>^$$\
MR1-O0P(MXN`'Y@`5LD(=?`!YO0$.HB#$2N$%;@`<IM<.`J0<&`'.IJ`*IL`*
MJH`*K$`/U*$;F"$4?F`*YL<5Q@`*2"$>WD#'*F,?RH$LUJ$1IJ&1ZS1RZ73G
MI@99D`5BH^(<%.$':@`7&"$*!J<,&.$>:E02CI818B`,D@$'I&`+Q,`(E"`,
M&O]AAB.5B8TYA/\*'\K!)B3",=HM:F$D*D7"&G[&0+7B&M(A&5`8A.]!LU#C
M9]:!W&ZB,Q-CE+I8,CI68*CADV8B+/`A!`V)+,Z4AB\:HS$8BOAVF%-X..X"
M1[QRN<CX8%ZBMP!T)A8!#.P8"J)@#$A6%":*#FP`"NX`#]3@7E,$#RBGL#H,
M-:4`#*K`##Y!$>:G'L13!WAA:!'5(^;`#C0N*ZZ!!VB`"M3!$=I5'4BADZ4!
M#LB@"DHA';;!%,IC#+Q`$12A$^+`?32C'#`,"G1!'Z`A6;T@%ZC`$0&T&5:B
M'"#AM.X(<#<:L`,["/72)YMA$:I`%*0!DIE@#ZJ@SDC_00UB@4Y70A%@0`RH
M80>0[PB(@`BVP)PS&K1O0?]*]"/,82WDH84SDBG6*&HI#H>CC"3HP2VT%H2O
M@5OJ8R;0-H_DX1G,BXA#XAS04CGJC1[&@34RR6\/R=\X1KD?!K2?^[G7`6+Y
M`2W%A:.W<-9"HKE1QASPY8B\P12ZX&KV(`Y&H0OXHPIHX`GV0!3NH`NH@%L]
M`1WPH1_B00?:=1:NX1I<`1JJ`4I7XPXZC!=\5X,W6IV>(`\.HQSNNPJ^80["
M-1OT8,#J"PB>(!6FX1U:X0>@0!3@P1SF@1JX02]`(@_4F^/:X1/V@`GT0(_5
M860,3A^X81'ZNEV00]_2N4[A_XU=](U0>)Q0SH$.*"`0J\`.J&`/IL`3\L$3
M[&!^(E45S.`/<`$'QED)C@`/AB`1_F)J,A7'H5LD;J'V9.8R\&$RD_AD%&T;
M)F--S:A?7L*]G)(>T($=E*;+\2\LAV(<//RXZH%-2U4>ZADDW(C?PF%.Y1)C
M]@52R=(IG!ARO=S1:;B[&<.-E&(U]-<Q+",LG+@'FT@X0((=POH=M"&\P>`4
M\\`5NJ'$D[4,S(`]\``.7*$>K.$5NH$)"B0:@"(90-4=8#M0;``]DAFAJ,D&
MHN!`]*$;>,`&F.`;5J&3`38(U.`>YH`2>R$:R"$2[CNF"_,=DD&1;*+!K(`Y
M/R$*?O\@"G1`#U#8'8Y"$F@<`ID:48V*P$5B)CSBLU;"Q_OW'.)`EZD`?7`/
M"E3."EY`@2.5S\0`&@!8"HX@%#P!!Q@A'@!SF9'%,N!M"C45:0Z=?B9>!CWB
M$BYAFKPB'$[ZN"QK1_9B)<Z!)][H47,DY=?!&I:AW^SVC,PA'%I5:;:-<4<U
MY:$EV3HBGB>S:,(PB",=,B9Z9-:B+`.7?0?[T3TKT6E(BJ:8AB+C'`XZ)-8A
M*_RB!(N+ZT-"-.?(LE`^9-[A%4[K%;`#:UBA&UA,#^)`$<#`[5=A&!9('**A
M&^)@"J+F';I!&]#!N.BA"WJ@![II(Y(M&4S!%71!/@?,$W3_XAJ2@`>>0!UR
M@09H8!28@`;LP!UT50=.@1C`NPIXH,.K(QJ")"/WX<VL0!82+A=2N0Q6,1UL
MHM.#Q1VX@:^70ADV(1_\(1CP`1,^*1A@R!""H1PFX1V801CJX1:.H1LT(1V*
MX17BX20VB!Z*H1;HX236X1;HP1F*@1XP81O281@0ZTJ5P1W>01CR`4SB81CR
M81RN]&G=00ZHP!:Z@`RL@`H89`[T(;U5KGZ-"B`\-3BR*X82)4>VE&JRJ)Z^
MAQ#SW8-(,1_%B!<=7MRX;^/%CAY#ALQTZ9Q'<L+T381(SUHZ?1;QT:-7;Q[$
M??C,/317CUZ[:\A6BO1H<>A&?/CT_]'39XY</6KT\*U;IU-?O77ZY"5E:M1<
M1YE"N<K49X\B/G+A0HXSAY3CUI`SC<J=2Y<NOJ)TP];=BY.>NXGTL)J%N"ZM
M4I4>EQY5O#%<4HL]]<W#MJYLI!I5[KBJ%^>&EU'WNL&+A]5>NJC$\$SILNM:
M-F+<\LF>&(<'CT]C[[W+9\H&#S4O&;F0$@>>/GA/>AA1UXW&BRH^:.BQ%P?*
M#5'3MIF"`L73/7LMRXT+S._<FR=17*E4YB0/'B]YOCUL"Y$:)&X;*2501@)%
M,`68*)/`)/DHD(8_#F@B2`;,8*#"*Q)H8H($#9Z@"0&9`&)!,`ZL<<D"E*20
M0#`6K*&)`?^WE'#!,1:DD8D!F'RP`B0%'$/"!>-X9`XCMG@RQ1E5>'''#XSH
MDT<01>Y55R<-B.$*$4@HD800>"2RACZ7(#`!!AILP,%2F7B0@08L**-/4IMP
M,`(F#SF#`@<D'/-0,"-P8,A6FY3``9OZ\`,(!RDT\Y!-KU0"43`HD."+/LVL
M$8@@@PRB"4P>M7*)/%I19,XUR]A$$3W8M",;1.Q8\Y8^YZR3%#W48+5,-!H9
M10]>C/'5D3SST)/6/NLL`Q$^\H!$T3R"/40//Y)9`Q$_R#HTEE+"*B4./KP.
M^BE6I^Y$3DC9*NG17=Z&.U>ME(K++4LP[5-/4N84>U$^@;E+T3G_R)YY43E5
M471/JEZ=Z4H<I,!:SDON[!!%'-#HXP@-3\3!#3?WN)/./;K5DT\T4P"!AS;A
M9&/,-?7`,\]$C-#@0QS?\-/1.O?$D809GL2##RA1>!&'.O5P(\43.H!#3`TT
M\&###7GHTX8./\A"SCN@_%!%)]S8TTX[^_"S#3R;WN'#%*6\4T\V<;B'1QRN
MK!KM.8TH>U$SP-#CCS/-8-(,/8A,HD\PP9@33#/.`.../\SDDXDUP?CCCB_!
MC(/).?U@0D\FS@0S23/%9$(/)L"<8X@RFE`R#B*46%-(.954TLTA_6QB2$CG
MP$'**3<X7<4>4#B2SQLT*&*N2!,QN84N_SB(00011R!1A"/W;`-))98T`D`)
M^KR813'*;&``,]$KD,DFU^MS00C-A("!/N,H4(@S!A2B#_>9&,*`H"@DX,R-
M$&42`"(/-1-`(908,!X@:UB#"0``"9&\XA)2N4@XZ%&.<M0J,$Z92%+&L0QL
M/60=\KC'RAPR#FR\8RZGZI9<-&B1>=3#'&G)ASG4]I#(4*0>Y)#7>-CRJ:C@
MHQUOB<N9&&..>LVG*JFZR#W80BYC%7%W2$SB1;(E0B4>Y2'E^,I&WH$,>4%D
M/`^)UKK4I4"LG`.'T9A#&;J0C'RX@QKN>,<3H'`'4^B#%#V`0A6Z\9![3*6!
M^M@'-9[0,'``H_\:W/"&3/;!#GK`0@=JF(,VP#,5<*#'"Z38ACX8,08]Y$&0
MT_@!%)[PC7(8H0=1@((-3J$/.$0A"J)XF"=L8(5.?.,=Z%B'1<X1#VZ8@PI1
MN$,NRL$-=9#B#IX811YVD0Z51:L<D"A'2**5%$/8;3Z(*=>I]H&7E>#E5QC9
MRF.$-1&)'.9=J&)$%:B`"BILL@I5F$,^0C&&1CAQ(Y[(`1AXL8.#'$0,2$@$
M8_`Q)I4LX!#EVH`$]*&"$3SD`O]8A_^8LH!R8&(!#Z$$1/OSD`ZD0!\&"(9D
M#)`2%7C``81XR"0N\)`-J`\B63C!0ZX)D5;<XDSKF@]2\E&/EUQD'=O_FD\[
MB#4LDSR$&P[A!C;T<BXG-K`>X;!)(35%+G,\@SY9)$>WWC$/J.[P3.,0%C[<
MP9)\F<.G\]&(IRYR1&^Q%(E-5%):WQF2?`AK'O+82#ZLX9.5:H1:QKHF%_6A
MJE^90S%3BT8>RG"'73PD'<SHQ@TV6212`*$*<8B5/LHAR8E,`VEJD`8S^E&/
M#[;P'L:X@1WN,`?Y="0/.KA#&4Q1%D\\X0Z=@`<]N('.)X!#'UWP012FH`-=
MZ&,.58@"'NK!C"LL]@W@T,4NI*&-:N1"%+S0AQM^\(9=T",9]X#&&_2@AU'L
M@AE@A0@R;3H73JQNK18Y*U&4U!'9J/>*<=#!_Q-*D8HIW.$.5;`='7Y`"K92
M)!13$(,NZID$(HAA"5AXA$Z68CV;Z,\9QM)'__3A`4`\!!`;$%!2ZK$`912"
M`P]1!@/H88'5Z2,0(U"&`?@Q$05P0A\O'4$@'C(.#Q3B$!V`L$,H<8!\>>05
MEIC/::RR4JM,3!_NN,L]Z.$I$YYI*ZKZZYG*$51L2-:_(5E'.B+#9'LQ)5?[
M!/-'RM$MO7WKJG"Y)E2C4D>]T"-:X;(AEN=,9UGEE"+N6`H\!+.5-^_$LQZI
M*DR4^:MQJ.,4=E!#*<3Q$'>8H@=CF`(H]*&('CPA#[4B1XXFL@XFA!(4K6"%
M)QCA"E*0PA+O((<1]O^@!R]X(AKW@,4-:E:%9-@#'Z2H61YDRXU'5F,?C'A"
M%:8PA61,,I2BJ`<[%,&#*CSA!SRP`Q.F$%P>V$*Z-ZC"+MY!C7N48P[<384K
MX`%HB"B/JW3I1X[JO)?W/N0<<M!!%$IQA]>^(0EST`<57M#?.8=B(,3`P4&.
MH(0M7"$1ARE$``2E#V>\KXYW,P`]+G#20HS`&0D`R0(P40@6A)@!YTB`B0/!
M@68HP%,EMM<&9HRJ#5R``Q9@N/=6]]Y\:"+(+%G'E<OQCG4H<R509@F[(CR3
M)>.1W1OQ]DLF0NBJYF0G$''(/LBUE"(^:R/F\/$2NP7G9;H;Z6`/>UUX&G7_
M'SI%Z)]"E[X^R#*R8N.79<!#*:31#6A4`0CUAL5O@1"%75-,)0U,AVRH,>PR
ME($[4K!"%=Z0SJ5@X0FC-<,3O"!L(8$A&TEA!!3LX(:77.,)U);&&VVPVS)@
M0Q]?H+9Z\*$(-MK!V4%2[1W>D`M]4+X*JY`-._31"CWP(0^R<,@#W1$)28K]
M^..0@QIL$8H>/';81;K#"T0132=.1!%-:@4$C'"0&"@"#EKH2"8$L"AV!>`5
M5K$()0+@O9.B(,4*@,@"@H$(CT>\_1<F03,,`&%])(`2>:0/'&!A^C`"*'!A
M'3`G!A!><G4)Z+<5];`-0E$4$0AT.^%C^'`.4V<L__-0#C;A$-:P;L>7#LE0
M4]:@$5D'5C1$9EFD51;!#P]D+-TR#R911.<P5I]B0FE55L?7@S[X$?1P=C)8
M%TTT$>]0%A2Q,JV0!WOP"9V@!FKP!D(R3MJ@#V]P`U80!]+`9526#O:0#\PP
M;%.`!W>`!U)X!Y_`!Z)@$[#P!'JP!YU0;U[@!>C$""M!,V7@!<IT#4=`AZ+7
M"BZ`3EU@'(I0!D]`"E(Q!YOW!OA527?@!8R8#/MP!U/P!K9@$>M`#]5`!W<P
M3%A!0^GR#I9P9S]89]8`!ZY`!S<`!)LT!DLP"K<S`TF"98K@`F"`"SDP!48@
M<)Y0!&S`#^.P<1?!`2!V8O\I\@$%2`(/,0(IP`\+("CGL&*;D``B18TCH`(E
M]0_Y8`#`T"?S1RDC0(`7P"?`D``VD2AR80GH5Q3D)DO5QT!ZL0_*\$#A$"OO
ML&[O\%7&)W;XD`XOL4(WP4(75!,440[Y@%<_E!0Y42_G4"NYPA3KT!$X82Q4
M$1+6H'4WD62EN)$<*1DX$5=*T2WTL&0>L0\>Z!$12&C7$@^D@`>?,`I[L`>S
MAU_>@5LWH`-XT`WXL0_F`!C3H`^K\`1G>%]T.#9C$`<YT@Y=4`9YP`A$J5I=
M4`W0H@BY1`>>9P5>$`52V0HX8(9YL!N>@%_])0^DD!E"L@>,=P=4``9O0`WF
ML'C_5:!W,!$5GJ`&H^`*?$81HDB*%:$O-P%-LQ%",)$47S$JU*20=[$/[;5A
M]C)-@_EU[B`'=.`%0,`#9X`>/)!OJCB+[T0;+B`&N&`$4J`$,2`%K@`!<F`/
M%A``?D`"*8`"VAB,%H`)(@``#%`,$;<)$@5A)%!R=:(4"2`(_Z$^P3!_DY!1
M!8@C*1!_*G=1$I8`PM`,&R".,Y96^;`)KT!31D86Y'`/>-$3,C,LY`"*9W(.
M.208,/0.&G5\ZS`-$T,.Y'4.`HDJV4(/X^!#\[$4#?DKC+$//A6$]^(I9:85
M1*44,M>1".J#-V0.Y)6$U]!U.T2>A#$35/<.]R`-8S,*_RUY2H\(#;+1!5BH
M!]S@-3RI$O90#NP0E'GP!HSX'K-S!TVX&_HP#%10!G$P!5Y`!7BP!ZX`&),$
M!'N0!\HR#530"7M@;,SP!)Z0!YXP*^*D;>R`:U`P!F7PHG=@!6\P"EJ8#U20
M&;671>;`"GKP":X0#_.ADN9P"59$#^=@1E]H$O)0+UF%9#!1%K."#\@2%[L!
M+TI1=2T$$Q;QA?E0%M]19$MD%..`!7V@"SG0;%'`1[#H"7NP"G0&"DG0!;GP
M!**9!*H0"T4@!_I@""NP`B0P`OV!+.>0`ATP`I10"#&G#YJ``1[P4JB2`A>0
M`FW**!V``07T$/YP`1ZPGONP`O\),`*"LA63<%XG9@$70`CQ,!&(X`]R<0N7
MX%GOH!CTT),F"A)\>D%Y!))G,@]2ED7S8!',\`[,P(/^15P.I!4^M0XW2%97
M1@_*T'7BBH-9%)(W-1%+QAA^=D5+L8/JFJ`$ZT3"(@^^(D(5B75(,:XK=9!!
M"%9Q@12P$`=[4`IYH`=FT`G7H!3W,`=YP*3;DG5;81'DX`A>H`=AB0>CT`EQ
MH`>=$`JFT$WVD`N>8`9CD!EZ$`O[Y`B*\`F.T`[Z<`VA4`JN(!_<T`JNX`JY
M\!VXX`FDP`OR@0N@0`JPX`JSP`J@P`JSP`N[4`[W$`FY0`S4$)#K0`W6X(Y*
MP4+F$`G_*@D1AJ``QU`"PKDAA=`!]+`)%N`V"'`+:]`!_<`"AT`BP?`/@!L"
MA'`+&%`,B!`"Z=`!C7`,'3`,AQ`"W:`"DW`,']`/AK`&Y>`AY9`&Q]`(C9`,
M*\`,E&`(1[0-<N`#HM`%/#`%W`$%?(!;0>`)Y<)6JB`$86`,/*`$$.`*>9`#
M7<`&$/I-%!$,Z):$IR(1%#,16O48-_%U5O%!?S<7^=`*J.:C45<.\'!"%`&#
M6_=D>82?4C8-Y)`=88</]6`-][!E?/40F0(1-D&#G[(6&!D.)N%DR^)`&]%V
M]7!E>%&B(4&2`5BP"(QTY4`.YLD1X4IUQB*"VIES9Z)%I#`'_V-#"J)`#/,Q
M#;M@"[F0"]>0%`9)$?*`"[H@#=,@#,)0#LP0#<3@CX*7+OI0#;#`"E:[DQ2Q
M9_$@D19Q#_PPJ/;`K_=0#Q2S9554%MTP,0Y1#L:05W9T>C=U97E$38J!3"((
M$<``"/T`"9K`#"G@#)B`".:`"25@#N-0`L)`"8*0#FD`"=N@`LJ`"2HP#FN`
M",P`/H<@".50`I"0Q\+0""=`#2<`"<<0K()PNA>`""QR"R1P`I<@`<6@`BB@
M=191#G+P`GS@"C=`!MR!;]+U`J5`9XH0`V&0"S"P!&&`"S4P!DTP"(H9%84Y
M&&X5$9!!5N_R%DPD12)1%-2[$=BI#__;D,4/<8]&+)Z2P1B9(K$@<:)640_C
ML(](-PZ9R`T@\1:9B"J*81/:!$TLT0PG5&;XJ2G;X!#7Q&8#6\MHEL#LK$00
M^!7]XI=*X2[1(BP\0584BA'W<`V[L`O18%.R80V&\63X,`_4%'7?,4LSP2O;
M(A'NA1@6<=!$D5X/#:CNY5Z,Q"C49#6SHA+K0#42J1OL8!P;D0XE^Q:*.5F0
M8$4BH1@H0,SBHD$0P:_D:P_N8`\VW:WY*E?Z\`Z2,`:0Y`.SY@7=H0]W$`2C
M7*#F<GTP$`:V8`1#T`E'(`:@L`9M8%85/=&_S&X'U-/,0,7W,`YZD1,,""S%
M0BU^QD!800[_RH"$[)8/$--V62%H>:03+#8H.K%FPD(/<25UGV)5%&$-S>"=
M&\$/6?=$.UV2[;S8WE+07M81;-;2:44MZ@6O%6%#Z?!!%%W0/A<K?179$\$3
M^]`.]2`/$U,-0IN$9S4J>+':0Q$.XU`/_FL.[%`4JL*^ANIE-Z48&X@NYF`)
M;SL7\T`"RE2RO?S0;C4J?>E$LR0'0=``DF`%9(!?25`'1O(";T#*+K`%VN<%
M7``!0Q`&B;`(NZ<82LW8(E$/EO!2NJ%,UU0/SM"@23$/!_INX94/_FL5CC$/
MS(`?=%84S+`MZX8/S7`J<P.$M=(6S\(N;)83[.)3;<%`[[!E;Q8M_\K0#[H-
M$:F2W]_$K40(H0>)WAP9L&1E$D6\$?1P&M>*XO.(O#*%GQ9!#SB]G[)!$RHQ
MDEE1%26*#V$1&>7@#-!,%UL]%->@3`XD5;J11P&+%?RPO.:`KU`'V#]E"0U*
M%Y0PSKV\W&!G#9+P!%10#:>P!%5@!9>F#W'0`VXT9XH@`T?`J%QP!U*0BT*0
M"%P%L2*^%_>@CJ@RA"PQ$_(B%5B>S1"Q#(RQ##K!#2S]3A*Q#55E4_A@*H76
M&`RH%//`#].D$_[Y%N'`9VCL$.LPGPGI$=N`/4D88;EM%+V]T\HM*^QUO!E>
M%ZG^ZF=&OGU6*RG]*^HB$QLV$U)%UT5V#__(0%X#W.EOMA7[8!/9^A'&DB^U
MLF#%PI.U,A6#DB-B#7;W8`W;0F4]J1NG<@Y#1%82VJ<B1`[;T`@=>^?>,@Z+
M0`>RP`-YD`LUH`914"1Y``6S0&>J(`9_,`VB"09#@`-<``*V<TUJYNKHG>>:
MD$#>/"C.0A_`4L&,4=I89$2$L2V!T4VSOCN\=-@\%9$[847U0.C8I`_DH#8=
MT0SK(-;KX`O(H@S``%<K%`SG8`[4$`S",`[CT`S!T#96$0S*`"_]H`PMSBC;
ML`W*<`[-T)#]P#?\T`P3WZ=G(KXR=2SLZU;C84.Z?,VZW"="IY#@Y.(BL?5+
MU'5K=<"H/AA"A*W_I^+$7J9-4D$.=\H1#-@N"]_32Y%>&*$I4C4L]7@3FSZ0
M@0%V](`,2Y$.L?$0FC8O,!U#A8V19](NA`#J1E'V!#L.C$`%71`%-)`,YU$#
M_=4%-(!P<P8&30T+."`%8+`%7.`%3+`(/G7+<L&#(4[Y_PT3KY`2[H*M9XW;
M^[#WJ;XN"VTL$L17YHD/QP#3;!4-R:"0F>AM[((ML3+?S$L5?DUA)*(^_G$(
M*)`%'&`.@;`"?K`!X[`!KLD!P#`"*Y`&)*`,_P`()$`"_,`!X%]R_H<(J=H!
M'$`)JZH"@8`)M\H!`)%)G[Y,)/296V$(A;YQ@2AM^,?A'*8.(T8$0V&Q_]`^
M??XLDC`$*!\]0,!(J!AA2%^^0LWT<<0T:9]*98+T8<)4,,4Y??CT&5(!:)R[
M?RA(.-,7;`6B%(;^\>-GR%FAHBKUT:.D8M(YIBC^T2ODK!F*0"@*%40!B./!
M0BB04@*4@E)/37[^^=('[%\*0,PJ43M7SYRA?<TPW62F;]*X?L'R[:,T:9*Y
MJ(80*<.W;N!F?/6NYML\$!^]T**;^0QMCAQJ??+,B::'[W5IVK5MWR9W;2"Y
M>P/K<6-]4'-H>N1HTT-.>Y_/<HO&W88.'?3FZ;:KZ^L=7?OF<7#FM)(#9,JG
M&U5`T;L3Q--V]J7!P/BS"L<1)43`A**P:-V^[/_7VZ\<*!__:`ONO__N@>25
MM4JCQYSA-CM''GT>O(JC<PKT2;;-VJ%G'68\,Y`]>(CA1I]SQD$MG-A(NXJT
MZC(+;;C]-MO@F0X4:.:?0OP8"!A.6.!)QQ64T8>$0D9XSH)`4AB(!$10X$>?
M"X#)!`44>"+A%BDW468<2CBXR8*!-C%H'!(P,8`2,RE1R9!`"BGDG'Z:&>&@
M"YZCQYT-Q+J`'W-&F,0"<YHYAR,.@EGIG`LN,(<#9_X)X)RT)#*DD($"&6&B
M%/SA8!QG2.,'F`V``<:">?1!`1,.F@$FRIM2H.>?3,[A`)!FFC$`D*0X^&<9
M0/T!9B!:"_E2F0U4P*G_210FN0`CN7)BP<1UE`D`DW!*T,>"#O3QH)D5Q,2U
MD!0N2J`00(+9!T3B>#K.FGT6;/&>["J$L2?/UNEL'G/H*2?$__!AAC1ZGO.M
MW\W@'8B>>T:KK<">=FO$N/8&E,[?BBDN;1LM+I&F"2MN\.*.&YK0IXH71+%8
MNS@@$..;)Y00@PLQB(%#BWI&TF<>>O*QA^+>8GLIN'OL`9K!Z5C#Q^&4:;ND
M%6L(?&<<"E^:)AQU7YIG'8(37ABU#/6I)^MMEH9NFL3T6<9@?;999]X&\=EG
MNGQ.Q2XY??BAA^X5@$%A$[.*PGF2%"3$I"P4/%!A'@M04$&02B892)!Q2[C`
M_Z82UMA@KA'\D1*%#8@%DYX-HL2D3)"*@LLR?9K9(%`.1NBGUA$LW>Q.>BX@
M@0,+_%D`A0L$*I)(?0Y!Y!]_$"E$!40$WR>0#1"YL,A@]>&@+42LNAM,<Q)0
MP2AE+%"!!.#/(4%6TE`0:)+272(A6!("":22@=H:")"J,NGGJC,)0H$O2C8)
M!K9\0BQLG4`3@5!!,`HQCA20(!C]N,")VG<!?U`B&$E3CCMJH[!US"9AI$$:
MB\S!D0SA(VL3PL8]!$0VV[1C&F`C!]T2QAF.+(A%`&(/:)"Q"-V4YA:$V`8D
M,F$-%31#$X@H!R2*H0]A0`X3AG@')(+!C$"4(Q.0L/]')80Q#B#6(A/N@,0Q
MSJ$)>A1#&/;81#.LL0E[,$,9]PC&-O@1C'H4@QGQ4$;4QG$SVHQC$+=@`A!J
M\(-/Q.$&KM`'%5S`BI>PD#:=B,`0<D$$,<1,"6"`0R+8T1FP]:8>,#H5/KK6
MR(=AQS?UD!?"@I,A&89&:?\!S3M:`0L4U<8:6^-,,]2V&6OPA#7R:.4Y)$:.
M=7!C:BS$AS6.H9EIJ.T=PGB'*]NA-`<1QX,;",8&9F(`8,!N'ZUCP3.*I*IF
M!(-1%\"$3SA%&0YL0B*'&,$R.E`)E.B#!0)IUD"^E)0+<"08=1I'2E+0#P60
M@!*(T`<E4@*Y?014&85@Z$O_-G`.6@UJ!)G0YCF`1@*7Z&,#(^"5,CP0B'`H
MH!#!V(0^`@$F?:S@,/1("2"<@:B!_$D?$*3214:@C$QT-!C*`$9"BH3/0G`@
M$/H80;!&$!F:%F(%`S&$(4@`"*D,1`6:Z$A:'$()8##I(`KXQP6488@$1(8#
MDZ`$"=)RC@0<+AC.:%T@,B&/5\*M-`@3#<:P9LJ$]>L=R(BF(VFSCFIHAAX2
MXNL\5%D;O(8&7J!I1B/401M(9&`9+%"!,`Q0"T1X(!@(V`0^0K`0$EQ@&QA8
M@R8(<`L5.(`9#EB!,`+@#Q5T2P%K\`4#;K&&!'0#`8"X10".$0(#;`,!:0B&
M`"@1_X(06&*U:\!`.N8%H&6PP18W$"004I&'*+A!'XQ`Q2D$2YLX/*$+KC`"
M?98@!C`XH1'M0(<WX+$.=LBK'N6H!SSBT;9Z\$<TON%(/=9!CWJ`B,!MN\=^
M7>F3Z8[W'JVPQ#Q,2)MRK&.7-2W:9NB1#MI<@S7\$*<^WO&A8Y*-'LB0;CG(
M$<T#4\.5YFCE0/A!#@\>S$3[`(0R4-#0#IP#HR-004(_^@]]I``IB`A$CANY
MTMGA8Z?ZR$()K(*D%`AD!![H`/HN,()1-;*![:R2/H[D#PN08`/->,@*+B#5
MJV`S0!P8%)CRL3D%6(EVN5O!/W1%#P\H0P%X^7,P+!`27?_EA0.40`$E_+&0
MU'"@,!;P"0J`<5;U^<00(\@1Y#C@CV#\8Q_*6``_.""01/L#$SP91P<P(5+6
M`>\Y)/"#/WZ'`D,`PQ\>>:M"SH'`8@A@I@)0QD6SN8D+$,2!$;R5M.Y:F^E.
MF)2PN>%`]L&NEZP&;-:PQWA#,PYOU$-A&8J-UVCCJLW$N#0.2T<C7%R:8K[#
MPNLXASW>X8YU;".:75U;,]Y1CG+<@QGIV$8_TL$,>Q^C'(QY1S"L80YEE.,8
MQ8C'+9JQCU>4XQ::L/@Q^@&)9FSB$LP`XB4@P==M>P<*/U##'?1@A2<P<@Y,
M((6V0],),?SA%40X0LRXH`0G+(+_'-W@1CR\@0YV%/@;Z8`'/'J3-(6UHQWW
M$!@JU]$.>'B[14&?+XOJ(8]U()@V>OT/A%FTCV@;&%XU+#M>HP<A@Y%C&_FH
ML8FM8>%RS.,=GB':51;L,+N5YASN8!&+1L,13SV,'DCASL[`UB^?-,A$&O6)
M9V*3C\9?A1_GP-OEQQ'MG[[D-?O85SFCQ(^9!H.BI!G'UE!T^9<$8X[`P`1-
MSV%JT_ND&>9PAH2:@7I`'`8UG8;<.82GX4R,QA_TV$>K,L$FFB8ET0-1QHEF
MXP]^1#\I434$NW9MY(X0C!_Y>*@@#N,/R^S-38$`!IX.48Q,3'LQG%.,`I]C
MB&`$HBCR_\L,8@.T';+3@]S<^;]\&`<;F@?/4(:GD3E^JX=V`(T!BY$"V9<"
M@8K:P)O2`(US6(07*@UY"1#/4"$!X4`=(SG_"`X0]*1H4QK0J(=L4R$;T[O0
M&(EPB`,CT`%1*(4RD((F@`)/R`<O>($\D+D`"8,8"(-<R+DM^(,MD((B2(1T
M`(=J\(8HE*]Z4(=O@`=UJ#JE>X=[2(=NJX=XF*]T4(<Q3(=TR+8K!`<K3+![
M6(=Z2`<PC(<`D9<Y?"7VF(=+N`1\D!O!<Z4;0HUWV8P5;!$-ZPG!:P?CN(?G
ML`8.8Z%[F#MSX)`)\3;0T)"K$+>[BKN7T*C:"`>-`@T;^L/&.O^.:.._3`S"
MI<&K.CQ%?_D_]B@':G,L5S$'7"J-3_HO`FFLVU,.4BQ$T:B'<\B'<N"&JV&A
M?>`-<F"1P`B-M8,07MR\#>)%AFB$'K)`[0@&F_@Z`9&;T%`A#('!@>B-#XR'
M>W@'>S#'H2&P<`P-:Y`$*2`%7<B!);`"*:B".<@'/'@!4#C%?/B"&/B#7)B/
M(Y`"+I`")&"$:L@&;\@&*,1"=:B';U`';NB&+(R'=""'^/J&>+BO>,B&;P"Z
M,A3#;_"&;E"'=,"Z,BQ)$+$O#R2-!OL/2,`JXFA)"EF.I+D:%LD'>#"\KQG$
MV$"E<%R':W#)$$F'PT(\?7@ZSO`V%!S_"!DBNW,;Q`ZCMN`(-]K0&=%8$)PQ
M$'M0Q54T$%'TRHIQ)099"PA<"X0!H5O</QD3O,;"(.5@1L[(L(0AH=*@&P%K
MD7>((9E;L8$(!XF!#J6)1NA(AT58!HN1#;VB&(SAP(>9EWS@AVP[QY5H3!P:
M"&Y8!"PHA2ZH@BJP@B[0`5-(I!>(N5/$@P8(`UO`@4Z@!2H(`S!H@D28AFCH
M!F\`AW;(!G3X!G;PABKL377HS6O`AFS`AFOHPOS"!G$`AVM0!W90!VS@AC$4
M27AP3H6,0@]4.E0BN=Z@O/]X!TO0DG/;%T:DH1<\F')4FP&I0./`A[OSC)\C
MFX!9AV:8#JD)_XUY(`>$.<'0^+Z56)!I^T;KN(IE(,\^7`X""<L$5=`%-<^[
M"BS:J":U+"4"B49Z0$`+1`ZTE#;6.#M+C)&5>(=TF(=:8B%S,(<%;+R^4XZN
MM`V$`8UM6(1P6,4,$1!BM+J1\(RX6<N'*3#ZHH>[^]&?M*N'Z0=&^(92@(([
M>(,I6%)2R`<JL('2#,(X0$U;.`(P\`(IV((ON()&6(9J$$EL0$AOX(9KR(9K
MB$)Q<$YV$(=L<--J@`>%_(9H0$CF!,Z$A$B'Y$W<Q`9LT`9Q4+JB>X?Z^B#9
M:!#DH%%BY,]+",]S&P=8U##`W`QWD]09"HUZ"`=/V@;26`=C8(>4L?\&9O"W
M!R71UM`_#0L'AWD.G8FV&VJ0`X5&2-TV4U11!K756PU"_YO0<L,0CL"83:R-
MN/RZ%"1$V)"-X&A#T""'=(C0I0&8=KC*=S!4D@M0[5@LVB"'1KC0B=G1Y+#)
MT?`)`7$'#$(.>C#'3Q(8WX"ZE^@0-NS->:#.^:JOFQD-H$F&1&`$*9B"."`#
M)GB"*I`$?1@%.UB%552$,GB$7%""(R""+?`"+FB"12`&:=`&;\A3-[T&A!S.
MA%1(,W73;!A#A6P'A$3(A:R&:,@&;<`&=0!9C$6'A"S#KNM"Y[R'+[PO=D@'
M=5&A;@2-=;V*>(B$2ZA`N\0&<S,11:V':2#_Q1/!(7QXQKJ))FM`!M0`.^H8
M"(>+!W.()GNH6?+LD%.]"HJJC3;40VX$D<=XD>-XB<;:A_RQC<&$#KC%U;D]
M1:7!!V#L/Z1QRWVQ#6"U0!;E*X3IH+BK5YGDI=A(SQ#!!WN[.Q%CL9X`2^V8
M2[TK6P!ICK.A#1;,-A4$(?[HD!FRNGIPMZZ3C7<XARV,A[EQ!WD;5"ULPZQ9
MAWDX5WIHAW$HAW18!S'DAC*L!W:8I@*[AGP=`SSP@C*@@B[@`D;8!R^P`498
MQ3C(@3_`!2-0@BT``R7<`D>`AFJH!FW06#?5!I7MWI*-!FU`63'UAFH0!VUX
MTVR(AN'LT_'=V(VM_UCCO,+J?,[Y`D-V*`?=+(=Q]`Q4TL[IX@9+>(6#<!A\
MZ:_2:-;00$8(M4MK\!KITH<RE=MJ/#'-P,M[^9FU>)"DX0=8+0W>V"!P739?
MY`S`1::JI=L6]DI3M$S:Z(<+IHT6U(Z1>$OBL+87BS98G;'[(D\69I`/J1MP
MHTJ\(CN'6;JOJXUT8(-HH(UTN`4\,H=\.(9WL(9FJ`=H>H=EZ`V"JX=M*(=G
M2C!N@(=DV(9XV(9[$.-[2(9N@.-[,*;?>,.<Q=EYLX?<I8=I:,/;W=W[1;H"
M8X=K(`4JJ((I@()#GH(ML`1],(,@T,>A=-8M:(`_<`4B4`(DV()-+@)&0/\&
M8H@&::!3:-A8]U59](4&:*!3A%19-^U3/\4&.L4&4'Y?*/1><8A"DT6'^.K-
M+KS?W6R',NRVK%,'#OI)-\Q=2&B%M&3@H#DWI5'48DT8$QX8SY@&;/B/="B&
ML>&7QH2'>>"'P-H'NDGBGJ#*V#!:?2"FAF&P<X-;%7;A>);G\9I<QHKF&]Z'
M5OP@=F8L<M2'7O*7>6`;2=R,#BJ-I]TV<^,D7&QB24@,>&D$`[@%#@B!3``M
M07``32@`2#B$`P"&8T``3'@'"4B5`-"$-4``:IB`$-`%!M`$$9"`;9B`-;B%
M`O@A#:`&#?@C"1@&0@`!9@@!0C@&"6@%Y;D%#7C_A4$X@=O]9C%,!W98!E#H
MS"E@.3J8@RD@A7KP`AI8CU/<`@CX`UC`Y.KE`B_H`D=(!F*`!FU0:_.MAECV
M4SIUTUH.W_)UWX6,AO+MWFAHZ_;=ZS?MWFS`Y;>&3OE*AY+MR.9D!]X4!ZIK
MAZ/336*ZADB`!1@F1=:(QB%]R@KQ3QL:#G:@!J@;AFJ@8=K5-WVPAVU0EW/@
MA@'DC%X,1-3@N@.=FI'0%]LPAW,X)IR1#?^2-AK^C\B=Y^$V,:\4$`QZI7*@
M)F86#89A#67,F_T;#0<D!VPHL;CEEX'85-'(SQ<[#EG-#'/;!\"KQG*(!&0P
MY^6XAUN`!&NHA%<XAD-@_X8K8@9$.`9?"`1F.`85D!]"V(1M6`-D>`5!X(9&
M,`1A2`-A@`1"Z`=!B(1:2(-A.`05.(9!J(1B"`%J.`032`86:(-;R(!;.($U
M>`6>S@(30(>G;H>ILX9KB`922#DS,`,U&(51J$=]B`(:0)E3#`/4S(8<4`(E
M,(,N"`4P<(1HV%YB4&OBS&NWQ@;KQ(:UG@;YC6MHR`9B,-\L?VON-5]NT`95
M?O*\!E_B=%-N^(:$!$[@++J&I$ZDBX>@@]=VB`1<@%7DK@T)DU#'.IC9\!H9
M6N+,Z`QV>-]['HAT0(8>V@9KJ(YR6`92[$1J!9$18HUC6@ZZN8YYL`:PU;!#
M9?]B>B;N3Y>Y<76DNO*_P30'>'[+S3;H060-`2.-=D"&=+8-9GB-X@B.K,SS
MN(7G"8F$9`";`O.,:/)`R7,1ONH72!BYWNB&>RA)?;C=>=#(IZ[(>O"&KG7#
M=!A4,,Q(>$"Z<NB&;_@&-S1CVZ3.*!S#8+X&8P"%.Z@"'GB"*.A,+V@%?7`#
M()!2F8N#&MB";-`!*`AR)("&+Y`#:<!R8ICE\LURO0:'O*;3O*Z&;CC9O$YE
M[AU?:%#R+S=?+"=E)/_8CE_ECHROA*2Z=?"&_G7.=$CQ^.)V;O`&2Q`&P2#+
M9\MUZ"A`$7[M2]4,<EA?:^#.TG@'<2C.J[`[#PY*4E3_,8<Y]2&E4#UW++BQ
MQ=IH8U"7^JEOT1`9D.Z\#<=C+-M@T6^%T`?!/=*HAVM(3XRIAU!U=4U_;>&&
MRFR&!,`B5'FI.@'F=GI@AW>8MT%E!VZXAT&`A'LH^355!S"5!C"M3758AV[(
M!C,'!VZ'^&M(P]ZLANA\>'"@AFH`!XAG>92]AO@:;.',A3G``SJH@B@8`SUX
M`R\0A7SPA#T0S5,,A3((!5C(@8&\I$XX`D<8AFC(A;56922'AF18ZVB8AHQ/
MAER(AF0H?HOG:[5.923/>.!7<E4FY2_GWH6\\HKM7HBLAFF0PJ/[2&O@AMM<
M!VHP27B@AD88!H;8U;H<6Z,=_]I`=$!N/-4%1"4L;@=K^-30.,3\[[HZ!PAS
MYLJ-PZ</W[IU\N09U.?PH+5F#1\ZQ&=NWSZ*^N8UI'>.WL.)%>O=&Z>18L:3
M*E>R;.GR)<R8,F?2;)FO9DMZ($_6<R>2XLZ3\U8&=7BS7M&#Z\*=_!BR'4AS
MR*S5<]GN&CZD("?^S)<4Y\J;VQI%H\>N7E5ZZ^"AG;>.W=EU]NB]:P=O[:M;
M\.!Y2[=77;5KWK)E`^=-739NU:IE4]>MW#INU\"),US-F[?%W;QUBU:-6^+%
MB;%=4Z>86S0YG=[<J5)%"A4NHNQ1<>$)K$M\?F+XV85D"YXC1I0@D30,&K%<
MTJ(Q)_^6#-HN8M*A)4LFG1ARYL:N0\MUO3DT:=#&2]<V'EHV8MJ8:\.VOAHX
M;-&F8>.F#ATZR>FZ<2OGC9LWU"S&C27"Z$/.3Q7Q<Y-&\UQTDD<_U3/..AJM
M<\Y$Y%RC3S[O1"/.--O<<V`SZ\RC(4CKU&,02/.<D]$\\ERTCCD4S7/C.%_I
MX]$Y'%JHSS[IG#-412+1X\X[]Y3#$D@,XO8DE%%*.25*5'*8H$/TU.AD2%UZ
M^9".#WFEDD!%.4A/50Z10Y(^XF`3ID?LI%/5/?>@]>5#*5E)T3:+&`/5/.^L
M\\Z=;[&C#UKW5)A..W"1$X\Z\*A3#G_HJ-,..(MAD]@UWWS_1MIB^Z6CSC?Q
MH=-.8N)((TTVS&'#6&#7#)@98^(,PT@WG4@1QQ14>#%%*_J\T<-M>W+810->
MV()$&'@,@<,40T@B#'+840?-,=%4)]TTT#"3C"[,Z0(-,MK!D@LLVTD737?C
M86-,-,1$@PUVTQB#W'C2E%<---%\X^EEI7'3#3N*K1/@-=-TTTTRD`SC4(TJ
M\=,C3^;H:+%&%E5(D3DF/9200^4@,T\XZUQ#SCKD>,/.B/.4N,Z(^KQ#SS[T
MI!.S/"'1DZ,^$9_43%!<AI..-40^Y-9!]."C=,A8`LF2S\9*/375+:59M4,9
MX<./TUEVO>,^6'JD$CX9<7D0/@95_U7/.NTXB*!&Y!24SDY9;5513#$_>9,U
MC23S#COKQ`-/.G&Q=1?A[,1CYUKPE/.-7_$`Z$T[_V53#7_@='/9Y8MY-B!_
MBPW&&37?=--O-=)\UOE@@066S36Y+))('F!((444;R1!BCY>S"#*TWO^`0,8
MN\2`1QQ&Y&!$$8NT\OPJK[2RR2617'()]*_`(@PPM[R2ERZ6O"*,+]%+'XOT
MK9BOB3&OQ(+)]^C?8LPPX\,RS'/:2J=Z=9M7\TTYVH&.:\@*'=_@!C.6X[<L
M18TBY"#'5[2D$K7@0V_ZN,<VQL$EN4TD'<RH$#W"$0YVI2,:W'"(DDI$D7>0
M8RY<RHB6,/\&I"5-D&SA",9*(*@/=R3%*2K!T$H:B+4A$E%*_`A3\$[R-28!
MA1\K25O9]*01G:AD'^:`(E`,`B.#-"1M:=I'.^I!N64`\1[O&,?,LB0.H^F#
M:U/<F(6D^!`GRB0CVV`$+M(!P'1X8R^2B\<ZO@&/>,0C'>501SS^=4B_')`;
M\/A&-KJQ'`%58SVK>M5B4N>Y;+!J,>!(1C4^%TKF)"8:VM"&ZK2Q26[H@A$[
M0(4MF+"$)T0!"IYPQQ1L((FIX2$">!!%#L(@!FB!@1%P2`0<OJ`%+7SA$5_X
M`C(3@84KL&$16FB#'Q[AAT3X01%PP,(@M,"&1"C"#UI(1"+8P`;_/PRBF]R<
MG2+0F0A'+*(1CZAG)"P!"4A$(A+[M,0E+%&)2@@4H/P4*"0LL8I(+,)`>%O)
M/.ZF1"4N322*BH>%$M*0>BRC9.0P!BQ>08RA*(D;1<''.YAA#@M6Y"-+S%)2
MZ.&,=HQ#B`X)A]+.=B"G(1&)1?PI4%^"Q*[E0Z<OD2(^>&BU=>@H'VFK(H>H
M6"0P#25L'],'R`XTC750""$JHHI#LJH4/8WH'@_2"!`SQC0(R3%K^BC'(EYA
M2,F5(Y$'(UPW(D<X0WZ#'?``T#H^DP[[1(,_U$B&OOC%G&@D-I2HE,9A0]D-
M5:9N.=JJQC2J08Q5F7)>S*ED-6R1"!P\_Z$4HKC=$Z`P!WTP@A&KF)HBCJ`(
M7M1`":P``PX8\04W-&$)0N!"#*Z0C41LP0QF\`(>FJ"-;L"B"SIX`A6Z@(0K
MK$(:\4!F'+80AF>"(A044((8(+"%*UQ!MTC`0BF.<`6%KF(<P8C&,HAA#68H
M@QD9I`8SBB&,95AC&_H]QC&$\;UAE*L=,6F1&REB5*,YZ1TU6AK'>C2/=.!"
M$\F@ES&,03EFE,,:%,E*,;BAMX:<XZP?!HE4P:0G+?$#9CI*&TXARJ2V!K7&
M-HZ)46'2M11G3*='"E,];+HCHQ@)*#4#TD_H`=:06,/#,N.&-0;+#6YLC![D
M0*O'0G*UD#!58O\ZDB!4^X2+0`KN@)':2SG2X1>_O$60AA0LY`0D26FLIQO=
M6E4RF(.+:(!#6YU;%;="^1Q]+59>Q-`L<RS+G/'``@Y>@$(5O/`&/%CA":Y@
MK15X9ZQ]J"(9SV"%#;@@!EZ(MQ.=B$,9N*"$(6!C%5T(@Q>DT`E7*&(9X^#'
M-1R1BY+,01K<V$8Z2`$*6G!!NW\H7A>4(&HQA**81S@"*\*P:F/@PA@R82D*
M<_P2%D4-'PRZ(E!V5`XZW6,N]9B'GE)6[7X-@QC=N$<U<)$793"H'N=HQCE@
M=F)\5_&*^9!C%R<&M"S-X]]@THE8L2R2FWBE'UL^25'%9)1]Z)1+#/?_$<8?
MJI*+ZU2*^=`;2QFD;9:,G&HT6\DY<MPU?M`XXU/D60UATO*;O,.J:%V&OA_2
ML2N_53K(6`9DR-&.ANQ#*Q0Y(KHU8HYS/_$D8?/I6_T62FIP`QW38$8UK,&-
M:4#.D-THI.,&-F5U[,>$\$G&89$!Z%55(\^@E$:>4X?VPC('L=+0!9ZUI;I5
MK4H;Q,`&,J@AGUO,P144@`(,<A"*.$@A$?N0P@L8,;4PX.`1L##"$8I`C#PD
MH1-A*$49B%`$6D##T6;@`A@440I0D((<_`A'+%0A>U5,XTBW8(0G0M$),*!^
M"[%HQ12(((9.^`$,<8`!*6`A@RT@`1:X((93_YU4E025[2$6O$?7QD'C>]#L
MY!3!?MH8;`]S'+$<]G`(2;;1Y&G0U!*^\,4KIA$/;\`"%JKD[S%T,8QWN&A(
M*+Q@SVC?!#5#/Q`%FCC11(S(^0')/K##/(R(B7`(4Z7%UE",5YR?4O5(/MC#
MB'Q<4=F#P1F%CR2)43C)Q8G@R#F-R.%)GD"<2G1@E7P-Q87$1#!(2H3@3^B)
M4[D<`+[5.^0#'=V$0;`<WC0$$'J;@NW(^5G<3:Q5\`SABT"=S;D<%"G-PSD$
M/]A4Q[P#19P#?R$#9S@'-]`++A@8V#!5S.0##]$8CUU0R;V$-23"(224)?23
M);0")#A"/ZT"0+7"'?]>PBOXD_5<CS_Q4R-`PB%(@B)"PB(TXB)(@BE$@B3(
M@21(8B5"@B200B2X0BL$E"FXPO5P8BN8@BE4SRWXX?.80OJ8`AS`P@X`P0Y$
M`1_$@0V@@CYT@0V8@M3@0WCYP2S$P!*(`1*$PBP,P1&,`A7$P!O80A=,@1F$
M0;,8GS'L`S2$@1#$``Q$``3$`&^H@CB(`RGXP;%!HZ@YPB@H`02`@B(,01CP
MPA^(P1$P7RR\2Q*U49A`6--5$4>@W#TZB$!P2%K4PS58`S*DPSJDPS@8`S(@
M@S&0`]VDPS,HPS*42[R0D3480RRL@C$HP]78@SWH$/9-$3TT0XS]$(7T#";_
M9`(F!,,M%`(P7((FN%\C7`(E6$(QW,(A6$(CO((E%,(K<,(K%`,PC,,EB`,G
M6((F"`(G:((AU((S^(,R%,,UO$(CM`(A:$(Z"$,Q&,(M!$,^'((FW`(G%,,F
M",,M8`(AC$,A"$,L;$(QU,,K](TO4,(D!`,E*,,K/(,SG(,\3((_]`,PO((R
M:`(S5`(SO`(E%$,QC(,R``,F,,,X](,RC$,FA,,F*(,P!,,V8$)]9<)'9,(V
ME%@P9`)FCL,XA(-IUI0Y^,,Y!,,YE`,/.<,XO,@\*(,R.$,SE$,S[(,SS(Q7
MO`,^S*8[*(/%E`,-T<--0`8]`!WVY<,QL(-'-@,__[C#-KA#,YS?SO2,.9R#
M.^Q0=UK,SI3;C@2%5-$#TB#GCG#<>';-%-H#]<T#S&F$%25(/=`-/<1,.A3#
M,3@'26C6IT##,ES11-`#![)$@MS@A[W4QSA#,0S#,)CE,;!D@`D#A0K#,20#
M@`&861[F+71HAUX")##"&\R!',P!([@!(\A!&[A!&U#!&\B!*,R!C-:!''2!
M(C`4%DRB)U`B)6)!(J0H'+16:\E!BL;!%\A!(G3!*O`"="7!&^P!#+A!/E3!
M#)S"+AY!.A(#$2R!$@@?*$"`#G2!.!P!%VQ#%SR!%X3!L2F"*(@#*.2`#<Q`
M#,@`%^0`#&RC$""!./C"&_]4`1@H@11LP1&H@BS@@">`@A%LHRH@03#"8RS@
M`BZXU<&QQ!1JQ#WD&#T080NF1,V8&-KL`P2]0Y+<PSSPA3'LEUG,"58QPP.!
MS#X,Y$&F0S,L`S1,PS)0FS!P0SJ@3)K1$)@PE3F0C-B,@S,0"3T`@VUN@B&<
M`R0$0R-D@!9\P`F8@`HT`B($`B6@@"9D00BH@B5D@0F$0"5\0"5H@0F$$RY8
M0B)8@CDE@@DT0B!D@1:(P"4,0@FH0#-T0"8T0R6\0A;DDQ8T0B9L@B"P@0F\
MPKDVPB;X019P3P<8`B240"44`@J0P"0$@B\`@S\40B'XP0<(@A8@I28,P@I0
MP@K_G$`E"((?!,(D3((P%,((;$(6C,`EJ(`@`$*U0D(E",,($)0@K`$AT.6U
M`H(A_,,D4,(F-`(ED,`E`,(AF$`6!,,D^,$:H`#!KL$FK`$D&((@;$((',,:
M(,(@"((A#$(69$&_9L(::$++!D(@9$(M&,(E',(@#*4@-((@0((F$,(AG,`M
M",(EK,'+HBTSK`$F#,(E5,(A7`(BW`(@0((@=.@F)!0D#,(P",+(5D(Q6`(F
M%$/24,05BB1&K`17-15&/-5#(`52,$,P?!`R&.>%4@-;<$/]08,Q6(,XW$,Z
M`)*OCDB:Q!2+<$E6[(W$Q40%480N',,LR,`=G`(5%($H_^0!'O"`#O``&>2`
M)("#&[2&&G@"'G1!/%"#*5"!KS#"'#S7)5R#-C1!''P"%\3!'<2!-F"!]=H`
M%"0!%4A"'MS!%GS"<WT!;>3B+H:7*NP"$2"!$BP!$K""&72I,<#!#,1"-,1!
M$J0I&(`"-!R!+Y7"#QA!%WP#*#S!$G0"+<P`!*S"+(0!%R3;$V#!.2A"`\1"
M*!#!'[C!'^1`#QR!&/C>O8@@2JC<#CZ1RM$,EJ2-.<B#1B%9!:7,6=2#<6(5
M9)0#B^3(.I3#3F3A,J"=SEW$/)1#)+0",13#J'Y8L)Y#D"6(5V0J$AW"VFKM
MMU9"(ZR#-9B`/T"",/C!)%`/)?]`0C51PDZJP"`D;1;XPCS`\25@0@ED`B)D
MPB2PP2`@Y2#DY"$<`B8@@B$+5"/HPRN<0+PVPB'>@@IL0@I<0B.L02,(0PD@
MPSJ8`,6RK#_H`R;X`0E@PLO"<28(`B$`[1J0,@D<@CX(;"#@\2%D`3!L0B68
M@$[6[2"$P`EH`B7P;86,[CZ<0R$$`R0@@R6<P!IDP1J\PB$8`B4@K0G<`B+L
M,B28<A:4P`D0`B2<*R'HPC:<LQ8,PC9S,L,NY2"<`"),@Q900C!4`B2$@"8$
M[AKT0\.HP!K<0BZS\3+?`C>8LC"@[3&<P`>(0!;0EWXUPB*<P#G?PB*0PR%,
M`OII1,3_M81%]%11:9L\>)_,'$->X$(_I$,U/.>O8>@P1!F-;$,K+,,T1`,Y
M$`K;_/3#T4S8X$/.D/0;SL0)DEP)Z@,NW$H25($;\$(#Y$$<Z`'N/,$86`$X
M@`(8@,$4=`$IC#5TN@,N.$(RZ,,WN$$N4`@Z,$(IC$(5O$&?CH</W`'U5H$=
MT!(-S$(<^``-L`(];.(K[,F(L,,6$,$CO$(,*`%X#4$G)+80?($VQ,`1Q((R
M1((G,$$B9,,C1(!M*0(I[`(Y#,,TS$(H^($J/$$##`$LJ(*L><(J+,,C",$5
MC"DWLH(?#(%C,Q\LZ-=%S"`77=`,<L@]8,2_Z43$E$W9H-@1_U7?T\"03F1J
M1G!JV"S%.;C-.K38`XV#-5BQ6@A$2C4#2=0)4XW#,#P#N-7#&6F?1SB#,C`5
M5Q4#9FX#/93#,U@#.8A0RIP<1UA1S>B$MV$$@0,)/T1D,^3#.;P#RS6$.4AG
M&^UET>W#.%`9]Y7-C<A#,^`;/Q3@F&"$/#"#->2,3CB#/IS#.$BEK"X)AMQ;
M.-07@4Y,/>Q#,"A#,P2#,P3#/O##K968+X0#C1,GAP3#C4.E3&V#62[FBS0#
M)C@#:>H#:C;#."R#DEF#/].#,EA#:U;"BQ`X1B@#)90#+2>#?GGN,QB"9/9#
M)6C",<S7)-Q",RC#_FW".PQFLVIR)?\,Y29P0R5P9B84PB8T0S%D@@ID@B%4
M`N)>`B&\0C=80CDX0R'LDUO>`H@.@R8T`B9<@DL&PB;HPR`,%%H6@CX$`\O>
M0CD,`B9,;"/@T`PR2-J<;GH27=ADA&E:A!$>A!4!9SE`D-K43#C(PS745,H4
MPRL<`SE0RC8`G<S<-WO3B)6!=SFH'S,L`S4XPWUNM]:<PVUJ$=@$<8"+B;=!
M-W0K"'K>1-C$3!1-W.A6!,7]&\7APBVX@AI8`1-`PQPTP1RH01[XP`T\`2Q`
MPQ>L1A<4WBI,#T&8PRWH@B;D13[T0S-8`BB4PB?$FANX@2(P@QO\P!.HP1QX
MP2=4P!O``@S_V($:D$(SP'6DLERE/LDZ&)\JK$(.@%>7BH$J=&D8X$(1$`$$
M/,(T#`$5^$(L0,`5S(+GL<(C@$(TQ()HYX$2A`*4^L$S*,(4,,(Y(($0$($J
M0`,23$$3A((.BX$2'$'S&8,O.)&>4!^E]M01,9$3R4-*<)$Y4`.1>$4^E,,Y
M*.8VU,.8&,2#GTPY7)&,H$Q#\,.L.L.2'/<Y#,ER!H-9[M>N)D1UZX,\:,41
M*3>0B)Q'C&0Q,`40`J%TXJ8RE)@R+,0S]$@S;.$V$*<SR$/213Z0H[@[V$-"
MK-2(@/=%,,4^%G@]\!R'%-6":-Q3&55*VT2-25'+*77%J<T$G0V#_U@#>EH?
M3'$("&*A6Z'8Q!T$I@H@V3!5BID[@9IGBXB)DM##5-SDH.A$S+PWQ3B$/Y+?
MT]##-I3#.WBDQ=3,1TSWA_F0U9BT@AZ50<P'0*SBH2:*D5VF&HQ!M>/&J%:=
M]KS!,R</G47MX.FB4H/&"X\T@MP!MP[:'#Q5]LR),P74*BHNU+BR\:,7*AY/
MHC"1=,])C5;Z[ND3.I1H4:-']>T+`Z$3+"-$E(@A@H05D25AAL&R.J13J2_6
MAFR)U&6*(F3)D,5CM@Q<GAQ(0NT1$JL5E%)^EA"AXFK5$!B>0,6(JD3)$5C&
MENG#AU3H/GI"QRE3YBR8N7[T^#5KIH_>X_]FF3;3,T<OG[YF_LPE->=NW+C.
MY\R=.[<O7&QRSL[9>U>OW#IZZ\9MZ]R9G[MWUI`M5H[/G+-Q]<[QFW<.W[YY
M0L\YV\;;W+UUY,@]5KPOW;IE\^CMTX>^:+YZ]9H!>F7HT*9`F2@5HC3)TH=!
M)A*9A`1.$!D!$$NRF*0081`I01`3-O%CDT8.J0018%#`Y!!$"*D%D3542.,8
M2@1)8PT_+LFB$4$,`4:38!HIYI!&(,F"$DP`,2288(I!Q)I`LK`ODW"`R>0?
M?X)Y!I%@#*'D%4(@,>221C!90Y@);VD&$V$`R:205S"!!!-_?"E&&$P,N263
M2H2!I!)+"EEG$TW_A,G$G&`J*?,S93+9I!E#7O'EF5<V.<<78:P9IQ)GE!EG
M$TJ4V62R8"0;IYES_"GG%F&V:2V86Y;99AMA@`'FEFUN&2<88<XI9YMBRA%F
MF5BW*>>8<8ZY;)QSQG'&'%_&R:<<>H*Q)Y]]F)$M5&6V<<>=;5(;2KRCS-F,
ML7D6XRS;QN:YQYQURAF'F7+(?689<G:KAYQMWH'G'GNJ$PH?[\RQAIRA@J)G
MFW7>L<=?[^XIQQSA%%NOGN_::4<]QAANV.&C2M/'F%=(&8@,'ASIXH4<XJ`&
MASMTZ8*,*+BHHA-/3"$'#AI8#H*&*%QF^896X'E$$3"J:&(*,NA`AHDJ_W:A
M@H8&5JDBB"JJD,*3=:CH`9:'H29JGJ54F26'(X20"HE.0B&BB5;P`",&,:Z8
M9I55(%`BCB[``$48H8[E1QHWXK@BCBT@"*,51G(1@H@B2`'%DR.4B"4,J)18
M(JI?G)FF8/46-DH]0DY0X(,4@+G@,4PTOP#)#E!0P)"D[+DG#1924&`2<Q+8
M@(4--LDD@15&V.`93E#XH`05@AEAFS4X",$"30@A1)D-2*#]G&,TT""$8]8-
M!X424!BAD4(F$:J^V%381)]`5A!DC1.F68<;>J9K1ASGS)EN6GGI>:><>O1A
MQH0L"`$PA0T*80:1<0HA`DL,XA#X:00(&M&($/_<@AD?4$$FJA0(:S1#&<4H
MAC7"@8AF",(7E=#`&D`0`D14:`VUN(4),$$($1""0BK,`@BR,(A!:*$1R;C%
M]?R@@D.(H!`AR((@.,$)/[`@$,I`09$V`0D5#`,1)X"$)@:8A34TXGZ;V$0*
M"A&.5P@B&9`01",J,0A!E``1_8`$)-;`A@^P(02">(4F-#'&1F3A!)GH@"`*
M`0A,*$.'G.@`)_(S"1-8`HC!``8)F$0)%.AG$DW"'O:$(0A(-,(_)WA0"/S1
M"$(<X@.6,$0*%D&(-:R!$)H(P2M40$I!$*(0*J!$E*XXB14UP@^4J,0:#A$E
M2C0C$)98`R(N88)5HC'_&$79EE'L$2W2%*4SU:%'4"(V%'S0HQSI8$8RCC&,
M=-3C'KSA)E#6<8QF1$X?P($-=>B1CGBHDYOJ>D]ON%$.=G23F<=43&GR@8]H
M1HV9_"R*,&`!BB5,@0<V<((KO-`#(N`"!B_0Q2T8404\2.$-H,#&$RJ0BE0\
MP0=Q8`<CC/"#3XRA`7-(AB>\,(4J*`$,K5A%`]P0C1X`X0=X2((-H&`'*WC"
M'G%X@BOT03]_-@P?8H@!*ZHB!J7ZC15_B`$25J&(62B!"$+P@SF^,`,B@,(5
MNXC&/'SAO6<\XA[?T$7@E"`#(F0#%WY#`BA@P0A2"&$(OVA"#*9`F".(X3#3
M_R!G9Y"B3WTD0!GZ"(8%A(*)!.CC`H<LA#Z<D8*"*=8>^J!$(,:A@'X]!A`K
M$$H*.K">!&1"'^%(P#@D@`E]]$,?:R@$)D9@#WZDY@+>(T$)WC$,>9@C$!Z8
MC1\`(106H$`?A@@`">;1#&M88!*PJD<[)!..=<`ML*/I3&7)P0QA**,2C7C%
M*TA[BRQ,21/,P`0PE`&,5L1C&)=P4S`R40QS,`@8^AC'O83RBA3X8A*'N`64
M;B$:0KPB&<-HQ"`:L0PT3N(6_T7&("QAB4H0HAGV*$0I@S&)5V2A$J^@$":>
M@8G\;$(_*<`$BS9Q"TCHHQ:D+,03(W$(0V`"$R].`__Q1E"/+6I"!9"8A#O,
M(0@5$((;AYBB(>B3!1-P@D6'&$$S@A&(8&2A$(8H!"=\D8E&<,(9APB$/PRA
MH$WXHQ"%D(=1)I$)_QIY#8-80S(:$8A);`(3(<#1(!81B39H892-N.,:3'`"
M9KAC$(`X!"%64(@37$\%E=C$&DBP!F6`2!B5N,0)(@&)%1S"'K=`0?:BEI[7
M$`PH\O)-_*C9C-&8HQSXJ&8ZRM&->)1C&,S81E#J\0YS]*L>G6E-,]:Q+6I2
M8QO=>$_IO'.<8:6C&]VHIKZ<08[5',L<YF!.9_))/WTN9A_XF*:W]9G/8Q4,
MV^'V-CD9IIY7$,,1/7C"%*#_X(-34(`&,]`%*H#PAEU0(Q*?8,(<OD&%!@"!
M%W*X12[`L0QFN.(4<T#%#1H@"FE,80JCD(,WJ-$T8GRA`27M1`V>8`4K\(`1
M]Z""#2(QU(?-XP@QZ,0JEK`$,2@!";3X@]:@`8HM)&X)('#&%%P@!$:TC1NO
MT`)5CH"$5]1C%6U;`@QB`(U'C$T)G0C#*SH1`QR`019@,((2IK"%)JSB%LC8
MY^,8DX!B*L,`*""!!3R@CQ'X*0$7P*P^4K-(S@BE&0EP^P44)3I#;&!TC"TF
M/2PPC@V,(!"!T$<A$*$,"V`B$,$E00=T-%W`3H(#0E$!X0UQ@<=RP!\C0`UC
M27N-_VL@PQK27,<\S+&/<\Q#'M_!UCK6P8]\,HP?\PJ*4>Z!GM\7I1[XB,<W
M]!&Q:1:L8?$0#[J!HA[Q9.LQP]?'.<:I&'[@G1[NV`<_QB$4?CAF-.<82FGV
M(7M[N*,XCP'R8RPEE-X(Q1R-"D8S2),;9P"#'_PX!SV4(1CX(1CZ81_(85=B
M3S'<H1BN@QG&@1^<01C0+1_.(1CJX1:`H1PNJ++&@1(291R$01.<81Z>`8*"
MHY@J(1WZ`8(V8Q(T`?]NX1TRX1BV`8(N`5.L80U&I)&"P1\@@1)4A1Z`H1`*
MRY^R9??>XRB"0G[X93<4`Q^$JIR`PAW*P1JFB_B"(A[>(?_YA&(+B\([AH4Q
M[$GER/!AL@47V(T'!NH)DF`/\H`,=J`5=,$):,`%;,$9KF`/=,$4:.`->&$+
MWD`7),$5J@$6%L$5JD`-4*$'*$`:2L$-NF`>YL`&C(`*VJ$+H"`*WN`+;@`(
M="H)&,$>\L`.=J$,&68=P$`)6,$5H((+Q,`,P@`)B.`(7$$+J.$+8F`)_F"<
MF``"0`$:P*`4YB$?OL&HD"`;@`(6PD`58H$(("`6ZB$4E$`(D``65@$.P(`(
MAN`+I%$)MH`+M@`6<`$9SL^8H$\?+*"P)&]'`N$"]&$#5N<<C(0#7$,?2("X
MTB,3G,$"]L,0]F$2^#$!@NLQ"`O_[RS@'#:``U0`!<8A!8I(`4C@`DB`'^@A
M$U;``2A!'][A,29A`U+C'U9@/Q)@$I1![39`!3AC\N9A"^G'.^3AS(;B'*1-
M'LQO^8CB'2I!$Y3A1>C!&C)A&U2@`R8``P1A&X#A4K)``AP``R"!'M0D`2C!
M'""!&YCA!#2@&[;!`SC@`S[`!#3A'C"A!([!$KAA'(3L&#C`!%1`+8FH'T8`
M!5;`!$K`!.:A&+)@!5#@'P3A&>BA&.C!$G9'$'Q#'RJ$'IK!50KA,(7"$`HK
M/93AC"JA/L(O'U3L$BCA$C"!&80B8/2A'0Q!!2Y!'^2!'R9#*.@!'^SD-/5!
M&$*#,VXA_Q@T88]@$ADPP1?\X4Q4RQD2(RGT`1.*J33ZP8K"3RB6P5J&PE:$
MX1C"82CX@1F:P1F8(1A:S[[&@=6VH0NIJRBB17+68V'&\"@*8?$X@`0XP`-"
M(`0ZX`(N(`2V,@0^8`30<P,VH`,T@`/H\P-"@`7@DP-*H`0ZH`0NX`/L<P5*
M8`1.H`-.(`56X`3NT2H[0"T55`54(`5.8`568"TM%`760'Q(X`1&*052"1``
M(0M40'Q40$0!H?(:+P52-$4/0<;PR,JJ3$2M;!(FX8SV@Q)F[!R1`A>$@11L
M@`>D0`J6H`I*H09>@!%LP19V(`JB`!I(80ZB`0=&P1;@@`OR0/\7P*$;[D$=
MJD$:WD`'YJ`7=.`)JF$./&$5G@`(=``6<N$EK"`5=@`GHL`*H$`4[.$-Q@"H
M3!$IS"$,EC$6<L`5Q:`3P"`LCH`5L``:L``JCH`<F:`!PD`;5$$1B&$=AJ$)
M0``)8L$=E.%LFN$1AD`(7D$?'&$)BH`(H"$1XL`3C.!50P$,Q&`+MN`(?L$8
ML($?*DMRIB5R"C)SA((2%LMS2$"U^B$!G$$HUK&X%$`9+F#\'N,?1L"P%@`3
M.D/M["L!SJ&Q"B9'@D&RZ&\#S,\0%F#7S&\3XDX?.,#Q[%%'.>"R$H^QGD$C
MR65;Y&$>=F4=K`\IRN$$-&$0/-3("$'_!31@DC!!`#2`$@CA`1X`!")A$PR@
MT08!`!1@$=8`$MA```1`!'`!``KV`T````Z,``AA$%XA$C"``!9!!$#@`0@@
M!-*@$D[```(-!#Z@`S8A!!`@!$:`!#Y@``8AF&AV`@Z@``S!'`(@`R#A`X3!
M!!B`#01A&!9!``C`$J9D#1C@!#`@!"3``#3A%A(@`<YS`A`@:(=!$RJA$C)@
M!$:``Q#`#Y3A`#*`$PSA'S`!`"8$$FXA`!)@&)ZH$0`@`X0G`13`3S:``"0@
M<3'@`HRA!1P@PRX$`";!5%#@`!Q``Q"`192A`SH`&`S!%P+A%0YW`0A@=IZ!
M5`0``1Q@`:CV_XP(P``6(`$.H`0:K%&.`0.;X54JX1@JX19>8;M\P1IX11E6
M<)<88[;R(2A&P!"R0S(LR$R$X4IN81/FS!)B4TTP$`-C1Q,N81/>Z+PRX8T:
M#!,LK1$@R'ICLQ+$1!.L:!,L`1(.01`@+(DB\XSHPQ"@I,PJH<RL#!$*(1`$
M(1#*#!"J+(\:#Q$:+X']((%10`4&N$53-`U25`5((`&VKV$B9AA>011T(`K8
M<`IR0!3R(`C>0!(B80YNX`9(@1@LP15<``CH@`JJ0!%NX1ZNRQYP(0Z\@`KB
MX`9JH!HB@1?<(@?RP!0<00J``*6@0`J>X";L(A^>@`9RH4^1@N68HO\5H&(+
MD$`)PF`+I$`(N&`7OJ`+FD`,D``)E.$E8L`3\$`1A($8NJ`(P"$.CN`5MH$1
M_``4A``"HLX2A"#LNN`*5L$48"`'AC04S)@PMB`6HJ$<^.$*Q7!7[7$SE($$
MU,,?2,`>,\%9+4`!2&LH*L$#Y-,9\($#-L`#+@`1-N$?A*(0$&L?``_O/)(#
M#D\?$&$2^F$!V/8",B$0$B`]#Z$*'X,2W%%=/:L9#(26A0)Y]$$!_&$SU^$<
MK&$9K,V&EV\?ZD$>@B);SDT?NF&09J052F"2`*#!V*`8M%8?LJ``!H$-+N$6
M,"$`9-8!+C<2?.D!$$`+"&$`LD"]*@$`(('_$`Z`$#+M%C#W%F:$#33@&(Y!
M$S3@`R[A&!;A%DH#$B9`_M9A!!!`'PY``W`A"Q8!`3Q`&5[6&(CL`Q``H2MA
M`$)`;BED#23@.OWV`$(@$A!`!."7>"YAE`A!'QR@!.PA$X1!`$K@&0*`(?>7
M$@P`$TY@$4X``1X@!)AA&"JG&QJ!&>8A`"8O`]*`7&J3$RPA`S+@%1"!'_PA
M`%*@$43@`"XA$BH!&`P`$JQA`4B@$4A`$U+@&1;@!))A#8!!9T-@$Q8@$R"A
M&!2L&-:``%1,&)B!`21`$$X@$#9$!1!:0R@A!"HAAOKKLB8A$"@!$0B/^8QB
MFM1C!%0+@VVX._"E_S2B4"/-@1D@.?GHX9N(8K;?X3N#JK4W\Q[NX>RH./GR
MP;>/]P*VTV%P(1<6H0>@(`F>0`=\@!>8@(1;`11D(85K@!3>X0M>H`=X@15L
MH1OT`1=*5<7L01I.00].009>`!3J`0YN0`>L0!H6H16FX`9@P0N"@`M^X`>J
MX$[YH0EJX&E^F_C$``;@:FR$@*J((!9400BN`!2^`!J,X(P[01\8X06.B@OB
MX!78P1I*M1AB(1^.01&.H!2.H`&N0!]@(0>(@`A4817"H&N0X`^)0`SVBC!@
MP1=VTS3?9[3'P3&^\PB5(3ID8S0X8QR$#3/0+3WPKMOTP1WHP36&8U<`D/\2
M,F%(5G,26L_59N,<G@$?UD$SLF-'@.$Z]"&]]$$3PH$VR&$Q9.,QF%RX%Z,S
M>JU^A*'5PB'\"D$!<".^T(L>'(`0[D$9_.$6\.$`.(@#"B$!@*4%!D$!F*$8
M$*!4UN&?S\0`D('!WE%SBN$<#$$!MN$0DF$2%N!0K"Q9"\$`Z`$V-B$`!*$?
MTB``3(`2DA6".N`#@.$#(F$0#D`8J,0`@*$$,(``_<`!KO,8$$$`#&$<Q)8U
MF:%/+"A,2"``"&$2\(0$@&$#$$L9!D&IW_H22)80%`![(,$`S`$0BLD`3@`8
M-&`#F`$?_&%-S,$$,L`8*(%*%*`#?($`OB03B*O_$`X@&!R@`]"$1,C!``[!
M'*Q,$P;@>A*@'X!0(]/\`.IA&RIA&$+``':Z>VZ!'"8A!1)I#7;=:D^@E`@!
M$Q#!T3#A`1FF--Y56W9/*.HAN)_P.L+!7JZ!&N0!W%YRU95C'^J%'/"/^:3/
M,6RX',Y!?LC%VH@BGW[C`,N#'.)AYDMCFD[3,89C.,C-,:"<.>9EW+QS/`0K
MN+WM^HC;82(&%R"*N:&`!YH@%?+@"5X`"\"!$;I`!\K`!JA@')C@!7:@%-Z`
M%=;A%I3@!W)!"IA`%\BA(CJA`5Z@"IBA!GJ`"9[`#QY!%W;`!M[`%=X`"(#`
M2=6@#KZA"FS`%`:\*-A!_PE@X,45AS"@0A7^0`D<815*X1&.(`?"0!R:P15F
M0`IDM1/<8!6^#[AQ`0Q2$0RXH`$>X1RP(11>]0]8H0M<X0C`@!>:0`F28`J2
M@`N(P!B>`1N8B2(91C2`'&*$2OK2(_VN3Q_`#\KS83BXC2*]C2)+(SUT-5YX
M,R:+VSKDH1[JY?X`0I_`@?K6T=LW$%_!9\'($=2GD)XY?O0>6GQX3R$B!_KH
M45SW3E\&2/KN#3Q025D"3`KT!?O@BX"^;0$Z>,"@0)"^3`320=3GH8,^?OH,
M<50X*0"'#!L4!-)W*,`%!PLR"+(W%-('"Q8*"=S`X(.'#QD0E(.Z0E\Q!/WR
M&?\*,,)#"`UK\NE+(,&#!PT8E#T,M,!"!W\52PBPX$"!!0;G=EK(QPQ!,'W^
M&*!0L6;#@LD="&S`L"%!)GPE!BA(L$"#@$S;&!2CEZ]BL`#D4'SH6,Z</@1/
MWQ6SMD"9/P$K.)0HL>:>)@)K3F0Q(0#3O77;SLYLIF^<N6/&Z%E3-FP;O<;C
M*)[;=_"B0(4C,'64>"[?/H4"]YG#AU_>^GWGSY&3AU!"]:RW3H'ZR+..//0E
MI(\]Y?@W#X(*H9>>>@_A0T]$[O"#'D$!6OC0.Q59=,X&(WYHD4GZ$!--(D^4
M0<43H<1QPP]OX.)$-50`\40<Z="S0Q"Z(/.%*_OL<TS_$C3<8$L]YX#213)T
MO*#&/JV\8<4-;AR#!QU,`*'&*5U$$<483S`2SQ,VL%(2B&ZJQXX1+H#BBA)V
MBD&$$K`@,40<J[!BQ!9)Y&+)*_4@X44<7G#QARK+D#,1,[.8(<46?Y@Q!#7,
M,#*+%$D(06<L6\#@""-&)"&%$EPH$<LTT^ACUT/F-/:F/ONX,R)!L8*HHD7X
M[%KKKO)8T\PX\1FDT#WGK(-//0O6MTXXSI!#:WWFC#/BLR:9,Q%]^=AE#SV6
M:)*),(=P8@TD#KPB#"&0O)+%,A)`$DP@P?2S#P.54)*`,P+XDD4'C1#0R"L&
M9#$()):,0PDB!ARBB2#E>'"!_S#*C(-"`L?4<LDA#DR3\"N-C#.(`XX84]8\
MY03S3BW,5')"`(3`<P`*YVS"#"8&!(//`ANDL((`:?!3"`&80))`!^7DAL`:
MPF!222/EN./.,L608PTYEZ@`@%<;H+#-,L!@0H`P^G1@026$$*"3)@$8<HD!
M"]#S3CT:<)!)U)P\,\\''SRCB3!N-[*,`=;D4X])SP0@CPJWA32@!(AT-`\Y
M!_AS#`-KK"'("8;D<XD`'Y!`P`'+"&37.^L`"^M`6,6:ZT7/#L2!>P]5I`PF
MPH3#CS*9G'-.)I.=HWLS\LPCC##`^&+./,7X`HQN^R"XSCCS%"3?Z=$J\YI`
MXY2#8?\SA)W33#_GE`//-LTX=)%']8VCWGFUJC<.!]6^R2(I4R11116I>&$#
M('@!%FZ(QHZFP`1NT*,(03!%-4I1BF&L(QD[Z,$/;&$/<<CB$];(`Y7T@0PI
M'*$'KAA&$W8AA1[P0!*GF$(5RO`$4;B#$7LPV_QNJ(]V<"$)LV@%$<1@)R6`
M`11(($(<M"&H&BA"'TSX@S"B@0,AQ"(42B@5*T`!"U"$H@E=8(48(%"*>Y!B
M",&(!@QR8`1'(`-/G4A%%[8P!2EP@0BP$(8U6H=#7Q'$)`>971YOB)[KX6,>
MYK"/-=8ANWU$:#YMP@>W'#*ABZ!(/0I1"#-88`AA9`(0A4#_02``\(%;G*`1
MG1E$!A:@B7YL0!F-&,`:1"`!313@,X<81``"`8P!9&$1D%C#!X+Q"@%`8AB(
ML(8!3B""03@B"PF@Q"'6L(@!#&(-C;!$)A9Q@@.,@`VOR$`&`C$)!!`"$R9H
MAP0"$`T,?&`0']@$(A@0C$DHX!`F4($&`C`)$RS@%H>X!0(D4`M@6$`"PD`$
M)$ZP@J,1`A`60$0C3I",#K3@%3\3!#"HV;5@"*`#)*#`!,2Y"01<XA*O<$`)
M-%$,"VA@'.,X!"4XT0BR6"(0K]"$`4I0C`6<`!+.*(0P2!"<"UB`$)L(A"8T
M@8!";$(3@=B$`()AB`5`0AC'J,0M_R`A@@$PXQ::.,`**H&)3&RB$H*X!24,
M4=2J3B(8F$`$6YEA"$Q,@A+^F,SM8B>0]EPD&"@`QB02$(Y)8,`9X;@`)NB1
M@DH8X@+G>04@.D`)W:``$)E0@3/6\2'\G(,??M@`1#9`ELD(PP+*4`@F+J"/
M89P@!0Y8028D0`()/&5V))@<QE+@%8*8@P0H(`%V6.<FA9R#L;52""YNT8H>
M)&$*/6#"$]0`!1N@(AI8\((+@_"&8ASA!38X117>((UA)`$(Z@"##G"!C"[D
M`0\->($=MD&%'KPA"EX`13:D8`,J'($64]"!%:0P!4^LHPE)>,4?:\4.08$B
M%T8XPA'@&/\**1@!!G&XAA+$@`MT.((*BF"$-UH!`1"P0A&T4$4LH(&+4)3"
M#ZS@0@3B$(](O`$/B1A'--XP!$O4HP@YR`$LP,"%.'IA"[%(!C8.G(]>J:>/
M&<H'?6"3Y-GMRH\#B0U%JFRA^<AC0#]1Y#K,42`E$\21YLB0K\9##V=-<B#G
M"$0A[`,(0U!B&X00@`1.<,Y#8,(:'4@`(32@@0*(X!+9O,4M`*"!;:2!`81H
M`Z,I459$]+,IT]0``MI@"1$<-`'ZN(4@ZJR%-A0B#94(A`@(T`8M6$(7`/"L
M!#302TL0(`3EN(`&$K:--1@.+^>`A#\@88!^&,(#'=$'(`*PAEO_6&`";&A#
M&R!1B$D@@A+!\(`#(`&Q#&"@$1FX\QH0L88`>%H"E^"E)@0@@C448!!9@,0E
M`/`/>W1``MU@!EQ5<%`'$*(;'2-`&IBA`0)4(A*7(,0`!*$+#9"[%LT@Q!H0
M$()CN$,8@;Z%%IKF[GA<H@0B8/0);H$(`5`"$[4XA@IN80D5%,(?F##$"FYA
M"!2,PQDHF,0DW$EM[(!(?B/(A#ZX%1L,`0([^S#$.6YANT"0[RGZJ(3.,V&(
MG^.C$)/Q12&^99%"6"`%+N%`,+"SB1(D6A^:X(!G!4*/"S"#$EX9QP5T0Y#%
M/L40_]#'!GR.'Y>H0!^!8/H?^<$!=[PI_U;4((8H?G`''D"AN;R0A!3<0(I*
MV`(*3]C!'/2AB!<`H1=04$,R]'$)7.CC&:^`AS2J$`54V(`&J*"'%6SP@RI`
M8PZN\((.2@&*'%C0"E;@`2K8X0,A'?A-^+B""U31BBUL00Q;"$,II%`&'>C"
M"0TX!2P2H450Q($4WC@%#;@@!B3@``F_N((0D"`&/S0`#M]X12?P$(HO*((5
MNJ``!+"!A2=,@12>F,(4GL`%6Y`+N!`-J(-#_*`0]8!7.)1W$'$DL4%\#(@/
M\C`.D&(K%T@0\["`5F8.[N!'^($/&4$/%8$/C&0KY^`,]&`/S9`KP?!*B'`,
MX4`.!0()*\`":__0#^60#\J0'/:`"/YP#Y?P<L"0!N<0#^80#_H@#-4A"$%1
M`A+G#OW@#H50`N^P#<F@"1_0`39A`0G0#\!0`N.P#<=@#Y-@`>?@#BM```B`
M`85PA":P!M1Q#YO@`+?@`<#0#Q>C#".0!I3``?KP#H$H`@E0#`YP``MP``=@
M`&G`<,[@#,$0`@0@`0;``<?0#1TP`O=P"^Z0.9M``"/5")/Q`1QP"`OP,H&0
M:SO3`0P@`7AQ&L"0`2Q0"_9P#)"@`")0"?V`"`B``!^``"4`"<<0`@)P`1+0
M`0BP#0&7`190C(-@"800``@P;_=D"($@`+>`:RFP,X'0"(;`!K5P"U;_%0R;
M4`ON4`NE9@CC6`E09PAP5RN0]1Y-5@Z!,!_TD0F48"LRIP^4@`+I^!.9\&:-
M40B&``Q^D`D448(:J`_7(PPCT'0)@`@;$`S?LP''4`_EH`PL4&PHX!64P`*!
MP`)>L2`(80B`P'?N@0+X^!#!P`'],#^S4R(+:!&Q,@RY,`=68%U0``5,P`K]
MYPJ,T`I=H`,\(`K@P`S$0"5=\`2C\`:K`"OP(!"W``=[X`-WT`,T(`WCP`M,
MP`,Z8`I@0`I>4`6\\`530`918`5V``6B4`X_0`.V\!/#IQ[S@`00P`JX0`1(
ML`5'H`BO``,R\`71H`1CZ0EQ4`HS0B?0P`VW_Z`$->`",!`#2"`$,C`#$$`$
MI?`-S-`*G?`)H%`*>,`%QD`*3_`+QD`$0G`%KK`%7B`%BP(+KP`-<HD>"!B7
M<FF;%D$/]S""ZU$?NTE)P35FP#40(X@A_!`N]%"!Z7`,VW`Q`A$/[Q`.!E$/
M^4`1_$`UQFD/6#<KUF$/6*$/TTD0W8DZ"'$/WY(/]O`.[(,1`I&=9F8K)N$@
MP)5D=J&`K.,.]V`/\?`M]X"?)7$0".$.UD$0ZR`,%6$75X8ZS6`/;4$0]*`,
M_.`,6`8,4\.<7Y<,S*`/QU`,L&(7U@`_)G$,DP`)=U01YJ`,P2`XFJ`/W=`/
MF>`/+FD2YU`,PA`,M?_@#[[@#N8P&>]P/OH0C`VB#^X`+N<0+JVS#_"#=K;2
M#.>0(3+Y$'>'FX'P9/HP5Q#Q#WXQ%,J@`G:U"?^`(7Q7")CP#/H`/.;P([:B
M$/Y0`OJ`D<;&=>[``4CJ#'_H$1>`'9/0`<``"?8S9D5ADHB`DO@X($ZF#\T`
M")-S8.?@`40Q/ZT@#*3``SD9!5*0"S>0`Z<0";9@!%%0!;E@"\-`#SX@"K(`
M!EZ`!K90#>A3';M0!4R@!JD`)O:@"<G@"/TC!;H0"7G@`FYP"OQC!U&@?W-0
M#E00!*YPF^HA#D0@`ZK@"C^T?+,0"T2P!-$``DN@"K"0!Z"@"*``"JS`"JW_
M\`KT``ZCD"4U(`,VH`-,0`K9P`[0L`JD\`B,0`NE,`=Q``O3$`<0X`M_``.*
M0`UPP`65(@6O&0UV(9P']BLF>*S%!2L9HA#R82&_@@_,8B&[26480@_ST"$6
MT@R38`@BN@:80`D@5PC1]DQ^L*5%Y0>"L`:5L`*'(`@J\`J0\+'^@`B?!@AK
MD`8KL`*0D`G*8%"$X"X90`C*H`DP@P@,MU.6$`*7(`C."`DFH`GM5E.5P`S]
M-`F'4`N38"Z9H#N:4`MLM59ZZ@^&4`O)Q@P^A3.0X$S^T`Q/HPR7H`Q:ZU>:
MH%3"T`B;2`G.T`P8V0A/TPS-X`[!H`S*4"S1<PO]_U`LP1`,_E`,5(,)RG`,
MP&`-LS@,P&`/UP(_P1`.^Z`,(VB=M-D/QB*%S(!([V`/MQ`?^W`+RE`.M;`-
MU<$/$#IS44@UQ3(3S(""_+"D[O`.]S`1S;`-'6$^+&@^^(`M$.LANJ(/>-.;
ML((/<N41@-`/SE!WS;!WF&"2QI8)^Y`/<G6!_NA(#3B<.^$!^;`)A\!W3[$/
M&X"A^J`,)"`0_#B_)FD/%S`9L5,()KF_S8N/L5(O+N%9"CL_PX6DO"(0Q#`,
MG@`%H5`%4O`$LB`)0,`#N<`,3>`#-2`*^H`%<T`-NM``4-`+\S4*DN`*IM`*
MB>`)3_`&M-`#%9`,SP`&7_^0#TU0`TV0J6"0`VY@"U7@?V-0!5#`".KP!#D`
MEPO[$.U0!"Y`"J1`!%R``Z8`"C@0"HQ`"CF0KJ6@#879"3,R!Z3`"K"`#>&@
M#]B@#=F0#;@`O,[@"[$P!YT`!G$0"ITP![$0#N8'`XP`"GAP!'\`"P0F!4.0
M"\;P*DB,L(9\8+YYL0*!H+(S@O=1;-Z['DS*#U^6!<70"/92`B,0`AV0`H90
M""DP<B.@"8?0`2P[%SM[`:NU`HBP``3``A(@``@@"+(,``.P``)``)H@`@+@
M``]```'`:),``(=`<6EP;EF0`06`"X(0-`2``0(@<X2```Q@``50S5]3`M6<
M``S_@`@[FP8CH`Q-80B1&`)I0`@H8`!KL`F]1``&D``8L`:U(,HDD`)(10`*
M@$_'4`*M:`'"W!Z%L``*((D$D`&CM`(E$`#0#`F`<%HC``C_H``;4(V4Y0$M
MP(T3X``2@`#Q3`B5$`(B0`ELD`8B@`&6L#6%0`E^0`D-!PE9T`BU$`)K`#?0
M=`*64`AK<`C,L`:$<`FW\&V:,`A.RSFO,%>3T%2$T`@J@`@IZ5=V)4G_J0\L
MH*(5`1L7V%8J+1`V&PA^$0S_4)*W(!#U@@B5<"2!``@JB9L5X0][%PP030+P
M0P]Q+1#-P'5%$77Z@`D>4!R(X$>%,#G\4%LHP*@"80X6_Q`().`/?V02X^`!
M3LJ\*X(,BB`%<>##7D`-3;!ZN2`-/F`%TK`.FQD*H/`-I/`"/]`+52`+C'`*
MX$$*KO"J/=``I@`/I(`'>8`+TF`*3Y`']^`&-%`#<R`)J'<'=U`%PGH'>]`*
MB#P0[0!'L=`*,#`$8.`*5,`#9M`)5"!"8!`#Q-`*;H`'G=`)<LP*\C`KPO`(
MEC`/OH`%L.`-Y&`EGO!^XQT']N4$2*`$6R`%I7`I]P<'_54$N_`*KW*PS&W@
MB#PBPIDA^\`/X$EE:+>;_&$.$(L0?'4T@K`-F7"TX^`.:7T+FP`()!`(_F"W
M#GT,@G`TFP`,AB``ZJL)$P``P?\P"`M`")2@#.5L")!``+Y0`BP[`!+`$B%`
M"9HP"6E@`"5#`!Z+;&MPXG!Q":PH`H8P#C1-"`R``)-#`@`P`H_(`9K``@A0
MY`"0`&E`TP+P%"O``">P!I2P``Q0"TH%""R)`#NK`0Q`"9.P`"1`"<*0!@*0
MAW`1`B7@`"$P"(0@`0_`#.I,``F@$@R@`I0```+``FE@"(<@````")`@`*1H
M":]F`J_```0@`H1P"">``-@F`B>P29\\2BI`"):@YO<@#"*@`1T0"0]5<`Y7
M"9<@`H=P"1UP"<PPTVM``IBP">.P"280`FR`"220"9/@#Q%:*R&@HFN&IK9"
M(2.8+0W_.H+E8=4?V!'>0I\/BG838=43WD>H<SX&>B&S&Q'!L(#T\'5R.3&0
MC67ZD`S)(`E3D).=$`E/8`<^,`T[T`"ZT`J1P`JC\`EN8`GYP`@T8`=`\`,W
M8`6\4`5!P`-D``458`KN8`IQ\`FCX`FOH",-(`F1L`-6@`JY\`11H`9J,`9S
M0`XZT`.Y<.#ET`0YH`KZ@P/)\`A%P`BQX`E&L`-)X`6!H@ZK@`=Q4-^E\`4=
MZ`A;0`54$`=*V061X!>,(`F=H`B*,`>,H`VF4`,/G`-O0/6M4`2*D`U?8`1X
MD`NO0`UX=.!S3_>2K!Z[(A'N6;$5L;'KD6:X\O<B(A\<<A&]_V(7_;``FW`6
M]'`+]-`,!E`M)J$S[#X!(:`/KLP/YZD`AF`/1NX6+:$/26AS^2`!ZEN^%_`Y
M`M'50Q$,[A`(J+4&KY8&S<`/B*T/"U`)^@`,Y7,!QY`/&](/#"`,_4`4+)`)
MB(\)M&(`B*`,"_`@.W@XD!``?M$,QY`&?Y@&"'`.P(`713B%5JX,P,``AG`6
MA`L.M5#-(7`/V[`""B"\Q]`,AJ`,F^"Q[**US,`RM4`(^D\)R0`,P@`0Q9HI
M@U1HT@EA*K:5L]3LEC)`AO3=4K%I'+T5A?R14*8/GSZ0(46"9%%+)+Y[^O+E
MVT>/GSE\]#[N4_E1W[Z8_.C1HYDOI?]-?3)OA@2J<B3(F?CP]0S*$R<]ED<]
M*ATJ]69,JUGU]?-`3RO(?"!AW3KU1HT:*ZY,50ARB5D74=3F?#HE*H\H6]WT
MV?+Q@FT0(#0$T_"AZUXN4IX\C1K%B)2N&Z764;E1H14C*VKLJ*D#[P:-7!Z_
MCCY:SX<+5I*,>,IE)`FC<[@8,>E"1<T31^URB5+DR4VQ5U^*>.'B1<J6,5Z.
M*')TC9$B15]658/5Y`D5+S_<R`&7#`J/2)'VX%A5CAMI].G5KV??/F0^?/Q&
MSAS)S]FM<<$R;>KG3ABS8R#9AA)E_,E$OV#&R429<39QAI]QFLF$&7^$44:9
M0A@PX`)$E.'_)Q@".I!@`PE6N*>0`$X0))`.&#B$GF``F$2?30+HQQX6#'!'
M@17T"<8<FKS2(`-($"GD'V7R@20`"TBXQ9Y\S-%)GS0NT`>0#8)AH*,$#'$G
M@(Z\LN>>J%9*@X$1"CD&I'$,:`:D2@(X1ID`)MED$THPT6<$"_1Q!RPR#4E`
M'TPD@(2#?-S9H`X,\JE%@$R<$<899>S14A<$]*R2M+#"4@\H3T>CYZ*@I/*J
M@UI<`E*HD&@Z"KZ=IBRJ58]X<B\K^(+*1Z9Z6+)IIYO,:>8<<YP*J5>:9ATM
MGWXD\&JTE'(19I4I-J-"&EU^>"(:"*I(Y;)11'%%%E9<8668=-8Q_Z6/SP2[
MP8=3[J&G%5E<2:445D;)PQ-H6'D"#EMH>$*=2)ZH`H\R1*'GCB!:N56K=I`0
MXA=HE.B-BR2V<(2:)F0Q8@N0M_!CE6Y<B2.6>9#@8N4NCG#9#R3$^`.$=F)1
MA!%CM''DBC!`-@*41WPQQ@\EDG!C%Y"A><4:HQYV^FFH2?LH):WP,8?,^'P,
MA`1*+-C`D$`"0<'(20+Q8),-OEXA!0XX,,2@3%"@9!(2"KD@A4``F:22?T9@
M``!#-B%``Q8PN,`#$CA(X`,+#+!@&`Q(,&0!"Y2Y@`%@2+#@@!$,2).#2>8.
M9)(1"$```0P22"'T$#88(8`+:AF!DA,`(?^!@1168*`6%ABX)`$2)F$`;*XM
MH.2?22;!A!)*4DC``#11"&2!!"RP0`$#,,E$@`TL8(!Z?KPVY!]*4,CD'T,`
M,8"2R1%9/Q@#W#>$D@`,L)^!R@-A8!+%\_EG`4SX(QC.6)X_#!$,!!YP',YH
M1C#Z40M,(-`?RM#$))3ACG,<PQW!H$0_`C>.<[AC0<W(AS_\T0],*`,8%SK'
M3<*BK*&,X!9!V4<-C;*4J_#$)1%R"3]:0A4;NH0>Y_"*#:LBDIY\Q"8XQ.%-
M7`665R$1)*["2=1"PA5[I"<7PX@$%]2P@UU(H@BI8(4J;O`$)N3"&XD1!2E*
MT0I2[`(;X1B'/9C_`0YL9&,9^J!4-%@A"E1X`A2D$(4HI,&**_R`"K/P1!F^
M@(LN2.$-4)##.KJ0`UA8423M,`(15A&+(W2B$T>X`A>N``TLY*(42IC"$;:@
M!"2`XAK3P`88MG"$1,Q"%5=@12)648I.*.$+6GC&,I#QBBL400I*X,(6XJ",
M+ZCB$4/XPQ&^`,P_/$,8TT"*)KWY3?>\$(:OLIJ/$$&"Q"4`$(780"'V@0)_
M!,("AI`>)MZ6`$P4@@29",0&D(<(0Y"`&?J8!`J&4@C`&8(![.R`]+IF@6`$
MPA".6\$_,-&Y201``2A`P0@$$`@.7.`6*1C!&BR0@#0HKA(:V(0*5G"!_R.M
MH!]I\$`"`H&)"_SC'P:87`(JD8(%8(``:P`J)EA@T7^@(*`D<$"7FH'"$0!@
M!#OM&_-2X`&_42(8'$!!1%G`@7\4HJ.%&$$F#``FZ[FCIFE8@"%DY(\`3%""
MA0`&`R**)@58`!`6F`3Z)M&!LG5@!9(C`2`"P5,/I($$)8"$(500B!+4S0.'
M2*D@+H")$+!@`YA(P0;<(5$/>(`2%Y`>,-`S@F!X4S[@9*W3FF&!)U9-'\D0
MAB-RX`525(,)<<`"*:[0!2_HP0G?@(4GYB`*/?""%;#8QSG2<8M(M.(>R``%
M,N@8#UFTPA-Q^$1CJH$,'=R!"E+``RM(`8%5K/^""5;@@23B\04W9#)441.'
M&'!@"EA(P0N="$,7D!`&,+!""]/`PA1LD`0IA`$)5W`##'``ACR0`@Z)B$4L
M6!$',)AB#D>(P0S"\`AE3J$,.QA#$881BT^"@@AE"*\96@8-83!MOJVE<8V=
M]I((-<.$X[B0.3)1B&84(E+*"`:1_:$/93BC$I0X1S,:&-&.4$(`F*@A0INQ
M"0$(8Q,"#(<^_@$F!`)"1LZ@1"8ND(`+C`,3F=L?_;)@06$`(`W]6$`::H&(
M312HKHB@A$$"P()`""*"*.B2!!*`B$DTXV^%*,;S-@$(9:0``,I(7OH"8-!,
M&"(`@<C'INDV.GH&H!#_A<#$/_21"0X(@`.4"(0SSLJ/,],#!0@@1"$,<(`2
M8,(`@0A&`%*K$GM,`A&B+H3[!*`!<PBJ$LJ[P`B,!(C#38*>E-A`&@)1I5J\
M8PT?X(`F1H`E%ABB2H4P1`HZ@(@5M+,$_]C`!?(6B'&D9P-C`P0BPF8(1!SB
M;<F3=NB6-[>]46(3F/CWG3(!#&#X(^'`"$:%#(1P!$:<R!$/!L)-6'&*%YG(
M%]+X`"GE#&?TXZE.[@<(07@.E+]$ASMAN1!KN');T>2UL;6*IZ`Q#$7<P0C9
M8`05(O$*.%"A!C^H0A+B$(](`+,3I1@%*/3Q#5)0@0IO4$1MMD`*>XP##JGX
M_P08.A&*6%2C"SW8@PVL4`4Z6"(.<Y"&+62@AD]\8PZ>R.0WZWL$;#Q""6!8
M&2U&200QQ.`+W2C8%'`@A2:X``IT,$4Z2!&*3IBW"8ZY62N^L0LJ/`$'.%`"
M$<Q@!2I\@QB=SX$1C/")3NQ!"7'@PBZ,<8UNVECVLY_/2;XRXZ=1P@`+P-XD
M\N'JO"9``7'-1`">I0\2+,`<(*$$`"BQDCT9`"284$`)5."U+"8``23H@.9,
M/=$2K"%U?\I'/?1Q52H-:B5K`(">G)$`#H0-=T31A^Y4<`@.&`"$`CCR.3Q5
M"P#H`$%0@1'@@&#(!S&3FR_S!7Q`!`70AUI@`'?H!_\`P``?,8!^4`8`D)XU
M$#=_P`0`R(1UT(?F\P"54(9]X`=^:`9@L`=[Z(<$"0KY.(=R.(=^N(0#/(9@
M.(>LF\!QX`=F4(9:.`<0>HA^N`5?`(9SN),,C#?Z.[Z1"*@44`&.0@%THD(2
M6($1T,(1V("0&H$.N(`.:+?0XH#0V@`/\!H/2!LTM(!FZRBOX0#7X0`2Z$(Y
MO$,O9,/0N@`^O``T%$,^;+<+L``'&$0^M)[J.3-$#+X$$+[J:<1'A$0WM)X+
M4`!#7(`+P+VL(`9L*#!;V(4C8`)1B(=6$`4U&(,J0$57^`9>.(52"`50X(95
M<`,F>(,JX`,HT(,WN`,F\(3_:&@%12B%4C"%7/@&4W""/"B#*I"".3"%;_@$
M+Y@#6-@#)J"">C`"&PB-;U('(H``4H`&(E`"<20";0`#,S@"*8B!1%`%6W`#
M<9R",'"$9I`9)-@"(C@""I@%)%B"<$2"4/`#7X`%["`"(Y`"7KB$5Q`",SB]
M(=`&14"")I@"UG,%7""'(Z(]C,S(?0@+>BB6=P`$2)B$0QBI%,`$:U`>N4&!
MLM$;3<B$#]0$%-B$2@!)SJ(;84B?8/B'-$@#?:N%8Q`V2G`;KF$?3%`!3'"&
M4:,$0`B&9B`X@S"$22B$AK.&2R!`#GB'30B&2J`L#@@!R6%!0)``!1`$?VA*
M9B`'_W/P!TAP!T.HA(H;AVU(`V'HR'[H&PLXH6`H!WZPAUM`(11H-AX+AC0X
MP'UP!AH4!D!0@35PJ0W(!)TH!!8`'F7P"DU`!'ZHA318P17P/6?8@/Q(*3G4
M@`*H!'LH@7+0AW/@A\2T!W=P02@ADS&AFEU9B2R2BGS(.OF`$JO`AUVI"N@[
M"II[&"C,2/3PE"KZ"!TJEI<@0G,8AY)[3B=S3B>;SI%+LH%P!B>\/9`@AEL@
M!BJP!4D``BBP`DE@AC:PA1JX@RIX@R>8@VB`!V@`!5PHAQU0SR>X`Q_0/"MX
M@C<X@RHPAU5@!&B(AUSPA*GC`DG*!4>P!CB8`AVP@VS(`_\HV`5^D()L!"=Q
M(((8@`58`+QFD@+4VX(8Z(0<`(4O8(1+.`(\Z`10\`,Q$`('30(CR(%WS`$B
ML`$9X((8V((K``4P*(,S^(12P($A-0.(I`+,<QDNX#MK>#WB?%(H!8ER,($L
M,(%`*`0-H$-`*$!G0`3C*803L(1*>``/8($14#)(*`$3^``-F``'&`1XJL,T
M.`$6V,D$6(-#*`$/ZH!,V(#-7`%#V`#)28!,P`0/4$F.LJA",*Q"8!Y#N`5!
MT+<1:(0U@`1".(%XJIM_\`=`0($U"`%$6!&Z21^:,@1!@(1*;81`V(014(92
M^X!KJP422(,4,*A#*!(+J`04\(#_%`C42HB_0SB!-+B%0["$>BNLG/2'L(K)
M21"$/C,$#JB%-5@!$4@#?F*>0,!,GEP#2A@$1%@#09B$%3B$$#`!2-``04@#
M%3"(%?`'%'"&*5R!4[43@/J')4.!?G!61*B%F'++32B$O(&$0>":S3R&K)2(
MX)0*,E&)C50*F>`'(MJ)EJBBJ?`(FJ.*I@$*C'TBF\B5V/O8*'T8JLD%72"%
M-T"%.`@O*[`"7<""9"`%*;`"'Z"#]2*%;M@&::B-'Z"#77`%.C@%+"@%6X@#
M*2@#4D@'7-`&4F`"*5"#*G@",(@$4F@"7<"!47`#*7`C3W"%=YB#&G"%BX2:
M=B""&5@%_U)8`I`)@T[P`UB`AAB0@B$`!4N@AF9@O3#``1<`@R)@@E``@U0`
M`R3`@2;P`E:@@S@H`ASP@@;`@2T`@RZPA'Y8!5,8@E8J!5[`@R[@.R]0@BU@
MAU>`O9`-7=E[!T$X`4/(`D,@.$-8@4R+"!((&PV@ATKH`'TR+#TAA!(@!&Z`
MA,D*FQ1`!`Y8@S0H@318`4#8DX@8@7)+@4R;A*6$5FGK5&E#A']P!I'`A`U8
M@!4`U$#0``-```+```-0*K9A``\@``6`A$.0`/SQGN=!!`Q(`W<@!$,3RV;[
MGQ#@@%L(!`4`@!0X!`00A@YD`0_`A,BJ!'9*OA+H@`0P@0T(`?\#R`)?V*A@
MF"IS"*DRW81,@,$-2($3"(0,4*Q@F(3J:9$"@(006`#E`01WX(`."`06.(%;
M(`2F(@0/6(%F0`0&X+-)N(`U4(9F<(8B([-`Z`=>6X,".($)D``.*,D5R#<'
MJ(02\(`LL#X6T(`U\+7V:(EGP0K1M;&B2%@KP@5<<`4OF`)1P`XFT(,X<(7!
MPX([>-`IV`,=J`([>($;\()>N(4Z8(1?U(4Y<`-;8`0G<($?^(0WH(([F`+V
ME()%Z`9):`572`(6NP-9\(0W$`5W8`(;<!A-^HAV$((&6`456QDNX"\M"`57
M:`4A>%$E@(46A0,I@`(I@`53V`50"`/_5I@FQ_@"49@%17"%-\B!+3"#.(`#
M<D@$(0@#S@V%,/H"[C)E)5@&8[!(,?YB;'8:H>B'6=F'>&O.=X`*H-B'9O"*
M8@F);2#"_KA-UNP/?5@^>0@&<E8&*?E!*>$)?L"$>+-!^\"$?G"BWBD$M#$`
M0F`&X1,$=#J!0C@'!7";O#%?35#,RQD!%@`$9F"`-&#H!"@!,R6!<T`!`[B%
M2?```PB!--B`70N<0N```!"$8!"AO&*``,"`MEJ!`'``WL,?BY(<&MDRB$"!
M?%`&%J"$(R.$-)B$<*,$@(*$-!`$D3ZR%4`!2%`!2&@&2A`&2F@L=\"3U^4@
MK5H#CA@)>@B$_Q'@K$%8A!-8@S70!V@-!DC0A/`S!$B`!!)0@5M8@Q/0A$KH
M2'IP!Z&XYO?@(T,H9^89B#S!B>5)K0^,P0C)!$HP!_UHB12"D4C1AW%`.'K8
M!G_0"?U8K<MVA\+<P?P0N2#^P9:+#Z\8E18R!P9AEHL(DI5["9#H2-%XBA82
M#?:@FE=X!5,8@RAP@CU(!3G(`1U@`BA@!,)S`R^X`2B`@AMX`T;0!7HXAE;X
M65(XSU/(`U<(AW@@!2]8`AMXVB?PA"+8!7#(@QTP@AXP`E%(A3T`KC<@!7>@
M@S+8!7!JAS`0@UCP!7$4@S`P`R_H@BWXA%4(A3\(O,8E`AS0!F/PA/]9@`4P
MX+LO@`5%T(;\]@(S&"12(`9M,#T_\`,=2`)/\()38(4YB`,O4`0PD()E6H)7
M@`49RV89MZ)^Z(=WP$Z(O9&F:`ESR(=RB+>-=$*7H(E[IA4(\>+9EH]S/@I;
M"6PIJI'E`PEUT@<%.-Z1,(`9H0E,$(`H]P<#L`ES:#]]2`!*&`GUL>P`V(20
MN``-F&T+&,.1<(`1&(K$*17<5@^J&8D\'XF5@*'?K(H\#Y5R`I:P2(F^+I5Z
M,`?R6X>4R!4@H0_UH`=_DJB,``8.`"A]:(8+F(2OX0`A,RA`X(`16%420(%_
M"'7710$]`80$T`@4P!M6M1W41`$54(%,<+;_37"WX/%",VLXLN:'%%!SL=FG
M?UB=CNJS0D@!U41)"R"WK0(L0.@@]N$HKQ@GK?`47"!9*)B"*B@#+_@&)V!/
M*C`"4X@$:*`"*U`D1B"&8H"#3GB"*-`6(."%)-`!**""+OB$18B'.=`O*'@"
M27"%:.@"'G@""74%7<".*J@"*I"#>.B")Z@[;VH'^X)ESDNP,-`O+A`#)/@#
M))C1HHD#4+@910"P+\C<*_B#3MB")5U2$V713L"#VU`"&_@8_NJ"%5V9,N""
M;4^"8?@%:IAQH7^:;<B`$L@"#Z"G?V"!1K@$IH8$00B!-3@W]CF2L.F'M3D2
M<16;%-@G$K"WS@H&_Q48GU?GFG##,T3P!UV5MD,@`4R0'$"=!!70A%LXLTQP
M>^TI!&4P`,4$A$MH5T$(`'W3A'$@`5_+!&$X@0#@,TRHD4!0!@4@GV8X!$JP
MAA5`@'&H*1A)W4F`!$QXA1-8@&+8GR.TAF"H'H8[AY"JAW*PAW4X!TJX!6#`
M!&9XB?WX0:M6$%\HD&UX,F;0!"$6AF9P!P;!A($H,F&PP69XAW%0,R)B!F$H
MAW*`$7/8!F6H!WN@AW?H!W^`"1\2(1\YAF)X:7U^!V"(-V&(\F80!NN/\O;`
M!["QIZ]WAOA3\V9PFVB_=&4(JTGHK($[=8`PA.F?/TPC`#G3A^@"I4*3]/\!
M0O$/42%]E!#IXS?I`B!_'#*1V!<HF#(#)"@%VI`B!25]*<YA6O$OA<<.F0(%
MXH#2D+]@@?B1^`<,W[\-'C8A,H3"$#U]3I]"C2K5*3%JI*KDF5)%BBM33VQ\
M@L(K3BQ59N9X&G4G"HTJ-8`PJ3`FBA4:0&ST@%*#CJ=2>;S$<75%SIPH=)@\
M.<6'B1K`7FRM4V,#UM3*EJ>*(P(C%JDC7[H<V<*%"Y(M891P`>/IR)%?I8:`
M2>WE3Z<M1_Z8`7-$29@K6SKAZ:*$U3,_1-Z\.0)&"A?12HYTV9(CR9-ML+KE
MNZQ]._?NWK^##P_U&(8L)D@$,T>)Q`85&BZ$0,'_(00)3"1()'!V@8.R%(8Z
M&$+)!2L$4TD*\F$B'R`CH.`!)<!L@`@E*`C2#`D6;+"!,YED,LD_(]RWP20K
MC),&(`P8(-$D%IR$R0("!/`B`)0`(@`!`>"8P'H)-",!`8U84D@A#(Q`R0(`
MV"C`!6L@X$`E!SB@C`J!3**"020$4,(M#C!P2`*'K&!!`(4()($`"QA@0)8<
MI&%!"0>2,,DD'HQCR(@(!!)"`FL<@H(**%A0"0(9"'*(!@!.D@`D++"`U`@L
MG)"&G3D%D@(&(5S02""'!((")BEP@`(@*102"""($)*`(!DHD(D':ZS@@2%I
MJ'#1)H5LD$8"RHCGU#F`_T`(B"'!-#-")L'H$PP*F:Q0R#_$!A-`,"04$HQ#
M#E&2"0>`%)()K_\`HH^']*!`J@J&Z&-?G884HHP_'F0R@C[_;()"I2LA,@D`
M_KCDC"'_!$)),QP4TDREF:`@(B;^I,#/"AT110(P'ORS\`B\BH>/4[@DH\@3
M;^AQQQMS:(,+$V[08(LNW01SR1Q=//'"'CH<48HGX(@BQ0U1C+*+%U[P,`44
M-$3Q!BFO]%.--''H@(</TISB!<AY)"?-/4\$X8H^V?5:63M$Y`!++HQ``XIR
MM(!A!!YB'$'+%L;L,D0#,1`12AE*X%&*&4=P0007J"D7"A)4X.&)%#A4@(,K
MN?]LX0D82'02!A>A=!$'*='DLLHXJUC#==>?@QZZZ-QMDXDUF`3"+R:(;%).
M(YG<4DDSDY`93#"4J+`)N_],0HE_!?'C#`F5X%10)L!BXN&__I`0B#Z5T!X(
MP/K\EP(PYBP;D2";>!!`E2A,N(\R`HR@0J&]]\,`"Y=4$L`:./V3R0D&`(+L
M.0&TI$`&(JQ!0@B0)$`!F"@!_<ADD$,((A``4$`"<+0&0U@@42FB!S^Z=X(5
M[`D#@FA3"M(0"!*PBP/_0@0+)+`&$Z3A$/HPU`DT((@0(`(1)0B$!"@Q"0,D
M10+*.(8'5+"`$AS+'`P*02!4$((U""(F';@`J`R1`@O_I(`>%TM#!PX1@@XT
MPTX+$$0E&%"+6FR@`YMHB`60U35_M,L9A4`$,"CQCT+LXQR9T$<FDE<(U:4K
M$#PY!STF`8Q\*<-9<_26/O;A1MOQRQ#FT(>S*!$,0`2B0]0+1AW1I8S4,040
MQ1"7"@IA#B<V9!SB,H0R#':L9TR"'X48!R!6@(E"G,-.DPB$'T3Y.5P,@Q%C
M>,,>]H"'-S!B&-+(Q0WP(`,J=$,2C)@#'J20!U?@DA1Q8(4C*$`'5P2F&Z38
MA11X@)4XY&(82EC"&XS0"EW88@MQN$,>\C"'.YA"'U^!QNBB0@[-S`(.2!"#
M$L0@!=Y`1SE;V,(CAM`%;9S"_PA=\,)"P=`),#2!"UW@0F@J]S,IW$$*I="&
M%XR@"#QL01%*``-OIL"<(_CA"UOH!BR\X;EZPC2F,A7//CZ7#\^]5"KT:(K&
M>`H5>FA,'^=P2G:&:H[LW#`?]%B'/CC@`7TLP'GE<(K&#(`N??AC1OIHRBT,
M$`Q1C@-_^3``)OIA#V;P2A`*L(@!G$&/H09"`.98P08*H8(L!&`%=+1'`C90
M"U%ZX`);I4<];E&.?FB"$L(XQSC\08ES.)(2SMA$)8IQ#F'HXQ:44,8D-K$-
M9PA#&<PXQDCLA)1W,&,2VZB%,%30#.H9XK7-.`$E-!&(8R@#$]8P1.J:\=I@
M$&B-S/\8AC5(XH]S*$,3ACA$,X)QBV#4(G4SA4I-I1)4JEKFNE+)CG:?HK'J
M/F4?X-58/C1V77XLTC+@O<<^%HD/\N;#'.`-#]=:\0I66.$-8(#"7SKAB3P0
MHQ2N&(,.J-"%).A`&]O0Q2Y.,0<O3*$+W;"$-KH`A2XPPA70:$4U2(&#*.3!
M"HPQA2BB<8I2*"(.>*#"&_*`AT6<HPI`T!I,-78-(L0`%K,0`X^E$)M.>($+
M8:!%&)`0`R4@X0I7@`4K7/Q0AS8!%*6HS9/WT(5VQN$/?MC"%(B@A":$(C9F
MH!P7S/"W*TBA&[,@QW3;[.;IFL-;R@"&[<:!"4SXJQ_.<(?_OX*QC68`8Q+!
MV`0P@*&)8U1"&?UXJS.8@6=E9*(9C0T&8\]A#G,`PQG]P(0R=MH,?]!C'/0`
M!C_&H8QQI(<>VRB&.YK1UV.,8PT"^"H#.("),0Y+'PRHA#X2@@(#4#!=!L@'
M>L^AU04\A!_U<`H@UKH/#'!@J,I@P!K&!PQ]:.P?!GA*`DBP57V,P`+TL,:?
MQV$/G%ZFO#>]C#TL\]+YW@,\.5VW=N8KNO%BMY#ZQO;6J%K3Z@9UON;5;GG#
MRV_S]KN0U<TI=:T;%<_-EVOT[E4NN-&)&ZCA#A!V)AVJ<`5/-($'4*@"%4SA
M8%+D@0YYN,,H1N&%.<R"<J/0`QY&_]%B5TC3"F5(0@]^X`E/=*$*M.@$%8*L
M!S>8H17OT(,=5A%3&TLN%K%0@A&.X`4P2,X,LXC&%OZPA"'$(0Y/B('4\[`+
M8BBB$T+6QB.@\09U=L$3QG"$V(;@-SCL0`J18$0N6.%0/&"=G\TIAC'8S/`W
M(S[QWAF'0PS!K4KUSE,H6$$6'("??_`6!8V(H`<PL(80-()4B+"`(7H8`D!,
MPA!!64'`+$")#:`@]O[YQU(LX`^0Y*14&YC)"$*0A1)L@@`$4(`"2*")1I#`
M``E8`/,MD(D`C,!9M`M`('!U(9#(R0"]4\`A`E3]3>`G!9GXAP(6T`$$&&`-
M:R``(%X9#/],,.!`_C"`@^XX`@$HP``H,H`R#"$(0#B2<B&"(!B"ZF%""MW"
M,A0#,!Q#4F"""(U1"@0#,PA#+<S."&@""1P")AR#,*``(FB"/:1!(0C#"M0"
M`FV"/P#+<D'"!C:6)OB$M=R*,`@#=#7#.]B6[51+ZFF"(-B2X@%A$,84U\#"
M,42"&\S!'%3!$T@-1CU!%<2!&P"=%?0"*33!S]T!%8`"D&&4%]R!#WA!.[58
M$E*!-/""%S#!*3S!)RQ4%6B<%##!%#"4$L!"/E!!ULS4-0R!$*S"(J"&%'B!
M&6R!(]B"(L!!#$B!%'P!,C`"%XS!$`S!%8""(LP"*W2"WT$`&)S_@B*`PBXX
M@BJ$`0X@@1G@`1RD@Q?(P!0D@2+X0C'$P1;@`83)X190`RP,U>$)82[JXE-D
M0E*@7DYT``=`@C^@``EL0NH`R#\0X`G\2:6,@`,(@B!P@`HP%@DP"""0``J,
M0`J80`F4RD*XDO>4"GM@PH+\Q!J4@`H@0BVP@#<VBP<$@S]L0"/XPP4X`S"L
M0/*A0&Z=PPC\PY2,0!KD2S"D00EQP`H`@R!8``F.@"IMP"9T0"-0P@JL"B"4
M``>,`S`H@)5,`@E<@.TH@^WXUB3XRS'XD*XD0#!N0@KD2P(H10(`P@=<9`JL
M@`*80`=T``I<P"9DPAIHP*$@0@*HP`BD_Y\$(,(&L,`%``,**,`YK``B'(`$
M'`(!2,#VK4$"$,())(!_6.-(`(*.)("$"(($G`"LW$(!CL`:3,`$9$`'_.`N
MPF5<7D:\Z<,P%$,KD$(NF,(=W,$GQ`$5Z($74($LM($K)(,-V,`.D($HE()@
M[D(9:,430&84_$`8-L$;E,(=)`$%Z(`:@(,E2!D3Q,$G2,$GX`$>T`$NX$(K
M!`,_3($-T%A,38/=&8,J&$$B3H%#$8,CQ(`9Q$`K&$,VP$(BA`(7Z$`-?,$0
MB,$7?`$L1`X2A,$7S,(??,'8E8$+&,%O,`(NI$/=B<$0Q$(R+-0=F(%)>4$^
MP`)3R>5Z*EYV*/^5/@"#/XP#)9A#.90#'R5+>K1F)OB#,_"#,."9,_@6/?B#
M.32#9BW:)/A#,\@1/VA".+R?(?@"<F'"L`!@_=!()IS#M:%$,1!")3S#G&W"
MG('/<F'""83:@_0."?`*)($:,!0)P-@0`*:!,1X"OQR(MH@?)F0")%0"(I"#
M[KS)13C2)FB(5'0D)9@((JB`"JQ!NGS$)-A'"D""<J5!"%0"L[Q"(6S")JS!
M!LS1)3!C+0A"(220(?0/)$CD(<20"D1$"@!"!PA+P?"#O8S`"12*07`"3@B)
M\ZF`MTU""<`*J@3#/JQ$"AS#J+P6>S)JHZX"+GQ!@>W!&T"!%+R!%TC_`58\
M`1V\`1/,`3PD`Q70P3+E`2A(C1OBP1U4`12"`1Y\@B<P@A<PF!<X@2AX@5]Z
M017D*A7<P2]-E"[H0Q7<0&S"U#((00S\0C3<YA9(`1'LPA?$0`QL00R4`@4X
MPB.@AB(H0A=T`024P9$I`0XHP18\@0X8`1'H`!DT@!0T#BC$!B@T0A'D`A'<
M@9=U@2PT01*@QA0HP37XPCPD7*,*['39F\$%K,/Q&W=T%RXZ1<'V"L-N5U14
M5U,TK';1`]?@0W;00[L]!5!E1#Z,PSEDASWPP]:X@U.$FLC:@SN<PSN4%UUJ
M+##P2CF,PWLUA3W4E#T(PZ+J@S+P@SV(5LU:_\,X*!4?!4.H^>Q;\4.HH9H]
M!(,SE)(^O,//OD,S:`(][,,MR)=0^<,V#.S7"B%=OL(P>`5RO$&JXD$>5$$7
M?,(;W,`-E`$43$$>L,(J6&(HS$$>Z('*E4+>YD$GC((GO,$JJ`(UQ8$>\$`/
MW$"I.H$>I,+/A.$=6,$4F`(_Z,`+4(9,B<,00,`OM`+?*($2F`$LB"X8/"(I
ML$(H'($0]),8^`(V*((K+-1S=`$OX$`37*84B((B0(,C;,$5[,9P>$(KY,`G
M','>?(,B$($_'=@K&`-302S82F]ET$,AB%\E=*E=&4(*<NE)X$0Y`@/FW80C
M&0(B*(-DE6A!C%$="?\:ZBG+,W":)I")HKT2NP3:G0U+,SB#,Z#:9F5+2$["
M,YC#.)A#/]Q.2`*#I=F9,O#1G?%#6=69G366,BB#9>W#3I%$<YW#5U'0/KB#
M.7Q5/?"9/31#/33#-IR#,[Q7R;K#8J$L/;2F,O"O,VRH6WU5/DA:1B!7/^2P
MO;D#/Y3:!>_#.\2;QM+#.YR#/="#.]0#Q8)7=3UQ92S;4[AGQ';7]&)Q/7%-
M+@C#5;Q!%="!+,1!%Y0"+\3"%GS"&/@`7SS!#?`"@V7#+C!"Q]%!-T2"-LP!
M%<0!*+`",<!"A^&`'>"!$TQ!&8R"*2#4)^S!)_P%'<1!&<R!.4R!'<3"3&'_
MPQ$0@2I$@A2PS1;0PA44P1!(00RL`C=@00R$@1`LP1+D@"C&`C58(AC@7!&P
M`BM\02S``C_X@A@(@0PLP2@K@D<E4PXL@1`@`1>4`AB8YQ9$`RR\919#<V7X
M0R`T@PJL0`A@@`/<2K<Q##!H"TH\Y%+0U21PP"0H`_DI`[=L`&?9D`U5`B!P
M"`GXPP>(@`I87@(40CGFXPA`"`?\`PEP`+580.RU`%U5Z#^4`+A\$,&HQ`;X
MSH=,P@B,0#\TSPIT`#E'GQ]PP"8L`"*$VPKX@TQ(2$!#$+L`PK:$`)D80IB,
M'@=XWAJ0B0@A`@=H``D4BIV@P"0H`")<R(J\45@&_P),KX<_6,`_)$#J58HO
MNI&P1%_`?)Y1JB#!'#6CJ("M00(E&$(F%`*`<`!+%@('8*\_H!$PX#/DW5ZG
M^"\'``,''$)68DPTP_7HX$(TB-T=J$$[@8$H4,,<E($5X($2,$(Y2,(<=,(3
M[,`=B$(K2(,IS,$F,@'=@L(VS<$N/`$0G&T<;)@1+,$8,($KV,(IC&:J`D85
MD((Y@`$91$),Q1LR;$$9S,(J0$<GQ,!W<H$I>,(M;,,13,$1L`V2,4(>W(`,
MF,$?,((B?($J^,)P/@(H),(6R$`,,`(>&$&0E0$-*((8.`,=Z($H2#<7X``>
M<`%S7$,L#%5<F_=3F$,@)/_1)@A"(ZR!L$Q(NM1*LU#6*XW?)/1#(7!+`4H(
MLV""5/B$D``")!!"")0`)>2WIY#)!4Q*(#`()90`(`QE(>AD19`S"40$[34/
MI42?"'DD(JR`(8#(2:-`/@2#!Z3`!JC>4ER`]CX@/ZNX/EP`"006);1$(7C`
M02R*DP;#$VU``DB`>F_`"-"#"C@#)8Q`1)/`\:R'"F2"BBL#!R@`&AG"`F#"
M`(]#ED-69XU$"EQ``H2`"83`"21%(%1"H%P`"]@5!_BS40!*"A1)/`;%?8Q`
M1UL`@RC%"!#,)DA+J:3`!T!""6!`2T3O>1LZ5!!A,B0"%.R!71<.+Y""#^S!
M#23_0S)\PRLTMB+X@`OL`0]P@3OM`AB4P0WP5RKD[0X\`5MX02=$@B4P@S3@
M`M-`@1.HPRG0`1[HP:0J@3340\P0:STMPQ"0<BO\!A@,`2:#`3$,`32$QA:@
MQA`T`31``RYP@R+@KA2P0BQ<@2KX@2K([A)`X3<P@RN40A/H0'A+P10\PC$T
M@2Y@@0Z4@0QX02G@P13@@C&TPZ&;MU)1;,/B9[")&C^4]T[MPSR(UUOQD1#O
M0S.\M<+U[**!FCF\E5.`5GOM`[&80PHK0SB`,#X8Z,(#@R_0`Z1)6BGQ`S#0
MPZ=5PE<UPV8%0^]L0C\(F@'S0WX#P_8V0S]`VCDT0S[[_P,I(0*R+*CMB)]%
M!,(MO(,[K($FO#,E]827EM4<!8,*6`LIN8L_A"0]Z%DY^D)N!0,P1)).Z=%`
MO!]2),0DI$`S;((S/.6=><@D-`,F`(/9\U9%2(D?`0,\!P*D=5]6%X2P`,*'
MW,*`5X(A7)N^(WZZ.<78>L6J;@4OM,$/^``>Z,`I,`&L)@$8RT(GO$$%J,%;
M/`$.D$$BUL!7Y(4.5$$HE$+?4D$K.,$R5<',P($MY$$7R*$>5($TQ$,5V$`K
M6'(,R,`O.((-L`(CX,`,.($N0(,BT,(.H$88B`$I5$,T,`(6/,(]%$&0-<$6
M((&728$1E,$94,`ZO$(G,$(T:/\#(S"![4]!CKF!YSY!$N!`'.Q"U[6#+X1#
MXI]W$1OLUUYQQ`*$/H$#"18DF"^?084+%>)C^!#B0X<0$RJL^'"?0W,&]^G#
MQV\@/GKZ,@J\&!%E2I4K6;9T^;)@OGOZ6AEK!:7*FRZ=>#7)X^3.$U?$;#VQ
MH@,('5C1YHQR4^4)%1^VBB2)$J5**3C?/KVI`D4''U>XND0!(DK*KE9<NEBI
M`H:4-Q\T2L%\B"T'#%APJCAQ]42)I7=PCL3@<G@*-&B@XN#YQ,A2LDY&MG@I
MLV0*%S!'0.7J!JI4GC>ELKDZPJ7,%B)Q&-4S942)(U!@(`A[M?&D7=V[>??V
M_7MA;IC_'142)Q[28T.!QPL>9RYPXD/A!J<OC"ZP'L-\$Y]+!_X=?'CQ+&]-
MB^3UCN,G3()8H1`-G)H;>WH`Z5$CR9-DWWC!(M6+%"-<N464I>@Q!8PG=C!+
MAU.:2`8=4'9X(@DJ2$G%$ROTR(.5<G:PX17PQ(&@`?]B@""64(;X0Q$P:B!"
M"2YP8(4;.#KII+%0$M$G'5B:D.((,(PPHHM8]ID'CE"^<,P31Z"!8P@PI,A!
MC#A6(:6(+K0I@@LEC'FE'9/&&Y/,,LT\$\TTU5R3S3;-K"B7:6#IXI-2;*C"
M"CQP:>669W"(H@<[JM@#BCSRJ*&'.UJQI`TY=+E%%SC<T(44_S=<L($1*IY0
MHXHJF)`B$F4<(>44*LR@PM`]XK"EG#?$`B\<,:2818X:S$!BER=XB*,3+Z;8
MXH@XX)D-#QQ#`>61=I3I)I=$C-FG%3F^,>89>3PIQ1,P/L&#-76:X&(+)<+X
M)%P<IKE""AB4N,:7C?2ISLUXY9V7WGKMO1???&?"9<\W7/GB"3V2<`.7(G1Q
M2U,[H,!B&G"Z8881+XR(0QM6J#BEBU%L48.),A@IIQMOY"BB4Z/R:*45.&QQ
M08\GC/`DE3?F2$>-*%8!;YDE<H!E#BJ5\&*5)O"`@Y49I.B"%U<\Z2041129
M9998H#G'G'-\B2665VZI9QICH)G%$_]0%`$%QT^@T46*)(A0I11%</C"EB&F
M6&*):'P1YUUX\]V;[[[]_AOPP,>LJ!5L2-%!F[]ZF!096%S1`2<OJB"%G&-<
M(<62>"C(J8HH="#C!BN8>.,),%SS1)=XB&%$BCNZ^,$+8Q:QA@DH?*"#&%&J
MX&6;)VPPY3?BGHG!A544@=&,)F")!08D9I$\%5+`"&5ILEF!Y9=]8OD"A!,;
M@$&((501!Q]H3'$%E+!!"26.2V:A;9;"2)$&"2G*$,-+6.81G/_^_?\?@`'<
MVRN,`8<]O$$73BA#*][A""SLP`MXH$(7OO&-7,SA6O-[4A+V8`<[_"`*:LA#
M$>)`C%SD(17_C&#%+KZ1*2_<P0O^2@8WI%"H8WBB!HRX!Q6"T(K?5,08.9#!
M*R:S!2X$JPLY(((BXC&$)6@C#'\`12+``(=8/",<6A`"#%S0@!HPH0$S@``$
M:A")=BP&#V!@!-FDD(PO'($9?XB!#,"@"B28P0Q26,(T;B-`/_X1D($4Y"`+
M,I-%^*(5-V!"-5K!A%8D(FTZ\$$9CM"*<HA"#Y_PQ"A$L0A]G"-H5&A")ZCP
MJ5;$8QN,.,4H.A&V7$BC"5/`0PW0,`5%G+`+T6C%#O:`AW=\Z&:^J<@T:O`"
M6(!B"5)00A/"((NYP<`4;FC`(X2QBBV$(A1=@(4XD!"!3^AQ"8K@_\5ZC."K
M"/BA':4PPXT2X8A8K"("16#&$,X`AE5\00E'")<2LM%'A!`2H`$5Z$`).CB!
M%(X1B3K".MPP!12^T"UPN`<I\C"*/(C"%:RXA3["<0WSX$(?Q)A#*Z11CG*4
M`A6C`,7Z0,%()>21#%U0A"AT((I6=$$'/+#%.)X`!%B\JS<5@49>=G&*)"A3
M"4L(!1)R$`-7@(,(4O"#-F"Q!2RH(AM#:$`<9`&&68""&+C(Q5?_,`LB1"`,
MX&!$&EM!CE^$80G9($8,8%"$7^#O",KD0C1BL8Z"_A6P@17L8`4R$WW@8AJ,
MZ-04&&$**MB!$;'(P1.>P`M=;+(4H2#%*O],88MHA.,<]^A'-9@A#6GHXQ;.
M&`<K1&$*T(3-%=GH!!*F``57P.(-->`%5/90!5/8@P][T`5XGK&%,L2"$3G(
M01*F$(,XN"()0W@$*[Y`A!C,3PJQP(868.`%6HA!#*M(!"EB00JG(8$+M-!!
M`V+1CTXT@1Z/@``1PK`\NF$3"5M0IAG$<`S]$1;``1;P@`6'BV%XH@HOE,(T
M6O&"*43#"'/(A2U$\0D41L\5ML!&/:(1AQW0@`8OH$$/H'`*>.@C&K<-12I.
M(8I2@`(:HUC<+G!0!G!<X@EWB,,43N$.WX7H-PZ9!@Y@X`A/*%$)2LC!%O!P
M&E9$HA0XD$(18`'_BU=,`P*?B(.X.K&*<5R#'=9@!BS`D`,EX&$*$&A'*T"Q
M"B(L80BI2,0JAB"$JB)!"7-3PA;D)(]]=,0A$PET0A*"#WR<Y-#)R4AT$)*0
MC&QG(!5)M$<*K0_#.F0[D`X)/OX<DH08%CK(2;2DD1/J48<:.95.SD0<S6E+
M<]K0[\+'3`P-Z4,?>CL=(76L_QGH6#^:U?\$=*(3W9%'O^L>VW&(L=^U:$@/
MN]"[)@FK9Y*/>F0:V,U>M:S?=>WLS)HDR;%TIY,=;(_X^I_UH`>Q&[UN;%,Z
M.?7X,T+N,6AK9_K0W[XUK?>A;$++VM"81G>FEY.WPJ)ZU?\6]\('#=2%_R='
MU8$6$ZBO`W%Q-SPZOB8(IBUM:C$Q'-ZD1GC#11[JB$,\T!W!!3(4&X<QV/8+
M-,@!*>)QA"^D`PXH_$0G\,"*:,Q##B`&<1!Z$.(*5(`)O(C'*UCAB6NU317)
ML$(JR.$%%Q1A%W.80GK*`(IQ)$$&=?DVPF%2#!*M`@YF7D(^C3"+/!"!$5UP
MA1M@L(0M(&,>BFB`$D!!A$X\8AI^O@<YZ&$\+A`!%#J(@"K600PI$&&):`<%
MW]V\!,@G60G66,4YPJV2BE/')14QK-[`'6G`_1,A'+^.3#H/5()_?-+WT/6J
M9^UH@QB6UK).-D%RWYW<X/[5#K]'O1U>$(?L'O_9T48UHBU-:$U[Y-(=C\G'
M-VX0<S/GT]XI_L>S(Z9_*B3W9?H\15IRDHKHC6_*UH<QD$&'*L2AAF\@AA=N
ML`-C2*$!HM"%*1CA"4WF@ARHH`'T@`Q^0`>HP!N:X`9ZH``;(!?.@1'Z[Q1*
MP1&B`0XBH!5>`0KL8`Y8P0R>((*\0!+VX0F"X&8F`OET8QJ&``)@@1%L0(DL
MC^^*8`:ZH!3B@`YT8`EBP`^:`0=>0`CL2!&R`1T2(1;TX1!BH1QV`4AB(8RX
M@!X2`0:&X`A^P1$<@0MB(`Q^`?*2(`GRB0NN(1;(8?L>PA`P02&:@1^"P1E0
MXCI`K3LD#O2:806$@<#_+`(ET*_4&&WZ_"W<V*TZNJ_4%@+4>$_36"\D^HT[
M3$+22H_WA@\Z\@'0-$W01,WDX$T.+RX2#^(@;"W\[C#]!`(6AD$2H.`..H4*
MH,$);B`(M*$;@,`.7&$<6L$-O$`4TJ$)&L`.H"$.>*$5;&$8;.$44B$/],`%
M($`Q0B$"C:$<8$$'RJ`>NH"+3H$4IB`*O,`+I``4Z*$(:N"GO@,;(``&5*%G
M<L`(DB`4MF`(E,P3<,$+;("YA@`6<,$%7H`(;A`48$$4($`,6"$&FL`2("$.
MO"`.ZI$(RJ$3;``,\`<,B*$3(&`*\LL+<,`+P47S_$H/!0(3,D$?E*$9Q(T$
M_S)A!0#A'.BA(\;!&O1A)*"C&1S")$UB(LYA(N@!)"IB)4EB'`3B'T8@)_G&
M'<9A')IA',[A')K!&91A')0A&,:!'HA2'H;2'(*A'(JA&:KF',J!:LQ!*^F!
M*^GA'?AA#3>B'@[-'93!'<YA'-:!*5^2*SN"*[=-)%92X?0A.^A!$"FB^R3-
M'@1B'>[A+JWO]F0BU[YO]%CBGPHQ)1#3X9[/+O(2#T'1;Y*!%Y.@"J;`"*S@
M$U[A"6X`9:C@!FC`%<QA"T2!&5"!!M0@9J!`#^;@MD)#%)A@#SZ!!JP`'%X!
M#.B`'IJ@0ARA&[H`"*S@!JUQ#\I@"D2!&\K"%<`#&_^,(`=<00Z(8`J8"Q32
M)096"@3280I@P`@4`<4:X`FTX1:^X!5&`AI@H`&D@-.>P18<81E*`09PP!W*
MP0F4"`RJ`0E@(0YRP`:X0!:4P`A^90NP8?/*D"$*`1,*(05(X!\&(@%((`44
M8`4V@!_\@052`!`&8AQ0``4X`!A(@!\F`1'T`04"801(``7.(1P<M!#X004N
M8!($8AQ(8`,0P1PN8`0XCV^:P1`J`1$FP1``P1`"(1`,@02"M!`H80,XX0,0
M`052`!(X`!(,`1&`%$2']!^`(04*P1""%`5(`$2UE`0JP0$:(0,05`4V(1"T
M5$B#5`4P81(F`4@IP1!&8!+_*&$3,B$%,F$$IG0%`B$%,&%+>W1+WY02@H%0
MSQ`%)D$9,`$8#$$99G0-SG0$`'43*F%+`742,L$?*@$3`($2,N$$!.$5E,$?
M)J$9@'03`$$3TF`C-V$3@@$8,,$?-M(9,H%19742!$$8E.$8,*$9,$$0@"$0
MZI03@H$2@.%59U43"C48@B$3,@$8,L$0,J$9KE(9S.$5A*$6#"$8$*%9_8$-
MFU49G"$8SL$9^J$9E,$:@@$3F/(<^J$L7Z$9-H$9M+49@@$IG:$[(+--#`L7
MDL$3H"`)H,`HN&`5=N`'6&$57($)HF`J<$$3\`$']&`4FN`-\@`:RF$=WJ$=
MFL$5_[A`"JH@%<8@#O1A%73!$KH`"K0IFEP`#TKA"&JK"HA3%,IA#O9`$G`F
MSV(AB<[1","@%'0@"2*@"Z!A$6I`!JH`"2P!&EZ@`>#`%)J`%*S!&12!!AI@
M!WRA'<Z!#:Y`%;9`.\OA%M2@N8@`%\8&"8P`!T+!#+8@"4!V"[@A%O9')5"`
M2"?5'P:"`S+A'U)`'RP`$T9`!28A`)1!(`"!!/0A!;J4$CA@`?QA!$8`!?X6
M&$;@'_S!`#9!`?)6(#B@$/XV$Q*5?PKA<[F214F`!`(!!0"!`SC`#]9@!3:A
M`Q)7$@MB(T:@'U22'@R!`_X!!2)7<$W@`QR`$BC!`H"!'O_Z02NIIA\XCP2`
M`2SI(1A&(!!60'(38`0L0`5*U!`\H!+&@0W)M5F#H1G@-%V;54%)H`-&(`'^
M`0,\P`$"81-&X%C!%5J=U1_*]Q^481.``1A4@`,\H`1(8`%28`-2@`5*@!)*
M8%HQX5,=V%4QH1)&8%8!%1!60`5*`!`\8'4-@`0LH!&RX$\GP5(IP4>#-!@2
M54LI`1`N(`5&<A(6H!$\H`,R0!`:`0$$P1`.`1$J(1!Z=$@QP6XG004*@0-(
M`!'^P1!0H!!40`),0`(T@016($L1(1!4(!CXE5XJ`A>J066?8`I^``IR`!I2
MH0=.`0M(X063HAK,814:``A^@@__YB`9WL4>1N)*/N$)YL`&=(`?PH$9O"`_
M^*\5%&L7W``GI"!@IL`3[L$(:,`3E%,(&@`4>L;RE,L-<*@&<0%5;&`'O\`;
M:J`!8D`1S``6Z,$2F&`.M@0+K.$=\D`*].X%AJ`9AL`%D@P,]BH)8L`(5NH(
M($\*PF4:5H%N(\(ALG0<YI0$5I($4OA"Z?0"AC4%VE`?5&!!,:$#_($#4.`?
M$B!T#8%R+V!U50!)<50?-@`81'024B"=_X8XQB%WPZUX@V%"S8%1QR$3`@$3
M#D$3>DW1.D(30*(CT#08S"%:PX$2Z,&'#<$?4J`G"VX@-B&>]:$?4``1VM40
M*CI6'303_RX@;_<U5L.-'J@W'/@V$YZW$D*@!##!`]!P(=AU(.@A!4I`$#2A
M!#:!!`"!B#V@$#H@1/=5&0(AIE57IQ%!$*B8$RK!<QN7FA5B$K(81B47$`H!
M!4X@`PAA#4)@#61W#5RO()SA0FMW$SA@<%&W`[1:`S3`@2^`FF]-B^WE%J+A
M!;V`!Z+@!J!@%Q;P#DB!#J"+!VY`%-S!#5X`"&2A"?B@+U?!%NX!%FP!'I+A
M">(`%1H`-/DA07H`#Z+A"T3!#9[`%A2!!Z!`"K""Q^J!"5P`>'ZCWJ!!!AK@
M!F4`"F#`"W$`%KC@!>:@2/Y`!GH@":P!&BK`'D&!$51!%?#A%?^Z01^`@1GB
M(18Z@0M"`0)>``R:`13@D0AF0;R\``;B@!1B`$;DQLRP`1KF8?Q`CXE1@!(*
MP0*8F40O%'`+X1^"X0+<11@4`!@N8$$#H(<!0!\XP+V#X1_^H1^:.0$>^A\"
MH1^.MTT!Z28-;CA*CB7*6SE@$J(]PCBJ3R7+X2U-DM7DT-CR0:`'8A_HP1ZL
M<AQ&W-W^[-",[2;?E23<;23PH1F:`;1PK=]4G!YJMW:C\AS<P1R4(1^(TAZ4
M01-^]2,UK=-&/'=U+1C\P1SR`2G'`1C*@5V;-1/L@3''`Y_?&B(,"Q:,(0[R
M@P>2`!6HX`>L@`;RP!;@P`J`P`QTP!3_F*$&:.`&2N$-Z$`:;"$)?"`9F,`'
M=D$7F"`.YN`%7B`/G*$)H.`-FJ`+3$$;C$`'WD`*]*`*C.`)6H<4\J$*@B!G
MOR,:+H45ND`&>(`'/)D)%*$&9H`1+D$18B`'($`6A'L.&L`,C@`"N.`*?,'"
M$\(1P(`(<(`+GJ!$OF`6&$$&<.`*'$$50"$&OD`5AD3*E.`+J2$6PD0EG*$J
M?10D!$)'R3>YFV$?EABJ!2(85J`2!,(?X)DC,R&+?75W_Y0?*&';!:(02``-
M?=5OFJ$2_($2P/46GK7?&X$3?"$I@4%'#6%5,P$1[M<?&EY68[4?CM)_E:%1
ME>%=C9)4GV$3__SA&2A!*8W2&4)>&2Q^*&?<&LZ!$CZ2)OG!'(JA')A!$Y0A
M$Y;7',Z2*(DR'^A!*\?!'+!=*YMW'_P!*9G!'>A9'_B!*R=B?_ZL*4WR7?G!
M'J(^'\PA)_LAZK&\PO>U]4R".,YAQ'4C(Z4#7L+^-]*=RR.B%9:!$72@4ZK@
M$YC`!H+`%';I&^2#!]Y`'\:A`GI`%[9!%6!A&^B!&';`!9Y`&MS!&4A!%*"!
M#E[`#FBB"J3`"$@!%S8;*6C`%/)`![!Q"EAA'ZC`!1CAAP3"&+B(%/!`!I*`
M!_+B#A@!!F9`%))!"FS`!DC!%&3`$Z#!DS_A#I+@$XQ!%>8V%B*!%?^V(`>*
MQ0:.8!G:]A*4X-<501L2P05J(!0.3VV8ZPBPP1+(\&\44W#&8>,Q(1@*`<$S
M@1(PH00(P4&[F04Z@`4B=!)F5%8C>!,PX4"#P=[K%!-\=Q(LUWH#`2`P;+!`
M*<4&0X4P(3+$<!*B8"0H%6)X2((@1(`F<3#D8<6%#H$V3$)8:%*@0H$,!=J4
M<E*A0@<-J<#$(5B"$B-(0.+@[R0@0!,1_4,D,5`*0)18E!!D")**8!="I/%0
MR`)"%8$F_0.J`D4P0X#`(EKQCR$E0YLFD:@T(A"*?Y.`G@P4"-"_3)-,OOQW
M,%.F8X&LD1A4B(2A$&E18BH4UM`D99L*51K_.4F0,FK'-@&[=4@3I$V.-U&:
M)'J<OM.H4ZM>S5HU/GW!)M%K3;NV[=NX<^O>?3K?/7VYF"F:$F4*CS&EF$"Y
M@0>6KAT]@$3A-<Y&$#ZMO)RJ=PY7DB!DHM&;!XI*LC@OZ.0SI09*#E&ZNN3Y
M`>0'(T55RE3A0FK>&S*D\&9;/J<9,T42L'0APQ,YV-##'1#P\((KILA@`Q/9
M@)*$%+'@T0`.M'"QQ2J/S`++*HZ0LH,9=[SP0C2L*(%$-;`TL`01T+2R!!1(
MX&&$$4DLH8,1U\1"CH"[O;;:/K@I29N32$89)9234():/B5\4(@_'6"R`2"5
MK-`!)22@0!L])/"#_QHP%@1"R0@II*#")!]<@)`!P*`VCIJHI1",/J^=4T((
M88V`P@6"F-`!4PE,H@\]]/!CCCF0ZH/0H_;P0T(*_XS`P@B@BKG&)2/(-DX_
MYZ1J3C_F+&;..,Z<,T@((J2A`0$=L"!F&K>H`,@YRB@SCC+!--,,9"N88VPS
MDZAP`@<H>`"M!8B@X(\A)&#BC#/!<$LL,.:D0(DRF0!3$`D;K&#(`">(0.L:
MD)1`B%^8`(-))<+XXT\F(]B+"2:&H+"""B:<$(()[G:@22`A?(;6),U(B9LS
ME$`I\<489XP;@<`M$\<34?"@`P]Y>((##798@T4>-P`1!!7A,/%"$'ET@?]*
M.8T4$84V1S!Q"S=NO.%)`PV,,@P.45#1Q1RDR`(#$&K`\D8/9/@0115SE#/%
M&`%JK`_'OP!)RALY-)B#$K+HX`($M^#@PBG2)(*$&6*`,0H9$1@!C2*C=/*,
M,[C$`DHHG30002F@@(&$(DW`DHT;-2BR2@,RA`%-V4DH8<01U\`RC]>@ARZZ
M@/GL8SJD]^133S[-F/9H/O;0X\XXP/2C3#.PT[./[KLS.0ZDO@,SFS+GX#,.
M/N;X$LPSF/!S#SWY*&..Z:\UPV<^Y1BBS#OT!+,/)>8P0TD@UYZCSSZE?XV:
M.<Z<SV0@F/33#"7G4.+,,8804DL*RJ#&9&K]^!/_:@@1B&#T`Q/,,$0PF+&&
M-.S/2JUQ!B92,[['/,P0S3#$&EY"`M>Q9ER`TL<Y4I"&300#$0N[1"-.L`9A
M?.`0M`E&(5(SB144XA@JV,0:/+`)$7!@$X?H@#M&UYK9$/&(2-1-/F"!#4;H
M8`I&B$(0;)`+*J3'$:LHA8-T8`MS7*$!0)!%'G)1#7V\XAAF;$4\B.&)4>R!
M!B\P!3S@@`,>4"$:BW"%A$H!!QJ(#`A5^`$?Z'$#&IAB=->(00-*\88E\,`&
M,`!#$V1`@SGLH@%3J`82E+"$(TAA"YW8!1T:P`4QQ,`%83`&!"`@`S/D(`*>
M>`4>H/C)+?Q!%Q0@@CR<_Y"#)BBB"S9(`A>.H(1I.()/24RF,J6$#TB5#A_[
MP`<T2P>]TS`I'P3B!_=">)O7\`.;Y].'/<YA#WO\CS?8Y)AJU+F;_]E#=.QD
MIQ)]@S$CHD^=L'/'.5L33=2XXQWT?-VCRK&-<I3#FLM,J$*12*!\M"(:GDC"
M$ZI@!2#T`!1&`((G2*$(Z]0`&JZ0PR5>4(4O&.$.B2"&:FX!AR<\`0^%'`8I
MM%$%'O`@$I$@14UMT04@0.$)5J!"#UR1CR<$@13@!!TV:@`#:'@A!SI0FRNZ
M\((QQ,$(-OA$')8P!B4T(0QFV$(DZD$*&31@!C!HP"I?0+0G[.(<80"#&;B@
M!/\I3&$*V<E!+.(@@PC$P1,0>((9E'`$:UABB`M-K&)3XPR&9*1*(\F(KTH2
MEULP!A$<@(E)3L*0A:A$&0PQ1"4$D0(.U`L8ON`$,#9PB!4@`A&ERHHA*(&(
M0AP"?I0`#65&0(E,W"(8F]`$"BI!B#1`8@692,LF,D$)2OP+&,[P!S#,!0Q$
M8"(8!JP%,P"1%D/XHQ#<FBXP_!&,<MTN&.,%1C`P`0EF6(,9VW"')FHQC$TH
M8US!4H;\G-$Z89W*6+331'RWT0]^!.,6VP`&L8(!*V65@Q][.@<]4J4J<QAP
M'_RPASOHX8QQN*,?[FC&.=P1.T@!CW>5DET_[E%.@*;_8QO8VX<[S)>:?2[V
MQCBNS6]6L;<:0.''-+C#*8)``SA`HPI!`,(<?($'^"3A#JR(`Q3FD(M6#(,>
MPVB%+:J@@U&<8@=SD(8G2B&*J.J`%[#0P0NHP(H8+"&020""*/*!9$F,#A85
MZ,$LXD`$&_R@%!]+PAOTT``73$$5>.`"%ZC@!2]L(12Q",8W1&&%0KY`!DSX
MPB[8`0M8A,$+;RB#%^(@A3\P0@HQR($LDJ"#/+B""D0@[!:P$8M[V#C'N!8=
M/OBQCN*511_C.,<XW`*G#73``A;(50AJT8$TR,]8MI,?\4:`76-Q`@5^0`$*
M3+"!-6A@`A*H!"0P0(E@2%<9_]/UBS-6H!GT4J+;(Z`5`DS@@#5((`V(L-,E
MSH(7LV"B6=UEBU!&0(@%&$(!(]C`G.S$D$`,124K4<EK)Z*!+*Q!!!6Q50@R
M<`)-:*`0B#!*)>CRDK"H2RC5"L$:!'&(-&A0`8>*5PK`4H@4."0%#L<$"281
M)T/\0P,G$$0C",&"6I0@#2Q80Q`U,0*4&()3#/E')9!2%\:PH!*4N"TD"!&"
M1FC@N"=(R3\"08(\Y?KLN";0/EJ1BR[<@#Y`Z+(.ZF,-7;Q]!]?0A1FJP(M8
M-``-MHC#'40!AU8LHQ5?^,03WI`'&M2@&Z2@`AW>H04<W"`.WF`"$*R`"B]`
M@0Q6,/_"#TS!CTF*XLXUH`$KNO"#&KQ!%A&H0A7R\`0HV"`'GI`&$^[ZA"Z0
MHA-YN$4S]M&-6\3C&]&`AC["<8Y5A(+,L&[T&ZC1!2(\80ISD(\.*``.*2S!
M"V"H1BR,B/;RAXY`UTV-8OIAB'Y8%S`KP$0:`&$Q_V7B-*^AQ`=\08Y-O"(3
MAI`,&H0(D,`"S$`;F!`Q3.(,6Y$)EW`"EM`!E]!R\+(!FL!-JE%>J$$/*I`"
M`*-R0A<PFU`,O(6`CG(:]+`&)I`%B"`54D$((C`J)H`(5^(_L)$"YP--AK`"
M^+8")0`2\S<":;$!_;,[NF-B^A`(>6(.L-$N,3@!(<`"M1+_`H:@"1ZP!OPP
M.ZD"8N?0#\"`@UTX#H9@*VF0!NZ2!AT@`LC%<\%`#\N"6.87AXEE"M`0!S]P
MAS[E"M]1`5M&`Z=0#K:@!GKP!'>P"VH0!%;`"WDP"K90#=A0#:*PB*5P`Q70
M"])`!V^`"JT@#\8`!3\`#D[`5GRP!RWS`U`@9_8`"J,`"Z-C#%)`!K`P!PU@
M!8.(`XS0!+8'`PY2!+OP,3^U!8E0:KMF#&`@!I9P#8J`!*N`#?>`#5N`!UM@
M!%Q%!:<`"C'P5$\P!'CP!'L0`8R0!TD``5)`#:]0#W)XCDAT:ZGQ3KFACJ>Q
M80V5&NJ$#QQC.JLQ&Y*2CZ[A/_1`_X_0M`_"\BCC<`_EL`[FL`W,,`YMJ';<
M]!J3DH/YL!GE8`["<`^GT@W"@`G"(&"ZPS%.0@_*\#_X0`F:D`P4N0W.`"[!
M0`G^`!KUAQK=@AK](!G"P`RU8`^-L)$J@0F`($#R>!KF8':G$1>8D`Z5<`NU
M<`FW``EN8A),B(Y0J4P<LPK$T`D\8(H\H`9S-V6]`$;JD`A5D`118`55,`J\
M8`4NH`=V0`,T0`??H`85<`.I$`4OD`?00`=/8`=40`5@8`R.$`%W8`HW,`9W
M<`<W<)4^90KTT`53<$A>PS&O0`0RL`I=D`->``%*``:X``Q,D`,UP"`PX`6[
MT`1$(`6)1O\$?M`.D:`<I;1)1Q`&5\`-S]`$/X`'8#`%/H`%T=`$.2`%.&`#
M1M`XI#`%2P`&5"`%7"!^Y!>5S$D;YQ`KK6,.YV`LPJ(,_F`.S30.\_`*FU`.
ME#`_S#"=]/`JK0-A^Z`LXQ!LYQ`,Y[`/'<8/YP`,VU`,J'(,Y?`.R,,/_(!A
MU31-D+(GNA-"S:`[ZP!LRRD@^/`;Y>2.M9$/4")/Z(1/&)-4&L..S7FA"<4Q
MK;`W/&`%4:`#L=`%#9`#GT`'-H`*D2`%4,`$98`'G>`)IH`/CU`#+D!D-.`#
M<,16.T`,Y;`(G7`'5.`#5#`&;I`,.O`&KB`%--``I/`$FW>*<\;_!#:P"OKP
M&Z`3#3`P`ZP@I5V``S(@`U*`"ZMP"IZ@`SE@!#(P9K.P!5Y`!)&@#2#0!$F0
M!%1@!$40!DJP!40P!&$@#3L@!4>`!Z20"T=0`T20!&;`"*30"L@@ISR@!)U@
MI]RP"@R*H5'Y%89@7;7U$HX5"((@"(3P`95@`AEP"!N0`@J0%PC!$!/A<YN`
M`IQ5"/\0$2]A%)2@`-Y6"&FP`2#'&"ZA$@E!=9QZ`251$BGP"AS7`1\0"!<`
M"367`H6``G81"(@0%XR!`C!1")F`"5D7#!^P!BNP!IB``BJ!$"?!"4`Q"=SJ
M=)F``BIP"\0R+BL7,#IW%B/Q;Y#07).P_Y*SE5L,(7S6<%UX<0NCP1#,E0G2
M!5SKU0SE52[2M1(HV0S"X`Z(D%R(4`L/D0GYE0G"$`S$`BP+1BR;<`ZOT@^V
MXP_CX`_<DH"M,YU/::DPBTZG00K4P`@W``51\`:P<`=2H`:HT``HDPN*<`=Y
MT&A?L%'1T`[=P`@_<`-$PY9,0`K=,`ZW\%=XX`5Y$&J@X`I/X'IZ\';:X`D\
M4`4^%2!"U35>PR2_$`,R``M@L`0NE0-6P*1-@`1SX&-)D`-$``&.4`IX4`K,
M@`4NL`1&0)PYL`0XL`5*H`0P0`2W4`U3X`6SH`@Q$$R9@P.K@`2D4)E0M05F
M8`1@X`V.4*DQ"_^5[^,HKX$F'&`"S+H&'7`"69`%+/`F*B!.?!)-3-(/)'"$
M^D`3_R`P!J$"M"("D%`+&W!_KS(I$F8^A0`,PM8](]"!99(`&_"#)C`2*S`)
M_>`,P>(/Y]4/AY`"`21B"Y$"%Z`""+`&&+`"5*%SVD,LF/`WP>(,(Z$,FN!;
M#60")H"^:Q"%0$<))4`4N;6MSM5<F4`"R;4)BY$&)W`"*S`"*Y`"+(`"$0$(
M*E`(!7L6*1$(RD"NK1H()G`(!2,("P`)$L`"'C`"A\`"JXK!@)`%C>`2.H<)
M=!$(<`((:;#"KN4!@%`"F$`6&TP7/EFZ1%P;_],*TO`&4%`#<[`,#6#_!Z'`
M"'3@!3P`!*8`#E20LU+P>I_P";=@#LZC"[J`#+K`"_%@8'`P"J7@"5-0!7<P
M!J&0#66P`S]@!W?P!GM0`WG`"C#P8Z1`#U(``YYP?OH0"Q!0`[#`"$1@!D_0
M`%2`>Y9`"L=`"C.0MU/0($?P"'\0`S@@:*+@"F+@";"@!*P0"YZ0`TD0`X_P
M>TK@`C"@.3P@`[:0#%^0"TVP!$L02=`(!MW0"B]9Q%#Y&L[0#_BG#^I*/+Y`
M#\#`L,!@")F0$.HC3_1P?VNRK\UP7?1+#IAP"(V`"2I`8ZQQ.S))KL>P&.-`
M`L)P"!BA%H&0!MC$)$]W&N:B#]:0`AC@`1E`_PG,4`*WL`90*`@KP&R9X`L3
MM`_=A18I@`*;P">"<`*0``P!S5K^@`)ID`EI$`BTT0PSA!J3(##\TG)I<`F`
M$!&&T`$1TQH<C!K*0`(O1`@:(`@:0`B"`"T_O-&LP8"H80\:40*%P`)IX!$X
MET.&P`%,^,O`?-2G8:6YT`]S(`-Y<`I>X`)\P`1NT`,\<#4[H(A3\`9O,`6?
M,`J?P`WV4`Z>``?$P`_&0`>F0`[\D`M5P$B$:`9F,`N,L`-E4,5[4)@Z0`.S
M(`5`0`-_+`4\@+:@XPLX4`.Q(`5$`"15\`DZ@`,[@`-,0`VF4`.HK-@RD`0N
M$`&CL`B@X`E?``JKP/\(@.8$IO`&HV`#$8`$0Q`#=^4%+V`$H,`,2"`B2I`$
M>*`$=W4$9A`/XX?4P!TZI+LQJ)$Z#LHQ]'`/SM#.&Y`2PY8"U#)!^9`"`&``
M@K`&#!``]Y</YF```V"?&Z8/&(`!^M#=U<T`V6T``=`,X4`))E`"WLL,RK`"
M@J`OVZ`,Y6"/$#J>]E2>^3`;[F`.V)-?RO#?ZB--ZF.$@6(_]4`/Y9`/UD`/
MX]`,ZA4,0Z0D])B#D@)-]'@,P%`.'V8.Y>`/ZTF2MX`)YHB!P;WBP$$-H-!J
M.T`&=N`*K9`$-B`#5[,$><`+;D`%;W`'>P`&;N`.KB!E/5`%:F`<5B`*]Z#_
M"TQP!WAP!UU`!6]J!$_T`CV@`V%@"5[P!%*@16@@"N^0!WK0"H0,"UY0!0GR
M(S5@!*5`"CAP![WI!-2`!V9@`S@@!6CE"HSP#6[+"G_@"HD`!ZN@"G_0"8J@
M#ZLP"FK0`$E`!#'P4Z3P"E>0!#RPQ'GP"490FHL;#;!@U"R.8U[(K=A57J)Q
M0H^17LZP"960"81P"X;P"IK@#YB0">B%L-JB7NH%&2B@7PI)7B<0#/DJ0^A%
M+-R"7?I5G?EE0M,Y#MM@#IO`#,=P"YJ0``Q```KPZAY@[1A@"/I0"`"`"-L`
MDLK0`0`0#..^``"@`<P00/C@`!RP?`90".8@#O(P_P_A$`[[@`D)<``'8`"3
M4`L(0``$$`"O4)#QQ9^FTT^S,4T$LFO6!#WUP(3E)$Y(HD[]N#%6:ALI'NH>
MKQJY<`U=\.4\0&1JD`RZP`>?,`4_Q@-T``Y%3FIP``Y/P`11,`8X^P-[0`;U
M806F``M%$`="[PK2(*=<G0=NP`C$0`P350-Q4`4V,`?N4`0ZX)B/J0^_@`,-
M``MQH`,2I01B0`Q]M@,Z``.*0`158`1GJ@:EP`I$$&M$D`,X,`2>``U#\/9+
ML`-=(`2/X`E1\`./K@-@\`6,``-)4`2$J`U-P`124`9'T`7,D`N@_O&)!2SK
MY0P+H0SU$@R9A0)MH0"!P/\!5QC",5T)_U8ES241$.T/HT'#Y'H!@(`"''`(
M"&`K*$&L53);G.7,)"U:@6`!6N%R$F#"_1L"AR`"""`!PT\):2`!$Z`!&@D`
M.K$"A'`!EB`(`J#\MQ``""``W:X`PI``&&`)AA``;;$0#A&M`-/]:U`)E9`&
M!,]"*H<!KXJM&E06_U`(FQ`6T=HL(X`6`(')4"9`'@1Q@(2BT"1$A0)-*O1O
M$B!,A2H]/(2(1*%@FC`18K8&$0H4F$A`-%2($B5$$"=EHB1PTB1#*3#YRX1)
M&:5"F51H$F0($R9*E2;UTY=4Z5*F39T^A1I5ZE2J5:U>I;I/7ZMIHJBDBA+$
M!PW_5(N<D*H!)0H5'59V[?K$B-NI'E-T,)'B(PD-'T]^!%%C39(74.`D67DR
MY8D-*;D80?,!!`>447F2V'I7Q`8KK%/SZ7L%`X*N.$FD>/&RA9&K)SARY-BE
MR!63)WF\,($QQ061!DJFX)ABQ$B./2YJN)`18X@G/%5T=%FEA=0,,T2VL,*S
MA0L7*5+BM'O56?QX\N7-5\6421\^??1(H$"TB0,E%"E1;,"T`84^K4W-_;M'
M*?D*B6@%0%2`1`42.#$D@6>@*D09I8(9X1]`4"!A@PU4`*2$%28)8!)E1G!'
M'P(IU`<8`"AI;QP41B!!`P$P4`&`-"P`P)`1*&'!`GWX_S$@$'W,X2>32NA!
M"@4,)$A`D`T4`.0""?Y)(1,2`AFGGW/&::;+8,[!)`5^G.FR)@Y@Y("%$%@@
M@0-_)D'!GWZ*4<899;[\,H5@E`'&&4HX6..$$$1`@)`3-'"@$$PX"$293#(!
MQI^;,`D&DQ$J'0J0%%+@H*#W-DAA@TQ2\&,324T=YSQ55V6U5?$^>X481J#0
MHPH8>`B"CU-$`8<4&IZXP8X;>*"C%&WH&)8*2:29PXU6GD#%%B]^@((*7G(Y
MY8D*K(@"BA[>X$42+$ZY@0P*HB@ECRD8H<<+&TAQ%587;K#EC2>2(**[)T[Q
MI`@<CF"BB5?8T>(+*!IX`8H:NO_(XXY/DG!-!T].@<,3%X`((H(:WI""E&QB
M@0,,Y9"`!A0IN%,"M2_$B66?_ER%.6:9G6)/GWSPZ2^??(BD9Q]SAORQ&6?&
M<>;G]93J;Q]Z;K;9F2_I,><<G_79II@]@\&'GJ/YLUF?HKEV9I)@]FE&0F#<
M$6:F8`HIT6;V\NG/'P`VT><><U3B)Q`!K!$F@!&4\0``0,ZYX`*;%1#``,49
M`(`$_NHI!));FIG$G$V`X:DDBJ!J!I.E*'EH'$/>-"082@`IQ!`5SG%*JTF:
M4:J9%0BYI)(UA#%!$TM4^*<6%2KAW)"E"D$]DT!`)X&2?T:8A$=^9H8^>NFM
M^DP?5Y;_<0,**?8H8Q0=@`#?"6Y::4*'/?:(X@8K8(B`CBXD<>2-.7J1)A)%
MW+!%#C=<>$$-'Z*P@Q>B\)Q8O,(-='B#%_!`!3O$00I3X`4\I/"N>('&.*W`
M0PZD@`<I:/`(<>!%)XJ0`].<H@E$($(HMH"'4G2B"T,X&0YP(`4JX.`)9E!$
M*I(0A2CDP`N/B(41:F":7<`"#T=00A+!P)TN6",6TX-B%,=3L^HIA1_CT%I_
MSO&S<]A#:5;)VCYJII5W1*6*-6M*%:FGCTP`P'-,28$`]F$/`2!"'_U@0`CT
M(0$.)&4!&R"0(5*B'J9H;2IH7,K+D,84-:[G,V_#!]R24CU#_]8M*37+VCF6
MIC.E1=*12>F9ULS1,S'RYWGT&,<XSL&/?-"#E(B48BQE21Z=Z<,4QIB#]J(@
M!5O,(0=X6,(8U%`-1N!!!S5`3`/XT`IX%(,4MOB$+DSA!&',PA.OB$4^2'$'
M(+B`#$E(PAB:$`Y=L(4,1B@"+#XQA21080J2L,<<JF"*F,4"G,F(`P^2`(8N
M%*$)70"G*3RQ!"G(8`DRJ($72@$&*1#!"$HPP@.E`(4R+&$)2<C!0[E0"E8T
M``9$`($/JD`%6\SB"UP0PT/Q@`<C;.$+X*GD+&4:RV`8(A"(6$E*''*($0!B
M$IO`1"`HI)`+4,("E2`0(`29DH:L3?^0#UD>)391TTULH@.3*(%-%1*3YE'B
M$(:8A*1@4HE-4&($F#A')I3A#V6HP!""2('J,&&4F!1"$S2AA#(`4(A:O`2L
M_;!``(+1#P"L8!.0*(0;$\`!8`C#`"H(AS*:88Y^^",8>\*$B,[1C'&80RC.
M,$38@D$F8/1C''5RAI;J=-IQ!",3FNP'9^UT#C)=EA^KU*0YW+&/<J"2'U$C
M$C!@QX]Y/$\96PR&.YJA27XH36GFR%K6X,8>RKI,*:C\D3WR<8Y&SM2[WY7*
M9V)Q#48\00IK<8,T=E"%'?"@!Z7X01G\\H0W*$(7<[""%Q+S`R#0`1QT>$)M
MJ)"'.6@#%$7_H,(3J%`%.K3""DDP0A6@P`MBZ``*4_""%!AACCCHH145A`6^
M8"&%B#(AB4\X0D0W.`0CN&`*7`##;XP`SB1RP0Q&H`*)D^B;'!`AB4T`0Q7,
MD`-])L$377B@BKEPA)-](1U/!&^4H4>/<VR)'F"EAVS?0P(8*0!&&"+!H@#!
MI6;TPQRJ++,R2)#*.E&"!/_@0(9(``@+?,`#E$C!!3;1C,L&`QC`\+.+'O7G
M28Q@)"1000`,80$5Z"<0.Z+$3"AAB)6HY!8`L(`@*=$!1*P@`!=`0"T`P`()
MA(`9"`B``#0PDP!L("4T"81#E!J"%:3!!(A8`"4\H"8/3.("B`@$_R"4&HA_
M$!NG"C'$/PJQ`A2D0*D;68$'TN!J#RA$J2@(MD)4@`F)S#D%)+!`K-.P"0_4
M0@$HZ("A-:"Z-""B)BD(1+`G,HE-7<BM0DE=(4)@"!)D`A'`SC<B8"=E@GNW
M>JNH!AS&X(4I)'@4IV#"#8!P`U<LPA7_S,,G^+"#&]"@!PU(@A5>$`4U\*`"
M5*@`#8(0A!YXHA1X>$(3&(&%18!A"6C(@1MV08<JC&$*'+.%.XS``WJV2KPN
M<($JC-`%5Y`8#_+UPAV>((LXX"$4H9`"#'"0A"D<`8E*`(,2I%`%AL?`#$GX
MNA&>D(,=Z"`.>1@%$UPABDZ800DVAN@=6/\AAB94`W@%!WS,!GM=>%/J=8'(
MA.E\6A^H[`,82PF&"@*!"5,98@TU-0$G-K$!"3WE*$IQQGLF@0FWI@!TV)Z$
M!][HE*`:X`+*>(<A6!``!I0`$6E@``LZ,.X3&$``>M3'`L34C")-8A^G%$0'
M$-0!$EP)$1U802U6H(*N-048@&C/>@+Q(AVEX0(K6`,+1I")273`&:'D!Y7-
M\3-`^&/]]+#2&A2T`@F@(/P20(0F5F"(?'3VMKBE!TQ`@?Y+I0LA@5H;`0O0
M@!)H-'_8/F7H!S)1AN<)O`J,HL]8!6;(I2BH@CT8*5[0A;:S`CZ8`UT0AU:(
M@S>@`1I0@PJ0@C?_0`5><"<>B((WD(8XN(,&D((G>($I4(0Y@`5KN`97F`(;
MX($OJ`=/F(([6`MUR05^6((><(4*L@07L`%88((B$(X=3((=")@CX"`O\#$N
M2`T4$@XE$(/M0"(N2**&XHX7(P*NVZ`D,`,I"(4XV((M2$/4.(U.D((K*(?P
ML,!!E!D*5*/N8@I%XAJ;21JD421$3`JMR+*>N:X?X9(MXIJL<:5.2C]E4```
M8!P`V(#!RH=C$(`Q$P9F4`9($,4?^40````!2+45:0]_.!M[V`:O<8=RJ!1E
MF`0L<B5-Q!E].(=@X`]7PHEFH`=@&(=;"`9[`(:!6(E(I,:C`0;688]F_Q`$
M35`&:ZB$RGJ'6CB$2@B&0!"&K6$*9U"/FH$(2@`M9=B$TJF)3+`I123$>Y29
MSX`%9.B$`/."*FBG-Q"%:[`$)N`!&N@#;<"#,3""?A&%4Q@%3^`!*U"#&[@!
M\WD"/#B%3W`%"J"".(@#.I@&6,"!&N`!*9"&4["-*G@"LCN-2UB'"8(7H],'
M8V@`"M"&-S`"(C"#B\H7*C""4,"#&%B"!H@"&1""3O"$%'NH)#J"[=B"AGJH
M*1B"&N`./%`"(N""&)"!+2B"=3("-DP"[H@H)>@$:S`&?%1+J3@M.^$2+@$&
MR=J$3`B'S7*&(O$'/W$494BEU$HE+CDNSHHMR?_*!"S:A\XZ!U\XAV=PAG`0
M!LY2I3.+FMPZL\.DA]]:&GK(&GZ(I)X9I:,91J=0!LK+19O1&9W@C\_(AR[9
MAWR(P#OI,V`P&J6H)=,T#TB\S:7(!WL8C]JLOK4$SIEACU?`!D^H@BHH`W<J
M@SMX@R[@A5.0`F$!`AN``2G0!E+P`B.`@B<@`RBH`N;4@Q^P`B-@@CCX!#W@
M!3AP`2CH@A_8@S?(@UR0A"IX@SLH@PW:@RZH@E,HAQ:;25:!E1JH@59P@R%B
M)Q)2@B_(!59PC24P@O)R`2-(!3L,A27;R2T8`AS@`B+X*.\@A2THA5*(@!V(
MN2+P2D?@A3G@P@?B@H?_^@)N$,3@E%%]V`F:((CF68A)V(!XLY`+T-$X8YY,
M>ZI@B[5@\P<2,`1`$(1`^+::H#=L6X`U\`!$^+844(%"4`@+N:E,^(>:0`05
MX)29$`H4L!(48`&1X`";LA";:@B)J(A86XB-F,M*$(1:"('P0Q`2,`I!0IV*
M&#W*FX1`,(1-J+5:,-1)`"VP,JRS<HE(6XE(PY1X%`A`4*M*,9TZ_0=ZI(1@
M**NIN@5,`(9*!0:=B!3$$QIF:`9[F`1#-01?/(:KN:PZ"30^4P8('-5G0,QS
M$(9:8`:=Z,5^D*SSF]%AO8K/:(5JV((IJ`)]28(GZ((I@`)&N($>D@)/Z(14
M_U@"*/@!'I@",XB",4",*1B@XY2P)]`>/?!`+Z"!*'B".2`%WV#7,B@#+X`"
M+X@#:7B',B"#*0R05HD%,G0%*N"!&9L"=DH%4OB"X6@[6XB'+RB#*9B!&0"#
M*V`$5O""46@"&GB-%HH#%9($&'"!)QB#QI`&'W`!'J@!4""%4'"#!U*"9E6"
M,+`&1R#6FJ4$0FJ/*BV$$6BT8AN!2WF/1;R98:0'%.B9SZ@$9UN!%>"`#6`!
M/WB15]B$"PB&5@+&=7`E?1`X8L0'8*B0]U"!!4"!$D`!"3"$2M@`2CB'?C`M
MHBD;SRH$MO6S0.`R$N@``V`!W7L`2)"/5@6T/XN43/]P!D'-B5`]@3186A2(
M4A98@0XH"1+`J4FHA*$8BI@@/?*;RPN!,T/0@!,X@0[0$$Q8@8<04_*+-$,`
MAI,0I*0UM&\#A%QC`0Q(`'=C@4+X-T&--SS#*4"H!$"0B&9#`148A!)(@Q-(
M@#1@`0&4"(<0U,ZKV>=]"F-EABOP!%WH@C+(`SWPCCU(@E,PA3SHA3R@@AL0
M3X:[L"DH@RHP@CV`UFF%@O=]WP63@BT`!44H!9WK@C?P.2_0@S>@@D^8`R]H
M!7R0@A[XSU41+]<@ABY8@AS@@BE8@C+(A2/(@1Y8@ERPA5UP@Y62@AJP@230
MP2'HA$Z`,"E(4%88`B)X@1[_X($&V($]X`)&@(5O.(5.@`$CB`%>L(7N6(*8
MDX*5@3+HO<>;L2Y,=)E]J`3A.BVR025+I93VV(=ZZ!GIHH=@(*5]J*G`+$;U
M>)-,N(5"(`>FX0^<80]A^!FM<(9_V`1A<`9,Z(=)8(9-4-),X``)J1Y%P@FE
M&`?(U01_*(%@X("A.(%#N`11@8H[Z1I^4`$5H(1:(`%-0(%-.(3I\^/]@*6D
M"(9)6`HX.9Y`J`0%.8000%)#N(!4>8I"<`:N`08.2(%_VP!(0(C[2!T/*(3?
MG"1]<$#^T`I#>!%(8($2N`!:1EZ:X`"MP4TA1N97@`8D\P+]Y`*.X<-3H`,W
M>`,Z_V!"-6`"<3U.*UA.^DK?'K"#*NB6XVPX*N@"4`A1+]!@/)"Z.QB%##,%
M(B2%=^#!5:@@4*"!&Y"&+L@7?)$"6``!'(C#(0"%&("#)9BA3YC0&I"!UA@.
M&,""3BC)8\H!D/6!C#N['>@")\`"3\B!*:B!(E`$1C#ADTD"/`B'M$3FE>Z,
M8[[E\[!'VEPC6Z8E->)->["'<E@_W_S-1^*:+=*:GGD'5WJ'*JLRK;`NI&:/
M]'L;<QBL<2B'5.;+=V@&36"&Y+HDKI$DREJ*QK(&>U"&<F"&:]R)Q-L$I&;I
MM.X:7+@&.*B6,:"-*IB"+F@"4I"%'(""CQ;7/(@#H/R!)_^X@SL`R,28+RM@
M@K:;`BG0@UH9`QN8N(L]C8?M0)8D.UUX!RD(@BFD25B0@1R`!4;0@;6[@5)H
MNCW`:PK@A5)0`AO8`250#FAP!5L0!3KH!##`@U9XA3R`L55(!%W@E46``-/(
M@2/XA%)@!!PP`M0`!6W0PBFPN2VXAEBX9+4&KV:X64J0%**@M$Q8@]()!G_P
MAV7H;@'T"7]8"<JE/(%8JTPP;TS0!#^@E#_+!%\X!&!H!%N\66'P,]<"M-$B
MFOZNJ<'2$E4B1TRH!=,!S"ZIDS(SA\,T+<Z"0-_:HLFRAKM\!G?XK?0;I<ND
M(B_2!R[1!W=P!WNX!V78!GOHAW?_Z`><CNFFN$PUBIJDX,P6CPKM*H]#K`?=
MI.X=9XI(.`9/\,X[R*\RL`*ES(5..$[Z>@(=V`%>\`0`)K$EOP.?VX,?N`&U
MNX,]R`-F<8&Q?.$[R(-=:`[F5(SWC`,S:(5WT`%ZJ:!70+I<H((>2(*4&04;
MT-@88()N<(4*T`$IP!<=J&@AX(95<`0P@`-82(0KR(52T()54(1N^`((<`UP
M.H(IB`%0P`9&D('A(`)%`(4G*$LL((<8Y?$H&P=A&-5^$"28&`K)0P$.0($$
MR`(-,($0H%1#$XBA>!2B"*L1\`A(`!T3J!!`B+-!T``1*(%;"(0/:1Y*2QV(
MP`1`X(E(_RL$#ZB)*^&`\EN!"[B0$4`JI:J)0DB!^B`>AZB/#@BV?]`U3+B`
M-<B`-2"$#1"V?R@VWH&W0HA'1!"V0M@]0E@#2HB^!6Q<2.BU-&AE-44$"PDJ
M/DVVN)K<WM$1>IN$.2N$KU)WX@G4M5&>E/B'%9A<<@P$9B@!?R\!2M@VI=I3
M2@.K3,ZLLP7V2E"&7G4M2``&CK#=G'B4URKUY\6%:,@>;1X#*F`$72!0B]2!
M.8`'20`#/;"""M@#1N`#5H""-\`#&`@"&A#R.'"%.2@%\KT#,,@#:\"%DEP"
M-7A.1M".AEO"*FB%=$@"(+!GFFP%'L@!7*@"'M@#)<@-'/`$5_^P!&D`!0C0
M`1Z`@N%(@CVP@@@XR5``A56X`EA`UD58!54X@H/)@3RH`A)*;`?>@FJ8@SOP
M!"9``BZ@PRU0`D\@A[C?><"[V>LB@:PR"4HH@8\8A,F5/*B@!T!X&4A8`Q-@
MB7@[@4U0@1.(-,YSBL\P!%.FT150MCS[V4ZK74K`#WVHA]94:A.A&ZW8XQ=)
M`18X$]W+`DBPA/G`AU$"KBJCATB[(MI*`\2=-FEK?Q9(`TW@'7,H,RYQ!K<\
MG3$A$^(9=^0%B!4D2@1"X0\1B4S*@@5K%@R8/W_]``$#]I!2BD,C1J18L&9%
M"0>')GV@M#"3OV`I@2G#"#$3L$"`.J3_^;>!P\85&X"E`.0/(J9,Y_01+6KT
M*-*D2I<R;>KT*=2H4J.VVA:GBI<J3YZ8`>=)APX>NZY!8^3HCQ<:0<BX(`-E
MSRPF=W14J2)+C9H74'B\(/-I3BMBTB0]L7&#CK<W9:94F>+%2ZYU>_;`FNHT
MG[Y53ZI,ZV($CY<<4&+D0O)%3HXD2980@=")%:E=KJ34,-+%DQ0G;Z1X4G0$
M1H\[O!AYLF,#QA,F2Y1\,88$&@@E1'*8Z;3DR[58EK=S[^[].U-\2/'MRV=N
MG]%[^NK1.^>N&3U]^]"7UT=//#W,Z,M9PY<O/C_CV!>,,OTXDT\^_NF#CW_H
MG4//?/KT0XDS__RX,XX]RKBCS"TP3<+/>OKH)Y\^S3A3E#R&:*(,/\",4\@Y
M_D!2"##_G*B4,LH4Q4\:A@#33R']&!),+86@@`D@F"RE3"4[&@+(),$8PHPA
M:0!3"2*3`$)"?$I-TDQ1RJ``R";!K*&,"L`8LH(*MUQPR5)J&A7(!X+<D@(F
MAHR`22`7%!((!YB!-RBAA1KJW3V8524'%%1``447O%`!5A1`G$*!&C_\H$8J
MMFRA@PM+O'"##4$`D<<//0#Q0A!!]&"$**CHX842I<#1BA<]D&&$(J6X4<4>
M=^PQ12[I)-%#989B=@D,,/C2A!%_*&%##5@P`\8G7=B@&@YQE&),%_])(/$,
M+*$N8<06.1@A10Y').'"%^8TH005MI3RA1%0$+%O+%S$$IH,2X@!!A&,7&/)
MH0DKO#!3^]!CSCGGF0,A/Q6/,]\^_.0SCH#AM`?B4>@AA>`[XA6%SSF",KSR
M98>*[-T^[A"U3Z+YV$///?:X<]]2^(#L,#GNV#-THOF-8V#$+"N]----Y7+-
M&T]($84.HMCRA!Y,/`&#*Z3<D>\41C2AC222,.+&567,T4TB97011Q>D***-
M*$RH0<44>(#A"A4][%!&$K)MYM@3I+C#A`VNZ*,>H9BMXH(1KW21`Q@R,,$$
M-*JXF\,42E`.S1=$2,&%$ENPLHL51#BV1!+_6R0A11&EP.+'$&!PL<46LX22
M@Q52A%V%*.!TX;D17BQ11#*J-+T\\TX%$T@A_TRRB2'_!(*((1L$8@@EE!P)
M2`HHC$#)!I7(]$\AAB""2`HI/(]((8#(-,(D_F!2R":3='`("90@@H(A)F&(
M0%#B>H;P$2;N1PE#5*)_%L'$3P((OP(F<!.5R`0E,H&)##K#?IM(()[\X0QG
M8*(9_ZC$)`I10(;X(Q,/88A%8$@@9U!B$^-01C/.,8X,!H,2S#"),IS1C*.9
M2!GC.$<S^I&C<00C$\T8XCC,H0Q,,+$A.'3&T8Z81')4S!S].$?$&H(/>I`Q
M'\>(8C#<$8QUD)&,__-ISSC&2`]^Y,<>YN#'/7!FGW+D8V?TX".$2-2\01*2
M.XHBAO&44`8\C`(L.DA"$UH!#BFTC@ACX(&NU`".8)S"%**`ABF<D(M6D`(:
MKJA')*K0@QOL06R=>$(R'($''DSA"52`1AYL^08EM.(;.J"!XA)F"1?48!I4
M:$`9XH`#([S!73J``;N,,(LXK&L+2K`=PKKA"2+LH!2B2$(-&!$-?;P""6#H
MPA2V<(0M\((V4X!`#FSPACB$8IU[6$(.%%$-[12RG\O+V!SU@8A,[.,\_5C!
M/U"@@@UL8`0H\,,(5)"),>D0B^-HACF$V(P1"%&(E"`!3O[!@0V4`"0EV/]$
M(59@$H:<A"']($%0+*(G0(R`!"M8``I6P`$)%*(0/4(A)C9!B4H<,!.("$0F
M!#@)#A2"!"A`A`$,@=,10`\%0^WI)`18B$F8SQ"%P%XA-@`(1*S`$!?04P<L
MD(:E(@(0__A'`?^$O@$N<*LIL!X`26`($E@@$!MH1`AZ&@CK42)]*7P>2@\8
MUI["=0.U2,,)3B""0W"`$G/]4Y8`40A_J/!/F@#$"N"W">PA(@.(X,`F2I`&
ME&H6$3?R)VQC6Q1%/<,+4NC$+'_`RE4PPA6Z\($/?G"',D#!"&4X0@,>)0M&
M,"(1NO`*%CQA"SJHP04VH((1DF"&.SP!"&]XA27_CN"%-R1A#GC8`Q7JD@QR
M[,`&NW"9/E31`!C`H@@\D,$J\-"`QNSA!D_(00Q*D0LC<*$)1.!"*3X!BF(X
M@QZZ6`5FH`$+>1CC&)'P0AZH\+HG;*$4I:!`8]ZVFRE$(!=26((,OM`-4@A2
MMBY>6$.*0H\4!.*)ACC'))0!C$*D8**46`H_E%043*3`$,HX1":\>@Q$I`%Z
M(]"14OQACC"AX!]Y2@@',A$(JF;/'TN9WH[^00+L5=8"@#`$!_ZQB0W\6"DP
M*<HY.M`!['E@RS[=@"$VP9'%)043B#A9(6K:U!$()!`IT$`F3B`!`9GL9/JH
M<5&"X=04K(`%-$F#""1@_X);8.`0^J`C&<^#'CY]VD+_Z,`(2E""#F`@!"(0
MP5D1P8)R/"R*+WLQKI?'.%@P0PY48`45:$`&&XAB$5K@Q1LJ]0,HU,`)N\@%
M.5KQA!X\80^]R,,;4,&$49BB"3WHP1>R80M9>"$&9%`#$'KP!EVX0A2FV($7
M;!"%5-QA"K`8QQ?P<(M"8<9QG2.&&I99A4XT)@E=4`,,:N`%5\2!"F98S-L\
M,8=IR",6<?@"$YJPA4?`PAO78$0G/O&&VW6A"U]H12>,8(,IZ,$'RHR#*XJ@
M!"5<@1JKR#7.#75KAC5:92J+2I?L\VGQN.-!0]DY4?+!CY?Q0QGFF-A0+H;$
M'/\VV-$SLX_(QI@2>MBC&?M0A@Z#4:9-@$DI&2W*/BBAB6`T?1S.`(8YA*%V
MH2;%9,$8"E'.$0A_C`,8F:!'"8M!"1440Q#+6$H_@&&4`]["'$*Y!23,L:;\
M!2+GEB>D*[;1!2K0X@G!90(O1'$*4MB`"5$80Q4B00Y7N,$-TL!%`R;%`RA8
MP0I,H,)F:."&9C#""Y[0ABFNH`0R1,$&=[!%''(Q!"@$9Q1VL((MW!&',23K
M4+%8PA*,8048Y&!?O"A"`_(P!QX00195$!L2IA"&V[$B'JU`P@Q>T(`&1,`%
M\[T"*]H!"RY,H0Q<D$(3W$XI4$$-3,$>Y(`,#$<.S%S_$BB"-R#,Y44@5#"1
MCN7(0EC@)&2"%MV=,`##,Y10)3C$0CC##"W1$UV1,&#".5C,T6R"._@##@7#
M%YG#./!#/]3@@Y#1"O*#.>100=W'/C3#.N@0/5R,B$#(/-A''A%%HY%1R,Q,
MA/33SRD%XT!%HS'A45RAU2&%PTB@%Q(29KQ"-&S!$W0"O-V!--A"%%C!$XS!
M$T2!%.@"*\1!'.P!&;P!+I!"%QQ!%=B!&^Z!%;R!#O"!+GB"<+U!'IS"+GP!
M%%3!/,T!*V!#+/``$/#`)Q2?*72##B3.H6"&([A`#/@"%^3`$M1`#GC"#O0`
M#9`"*30`*]J`$O#?%GA!'!B#_R+$0"G*WQS$P7S)0&O,31Q(P1;\GQ0<01<0
M0Q%P@38400Y`@"<<@1$L0>?$@34HSQ=>(U($@P`A%90HE9ZT#P!Q@"&H``ED
M`91LP"20UI-LSY]00F7%3_6,0/0T0I5!P@4$`@M,@D(5F0H`4`JH`(_Y@_R@
MP&"A`)ZED)Y@`@NHP`>D%/H$PO546?2HP"0L$/PX&5%-`B:H@#]0U0@`0B70
MC_H@PD-"SV:AU#\8`B2@P&9A@I0$0QH<E0IL`@E40B%4@E!-3T520@]5P@+Q
MR=X]A`O%CZ0AI`;E23`D4%(VD4I@4"90!!,U@R:4`R4(@Y8]PY#`1$4\1`L9
M48$PA/\S$!5&@1$])%4_!((FH%`0!<,(31DVOF5WM,(U>((+Z$$I@,$3V(+6
MT$`#``$0P(`I[((C>@$=T$$9,$*)K$(3Z(`7=((72,W-M0)C[D%6),$LX((1
M\$`56%<2,$(N4$$43$$>X``4D$(Y3$$/Y`*_B8@^.`(,+`$T,($,(*`,2,$H
MY$`#-,$KS$`11,,LC(X7)`$<2`.)3<$NC!<<5(,NQ`$><,$L($$#2$$K8($4
M2$$7-`$C$$,<1$`<F,)K@@$HX$#W$8$2*$(ZO`)<IN?B*1Y1F,-@I<\(^`$)
M%$(6D("5'=46$L4XJ`#:?11$6D]H,5D:^(,A>$`P?!K%M)'_/@!",$`=,*C`
M/Z3`"&P`"5"5"IR5(:2`/^@0#4;11=%#^DP=,!`D0O&52.D4]XS/0\00,+BD
M,N19!ZG$"/R#"CB4`J0`"Z#`!90`)G``(JPH0[S0%`'"VU7$F(@/("1`3E'5
M!0R>BB95#_&DD5D9)K0HFND)!P#"`FA"`FQ`!GP`)B0$)DQ/_F15!DT"4@40
M)OQ#1*U`(7C`/_:5`DS""8#D`1W0:ZFGGC:%&'Z!%S!!*;R""^3!'>A!(T8!
M#[P!.(!!,EF!%YR")X#"-92#.=S"(J2#/B2#(K`(.^1"'GA",'K!'H"!-$2"
M#I`!#S@J$^A!Z<'"$ZR&+90#$8C%_VHZCG490V8NP7UQP1M`P!,8P3=T`0X<
M`2A\`RM$32XL0@380">`01R0@BL@@S&X0BB`@1?L3@2$&Q@`*C$D`QT86#;`
M00S`0!=T0@R,IQ"`03O<W)["Y<2<#`R^@Q3E@].-PS/`8(PI11"J3(L>43_T
M(##00S!``B6H"<@DA3.\C#*HD#,HPX86`CD4%B?<3]DEQ9L113^PI-\A0L9N
MD&9AP@9XF5*P1%&8`P=09$?>229L@@IPP"1X0"$LA93,"9YQ5O7@25AEU08$
M'5+<6*11%9^P0"6H@"&LP49@P@4(65+("6M2`D=,@O70V%<!@B8,@@?(3+MF
M[5(P3B1$@_]C&D&]=,$>V($4O($/W$"DE((7E,$==$$>C`(I,`(RT`,S\((G
MG<(I]$(ZV$,P+((LR,(G.`9HE$(WG-@3W`$>G%<#]$(LU,`>E`$I;,,.+(%J
M5J%W]%M\U4`,_`(5L$9J"$$J5$$.Y(`LL((.^*(VL,$2R(X0),$GX($2L`(C
MP($U:(,B.`(K;($9?((1R``KL$(8.$$W7`'W@0$V2`&'A8(28-\2',$2)$(T
ML*O6:NV(#`J#")U1:.'(%,KU+@A3+!U16*[W9F&$1*%\E(<[[,QZ:._Y8H9X
M@-&"N.5]T,,0?='X7AU1T)%X_$?`Z@/$Z,,V/$PS``,U!(/)B"__>MR'R33L
M_/J,U#$#@1BPR;#O]+;K*U"#(C2B%?B`-G1!`WQ"*>#`#7@"*90!5G#!'N0!
M'IB"/EC#)_!%$+S`"]``#5AB-'3#+I@!&."!&1#F)_06&>``'GS"$N`!+^3!
M%$1!8T2?)^B!,2B,*CR<+VS!OBB!$<0`&(@!#B0!*\""MLC`$4`#$OQ"$\A`
M*%#Q%I!"-_##.^S,.#@"%4N!(A`!$F##%M@"(\3`OD2#-G"!#"!!*)"G$AS!
M\BH".4AO!</E%+Z8%DYP(C\R)$^OHDQ#&&`%&0#!)X"`#=A`+[S""XP"+Y2<
M[]C!&\R!+N1"$=A`#L@PVL[P"[C`#]@"_S7TWMI*01FD,2PPJRWHP`P0`2P8
M@1(O6RMP@Q=`0?6!!^8Z0@T0P3149Q*D!@_D0"[/`!CX@2N\:A%T`BRT`@2\
M`!5\0AB`P2OD0X7D0SBLPRNX@12`A@OX[BJ8PKX002DLPBHD`1',PA4LX*\J
M@0R`0CCP4R0'M$`/-$$7]*"HQSV\PC5L`>WQ@`VHP2Y,P0L\02[4`!!\@S!\
M@11DF"=(`RK,L"S,P1-8@2EX@V=L02KL0`.<@NUBA1=L02)8@QLT`"N8P@U`
MBB?<0`]`P1/P0.8E@0P$TZ"HS".8HB]HRZOFP.'&@0OT0!PP0AZ4@0W(``3`
M`BG(,!,H0B=$P_\[P`(2C,,ZA($OG`,U_,$G5($,9^(.P$#KN`(<L,*[=((B
M*'5V)0$/,$(Z^()![S5?][5?%W0K@,L;HF84D`(%+($/M`,HW,`;[`(QK$(G
M,($K[,(-!($>S"$H@\,M?,,NE`(IC`(QR0(T4,$;L"(XG`(./$$U[,`,V\(;
M!`$M0<$-M$(]5`$/J&;CL"8CR$`2&`,3)($2`#<M@,$SZX`B\(TJ0\$1X,(<
M1,`+@($B(($N,`,C[$#W#8$C6$,R'$$GS('\P0$QU,`30*,4K((KP$!M*D(H
M&($13,$40($;<`-`_S5]U[=]WW>N*4HRQ$&J5@$:C#`<K)(K1((1T/#_`W8!
M*D1#%]R`*)#"%'R")\C!*R0#PY6"%=Q!*!B&-,P!;]"##]#`#>!!.QQ!%*@!
M*'`!$+SAH[A".H2%-"@,*,S`#CP#OG1.WL"`*B]B'/!"#<"`$=B"/KQ!!."!
M.%B"(AR>/K""_24+-8`!(ZA#'+S`%^B#+90!#@Q!*>!"$YR"NA3!'-Q!$K@W
M%S@".<PW?I\YFJ>YFB=,)%1#'/R`#HP!%.@`'G@"#/R`*1`#*"AU%.0"*,B"
M*>3`*`1N%8S"<XV#.TQ#,9Q"II2!+-P`'V`#S,%!$@3!$VC#*]@`#<R!)ZA*
M%23!$T"!+8Q#$TS!$QN*>CP"#=1`+(BN$@R!_Q+H@6CDP!6LPBFX@0\45QR0
MPQLT``5TPB[<2C&\WQ6(`1(,PS&T`A[L0BO$0`,H@CZ(PG(8@6=J];GDP"=\
MC1)TCB>4`WHN\IJ'N[B/N[@SCB540Q=`@1(_2A'HPAW0`!\X@BT$)P_PP2K@
M0A?0@!WD01/0@2.D0SWDPSWX1RML:Q64P0O\0"Z$PBY,&P^`PARL`NV1@A,`
MP0^P814`02YL0RFD`BXH3"SLPBT@`[OLR[J`02?`0!%X`ACL(@_$``0X@B38
M7WD.P2ZL0R0@P3E8`Q*\`CK\LB)@00.X`"EL0BHJ01BPP1=H`S][`?^U]Q00
M`;7+-[E7O=5?_7TSSO\PQX'4@'H.O($MT$`/S($I>-(25/:H&\$+`$$OE((N
MM,,Z*,(WZ`,IP$(]+$,GC`):TP`O:*(-!,<TT,&>ZP`O-(%2SUYWY8(U.,K'
M)TPB'$$31(,1$,'K9!<>9,,6&($G5$$N@,'H3GDN0$!==@*QOD(\',-\)$,Y
M&$,@@\(?S(`-Z((]!"<22,$V7$$H_"HQS$%J3$$2D`XKI,,Q8SWQ%[_Q/W(K
M+,,6U)(4&($9C,(3@(HH=`/7WT#QR4%XNX`4G`(8V`(YR`$,6($H-%LR+,/;
M2,$,]P(DN``/T`45Y((C@#@>I$(7G&H;1D$K>`-JZD(GZ@,8O`!`Y+CVI$;_
MDB5)<KA1E.2.K5-NB/1XTBW2-28[.A'A$B91.7W[Z.7KU@G/EB&*EG`I]PH<
M#R)%&)$"U4G)JCA*#";A0D31M5;Z@`85.I1H4:-'D295NI1I4Z=/H4:5.I5J
M5:M7L6;5NI5KUZJMIGV!<@?*F$Y/:-Q`Q6@1-R9`U*#2%\M%%7"6YFC3E\\6
M#1I0XNF[5F5.-"\OYN0KM>0&$U>L&'F!`N3-IR=1HMR)0NS<DQNYMN;+%\9%
M$FM2DN@P\H2(*RHYI+22=$0&D5V6OG"#A6.+(B]*XCCR1<X;-$M=O'119$9(
M*VZ*2KE*0N0)KDM@8"C:/>6@ER>,GKW2=\]K>?/G_]&G5[^>?7OW[^%/S:<O
M$C<P4*)`L2/K1Y`H:ABYQ14CHAACCWIRL>$'4[3Q!"QR/*GAABAX^889.FR!
M9HD73-&'E!Y^X"&71Q(YA0<>GCB%CBCV>.,-:*[1@0=HLIIO/C]F>$(9*9Y0
M`K4P1'&!AS`\M&&*0;;I1`HXDHDC@B9HX4*11QZ!!1907.E"BE20:"`1:;"8
M(A1WFB`BB3GHH6*)(F")PX@II`##"T^8^0F?^/#,4\\]^>S3SS\!E>^5:^)(
MXHD??ABCBCMJ^&$64[H`0PT@>"!%EQIH^$$6*TQ)9I4A/+'&""^,(<8)/IAX
M@89>;O&!!RBJ:.(56'8`8O^/+E)Y`L4JJHAF&RR\$"8T??QP00=EFC#B""64
M`&45(G)`PA898-!%'%"VP"..3K+II($MS`A#E3]R@>4+4,#H)(<&OJBF%)*Z
M6$4<4G1HHAPG9(`@%D^2F(*++:;P9)N?`BW8X(,13ECAA??<!Y9QI(#U"2"B
ML(*7*H"`%!91;H!"BFKT:>(%-63A`15D]EG%&WU\,<<;4GR018T&:`#'&BM^
MN"&/5JC@`PH==OFB!S(NL\(+7;BA!IE^0LM'D2DZF68++J10H@M/BIC"B%Q<
MB:"48K8(Q1,PI.@$%G"ZR($('""`(`PNVL:!"!@Z68<5.3UY%PMIO(A@%>FF
MN*+_%#"2&'4*4*PAF.'%&6_<\<<A!_2>5JB)(XK+>!B#"5/<L(,54EQY:P=H
MH%'&D1E"H4(-6N;H1A]ZZMF'GTCV&&,+,&A0XYQM7('B!BMRH<*U.(C9@@PK
MIO#B#AUR248**J(9KT9]PLA!#%B6Y8(+-ZH9(KM7XM#N$S/`8"243CR9A1AU
M6-D!@A=F>"&"&1JH`8E<TH'&%4\4"2641#P!"F+\01')^((,BD`,,&C/#%P`
M13C$$SD)3I""%;3@!8<RGT@DXSY24,,8DB`*4Z1%%+B``P_*`(IEY"$7R$B"
M'D81A2KLP1;4B(<ZVH$-43PA>:FX@2O.08IHQ,$..O"$_S1BT80<L$(/%5,4
M?F"!#1J@P75:F<\7(B"&:AS!"$HX`BE841)7;`$&6R`%*3I1BO.A#XS)*,<W
M6B&*-S"!"F^0!#'BL0UBK,(3Z`L%*.9PQEG@(09?&,80P#"+4OBH"DM@A35@
M@4%)3I*2E;0D>T03B=.,X0X\K((KF@"$'W3#%!0K0CMRX8,NC$,5+[`#+:Q@
M!5'`(1>K(,4<]F`%5-BA`7EH!RBL<`IR(&$)7B#%,Z1`!CV4@@I6X.0=IL`+
M9/``"-&SHCZ^X`(P:",'7#`"%HC1@#N``A196X(4F!$-,(!A)J`H!2NP<8YA
MW&,;PM)')LI!CU<4`Q:.Z&,<^O^H"%=$HPM(\%$K0@&&(03M33&(A3(B>$F)
M3I2B%;7H7N8C1"K<P0M6@$(G>&$$&>R`&IZP@2O6<0U0W"$/NS#'%AI@AU"X
MH1>HR(4P2*$'/."R`3Z`QR[H`(8X<&,:H7@"*:Z1@QLPCQ%3L(.+H!`-:D"!
M!]:<WA4@T(5J3`$&8&!%%XS`B#@@`2%>B`$8L,$(H:[S?#1*AR.V@`15..(*
M7_"%./1QBT3(P0N=Z,0C%`$--^#`"TMH0A<ZH8@AR.%N-B""*J8AGCMQ91^B
MN=,^@H+9HTQV+T+!1V6+,I\[X8.S1='L?(!R)]1FEK5!X>QJL:)9?93VHK6U
M[6TQ&PG_8GC!#G'@U2GFT%%23*,!3E"'(T@ABU+<H1.ZD$<8:A"%&P0A"&HX
MQ72#0(9,?4,97:`#*T*!BEM40P<UL`48IG`'5ZR""U.(PQZJ0(QHO(H:H=D'
M&;N`BZI%`A12^$(W6L$%*-2`"V(PPD#1U8D_,$*%V,!"%XX`!F91P;^+F,<J
MOO`(="FB$]J(!0ZD@`<02V$5M_""%$AA"B6DJQJQ\`IM9^M:I<B6*+*=+(U+
M"V,9,T7'F:5MCVE<XPKVN"A$QBR1=VR4(,M8LTL6BHT_\F2B(%G*27'R;2E(
MCU9LPPUDN$,9JI`+-[R`";J`11=XX8HYY.T4C&#$+KP!#T;<_\`O-`@"$*@;
MA!LH(H_[>T,I9.$)3T"#%$_H132.\`(@_*(++,7#&')1C5%\HKY6W(<B]J"(
M:!@!#]G80@YVL(INB*(394B"CYY0"FC$HA/_@^00M">%`A]!UO\:0C=@$;9$
MY"(;L"C"BKG@A4>P(AK&.$(2KJ`-,T``%->(9%?&@0(2D``%_3"$.5Z'B'$4
M8AQ`.8<A,*L,0\R6'H;@QT<V88A`%"(<^C#'N/7Q#G!C(A"!P`0]A&*.2>";
M'OZ8#SV"H8]@3&(3P!`*/3+![UOD8Q^9J`0F[J2,@.NC&=T6BC*P#91@8&+B
M`L>$,X#2#XEG@FG.H$3'@P&,<P2%'O\6IT<SG&%Q?F1<'_P8QSG&8?'4C@/?
MG8UR:X$"$L[2@Q[FZ'G137ME/<$6RWVB+=-GW)3+*KT\Y*%/-/8`!"HH9QIP
M<(PD8MH+5S!B#JB(0RA<(8M3\"(?YU@%%9"P@QW\X`F@2$8\P)'<4K`Y%(PX
MQ2X^D80KT4`4Y7"#%?*`!S400QAO<IW5KW)%&!RA&IXH@R?,H`0SX``:(&`%
M&Y@@A2TD@0=;@(4V0!$-<H#""!LQPQ:P(`8NT,0+1,`%.UJ1"&ZT`@M'(`(8
MS%"$+K0"#N(`06&]@"XPN((9S]8*9C.Q`']@PA#GL$`S]'&.!?0C`1,/1@+N
M9`X%4$(?*1C_`5#HL0`4!&($&]"'(02`"8H;@!\>X``@+O"/GQL"`)-P=P`*
M01^4X0+TX0(L(`4N(!!BK!D`(`#]P0/TX1\V`!-0@`!1(`#P#1!20"CX(0!0
M`"@*@0,*X0)((`))H!`6`!'X(0%(8`02(!.:H0,0P0/.SQ`XP!`Z`!"`@@,2
M0.,6@`0V@`/T0040(<9(0`%&X`(XH.?&801(X`;U80-`[AQ&@&F"00%`CAXX
M(`508`/&K0(O0`%*$!$ZX`(``=\PBQ[^P0,\8!/TH1\L(`Y'8#Z<P0(Z8`,N
MH!`,@?ST(1#ZX1DX8`,V8`1HSAQ48`-2P!PP"Q`V``6Z#1@4$-\"_P$8@"$%
M2*L/R6\<`$$%"@&S)@'D].'C@N(<`"$0_"\8`L$0#"$%_`\3"J$0Y@']#.$?
M,A'B0E'^AL(02&#B,`$3:&SC>BX3[.DC=,[=G"$8@D&SQD&SS`$87B$91_'H
MG$%V>NX<"G&RC(X>PL$<SN$<>@X?BN[HZ($?^&$>0.(<SBTH4(L>;JSG?FZV
MVC'H9`RV<FQ/Z&$1DH&WK.`*NB'TWJG+H@#-H,$3XB`/1B$5;,$5=($9;L$<
M[L&-SJ'B\"$;M`$6/D$67"$42N$30"<;YD`*E@#M1J$+YJ`7=(`*\,`*HH$8
M:N`)N&%8PJ`!PH`;D`,,B$`&GB`'=N$2?/_A'-Z@-HQ@":;`"1X!&D`!`I#@
M"%0A%C!,&7QA"US!$=Q`!XC@"JP$%)B`"%!C)Q0A&RYA#FPA!LQ`*!.+"V+A
M&(S!*_SA`LRA&8AN`U:.'RQ@'#9@XNJ0'?4!&"Q@+5?N(SR`:0:0'T9@$LZO
M'Q3@'#A`&8#B!8/"`PS!_<PA`1)`&090'RQ`,>DA`4#1&11@`9J1!)3!`H)B
M!"BA$`S@`S40'M]/`K%O`_Q/W/2A^P1N$I3A_*(L$%:@Y@CQ`MS0&9:P'Y10
M_C#!-A6``A40LT9@XD9+'Q#A`YMA`YHA`5;.'.92'U`@!=\P`;`M&`+@'"X@
MX.AA'X+!`##+`\C_#]\XH`2YC^,40.*4`;/.(1-4P`(PX3GA[0(RP1`L@!(H
MX=K0SP(*H1E0``([8!<-(0'H(04``.24`0#H;4'?$`#TSP(``1B<4!\6(`$P
MBP/D[TY08`4R@0-6P!G^@0=)@!(J80,*H42[;0-(P!`2\`'U81("@/QD"P<O
M`$%G,#UC+!-<U/T8L0/\+Q\$`0)CS!`"@`-(4``#`!>[<`15(,I*$2@FH0='
M0`BM<]SN9`1P<00R81,8(`$48#*!`A@,(`XWP!Q0(`$L8`%68!PN``7FTQ^"
M@A^F;00"$!#DCQX`8>7.`3I?A]K83_X"8=HNP/]DS!]&X!]&`.00P0F3__,]
M]B$2NJ$+;N`-,-(&\L`-[L`**,.]P&$48"@/\N837.$>R($;-K5"YD`.B$$<
M[B$7/"$/2'44YN`17L8*RL`*HB`4Z.`.=H`7%N'$H*`:J.$)BG58MD`&XD`7
MJD8*O.`3I$`&<H`**``,JN$+&D!KDB`)<"`)8*`(<L$1AH@1<"$,0`$7K@8:
M(L$3(L`%GN!;B6`)B(`(/"$92,$+X&`+B*`3MJ`*UHD+F"\MNV(\24!(]<$#
M5FX<%F`<$H!.!<X"*@NS`B$`0&ZR-L`#2&`_@>$"Y++B#``Q)VX"-6X#]N$[
M_Q03+,`W"]#@]L$"O&\P&Q4%-J$$S^T?5G022/]@$@Q!!\<1'SQ`$W50&081
M$!13&3B``P(!'\;A`%$@4C=6!;`O$Q)@45?.$!"!:/7!'Q+`!D5S_6)L!%9`
MW>AT/IK!`C:@$E:.!!$A!1*`'WP33HWN`@S!'VRP``T!$R:A&>IO,,=ALN"T
M+S&A+BW@'&).*"B!`/6!!%*`$B9A`0:.!,1SY>9#9]$O&#)!<1<W;Q-`_PR!
M`3*A2J,T$`0@$]@O*"Q@$P)1!T<`8NEA/_5A'!!U$W+S=2V.!/YA$Q27%#<!
M$/RA.H>"!$RQ'[PSX"Y`,:.P$EK68Z.S_)Y6'@.A""T3%5EP!Q63'Q2`:01.
M<=.V&2Y@`Q1S9SMK`]S_,`J#014_@A]ZCA(D=Q\XP!\V(!/VP1J#`4MA]$@)
ML`[U83!KKCH#@0'&K1\VP!WN20'XH0.2T1N'0AB.EQX*X?SV\QR"07O70[0L
M`1<*BQ&RH0K>X!74U0IFX`VLX`EL8=0$+0\^80]V01]>80ZL8`_F@`I4APY^
MXA8*DA'R`!1"`1IVH0DV*@>\(`[B0#H801T.[PZDB0=TX"6O"0D@X`JF07N\
MJ`M.`0^2P`R(8`O8(!DDH0MB8`ET(`>N(!HN01L<(1$Z08@=`;`401$@"QI6
M013J-0FDX`@Z80[2@0V^@`BF``>P`!3PP`MF;PM6(3S4TOV`@A\<@&DB<QPZ
M_P#[!%!S0Q$".>L"*$$9L&\%E-8#`&$%Z6$$(-D",@$H*A#_2$`NK1,%/O!X
M@8*5MU<?MM#>A!"S4&`5]^T."T%E`X$S&?5M%9-Z(Q(?^B%I';D?G,$9;(X?
MS@$1#."8\R$8`&$!^$$)`<$`).X"CI%+<38H.$`%-@YY:Z[A4,`"['0/*4%B
M`V$!'M<-%0`0/*`'\\$".!$01ID?#J$"<;$V:RYBS100:!$H*E=Q1\``G-``
MFF$2#(`$XC0H5O1U\,T0/O"A4Z`4-Z`?&+4T_P$%^$$%7A00SM,Z&5$9'A8%
M1CGD1L`"OA,H*N'\@H$`,8M]MUE]*6X!S/`=YX,N#?]@$MR7:>*WE>4O!0K!
M`V1'8>FA'VP3LQYX%=.4`\QA`^AT!#J`43<P*.HR-/M0;Z.4`\CO3CB@?.O2
M$`:S$"9!-$*Q48%!"N_/<9OA.2<A$\`VW.YO$U9NVK#6`LS!3I]S'YHZ$X*!
M$CQ`32G!'S*A+X-"$'2PE?V!!#"!,J$N/>I!MXR@#'*!$7H`"DX!'%J!$?:@
M0#A8%[Z!%\"H%&!!&N*`"A9E#V"%HZH@"E"!&_BH%$"A%:2!M+G@#O9@"N8@
M$JAA%SJA"DAA%>9@"&QA&*R@"BJM1O;!#XC@#^9A"WSD"$["%8H@!SS&".*@
M"RP!(7"E$UA!".B5"&(`O.'_*@=LP`AR8`J$8`MPX1',0`J:8`MBX5P,2@>T
M)N]PH`NXP$=@81@(EBLP@0`G"P4X($2%T`+6#Q$RP0#4+0#U,\9>!PLUSH`%
M<`&`P8`MP-Y4P#8==N6(MF/!<4PMLQ"`805L<VM[T!P8P/WH]APJ00$^>=PP
M`0`4<.5ND!^\5V7]K\*C<Q/RH<6=X0+ZH1F>@1]4^74,(!-@MVDYP0.4P1G,
M+T2!@G&CU]U@N:27,P44$'N=804"SAPN8!PX`,$#@:D]=G_U[\N#(A,.NT2C
M[`(,SCJY')%EC!(0F7\3-C^Q5"@RH0.\C:0WH.=.\!]XEG%W5A`0X5$+(14+
MX;`+_Y#.QX%HZ]+;RC<3))PP8_?/@8*C`T'_LBUS]2&JA^*SFN$0*8$#NDV4
M@6(##&X$[A9.\8UE8VP$Q9H>JO1`2_!%,2%[4VLU)^$##?P?%&!_MWI_R]<#
M@,$0'#,5-<M,E724.0`%_D$%5.XT+R!*.1`1T'9Q20`84G1&H1-F+9,$$@#3
M[Z]G%?/*R0_;7E1LZXWFVL,2KB$4\L`5IJ`'[*`&3D$23"$28(!7J$!?I>$;
M3J$5T@$6>F`/EN`-W"`)R@!:I6`,=$`7J,&=*B02C,8+WB`'8,$58"$9NH`*
M>.`3M.'!YB$9\D`/DL&^WB8,EF$(^B78PN!S8*`,C``,8/^!%7+A"W;*B^LU
M!Q"B$YH`))6`":I`"G"@"F)@)ZZ@"TH!"[0`&;0`>[@@#IH`%%X!#/#@#:9`
MPJ"!&J;!*TR.`P-A_;IM$KAP%PM53@40WH+.$"`Y&)37W7PW$!Q8V@(AXU`Q
M*`"A$@)AY?QA`P'A2E&`L)OAL!>=XD:`!4;`X/X!%P$A`#/=XB9!!>@R:0-N
M+0=1&?B!`RQ`3!&!'D@@!#:`_(+!`_!P$Q`!\L^6:MD4!>@A$`R@`XJSFC<@
M`106*)J!`Z[T'SXYX."4?5.+/@EQI@=P$,W0.U<@\`/N3OX[$!B1'CK6P8,B
M<5.=TQ,`$S;!`!#!GRDX:3-7"$O_=!,"X0+VX02!`0!RW^P#(1C0'P5TT`+<
M?@0^4#/?#P`F+C-70!D"'R@,@06`@E$!0AFE!,'P72ATCL0%8!WTC3.`:9PR
M?117`"HT(MB(2<HNT`M&#P4@>@N:;0B&Z0)%9QPHXM.7`A!%?1<H!0NVP-F(
MB85(S-1WCH/'31NV]=LPZ=^D?>;TB:1H01F@23\I8D+QTT.PF<Y4TO2G[R6)
M3103*$-!B>*(?B0"^0*4@I]/?2K2CCA7=>:F$13I11WAS&7>P80+&]:7+Y^^
M2]?@Y,DSI4:9&G-(6>H'YT:5'UZ8=+'%"YPH*)Y%:<LSI]1G5UV81#%5#1HT
M*D:J0*E2_Z83,#B@2.G(\R2/*T]>IN'2\:3;X>6$Q;S8\LR($B5FP(#IE$U.
M$PA<FLRIUDJ*ER0OEH`!,0L6+%)=A`QQ-:L4JT1#\,"8,07,EU:7%L51,@06
M7V2S12=X>`&&%TIH4PPNS#T(H3[[1$AAA1;N@P\]$$XXV$L4<:@//2#N<XZ&
M(.+#SS[TG,-/7^.<TXR&S3C33#.*S:1,,WUY6**(%(W#SS@\FF..,\X$H^,^
MP62"UT_G8`+,2_Q,E)<Y6^GCSY7`-.,.)89,8DB3(7J)"8>9%!*F/L'X0X\A
M^F"R)C#[%*)/)F`Y0\(_AFA8R#@4&4*E/L[$](^?=5(E82$HH/\`#$7!H+""
M"OR<0Z<^DP0R"5\3:F0`53IM@(D^)&`2T@B!Z+,)!QQ0.<X_/WVYT@@>CD!)
M(5=:$&I8^@2R@5-N8ME!"@E<D,`D_"C0@06N!K*`!1=<$-B;#>4S(0<*;'`!
M(,TDT&(F"6BH9@(C7,`7"6D9%,@(^^3#CP69H#"A,PJ,,T(''WS0YZDSC8`"
M)R/0><%6'EI(\$S[K-(,&%.\\8D7;SRA!A5@.-(8%&?L$84=4-B10P-SK`*-
M)W20`LLGI\`1QRY?2-'`#WI`P04>5>C@A133O%**)Z`\L4<2H(1RQQO?X&+#
M$]P4G->-^VPQPQ;12+>%$F"8T447LJC_\P474N3P!2EX*!%&*5]P`PLKH6S1
M!"]?J))+$UN4XHHVJWQAB11@X`&+$SGD<,2`K'1BAAF=3-U$$@@[B'2$+WE(
MK<&"#78C80,/3"'EB5].6.28;\[Y3Y93J'E5E(>N>&&?A^Y,6C/Q`Y;C^63X
MDHDA@HL8<Z_[*"$]]$3.CX;F<(C/.<*?TT^+12KSDCG-!*.,,TV%J.-,X]P4
MC#/[1+N/,K3WXP\P38WS/))^3IA)]3,)<\XSE5!R2##A?``BJH?X$A:;G5>X
MCR74Q%%&%V7@,8H\Y&`,2X@"'?K!B$\\@0=C8((1.N&*;XQ#%Z3(@RU($0=;
MY($.N0!'.T!1_P4>\*`,GNG$%Y;ABBI8X0DZN$,J/G&@/'B!&;H0834XIQAJ
MB0$&<;C&$90@A2YX80L'Z@0</M$)(T!`"5R```Y<H9Y%=($+7@@#%T@Q"U;`
MX0A=P$,<5I&>:7S!B5[(01*\$`I2P$$1<:`B'LQ`!2E,P1?&0-S][HC'/.IQ
MCWR$T.<^]R'+`<\E]U",AP;I$@_AXT:XDQ`^+#<Y?*R+(J_3E27C-Y/%45)7
MI'N<Y`KVDD[F!9!]A)`\##7*4AKF'F&Q13HZ404OY`$*G]!%$J!@`S+HP!9N
M``46JB"%4IQ"&HRPS0]V``4:Y"$7.P`"#WY`AS>80AR>F`,48+8+5_^\HH56
M&`4/>`&**2Q,#UXXQG%TH)S[S0,)$.@",7!@!":(,PE/F,(3C"!'"E#!!E.(
M1#;,L(4N;"$.7QB<%\J@"$5<07!F.!`8N-"%1]AB#D^H063PT(0C;,$+1[!;
MS;JP!&@8(Q;Z8*4J3XK2E*ITI2QMJ4OY2,I4%FP?F$S:2V="CU=L0PICN,,=
M[.`%4*R""568V2Z\8(Q(S.$4>>##'9X`A#/0H*A3T"44DC"%&T3A!C^(0QX\
M00HL*,(5(-@%49/@F5UTX0E5B,,;O-`-7%3A#D?K'+6\,(5'6$.HK&""%+@`
M!B,<*`=[N`XKE-"$+APA#G$`0Q,Z$8<F*"'_/UR8`A-+T0FIE2*Q<9`"%43A
M!B_H`;!;6*QCKP!9+OC"&L:XJ6M?"]O8RG:VM*VM:_-1#V),XPIOR,,>Z.`%
M,WSC$E=X0A1(H0MF0$,1HJB"#7APAR*``A2N&(X.<E"&5;`"#WBX`2UL0`,O
M>$(5FF"'-EPQA#(8`13W8,0=RN"%.-S!#/&`Q1[>0(T[OD,*1M@",A+QB$?(
MD0I=H,[6\``&4CPBL5TXXX&.`$,I_-4,4Y#"%L``"D5PX0^J$(,1FE"$1.#"
M0'$@PA^XL(6_B<%IL%@%-XI!/]O*>,8TKK&-;XQC/=K#$LN0+QWHP%@\Y,$4
MV8A#$I0`,5MT@A94_U"H*W+!BUPHP@UJ/4(N4&$&6:CG%$?PPAWRH`=L)%$'
M18@#+';QB3O@X0T-U<,<W-$*&1@-AQ2I!Q,:\(5AQ&`)2U#"$KS`YSA*X0D5
MJ((,IN`*8SBA"W^H3ARJ$T3N'@'!8=!/)_YP!5!\PQ-%>"`%\&!A)BY!G$H@
MPA&0D`QAM#;'K&ZUJU\-ZUBGU!ZK:$<IWN"&QN*A$Z-0@QYD$0H\0"$(:F`"
M#]Q`CFA<,&>C)<4N<J$+)^"!#J/8!2QRP0XL#*$*%!V#'ACABHG&P0MXN$/-
MRCV,7/"@"NF@<S[H<808Q.$;$M["%BI-A?B"PA.=>((+GF`%&,1@%\1@A?\C
MV(@'B+*"%;+X0A<ZT0E%/((4K%`9#BBP!QG$``RA\$0<`JH$/0Q.#)6&A3!B
M+.N4JWSE+&_YJ^V!"V0T@0M?J-E&]U#4MMY@#&P%12Y&(0I//"8/NQ[W)UA!
MA2KL(<UW&`4H&.$)1GAA9A5.11X\V["W>L%A=R@',7[PA'9O[D;W0$(,$D&,
MORIA"]4)0R>@D0TD;"$',6A%+!Y1H%!\H1W0*,7'P1"-+JS"%1KM!"NR`8HP
MP&(+8E`$*XS0T2V$HAH8O-O'K<@%2_A"&"[OO.<_#_K0P_05Q8C#)V`1AUBF
M.0QV<%DG2,$(->P!%6\H$''PH(<WR)'<5:5#'E+__Y@H\($7>FAR*5"[A"HL
MH0P$CF4<JG:.6R1_'736ASF*$`,XX`(':Y<"A4EAC>+*H`R>@,4S%&$$+ABA
M`4D`PQ%FL8I5F`(,0B`"*TH!"EFXH0EWD`$,[/8%VF`+8,`&8:`$CQ`)L#`U
M@)4@4V`,RT`,HB>!$TB!%5B!.<4,I'`*NB`'7/`&I8`%=+`'3S`*U00.C*`#
M/B!.I.`)2:`'H[!U5#`%<70'GQ4*4H`'HK!/-:`#NP`.<)`*3Z4'95`%J0!J
M<_`-NM`*XU`,W$4.^@4&2T`*X(`#%38=;@`+80`#>,`UCB!4"?()8$`$4V!&
MI_8)2``&21!'>#`%1*`$_Q`P!3C0!%JP77"P#JKP3E-P!%>01=:Q!5JS!?/P
M"G9D@85HB(>(B#1&#ZWP-&WE!4^P=0<E3G"P`Z/@!%3@"O'@"4WF"4$3!VS8
M19_069_@">0D9%`0"?%0-W%@"E)`"P_U!%1P!US`!%3P!F^`!]SP"DK@!4\X
M=A11#DD``U^@#G\E!4J0`ZW`"*-V!#F`!8\0<4F0`UR@"J``"Q30!#B`!#E`
M!#$`"D:``S@P!#'01%_@"J%@1$F`!*]``:V@!&*`!/`(#8IE17@U#H-8(3'E
M1X<14S7U.(KD.)`D.C?R2)[D.)XDD`;9(:+C.8GHD`_I<K3&#<3Q5MSE":5`
M-?\L.`5)P`-=X`-CT`G&``LY`PI(%`=C)0O\`PJ0172O)PEW$`5WD`1&8`1_
M4S4'\@9!,P5%-30U\`3HT#FLM`Y*(`.,$`T_]%>=<(,[,`5",`66@`LK4P,\
M$&]B``VO$#)YT`75L0J,\%!QP`BXH`O($`E[9EE($`NP\`V3=@6T0`2J0'CU
MJ`2O@`P16"'T\#RNY8]XI(\0*5,IUY>@Y)>B]VZOL#]C0&YZ<`>?Z`KJP`@R
M4U2FP`AE<`>Z@`J\8`RK0`L8]6RB,`M;D`>.EPO516_MYPE',`5(U`NSL&]W
M4`5L5@5C@`?4<!Q/\`UW-`]-X`*>@`U(@`1?4`93L`3_17`%7K`#KY`+7M`T
M2(8#?-8`:%EQ74`*O9F`7R`)VA`+G=``$+`$.;`$1P`&2H`$OE`-6&!J(`8X
M9A`&9B`%N'`+G!<A]?`/!L``%E`0(W``":``!A`,@+`!+\%*%Y`%,]$/'(`!
MSV()^M`,'I``%J``*#`.-?$F'O`,%)$)'3`"*Q`"*M`,)F`-=5("Y8`)(4`"
M*.`!FA`,*W`")9`%5T(/_U`)B)$/AY`&_Y`"H5()B/`/@?`/S&,($_(*E:`,
MAU`)D+`HS'`"C;(.*I``@,`AFV`!'!`8DZ,/A\`)^M`(],,/@3`1^$`)*V`(
M+9(7YV`.E20AFX1)+S$AYU`H_V?J$DKS(?T`(OW0)'O9D)GT(;VCCRHB2GEA
MIYO$2%6Q+HEA&!PR(K]8(7U:4K5#J+93.U610W@4.J03J9#J:O;P"M'`!7>P
M!VRT!UY@"ZBPB?'%"*UP#0^W!S?@`QMT"MFD@44P!:4@"J"P"[@@"I\`=GCP
M"6_@#8E0!(/&"*?@"HS@<)P:-+GX"CT0=NY&#TC@`G!@#$0$!V8T!2#0#HR0
M#-R0C;`*>4T`"],0"T0@!4Y@E`>7#6$5"Y[P!4H0`U8&"UW@AEXP!%SP1./`
M"J[`"CG0!3CP-E[0!+A@#-%`(9,@`(8`#/LY#PG``?[P)?/``0RP#B]1#P(0
M`KH"#/\`4!<7``#!4`P`@"F%0!47P`#B8``-,2'`D`4=(``K0`B8L+'Z4`@`
MH`PK,`"04`B!P`R"``"(T`@&H``4,0D`$``Z0@\,@`%K8``"T`P2(`"!D`(E
M\!8!0!$9$`!O\0$`4`*(L`D`4`GY@``*$`@!L`"68@"(P`$`@"B"L0`J(0`+
M0`_\$`!IH;(;8``&,!&:`Q@4,B$EBDJ%,0X)("8<H#H6$@R(H`\C(*:%00)7
M<A@:<1@WHAB98`&_L@][$@A;H:CF8+8<\"N<`Q*;D`G,80Z5H"$Q90WT``S]
MX*:#,0Z!`;F&&@R*L2[*D+C^2#RK2SFCDQB5I!A"^B,M,B'_FK.[?VI)L953
MW2`%[Q5?<<`*VN`$=D!"TI`+_0`*LMH%^/0&-S""I^!45I`$0C8*/J4#7#@%
M7B`*IG`+W4`-N8`#=R`%I@`.H/`8BVF+][!-4^"+F',CZ]`$2[!W<(`'I)`$
M5;@%U4`!O.`$;H@'3U`$C+`.MK`(Z4L%4,!X?W`$7("&G4`%94`$H<`.D!`)
M]>`($%`%]W8&:*D%;)`+,7`'4]`%HH!@L)"I%((`#2$HG-<"*)`^F8`/(V``
M\Q`[!*`I^O`,`)`6ZR``)]`,`2`,1Z(CS7``!X``?F)2^L`)`?`.^@`,3&P.
M,;L-).``^#`.?A((/TL7`J`A&7`!_P=`)_!``&D1#`#P"AJ``8(1"`F@%@R@
M(90``,6@)@``#(`@`.50)SXQ`@JP#?PP"9Q'.19``O-@``#@!_L0`/[`Q_2C
M#!X0NC\1#)T2#(9P$E^*`L%P#I5@""30*&>!`LV@#`I`%I2``F01#)-0",_P
M#("`".<P#@O@)8&!`6F!"9,0/3/QR3HR*9BPR11QQ\[@`<`P"882#)M@(B\Q
M`L'\/$^2N/[@)P<+/0J*N3\1#E1"`BL@ILJP`!&Z"4`B(?OP#.)0%1R@PYU\
M*M<#O$#A#A+B)[)+._HP#XJQ#O,@(18P#I1`%B'R(>L<%HK1RH@$I\)@`?K0
MS!U"J*<\$_^:<PXE\2$6,,R.Y#@[NKH&":<SP4HI@`%74@BY$B&'^I>%@2%Z
M1`^W4`YE\`958`9<8`J[8`0`!P54$`E,X`K`<9%9A`2WU`-`T`,\<%!)H`-2
MD$LZ0`5P(`O\U@49Y`3&0`0CN`1OD`M_:`?N6P7K0`QOL`?;4'WI(%FJ8`P0
MH`BY4`0[T`7;,`R,D&_2(09.0`S:``N[!@?;H`B,5UE20`1$P'9'T`1-,`^K
M4""Q<`V\D'I@0P2&%W.)<`1&D#(_A->M%9@4`<E800\>@@$!H``,8`#R\`$+
M@"'X4`X!P!?R("@"(`B*0<?,,``^RP!8H0^#(`")T)"%$`"$+`S_`J``"H``
M`D`-*B``]!D`LRP`#F``#G`JO]T,:T``88$`&G`"!'``[)`!!.``"S"V=QP6
M)A````T)```6P@``OO`!#F#0%-$,%@``!&`"?4L1"E`"\U``)D``G>P+'.``
MC8.G/Z(`P4`""U`)F-`!YF`("1`.#$`)E+``YW`!F*`H_4`0AC`"S<`!E^*Q
MDW`!F2`LS;``*.`'!K`.++`)&)$2H3LAB'`09H$("U`(DZLK@+``WD("*M`K
M&`$(%X!*XX("%D`/F)``)&"?1S$NFZ#AYX`KPK`!3YXB%($('=`!*O"W%M`D
MA=`I'^`!'>``S<`/*?#D%>HH#^W>P$`/_RN0``11#B2@`(:``D:>`H*R`8ZL
M#Y#P+).P`1Q@G_X0`"A@"#&J$!M@#@G!`KBB*]LR`AX0)B/`)P4M"`8`#"5`
M`A^0`AK"*X&0Q111"<HR`GZ""2RP`D`2X6<!"/,"LZ.B#\JP"23P/'Y0`H5P
M"$V1"2M`%<!`"8$@$200I@X1"(BP#MR``(+0)#<Q#L"`"=*,4]8`NA^R"90@
M2?V0"8U""6BN#_Q0[1)R#D>RSTH2#!.R#S-R1_9`#-0`!G*4(*<0"D;P5%;@
M!,EP"J/@`U90!E)0!>!@=XXP!Q#%!,[V5UWP!:`0";<@#:%%!5$`!:[@"*V0
M`U[@`WM@!6K#4_];%P78\`HVD`1UU3GI0`0RH`BMP`4Y@`OK'@?1\`5+(`,V
M<(Q<(`ZHYU80QPCO0`U-4%7JQ04WOP6.H`^K$`?I"4$G:`1?``8S`)Z[4`T/
M%0N18`9$X`C:L&H0\@$V?`A\X0!TPB$=T`(N00\#@`*2],>40"T&X`?F$`##
M\!/`4``.0``ZHABL=`@$0'W!$`"-4@E]+`@84`_\H+J!P`"^X.5XX0<`P.<"
M$"4$P*(J,!$.X`#,L#SZD`5F[L,`W0@`P'D7^PH=<``4<0Z4(`_A0`Z9D`4"
MT`&Y:]_X,`#+,`((8`"^4`)F3`_-(":4!+@HX"KG,`DJX`$*T`]"OLO_6ZH`
M*>`,_.`!A]L!AN`!;<$7\\"P;JX,"5"F&UX">AX(_B`N,X'H<!X(6`'*9YHI
M^V`!36$!S]`"E>`,37JFJIXG(^`FB)`G?J#%!&$!!D`G),`!X\`)S^,,YZP/
M"N`/A2`34@(0%_9Y0*&/A"!*&?0=6J#/(:4-^NA)U!?H@KY)))PM4-8O`"9]
M"3!M,*1O1*%`%NA-.J0O!8:0RE`@^D="7Z$-P0PXP[3@G,-Q!C`YNQ`L0;!Q
M%G[JV[1@'`<2SPQDHF2A&8F"^_114I"I@Y]@"BB1N#!N03,%@0X9X/?O'S`%
MP0(E",3/82`%EA1@VG1!TP5*A@3\ZUN)1"%\_PI2E/BPS,&)<0X/3PH@R$(A
M??CT^0N`(H$@?1M2<$@QKX4"0"D`K4B!CP,@"Y3X&5#AP:9F>B-4<"BXP<(*
MA\&%#R=>/+@]2\GPF,&#!PP>)E*:+,DCK1>/,6.F='H"!0J57=FDS5&T2Q(;
M;:!"33L'K0H3'E*\Z%!#!8NT4UZ@]-!!9=:;*+SX)(IN7LD!"F^,4W#!>QQ*
M1XH9XI`&AQPZ8:6+)]S`8XDM<C`#`EB(^0.,.+J(`Q1%VM'G&T6.Z&(6,*3`
M(IIU]`'%$R^\Z*03,&")!@DEILCA""[<*(6(/VSI9(@IB!'&F`6+\R4`$@8!
M("(%'$AAM&<X$`"%$O]&:,:``THH(1!@`&#!CPT$Z$B`P_XYY!P#'("'``LT
M"RX0`<S1)Q,WF0)@&14.T*022II)@8%]Q@G@@WT,Z*"00A;(DP!*]-3'`0>:
M"0:3>1`!P!=Y'.C`(4X`"$8?7P!X!1,`&L&GA#X=4$@>`SZ81[;@%AAAG@!\
M,8<!`7QY!8!*,`*`DG$R$<X#<P*QJ9`+^#%$`642V*>9!)S9))A_NKV(@T*4
MF023%`HR)(-).-F@&:7TX<`0$CC)X!]#4I@D.`M6]><"0`"Y:83,]#%D!',L
MD"B#9Q)0X1\4G'6(`V4J(H&$R/SA@"1]9MO$@19`.V<$!SZ(#*-3]2G!$)3_
M"CXG`7TN\`>C+`11`(403)AHLXNT<@88%/8]QP),""9JHD`V;L;@PS`39@,3
M.E`@YK8*X0"D,3>)B!X%G'%(&84-0L20?RCA0!^M;IF:@YDYV(2$$29!06'-
MY,8HA4`"D4@!?SR8Y*)Y$O`G+4HN2`&1@H)3(05]_$!D!!1N"3,0X#@HX1G8
M`"%8'FP_\*7@I@L*YFS-@HE(F0TVP=87!9[9(!Q].B`!F+9L4J:HB,918*E,
M%#Y'`5]:6%K3*(L_SI)HXM`CE"YRV$.'4U9AY9M(=*BBBBFJ\"(.5A2I@8DH
M>,F#$4F@(<841D1QI0L=7)A#%2K*&,.+)_9PXAA'_U:)A90I[O`AE4_@X0W=
M6(4-R%`CXQDO'PYIQQ%>H`ABY.`),I"$*!J`!U-T0@E)(((<MM&],'@B#J5@
M!2B2<8QBZ$,8%;/'+>HAC%ML`Q:@8,6..J$(1<"C%4'"`Q=(H8@MQ"`:75!"
M%X@`"V$L(X'"P40&+I"%>;AD`QVXP`(T,0D/8"`!"7B&"A)@`07DQ`(66(#G
M]'&.*BY``1@HA`&$\:<`8*9@D_#)9G;"%`$4HQ($(`"Q]&6`GW`B`"P(P#,T
MXX<`;(03^*"'9C1P@`,P``"&*!4#%+"`9SC$$*K21YJ<E8(`+.`C^KA%*`V0
M`'SX`P!><T@`.,`/`8"D$/\```DB1>F'?/PC``[1B@4@9Y._6<T`.N''F."5
M-P]DJR(L\,<&*)$"FP!B`S)10#@"$(A)*&P#G`A$(<+!@7UIYF+GV$!J"A((
M@FFE*L&PP#[HL8!PF(`2,9N99C:@-PML8@7`(0$@"L&"?1BB7Q>8!P/\40A_
MY&,!(-$'MX*Q#[[]0V":&=HX+@`21*1@)/OPA0H<LL!Y3>PP-LG$!8!QD:!X
M[0)87-66`O$/D^@-$`[01SO]B0*89@L8'I!(`I:FCVQI902:2(K,T/:GAFP@
M61[`1$WH08E].20C^2C$/UKV,G^(I&<)`$9LFF&(8`@"IOM8H./T(8A"D(`0
MP9C_Q"W^H;<.`,(7E,@$--&6`$V@8%6:&<$AR-9)GCHD$T;S0"-6&@A$$.4G
MRK!:"O[!.'H0K2#\L``K)Y&R!.!D9TM,(#V0]P8]D((+/=C##G3Q!?*=@0IZ
MF`(5C,"(;]R"&<@`!0_4\`9>1.(-7W`#+SSA'2P@@QFZ@,86BM"%,MRA#'O0
MQ1M8P88IZ($'=W#%)P9X"1A4(1Z<3>`ZC-``+!`#!UR`0@U<80LC&&%".,##
M+APQAU"$(A%Q\(0K6'&,<Y`C%G'@0A.V$(=5<$,?Q5@%#4L8BE1T@A2S*,46
M(C`'4TAA"P5&`A>XL(1<Q"(:!>.N@HAW5.-IJA[XP,<"_^GAI^`P4BO[,,>*
M^2&/>\P#'_:@1XWM@K9P-.,<^-A'CW6L8^&48QWEZ(<R?K*/?H3#'"3.!S^<
M\1-Z.`/%X7B&.?*AE7$$H\KZ:%@_T+8/?R@#S'[B!R;&D8]\-$L3^LB',C*Q
M0(<$@Q+!\-H^,&$(9?AC').H\9J;@=AS/'4B8TE6)IR%#T208!*(4(8AZ.5E
ML.XC!19(5G#HD;22(`(SFIBG0^CA`4KQ@QXD.`<_1@`P.+N$+`(;&0=&<(Y<
M?E$9X8C(2$9W`3]LEA(CX(#>`K&)@NVC`Q#[G"'TAH(1?,`2#BF=JR_P:LJ2
M8`.9N)T^^F&`%6R`8!#9#3\0._\P0%Q@`_A(`$X+P:T4;&`2P;C([[RLCW$P
M``5D$>K4@N,,!AB"8Q<X]P4V80&]:271^0`$"?B1@$F,`&$&H'4W!>`,=`+C
M*/\`#IOSL0*!J0`06%3&O%9@DZX^PP\:,8`F4J(/!0!;*RPP1$8W`[,X+\`9
M?BC!/"P@#&"0.@'C$#9;+U!2B(_`&5M+P+N=815@.`!LF^WP@NA!"FX@X0W@
M^((.F$"*;K3"%G-@0A7NL`52$$,=NW"%)])A"2*\00ITP)`4J/"&*NP!`KDH
M!B-0H8UL[-<+9<!#$7@!"FA8H@M1>((G<H&%/7SC%7NX0SE2W?3BD&/O)C3"
M%F+$"%S_S$`&C&B%&;S`"C#DH1.E2$0H8&$,:,`#%$-PP0L:T(`(O!X'BL"&
M.&;ABE)XPD*A``,CB+&%+[3B"C/H!#FV\%\N*($8N)@&Y+5RU!YKAJSTZ/$"
MF<QLM/'X^5]F<V86^/CN$^?#QMD^+\N_(+(&1RMP1K-PMK_`\P=#8B!^_O/A
MKWZFB[\XXX_2/OC/YIT!/UY2/^E+->+QO^W;&4VYAXG0C";+#,T0-;2AOC/J
MF)]ROXDX/U[2#.E#&YXC#B2+#*V(,KLX,:"R@"P[JG-P!KO@!WM`&V<0LW/8
MAQ4\A\@XAV#P,GKH!QYKAN>CAV9P,RO3!Q70&^%0!DQ0ALAH_P:OV;-5N;=5
M"4)]"`9#F"=ZP`1^,(<JI`0_"0QG`88G%"Q@F,)5V80UP`Q@F!FF4`%!R!BL
M\)I`",-)\`=#TP>("XZL2H$1B`Q,(($.>*A`\)--T(U5J8016(%QT$*T^8>E
M8`H.X(!,&)DH@KP%>0=8&`8NJ()(L`4NR`-R>(8X@`(=V`,S.`)/^`99&(4\
M.(7Z4@98V`(J4`,]R)%9?((N@`5<(`59H(52<`5PB(8O"#VXRX-68`=6B`(I
MP`53^((=N(9AT!X!H\3A:+]K,((<>`1?4`(E.`(C.()28`(R,`)PX(((V(5(
M`(-0`(4P`(-':(9A:((<R`$(<`$(P/^#'&@`%X`!'!""6+@&4B@1&N(O8F@"
M&+"&2%B")?@"6#@",/B",%`"8S`&;)!&BEPB`:S(_L-(C?R_`12.5&,_AV@0
M[/,T$&0SCAP_#520B^1(C>0LEHR2?N@`#13)EA0.%."`DZE)G=1)3%"8]MM)
MH.R^=["$:^@"&YB#7'`$*A`%4O`"(=&#))@Z6_"$4!@?46`$6-"'<)"$)Q@#
M18@#+^@"4%"B15"$3_B$/-"#4;`&6'B"-YB/*GB#5G"%*!@%=*"".Y@":F@%
M&WB"=*C)!;H&')`!19@&;3P"*<@!5_B"&&@`4M"%'&@":CB&1-B1.'`%6(@!
M".B$+O@"4%#_!6V`!45X!"G`@P:``5C0!;,,A>"3!E*`@"T8AAI(@BT@ACBH
M/.DX@FAX!63@+NK3$YI\O'S`!W/8K.%T)^$XP.*@R8[L/I`\JN_[J!#3R)0,
M2NN\3O6KR9?$SA3+O^2D2.+1DWZ@/@IT/^(PP,PXOP\C,3W1OHP<R9$LL>_4
M/PX3CG,`B><K,1X#L>8<SN(AL:!<H'*X!&IH@C*H`C!(!@K``[24@COP`C<`
M!VG0O5$`A5(XA53`!G-(AG.XA470!^2(A'%0AG6`AE+(/4_(`SPH!758A"?H
M'R9@A$6X`QSH!K`T@BKXAE;H`2I`((ULD&NH`1DH!6-(@A>=`B,(_Z`=@`!1
M@(<N,((BB`1X$(,K:(5LJ($&,(-0N(("\P5+Z%(DZ`0]:(`'T`9HZ`(I,(9N
MP((NF`)CR(8E(((B(`4ID`(N\`(I@,A8@)TEHH<.>+?S>SRN"4/-*(2"\,[]
M<XAF8,17XR7T=`A,,,+BV#Y\,8YQF"=,6)6+#(Y-;;KM;$[SY,^1M+[[ZX=#
M,TGCN#)/J\*C\A-EJ!C-D,+ZM#1,R`04$U7G'(>E,0=E*(<;&X[MD\__2\GJ
ME$YFXT#(TY-.79"?G,XH^51'Y<Z67%9I+9YW:`5JZ(([&(,JT`52P(,HL`4G
MH(`WL`5>,(4\0$M0.`56D`5L.`=P``=>./^O4[`%:?B&;;@&8F`%W$M'4.B$
M7-@%,+!&4C"%5'@"4,"%).@"*LC15I"!*BB':74(<LB!%P@%:(A'*)""&)`"
M:"@"%[@#1F`$&2""+4"&.(@$?OB"'HB#3JC34H@$6$B&7.P$)$""YR`")5`'
M9&`#:%@%',"!,+"$2,@!'(`%4M!9+DB";32&5U"B/KTH0)B93*@'H*H83RN$
MGNP'V@$J<_B'$F@&/^%53KVSI0&R?C`'2E@`=D+"DT%"B5W!8`C"<P"&?BBU
MAGHH14T8QK&T8+"+;#*(DL`'O$6;<R"S1J2'G.34XBE/BA`.[RQ6#S..GIS&
M**$$D>`E@BG"HZ+_!#DB#HNZ``XX"@6)P\&JJ1$@@9)0$*K@KO=+H!5@*,YZ
MOI:!/'H`A/P[&(E"`4R@!*_1C%K%U3AS"Y``4%$=AQ$M"65(@7()MNP+MI-1
MU>!HAC%<O^],OX(Y23C;/F?(![$MF.*LU@0J!U@XABVH@BZH@CBXABEH@#RP
MA2[0@UWPA$\XT5#PA%,(D7D@!T\(`AJ@@1>@@2`(`B"PA7L`AURPA5+X!%(H
MA5%@!%?0!CJ0`6AP`QJP!2>=@BY0@RB@'HCUT9:\!B(@@D<H4B.0`B-(`B,H
M$2@H!4<0!13&`4;H!DW`A0:8@B]@@CU0A$88P7O(!TO`@RT@`BG8`Q?X_P5?
M<`5=@``E(()5@(1<D((A<`0I.`)M5`(D,()7B(5,XBP+$`T+0!V06"E/VP`4
M2`%`(ET+&)N:\#6"$:<-((&=2X"2Z(`1H`0`*(0$N(`+2("52`#?H(=_8(#7
M0(%->,0`,#0^M@G5(0$#0(2"$2@/L`!@^`<!0(0O<H81V`"\^IT$D*;1C8A_
M\8`1&+55\:?Z'`%G40%@J(0->.6*&0V3.@?>N"=.E99I,P<4V`=^P)APF1=7
M.P<_A"E_0`$5&(&*,=01F)I,F+<QS(1"@&2?V9*9>>63R80`.*C)L,-5F804
M4$.',&.'2`&8:8:-DXAQ@(1+2(MS4`9@,`!W7O\59T@LM)D$0("=#:BX*NPQ
M3\/!2JBQ+!M#90"V,Z('NPV.3%B5'E/""RB)B:"'=W!48,!:>N"'8("U,QH'
MA9.()U/!B0@&/]&*[]6*<W@95@J.1;.`!-`H#QA#X%7#S6J0K)H$8%@`CPJ_
M%3.)0N"'I4*$=5L0;Q;>8/C<)>('%,C`\!0.B[J),-P`<!;?5)6(I^V"-WB#
M.ZB"4KB")7@"<'B&%Q@%7H@#4W"%4\`#4EBV5M@!__W?'ZB"`/Y?-0`';G@%
M/-`#5AB%44@$</`$'X@&5K"!S;,%**AJ/*B":K`$5918C<R'!LE66F`%8<"!
M*B`")!T"6V`$'C@"5H#_X!RPQE70!T5X`1@@!2(AA6-H!V*`MV6`AU`88E;(
M@0BX`GW0AB<@@AQP!&-(!%)8@AFY8B5(OB/P!EBXAMGE*B(LFQ1@IYV1N#,Z
MBPNHF(8.A*F-"-+5I&!X9W8K"8(P"G[@B)`0J%49`<0I"*MQB$.,+&#`!PL0
MA*O1AP6`*<V@!"QLZ),R"$R8A+/I"WQKAFM3!GZ("PLHB0NP*H*Q@/ESB`0`
M-J*18WU8#<PUF*-()&4(@)]R!@48!T?3'1I4@'Y0`%8V`!)0!MT("90P`'IP
M-;CH!]@PAP7(!']PBB^NM)@)A$S`%CT\F9Y0E**@M*K"B:["VM#X*7JPAVU8
M_RD2^(?N[H`U0`!`,`2N$@H.H(1_^0<%,,0C3X"A\0!:?BR;$&D05[C(&O!`
MV("-H8="\(`5L`!.,(@1"'!Y48!_<*81`(D1J+1\2(,IP@R%XV->M6,#^(=]
MV&0/"(;1N8PQ%QR#&"-@,P31W;GB,.9PY@`+X`!ZR`1,:`862(`5>+[94,.A
M-AC?\&\4\("4X``YHP0&*(2)OHE\#D(2X(U1,P#J35T@;X9YVC5#V"RVPIN?
MV`2KFD(&F*=\H`=-T(I)<`9S!H1F2(I[\`>O,81L&D.H5DE]>`?>/%^XLP)7
M@`8CJ`$G>(4:N`%><`9T_03=ZP93>($H8`2W9()9B/^%)J@"*W@#&A!W;<@#
M6B@[6V@%4X"`&SB%>/>"RYX"*;#J*N"&5N@ZQ]-):AB"&<#*'-`!#I*"*8B#
M(ZB!,LB%*P"#)%@"&4"":4B"UP,#);B":1"&*]@"?7"$)CB&;M@""O`$&VB`
M(J`&.)`!*(A1W2Z%'D`"5N`"*2`"),A3,2`&7Q"'V?4`+PN$%-B'9\,,K=":
M,TH`L(F,E3+4F/D;3I6V?X#GN#&)$,=R"_"3>?&I!E<-S#@8?;A).UP`L>)=
MBM$'MRB83-B`<)E#GAJ!8,";CE$`++)#/XZ9GC1F17N934B9[?,`9W$F$H#D
MH^.WJ:^*O3E5)]<K95``?JC_J`M8&IES[Q'X!PO`&YO`A`$O"&"8M@4H.`.8
MA&DJ&+C0"F,V-A6\"-5=^T*8A$+(A)7VA_)\%U0=\V=`A``(ACIR`'_H"V7R
M`'K9%W\`ADV@!%1?5%5/Y$Q@`((F?KM8`'^HK'.HH]<H!.#`[TE(@#)C@*1P
M%@OP!T`H"`Z/N6:X!08P"@'WBGTI)Q0H"-(/A@!H%O*_=('B&8#PMX">LP7G
M]-W3IW"?/A0K%%X(M"]!)A+__K$XIZ*<PH('%>K3M.$<)0_*#$QJMJ%0I@OC
M#``C00G3A7XD4J1`-"X!)D,F-P3;=.%C)0[`$@1#X4\?/GTC>"I@2?$"H&`P
M%9ZS_\#/G()@%PP5LN#L@CX+F0!]#;"T*<BV;M_"C2L7[CM+R,!X@5)FRB=0
M-:"HT<=H"A])UT!YF:.-5P,CL][DT75*&*Q<Q/)XVM/@2;95C#RMNK:K"Y1J
MSW#TD#*Z2A4\=ZAT:Y7CR;I\<V_'G0:AAJM<LY\8Z60&QA0CKKZ0<H)C2@QB
M['`T<`)+%:A-PN+`:$+D"[-;9O(8X_$"QS5L1;9(R:$H%R,=7(A(8:5$"1$O
M8J:]NH:[+3X#))0E`(P^)`C0CSX,F6.6(0'P8T$AR@@P22`CZ`,(`)0<J$\_
M!CCCC`#-L/#//@N,H,P"P20PCCX*5#("(/I<@,D*A>A3B/\*ABPP3C/]>+`4
M"9EP,(D^"?S#U)"5P!C(44Y-,LD&^F"2@#\6Z*/,!?24Y<\&`OXCI`H,3+*/
M,VTE(*0"F*#`08TC(/(DBE'J8\Y5^C@C9"$P4>F,`N-<H,R*RHRX"3^%]$0A
M)AL8HF8F9BF@C#(J-'-!,"`=U=0*B!3R8E/*4(D"C8`84DD@X_24@"$9<K")
M0I5LD(*IF:*H8@*^E+23/AM,,@*2YCB#P@:`&*#,/X8L"D@*)$RJ3S!4PIC)
M!OP\PZPA)`2"B#Y:!J(`"2L@VX&`%U#"YS\I&$D)B1QX`(P%DUY0B4OZI``(
M"4B>)*\^_"!B@%@C6$`"!R7\0Q;_/2FZ9=L(*BAD@8^%%/*/2A<@PI`^XRQ@
M8)S.(&)!("B,L"R6(VP"#%DIIH#)/X*`%,P_A2R0R22`"`464@K1Y,P&_VR"
M94(DG%H("3PKJX#-##4U`B;!J`E,)8!T]:0'E5C@IP>8[%>UU7/5-<T64TS!
MFA+0Y&$#$*NLTL4/3_3CB!NZN"-"%:7$\00=D8@""RRO//+&%*&X@8,7T5@B
M!3>^P.##&[F`D@04JY32=1=X=!%%.J_D4$4\5]]FFS[50.""*;#D,,431.`1
M"FI<S$*!+E3(D$,7W=13@0N\0!.&(OS8QD0#.*R#D"E<$,,+#0UHHX\B,2RQ
MA3I.,")+_PPQ;$$+%TIX\1XQL)!S=3Z8%))")DU1HJ;$RI(`R#_T!#-"(/_X
M@PF2P"S`3UN&;!`(LN&,8-$D]'!@""+F-`08YR#!"%)`CR[I0T(KV``'+#`)
M97B@`R3@!]*>(J2F!&(#/TN!.1;P#TPLP!D+G-HX*.0,"QRD1/ZX``DP,"E_
M,$`?FU`36P+1+P/X(P7:BIH^.#`"<"WK7NO"2@)&P`$4E`5="3A'`ORT`#]-
M@D@;4,:$$KA$"ZR``P;@'PH`88&!)4LA*+@)60"AJ3@I@!*7&A`B)I&I$3C#
M`T)B""5,M8D%H"!!P?!)00RT`11,HB8+2)(A7,+")P8C`,W@6/^DSK'"?32E
M&0P`1C"$IH!^3`08^[C`)A)5H15D(@'ZR,0(]J$``9G**0!82]#<D95F)$!5
M"AL!C2Q@/G)A8FH=&.6+_C&"0^Q29;Z@4C,48(YQ?"1#/U.(!R8U`D,8`A"9
M<`977H2E->K#AIYTAI*NY!1,^$--"6@&(/QAOE%.@@.%X(<!-&&(0.32&<$(
M1#-HYH%S`,,?"BA2T804"!60P%K.0(H'VA*,#6S`'U:B1$NL!*-`^HD$`L(<
M1:^VCE8<8PM5\$(5II"$.:@"!VIHQ2G>\(0G-*$;IE#'(GX@"RI,80NB&`<_
MYL&/>C`C%%-@`AY800->.,,4T&B"Z&S_80I/3*$(L.C"%*@@!=:HX1NKD`$5
M-%?1M^3#-MVH001($8L<&"$)1E`"+;KP!!@<01MR*$+H<N"$9-3@!1`@!1<4
MD0YC="$'/X#!%8I1CD<L@14@>`$,J&&)))S!!D5X'1P@(`4EE`(/.%`"%Z2`
M!&SDYZHT6\!$X8(/JX)D$P[*T%OH,3ZW2.RS^Y$?/;"D$'X<!+3G`""66JL/
MT^KC'*Z5'S[XL8]][+893=F'O9("$MN<`YGZ8($*Z`'`VS;C(/20;C]<&Z=@
M!`-!P.A',^BA#'/D(QCRTP<P#*&B9DSJ'.F=1#Y_BPE$&$B`;=E'3_P$C,Y"
M:1+^$%`F*"D@_T"L`$-MP<3/J*8L#G"@&>:8X"@OX,9Q()%0V?1`(?8Q"0O\
M`P69X)0R<AFD#'%J@9C@!P<.DHD0N*A"%QAC=]LTVO\T)!/Z*"1IU\1">B#K
M5L!020HTM@^.)5092.Q'`6720U\A,04<($$"Z)%BA30%!>321S.9]+(+%X(#
M?F*(,A1P1`4LY0*^+-$7!^0!^@VI&8%XH`4,H8!T`F(2#)C)$U?"-!7I@Q+K
M4EC_C#0"(<E+72TA5P("T98%*"#/%E`SGLK"/:6HQ4B:G?1;RG&):1S!"T^H
M`A>20(=L5$$*KJ`"-,3P!"B4`A[7P$$0\O"%-WA"$O:X%S^X\8Y&>/_""GG@
M0@7H,(]RQ($'.G"#*^;`BB6,PA4ZB`(4JO"$,?P@'8Z8@AMZ1^FW4",)26#$
M+G*@[23(``:G:`)Q3.&&4\!`!C(`0S=V,`,8A,(3KD#'.A)!"L'XH1_IB,07
M.M&`!NQ@&W"0`0]L`(HVM((1.2!"*;I`A+%*X;'$B$7VKO;9?#0E$Z=R2U,P
M#F4C,83`UOWX/FS#EI+7^$#Y^"U30"OIC[\<(7`YK<O9XMF%U&@HN;48Q[-)
MHWOD(R$@L7E;7$Y1MAC]N"FW:M*'?FVY$!TN(^>/LBSP7)8K9.4*6>/XS#%>
M?615(<I8R5OP4<^DF]:UYI`8;C7T7'WL*.O_SBB'_&CJ%N=B!4OG`&[=@Y%,
MA="C&<H8KSG\,2F"O'::]02&=U6D#$H(:!R3P(3@\QP.?AAB$CSO!]6`$8BE
M@&2:RNI\YK&$"2&!?914H\<D_E&)3'`^@=D-!*CJ^?1KV^8=N"#&%I(@!1X<
MH0EY"%L9>.$&4U"!!TF8@F5L\((]Q*(+O)@'.&3M#D:0PQRE8((M?/"")^1#
M$C?@@1%R08HX*"();N"%%7C`[#=(80_L@(4>Z,"1VX,$&5*8`BQ8X8(G)`$1
M+($-S$$<_%\>S,$<0(`1>($K1,(C-(`2=$(<=`$IE(,RE$,^N(,U7(,B=$$<
M@$$--,`5(,,P])X._\0!*\`!*>0`%;@"!2A!`$[!?%2#,8B#9D4=_NG@#MY&
M4^`#/IP65J7>5;E<T_U@V<T72`3A?&G.$GK<S,4%S0F=$M[&^!@A2-!#(:A(
M#F9(J)#6$AJ)(4P9#Y)A&98A&&).QYGAI-G&.JP",32!ICT!&*0.$/!`%]B"
M*UC!#=@!%5!!.9@"#53`',S"'9C")3A"#.2!&MP`(PC#(WS!*QC!"_2`-%A"
MY7#!!T+#(]A`%5#!'8B"$4"!'T9!.;2"#5C!K.U@,L``#)#"5.E`$MB`[^4!
M!%0`&+@""T(!#I2")\0!-<#`&RS"$4C!'-C"/?`#/F"),%S!$N!`%[Q!`__8
M@B,\@C'@0!(4`2F\`@OB0!Q(P</-QQ$<`3880SM0&B0UQ3D8R!$Z'7],W7YT
M'"3AG%RPW=&UW<<UG=)93=!I3C[.'!JNH0X"9$!"':75'$'B!A=>&Q>>EL0`
MI$+.%T2FE@]2(5.\(T+>QCJ\PC'L'Q60P2=X@@\$P0WP@A.\PB[$(A7P@C[,
MP0O4`3A<`BI`0SH(QO#P`3(:0QP,`S3T0!"`@S[D@1?P0!6D`QRT0B=``2HV
M7!2,`6ND`RC<`!6X@T#JPS3D0`ZX`NB<E`X\`?H]`0'B@AK4``7D02X,@2)<
M@\)U0BH<02*X0B*T0C;\0B*P`A@8P6?D0!-(@R+_-,$J0"41:$$KD,(0)$$G
MX`%P&,$6<,$68(,O5-S3`1)&*@.-0*1"`$.14!0E(!%#N-%M=!@]H,#?O<4Z
MK$$:G$`);("`70TF6("!Q85MS`0\MH5R@<04WASE#1W1:<YP5<FD0!+&T4,R
MQIP5.ETSX-G$C`D86A4]C$,0$AW?F8-N)2','0B61-U`8F1V:N=VZJ!ME`,L
M#(,5-&456$$HY`$4T(`5B`)[\``0J`$=4(,GT,`/H`(IC,(WL$,RJ($-[``=
M,`,__`(5G$(KW``-@$,RO(&F,0$UD,(<1,X/T,$G3,$=V$$5Y$$^D,(-W,'E
M["`VV$`#2((HR(`1$$$-__#B#M2`"[3"+HRH)!!#*^"!$GB"+L#`"\0!*&Q!
M*9!",N!"-)!"*4B!&8#!"S2`-+@"$6R!,"1#%S@C*Q`##AP!#GR"%.``$7"!
M&!@!-<"".5Z-?&&",JA7(&!(%U6)(6"";9A3LI27GQ@4)?B).6R"H%0)ECC#
M.!Q3($R*"GB3)F`"T6#7M5"->M%,,(R#//##.%#"1S0#;L(=,/38;>G#N*"7
M/H1#;%F#Q/A+,2F#,TC,."A#/8"$/2@#+$V",/A),V2@,A@()/&#[<6)="F`
M(>C=QXU<,P@`653D;7S8U:22U5""H<T/$ED50X*$O3!$3@PA7"`",#C4;3P%
M"?]L0`)@"$!.PL8923#02*Y6)G=R:[=Z:]'I0SF\@C%LFEGI0!>DPANX``^8
M@B.P@AOT0`_H`"R8P@L$@1WT(CN,PR+L`"_$P@Z0PC7``AR(@@Z\@`\D@QO8
M0!1(02<D@C50`0TD`2GP@10HS@^PQCHLP@M0P47BH#Y00PZX`"FXPL+A0)5^
M`A74``00PQ`TP"HL0QS@P!<805^Z`@Q$`"O0`AATPBJ80RO$`1S@`2TTP`N,
M@BF$P11X`1(H@C:L`EJ]`@3$P!&4@A$@CQB(P1'4()=:38"41?<L`"48`"94
M2S_$R,VH"TU40B%%46<E2KX`PQ%QP)/,C`54`B)$!)C_H8`!/`-&'(LY7``>
MC=$&K``P4(@1C4"C:-`&6$`^``/A7E*D,!FSS!@><=8_6`N-W=8%*,`F>%D"
MD,NB7``'3)W"C%("F(H%1*LAG(,'<$`1S9@%)`"A!,`&](H%2,J/)<`9(8(1
M"0@_H,"*&5HA;<D^%$+P%@(]&,`%C!<]9-"6\,/ZQ$B5C``*+(!KOE<@#`H)
M&)@A_`,E!(,R3`J!48T6U2D@J$!S!D.3&.\_^`D]4$(A_!&D`IB9PAV6F`.;
ME@6>7H#+,`0_:-S;Z0,&`"LE,,!!:((6*@2V-L,^B"]Y&8+\V!!S;BIY9<)X
M-0-^?>L&<W!VAMTYM((U)($7_TB!%TP!#WB!+4#!$K1"(NS"$_2`#\P!.-@"
M#KQ`'M@"']C"-C2#)2A$))Q#-^P"'XQ"#KP`$Z0#+.@`#_S`@$:")\#`%_""
M#MQ`%2A!%42!%Y3#*MB!&WS=TS4%,BC!&3@"Z&B;E2:!"]0`(VB#"R@!-8C!
M$BQ!$4A!''0",;@"#ESEO^$`*PP!!,"`#N``#-@">^S?%"RF$U"#%S0`-B@<
M$30!'@R!$"RF%$1#+`CP?EC`MU#"/QC:GP5"(112#B7`"7W0/$S"`E2"/[S=
M$'$3"2C$]4Y16<0O$E$+)F1$`&"",S!`E"P%A@4#,&S"","/AES2*0T)3508
M`8V1/O\@0J(UA2=50C,YC:I@"8"=@P&80S\$P$`)R04@3%M8P"TDT$`HPZD<
M@@+P0U=T$(\4`N=UD+!XP#Y0PI[PA.WMPTC06""HR0\M"^>%T`),0B(IPY/1
M28(50@)P<[4:P":I`";TLI%<`**D0"!L@K=DD)RI@,\80ILIS`9(R@8@@J_T
MPP(8@"%PC#^0C`5L@@&\"$,$`@/@""7$"[P\!$,L`+(80`;!\I*MP`6H(0<`
M`DT!@BCY4@;Q@U#L;2!$$R:H#U*L0-@J@`*LCP\-10E8@`=X;`=S=5??GG>N
M`KD^@1)TC0[D`1;H`!GDH13<0`]0036X`2X@@0Z,`A6XIRC_*$0]?!8_/$(5
M]$""-D`I;((IN$(/W,`/D`(L@`(1O,$H<&6H18$5>,$VM(*%;G5%-04U"*`B
MM((,`&`,N((H-(`7_`(.R``>D(+O*8$4X`47>((Z=$,7S,`+S(`+O,`+N,"[
M?4$\W(,C@`$8;`'$20$HK`(1A$$K*$$#Q`$T0(`29.T6<,,K6)O5#)$%4`(@
M&%K_Q%D&_6HAF`,FJ,#-\(/)Q!*4+1K<_0,LEX63U%./!`*Y\`PE=(P!9-@*
M>$4]C<,*@.XF\`R%\,,%-$.)W0IK^O0D!!B44,FQOD@P#)*#70``P30*L!-L
MX5`"^)`ZU1B8U0@LVP0+,-DXE)E)__@"OQB"*37#"-Q,>'M,AFA"`)"`!S`(
M+>79,VG,/RA`0^G#$P$-0]"#&)(`@#<9/6SR!3!$:H+$+$<%3?@2U9C1)*!`
M/;-7C:3`24R"V$Z"!W#J`BQK`@2OC*D`$C7%/[Q((`61US)$__`)E/1)*>_$
MJ32%!Q0:`W"`.82#`6Q")16"T0S(RF!WGPA)^,B)UQ5"^`9+F]W6MGIUHBNZ
MU8AK-"B.%$1!%!"!+7C!#B2!*9B"$=@`&4A#',1!+I0"79<"%U0!+[B"*8##
M-[2",:0"(LM"'N@`-)`"'7A&$O#`#"L"#00!*G2!^]EZ%:B!.D2"#70L#Y(#
M##0`(\@&#_\@`2L<9AD801Q<)0Z8`BEX`1A,`7SH@2(L0B3,0S.L`G`''QZL
M0C7<`R8X0B=P`5Y,`1A<02=X0A?$``3\01<H0>DP@CA>`1=00RQ,=]5L"R88
M@&8BS$H@0@H$N)IQ+_..D;SD\ZDPQ$T44R#MEP$$^(-,4H8Y!2*$DDH,W@4<
M13/\-Z]$18FU3"$H0#$92.>F`(V0@"@_25%#:B`4%"`\B2$(@*&Q10J@P$LT
MYZ)]Q:VH)M@A,S]GTY-,@@'LA&E=@#E14+`L$2!02"8$`A,=YS.-ZA%)/;QP
M`$THRS_T@U@,B3)\&)84$N8I=),Q43!HM=`;295)*[;ZP]3`RYK_2?AD<M;&
MF`@FF,Q!G0,_+`"Q$$K39Q.Y-`6R"L6M$!#.R<18C%*"+0!VJX",-06NQ.X^
MP!(BI+<F](F4_Y,SNZXSR#<384E"ZU#<#OVBJ_[J7XVX^@)73@$4Z(`9N`$/
M3,$;Q$,7^``3>,(]D`(3N`$X;,$+Z,$H.($>?,(I0`,TK()O=\$H`$$#$#:P
MXX(R0(`._``OS$)[@D$>M+47*$X4=(9;7_95K9H,E,+3YL!R1X`7N/\.3($S
M'H$W?($4+,$14($9?((VML-!O`(``80\7_OZC7-$ZE,G+DJ4;/G2[0H1(V>X
M*.KR)H(K1A"DB+EF+)T^D2-)EA0Y;L2__TG!,F'21PF8,D/Z,'%`T4P?B@TK
MS/$CL0&1OGTB^:7@,$E?,`XC,B7=`"A%L$DS$2&U@`C8A@LS1_339\C"!4J^
M2.C+!"B0!67_S.4,9HX#"17G?,I%(92F!Q(=<)XSX$QD/GW`%DSB<$[?B'%*
M.6Q`/'+?!F7Z)@$:?`$%!P_.//#CMZ'?/PXI4M!+`'BT!13\+(P3J4Q!VZ0)
MFG&P8&!$8J,;Y"4(ID\!L$D*<+[<L.D"\03C_)X;0<(0@*8B+?C3EV*%OP2;
M*"T(M`!0(12&-@0SX`\2`V4;#!GR33LQ"L+``G'P9^`?7A4*G#W]"@"I??#1
MAP04_%%`'^W,2?\@$V4\^(VZF?3AX`)S+L@DLDS^02&8!`+YL#U]-D@A$PZ4
M66`P`\X9AX%@Q$K0-9-DG)'&&FV\$<<<==R1QQY]I'&=88Q)0@<EGJCA%%1H
MH*$-)8$`IQ\J\.#B#5>@B8$&/6C!HQ1HJ*DFEU/BF"6*!JBHIA0@]&#$E7E(
M"6(45RB@@0E>F-!ABB>,^$&=56B(0[`?3<KG'GVHP4$&1G!I8`H\KI`A#R^,
MP`$&"'20815JDI@B#BG`\.(*>LQQY0H<XHCD"R+^0(:>=9KPP@PIMN!BBU5@
MP6$*''(@H@PC2(&@"U:XB&$+:U9I1]`9AYJQ4),&E/%9D985#)]]EM7_AQZ3
M/,-+F1$PJ<]9D[(5=ZAS1`L4,GJ&LG8H>F(L2=U\!!2)GG#H45<V=?7IISBZ
MA`HFQG*6Y<<<>=N=I))S`.$`6W\@#`8Q9\S9)Q/`A,ID$F4@#H8?BO.AAQ),
M*AXI$YSV,20%EX"A1*E`E'%I0TKT6<L9<U4(YF3$S$4AP'](`$3F`;]-2;!Q
M%'A7'^0R44$?9\H"AH0+`B$)A4I$,L>#3)226A^%?PIDJF82V&`$>H)1X)\1
M^,D'$`M6L"`8%%PR`*ED[;X;[[SUWIO&=%Z)YHDIN-"!"5%V`$(':;IHP!9;
MK+#BB3+,4"077&K@88\?;KCAE%%H"&(,/BJ0_T(:4JIX@XLGWG"D&QUHV,6+
M)'X819$;@(@BBBK4880&+\;-6S!JBDCT"QO`:,*(*4"1)HXWBMB#!QZ.L"44
M):KH@HLC'AG&D2.X0$+2*J288@A3=(F#""_"V.((4+2AH@<ICI#!B"Y@>66+
M,HB00M9H8EFG1_B05[2:%:AUB00?T=*'`A=($@9>JT?HRL0(.$02"#X+@C)2
MQ@6\DD&^[6T<).``!RSV01O59Q(7@)`)1Q*,#4R-A20(1#]>-"!YT8@>^<"'
MOO3A#@^R$(A!%.(0@32,7"@!"E.P`168(0,:>((//H`"-/(0!3",#P^?R$,W
MQ,&%)?7`!D`(PN=>4/\#1NC#%7C`@T).9P9>>((&J?B$#EQ0A5#H('=5\$(Z
M'#&*.Y3C@]/@0A56T0H*=&(+E()`)'*Q"E=<3@<QD`(CH*$(*32!$>V`P`V6
ML`0E&($)[$->#HH`CQ,@@0MXV`4K$GD$(BB!%:YPA2600`0<&.$31QA"-6"!
M+"+^$D<,%)0P@<FC=HWCA\E*IK3P8A9$`.9:Q*11M(CYK&`$XC$D05<$2=*,
M?P1B$\44YSC)2<Y[<,,8XYLD*N80*U!8P093&,4IWH"'/%#!"Y]0!"FJ\8U7
M.*$)0X``#&QP@S9THQS$8(0G\H"'.,0!#'-P11QX@*0W[.`3KJ#"%*I@A2K_
MP,,23Z@"`($GDFD8@0B1:`43[@"&'%0A"5U@!!*8X88J^(`)30!6*U0IC2\D
MP0>85$02OM"$3CA""40@JC0<P0A8S`$"2J`5%X@`BRPL8JBI\P(BN4"-562S
MG,#<QS;#6M8&FA6M:57K6MDJQ'((XQ5=V,,.J#&'&Y0"#GBXPQNJ``5>D*(+
M>GU#*601"DDPHRW;0,8QE*&+=."#'YH`Q2E.X88WY"$/GDA&*ZH0!2I\X@V>
M:$(3>-&%*.BA"NEH10WN\`ZR"BI0W,!!`QC!BAPTX0XZ>((.W%"*3C2"&T-(
M`@Z>P(,DV.!Q#:A!$U@1B55L@17E2$0<2$$*+.1`_P8YV$,7C+#;)"AA"A38
M12XZ\0LX*$$*0_#"'+X0!VYH@J1ME>]\Z5O?#R[3OOG5[]W6<0ML-`$*I2"%
M#^[@ACT\`0@WL,,-YE"-.)CA#EWH1"GN``U]P$,7=,C#-[[1ACD@@Q_K8.@H
MKN>%-X1"&U)X0A2>((4[4"$/-!@%(]Z@@X_>8@=3B,=K[78-&,!@%:1(@E*E
M\`DHU,`&.3!"+KJ!A2,\`<I@W`$,3F$+4C!"$K"P1!-B00HJ6$(1T`!#!%XP
M@QS$+KU;P`4TFB`14'YB"]B3PA?@\;_]WAG/>=;SGOG<9Y&L(QFPD$(5\*`#
M/8PB&J`X$A"`\`0F@,,43/\HPQXZ\88H&.,;=*C"$^SP!B]$@5.1N`<<JJ"'
M3NAA"E[X!BEX`(4>R""FI&B%$ZR@!BHDX0WI6,4-GA`2OE%CH)&(10[D9P0W
MXI;8,5@%*/:@U!S$``*Z(,4I7A$&5GRA$VYH!2D4`097A,$8J[#%*2*`A*02
MH1.K\`42IJ`$+SS!%:&0'Q6,<(1MK`)I?M;WOOG=;W__NT;I$,:M]#`'*20A
M":2(ABM:X8;DZ<`+J8!%+N"0AR?`@A%=^,&*41L'.WAA"FIP0C3<H+H\.`(7
MK&A"9ZM`!U/`HAMSH,**/0$%)L0#%#=H0GSO%BAL$,F1->!"ZJ9WA26\$@>F
M@`#_^G+`A3M\X@I#@'4#<I`#&$C!%2!80G9AD`0($,$3K#"#*Z_`B!C,P9-+
MB$$3M!&&,'1!"D8(PS*^"G"[WQWO>=>[6<NQC&H4^0W%/0,1<D&!7$BA#%,8
M0W'=P`M;N.$5X3`"GG1P!ST.DKMDL($MI.&)3O""%Y?$YQ1R<`N)T@$(&X]#
M*:#@A7N\@@^E^!W>AL(,,Y@!%J18@A1HY3UHK`(&,8@!*(BA#4;`H1-@L($,
MH.`"4K[!<%Q(PN!*D0,<S$`&9V@`NA&YB'*L8A5$F$(2.D&,/TC!"USP`AB*
MM8IY[!W^\9?__.E/(\'0(QK&>,(=2B$%/-7I%%S!&Z[`_PBH8`RH`(\^(15,
M8;>D`!1,81?@H!4\80ZT@12*ZP?V@!=*P:5XX`W&)PE.@1O@8!>ZP`>JH`8\
MH10\RQU6@0>Z`)#X)AIRP`4<H15RX).\9PJZ(!<`*P>\K@ON80YF)0<:P`J<
MH`N@(0Y$H0M@H.J\0!%"P15P@`N,(`)`P`RX@!3J@1&*0`ERH`NZP!5`00S"
M8.B&;@MT33;JCPW;T`W?<,_>(1E<(=7>X`Y&P0N80(IT0!9,P1,HP`N\0!0@
M!PI>X`<^011L`0X6H15<`1<\01$4)0Z>H`%LS`C`P"*,8,Z^00Z^P`VZH`GB
M()_>``KBX!XBP06DH!X^"!N*D/\4(D&2S&`+^(<+OJ`5*.X)H,`(KD`)<``"
M9,$3/B$4P*`7B2`/I``'M@`/8@`'N:`4O@`45`$'ED"FE,K=7&$5OD`)Q(`+
M;@^\NH`;5H$<X)`<R]$<SY&<WBH:T*\+1&H6W``*[``*GH`1HJ$3IL`(H*`*
M**`+DH$8X,$4;$$4/F$6&($4>`$/6,$4NH$:&&$.<&!\GH`*OD#A&$$*EN`)
M<``.3F$+%.]ZXN$5>H`+9N]N"H48:D`&7$'(IB#QC&`)N$!6&*'ZO"X)J@X,
MXH"[FG'\DH!_\-$(BI$*3\P(<N`)B(`(P&`(6"$6I*`ASI#]M@`,N`$62!(=
MJ](JKQ+_*W%$#N.!"Z8`#.Y@"G1A#G+@!Z#@!_+@$]./"?"`$7;!<*J`"4J.
MT7;A%%BLL^S`"4QAHN!N'DMA#DA!!Z#`"LA`"L"A4^Y@#*+@#L[A%6R`":CR
M;I)!!F8@$A0!W5Q)JHX`_;"`%*ZH"[Q@#*``&36QW00'']'KX!:"*='+"(P`
M#\H@#I*'(CQA?7AO"YK@".(LSKC!$2"31ZA),'@L4`9$@$:B.!TH*Y-3.9>3
MG-9A&5XAE:C`#$Q,%*`!!\J@\G8!X\+`(._`"J"`!WH`C&(3"OAJ!Z#,=H(@
MP42A%$H!"[#@%*X@%W3`#G1`"DZAYL;G#:S@$_)A%9[`#7@N_V^@80F@(!>P
M(`F>L0G>(`Z:P*&Z(!8BP1DML@9R8`F29PIPLPOHS0S*P*6\@/>(@`>0*`=J
M``;R`"&HH!4B`2JY(`X\(0Z8H!-V80N,@#??X<ZDZ>YX;)QT=-]\%#G+"DB9
MD[[(01=PH0O*(!`'+0XJ21&0@$$7LAOPX,!>0!]W`$:E816\@`>F@`I.00_V
M@`IPP`X:($L8X16J01M,P1%V8,BJ81<V:@JFX`ZBH`OTH1769`WU9AB@0`E6
M01&J3A.5H`AX[PB.@!1"%/W*H`Q^T`AX4L6\H`BF@']4C"$0#@I(Z1,\-'FH
M8+H:`NX^DR=!=`OJ`1;V]$;&81,`B?\2#B%;#"$86"83*J$1*.$?_,$9($$D
MB@$2Z*$8V@,2#N$WE$$%5,!BML$0,J8DUJ883"9(1P(3D*):H&4DSJ$9K,4X
M1:(?SH$>P"I<LA4Y[\4DKJ49D*F!=N@X;60<?--NAE1'GD6!W'5O`H5'B72(
MZM7?R`$:A@'D(.PF3>P4KL$/I$`T14$4\J`']J`4MN`4VA,![^`)=B!YJF`*
MYL`3>"%&/^%T4"$=NL`&=*"JI*T*P')D><\*ZB$2>L`+5E%O"H4::B`"+,&V
ME,`,VDT*D*`+P@`4/&$BB(`+:#`)9.%XS.V[]F=*RB#N&,+ZC"`.8L$(/M8(
M9*`,AH`40.'_"-B/]U)-"6XR'52!74MB*"8!`(+A'0)``*BA&03`'P*``Q"!
M`P;``!1@$@H!`,()$0"`'CH@`#3@`A*`$HJ!`"[@``1`&8QF`2Q``"1$'\9A
M`T2D;F@$&!@@/W`$$12W)%+`'Q"A$.QF$G)C1B9A`8)"'\P!$<[A`H2A1H8B
M*T;``T0W;\[!)0+A-^1U1@2#'PR!'UIH9J`)@9II)#9A!5SC'K;)AO"B&8`!
M+S`H*93A'`!#AP9E632F=R'C6\%61M"EFD9B'#!A7"9&FV2$77[S1FAW.06C
M'7+A&<H`)M^`"EH*+O.`%[RT"GA`"G)`!U(!%[Z`"Z@`GV9N#^Y`_P\@5@JH
MX'3>P!2P80AJ0`VZ@*6BH!32:`O>H`RH0`U>['3JX1%LP`OLX8.B83)7@1&4
MC'_`:PH\(1I605=DP`N(X0Z.#@^:`!1F`0S`P):X``=N6`IJX!+-@$;!H!2Z
M;I^>8,BD0#L[)7"XH`RX,0RLP1)0U4;.00`@01@((`"BU0#,(0`\5P%*0!_R
MP0\```/T`1$"0!\PX`1((A`80%0VH!8H00!<@S2ZF"8"P!\H"!`D!!-0(!/&
M91]0H#7ZP0\JB#+^P36`06Z6]QR481(FX1P*H2DP81R^*4$$F63^`4+\(2I$
MPIMFPA!RXUGH81)<0A\LH&Q$`A,,(!BJ`_]73P(3<.)9FL$`9J(9O&-Q_0$Q
M1(5YS09Y-1DP1(4?`".1AP(L7@(GMF59('/V].63B4,DS@%!4F!S:\09%*`1
M8G"!>!08+)<D*B&;[P*_:&)JJ*DD%"@8RJ*9HHDDFD59NL8"-J`MZ$$Q@F&7
M:42&LI42[L)&,N@<9B(0FB*#J*5I1N"'E-<?9&9&,&$#-$&$`H1&+BC/R@$6
M8&$)9%&/\(`*I&`_1R$4F.`-DN`30$$4JF`,..I_H\`+Q*<*RH`)<B=/1(H)
MJ$`6S*`3FH`)U.`)3L$+EH`*F"#5*/8-WH`.]&$5>J`+6#9O"@468$`&,.X'
ME2#QND`;5@$$AJ#_!\J`$73!'"9Q<5P@5Z2@$SJ!S>+N"+Q@85.A".@M`FQ@
M#[A,'R(!"<S@*!\!%A2A(60E>]+0$:PY1S!`!4A``S2@!%0``?`A`,JB'A"@
M`T0"!1`@```!$P2@'CS``#I@`S"`&<;!``3``F2F&10``!8`=QOHE)TF`4[9
M'\C#A3:7'OCA'WS#`@QA$PR@&72B$!0`$TI[*U!@/!C`/2Z@$,Z#`S`A//QA
M`PIA!()B0`J!/=R9/,!B95[[M3'!`[37`I:"`\;!`BS`8@HA`%)H`TC``IIA
M@T9`A1J($BR@@0H"$ZI;A3)!`2X`$!*`!!(@!;XB`2Z@+#9@`4;`$!0@_P&F
M&P48@!)4`!C\(;N9QA`:([Q'PAQ&H+K%6\&1MQ#"(@%DPQ`$(!!:NP-(H&,"
MX;M=8T!2(``NH1M*H`-2P(<*`;X3)"Z:=Q+Z@1("802"`1!6(QBDXBZ"0052
M`&DF*!#HP1DF(QC2(&1^6;@Q!)0=^RL"0!DVP36"H1_,029FIA#\816%P1#F
M620*>C)`=S)V"!C@XBZ4H1**8R2483WJ^Y;W81(:=UQF[QR$H2WXX98'(P$F
MQ!#.03;R85T9_!SVF&!&@AXFPS@3O"2RZ3A6@`6`0927Z9/UC!Q\P12L8!>,
M80N>[@Y>%+.\P1E/(0^L0`?*,@I&FJ,@U@[Q`/]WQ%2DRL`L04T1+"$5O,`5
M9B&PQH`,(N4'/.$4^-<>',$&GN!K>Z107B$&&B`6'"$'VNV3]DD'?CT&=@'E
MF(`)XD`1HD`&EF#[.,(,8*`,<,`+<N`3="4&;HD&K,`3&($+ZI$45"$&R@`"
M2&$7!HD*Q(`;P8`<5B'8D3,+!H``*J$2"``!"$$?`"`_\$$!S)D$2@`3&(`%
M#.`>,$`#**$1#*$?[B$8)AP`+,,9.AD`IELDS`//';<Q.O?.!6,36"`?*,$0
M`N$\+@`QE,$?P,-J4.".&W<I)J002"`3"J%S;V8%+J"!"L$#)F&/7QL8/$`Q
M-N$91B`%-`'H!V03IGO_'PP`&$:`H3E#'UZDN`&!PZ,&+Y1;*)9EQ2>A`]8[
M0:X8'_QV`SIF`2C!M[\"9Q)@$MQ^E!$ZG"Y@$G2"0.Y":%*`'U"`!-9V'#S\
M/A39`&)$&=3C'RS`'"R@$`RA`YS#<VGB+Z!C&19`$]+"P--B$@*A$"K!-P"@
M$%;``#!!;@L!$"9!!9I!`C(!!7)#=4N;!.96;:1F!`!@'"[``[C;&1"A`PP!
ME3$A`&+[-Q2@$EA>;GP[NA/`$`Y@)L+V*FR;Y0WA_BYD`S@@Z@.AM,T[`?XA
M`#1W!;Y"!3:!OQFFD_$B+<"['SK_*\`I`(X_`71"&>""0C1F`QP_*DA@\3?`
M_VE&@/_W`2!&D-B@0A\^?>=(C-@0+).!-1X\8)JDSU"'%<'X!1)XSAD@#A,O
M_%NFKZ3)DRA3JES)LN5*:L1@67E318J7-U/,Q)'R)H^5/5'XO.ED)<D8.U"J
M3"'S!`^>-TVZ5+%296J5)V6HS.GT"4PI5UWNE*GRZ<V34:>J4+$7BXR7=R[C
MHKRGS]>4,M!(Y5"RA,@6;46DX'A2P].1/SF(*/'R"-21'5%L\+"!`\LN)CEH
M0-GQA,:;5:KP&,FQ!4P-.D:N[-#1Q165*4K$'`G3#18]N2>%!1`P;IF``<7V
M!0"D;]^"@OH&ZO,``$$^!RF*E]Q@H:2!"X42E`04P/]=27\.]&V@N*$2AQ29
M$!$O66G$N02`,%WP9V&</DR9*`6R@.C?/T,<)&=(<I.,X$\@DW#000HD#%A2
M,(:08$$F&_Q3R#_^3&*!'Q\$@DEU)4T2G3X7)!B(/OGH$XP%^5Q03'*(I.`!
M"A6:9,@%**H8R`;*Z*.,!Q;I0V%)%Z0P`I$J=)")/H@4N0`@E&Q`HB$;\,/D
M"/]05*!TX:P@H0K^'!G,!D;JPX\%S934SP+ZJ("(/AS\HP('A@2B@'WZ-*.=
M,X4@H@`E%RQI#CTK<%#(.`4J@^.']Y%02"&&I(!)`I2D80">*S9(3W^%H(#0
M`LY<``R)F5BC228*%`),`N;_@*J/`I,`0AP'+"BC`JP+#)()GO0H$$Q%%P2C
M74G\)#!.EI,H`$PFYYAD`2;B!4))@!%NXH$R"L`YX&V49$)/`I,4<B(@))R#
M(PK_P%F("B0PR0&J_"AC@#EY+J`,"M'1.(F4[$I'0KN(;'".`LJD`0@P/%YP
M#B8D3.(I"APHLX`_E-1G2"72X:;QQAJ/@PLN7HQ1!1YWW`&&&65\(8T33T#1
MPQU,J)$'*5TD58474-A$\A136!$%&4D`\08>GE2AQA,[3+%#*6Y(44427E#Q
MQ!-&>Z*/(V/$<1O'+*58%Q$Y1))(#D?T50H>0Y210Q)44$,*&#GL)4,$KK3"
MC#>._ZS"B">,-&()(XJP@@4WMTRC2`-++"'#$IT88XH-4W!AAA*P@&&$%%PH
M`48WL6RML3D,,$"/<0'0PP\`(RYPY'(X*K,;/1X(8``#`A3B#P`*)"``)<T$
ML,`&`D27XC@+&,(?B9-$"4R<!E5$@KS`4!*`,_ANDD`@%XSS+[X;P9DN!SL"
MDT*X*"34;DDC%$*/!90`4H@^)128PCX;`%()B/HX8X`R_ER*PK9YLH`YGJ6/
M$2#"$$<J1+L.LH\$%((?P0C`)DC@*4",`%#Z\$<`FJ$,!@0C6/J8F*A:Y8]7
M_<-:^IB0!S2ACQ7\PP^4<)YT9J2/%*#`'P$"1@?DHX]Q6/^@6?DS@#Y00)P1
MN(\$_$C/052T`'Y<`!'C4``F1C`@"`6C&2,(%$.RE:!&5<(0XIJ6,C)1"._T
M4!F;L,#_9$4<?BR@'QM8$D,*40)+7(\^YC!`LV"5@A-UH`.Q2L,Z,A$(#`B"
M6`E(4R8L``P0X6-]YX"2/O9U`6@5)P&_`H2'`D0)$O"0!"L8@952A(D-D&`!
MF_C'B0RA@GY4!P4Q=%2#?,0^#_@H`?S8AP4&U`$/*.0?_ZO(D0ZR@1(N)Q@8
MH$<*"M$,%03B1,3$T@@X``P<Z>,?"5A!FI;(M6YZLR3M2`8LJ."%,NQA"G&(
M0Q=(H0M1F&$J>6`$%6J`BEW,(17_>X@:U?90A3+<80H\^`%/\B`+;>P`,FZ8
MPA[(T`M;>*$*7/BG/ZMPASB\PQ$O>`-=OKD26,2@`:YP!-FX,`71+($)4&A"
M-1B!`R-P00I)D,$4YN8(4)!"$5\`Q2JT``N<QB(1L&A"!"23A)I0(09^*(8K
M:L"#(1Q!#+20@A*D(`4PK,,2GM-8,&YQ&V74HCB8^)6*>J2B40F)$OC(A"$H
M80A$E#`8C_I5/I2!"!5@["1MI<2O)E%"$07B-OOP40PS0<5"*",?&_D5E0J"
MB<8.:!(82YXAFD$):&T$$+<Y"#]4L('WG<,/(T`!/93!`1($HA"8*,@^FM$/
M#6V`$OM8_\$DZ#$.<^P#2RI@H?OH@0*!I,DDSAC!"#Q`D690<`3-V,0*[G.<
M\52$`Z%-SJ_^,8(46``0_8`5-1<YD'Z@@"(1LA'X+)`"2H@)1Z5=@1Y+<@X#
MI,"%<$+!.,9S`>(<!!@+@!V4&#`);"'"``GJ#P<V,1\&3)):*`A$6U%@#@<H
MUY:!K28P_@$(1)2//RL(@+GD2%A#!(,`@8@@PM*`B=VI@#B%8,$XTI`"\Y0C
M!,L-K!&=`3YAF>0]YDC!,HF#@H*DR(#T,("'I$1!5-T'=2<!5P@G$5X.H*`?
M"<#'=UMH"$!$9T>+["&K2#`B!>MC$X8(;R!"()WT,=<='C"'*O^5X<DC40^8
MD_0PCIQ!"7Y(2!]9Y:B>XQ*.5X"E*@_M@AMVX8@]V"`)-VC#/+@1!Y)QA@YO
MD$45OO`)'?Q@!U+X1!5&L8=24($"7L##*$0QCR_4@`E,<`4O0-&$EU+T#6J(
M`SQ608,X;'3/):&+,6(@`UBL`@9>4$(#=)"#1,3"$=(`!0R(((4MR,`&70@%
M*7"0@R%XH12[<,,JL'$%4.C"$T_(@0ON\(DOZ(`'3#"#8B!0C;Q`XPI&4`(.
MS`"&JE9#%7GNIM=P39=]YPC7`&\)/O*1#WDT8QSG,,<ZPF$.?HPNX1D++$KV
M`5A\[(/B/?3<.9KA;Y-X[C8$QK/'@7C_$M:*G!\)#VP_@D&/?/##2OR@ETGZ
MX0R4TZ-9M'V0,IHA\?SYHA_V.7@/*>&/GIMC5.<P!":4,2IEV*Z'CQJM/_@Q
M*F>4D.G!R#JT,B&(25A).IM8)CV``8QY;`)*=YI$/_1AV&"40`63F,1M"^&,
M%10B#=V*H3!),`[>AD"^'J=1=)QQ/C.1H!^W2$`F(/;D&_MR!),PET!LMUP2
M.<,@`T_0ORJ!CPUX_GWDE>3_Z+&0"SB#L'F*HP&RR(%S"(2`'AC!=7.D#`N,
M`%8-=,=IFQ$@X6[`$-K;SR8:F?I"4)&T`4]^2M*!C%Q$M`L/K0(O>*&#,?2`
M%+R0ABT\P7TI_^2`##^`'!1X05$H_',4>?C!#6QP!QCH8`^>($4NL&$,4.``
M"D;(ABNF0(6JY/,.^K`*/?`&\)!\=/$*+E`#ID`*/?`)3^!^-&`*5]`%I@`!
M?9$#.%`$KL`*K=$-C%`#1%`$1]`%1[`%1/`%\)8#1B`*T=`%G\`+5``#3R`%
M\08"LX`$L7`%/.-2G3""R<`*^287'<<Q@=5SS7,2^7!K<<%-*5&$)M%S3*@Q
M1K@/^7!S#J<,XZ`,SF`.@U(24>A-_F8ZZX!PYQ"$#^(IRK=G0YB&'$5*SX(O
M3WB$)>$U]?!U)O%(_+"&*\&$7XAG14@/HX-R@U(.^V!;IK,/Y[`CQ?\!B'VG
MA?D`%S<G<L7A#H'E</I0#^9P$/1`+S=G.N8P#FFR#UA8$N:@#/R`)^P%#/:Q
M6OC0#.<0+]\A5ORP=`@ABY7P*^<@5FR8?.U`#-0P!5'S!E1P"J60`TT`!E#`
M!TY`!6\0!4R0!ZEP"ES`5#GP!%&P`T50"J;Q!#K@`I.1`V#`"Z@@4:+0!*R@
M!'N0!,_H:7<0!64P!7>P#Y'0`UW0A]^D:S9@`[!P!2Z@!SB``S#@!N+D"9TP
M!8FA`WD`#;!0!5T@!8M0#D7`%TL`47Z1!%RP!#C`!O10!%8@!;%`#*R@`SB@
M!$1`!*Q0"KP@"DS04EP0"D,`!N7@"&:XBS3_69,I83J;6(8X^6^X40]>>''?
M5(7[\$@MAQ+V:),<980G$87^QD`J$5A.B2)?F`]+-)1"@EI.6!SX<`\$AP]>
MZ37Y4`\I,G!S2`\^:1!6N91RB(1#25L.5PZ><VMDR9/-@`)D]83T8'%XYG!X
MF)<&X35S>909LY9'"(4K881+))A(J8;D0`RY0`5Z0`5)X`:\T`5D@`=38`2>
MP`M\0`4Z``5CL`-T``ZM@`N,P(%NP`C1X`CD5`J*``J@\`K)4`0UD00_,`JE
M(`I$P']C\`;?T`5<4`9E\`1Y<`ZMH`>@8(<!YPM/P`/:P`@ND)E/PPJK,`1$
M``%/0`0P``JSL`5*_[`%.V$$<!`/<>`$/T`U3$!52M`$T?`*35`$7N`%4]`$
MDC`+,+4$4D`$7<`(T/`()"4%8<`%6]`-K3"3BWF@`$</[@"(94B82XD/\[")
M[H`/7`B(YI`/AF@.Y]`/70B(+D=Q:2D77GEQ2HF@)GJ@>KB88PF(HW.@+?=(
M^!!S%)>B;*B8)\J8VA`)3O,&=S`*5J`#-[`$-M`*VI`'%#"<.*$#4G`#<J`-
MDM`*<8`*VI`(EK`+C"`*EB`-,,@$-G`S36`6HL`,H"`%4,`#.D`'I>`T=T`U
MY;`(41`')<I1![$*$.`"/=4`F28%#8`'.%`%-]`#8&,$T("94+`%7*`(9O]@
M->D@#6ZP`ZX@#5C`!(IP6-30%%L@!51PD;/0"`TP!C$P!$+0"4W0"3;@!:JP
M!3&P.9USHZSJ3?A0#YM(HBCA;_.P#^M@#L[`<.=`#H-B<9E%HW$X*(,2<QH#
MB*UZK,B:AK?!E5S3EGUG<?NPH(N(<7&J$H^D#PMZH7J9K-RZ,2ER#;CP"E.@
M!Z'0G%`0!;:P"J!0J5'P!&\`!650!'?0"4PP`U7P!JP@"J)`F=JP"#9U"D]P
M`PU`!5WP!'JP!W>P!%.`!=T@!WO0C$!@!U60!W@0!71P#Z!``UY@H!SC-;``
M`S8P"W"P!#6@"-K0`,*Y$U!0;:'`"U0S!4D@!:7_P'W`X'#T\`H4:@W&@*W)
MX`B>T!5*,`7U-@71@`1&D`0G`P9Q8`4-\&XTV`7IL`H<VZTGNC4SNH>5:(J=
M.#KU4*UZYI>:B!M^2;5D6[8H`5C>RJ+S0`YC6'-$V7"/E'`ZZ95TL9-4R!)D
MF7)C:[9\FP_D@`O",*X[\01DT`.Y4`3),`=2$`4/I0-%T`JG<`K9X`A,\`14
M@`>R\`5T4`6,X`KR68V\0`RN\`D\4`/R605CX`G@T`6_L`4\``2B&0H/>PZK
M``1>,`\!YS6X``-V"@<RD`-5U0I>D`-.4`H-@`-=T`G0]T]2!0:P0`K3$+57
M4`0Q@`,0T`2-,`WT$`NK_Z`(Y10YF/D(M&`$RU8*1U!OHE`*2V`$Y]L-I#"U
M?%NC@.@.,K<2]&`/M+5V]%`.<@&542AQ<UFLA<BQ5,F3\7O`)WJM0HAG$RJ4
M-MH25:B)M]&B+F&L!HS`R-H.MQ`+.#`*<Y`$.?`#<R`-D<L$2?`$/F`%HP`-
MTA`'-],-6.`$59`SY&2-UD@&18`-I!`%=\`+U0`'78!2X28+=P`-3J`#.N"N
MHP`%=)`/#-@$\(L;!*</L-``(`4'.:`#21`#J%`%$:`#LA`'.0`*C)`$9JP$
M7""@L'`/H0`!$=``+O`"<FS%$'`%;`L'7W`51Q"T8D`*7H`#7U`*20`!I]`*
M.?^P!+(!!MP0"\#*-5YS#F5X<"Q:A=8ZEG[8/!AW$`4<P$E)<0CGE96\#[6U
MK5WSB>2`<!IZ#NYP#MS$HIO8=X#XP"41HBXARQA\RTCIE:#LH',(<)H8H[=!
MHX$U#K:,R\GGMZMI!5/0!49P!WD@#:W0G%%`%3[0"[MP![T)"E>0![E0"D90
M%7H`CWM@!4S0!:U@#$U@!Q0;![8`"TP0!5*`!UU`!Z20#)L[@YX`!$\0@#SP
M!<6,&Y8P!5+0"H[``SA@`S(5!4+*"-(0`7#0#5)%!$M0!F"@",FP!1$P!DOP
M`@W0!;8``2]0`W>`@:NP"PU9!H;:`WZP#34@`_"@"$K_8(P%^P1HO#E2NV<'
M\4@*Y\GCX'`71\II^X2GV--:V4V;Z(K*:90V:X]$B7`>-RCS<!!*R!)0690E
M$<4FT<C&O-4)?*$N,<5C6<#_EI?_7)4'4:M!:-5<C:#7``O$4`-GD0<VH`=8
M8`9)T`,V8`<],`?4$`=@<!/.[`3,$`_0X`=,8`6>H`A&H`.,T'=4$`>*``9X
MH!;2,`<Z4`4Y4`,]T`FBX`E34`6>'05O\`ZP``2E\,\N80\!F`1+``MLT`-Q
M4XW0D`,O0,A,X`*D$`]P8*A)\`?((`414`2S@`>?0`K7,`RF&0>L\`<-``.E
ML`I@H`1EH`2>L`V)\`)<8`DR_T`$BC`+1PN\2A`&W'#37!.C0(35-1I8$ZP,
M#:>'I[@.ZU"B%J=P46V_S0+?@[*W:4BA\$O!:_W?)LK)(CHHB&C!<Y@/0#G+
M7WESYU`/72MPL%J%]!*G+8K>-#G5)YH/UH`+T5P&SED$/``*\/<:3\`$WO`*
M0S/9>>`*BM`*/2T/KZ`+>`8)N$`/Y+!2GC`*71`'=]`%GE`-1'`'5N`6GS`%
M=E`!MI`'7H"0^\`(06`%9PEPJAT+#5`#J_`%:Y,#,H`#<V`$4Z`#=4,!,>`$
MWV`*3M`%LP`&$9`#J=`%6Y`'K+`,MP`+H)"F9D`&$3`$YV`YI-`-N.`$1%`#
MX/`(-_]0`T?@&$<K50,:"U[+EF0-HXU^DX\$E4]H#Z"\RUF],<!<J^F0B?K`
MA8$5H2EQ#T1)ORI!UA0G#UWCRCJ9DPVZE9BN?*@-X+3.-18^RQ<LQ9K8E@IJ
MX$:9EU5HAGEYZU1M$/ZM$ESHE0[7H'=XH($%KK"@!%40%*2P!TB1ICU@!:Z0
MN6^@!WA@!KDY"G5&#NV4!W0`"J:P"]_P#K<0":&0"G=0!7'@!9X@#:$@!0+U
M"7NP!SO@!;SPS@BK#Z;0`U2`X6VH#[$``32P"U\`-CQ0NIT`G6/\"E(``S%0
M"J):"J<``U/P"7=@!*70"HNP#/7P"I$`"S3X"64``8D`#67_T`2Z$`:_&P>O
MT`5$T`2VD)V+?3EQ4`ZPT.@37%MJO8>O6HBEJ`Q8V.K^5L!6>;=;R0_EL.P:
MFM^#V1+T$`X<!,GF4*LY_4A<WX3K4`^WZJ"`2'&>Z`S-8*%4Z*M027`@*G)W
M&Q<8)W!QH=6U?O>9+A?'3I/[8"7TD/9[:"5>"YAROXAX=NRSOH0TJ>&P8`I(
M4`9JX`-T``LT$`2H4#-JD`M8,#+Q"7]R$`WZ$`E)0`.5_P)!$`0T\`.H(`W?
ML#<>_P9OX`6*8`IO<`-,4`I60`.IX`I,4`5V8`5W<`^D<`-QD.O?I-JO4*?9
MQ@-)``5)4`1-0`H[4`-Z$`EBC-"S_S`'K4`%+H`'7,`#9:`(V["(=.$(PXL$
MH<`##1`-B6"E,("!L)`+8+`#FID$09L$1\`%M!$+>V@ZQ-R_`&&.'C]W`^GM
M,R=PGSZ&#1T^A*@/7SZ)!@O2TT=/(#V,#>F=FT=OGD-YY]99$U;,7$1YZ_#)
M6_D0WSY\"<OQ.[@PXDZ9&77R=-@1Z%!]-(D>19I4Z5*F38\*Y8F/Z#ZH1*5F
M+.<,(T>/*[E>E4D/W[IU4?6=J]IPXLY\&@5FI*@OKM.F8!W:94KM52LI5:K\
ML/*EQHT?X*3<J`8&2ADJG_#0<56MRPX=-&B\N&/E!8T;/*!(:Q4'#QXO7=Y,
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MZ4>@MO:Y,BDPI])GFE=<D>*)'WSH`99/>@B"#S<:\*0;6-S`XP[_.QSAY8D&
M^,C%C2[D`*<5)[H8998&>N!E%3.ZJ.*(.(B!I@8?DM$!""I<H4('**#XX8U[
M5MDCC[*`U,<2*<K0Y8LDB%`"!R-``<,%&-S()8Q.<EAB!C=8:>"%'#KYXI5Y
M0!EBE6^02,2:9.+X`XL&&C#C&AQDR$&*5A*!Y8@8P"BE"2)P54*).*B)!:.V
M9A*+)X/P8=*L?B+\$*%SHE2+(WPYVH>B$VT<:L9RMAGG'&7&2:B>>LKA!DJ[
M.!JG&&66"<>A?>H))TN9S!GK'')<@HD?%,4ZR)QW\L%I38]DSA!6FV_&><>/
M!HP1PYP9HDH??J1*4ZF"ZW'PK8CP?1FB_WTX-(>?<\8Q*B-SY)''0;,8PDD?
MI)=FZ*"IRZ$77XEX.^AG?<8QQA4=EIBB"A[R<,*&&_@P#(@Y=-&%E"KHH(:*
M!M1`A0I/=LD&FFB@D26.4L!H@`EP2*&B%%*J<<4+&WII93,J6-D!BBE0I2*?
M2**(0T4@6ZE!!E?86"*))&(HXXT<B#"B"U(BB:&&,JY`QI$(7IB#%"QNV:>8
M+QK`@0A7R)&F"RQ:<2$")M+!0G0BL(@%%B1PX((+6:0@8HHII/BB&T?XZ2??
MB*8D^2'="LP1K6":H<F>I@2.42-ZUHG)/N;1#')`R2%(.X<XR&$,<J0C*-8P
MA\^*8HYP-`,3RO_`FET`B#%R:&0D-.O?P(:V(ZW1Y49J0V$*G<8/`SZDA6K[
M&%)F4A'>4*1J'LM(/^9!I(5<Y6()@=A.\(6O'.4#+?IH1C_.QC,>)8B)3,D'
M-XB1BR?T16Y52$45;J`&6RCB!C?(`S6ZD`==F,(&>[!%'/9P"E*0`AO3\`,H
MXN"%5.2A!I?#`Q6Z$0D7]*`*O&`$#\C@B4YX9@Q0N,$=]`$'&E#AB5#4!RD@
MD`-8Q"$'3S""%#Z1@QK8H!1Q<$(W>.""):A"'Y%H`!FT\0HPY.)?NWA!`[:@
MCW(D8PZ.(,<G(M`$?9"#"C8@`BO"(81=;($(.>A")]K%!2ETHAR1<$?_3")B
MI(04K2@O,@?^G')"^44)'^$(1Y<X<@\#6F,<^*B'D_ZG#V<(8QO6>,>*SA$.
M>2CC'"TZASSFX:"#.2U&,WR*^W92KZB`D"TJ1&A"D;*/5X%M*/3@)D`3Y@YG
M",U,1/3(01[&$7,8"8<U.1%4Z'&-<)"#'#"*&D&+DLXQ-8Q)!H4(AKA)%`,I
MA8G<@`6<XC:Z*.2A"$E0`S%.884?Z,`3U9A#-)PPAO%)00^P@,<VXD$/:VS#
M$T_@01UWL(M/F((51OA!#VS!BRW8[11<2$(41@>$/$2RD2_TD2E<4(-=P&$)
M.C""$?;P`Q[8``:?(`43F)"$V.4"E2]H`BS`_T"*8#`B!TWP!`4&<8M;4`$4
MH-C6%NCAB1I(80E<>$4IX)`#+BRK$TM0@A&4T(EUO&)`'GWB5I0QTXK@"R%I
M(^A;!-(/9YPCFEI3Z3Y@0K3_U6,=R`B&+Z39$`H6PR3KN,?)Q@'`=>B(@LIX
MQCAVZ)%RF(.A\_1.1I+D%6MF-*(Y@ZE"U9LS@08E83R:"$?L\2_:!LQL^&JH
M1%`4DA.%HX<;K`J^FO&,<%QM+0Q!4,&B0A&N#*0A8M()53BJ-)7^Z$4/60<U
M7&&$N%$!"D9EQ0V\T(HYQ,((/(A"+W;1"AC<X!.=N(,C=+&.<N0C'\QP1WS>
M\`D@O.`4MH"&&7C@`_\ZF*(45.C!*+X0-RA480I/H,,B7["'FZUB6]"`0P]D
M=ZLJN(("/8A#(O+`V1K`@!'=V-81:&&$5=`C&6ZHAC[(U8YD["`.<1@>*9J!
M`Q<8P0NG:$,LQ"`#,("!"[AKUQ04T0Y'+"U"43&'5HQTI'K<@Q_V/(>`_B47
M*N&P(BG]$#[.T0QZF#0<\X"KC;?1#(B9Z&HPV:!#.%0,8#1#'@TARXE>)>IE
M*,.Y^P2*3CBBLH25=[W'1C;.TC908Y.0*LV.$972A*\CZF,=(C$)!3<=E(%]
MA+KK*'!UKU239J#EV31\L)IR=!66T07:#+%&,$A5ABK(R0VCB`,-R-`*2:S_
MP@I`($PW0$$#&^1!%J>H,2GLH(]MM$$:Y8#&*#XQ`QJHX1Z+D`$4F*`+1<1B
M"C3(`RF*L)@G5,&I\5A$#[H@P1XMI!4ZR`$TW+"$)SR!"$E@`C3"8`11-($5
M7:#!$KH`CF_LH`%44*8B!C$.JJGL'IN0PQ3,`+D&Y.*4;QM"+K[`BBL081:E
MB)T4E.`%)20"'99X8<&6#9%NX\B[&UDN3^8R4V446"QHB5`VFR$3B:WC&<\X
MQY,:4H]WZ$^_S:B[?QL"ZWWB@Q_D`.<Z5`="B2Z-9H]T2GJ3O?FZL%"(3/2H
MSI#B79K,9&".+Q$]AK3$<#BC&>&`RCQ&@C2I^"_3_TM;!S?>\8Y[T,,=&6'Z
MME$(%H@"Q?%/6=LP2,$%+U"ABK)P`Q5V\`17M((*/QC#%+K`C3C,H`:G``4J
ML.$,+=3`Y#J(!#=(\092U(`&0`"'$XA0!BG$P1':,`(-GI"'5##!+R57`WMH
M!3[@@]^#E5;P@CN(!C#(`1QH%R.@`T6`@2D`A5*8`QS@@:R+A&I@)$\X@B?8
M`E!`AG3""'90!3B8@B'``Q[8`750A6SH@AS8@BY@A55@!"-H`E)`@BE0`BF0
M@BT`@VVX!+4(FH&"J#3AB"2\(1=*PJ[QFHM*0M=+B!DQ!VOH((C0"&50AG*@
ML7*H!S1I!F"SMGUP&&<PA_]X>+!Q$(<"L[9P$(9G^"!]0)$"(D-G<#WM2B=R
M*(>$63NFB)J;P3S.$\2E"**=B!\MV8TEC(A[F,*S,;Z2\05A:(='TR^3:*%Y
M.`=@\`=^&#<?BJ!UV`9F()L!Z8@<V0=[*+VPD8ISB#`G(9"I$)-HVQ]RX(9E
M:(4GT`/&*(4WT`$>``->,`)P$`4=T($W^`9]:(U>8(=&<(5XH(@_>($@X`6&
M^)-=8`4:^(%T&(<XZ$$\:`<L.+)>S`-0>`,R*(,[J()[<`25,SP?60A)<@%8
M^`*:DX(I,()44`0>0#]2T($:@(!N>(4AL`5JT($=Z`0]\`%A8018@(5;`(4_
M&`+_+@@%XFB%=/B#+R@'<SD"4W"$*9!!;;@"'U0"'OR":6B$HN"?B!"+-:&'
M`@.3='H'M]@GEAN*>AB'$#&G%BF'>YB'<-BV)RDU3*@$>@(+_"*'=RB'I(00
M`(J1<R`1&@N&8<`??:JTNY"(>3`I<!L'FGR(/ER*XAO$L!3+&(F[%((KE5P(
MS).*'6(H<R`'DJ&'=/+"AIB'8@@&"'K"3%LN!R&'NEL'>9`@&O&8E9@GM!B:
M0S0:E#00S#N1W;"&86`%*;B#*6B,4:B!.T`"1C@%5^"")[@#)A`%?8B#(&`"
M6\B%4VB%8W";R:`"9JB%4T`%UJ`!'X@':M@",W`7F8,3_RC(`4^0A2J(@CN0
M@C<H!T8(`BD(Q*18"$=P@1R8!M@X`ER1`E:``!M(@GKHG#>PA610A"9(`EC8
MA0:`@%!P@RV8!5:`!DN`!58``T58LPB`@W10IO0AA?/A@GOH!".(@5#``R7@
M@B-@IB_(!O_0B)T@)YXI&=7!0G+8AG<P0)Z@"HO9!B\L!VNX-GTPH+8XB7$@
MAQ.A/3GL4`#:(12QN\'+F&7@AI>0O'5@A]Z;A]TCAV?PA6`HAI;PB;NX!G'X
M2]E#)[FKL)[8B2^\&<T;RR+M)9XQKB$5OHA0FH,:"WFP!FLHAF9H$384-0R1
MF')HAFU(B&W0PX=`D;_4)XE8/?]9PU!Z<`9@<(9YJ"ZUN-"C"#T?=1#!FZ9W
MFR9OP`978((F`\Z_Z8(:\(19`(.?>P(=J()CB`6"XX,YR`-H"`=&T`)Z@(4F
ML(7GO(-1F($74`-DZ`(=L`,O@`,W4)_!&2,JD`(OJ`(N>`-[6`4:>`,B'0K]
M484&@(%D``/4$KM.V(4FL$Y6H(!X[)LKP(/VM$5:Q8,C"`/=\84K\`,DZ(0G
MB(`X4#\\,`,O``-BT`4NB(%5^`(92().@),?5`(PZ(1(:`5[>,EC$`8A*H=;
M.X=GN+6@6(9,8`:(>`=K*(>8)`<.-3"&&`=N\+UR2))AV`;_489W(+QK<"!]
MN(9@Z*W__**E<+`&>K@'>Z"';9C0L!D'9\`&;#"9=2!!:R.+$BE,V<LG`M$(
MD,@:60P*:ZJ)K1FH^C+2F:V+<>")$H%0"#VA4K,FK^S*CB!#E_`2(M2O=XB'
M=[A)%"D\**G8AMDGC8"\CN$[`!*ULL#$:GL(3#P9'W)%M4"+A(!3?7B')<7"
M\H**?%"':H"%69D"+[`"(S@%7B"#-Q`%.,@&(XB"*#@%?8@%(K"!5)@#/'`%
M:A@'91`:9:`'8XB#+DB%''B!MEH%&X`"(^B&.,B#.?B!A12L*AB#-ZB"4;B'
M1'B!*/L1&],'4'`!%X@&4$"M\`$%*9B![YP%%_"$<,"".?@$_S.(@U"(A7V0
M!2+(U//H`268@1F`@!K``3Y8%3@(@]TM!22P!&EH@#CPABV0@B)8!6[T`N8C
M!4=HA1N)IV'0!,-ENQ<)!DW8.Z_A"F6`A%N`"&6X!4WPDF<`AF!PB'5HAG+0
M0Z=\A4LPAGHXAOY=AW=8!F`0!J8S"A,I"6NXI_MM!@OAO70HM>HBAVMX!F%`
M!FN8!G*HM+3ST'E@J;"@FG48VH$"D_8ZBA*BV17VD=LS1#`Q&T0T4,3TIZ@X
MF"2DX0>1BG(XAX4!$7*2&*2]!XFI!W+`A(D=O#FE/5WK4+S`!RFE()>8TX,P
MJ'HY,$=TFH)!$RWA2BW)AW&`AE60`O\R,#G*+(4NF()4:`57^((XF8-OT(5P
M0((RR`,FN`-/^-Z%\`YFD",F&-8*X`5F$`=%,`(H@(-8^(10L`++,0(J`,X[
M>`,Z*(>.]`1.<\?370(HB`;8V((ED`)OB`,7F(-5$((]@(5'V(,X2.104`56
M@(5U4(<YH(`7B*5D"8(>H`)N6(=5<(7+`H5.8`3^[*(N4`06RX%=*`7S`0,O
M2(166(4$P8=W6(A[A8HKB;1*\SUA4X:AQ1=W`,-M8`APZQ@3.0F0I3&0909-
MP`:36H9B8`=:N@5@R(0:C>88*5S\F5,>AI)Z$`9?>`:*%:YI$(9IB)!U*(9E
M:`>J2E^UF)'_@Z"'IC%34;-90RQ+CW"*Y&3AC`:*=8J(>E#0%)(9F@@)G/@)
M/9Z1EW@))1&)I!2)=*@'=E@'9A#%L#F9AW!#FP6+$GE*=BN1'L70C+@'`3H'
MJ2$ON3BA>WB1&X'5KN0T=(@&4MB",O`"RJR"7.@"%W`#4[@$(`"".&"T46"'
M1Z""4<"#*K`"5(@,;FB'G#(Y.I`%/'@#?;"%51`&1:@"(R"&50`%&[`";>B"
MOAB#*J""`,R%/0`%.TV*59@",1B'+\`5*'@%1W@",(@$.&C.A20%3P`#/""D
M3B"%5[@%>^B&71`%4<`#4D@&=J"'9H@%5@@%4)@%3^C>3F"%6?@#_PHH@EQH
M@O;\A2/HP2-0A'(80C"%/4MFB+/DNS0QKJ)!)TRTT!:BEW-PAI`QAWF0A[B4
M:6'H!@Q%D\)]!6:(L'00AF#80PQMF'M"!DLPAF$0!^TJRA-A4QX-"W=(!VM8
MB"L9+QAA*`B]XJ3PV4[3Z/624IIQAF`HX46TAE<H;X=H!U]`!H@XAV5HX)JX
M/*&@AFL@&G$H2J`06($X$H+YB+A#:@>9AXRY!68`V7<XB04GAV*0/(>0/8;P
M+GP($2HM"NX^KBW$9J2VMK?$$`'"ER_\497$F7G(A\=TA2KP`K@FCS9HEP*D
M@BB0`DF@!SDH@U'X1A=`A5$P`CX0!3X@!?]C<(-/L()/"+$;6"4U<(-U`(4C
M*`UUB`0>.(.0*P,R?@//7`<YL`$J6.J<?80&D`%8"`/4:H)M@(`JZ(10.!4>
MR`%6*`<P4`(SP(,X8(56@`5PT(5R>(9&6`A@B(5ZN,MBR&Q%4`0Y`@-8R`:Q
MXX(P\(1/H(482`16Z"PC>(1C\(6NG.BXD*`UJ>Z=8%-T@E@:HSV@?&=^^CME
MP!#3:XERP(1B&`9,J`8MY8=WL`E\96`5$>^-*09LB(170(:;)(MM((MQB%<$
M:Q$346YJ$`:>X8=R0(B8ZF*@V9\UZ?,`WXUZ4(FA4`9,D%I?;X5&P`:($`9+
M>`6("`<#AI)Q.&#_(&V(9K@%<!X'3+CU?5`&7[`&!ED:+1QR;XJF+?8(DZ`G
M<E@&`V>&<0!MD+V':SB&K920N/0A$WE8U3$N:Q@BEQ:)=SA*#.'Q.:WHA<)H
MI7`':E"^6<$#3-$&5X`"&P"%5["!*OB&;F`%//B$48"&;$@"&DB%3AB%/.`#
M7C`&43@%13@%Y7`%;P"%T7`%;OB&OZZ&2("`'J"#M86"!*R"-W@'4N@!-Y!9
MI5`%&$@":-B"&8B#Z&&S+F"/!IB")<@Z5]CL/``#3^`>?1"&6!B"'/`"15""
M)7`$7)#\+U"$3O`$T?`$:T@$&S"#^7N".`"%)FB"7?`$"'@"4*B$5@#3_Q=Z
M5W(HPHAP!E\X<*#9+GTHX/P"B3G5AWE@AF*PV?\1&8G(MORMAV8`AE=(B4D(
M!$@H!DH0AOZU!&$XAF)0URA]A5>PA%4PAN*6B+$E"ZSY:;(\!RO<"6M8ABLT
M0O?I^8RH=WO'?[5()Y6$AH*'B'(`B&7Z!A(<>.[<0'/DZ!5D6%#?N&#I])43
M%FZ@,VH,\SE\J.\<LG$>"9H;1V]?1X('Y:TS5V]?PV+%E@G3Q(Q<N70.]^U;
M%N[<NGOWUNDSAT_A/7KDT*VKI^]=4'SERA'5AX\@OG/CRHTLF*_KP)1@QXY$
M%XT5GDYXO,1Q187,%'98:$B#A><3J5)Q/(T;9_^$!P\:-&ZD>D*C!Q0U-J)9
M8[4W52E(R5PUH)*LR1X[KKY`N;,6SSU&/#J1+>WQZRH8.)(-@4)J51(OVXB!
MV>'#BQ<D>-"!ZA0G#IY5OH1UD3*E3)(D>*YPN6(,%QA&H11]*M7/E9$N>(PD
M>4-*&IPPCVY)H:4HTBN"^[@^G&;,VCFQ!-<A\T7.X[RK5JT%([KO*C[KS&.5
M/O0<(\P[0YF#U7_FM$-0/,7@HDDUY=!S#C"7"+(&)*]X8PTRKP@SS3$BPO**
M->V0,TTY^NFS#D_DR#.2/-:$X^)`7UUC33GQ@86/?O=\5)5'^,AG&DRF*;DD
MDTTZ^:23/.%(4#DBZ?/_E5=78MG0E$P*.9(]#QDY9H[YF#D0/LZ,\]]([<PS
M3TLX<K3...0L@XPEFI!#SCK6C&,-0U42J8\\S83SI53>)$-,-P)2M`X]?9KT
MT#WS,$3/D:9E"F4[U)#RA6]@N`)-#C2T<HL=IR3#2"FEM`)*'K+PTLTYBM0P
M@V`TV"`8#UQ0LPXLIRCBR"FGE&)*-6]\THVM-+CB2!1VX`%&'OO$(<,;6T+Y
MT%>@--#`+G,D,0L8,>00QSJLY%7#$5T0$4<NV<#B21WIQ`+#&$\H(44.21AA
MA!1X0!"+-9A]HLTNKR`A!1A*>%'*)\F4(@4,1.CBR1".3+,*0?3@*&0]YP`Z
M_])1^LR#T$/K3*E?4VRF3(Y3!:F\CSE)ZF.//>L$(TR8^+SC#3O*-`*)):^\
M,LPU^B1SRRN74#.?BL?$C%4XX=A<4#O6D+-@05GI@Q*F6`;X$,TP<CT2RMMZ
MJ3;;;;O]=6GFB#,UVM*4\V5!(P]T#SOZG=15EP0EA3>:A%N53SWT?'4D2FIV
M51*,=`\D)57T?&G.)HU0HDDQM]RRS3WOE,,,Z?FY0P\US(PSS3#87/.G-<O@
M(]1\7,^C+9IOLTW.65[L0447N8B"AV446%$*+Z:$,DJQKKABBRWCY$,-*'`\
M(44577P!35*SI.)**)Z$DE<INLB2Q`[:-#$%+\,T<?]')UWD80\H9<R!.]M?
MJ=+)',0HDI82B("'!N3"#6^0A!2,HP0D(*$+XHC%,I8!"@I000J>B,,1I$`%
M5KB!"T-0Q#6DP0AIN*()8E!"%8P0!2?X`@35R`$>N%`%1G@"#*VP!L<*%#B3
M#6@D].@AR;J2)!SA8T9"(2)1UD&D>EBC)?'HV#*8DA!(0$(8WGA%*Z*QC&V0
M`QFRZY@UBG$VDEQD2OLXQSSX`107K6-&`^%',U"&*3$!Q6I=V=0.MY5'W?&Q
MCS>STEC&L0ICC,4<NL`%>PJRD(&L8QBW2&17^I2I.19D',I(Y.)<M`]W>(0?
M<.)'),<Q1H*D$5,X,@=0SH'_"4@LHQS;>(<P+J$):J2C'*_(!"XNP3IK6,,8
MW"#'.\+2E"+J`V_TX(<I^;C'L6S)3.3HAEON((5=F(("ME#7$Z*0A#S``Q:C
M$$6K7'$*7FQ#&=-0VC<&<HQXE",8U)@%*F3Q"4]X`A2J^,;$RO"$7KBB%#NP
MA2EXL(<[S`\45?#$IIYDID.L@A',Z(01OC`%'$P!!*9P12NZT8H&)"<)4UA"
M$U:A"!@,`0F[(`4CX)"+7&#!$:SH!!*($`-&O"(11U""$I90!2(XH1S+8`4T
MBB`%(\0@#GJ0@B-@08P"`?(A[T`&,P`W$'F<@XWR,8>AS+&.:S`D2>N(3SI4
MIAZ6_XB)1^^PQS800@]F@$Y([R@&H&R9Q5@D(RS*"`?=YB$,9WA,3"'#D1*M
M<HZ%"&D>AR((1\YACL5VQ49.DEQ#%.K'R5(V=V0QAT7&\HY^,".8#S&'0^IQ
MH)@%#A\[8M(XA&&-8B;.(S7#RMDF(J9[F&.U(RD&7ST2CMBA[!S;J$0F7I&,
M;G01&<GHY2NF,;>PH".L]6`C48R$%7[HYVI?NTI"E?D0=+S3"$^0136Z4(4X
M+`)[0-B##TYAC$[LP1.=^`0M\I`.>^#S#G&01BNH0`=P"(@1>2A%)SQ1"D_,
MHAM)^$07O-`%3S@">\QXPP^L0`=S)((&7;!N_O21B`C@8/\:6U""$=("AB7P
M8`DQZ`(T7+&#*DS!NS;0@0N*((U=;,82VK`I-$`!AFBT`CL00$(-EL`%,92A
M!J#`1BR*``8B&*$):@$#%\RP"DO`0A^+]`@]FG&,;7AD'Z`<B#4RT8PW-G5R
MPGC%F,,AC*@:Y!GW<,<TEN'9?33#C5A1AC5FMXQ7`(,?Q=@(16ZQ('HX8QO'
M",8QWL$,E-VC+V+]VC+:8347`0D?^YC'<QFIGZ.0XRHP<VTYG`'$@JS'TEW:
M81XQC*3*LKK53ZHN[D!;S"OA`TO[,!R:[&P:<Y2C'ML89<?0=#64-&0?\L@*
MANO1#&44Z:[[F)H]R.$Y9B2#&=3_,`8Q<!&->@0V'PG2![?K`15-XH/;(^&(
MF"XUR<KFXQK&8$0GI!`-4MQA%-^(!1AZ\`0ZO.$.X,AQ'CPQBE(PXAW?<(/O
M]G`%+]QA"FJ0ACT2(>!0A#,=<)B"&89:!>%XP@ZK2,8./K$'?:S"!G'`G]J^
M$HH9$,$;C``Q%XA0BEWTP`P4F`(%H)&+/.#`"#K(@12R08I7@*(+5SC"$#RQ
MBB.`(0SG<04KNG&$&CQA"3GH!"G$X0<Q&$$12_"$*[BPA;&#@12MB$5?P$(G
M#%]H/LIPR%74'`P"Z>P9,*F',\8\D''TL!S-@,D\]*:>9=Q'2-MX!2:^:";,
M$N4>PKB%_S*:88_'C^,8R'!*H\=1U<E%%TYHXEH1P_$@5!)H;Q_1=4'"T0SY
MX`T?_,#U2)#)1Y2[NO;*7`?M3_,0^>0>*V`9=9#>`>R.36KW6/D;N)VBGWH<
MV_.:;$839RVD<12#*XH>AC"2L0VM4<.S1JJ3X.A1CUX7FTFN1WX0T[\M;$1C
M%4KX1#2DH!Q>+",7>J%"'NRPWV_PHA2RB`,W2((;4,$;5($T1<$;X$$4W`$C
M?(.Q7-0N5(,E@`$8[`'_E((QS`,<0`$7Z((C3($4Z`,HV$`I7,G;?,4^_`$,
M2`$\?$%.@2`8K$(1$$$.0`$/E`$.D((7&`'6,<(?$($-*($,Y/^`"\!`%\"!
M3.5`Q<@4*ZP"+;@!$QA!*S@!'+S!$DA!`&'4$$@!%W#!%,#"-+R"[)&%JIF@
M[RD#(%S`"%P`)SQ;4TQ.Q^R#HWB%/(3#H%S%0>3(0$S#GPW$^"4#5Q`:-T#"
MW`U$.0S#-'!#-=!#,/655EF%&[71@VR>'YK#3Z@:9MW.2*#$.`P*W(3%U6P$
M[FP**?Z([9UBDUQ([^D#-KQ"-9@AEM5)E]C,.Q##,ES*UK2)'17)132$<4$6
MFIR#,GQ9EU5:05"B8;7#?^!(?M"#-=@,MY'#E[@#,U0#-R0#9X6%,'`9FI3#
M?12$-QJ.I8W$<XF%D7"2$'5%/I2ADKC_6RO@02F00ADP'!5P@PB4T!T\017L
M8RE(0S0P0NOH(UO$`1-T@7+,0160P1-\@S2<PBYX@RLD`AA\`FXX037(`3?$
M@1H\P1U<@BU,02JXPQ?@`",L$Y-\13YLP0L403<@P14F4,`D`Q,L01'D`"_<
M`C7$@1F$0A=`@`R4`0Q40<B]07$0P1ET`1T801G(`!3HP!"$02G,P1=4@RGL
MPL7E00RLPBN801=BG!2T`C2TPFO=D6>9'F*AB4,`@@48@D-L@"`42-J$!2B-
MVCTLA!R>DE:Y2#W<`S*PAZ60PT34`SE0P^>8X%?4`S5,`S:@PT*\`W;-@U;=
M2##B`WR4GE6L_\,S>*)57(-T?=:"&$FF6449HI^8T!X[XA$JIJ:F],,>X<,R
M7$)=@84Y&$,X`)O-C$,LK,)]6`,P,-M#U,-N6:8B805@"H,PB%'7?,1@!0YD
M*LY#S,-]R&&G>40]D%XB`:="8-XV!$-GC0,W<`4U<,4]Y,2L0<0W$L0[@(YK
M`5N:'(FLN1H_[$,^6$,TQ((7C`(HZ(`5.($50$,GP$(V<`:+>4$45$$N1`,Q
M/($52,$G[$(K?,$LK`(HP$(<4,$4=`$O@`,O,,+Z3,$80,$;X((T=$$U%$$<
M0,$3,((LZ$$>N$,EN((IF*23>-T?6`,2),<4<($7B,I+$0$4[$LL"/_#%60<
M!-``*71!*=@"*LB!)`S!3"V/+)00&"CA$61<+N""(WR!(@A!)WS!-TA4&."&
MV"E"*ZR"9OHA/$Q#8=;#-4R#RF#)5RA#,#3#!I"`0^0#/SB#+^A#.&B",,P(
MD*`)$#DC,D0707B2?"K%,XC1/3##+8@$C&`*5-2#,6##@N"/.13#*Z`#10S6
MWH0#.?0B08S#,FAF.&0FW>0#RJ`$/V`))5D%.5"7<&+%I,@GJP6J:N:J*9(%
M/7!#F("%4ISI&.I#-"1-@606I006R?C',NK#->B",UR-0@R:#RU#F85%&I79
M5?P'C)C,H-&#YB6(/91#,?@6,'`C/6P1,[#_QW?"83,XPV\R@WPH%I99R&F,
MY9*L8OIA@S3$PAV\01Z4`1Z$@1TPP1PX@2[<`ATHAQ?@`7]R@0LD`2G<@BTL
MP@A)`BNP`AW$PBZ`@1C@0!50017H`8LIAQPL`QR<`AU``1@0X(K:`2-T@R24
MPBGTT5<H0AF$03OXP5`U`1[\;!ZP0C5`&;],`2F8`1%LP2ZH02X,`T]N01)H
M@R>00C4TP1?,P2I4PS)P02IXP1&0:1@LP1(`SS?D0B),`1BL!1<H070D%5B4
M0SPLPS"(Q#V<JCGH6D\$`PD4`DR4VS@.Q#(4C3/@2%_YX3(\0U8`"+$5R#U@
M2#&$B:.^`M_I@UGI_P,6#4CN7<,K($.!-`/=#D0PP.N6F(,R>.)+?`2^7D/,
MT,-[,E9#>$RF\`,DY8^,ZJKMFH:VX(Z^AH7@Z.&V5-6CF>![=N9`C)I5L.ZE
M[MXEE6=8G$,]3$V`N%XZ8-=X_MKH"`.<'FLYB$Y"C"7-&`G>N(-)7$WBNE9<
MLDWM9@E]VD(9W`$5E$$GV"<95$$4[($MM,(<Y$$.M&\1=($KZ`*PE((H?!,C
MG,(HZ,$IV$(ZY`(HO$$.W$$5_``>=`$LE$,G*`$9\`!;A`(>Q,$=[`$C<(-A
MY`'MG*`^^$$#Y$`YN.#:FD$-_>R%Q@$.R$`-)`$,[``CN`(L*$(>Q$$GX/\&
MUH&"(ES!%Q1Q^)`"-)#"#N"`&1C!$#2!#RN"&4!9)X!"&"C!%GS!(+6".G+-
MU,@>,7X%)7"`-23.A:2$8&8-:;[6WZQ#(_(NFHC#.I"#.#C$.B3#,3#$.1S#
MZ8P#-@"C1\B#,1@#3"@#,KCJ*W##7OHA0FC%\J$,/L310(0#,6H:\S:$,J!<
M'F4*\::;.MXN*(?%\)5)43!#XUG;2*1#/9S)Z^:(*+FJ1PC)JWZ6,,!$)=<#
M,[B#/?A(9(7%I*BJ4]%#CXQ$,)QO;;F)(6[-4!S#ZF$8S9A#6,'#1UQ%IG5R
M@<SRU^`/S<!A<KI:,#%#,52#%+"%-!'#'*`H%?#_0`^W@B14@16\@?_M0A.\
M`0]$@15$@0^X0A?\@#[N&Q6XPBZ$@AE,`1-\@BL<J0\\P8=F$1>4P1L4:![$
M@Q?,P!Q<LMN`P0PD03+@@`U<81(0@1041P9UP0Z<P@X8P2E\PQL4P1:HA8X:
M)!<,%!50`1A\01:_`1AL01QD0RP<@0U\`A/'W!%L07%0@1=P@10,02M,@R-\
M8D.<;\>D1#!8`+S>A#NXR%?0R3WH!RL[15]]25)@,TY<C35X5CT40R.>0"$L
M"3R\`B[``V5BFE>SU1M2KJ>)U7HT1#-L#>H![O`=4^%VLP\!#B>'LF%WA>K!
M7D$XPRL<@SZX@R58@GP<_X,Q_&I!\(.5K(-;QPP_5+(A'EI?)0D<U19$O`*S
MY4,X#+(;;V+QQJ>0G!'Q;</X,41UX8,E<;,SIDTX`$."'$@P*(ZJT5D3;2^?
M?(13M,A#?!GATG9R2Q7)C&;ZY@APBH,I-$$9Y`$=Y(%!1T(1?((.B((CW$(N
MQ`$ID$(>6$$*Z<$3W$`<&,$8U"\37,\3[$$/5`$>@$(J>(+_.@(<@`(/?,(3
M_+,KW,&_TL$8D((]Y$$/B(+-Z@,<S$`3,(,I(,\<=,%$2D$>[*!O\($TQ($-
MY$#_4J0.=$*\8<\4/,$45($4=$(H'$$<A,(7S*`2M(4I_.P1<`$>M/0=;,$<
MP/_!=$P#,G",,_9A0B"$.>36?$#%,&09!RA#@C1#(M%#)C#$-@A#Z@`?)<*$
M-X;#M1:W>B##-4!#,`&#2`A#(ZR`!T#U:7S)*Q`2/12J/FC"!;``!XP#/Q#%
M.0Q1452GM(8#D3]$+F)95Q4?'#,).QXVHG^6FNLA/H0#G-M#,D3#2'`#-4`6
MG0T$.>#"-+BJ?+R5WI&22NQ#.&#"W-$#,!B#,&2*8EEV\U[)&>^=0YS,WKE(
M?GR1:$8J,P2#;9'%-2"#4#RBR13(U&17QYCD#J%FD\`#-8Q#T>T!'N2!*.P!
M*9"#$QAD'C!"+J1#*\1!*5!!#?RK$?#3+)1"&?R`#XS_0BH82P+=00T4]!R0
M0C)0`S'D9R@X`3BX0AY@M[,_@2GL0QO<0%/OKI)\11>\@`Y0PQ4XS+],@1=P
M(1:&P1&P0A<PP2(@$!7X\!/\QH<]`1>`00*%`8F/LWY3P1PT@1M(J`\/P1:$
MP8I[P14X0B2(%#)80WI8PR58PCD9Q((T0S$T53PTJFEO0##T0R;PR#$N@#/4
M0R8XTB5825;?!S^00'P\GC``7^#9C#D\PS)DVRLP0S]`!"YTP"8$PI((13YL
MPAH4`B%1@@=0@CZ0`-DK1)XW!#ED@O'J0S,T0Y<81<D4Q'L6!22/\K"*2:(7
MON[<0SY\R2@*"?Z,F3-8``9@_\`*N,-7%(('Z$,P;,`%6(`#!$(A)(`':'XS
MD,`&>``)K!8_A,.@L\,\V`/^8+;-T,,_D``FC,,_C(#;ZP,PA`"75<):4X(@
MT$,P!((@J,`D\$.H^@,*3,(\%((@A,,R0((F8#XB8`)94(,P#,1>"VK7+,@H
M;^*1_&V7O1I86,,TT)L9Y+LBT&\H1,,N2`$=,$$5V((KT`+\5`\X7%0IW($H
MP((7D`)`Y(J3BE<L;7"HO`$3!Y8N*DGV/,FUZ],1+W@^X<GC!8X^4E5`Z1,Y
MDF1)DR=%[DNT!T^X(T2X&)$BA4LH,$FFA(G1!8<41ZXZT8FSL5.G.%NZ>,+#
MQ4PG//]>MG@"(X44,T=FCL3!`0:,$BI@MC2APH@1&"*KML'2=\^:-9+FS.GC
M1PX?27KUUCGCD$G?,V'\2BI+,.X=N7?-@M652X_>.7TI&*Q[=XM:/9+U]NF+
M*](<O77KQFEBMBT=O6'!+.Q%.7(?HD+T1"+BL&$!I$L8^KFC1X*3OKK!@(E4
MK`^8,M@DS^UC3'+?N)&=1X[#YXX2['WFZ@XGF<_9<9/>369>/9Y\>?/GT:=?
MC0_\\W(E\^G+MUE^O7SQ2\;=I$"9,`X?1+I``'_X468$#IBA1@)`S@E&DW,6
MH`28%!*@KQS'?&M/)'XVRPP80,:Q(!`+_-EL$@`HT8>!$?3_(2$`9YJQ`$89
M&^L`F!$006$2&0U@<8-,.%"&O'&:P><>PH0[Q[*1\.FN)'JT$VD>]M2KLCQJ
MILG%BRF\B`,//.ZX(X]33BFE"AZ^>D*'7=3!Y91>2@$##RILL867.2[R1)9=
M;.FFE1RFF(,*)O;0HQ1;2'$J#D_R>"H/1LY1Q`Y2K"0OGR^2,*(<1Y;(E"LY
M.P%%$3RF2$('*G)P891N;F$%%#`4^6.+5$HIQ9,FRI#BC5%(8>4;4&(8X@LB
M=/`BCT\^\8*KC+X(`PPS5%GF%936T7!#V#9`1!_I1%K2LDE2T*>>>NX9B1Y_
M8*L+DQ9(F(><=?0I321Z-ALN,W/N__F,GG+*8<::>A;@0+S5QC%DA$+T&>&#
M=_198P,,FI$/PHCG#<XW?/+91QE^SH%.GWV"F>?C?42>E[EQR-'G''SXV<2[
M(^E[\N.3K/TXRDIQSEGGU<RYYAJ3\"$2/Y*FL:0;D[B!A1G?NHEFGJ%'XC"3
M#=)Y)Y@+]*&$A$TX$*F00/0AAY!`_,'$F7T4Z$<D`R;1;+EUN+&O7)/>*RF0
M%`S98(1)^CF'$@52R,2"0LQ1P1`4S%&`A']2:$:99N8)A@02VO;@'$-6X,>#
MQS`I+Q@ACYP;GW4&#CMFW\HY75P,2\*'KI/.<6YG^?39YAA/I!C#"SV>>DJ*
M+CYQ@HHXGO^XPY17&)E#J3PZ">43,5'QY`T]\HBCE$<]<024-_8`H]0J*IIB
MHSSN>...,:KPI)XM:/"$]MGQVZ*!)ZAI@H<EIN@$#"](<04:)'2``QV(`A>@
MZ$08NH"$:+PB%J"(0Q=D@84OV,(-;BA%+J#ABBL\X@]EV(,NX+"$)82A">W8
M11S`X)1.=&$+7'#$,"R!NI6-Y!SPNDY)G*&/0FP@;)F1ATDNT#E]\&LDAK``
M/O;1G`T``F''*4=F1E>7><0E._E:!SL84XYM'.(=XUA`#LUCH!600!_OH$<*
M!+"-8"Q#'YNX`#_HD9EPD&`$>Z,A8.C1C,V88Q_Q84]G\$'%F:G_S!G%0,DX
MSF$MQ<21)#=CTNP@N1Z;?2P?V?%-?*"6,WI8HVXE(=))K-$*;)1D'P6<ECD8
MZ`V:*2,3'GA%(_RQN1*,(!,!\(<^&(>/5A1C!!NX`-@4X`PD8@!A&-K',H11
MCG?80SC(&4E\`$%&=$GN'QL(Q.0N4`A#&,(#*%#`U`R$B&`HH!##8,$\4H"(
M<;`($R/@!]8"(<3QT$,8VQ`7Z9XS-]^PCDDS+,GK3!(.P)C$'&`$FGKB,XYH
MM$(2KF!$$[Z$ARKT;A36FX,:^.`)+W0A%'E0@R="808UO*%Z4GA"'O+`!8S$
MP0FFT$45NE`**IAB#UZHPA0>F(2$>,$*_Y+0!QAL,(I(OF\+,Z!"-X8P!2YX
M@0M2>(0ZFD`$0+D"%^,@Q1?BH(0&+`$/$#A%(F;!"C`8`0=Q8`4KBA(#/1"A
M`4K`PQ>,`0U6Y,$)0P"#'+(1!R^X@1&.^,(18+%`?<P#$YM@W3D<<PUCC-)<
MS;A`/S;S#&"$8V;F:(8",$0/>\8%!2001G`"@0)G^.(MZ_B7</R2LGD@HQC%
M(,<QA'&+<2Q#&>7(P`(ZQ\CQG$,`9,P'PSP@B&9L`QDMJ@X^SM%+1$PB&"-`
M`6P0$8#<GJ,?F>`CE68VB:Z-)!,J"-HSR.:;D=RC+E`BR3W`8]X,27*H[;52
MZ:R$CY)]9[XDF?\'-_0YDG[!*VS1N$8F?=.,3%R`&N28Q`::D0`5_,,"*]"'
M"@"1#V:L04@;4@!E$]>YX5`#&??(ASWH]23+0"D3#$A!(``Q@B!^[!`K0,0%
M)D0"9^0#!2O@`&,L8(A\0&B)E-@`"0"A#TR0<06%&('LR*/%<;W+DN)MYDGP
MHAUZY'<DZS!2>&I6I?@L8Q@-W(5,OZ0'*8`)>`.Q!17"P@1/C*(*51C%)][P
MABB800IE*$,>4C'F5-P!"CIX@A>DP0I&N*(+A7K"*?+09EX0HQ7)V`<8>L"(
MH6*2"C.0PC::X`4H2$$)76`$%XA0!C),@117($8<J-")C#PA!S9(PA#_NF`$
M+\R$"TB0`@3*((,EV*`*<2@*'(C1B%T<@2D[`$4HPJ`(1GP!#D?0!C5BX1M-
M3`+)'0N;+RB;$GQ`&#OZH$<P*K&,QL`&$!8823VL00[`D"`8OIB$.2Z@B4P\
M@R3D,,>4NB6,5[!Q'<$PFSZ$40EAA@,?"MB$,,SMR)(`PP+ITD<P,$"/6PBC
M'IO80&,8;@B2Z7`$@)!'(TC`@7]X6Q\HN$`P]`&(X&2&$P"HQ#[J@@@`!((?
MX\B$`;+-)(7#UR[N]?F31=*/36!N-A:XP`9FXX$+C(`$A@@&Q83#<_@]<SL`
M_@Z5-Y2)@'G``<U(@8/=H8P%F..:(K%``CC0_X$5\!@%"0C$/@9:DFW8$V@L
M,T<^QA$,?Z!K[_PHTCB4<8YF[,,9P$AD,:RA#)'Y6RZ;*`0G@I&)0@#&LML"
M1(7-4X]VI(,NI,-'7?;!7\5@5[SS@.,C:882<SA'X>F)CS6Z(0J5EN$--OT$
M3;C@"2I$00U6\$0VK`&'/.B!$8WZ1">L<`=:F*$,=LA(')R'ATYH`QIQD,(H
MJ,`2+SQAS#-Y`A6Z(`5&X&,++J!4>_/A!1=L81U_D`(4E!`#4^S""'FP-0Y(
MD:@I&.$)G8A$-9P@#HR`!W*`"&(@%+3""$SE":``"W:!$10A#(B`"6+A"T!!
M#(@`"4!M%E9!"<"BJ?]6X19B:,=.IV3@*Q@20+<X8UN6(3,,@(Q$XAV$@1X*
M00$2H)H,P1\X`!'\0"3B@QZ6X8=(0ABHX?-4QAI@8QR,81TJ81P^(,CTP0+:
M9CPR`P4,89`&9QS*X16H00$P81_"00%2Y!G"81\,X`K[80/((06$"!,4P-_\
MX0+FAA,2H',$"A$,0(BTKFT(;B3JBSE6(^[0`V-^SCSH`1,`H0,2(`%(``7^
M@1(JP1^$0>\FH1",;`,20`%^"5W>1SU&AUKXJ<JP@9FL3B36@1S$P5JX(Q,,
MH0D?#AC0*VOTCB_T01FVR1`F81Y\P1"R8!,^AC$48US681N6)#^<H=MZCA[_
MSD8X4D9EXH(>9,<<ZF$<UF''C*%)4,[)*J4>CB$=VJ$NK`Q#D.@3YR4NZB&S
MLHPU4"+$(LD;LB$9]&I71.%84.@1>@%WF(`*JJ`'?F`7?&$51,&`\"`4ND`4
M9L$5W"`/6*(4YD`26H$5YD`*]"H'>.`.4J$)@`=,RB</S$</X*$4]N`4)DT^
MPJ`,P``9D$`)CL`,S"`4C@`&O*`&RD`5ID$+S*#5J@`&D,`37($=="$/RL`3
M0.$1'&@.0,$3<B$95H$5##`FBB`40*$<$D$1EJ`3B.`16H$+N``,M)(4K$$M
M5`\E4`!L3D(9Z.T?`"`3D(@>CL&0@*$#+L`7<LCD_S@`ZLHA',I0O.3ANKHE
MB?)E&MIA'7S!FF9&&=*&/,[!`IPC/ISA`HYC'PH!`T1B<N1K'IZA`U@D83+!
M&1+`,8#!`&Y)&?*P+\[.'"AK'BZ``2@&-0P`0^!BL%2GO%`"9`31/*2N$$DB
M&/XA$_=&;="C8$9@$0L!C)((/>I!&82PD:RA!4N"'X!A%:!AGEZA%<(A'3+/
M&C+A&+9E&H`!R4YB'YY!&>"E&7S!+33F&)8&GQJI'=S"))I!21I)'@1OH$+L
M-<<!&LN!':ZA/:,$YM`C/MYA&^2!8O"!C5)BL(8C7<"CCTYBD=8Q':MD&1AM
M?_"`4<"@"R)!&J!AIZC`$_]4X0Z>H!1.@1&T81<$[0WBH!LD01I:80[R0!22
M4A1XH168(`_XX`NXH`Q"01)X012D1R.^I`OT8`[&X0N@P'U:KTH\#`Q@8`O2
M(0RD``S"0`FDP`CP@!'B`!I@P0R&8-;H;"4A``8>P1&,00L<(194X1%F`59^
MX1&T(`)@@`M&:`N@8@@Z`1DLX0K`X`B0X`_"H!,4H85B81JFY9#:0QE'0)A*
M8AWB8AZ480,\0!E8YACN@1TLPQ!&+BY(@``LYA?E*QRPP_20"P5"#SOD81^L
MH1W:81/LR)(H8;L:M.1@51\ZH&TR8Q](1&1&X`HUPYO(2#::Y`.<87)(H!FT
M:P/_#($$9DE;S`$34"!;MB4%.B!912(8!.$<GB&1:,8[[0(N(-0NDO3G_&$#
M+("6[")B6,D<7B,8P&82@B,8P",34&`!?L03UZ$86:,=R&%H\&,<-L$M2A$?
M1/`<&.8D,N9]F$$3[*D;,B&92`DVJL4<,@$3XL(:-H&T^DT3G.,^STLVF>/;
M3N<>L*$9JVP>EN0<R,$=Z@$;H.%;S>,^]&$\F]$<^(ECF:1:OD-#K,,DRF4>
M_E!GKB$:(J$H-"(/4J@;XL`,=*!Z3($>-,$/0*$);"`*C`(<RF06XF`'J$`6
M0.$4P,$1&&$*_DS0B.$9OJ`)_,`(3D$6""TJ&$41O"`D_\+@!80JD@[V#R!@
M"\KA"SX!%(2`"+P``F!A$&+A%21P"I1`"88`L*JA&I!@"_IT%7S!#\[*#V;A
M$8Y`A+:`%PKB"I:`"Y1`#(3@$:X!%E;A%X8@#(R@"01-"5QA&`KU).8A,^8&
M,("!`W:,)#A$),ZA`RAA!,SA&2:!\$;`+2@'N?0!`WJ0'^CM=IW!'SY@!.9A
MM(1L`YK#-\1!'N3S%3I`B$9/AQ`&)2[+H,CN8O3!$`!A'Z8%$4A@'"8AFW`)
MZ>3!9Q'!`[1E$QHL<CC`$)2!X?Q@`U"@&<;A63>@$,`36975'^ZA07Y6'W1#
M!<.C)+#.7'"SD42"$A+``%)`._^`(1B2:Q^`H3HRH3GX@A)*A`/,01,TC#,J
M00%R#.C:JS9;1R3<03EJ1LK*(1_(05_Y*S^X165<\QFNHS/&P8_T*;^@IC,8
ME"00Z9^@SATXD1F,(3DA:5_HX1E$QG7LY0_G(12]C5OGQ8N]3774L4JP88&V
MP`Q\#0]H819"80GV(`=<@1B@(1E^0BJ(0`]^H`K>8&N]9`GT0/GHX`U,ZB:[
MA(&6(1VDH1-T(!2^H!I>(0[B@`L6!0Q$\@MRP'V&JH_"``+BX!W^``Q880N&
M@`J:8!T481:P0`.QX@A"`1P$(A+6P2I#00S\8$J/(`P>(0S^@`A:H1U6@71A
M(8V98@O_;#D2KB`:CD!6NL!5P@`:HB$6\/4M.HD>`,,2]:$]-6,X"B&`4^`9
MC.X?2,``@H,#?`$P?,Q#6&17&U&[]F$$4@!M*(%1?6,9XH(2+,`7^L$#LO$Y
M+H",4\Y64:)QTN$5PN$<6&`#_"`8.&0?_DT^22X<3"N+02_O*J&?548?FL&0
M?`$0-D$\6,9:CJ,]C'!>!L9E<3,S&I-MXLX<1N`<,N&6=,N1J`03//BEE\,<
MWC<!;JF"#5$ZL*X]X$YD[J)U&H-D2T(<EF&"O0T\[.$=XD,WY@63>)<?>M@W
M0'4D@L&0TH$9D#J2/(,=VH&\H$A*/JQTM-6^.JF1:L9)O@.@_Y7C._5A&::!
M')XE::E`&N1@"I#`#):`T$A!$I9J%&S!%/P6#Y)@#!YB">8@#I+@"9K@".Y@
M"$"!%78!`0<B$>"@%/)'#*;`%7*!"U3("TZA'A2!""2MO>[A"1J@"W(!`L(`
M%R3PE'T!%&:B"LK`"/):KKZ@%+Z`&(PALJ=@"LI`":;`#)X`?Y``&G*A"SJ!
M$3`(%CAMH\"@5R#Y"'``#HPA%(8@%I*A%;(LVZPM85#NJFG(`OKA&18Q&`IA
M`?QA!!P:`$AK'`[``I))"O6!!?3A1U"`$LQA`RY'`4@K,\@A8MR0M/"AG0)A
M',0C1L1XD,I8.*S#&:;A'.9A',B%&?\V@Q[:P1SX*XG681F,,*[W@1PH2S$:
M?!G4$_2,21##U:>M)#X*P0!4`,DH`6PX<9#&`3`4PX-IAB_^09Y2+@%0`#!N
M$\;-]R20T1WH@QS]4&3X"&B<X:NK3!OE@V'6X8F>0SBL;))41C=*AAR*P3)N
MH1L(T;V.P1ON83/6_%I(SUR\8QVR6&8:5+WHG&9*41^081BNHA,P<A1XH0OP
M(`[&P`INH4[&:@S>X`E$`99C(1$<P0VF``_`P0VDH`JPE!0L@1U(H?:JP`KV
MP!9R(1'R,0^@H!2TH0JZI`O,8!2X`5,4P;WVP0MX``^(00IB8!5F00J`+1&,
M(`<HH`J,8`?_JF$7X$"20Z$3OF`9YB$1NH`'S*`+W@`/O,(4L@;Z0L$3XF`5
MO,$5DNH3<"`)KJ`4T$$1G@`45B$,MD`1HL$8D)&@RN$:%.,<!D,S.KPD+J!M
M#D$`?+%6,?4<2&`#**$?:A4`3L`$%.!\B]P#G.$#Z.$$"J$1"H$$C.D59NL"
MA&$MYF424,"YQDC(*R4\Y2$Z\V$;;L$[Y$&(&\D7J+P=$*MT5D\S?KBIS<4=
MA*,V]R&1:J:&D-Q@AV@V^KD0K*N?7W-8)YY7SX%M>!<0$`'SMH4>@"$-1J(9
MR-7I>[Z1WMTN,F,Y[&M@_$D^A\/T?`.@G*P9**:^^H4;#A0,UZ$=_XHQRFF6
MYL.A'&##&H;!.GT.[XR!'!:X;M;A'O"MYPY4).1AD>QE))@)$)7<8Q7_)/AA
M&HRA%9ZB(Z%@_Q!;U-U`!_8`"NZ`"G1@"7A@#KHA'&(A#UA!&[``%G8A#T@A
M&L"!%)(@"7)@#ZK@">B`"5RA&U3!"*;`!I)OSU#T#CP!'DA!#T32;N\CE+M`
M&I#`"+:@%1IA"$RR*Y2@#'"`%7X!#\`@V>.`%CH!&_AA&;`!"YK`%V"A"<*@
MPO7!$A3A$Q:B*$@!&KH@!W);W<T`%([@"V8!%(9`"59A&@#"5[ER^@H:+$@O
MV#Z#]$@TT\<,F$%\^E"@T-<L!0E]XRR$X__@+$4*918N8"+W2L4)$X1&F`NT
MXIR##9`T3"(QJ6"^<^'JG1-6[][$@N."`3-W,*G2I0;E!=/WC)Y08><.+AM'
ML>`\<NNL+2QXKYX^>N>^ZCO'KR`^>@;G9=7*5M];AN;B*ETW;A[3O7S[+@5F
M8,1"?(:4*>MGT-D_$LKT!=MP[A^@@H)(I"A(:00F"P_I?2VZS5"^A84,&/*+
M.C73<TC?ULLW=ES:I&OU\6MF5A_2I?3LCG6&#[=!V/6F65-:;QU%?!3/G>L]
M=J%L?.7&+6,FM&#NI+!5&WQW[9J^=<4,KKOV-N[;KV*UNYNK%3[3M[6'KIXV
M#9:94J66D'D21S3_JV@CC1A53%%&%6](04HN7^!@Q1RE1,((*=6TXH8HIG3R
M!`5,C!+'%GB\08444[AQCB2NP$+%&$^H,4HHG:"R#A8\E.*=7_F,=@4,6QS3
MA!=$?,'*$'B``DL38A#A1C>LX!%')XJ`\DDIL(0C$3G/X#./,?*<\XHPK+"2
M2B=?D/)()[/L\H048/S!RBA@Q`#+(T7@040KW,""SW%*W;,--P?M0\(M9Y6C
MESSZ4/(!1<($((P^FY"`#PH<^)'./,H\9!LY^F#B!V*(8*)/)IOHDYQ'X9QE
MSCSG=*57CK+J$XXYU$1ZUC)BP5:..>-\MXT^[E154%T&\2,4/>V9A\\^_[XA
MY!53KC)%SSR[S2IK=Q1QPD`A^NSS:R&-';1!88W1<P$)"3S%SP8D>/`K(",`
M<T%CDURP";'C4**/,FPUH\!%^\B'[5[,';0<L0=E$@AC^FBB`B#C[%,(691D
M,LD^\E`"#""&!%)))?^@,,DXAP1B2%V8!)*)/KXTPP\FA@2#SRW3K*-).;=,
M0@DFYTPR26,#8^2+/N0\9$XFYMRRR27P<$6/,,$T=@XPP01353/`K`,N6\XX
MPY$S18TSCC)8T_,U4N-HLHPUFXZSCC[%!#O1L_B8,YM:QJK&CWH'V47/M=R]
MPPPSK2AB"BEFQ.$&&.$@D4L78'!AAAE3="&--/^ZL!-+%5*8@8HM7^QAQRFV
M=#%%'+;`0TT]L101AR>3YS''+5A0LX,>99"1ARM'[M-%#J<4S-1H8<#0Q3)7
M4(Z$)]K\@8,Q?N!@!CB.F/%)*J!T$HHKEEPCSR^.'"'$$$-<X4<L\V#C"RFL
M?`(*(Z%\\L4JT(`!01R^(-$)*TER@0<CQ*(;K]"'-8+EFW<HZU=RT4<@"K&.
M>M"C'!3!1`=690@6!"(G)#@-)2Y"#F:H!2W,V4W@"E(/@N@#&!S`1SC.X:EZ
M.,,:JR(>:A9BCF>L8QI!H0<^R('#N,VC'+!A1ES,T1I/,80<=X,//L[A)Z4X
MARFM6LIZ;)@CB@2"`:?_&HO$#'(.;RV*`R0@E3XNX`R`]:,0ETE!(/3!`4I,
M@ET6"$8AWI@5<Z#`'<5*``>P.*L\+FN%<00$RSB0B4*,0!D+<$X",A$`I=41
M$0KP`R4N8`A#^*,0'`#&!]90"0Y40@'-X$!&.GB!6V#@!/I0`3!&4`A#8*(0
M'BA$!\2HCQ(8P#$+>(<P+M`,"P1"`X+@([T,$4=$<&`3@#B'(480B`L$8P3!
M"$0@H!D,%%P`91PH!`J`\8]R=7(%&CC!&@RQS1)@XATJ'*%2FJ$P\\038<]R
MEC[F\2S[+,4=].#&.!PAA5VT0@D`RH4S8,$*+W!A#UUXQ"_2H0M3A"(/W<#"
M_Q\.U(4M2`$*=Z`"'LKPA7Q(HA2[Z,8S(M&%3MP!0+PP13<2T84E4$$7KIB"
M*_01AQR(`I`'@<T68*`(<5SA"&;@PA%*,00:4&$7IT@"-"3AA4]\0DJE:`4V
MR)$(&#3@!3-XP0M<T(`8'($8Y,`%+T+A"4^$@A9Q4`0TMN`)6?@A`EQH!QRV
M``8P(`$6PVC%>$2XQ%VUTS$8\!-;"O$!I%0B`>'`!`?090UDL$4HY:@'E^)6
M+$\)ARC,@(<A$*&/982#(N$(QSIJR-.^/.,9Z1#'.]+QK6OLPQR*TD=UZM$,
MH>1#@LY1#L+2N)1I6?%@M,E*.7S3'?L0++4%66QG"O_Q$(HT`VPCX-<Y+G".
M3/!K9OT:!W2:X2\Q5A`%923*4_+!'$-4A1X>V`!S994=+?[#(!LP(RIAAI,1
MD``8'<B'.1+0CW7<<F:&*$0Y5B`(2CQR$_4@P:0<=0L42$`8@*`$3C:AC$),
M9IH%>48@UJ`):V!`!?[@0##^^`X/1.H5&T'$"@SA2J5Q`"E6VT`F+$`)9^3D
MQBL<03-:UL&*7+,1M]@&)CX@MQ!H`A+)Q4=RDL(/P8$QGP8<Y$10BS`G[Z6R
MUCB&(VB!N3GDX13P6$4<=N"%/92A$^:8QBG2R@HYF$(<KV`"&/9P!R:\80]>
M<,(CL'$+1I0B#ZR8Q3=>D5+_+]RA"Y[`13P4,08W(",/57##/;H``U"\5RY%
M>,$1DG&$(RSA#%,@!1W,D`-2D"("<2"&1[\0BCCXP1?&$`(,N%`#&C0@#T_8
MZ@V6T``\?(,1<8B#H#UQA5T\(@*PP(42ID`%4AC!"W\(@Q)BD8P"CD4J^KC'
M,MYAD+`4Q!WOJ`0&*#$.7Y#`!#3>`-C"`4QW%(,@V=E&93%K$&LX(S=+<R"I
M=%@L>JP#*<G=]$&P80QTD*,;L9H'#=]2CF)@%A^P<8<P!O.W;<#'A^.QFT&V
M\[=![D@?L,D''Z%C<(,,P@&K\LPD%!:,%&0B!1M(2\,"(1&2^P8?V='Y0E"`
M"6=T_]&:W\),60I2`A+T/.5[$3C)'?A&?CB#!)4H2`<YHX\-_`,1P?!C/OJA
M`&><PP,R:X8A5K"&#C#C&!FV@#(Z^,9":"`0*JA%"=(PJ7_X(1B?[1<'W&*(
MI*\`&(@XQ`I*$`P/!&L$AO*'!5(P`GXH\H'.N(@A2+8!98SC'QPX#2;<^QCR
M\B,%'-`O/S[P@1"D8!*)I<<',N'=K"Q'/O!9",CSL8Y8)84>WEW*.N;Y<;&0
M8QFL2,),"^2).>QA"E'P*!-L,0Q/2+43ITA%'M9ACVATH0I48(0BF,`$:!C-
M$ZF80RA*X8E3//H)G^`!%:IPBE+$00V\@`4/]H"'>BAB"O\X8FX^^!$'4P`*
MX:`$4B`%7H`$I4`*,C`#;@`/8&`#K;`/JT`%G8`'T/`,$!!LBM`%?&`*U>`*
MIG`*=#`*1M``8.`.I/`''.@*ZQ`+.!`&Q7`%1*`$L"`+2L`%6[`%2D`*RZ!M
M^`!;/T0;X!8XL.$/(\`"'\`)S/%YRU!TP4`)V[`=^(`,X)84P0`V(Z</V%`>
M@Q=:XH$/1F0-RV5P^R`,Q[%V1=</19-<U"!E\R!:@[0/>B%E>^,6#.$;GB$7
M\O$K$A1<P)=:%*%@3J@/*>`/!7$.E,`6ET<QH$4/>;,/(*<3D:@=D0$(;$$)
M?Y2(67$.@?`5L-1`6(1>WF$-\%#_#]2@#!S@#QK!0OX0")!A$I107W^D`@K0
M+P8P#N9@`9DP-2G`+Q@`"6DP&1Z0&<!P`HB0#"$@+_Q`"0$0#!?`B\H0""C0
M#%D@"/@@#QMP")MP`6R4=0J@#!C`#).P`0N1"2N02YNP!H)P%OV@BO3P#Z](
M"6_4#`F`#Y^W0O.5%B.0+RAP#AL`#)6U"2P@-R8P#<TB%?=@A7\3*^9`7%8&
M%K8'?!3!<4J!3[Q!$<S0#:O`!6<&#J!@!*8P"IU0!5$@!:(0#[?@":60"I[@
M"JYP"NM`#N3@#9:`#`;4".G`#=O0#JP0@OSA"7C`"^+0!7@`!GB`!Z2@"#V@
M![H`!9YS_PKT8`9[X`H%!TCT<`4Y\`764(!2P`5&P`6D(`4RT`7CT`D\`(/Z
M\`5&X`C7``(-<`>IH`1@D`>BD`NMP`BF``9QT'X-\`C9D`A-0`KC<`57P(/Z
M``9)0`3$I@1;X`4["`NWH&WZL)/7H'L'<0W$(GO"0@V-\`$,U&WZ(`QT<Q#U
M8`VP=1#F<`Z720[8T`[-<`'L1`[1,![K\`Z$R'2[1PX$L0ZWD!W[4`P*LP\T
MA&]&8UO4,!'GP(G7HGOXP#5R`7($<8>[QPQ*A!SA((D\]0P&(!%D$PRK<@XE
MT$7F$!-A^'1F00_IP`RW<`S)D`S;H$`(4Q#^`D=@@P*XM`_/L?]>"I`3@;@7
M0Q-NW!`-@J(,*5`(5>$/:7`(QW`.&18(_;`O]S`.DT`/9A<WAI`"@%`(FP`,
MW$!XRJ`"*W`(Y8`(U:$"+!$:55$(P.`'):!ZP;!NC5`,]&`-8O0QI`(,*\`,
M*Q`")0`,L`$,WA(,66`)'7`"'G`UZ8("(6%'''"?CJ$"&#$"(]!Y@7`JGT5S
MI4<)'4`"''`+R]!%Y9`.\#`1;F$.\945>1@7LZ4=<Z%E5L06*#<<_$`1Q\`,
MJI!2=T`'R0`*<7`'N@`!5"`*TD`**UD*HY`*KF`+ML`,[H`.Y?`*IK.HW]`-
MXY`,KC`FLA`*H*"`T,`*72`%3:`+C(#_!U+`"W!@!'R&"O5P!#:@:59I0_N`
M!"X`!M2@!#J@!+EJ!*[@!A!P)+!0!#T@!;>0./5P!4G`5KG:":0`"]>@#;%`
M"F`@!E)`"WL0`]#@#G2P"J^P!#G`!7BI!#%0"JQ@!`:(@T3`"L)00&+Q#J^`
MFL,Q%L)PF2AD#8<P`FH!%N-`#<W@&_%0#O<0+6H1-^L0%_Q`#A-$"2R00O5P
M#>]`L-P01;E)<K#A#*]`#_!P#+MA#?*P#+$B6K0R<4<T&X^8G)Z23P/7+$H1
M'+6E%/"Y=&JA*//*7!;0GYN`2Q\C"%]!">61%/5P"6LP`05```0P`$4[M`JP
M!IM`-WY8$!M:_P@;L2@MXQCS12L+\`RA*+%)00[#$)IMBBK<X`SV,"CZ$"RW
MF5S[8)W,4`[@=@^815EE&P]>:PV]=Q#K@)OW!#9C`2B>0@UN*)]:>!!Y4Q#\
M`(E908GX&HEDL0W68`W<8`_E<`UQ40_;('(5B3#RL'0<-Q>CB*_RB1#H21L%
M00[6X`EW8)148`N^$`,\H`N>0'VZL%:C4'VIL`O0T`WQH`O!$P1>%01`H`-X
MT`WY(`RP,`O\P1^L``K0<`I<H`C2L`-0``ZPH`1TP&>BL`Y;8`.C\'2I10](
M,`-Q4`U)``5+H`1)H`130@6*$`IT``<R8`1(\`VQ\`P-<`2>4`1>T/\_X/85
MS,`(0L($G2`#6,`-C@`-.&`$2]`)@M8)4D"J2G#`4O`$2L`*V:9SY=`-5/8J
MP+<-Z>`V2=$,FD6:)B<6O>).L=%M!WL/]\`!F&`/8M$5]9`.!YFU26$-PM`5
MXW`<^[`J[3`-D0AP]1`.0A$WE.@LQ&400$P.+'L0UB`>2S$.2FP0Y&`/]!"W
MM"$6<LI<'(".\Q`.D%@5@J`";`$;>G@/PB`"!!``#I!@P5`VQ7`UF$`('$``
M!R`!3K-MNI%)<:$,2#H6OI(6A6`!H#G#HJL.W?"NW284Z8`+[;00/D0/X?&R
M[("<QN`I;+L.*E0.=',/QV"XWO4.UJ`M<,/_#:M)$=90#$YV#^2@"?9@#[A`
M#%88B<ORI@Q1'YT[%$+!3_E@%^5`#=;@5_J0#M70'O2`#%)&-K21>THAB2F+
MQ;J1IG^SIF9Q0*0P!K)3!0IH(F]P#TWP`]]`"FYP"K(@"HI`"MZP#EV@`SE`
M`^O\!CVPSC8`!>KG#:PP!Z"0"JP0"K;@#$9P"NA`!4;P`[*@"%6@!]4[#Q"X
M4_ZG#V'0`%W`#$,P!4LP!48P!*&@"D0@/$Y0#4^0`SG@!/J@"B\0`;8`!TG`
M"M3@#IJP#_SP#/F`"YV0`ZX@!3.``^U@#DA@`V!I#%=`KE(`#HD9P0>(`[$P
M#(9B0.90#X(R*,JI_QN".T$480XF:UL*8PU6&#?$L0W_HGMPD\QRXP'Q4`]!
M,0XWR0S%(+,2.P[<`+#SD'OSP$#A8`U1W1[M,`Y<,1?TT`ZOD11V2WLOE$_$
MLAWS0)H063?^20D+P!;\0`*M,12`\!3WP'''@``"H(V#12V>-``&T$7V\!72
M\6(.T;12JU]%-\A(/18\]`[`,"[.H`G"X"G`=0W>50R-P!8#81OS4`Q%70SW
M0`W,H`QK>PO=0`Z_0KGY4!WZ8`\.J2SG\`X.FYGX,`[=<&_6\"K=U@S#$`_K
M@`N"8GNPT7.PD15-UE.P$0_$D1X4.1;0H`P1!,SVD!WL%`]*/1I#I!U?T?\,
M9PV('+$-L)K82@$=RF(0US#`7N`%8%`&=P`.G3`%-H`*CE`#C-`-U"`*>9`*
MH]`*V?`$,$`+;V`%44`'N_!]5*`&=^`">@`.N9`*GY`'I'`)U>`'+J`(J\`#
M>N`)NQ"`8_!1GB`/74`#C+"]@#0:6Y`#7I`,2)`#W:H$7G"`,&`$O!`)7.`Y
M,U`#L1`&+]``J4,%X+#3.2`.PD`$L4`.C)`$G8`##4`#T0`),("#,0X*N3`$
M,>`)7O`$1&`$4V"`L7`)!70-F)7)?Z,PH)F?J9G"Y1"QY=`8W)"'`X$4THP.
M0M$,(7`+L"6VPPT1QG#63/$5L.H=Y3`-MXF([4#_#]U1#,]@#AA7PZ1=$._0
M.E:I#,^1%/N`68+[+5_A=/HT'GB(,+*.1?S)$1.S%SLB%.-0`@(0`H?84_2$
MQ>'P#P,0`DX(&S@T`CEA+,["#U5A#@M@[/Y'7&S1'-1P#Z-1H1@@`0AP"/2P
M`!B0`"%@#0&P`?5@`!OP"@8P`0>P"1A0"/A@&AUP``-P`B=```FP`<&``..^
M`N40`AX@`?W0`2*@#Z`H"`=0UQ?P``Z0`N%P``^0`>JN#X5P`1B``)2``1GP
M`&MP"QF0#YDP`N1@`AE@`LPP`A>P3<4RI2E@#LK0`9>2#Y/0`=\@#!YP#H#0
M`1\0*8-PC?I@`JY@#G[0_PAK\`W)L`+!L@[!P`;?<`NBD1?4L`;EL`^PP0Z>
M,:].-Q="G`S40F6SM1L+@0S1X`A=H`=F(`7P%U,\T`O[``9O``?)T`UQ0`6F
M``];`)>RX`6\X`JM8`JXL`JND`>V``4O,`?Q$.=Q``W>0`I,<`?WP`@V0`.B
ML`I54`9F<`=WT`GX``ID4)7^QP]A@`>E$`U'D`1+D`1YX`D0X/JSH`6P$`<P
MP`/QK`](T`!0``VSX`FV$`VM@`,V0`%2``VO(`F?``USH&M(?P40;`2*D`N,
M\`4UD`0Y(`MQ8+Y<$%"O$`LX/!S[C1!WS1;S,`_W@)[I0`XA'!;3P`P,]!;-
M@/\KR44,[4!RH_O)]3#%UD`0Y0`0QM;I(UA0'SZ#"0WF4]C0($)SUMYIJJ?/
MW#.#YHSIJX<07[MIZ?3M*RAQVSN#Y,)97%EP'4)]\_@5Q$>RH+B!]V`:?(GO
M7,.9#H4V)#F)`\%-AO39,V?3X#Z2R18X$$:0'KVA!G42?.;`@*6#")M1TH>5
M7B:$P5`0I&0AZ]NW-NN%LSE/'Z(+^OQ1(O%!WS8#DP@<$";@0R4,^AR@V.!'
M7P"R'03I&U'"'+-F#')!,I`I0"5$UC2(2->AD.(!E?0-&*0M`*8#@["]*H?/
MW"$!EH0%8';H`"0"^@Q=P(1`$X=:UA8@HH>0PPAE"8+_*4!QK@6B00!TI0!`
MS0*E0,$E"&CV.$,F!I<"0/JP@AVY=90`6&*S0=_/-0!4YZ-7CF!M@\ZIJ"*M
MZEF'P(2P<H@<!0EB!AE0I*AB"B^F>(.7(VP0Q9A0?-"!%'CF..4;2:380P\J
MF/!$E%9>*<811IKP(I4G:K!%F$X4H2>,''Z8PY@X>*!BECBLJ'`/*.8X!PP@
M1('K28+RV0>)!KH8Y@@IDI"BBSAP2,((6)J8A1$8>L`#&GV*:.`3;!IAQ!N"
M%&F@`33UR64+6+R)HH%6](EE"!RFR&61+EBQ08<<.C&#""Z\.`*6:(0Y9Z=[
MWBFG4KN<&HD><QJR!AAV@@$F_YA]$!JGJJL(*J:9=U:E9Q^LTDG'FGSL*:N<
M=-;)QYQKEF+&F'D:U">8<<HJ:!^FFB-GF7O*,F<<?FIZTIR3?,'JG(UNDO2@
M<\(1IAYF.C5UG'S6*49!7IO-YQR[[ONI('K:[?0A<O#!I]F&&&RH'F&A5(B?
M!8#19YP&#2DV(80T&:`$6PF"RM]ZY"$(D`"R:,B9%0`Q:UY]+CC-7Y`+.D=B
M@A#*8JV*/"#$(@,HF6`"#3XHP9(`-DA`&`P`T4<!32@+1)\.$/A@`W\6>."`
M%.HY9($2J`&A`!`.H,27"QJQ[P`''B#A'`(R\``18_TAH)YF`@CA`1$T64"X
M"\H)(?^#$[91;!*'%5"&H&`(Z+00#A`18(TU$CAF`T%*"($2$TXX1)\-$'#"
M[E8(D`"?>HJY!Y,"1#B!A++2T2"1#]*YAYN!]-G**IHTO50?*1,DJ=^#^#4(
MEV$\@6*,*:8H8PI2MHA"%E)8V:**'TP!!Y=R=ACEDR>\X&.7=>ZYZIU=XO!B
MBUG&4$.?5XR1Y(DQO."EE3F,H*(4*<B`@HHJR/!D'C!H\"3DK*0<`H8XDD$B
MARF,@,`34"0A!C!PA2.DP(,D/`$'QO!"`VKPB$?`X1G.^$,,J#"%(:RB&9?H
MPB,8@8,&D,(?B>!"#IZPB%:$`@(ZF,(G5(&$(RA!#%(`127_8)&0BFB$'/=@
MQC+L<@]R!&,8^$C',]Y%D&M8XQ4'``0'5%,,:BBQ%INXVR0F4X\0],P<],"&
M,%YQCS5LHAC,^$LP7K$.<FQC&]%X1@H(THP1J.`"F5B!,^8!C$T8)`LFL`@'
M4#`"0!"H',JPQE-@`@Q_:$(IKY!8.,AQ,&>08`0;^%0&LI"%1H1#0?L0"4/H
M\1-\C`-!^B#'/,PQJ83PPQSIV$E![A&.TBG$'!Q3R*OHEY`_'@00=SO'.`#Q
MCTQ@0D'-*H0`!C$23>'K2?A(E28"<(*",,0?',B$*_4!B&)EP@"P&PI#'.)-
M61[Q(/K0IC5(D`)(*&`;F#``,!PG_X!"?``3">C'./"1`1*8XS/ZX(!2+)`%
M;@!#&0JX!0(JH0DW4J<#T.3`)%1P``T$H!@*J$0'4&".`;P"&.5AB#(64(]@
MK.<`:_"H/B:Q@4O<8AROT4<"Z#82"P1#'X78A`'*\T=`E$`"'"C!,32PADJ4
M0Z<2Z$`Y)'")`A#`&==P@&KT049*J&`1`H"F/C!!@!,<8!@<:0@S#?(.`KT#
M)58)BL.$,J^=6*,:C*C"'B94AB>XPA4^4$0>6!$+'9`A"K;0ARH:<`-0N&$4
MDCA&6>H!JV0X(A12Z$0/:,`+>UQC"C\`TQQ,X84H2&,.2YA0%=[PA/EY(0BH
MN*50I"2&!O^`X1I(,$(2<I`#(>`A#C)(@BFTX`HIY*`'4`"')!HP@S@P@A3A
M6@48],&-+4BC'+A@!2@4L84&R,(17R!"#^;PB$:`P@8UV$,<=*`$)7#A"&9@
M!"%6H<R"U",:Z:C'*UZQC./>XA73@`<VC($1TZW#+H?PBR%*4((/-,($JK!$
M(]8@"$IPHA(H2,`F#J$%05C#$I6P!`(:(5](F``6KRC$"%)0CBR,H`,$(<'/
M@(&)#7!`$Y;PA3!4@`AF2&`RV\``,ZA1#C$BHA+$$$8QS!&(%$RB$/C`!`HX
MX`\36.(:AVC&(!JQC(&$`!-6)4$6,C"!+&#B'(4(A#@TX8=)]$/_Q^,H1SE&
M>9!I%+(AS2"'0]A%E%0Y!%:E+5D"!+8I?2AC!"BX``I2<$1(P'.<(RE9/@S=
M$'@XA%/ZN,7?3$<03,BM&9$FB#)LPH'3@#-D##FTIJ4GDH880@(;N)L*/.`!
M3)AC!9NP0)$S00)#WV,3"K!`4?61@BFO`0$:R$`E+G"6EBG@`QBXA47U@0)`
MC$"F'$C!',LV"0PD``$CQMLVE6'35]BT`QXP0"'\80`22$<?%E!*13!A@0M8
MH!__6``'%!",%:1@`_\8@3\L<`M]E$,!ERB&`SAQ`62H``#**`<"-G$,%3A#
M'YP8@3X6T`%,5&($'+@%!@)QB&HF9!UT_\$A2M!+:-9QDR!BC1(]&-)#5SPA
M"D^PPA/4@+X<O,$6K&"$#YY@@S?P(Q$O"`(OYI"';XS#%:1-AB3B@0TPQ($4
M-!@M/;Y@@QM4(1=N@$87>G"*4C#!"%-XP@5+00\G!.$4=&Z(E*[0@#C`@@A0
ML`$/%-B%4L"@"*N`@RJ*H(,GZ$(2D7@!#=[`A"TPXA;OX(:AM\&/1UPA#E@X
M`@Q\D(M$,**Z/W`#&V(!@R3,H@@W2((2B*"$#$8"%PJ!QS3F00TT(L,_^4!&
M(>\QC66`.LZ94(`*5"`,"UCC`S_5@B.T<`A![!D?*A!$"[1@R5?$P@0:.#@S
M-A$(+5B"!/PX9_\)A.$7?DZ9(!X(1C`:\8HX>F`-*G@%*=OM`4-L0_RW8$,6
M,"`(02B#I_H8A!\0@0@-I*`2)_B`%C2@!7C8!@>8"7,@`4%8A!,(A'_X!T`P
MA!,`@4'8`$1@@6+(,_]0"&>()8.@AW$X&$VS"W/00']II9`Q!/NXIO)@G8G1
M/H1X!0``FT%["WH0AEN(!X6HAWRX%WW`A0Q8F7+8AHH0A@-;@8PS!)G"A+QX
M'9&CB6VHE\XAD'1H,]9A"'C@!K-:"'K0!79XF'EXG>,JK)J@!UMA"'*P'(58
M!F?8!FN`E5UYAW$HAGH@G9K8!V50.'IH!E5J#G<HAW%@AFU@AGB0$F;_"(;R
M4(9A8`=-6(=UR`1AP(IER(1W:8:?\*9@H`0%`89)*`]G()8^I`=EZ!1[.(:*
M"`9G<(9P<`9+:(9XT(1S\`<'V(=[<`9\"X9:H,%;*(]@N(1#P+>$8+.$N(=[
M.)"&P(I[T!1C^8^$`$)J<`90F(*5>X)1\(0=*`,;0(5B((4NB((]N`%7X(<F
M>($;2(52R`/W8H(;X(4F,()6F(5..`7?H@$[.`<M@`*WP@))J(8NT($R2()2
MZ((EZ+HJ&`5SD`(H&#NR2XA\X(<M2`(O2(8D0!0>T`$=``4D<`$I,(5H.`(=
MN(%2<`4LD(8=F`)9X#HO:(5T<(=/HH=P^`(K_[@!-=B#%Z`#:>B";W`"&]B!
M.2`&4S`"'`B#/_`2(R""*8@!5F`&8M"7@J`&N:D'E*`<CL@)?1#&@Q@(AFB+
MBF"&Q"@!%3`<2X"$#4@VQT`!1,B`1CB$$=`$C%&!/*J'$:B$#!"$%=`'%>B`
M+)B&ACLVG<D$%&"!?DB!?T@!%!B$0\"$$_`'?6@&#`"K<I$`0W#+32B$%!"&
M??"#%;@'/R@$2BB$#.,9#&@$06B$>!B'#A"83+@`*4,$0T`$$B`+$\B`25C`
MGZ&6L3*(F>"'?O&F8/E%FGB*AS#&#:2S"W"J8,`*9[`E3``;A%"&`.`<D%$&
M2K@$-4,8AAB&6Q"&!/_(!!PC(T$HAFT`!FK+A/*@!PNH)GP(!V.@)=Y<AU9P
MA$*:!E5H!7M8AU4`A61@G68I!RD$)YA`!DFP!"#T"%M9AV2(!V;PHOHD!_E"
M!F1H!V,8SI*A!TTHCWW(P9%3Q&1`!BF,RGEP!HZ9ANC!!GAHE?+8AFX8G740
MAFG`AFBX!P*9AU;"BGV(EF.T%]Y4B'S`P;)H$&:`0P:AAWHHAPK$AQ\:*Y-[
M-*PPAU'"!WD@08(8AWYPB'Y`S_^0RJ\J!V>PA@BY@S)X@U'X`B/@@>?I@7B`
M@Q_X`3V0'ASH.5V(!%L`1',H@A<``G#@AV;@A5/(!E-X@>V!!BJ0@BDH!5C_
MT`)>>((DZ`%12(4JH`(ZJ()3H`=/V(-4.,A:6DA/0`8B2`($2J!.J((>J`)M
MV`(;>($[\`80,`-3(`4(V`)9\((J2`5':(U=<`10P`,>^`10R(''FL]6(`88
M@`$E6(53J`$>\`)2@($IN`,O\#Q92`9B(#-S6`EQ:#-O&JMZD%9ONH9.B9>"
MP(04X)1M8`%A"(8L.`%F(`0-2`-#,(1)F*1G.`0-.(1`N(5R6,T-<(=;"X02
M:(0TT(<2N`43Z``5(`ASX`""#881&(="\`-<,X$2J`5`J`ISL("A$81!"(82
MJ(0L4(%`\`<_4`%+$(0.&`%N10%,>(4,8(="^`<2_P"&;C@&@QV!#Q"&$S"$
M-2@$0"@RR:C9?Y@$G>E18?DD9-H):;&*=CG&DB$0GW`=A_`J^G$&!=@;F3J'
M#6B&N\&'F4"(#R"`V<P*'RT981@&!-&TD6L%A%.`99&;%:@$:]"$?46(XKRF
MHZB'9;"6H<"'6(B$8JD&4FB%?&@'&+DA@@A&?"D5@HB6<K@%4VB%>MBBG<`5
M8"0&2"B_=7B%5D"&@;&$33@8CF@&>T`O3WJ%2[@$^.((?+`&CR`(=J`&<:@(
M:\"$2U@';KB'="@'<Q$'8\B6AX"7W$T(WU2(=SB';;`7K!@'!MD(<Y@&<C$=
M@K$4TWD'N?D+_W@'<@"GG/_HEW=8AT!LB'$0)X,("8>8!F8@H0F1@CN0!3=0
M`YPC!E)(`A^P@RHPA7?0@1>P`UGH!%F(!WY@A1MP@1Y`!7=P!U/H`LUZ@2BP
M$RK@`A[(`VV(`^]2N5&PGBIPWU#@!RK0$)"3U(0T@A>(`V/`/".P`1N(D!=P
M`2R`AAA(@E/0!5(`!4EH`UAHH"50A3A0!%-8A$?(AEWP!"JX@S]H@`@@!6CX
M`E+P@U<@!2!P@2LX!R-8`@I0`RN@`E)@A"]P`5<0AALZ!EBPA&.XP"FDAX$@
MAS$DB'2@!F%HAVA2P7LP!B"-W!MUD'60,&&H%Q\M)!PM,^(E"&2`!6.PHUZ*
MAFK_V,`"'0;_X`=5TH=GL(18.`88#0=E4(9,N`0^/`=^D*D==(1QV(9C:(9]
M:(9G\(5E&(=E(`=A(",^S#=-8(9R:`9FJ*>[R81,R(=F`,][4",8;08">9B2
M>9=90IC"[1<AU0=^*%K=530FA8M`6`M]V`2%PP1*H(1_``:EP(I7$`"!*68<
M.C,;M0=O,HNR8(#)8(A@:+5!RP<5N!O$G)0M.K2S,@=\&0=QL09LJ(E[04^$
M(`E^&(28T0!""`$C(PMK4(`*#`1,2(9&V(1;P*1"<(<.&`02$+(-Z`!"V(0.
M(($2J,!FR802L(9@8#C"F:D-8(%_<`9$D)XU,`$5N*24_QJC(;.&?U@'$'N%
M0[B_PAJ604`$0=B&6UB#00@$?N@'(,.$?#B$;3B'!C2'8&C,0;@$3H"$0Y`(
M.NP492"$[SN8/BP(<R"'=K`)6(X'=F@.JR`0],(*3PH*>1`YV/E1+DZ(8B`&
M59`0*&BM/4`?'K@#5U"$4&`"('@!*V`&*>B[5/`$6U"'99@"*9B&+F@"7/`&
M4\B#/&B`(-B#9)`")B@#*8@#48`&7'V#YB+4)WB"*O`$<P"#('`228VF=1@"
M&L@#9U`"*-@!&\@!3P`#QXJ%+8@`/L`&/R@"+IB#+Y"$;&"""+B#60@\.(B%
M7[B"(XB#5("!F-2%+O`"3TB$*_^(!FFH`1>(A2YP`2-@!2]@`BG.D%W(A%SX
MBTN(!'SS)GQQ7FO]CV%X!6)H%O1Z!VO8AO(N/XYXAQM]!4M(Q'S#BI/@"&NH
MB&WP#R6JA&(HAW-PAVCH%9)@B')`!F!`3W.P!*%6""_2W()8AE=@!F^""F,X
MHW!`AFDXB&VXAQ"LM!%]AV:Q!JQ@)FIMD'DHI#@KB'+H%`PO&9_@)D64,VN^
M8'_Q@#SJAW<!!'EK!D#((X3``.9\DG@XAK(:M!J_AX91P7VH"$,P`"Y^!TWQ
M"))@`;+@987H71OE*OUDT7M8!OK.@'K8/W)"`'J`!`D(6`]`@'@8!$(@`4(@
M!T``!@?_Z`9BZ0!_``9F^(=C2H$0X*HU6``KW0!?X`<5N`5,NX5@T`0`F`3Q
MG`1"<`!(@+)B4($%<"36T(<5*`0"@(1`\`![/8$U`)H4((%5*P1SV(!"<(80
M&"A-"`%A\*]F0`&>R8(/V`9$*(%A`0"!^:E;D`#MVU&#:`8%80@"O?&!*(>M
M!4:"Z(B2`9#`]0A;.A:3BX>M#=QHP`9%2((J2(+<R8%3&`4:H(-%6&$>``(?
M&!$O`,=3.`53(`9]$(;"&H=7J`=L*`59F(,:&"USP`.\I@)HB(,(H0%;4`0D
M2`(HJ((HB`*!#(,;(*W2CI)Y.((-%H<D<"T;^`$O@(`:L()L_SB"'9`&*E@"
M*5B"+G@#+P"%;+`"%Y"!&9"!(?`$(Y@3&7"!"N`#:>B$.$#6W4&":7"%!AB%
M9*"!&B""4-`!)K@"+GB"4Q"&\=:'=("%4?(F]4IKTT$'<JB'>OBX;;`+HR20
M-"((:S`&K'#ID;/"62F(=S"'<F@';B@';/!18OB&>P"G>B!></(F9@!$WAR'
MED@(<V!V>^`'FQ`&'UK0:9">8DD'9N&&Y[4'N=GQ@AB'=0"KA,")<_#-<-"D
MAK@&[G48<CC]82YM<U``A6M,JZ"$$1@!SD&(2P``2GZ288`$@=&T9G@%BC"M
M6R@&*R0)9VB&2;``.T0!9:`'/UB+G?^@AW:04J'`AV$XAM(1P9&#AER@AF06
M]DQ``$+(`D*HAPV@A'I-@10P@4#8<P]8M6!8`$)`!&5@@1#X@%<8CD,H`>TK
M!A1(38#0Q$&?KTW'-J3P4RD3AQ',0NAK-D(?16<=,AF:U\(!,#^<,N#3AP*2
M/D`L-*VHE.4$I$S^4.CKYV^<AV`J4E`*I@_8!GV%/@S;M"(?(D.`]+%@$TR#
M)7WEN+&CJ,]<N)`4\[TK1D^JOGOZJ)7C2K&=OG1>N=:CN"\?5WIL]>6KQ_;>
M.K'TSOE"!DH*E"E/IDSQU`2('5>DC/SHP4N:)%@R[-PQ4J43-'W[]H6\]85)
MDSQ/;NQ:!2[_3H\G<4"!X@*%CZ(M3Z!4N0/%T[DK-%S!%:M[-V^XZXPT\&(L
M1@X>/?;(NJ$C51$(3T(9L5+%BY,N7L!T2W?*APL;-1J\"&]##2IUJ[A(H?*$
MR/0PIG(0X:.F`1!9/(PP2:+#U:M;]=Y58XPU[+`S#SWWW%-/-/5@P\U97:7#
MSCWT-%,//IB5DTY7[R"3#CWF6'-@/?5<4PX]UL33E3[O7&--7>_0!8PY]7@E
MS%;%X')//O@<R%4^E^ECU8.][98//U8)0\XU9%ECS3)>K3,-.]1PM8TU[XAU
MSS9IB;6.,KEUV<QNZUBSCV[[D%//5D2RV>95^E#24Y"Z*>.,9?I\__"!/FNR
MN<\]PUCRY9P57=(*E[R-4TPP:XX@#`G`P$2/,OT`XX\'8H4CS#-N4L2.)8OD
MH@\Y\^QV3"2>5$;)0)F(H$LDMUS"@2`;4+*",(TLD`(F,7D`20G)6"*,"+=L
MHT\@A&@BP3CT;*-))6MH(,REP33RRB29!-.,(8($P\$MP@##`I"&.!#,,\]\
M($P''QR2`44A;**/("I`XJX)66@23"8394*")AT0"TP@).B320<^77!(`MO8
M<T$A"?13P@D?K+%5/_-8&.16A^8SSCH:<G5/,UB*54^(NN%SH552T;,FC%RM
MPR4^Y.@#S3**2%8&%$GD80L3-^R!S1<W`/]!!RQQY$'-%WO,$D<4HX`#BR_Z
MC),,-'@\\8DM3ZAA32BD"-/%$D;H$HL4-C"Q2Q-)5#&%%5"4THP;8ZP")J=$
MLF5.&&#D84P..<``"Q['58$'$4'8P,@S8'#AA2AT@!$'*8R4$P\TC,Q!A1IT
MR"+-/;:0$@<887A"RB%T[`%+%S!`X,D<1W!112ASN"%%$JL@<XL^W[S2"B[6
MP/-..2%90W,]Z%!SS5;OC'-6U?/DD\XT&R\#RROM7%-7/:2NP\PQY,1\CSWU
MD'-]/-T,T\TKU<2SSCVP6*./-98P<\\[6*83#3/\3,B/.?_SR!V6P<<Z4C:-
M["$('NS87CN048[_"8UH'<GX!C&RD0YLP((:]5@'/,91C75\`Q[J@$<R7@&/
M>.!C0OK8QBW>D0\$(>@=UDC'H=1R#GS(PTQFH@@`4TB1L[RC+G?I#3UV>*:[
M;84$*M"',@CFE$(80DQW&D<`*F$WL?"O*S!<1['@D@][J*4<YZ`(&'=##@U,
M@B+X&$$P4&`(F."#'_YH1C\LP(PWD:-X;<H'6^BQB450`QY4VLTT(A$);A1L
M(IM8PS8N(0()Q$L9&QA!,?3A@#5\@`1OU(0*@J&)>(0@"X'`A`H,H0]#?(`;
MEUBE2`Q1"!(TPA&8L`0E"H&1$NBC$J_(Q"TL8(X57D`8WX($!O0!"08,_\(!
M_CC!!M*B29$4(@LH\$4FQD&"0OBB`Y2X@"4P0`E,'"P3%O#)1`*A@DG\8QPJ
M(,0&AI$.#_@"&&*BAX;6828U480>`CP'G_+Q2Y)Q)8\KXXH\Y+&;>80D+6_1
M1SW"4I:M&.,:C#`"%,K0MD\8(0D^Z$4LB/"#'23#&F"0@BMT00$?R,(-=V`%
M*%KQ+45\0@IS*(4-:""-6.SA#?<`A0MHH(9Y?.$)3\C#%7A`ABY,X09\J,<<
M[E"*N]W-'$B`@2=\`0,H'`$6]''#&Q#3@R@401R/:`(C2+$(1GRB$Z:@1AX?
M`0DJQ>(9]%@',42!AU2`H0N.8(04<K$*'?!@"O]*N,,4\-``)T2"$4[0P2Z,
M@0M]',,2ET#&.AQ*$9I19!W(>$58'LB5>=!P'6M:AR\L88EI8&.@%!$&R,Y"
MCVE\XQ[5P$4KH.$-#9$H&W011OQ>Z!1<"&.,*'N35^8Q#&,X"!YS(M,KA*'&
M>F2G',=X8#62$8]XJ$D8]3MA/:I+#.Y.J!S,,$?]&'J/<1QC'O-8QD#;4<#*
M[BDDZR!'2.A!CH6V3Z'E6*A8S"%<W5"(-T;DAU0N8,I]+.H>*SA$(SB0B3WI
MHQ$(.!!_6[:/`X'PA-S@AOM.^(UOI$,=ZF`'D/@1EW+0:$Y;P0#!MH()#R!"
M&5(,QC\HXH$TMDE':@S_V?WNL>$L420>UQA''\>A#WZ8:!SC4$8ZXI&/9C!C
M*^<PQCTTL0ERO$,8Y:A+)B"QB3D:61^8T"PW4M2,8-A#$XVX1#*$<0A#3&(<
MF^@'/9C!84U<:1N&R`<S;A$)3=RC'9QP\YO#G(DOG6,3F0!$(%(P#GX$`@6;
MH(<A6*B"-7Q)&84HF"DI'0@QE>,0@[#1)031@4K:@QIF4=$V$G2H-;4LGT9D
M:`%_*18"JE8JXXB*;MCQ,5+I`Q?&Z$02>``%8_.""SF@@2G"\`)1?*,5</#$
M%/3`BU#,``B]8$0I4`$.8BRC%:*(0REN0`-;\,(+4AC%')*1#";8@!=^:``-
M_SY!"AL`@0I3@`(=UK$%&H#BBE#ES3F$T(`W4`,&/<"#%&20ATX\`0<N:$`.
M7$"%:%"A"U_P@QN\<(3*&`,.3?"#(_R`!"7`HA_Z.((2XC"%+G1A"YT0!@Y*
M`P$B")413ZB!%QX!`QM`HS_OF,8RBM$\$WGE'*1B2SZH40P4=[$MTXB?6I1A
M"6Q80Q@%Y,H[P!*6LSAH'/!(QS"0H=P0W<,:]8`'.:AAC#*^L!C+N-L\E+&,
M65_V&-O(QYJJ48]^J)P>[0BSC^?1/(HPB!UBE(KPO+(-DM5C&VLZ1UW4\EFK
M&(@KY0A+/MS'%<P0,?2<PD<"**$/?^BD&4N$$TQ(1?\"=_%)*OC8T3VZP8UJ
M<".(PXB$+JX;0G"<[Q*O^)`^V%X/%+[#+>^X!0?LM!5Z$+AE&T,D"1!A&3`&
MNO*??\L^S+$.=MR/ULP0[9[H88]XC%T:VF"'A]Q"X(:VVBO<8(8]$%2/<:B)
M?.ZC1UI,M**8\=]67(/BO0./@`DR4!T^]%\F5%Y:+%^QU$4W$`."%,,UG`,P
MY!,]J)9!R1Z1Q,.0Z)B?V$-(L`,Q(!(S:$+]?04BY88Y;!G7P<7PB`5;O"!%
M<&!FA=ENX,,[I,604`0S&%E((,,TP,$4D,'.F,$</$$/T`$XS(`:Q,,B=`$4
MW`$=5$$>3$,<N,`>#(Y/@4/_%^1`#XQ"%3R;,GQ"&;S!&T"!&MQ"+-`'-"`&
M%Y0"$?2`=$!!'I0#&/3`4PT<F^3#.>3`"Z0")L!`%30!#"0!%ES.&SP!%R2!
M=Y1"TW1!',3!#GA"+*Q"$5C!$X!!$GB!%RA!#<"!,3"")W9!7BF"T-2`#TP!
M?E!!*\1"&)0!$3!<$K0"+,#"-:P,6W"#>]F:/I21/LP7;U1##DJ%/(3#/:0)
MS/0?K]$#D3546(0?/2R#.1C9T*U#,!0+'^U([/6A5)R%/;`%/MP"-X1#`9'#
M,V86S>@1/C@#9N##.;#%.S@#EXP=1=0@#^DC7(2$]SG%#?Y09Y&,#_*&.>#=
M-[I#_P*("27XPU24``HT0@D(PIRT0!:HB`ZFR"T@@,H5@A98@B:\`R!(0!K<
MPS$00B1`PCM@UPRF$#4P@R'L2AR-0TB\A2#=`CP`P@J045EH%YN,`RY$`YC,
M`V:]"5S,0RZX`BQHB`*FC)IXA8[<WS$H5]<)H]MI7?W=`S/P8#DD0S?`0SWP
MPSH<@SKH@C#\"-^5PS*D0S>4@X%P4#H@PS&D0YH4D3'0'SW$0S+HP@:1`S"\
MPS)LV8\$20J-2#CP`S^82<O$3/%UQ6(>B`8>R9Z<9<MDV2L$TC"X`X*LPS"D
M2&YLPS'HQOET`UH@TC=$G3XH74C(P]9-A9E8Q3J,4?OL6/]F<=A9($,T*,(3
MM(T1L((<O,`/H`(=*)4IO$$94`$4O`'JD,(ZD,(.S$!/T0`0O``-!`$-W(`K
MU,,HY)092`$9C,$71$,31$$I=`$-T``J3`$0E,&^\4$X'$$/X$:N?:-:F$,,
M-$`>)`,,E($7U-0.:`$TS`$N#$$/[(`.Y`!E@`(;J`$8Z(,3Q(`1+,$=X$%?
M4$$1Y,`9-``X.((4<$$9?,+1R$`.,$$.Z,$IP,(T?`$.$$$7,`(5P``Q"$,N
M()1[K0E=3`-HT9#F;0.O<1U9;,,OZ=@V%,LY/(.MK4.%:$Q8I,,U+!V6D1\^
MS`,P4)TQD$,Y_)(1+93,$$E=C(/_G<B>5WP1/K2#,5`#-HC#D.F#+A*?/KB7
M_!`811C9.2R+5.3?LJ286M1#.(B%F<S7?Z$%D^Z&!@H80-X:IS1#`HR1H.J#
M.RA#):B`%)T#`UB1-XH%)2@``9Q#,`3`*PQ")6`"`Q2#`60""I0`,6C`W-40
M5S!#,70`29P>"<Q:/)3#,-0#0W#%.10#44K%K`$#)Q@#UWDC@NP)-)`")"1#
MEC3/D/C?,M)#,0B#,,SI/(1%2*2#-0";TAW#+5S/6:Q#Y26?5)#*.P1#,8#1
M@8R#.>##,3QK79P7/?!@'Q+DRLBG4PA#-\2#.;B#]OS/M.[)3.H&95TDXKW#
M/`R)?>U)_SNL3*R%Q#O\5P$.2CA<@S"RPX]$0S0X0A?\0!2<PACN9R?80!#8
MP2EXPAYX@1E(:!Z(`C1(0S4D`A,``7720`_\`!^``S?D`AWH02=\XAN<!BM,
M@0X\`2TD@;:-0H=ZP12@PCD<@0VPPGP2B53!P!L@@Q&4`1C80`],00V8%"_`
M`10\P1$D@0M\P2HDPHF"@G$H@2*L`B.XP1'D@2?L@`W$0!A`PRZ``BNP0B*L
MQQ1X@14P`B2(@"I``-^20B.XQBX(`S&PZ2M<PMQ11#B0`SD@@X!(13ZP`SS`
M`T)QQ:KA@XND18"Y@[/Z@O=-@S!<*6KR`S=`0S1XUCJP8$@H@_].""-[C0/>
ML06N>JF`+0,P)-I$2L4U%$/\C$\U#)\U3$.8D4,VE(,106[EL<7'_**N%4-:
M#)0Y/`.A4D0SZ*D959(.1F_)$!%_]88R)`"!E8#L[H8R",#4L,DDK`$!F,,D
M&(`^2``&H`,"G(`"Z(0U9``&H&MO((@"'$(^6<6.4$2VB-E`R%[*W-JL7>!_
MS15<4.J(#,,P^&"LZ88]O`,YG(6<CL\XI(/V*:"HJ$E8C(-EPH,U(`@R!./_
M!$G_"1.6A`@!O8,RW`*6>04S-(.0.NW=L$4R$$,W&"0_C.8[V,.%@6M\R=X^
MD)]8R.ENG)=E[2JI'*01G8.M$1`84</_,G0"&`!!%5P#!`#!*%!BV\QL,KR!
M&>!!%;S!*:""'HC"M[H;,40#+TQ(/SB"(HS"*%@4'KP!'T`#%D1!%%0!';R!
M'M3`)^0"#N!!&>3!.8""'LA"#_-&.'#!'O1-$DP!L27!$3B!VG[!-H#`$MC`
M&$@!&/C!%VP!!-!`%+R!*X!"(B3"+K2"$YR"N-G`"\!`',B!%'2"'ZRR%$"`
M)#"&*ZA"$7@!$C!"(GR!$>P",.3"G5F"0\U#_+0#,.`9XW$)/6POU=C:B&P#
MS0C/BN!"+GAE-0P#,_"7-;R"+[`6X@D#J=07,M`,/6B=,E!=Y8K*EP6)^.93
M,(P9,#@112"#_S!,;^<90S'<PS7@`J]A@S%$Q5S$@C&NT*_>FC7XJ50,XYYZ
M7T;#!690:@?R1A&--$7S1C`L0/3M:DB@@)<&`P.(R4'2J3[<0@!(G@9D0/T6
MPP&4P`)H`A-U``A($6^DA0>DP*#HLSX@PD]ODYL,E+RN$`>K$#@ZQ5G@G:[J
M,S/<4<A0!#:`C!J%!#;<73[1X`PMI1H9F3FL24-MQ=;=PP>V&OG<`XI5*T%2
M,A3?PEHB$CUPV&C9155D5DA0M-*EPT&:0S'(YUU0JJ"Z,)T:63NS0@SLP2AX
M00WL`18,3@_PP!L``2^T@A>0+!7D`1W0P3>LB"E4`2SHPS"T@2F80_\^0(,9
MC`(=<(&$TH$IQ`+0+($KYX$75$$-\$+FS"PY?,$8G,)=ZP8Y#`$,?,(K_,W?
M[$$<U(`-X$`%=$(VP$$-3$$/#,$1Y``05,`<=`,<@((JP((D[$`ID,(C/,(<
MH$(ON(`+Z,`-/$$1H,<.V((WM`$%(($0[``?U(X4*,$3!%TQ@L\VBDKE'2F?
M9.8Q;IT]_="&E$.Q>$4ZP(-7+(,P`-3ST0-E\5'QX=^:E,,[A/`ZV)[J4NK,
M[)!<!.HOG0,*K,P\/%Z0C*F&+,,@N4.2N`5%6,,S('$*I0,U3,.0S$-5:*Y4
M^./V<`4^V)H\U-"%!/9(AW1C"IA'%VHF&`#_@?&N6)"`H`!#`.CIO$J%)A"`
M-73#&AB2)63!_"K`&B!")7"#"#A7;^CP!QPU?V6,!G=#/6#".`W*,J1XZ1(8
M`U,$A["X6M2?/TV#;A#8/1@(02KC.$BQ5#1)[.E0,*2J,")#IJ]#-]L/;`(;
M7,"(CF"7B42#,:B#P"$W5]@#-]@#+BA7/M"S5)P#/B%YD#0#L/ECD*CU8/:7
M_0`45XQ#-]^:?'+#/`C;'P#!'E!!%-R!+/@"&.@`OI&!%?!!.KC!$_RQ'EB!
M%5B.&MK!'G0!'O#`$]!!-T0#%\2!'WM!$T#;%N@`%.1`$!R'*7B"&EB!'CP!
M&?#!.$C!"Z#"J@<4_PXX7#00070D@13P0A5401(D`0SX@2IT0@_0]Q,T0"DL
M0R/`0AB$PA:0#B\HPA^$P2<T03N_`C1`0`U4@0[40!GL@30@P13P0!GH`"J8
MS1.\S>U89D1PGOVH\`_-P_]^R%QXQ0[.B$C+CS!X10TQ\5?7@\!4`C.0V/-J
M2)7.C(:D@TIJ22[D<P<"`@H@@LH5ZE7P`PF\J8K,@SUT^*^ZPR7$C#GPEH=<
MQCFDPSRTPUG,Y3V(`Y^<")=&+`\AK#X4.;C^H@NR#!8S<4D+F$E+162R23`H
M`($%@IT$PPBH``E<0)@!`P,0>Y'0M`%L0SDH0!LT@C`,PP(@0`)8PRM50O\C
M3+I8+`,SI(!%RF=6;$(Y5(*?F\F2#75NA$,L6((S$'K>S>:;;$.H4T2F+L,Z
M&)XR>#0S#$,QX)W]"&.@[N*B,L,K/$F7/$-]:74]-`/AR0\S<,D[U$\]^,(U
MW,/P"[Q4,`,\=`-HKDAY\1!%7\@YW&`<6<;_7M;*O.":`H0^@?K6Z:-W;V!"
M9^42#JQ7CQBV,%`^2>'!XXVN:*M`37E"Y8<H7J<^Z?'2I1H<+T"FD-GSI,L;
M*#S"@-+%1`\83Z:T*7HR1<J;.WQ<V6(RI8:=.SKHW`L3!%5#J5.I#LQW+L<,
M4LMB<)'BD=2<'#J\]+ASPXN2&TPZ,?)S!(82&3G_C,3YLJI+#1E&&CQI,$11
M+#5S0#W)\T52$2E'C.#0I:A+'$9=ED3#)<T@L&#C])%C*+`;KFGEZK&[AW"=
M,'+Z\A4K*!#?P'7SQJ5#.#"<-638ZNDSD693(TO%IB$<]TZ@LF'8T+$>9VP<
MOU?0V,%CULR@/A7_QDT:H2SA/H'FKM'+-Z)?]G3,J.GC%JL=.7:<]2$C=Z_@
M/7+F.D?K38Z^<:P1:!UG8KN'GOS&$2<V@<Y!B)YQ\)E0GWU6,XB_A#)DK2%^
M&DPH'WWFJ2J=$:L2J)D$Z$GH'&><`0:[V(`1`+Q[/I0*'WZ:25`839*Q1Q]F
M$`FFPF9NX0:_J58LYQT,_TK(SIE*,!&FF7SR(:<8?"C90*`0^5GF0@V+B27,
M@<QAIBIZ;M2GG5>8@2>?<I91IR%ZAA'&F7HR#/$=Y/0YYS6!QJDG'W-6[#*9
M6X11!YZ$YCGGG'S6*688>I:A1KS8EKFE/8&V*4B99?"IY\803SQU('PD92:=
M;9"S;C6$]AGGG(;"$;5./1NJQ\394C5UO!7GV7`@>O@YM*%\Y,&%&$6.^*2,
MKS"*Q(E5BHB"#"FD>`(57CKI9!I8:B!C"2_>,*(*(_*0PH@>K(C'F#@4^4:2
M)GZ20@<F<FG"&"E^X(&,.#IYPI5SC+C!%7W61/54<7!H((Y8<N!B"R6DH`(6
M:?\@T(&&3ESI1@YS/6FC@25NJ.`'(WIQ)!$*NE!W"AIHF"&*%Y;(@Q%"L)#F
M$D+B2.()-W#I9(HX0$GDY=!TT6>;2")I11UK3`SRE6(Z&U"@<FXY1I]ZREEG
MG=@.I8><>M[9YC,1*;V%G'=0V$0?!&_9I!QZZ&&GMWJ*N:45<>+6!Y<!US&&
MFVZ$N67%2E`8R!`5*E18S7V$N02["\#[,Y-+)E'A`Q$$":$$$P;9I*!TN"FG
MF0O-P68>:ZSI3>%U]%MGQ17Q>9T:J</[\S5\1MPGG#]K;>@V)8GM,NZ%"42V
MJF8LX&\-\,03R!GL.@L`$X65%\AN\=9IYV][8(==H'K_BJ=J@4H>#Z<00SSX
M1R`5--''.X49GGYZ@:Q)ARJRI;H'.06Q&[#B]JG7`*I!XP"2PL)Q'T'!+D(#
M*8<UWE$/:_1N0(\R&VFL@8]PK`@_RN@'[)HA#'VX`Q?M6-,^\L<\AC5$0/<P
M!X+*,0_PL68?[DA/JL)Q/'V4PX<BVH>:&A(;?-@M(6$+SXCPD;\NN4,>N</#
M$_;P!ALDP0AW@$8KP@$+&4#A"6/0@0_N8`M>S$$'5O`"'JIABB[(`@RDT,87
MD@`$@HW$BE#0(P^JL`M=P"$9.ZA"#7HPBD\8)AQ'Z`$K./3"4XGG'$?0`2-@
M01<I*$$)56@"*SRAAQTP`0)8_X"'*9BPK0;\0`U4D,9DO)`$'."`"Z&(0R^L
M\`0HN,`%77#$(LJQBB90`6A5.`4KED`&*F#A"^R"QBN&$;=A$,,;Q$!3W/(Q
M#C#IXQWI((U!E,&0=]2.',@"FVS*$1MSD,,:V]"'(=+@M7*<0QG"6$&<D`&[
M;5AF&ETS"#;H%`UH<`,7:%+&!NBQCR;J8P1$$DBFBB$,_J#`$)-8P08,40QJ
M8.(5\;1&,"IQB!*4X!#DF$<Q_$8@88P3-OIP'?A.,Q`!'81\^C#'!7='D&DX
ML5B'(J!!^"&5$"%Q*J1"U3DND)Z>&J2@^O@'(@:2`*9NKTL?6D<RAE&.>YA-
M;/00AO\)BT=$4Y6#&0:8'Z3^=PSLU&\@^UA'3&5CCA`!"Q_>``?L##J0><AN
M*NY`%@'ST2A'D>8>W(`ADKZ7Q)8RSQJ'"D=L^.&G".)CF_4H2#D:58YIO`,?
MT[@&5%/JR`]I%1GS`&+9Z'&-\7!/-F$+E$#F00]SX+0SP9.*FAYR(WFL-E4N
M[),^AE&,/%!A"E.H0BF:8(4<\(`*NHA$%W10!3W<P0=V6$(#JN`)6)`B#G$X
MA2YLX8E%K((18'#!"\8@!2CH@0Q0T$$72+&+)L3A#4L(2AG,%853N",4?&B%
M(QD6FW-TX0Z*^,41MN`%+RR!"UQX@RA@(8HJ3$&^4JA!!/3_D(HYG"(,7GA"
M#L!0A1Q`(0Y%4((7MA"+4+P!%34@0A=`(88G6.$-KJA&1Y[P$SH`-PG0@$4R
M&NF>;^#V-`6IAV<&<H]/P>8<JM*';<Q7OK`YL&L?.(<]5),=%$Q"'\M@Q@+O
M`8]J].D=^;@&-NI&C)/&9@/J6Y%X*!&(A`!5&9.P``<F`0QSK(,=RW"-,#A#
MCV.8YA:"^,`K"#*V5\RC'@=1V#PN@0U]X*U!J2G(A!J$CV=<+JT&16?_II>/
M?1!P82%2*U4*V^,BZB,!V0M&)HIUCA2D(#L;^$!VTD1$?*P#%Y8`!C9[DP]Z
MW&(2E;!'\9@(&V$48Q#+H,<K-!&(_T`$@T(S?44]`K$X(Y(#&]9+8D-+*L%8
MM"*?^3C?.W!;+""MXQHQO>H[MED^=)"C&]9@QH:J$8UJW$/<(6I',]J1Z(:L
MPQQW;1`]F.$.>RA1INMX!S-Z\[4^C:,<WH`%[6[$6?N=ZG:O0(XV5_0.<NR#
M?$RD1Z^0=><_36T@Y"B377$E%7G@0QX^_=L)%<TL14B!"S5.Q2IT,`8KV"$*
MT!!%'H#0W"G`P&/=,,<J=G$*6;BB"Z=PQ=,BH8]6S,'#;W!"#L8`AEWXXN93
M^#`M1`&4-_P@#^7HP@_VRU^&S<,(+WA#+I*@&"DD(0E;`(,.KC`+(A@A!E?\
MP1OP``8E&/]!#5X(@Q*(,`4#/X$(2WB"$7*0A"ZX@@D\,((4;#`%'7AB%F"8
M0AG*.P4S./X)O,"$,CPMD&HDHQ[M2*Q`($0[=OSI,_3X9D/,0>ZSI:,W]"@-
M8?6Q!D,(A!G((.(X)%".;7!C&_Q!"'+(8=K7*;P<N.":+T:@C\5ZVE`DN-`1
M]?$,$HR`$BCPP]]B,PW9#^@>Q<A@W"B!`343Y!C+.,VAVG&-9?2.0,8A'&+.
M=WH#>,BJ(;S!&M@!Y1("'^C#U&AM*J"JW!I"/"A*'_R!$@SB'T;@'_[!&>P'
M$3!@YJBB]09"&3`!:ZY*'^RA&2!!$YILH>HJ;I#!$=;@FUX!&/K_H1`4P`)V
M+1TT8;\Z`,N,:!R>0;8T1!->X898PQ[(`18<(1I:*CLLZ'S>S'RZ81CX)R'J
M81J$09T2(AJ.[17"!!_881C*1B"X01C\HQMNCPH-XADV)!Z&`1?H9.:P!!@8
M@A[09ASHP1JP@1N2P>+XZS;2`0Q%A!D:9!^:H4$0XA[>"5EV*]$.94T:Y!UN
MXS;4:K&F8A],3BJ`KT)B(T1PH1I800JZ@`NFH`O"80N@X,-^(!*8X+>@(`K>
M@!%L@1&P(`Z\X`Z6X!:S`0]J:0_<`!3<H!=@X22.H`N\@!%6P0]TH`FJX`92
M`1;XJ`NHP`I.@1NZH`<2QNU.I5"(H`'R_\`29,`+N,`(GH!=J$`*D.`+\H`)
MSNX.PL`,=@`'E*`3$@$,O$`,C"`)OB()IB`)+B()&(,(C"81,L\*FJ`4OL!B
M'HP=O8!=I,`3&B$6N"P9N@$>>.4/#6)6Z*&A>F,=QF$>=@LVO(<9Q`$97@%Q
M<`T7D.$:DF%O..!0N`%LQJ$@#J$0BD$3V,$:!.L>^.<=K*$VD$,+F8&9/H#/
M7H%KSN$5QF$$U*>N$&$#**&G^F$3V`8ARJ$=LD$8KFH:CD'(R.&DF$$#YJ<<
M5(.PS&<;D&$=K&$U6`CFR.'6:@5VUH$<"N+E$L(KNZP"%09K+LY,3-"%4B4P
M4P6AW&R([&8<,O^D=O0A$P3`'S!.*DP$$LTFT3+1*FS-1E!M!>*F'I;!$-;`
M#Z"M@L:A43P@>]**'V#+(.P2>88-%J*!"U&K'I!D*O0#(5KG?&1G')#!KU(E
M'3+!&&[O<<@!'5PE:W"A/5RG@I!''Y1A,-_A%I8A&;2M:QIJ0\+!>J8AG98A
M'$]E':*!&$YC',+P3[23(#JHD2*1'LHI(6).1([JT6)*J(9E*NY*YM8A'J0B
M%Z#!$<SE#:K@#O0`ZFY@"GB@NV2A"[K@$S[!$YZ`!VP`"FB@"J@1"*)@#&Y@
M#"HT"6S@!N;`%#ZA%TMA#N#@$YB@"X)`#48A#H0+#*:H8*@@!TYA/$__Q1R&
MX`7P8!6(X!,Z80NX@"(+3PJ\`!JN@!5"P0P:H`:P2`F\BT7!(`?HBPLBSPR2
M0`>T!>^:\0V,AA'FP!7"(`[P8(W2T0MDP0M@@!$:`186J!ZJP3;F03Q,+AWN
M5!C(<B!PX4*Z:LF*X14N81@D2QB821^.`1@(X?A.0PW703R+P00*E36V@1GH
MH=\$@AR,89JX(1)>`1(^X!Z$P1*B@2!:01,H`7[$(PM4@#\*RD@L81SN01V*
MX1J>(=V8H1RZH2#&81KP@1KP81D^@#H!J!@0@AVN(9SVH1V&IQZ487@L1"#D
M81EJ94*:@3[O$A)7+E6TM5BH`A^"*'889A(X_\`@4B`$!84>`"%[8L,!"D&?
M^F=A;(?=3J.E6%!A[($>Y`%!]*$8#"`8\B$V#D$!5``3#*4>(DH?QH&@<I0U
MWN$8BD?<N,<:K&0JI(_V6(0JO.8>QH$;F.<:KB$>F--&8H-VVJ9"3`50DJQ"
M,,L>E&&UUK)XUJ&>#&(8UN$8*DT"QW,?IF$8X"&;ZL8@:(=8TL$97*@>&.Y\
M($NFB"5!4BYM8!-:IV(=!*O(]"$7B&$.O*`*HB",@*`4ID$'B@`(]$`2DN$=
M7N$-/@$':(`,DH`61T$6DFGPU(`7\``/:L"67N`)4L$3;($9DL$5.F'S[.`;
MX.`)RL#QS&`+9N$<BO^@!W:!8:MB'7#@!;Q@%7+@"([@*YY`![A`#'3`#CB7
M,6Y.#S@7B[:`"C1W';<`[Z9`"0IR"L0`:,#@#\(@#(C`#:1`$:[@2+<`=;>%
M77)`&C(A">%!'>H!'HQ%--]!-1\-I9;,.?U$$X$O'?KA-=Z!&ZPA'KRF`UK3
M"B6H'$S@%8B(W9C!&$R$>8OA'3#!$KKA%@Z!#>HA'=K#'O)A&Y3!'5!@15)@
MUBA-'X!A!>SF'HP!/.MF&A1N0+:A4TY*'X3A`U8D+A,$%QS-(!I(IC[(5$JR
M:X#H8L/)(&J+]M*FB!J01:!V>&9K,$\D17I*31X0$RC!$()!$.PG$`(``CW_
MT8@:Q-_&(1,@P57,YZKLU2!&)39L4+!,Q1R`84C&@S,,H0/T(1B4H1"GIQV(
M81OR@1^DV'[PC7O"D&PV2V%TLF'-H\C<81\@D7O*P1[",!U>(T2N`4G*08W]
MC1["0;+4.(D(XN-RZAS"9,C4$$'&K#?88QS"A(5R](B"81FF@1LJ:!LF9(9&
M#5/7X1S\9""*DJT25F438F-ICGE:Z]1T!43NF).MEAA480M&;W.MP!.D814N
M21JA80Z`SA.8@`Z(011&@0JBH`R&0`>,H(J\X!08K`F`X`[4(`]T`1>*8/.H
MX!M<@1&$RPR\(`JBH`I$H1^ZX`E,(0(C]X>:(`D\_\$7<F`*WN#%H$`*P,`*
MJB`5C``*;N`'.(8'7&$4GN`&Y&M!><`+IH`+DF`)[(4'>@`*O(`5J*`&<*`,
M8&`*?J`48N%(PT`*JJ#`A.L)P.$5KEA09(>('*(8QN]#S.%33J=\NJ93`@O*
MH@$YF@$#MH$>ADW_ZN&,@200U@^-@74:@L\]D&$9-$`8N,$!D"$9"H)B[8<#
ME"$8+(!.IT892*!KAF$5LN$;JH',5`H=JL$:4.,8V@%QJFW)D"%W1HX@Z@%9
MZ:$97DLV='*U[N&N1,L:X*$C4ZXJ\.$*98,JALA;29@J+(#5@L'-SH$#@@$0
M,N$"Z',=`N#X/@3EY+J(U/]$&1JA$MKZI_Y3$WOMAW(M&?9O1Q*B&390'U#@
M'^@A$S(!-I-%($3U%NZA#LE'U.*&&GIC&F[A%OAG'&X!3>XA^5;+/@7B'1J*
M'-0)(:[B4([W4-Y!&8JAG)AA&&ZA'.*!&G2:'=+!OS9YY*[A%KH!0C#KM@I"
MY;;!'M+A2*+A,T;;`D'$I8H#&6H['8!JK61*'DAR;)(*:*N65J;B:\ZA`;&7
M>\A'LCC9K0CB0T(D&J2!%(:T$\S4P+1Q%U;A"3YA"<8`""K`!\"!%;H@"G".
M"Z#`#O1@##ZA"I*@"E)Q#CR!%R0!`HR@O,I4#Z2A%9JQ"LST#>C`0%$A'3QA
M#T3_P9NG@AFVH`SR(!:((`F\X`@\(@KN8!9FX0@@3PE0P0K(P`8>H0N^`!HZ
M`0Z,`$-U``9T``^&H`>J@*`[H28(*0KHP`K`J`M@`1J\8//HJY4\SQ9>H1O,
MXQZL`4A@^F+UX8`MF4,JV5/N(\A\.VNLP1WN`1N0PQ^86MS2D_;NH7[]80/Z
M(4,:KAJ0%2'J`:4/H1*$80.\(1E:03V%2@4FH0.`P7<28APNP!YN853C@1B@
MZ:J*@=6SYMBX88@LP$`T`1FJPWS@P5%?IWP:I!P(!SDOEF.Y87OC`5GP6B":
M<(0?IXBVAY)?:`.8NAG\03P,X0(NX`,TX1R0"!`(`#M,_^5#C@A9"FK@^J$<
M\@&(NP82KRI$8F,$/N`:,I$>4*`#..#X5D09W!4?%(#5G.&&3P1@G<'-XZ8X
MUD3<F#,=[@0YUA([Z@&H;S-G#8(:,B'Z'/`Q]2$:H$P?F@$8;F$T8;L;]"$9
M7D'C;F@?:$-L,C43;J$?W*'0"&(9U.JRF&$HH\$\03(<OXHTCN$SY"38`\Z^
M<<.QCLH<R`>R1BZ(R.&$&Z)M:%`V_&KWN*<)`3P:/,$+FL#`O*(+J@",\`!=
MC,`*[F`//D'#H@`*[N`.MN`.U.CT?N(GJL`*W!$//`'`4,D'Z``68N(.'`\*
MQJ"4A#D?KJ`'HF*G(C<?TF$(&O\`[XF`!Y0`**:`$7X!":0`!M2@#_A@'D!!
M"LJ@`1H`BW9@%$(!CG2@!_*N%+I@%(Q`";@``F!@#[Q@#N*A%7[)"(Y`$4I!
M<+T@#K9`]7D`&6"A/21E&@"V-^R5W>(&)04B'2QYR";+S\DM$LG!/_3!V;+#
M+%]#T?,!&#8@'YBA'60'0<!G'#YR&O+L`[*@$=R#Y&\#8/4!$`+!%PRE(<YA
M`]YA&4PH'7#!K]8A$_@'/^H!((Q-TZ>/7CY*?L(58S>/7;U[]ZCAHG:/X#U\
M]>@98T:P(\%UP^9!A*AOG[Y[[3QZQ!=.94=\*5WJR\=/IKYPUFRZ])>`8#!_
M^L9MZN?_D9Z^>@Q(E'19#Q^^E_E4XJM8T1ZW?/&HWK.G3Q,`2C/U_<.D3]F&
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M\4(>L!!1Q113/'%'*%W40(8+HSSRRQ%$<'$@#4&\`(0,0W0"PQA)3('#&TE`
M8,,,5;C@`QV*?.$'-JK0\H012"@R2QG]>:&$%$]$\XHU^-"33F\GU?/6..58
M5`XUG3'SU%SV,,.--7&>=,]W^I!C3$XH@#73.MNLN0Y#^O!D4C?=<*.7-?#D
M4\XXZW2##3L93(!,-_>4`TDNZMCCSCOZ8!)(0<KA<TX&KR!3SSG*;$</.:]<
MH\]3TT03C3?WU'0/,A<4\PYFQ]Y##C?7;$?04]9@(XY=@=VZS3@DJ;293?6T
M)-,ZUV$WF$R8FEA2`L&DFJY'FFS@2_]8E`B0R:XN/;=K8("]\U`^#U54C[YY
MP7//.`28H,\Z1A4"R%,D**-/,R40-`(*!9D[4V`TZ5..7AV9=%(\)\F$JDW!
M`=97G',!ELXTXJA4D35LWGNP,DT55T\SX;Y5CC'J=+1..->`_$XWLAK3"CL>
M(6=B/NO<$BE'!UNS753YO!.38..$VU$YYNQ#G4?K/(61.3&-J](YS(`LTS;T
MI.QS9Q5)@\T<7NS!1!=[W%%%%7&`84H<<>21X=Y,O!@C%7<<",4=9LAX8'LQ
M>O%&%Z$P8LH7NRBBQX6=?&%&%QU*P<<^BHQHL8D5B4,$#9Y``T,22R1A!"]=
M\*##$3&,X</_%#WTD,06H,#"1`55T&`%#C7H,(L4,.3`@PL_T."#EWZ$8801
M9E!@BA%D'%'$#[Q0H408"_J0S"O15,1-.F_1X_ZD?_G<SCGU6*,752>M(XPP
M>^6CU373H$<'@+&K-,6)'N581R;6$`P##`8>\?#5.J(A&7K4@QO3@`4^/C`"
M?;R"?^DPQBND@RI?4.Q]'+O5!RRQCFF\8AM;J4PTUE&/>D2#9<APR,&`$XA#
MV.,>["!'-(RQ&63$;SG8($<[FK&=N9S#6/.PGW*,H[6SC<,FY)"'3<Q1,H^$
M(S4EBDHA.$"0<_##),[(!#V$D8+!F$0%!N"(8_#QCT84IC`6#,M1__Q'F5"-
M(Q/"J*$%]:*!`Z3&,?3(Q#E0@`BQF2--"9A7%T_WE&V=[F`>P9?;/-*:31*$
M',?H4T'^0@\^<6P?'EN&K.CU%'X@XY&!:4<Q.).78E"D,,,HQSU>P0E+P`(8
MF;@'OG12CELD0QW<^,PVV+$.5.7#'9C2(KT"U8PC=J24UL2(QYCCL8.5S'U'
M,<HPY\&V>KW#+F')134D,84J4,$+5.C"AJ"0AU0D`0PN>D/=2.&%*4A!GR\J
MT!T`]"(`\6`*9<C#)^KVA"DHP0NL`,,4XO`&+IC!G50H0R_PH0@:B$*/E]0)
M.8;0@#?`(@=$,((-O.`)'$`A!TKX`2I<T?^%'-"`!S:(@")(`8MMN&$4>8A#
M*$@!BCS<811;@`8L2D$+",#@!S@H`AYH(8T=2$$)7.C!+$)A!"I<E0G"V(4T
M(%(-,'JD,!1QV3J6L0R;C,,8Y%B'5I:C*WQTH!B=H8<SBD.)#33C`M>A2CF^
M08WTU;`PT(#&!PIQ%&2\(B7%B(4U4@,,$M`#'O7`;$6N48P/X,(;MB#&/;B1
MC&UL@QM`K$8UU*&.EG1K&7:Y!0;XU8YH0",=H3J&^Q!H1(*$(W[*`HX^UK2K
M39K#K"H91TUD<ER;Z#(Y+AD'=$TTC@4X0Q^5((L^$.$'@I3`8;O%``+BE)I)
M5*(1F!"&-?*"VWC_7$:N&\O3+4QPB%?,(QVHRL(`"'@=94R"('HEB#-0H)="
M6(`@W;S-,!'\#F>YI)DV00VWYJ))0$DE'?!@1S?TD@]\1&5:XSBE4=BACFN4
M#!_-2LU(]+$,:URQ*?-XQ3>^8PU+M"(1B$A$)"ZA`C9TXS:N`D8RRC$/<KQC
M8_=HXK(.=L3-R$-LG<&'/;;1FWQ0[6`)3+#&`*4<?F&L(%KVB#U$J0^8K4(*
M50`3%.#9A5)`0Q%=*,,/U$`%'?B`%['(0QXJ*@4?[$$/5=B#.[M`!3?DH1.\
M",40C-`%*;CG$^?[PQT&*KGV[.$4YE`$&3ZZX)!Z1!PQ*L4J<K"$&.W!_P@W
MN`$0*J"+56P!!E9(`A1TX`(81.`+LU"$(N``BE*T@:ASB,,?5.&'"-C@!C)X
M`A3*8(0C[$(73K#!#G9@@T[T9TQ/F$8KJE'#:7#L63^D!S=D4@]T\,F3UJ#A
M-)@AF8K,XQKW,,<&LF:-Y-0F9(9P`"4N$`R]3,8HW'`:A>\A#`40HB#U(,8N
MH($.8;0"%]<8A%+F<3]]<.,2V/A`KJ)1#6H8XQWQ2,8ZO$$,;L"#Y.R0!S*P
M(9)Z'.,"E[K%--9W#VO`NQS,:,RSQ&$4<C#CB@21S$N*@TZ7F"-F'<-'%8OB
MK7J-(\PV><H__E$2>HPC'\%`@250`(AK1B4!#O\PRCA*T(Q#J$#KLZS'9[3R
MFFVH0!"#((0*#G$,?<!C#0!XQ3334D"G%"08)NG`?RW6Z;Y\PR;K,)M*[/4M
MY(+M.QC#1SKL0AER1,4DN-789SA&F>C$SRG3@*]CE+4.J9&DL-4P!BPL(6-\
M&,,6J&H$)#J-RGJT`Q8#V8V1/U(.=Y2#*Z':50V?K(]K=!-1-/3D;L8Q17TT
MF![G0"XX7^*QZ;J,S`!,Q!3&@-`R5,$-ICA%(HR0A!W,X1V@,`\7=$"'4^`A
M%'M[PPYXP(0\="$.I?#$+*X0H#N0@AC2@#O>MPNP$`?M82``!0KZH`A[0"*>
M!A?A(`4]\`C3T`-[`P/_/*`$5/`+H)`+O^`D.2`%.)`#1O!GT:,#5``*N]`)
M7:`-53(+K/`%,/`"-$`'>$`$0D`$4U`#21`#N%`-GY!K-:`$,9`A3V`%W[`*
MTD`/\3`-^.`Q%?$^XV!A(:-V[5!ZY8`OY(`R1\8-J#)!08$!US$.T4`-HD4O
ME"`"D7`!TW`-^O(O%;$-Q9!,[.`O!@`(V\`,\``/T9`+T%`-Q.`*N9`!)P`1
M1Q8/LY$,V5`"EN`-B35#[X`,T]`-%%0/\5`-W.`-U#!NII$I6:`"W,`:W"`I
MT7`-T&`-BG<.P%(-KS!N>F$/[-,1]R`2^F`.3:<2:B<3^%`.BB<8UB08J=%\
M_S)A$L&P`#5!"2D@8(BP"5&6)@6A`0&@%LPP`J]P""@P#2I@"?IP";Y0#,40
M",*P"1TP#2.0!24`#!W0",D!C9>`22[A=\)0"01A"!<P34^H$U&F$]\@C`<#
M=?CPB]<$D)^D*X&1%^MP#1P3>ATQ/T'G#<0W#RACB]*$#G9Q3O/P%.:`6NM`
M#481#Y#`!K`0#_`@#;M`':SP"FKW"G-!#Z@4%HB8#-'0-GK",?G08D@3,I]!
M#LS7$=?P%/M@#M'G32NQ&<W@-O=@$L448HD!$;&Q$NY@$Z;!,<1`#7`@!=Q7
M!6;@!=IP"C1P!$`P"M+P#:\`"@,5`S90!C6P.WJP"_]>8`=`<`=OP`MXX`4U
M@%`P,`6E@`?24`W,T`J,P`-)\`7?D`=2T`55\`9@$`6HD`]=0`.G\(!P,5(-
M$`>_D`-F(`4Y<`-+D((X(`LPL`1*H`0Z4`%Q&0>,``ZG4`,_H`-&(`5'4`5/
M@`=;0`0Y0`%Y(`VQ``JV\`8-(#LPT@2OH`5J,`<VP`4A&`I<H`3$``O:,`\1
MM)+[\!3^(QW3U&$:TQOGH)0$X0Z#I`_MH(D)Q&W6,`+)D2G6@`OCMA9K\`H>
M0`[8L`T;DWSWH"_%8'KV$`!9H`\E5P[<$`W?``[5T`K=X`@F\"^Q,0S&1`K9
M$`B70`RYH"N#<`B)E0[L@%G_^H"@F_$0\#`/S,`,AM!UDA$/Z:`.T`!`&#$3
M1F$-X)")($,2E6$R'S$P10>C)D8RD[0KYR",ZW`U4/>.^H`"@E"+TE4Q*^%A
MEU$"`=`(!&$.65`(Q8`(%O0!@&`(AO`!);`)"E`"C2`(KW`)%2$,!'```R$I
M[_A(98$)[F,!8,&/,I$/-\I[NAA7V!$.GN1;)^)\Z=D1&?$.U+`.[=,,@]$.
MV#`5'18.=E$//X9@:$)7*]D,R1$GDS&)A-`&S#!EW1`/X(`-TU`-N(`+N>`-
M_E.+;?,1VG`+W.`7PM!6#Y$.M]!6>K0.Q4!D29,:[W`.([-E%;,..I=\*O$.
MUH`8_R&C1PT6*6ZC-"+C3/HY#:1`!-S7!4W`"U^P`SKP!U!P"DY0"F4`!&IP
M"KK0!4L0!$!``T`@!48P!?L!`U5`?E!%!"S""F[0!7A@FHH@(T80!ZY@@)*#
M!U'`"_00!C;PF)!I$^(P!"_@"8X0`YU@!#)P`U-`#)8P!YX@!3*@`SA0!<E@
M"W%`!$>@!=S@`T\P!$_P!%WP!#X"!44`!3A0#U_0FJ"@#9]0!36P!#E0`_1Q
M"K)@!$2``TJ@!TI@!-FP"M.@#M^P7L]R?+=8%$UA$>G0#=MQ#M?!-A"6&["P
M&QWP'>_P%.E0#=Z0$\"@<9E0#LAP<M2`7Q"Q#?90#]^0#/_)4`P!L`((MPW3
M@`S#D&35<`G&8`F)@`VL2ANO0`QBD079$`\@(P@2D&[VL`[JP`[E<`GIB5D7
M]`K'``P<X`[<\`W=H`[$\`MSQ`]/\5;V`Q'V$!7V4&\@91+R8`W+M7C+4*=6
MQRUAPUP"::-&T0P&0!3.X+:[8A3.Z!A):PD!@`"WL"N0@`D=``F5D`4=4`D)
M4`DCT`B',`F-H)+Z0`TE(``B0$/?\`Y09Q*3X#!BL0&9!%)PP8^ZBF!G<S4O
MH0_GX&`J(:L=$Q:LH1)UN`Y0`V#D$`[[@)!)DZ-R:A(500[JT`W?88C,D$#R
MJ05M$!MY@8G=T`[B``W)``NK<!W_/UD0>.%"PI`.F1)Z[%4-MO5M*($,UC!,
MB')D7J=#%N1@;?-MMT(/)OP2%9$/RD`-7.$24#<2<T$,T:`*2O`B/_`&V!`&
M>>`#4;`#KN!^/P`$9/`&3A`-MA`*H/`&$7L'G_`-C"`%7O`)4S`*BB`-EG`%
M_30%+$4*<?`$2C`@IV`+3^`%4F`'4X`*]%`ZGA"P`BL$+L`B-F#&1Q`%IK`*
M8D"$MB,#^_H%1\`@Z;H%NY`+32!K>%`$7F`$8^()O``'.N`%9>!0>.`*3`!3
M7#`$8>`'OI`+56`'.@`F.@`-V\8.*T,R['M6('P2P\`-S`!#_\(O-00/IJH,
M*\`7!,$._[7!#7*X`;<@&=2@#A!!#L_@#9@5#>ZE%Z]``(.`7\VDRK>`"WI!
M#L.0!8M07]$`"[^B#N0`"/GI7NI@`@Z0#YA%#^TP#)=0#0Y!7M[0"G[+#!>@
M=M&`"ZO@MR=A%'E!#V>2%]'!%[P(HTO!14Q19LQ0IPCC)L_2$>8@D"Q1'&R:
M#RVI-(%`1OR0-0;A8=-T5O`@#!\0`!Y0"7^Q##)7#X60"8)P/LSP><60!0)@
M`)80#_S9RIRD#Y,`%,!@`$"7OK=A?>]X#CW*C_B0J#8,D%Q1#JTL,&5&89]T
M#NNC#VJ#9>0P$`X=8C!C$65K#,%P+.OP`=M&#-5`TWEH#".J5/_8,`R@D7GO
MD`S"0`S?<!JR<136P`SF($KU8`[D0%Q'X3/+<*M1T;FZ^AD6X7R`HB;@],)N
M^A3J4`[3D!4+1ITN`P]^.A[$\`55P`,_<`>SL`4]P`,X8`6HP`V8;04_`)M)
M@`=ND`S7L`JL(`F[0%.Y,`N9#`OTL`H1FP-[8`5,X`5=H`N[F02//`6G$`=4
MT$Y5D`?TL`4V\%%TO!+%AP,N(`F@T)MXD`@-P`?U5P,V0`-3(`.CL`HD2R9X
ML`=4L`[V``YUY@F[@`H40`>LX0Y-L"'M-`5&T`JL\#HYD`-,(`5(T`E$8`5S
MV0!+D`R,@`U["$.(9Q/[,*CO2`VZ<'C_+BQ7$.%[M\`!OR>+#4P0S*`!PE!W
MZ8`-O-P.R\`,T.`-4MT5"F`"PG`+-61W\<`,L%!W)]`(U)`(J[`*E]`.\$`,
MQ"`()Z`/X``+T*`"#*`6[\`-Q4`;HZJXUR`0F?4,'5!FMI4,'#,7^#`-P]!$
M;^AO1.L2\T`<A'%DW];0ZR!-8([F9].+^%@O"3!XB``4;+H4^A`,&C``!7,+
MVZ!S_$S7MR`(&!#3A[`=W0!R66$3S6`(`*8`_S7G4>?3'J&341>[E$$RA.%\
MND(OAO$1Z$L0]E#5[S-ZXX`+[7`1+EQ)R[`=AU5#Q<`1:1@/ZI`,Q%"'\<"G
M/`,+KS`,@+@=_^_`#+<0#92H2VA;#M?`#FV#-FYZ*7\Q&2'3-N9P#3DA3+*X
M,^W6T*'BII#Q;>]PJX&"7\XWU4,I$X<K2M&@#5><9L*]!'9P"G.P"MI`)L*M
M-SYP!T_0`%#P!J=`"GF0"+8@#:X0;*80;#5``WL`(P/%;&`@";`@!730"0\E
M./'J!;Q@#YUP!ZX@OL_M#&(`!:Z@"DM`!%00#3)P[WG@!4G0.U20#5_`(#C@
M!:%0"NW>#-NP#[%@?.,0"_?0#^.P"G,0"J&P!?FQ!6&@#6ZP!&(`!E70"4B?
MW8Q`!$O``[FP"B8'#]3P'9.TDS)QM!T1#[K>#;KD)_?P&\R``/!IMO]!EQ)5
MTP&:\$+U4`WH\`WN=13E4`VPT`U<`0D:\`'TL`POY!T/00T/!P+M#`LXCNN1
M``GJX`L=4`ZO``OL0`@+8`CM,"BU(!G`LE;3D%BM40_%H`'7@`O20"I'21#6
M00[0@`U^<A2240^6T1&!P1*Q2V;[&W5F^HXSZFG%>%WT8`[-T*-%<1+4,`@/
M0``"0``<T`$EP$$?8``",``+T`&W\!WQX`[N`!%4J!+.8`@FP0$=-+YOZOHE
M,4SF4.8=P^8%4>LZX7AG&RB0.A/VP,_MX!";U`['(!U/`5WI\`KH(%<G81+K
M@`L`\2U?/7WW].E[E6[0FGCP]''#]>V>P63_C;+IVX;+V[1;P[IM@X6-G3YR
MN+B-HS<Q7K=XW*C1.UBOFL%ZY<09I%?NX$YSXYB-VQF4'C-RZ\H9W/E.ISYZ
M],SE.[@M7="@Z_91+<@NW3VHT*"!FO(IC`XH.NP`H[(+3I,H5N[D,/+)%3%3
M4IA$N:.K%!567$+IZC)E"I5<NTAY*2(%S!0H7K#9FC.+B)<<3$KAD4**'YPQ
MI_)=Q1I:=%!\^J8AL>%)%1$B2KJP"G5D"RT(-J+0ZB1FBA?%7.:8,F;.EQ\Q
M0X0,$?/'5[U6<^)\`>-ERQ<JBD)Q$9+D$V\\54J%$:*$2C17U?3)C,?T7;UZ
M2,L1#'UN'=9[^*:A_P,'35<W=?K2V?NFG`OF<^D:=F1BQYY\3J@%&6ZBR269
M>-;3!Y]\\CGG%6+4J02#$&#B!A9MTN$FG7?T@20+7%:)Y1M7&+GDE55P\0>%
MC*C1IY`21D`F%V@^.$8?:J;9Y1MHDF$'GWWP">:#:[31!ISV)K(&F6N6(:>T
M"_-)29UNCL*J'G+$H8^D$^E;I[2@H,*''/BPD@>TT>:L4)]`+(!IG!/.I%.?
M>-R[!9(1-,`@@PDT6*.2?MZY)QYUUEDGG73^A`DK>@(QYZ!"+&!*SCX_W8D>
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MGW"(:("46%A;`H8X0HG`"%7,R.&-5HY0(@DNO#"B#%#JB46(&69H@((<8(#`
MA1F4@(8>1\"((P\NN)`B"5I4$:,*6,)HH)-?CD#_P@@EC*@F%FGJ@2<9=?)9
M!YY[X&E/2*`^H\J<?@]24V!'JZGFRS^[>8<$879:QQIKKMGVGA)J*0>>>%I9
M(YJM&CZ('!\K.8"#3-_I)AKGHX'&&!/:<&458UK!GAA<8EG$$A$6V64J%0KQ
MXQ58=!<D1&1VY>8>=MBY9AI+1A`'FF^D\;P=9JI)YQIRD+I7HY)AGM"0PQL`
M#,HY3A<4;D`L-.]HQZG.,34Z<6`$3-&',F9'I])`ZCP+W,D],/<-;7SC&_'X
M$SRX%)1]-(4?D\B4+PPP*A!2D$[;6`JL#*8FK*0I-/G8!D$N%)1Z=(-A.RG'
MJ(*"E&M8(QW?>-,]TB&._W3P!RGW*`<ZOI$,B12$'HUH@S2Z,1%UP",7EK`$
MQ*KQBEO@`ANKL`0L\%>/<0AC&@[9R3B,@0Q4#7$=R]`'I.J1#X-$JB#;2!=.
MND&5=9"C'>@82:H@",)RU-`_"*S*1/1A#&-\00IY:,(7JB`*:23""US``Q=B
MM@M>*"(.G;C#&Z#AB##,;`]Z>`(>IE"&ZKPB%UO``QY`<0IM*$(*9N@"&!21
M"%_`8@MF>,(=.I$#4>PC##R0F@W[A(TAR``5L="!$GH@@S%0H0<WZ$(V&H"#
M;KB!!T9X`A7`@(=9.*(!NWG!"V[`"Q\T@`9H6`($5#&+/\"A"X7;`1.RT047
M\/_B$4C0@0_>@`,H$$$*1HC&*J0Q,&UXHRGK&$D]&/4.6:$I*`CC$CZX^(Z1
MK$-;ZZC'.E:P08/<@QO6>$4R]($!0:3#&_DXA`FN88QH2&60#MF'_##P`66\
MISW:@,4K'.$(#9`B&[DPQ26P!XM66((4L``!%DQ!"&-\@!,LN$1_/C"!-4*C
M&C"M1S:,`0UQ3"(+]*B&.L#QD7%4@QO$F$I-[Y$K7"R2/N4`&$&41#MYB*8<
MS!"-PNJ1+QZNHQV8'(T.1<."%!SD%H?XU#TH9`]S8+$<U>(&-[J1CC)ZJ8S)
M`AVLD`((8!RD&0[P!P:U.35Z7&,T*1&-.7A(&FL<\2#_2C'(<.^QC6VLJ2#P
M\$8[L@&->43L(25:;4$(XA)O9.-_!K%$%NY'C<N^0@N1X"XQ6A&)2+0"&K@P
M1BY<88E7F*L@]T`',H!Q(D+>:QRW"&((#Y*.FN`P*.8PE3[@08YK,*H<PXW)
M.[:!0%B-`\([F7!HZA%8?;@5%#78@R+<4(8]N`$,-H!!/'50"FU$1P]X\$(9
MWJ"/872B"56HPARZL(,NF`(>R_A"'O+@B3UPP135N,)N>L"#),0!%IVPV2B.
M4`94S`,,U-PMG9@1`QB(PA$PP($-7&`#6TAA!B^`11P:D(AVD.('=S#"'7;1
MA0C88!:JP,,I>"$-7J""#J*0_T4#7N`)5H"A"5Q0PAO2L0H9`.$60\B!$F31
M!!@D07*46P4XYJ$.;^Q"M.DZ44WAQ4)\P'0G^R#(59J1IM.>IQO)2$8Z5E`)
M[?X+'NUH131"L(8,%Z(#]X@&,;K!#>:92![M.(8"6-".752#&BY=A2,BL8P.
M$,(6D4C&+<J!C&L%6Q\J&$0T8`$-#80W"[F`Q0<<D*UO&`P;PE@&,N`!B$#H
M`QW<T`8SS$$._L4#/DTYR#2PT4=8\6,:[=8D/:JK#W-,,#3T<(;G=L*J>W0#
M)C`99,/"X:D*50TK%Q8-!];@*T-@HDX?/T_H:IH3>(1`&)V#!SS684)OP.,;
MODO/Q/_U$8QF-&."P4@`)?0Q#XX?A'05LB2HQ(19IO0**^T(QZG`I?,+I:,=
M,('50+C1#Q#BEQQ69\>9;,J-6Y-C&U"Q1SJTD8TD#HP>(;"%-J;!#&)HP17>
M>(54(V&+5L`B%\2HQAM-88MDU"-@_8/&M%X%E76@XQJWJ"$YF$&-47/%'?:0
M8FKIP:IT##%>YW#'.IXR<<\G.$S6#8H]():>8,$A"5`HA2EJ4`4KC&(*!^6"
M&GB1"#"8P0MWP`,J1O$->W@C%G"`ACV0D0A8(%8;GDA%'+R`!T]X`A:QN$(G
MI``%X!_T!KH(Q?9[L8XNW$`468ZLD(Q@@U.L(@=)(((-=*#_AQST(`BS@`8,
M<M`$:,`B9JU0A3K;CBT@A55`MUT0!5%(ICF@`1>8!5(P`B_X!6CP)!UP!6A0
M@ARH@5#(@1Q8`M;(`7!8A6EH/!)BAW*@A@V+"7U8&(,`C=`QO),[D:N`!XMC
M%/88"&9XARS(`B^B!WNP!\P!EC4``5P`AWF;H0U+ARS0@FIX%G90AWI8@`R8
M!VQXA?;J'FKX"`VXA7A(!UP@@$6XAG9HAWJX!F8`A!!H!VH@!Q-80A"X%BT0
M`2U0!V@@AF%X!5P(AW-HK'\(!G$@AEF8+F.PAJ,0K9JJAVV8AFIX'WS`N@HA
MAV=;!X"9")BX!VN0!WPPKGW#A_HP_X@58H=P0!4UJ92B""$U<410H0?0`!A]
M*(<.4(%,P81FL(9QR(?A6JQ[&!81DB(M9(8!:(1[H`:R*T-X2(><`"G/X<6#
M"`1:TX=,,`!#Z#C1\#C401VFHXH+,P=XZ2]<F8].+!W3JXKF*HA\83QL@`\=
M.H=K*`V5*QYJ8`=X8(8Q>A4QF89RX`8#4S#;L09.*H<3:(5W,(9=8`1L02,T
M8J]L<X588"\0""-8^*II4`=LN`:N.`^CN)UPJ!2H,(AT8`9K>(?A@@H2:1-P
M@95Y0!6&8Y?2*(=1$XJ4I`J`HXJ17*0+@1)%J((D<`-;"`,OB(,[4(0GX($W
MX(5=F(-.B/^#,L`#5S@%47@%?A@'<6@%6\`%7."%>-B&<0`%/)`%4`"#-\B#
M/2@%;U"$,IB"-P@%+S`#&2@%6,"![N`#?0"%/9`:S4*_@\`&,5@"4G`$#\P!
M'L@!+_@$&Z@!1C!*%WB!+O"_.:@&W4B%4,`!3YB%5G`%%XD$7C"#(0@%/;"!
M+8"&46`"1WB$&+@!)E@%5<@!*1B%+_#`(U@")5"":K`$<"DC:J@YW\&CXZ)'
M?;B*>"R>W*2*<FB'=4B6220(89``7(`&:G`(8OD30LB`:-"&:C"!!QB&`<L`
M"1@$;6BC7.B&%4"!:VB%6,"%:J"[5C`%9M@`9YC'2R``+4"'8TC_!F1`!F+X
MQVE`!C_(`'0@A#50.Q.@A`\P!EBPA%SP!F_`AV58AE@``6*PA!C!AFJH.8L\
MCS,L!FMP!Z9@AUH9)*N#*:XP-9PHAZFHQH89APG"!^&JJ?-X"?K8!VQPH!:2
M2:,#.4::AWN8AZ90K`_@@.JZ!T+8A`I9N$`BB$;!'"_\ABP@@`<8@`-```T0
M!JV(%/:8"/8('7V8!%HCB$I8@-I2K)@T.HY;DB6A1JRX"D)JR2I5D)TX!^-"
M'1]*15)DE_L*BG?`AG;;"0M1$DA)"7R)F'4HD71X*1%BBF(8!XY@AGB`E'O(
M!FR`!6'(`C:8!DQP!6M!([^J!VIXA4L0_X9JR`4M<`(32`1<:(6I6H5H\)R8
ML@9R0`=R*,10P2(<8AW'NH5J:`\A8A7AH@>C,#6FX`8W)=+1J%%)\14HP1@H
MJ`(I>#X<\()2*`(>&`5/J`([*`,OZ(3J,X5O2`=8N((<D`$;D($:J`$?((5N
M>`Q/R`/@FP,\N(.ODH(=\()4T($J,`PI&(,NJ`)4X(<KZ`%3\)6[S%-]"`<A
M@`%'^(,AB+\D4`(A"+\7R`-;(`4=$%=7(`6/B8`Q^(,BL((N>`5\P1Q]N`0O
M(((:2*4&>)%08`4(&((\&`58>`0<4`15N`(D*)PD$`Q3,`5<B`=T4"^=XH:<
M`B!@8YAU0(;W>/^'==A('@*6[]*N$PD'#J"&8;A#:IB42]($#9`&:>"&$,B`
M1F`'_-*0$DB&;L!#7%"!!.B_;#"?81B2=%@'#L@"2_`&3/B`0K@'7'@%8R`&
M6$B'#X@$?2B!-6`'9(#2:,B":V#":^"&:>`&BH110?B`;!`'T`$=T7/;:Z`&
M9KB&]UB\P6(/0)V*E"`D0GV'6DPNI-N)<'"@:3PNESRU<("7$OVA]/,X=_'$
M;\L`9S@/?1"$28@7!+NB85&*F,J"`2```CB!:YB4=(#"7H$'IT(19=B&93@1
M0="`4:F'@J$*$4K%V?V4[C4(:R"3?_67="BZICM3T#`(?F@&2VP5;&C_!SP:
MKG,H1(5CF)P07T(,H?DH![;%!69@AF28!FU9A2*`!4SPA1.MAQ`9AM0RCW<@
MPD48(&K`!>$Y!ER@+[K;AFX8!U=%%8,X!D0"W?30H778AE<-#?.=Q!L-"F]P
M.IV[1&!-NJJ%BES0!D:``C*(@AW(`R:@`!W`@UW`@5%`A2>P`AQ[`T]0!%/`
MAB[0@22H`?DSIR#H@1TP@EW@!E'(`SVX@RT`@RI0!&U@@CPXA2VH@1M(!2]X
M@BIX@RB0&GZ5!?(%V(,0!R)X`2^#`1ZP@24P@A@`A2YH`"]@!%)0A1@P@AP@
MA6L0@P:X`=@0A5;X0AQIAEC`!U*@@T\(!0AX_P$WL(90*((82`)&D(18"`,I
M*`5'.`*%)8(D6((I((5%:`5XD`;Z>H5Z(`:MVCQ-4D0,6N!L.Q%N0-&3NX=I
M$`9^.8B:N@H4$`9NP)9;Z(9^TX=;R();6(57^(!+$`'HV=M'98$2R05P4`$'
M:`2-R(5(,`9]Z(=@.`0)&`9CR`81R`(0>);Y\`9QX`9"<(!$T`)OT(9ZX(!;
M@`>_'803^(9AP`9JB(;IB@1YAH=JD`:WD@;GL9(&VE!\X#!ZP(9IF`9K&`EZ
M<(<W*0>I&!:AR!-K,!6/4Q-JL:249!-@M49J]"%=+`A\()A*,`!G)(I-0(2"
M8.'U.)!Y\`;^4`8!&/\``5"&=.B=>,@&$_)"D*H'3=@&2`@2?2@&#U@!G;"'
MD+04KK#+W>*'R4(*>/`?IL,'>?A2%D()WM0A7?Q5H=B*=@B6(0T5!E/<(Z('
M=G")\J2&$]DP?X.(84@&;,@&:3`&$""$+%@$86`#+8@&;JB&9#B&=?`&+<B"
M86`=^#!A98"(7,A#:8@U^%!";HB']PD[$BX(0%VMW<2*<%@&#\K&_[$N6)F0
MR!*N'U*'3]0''U&$UTN"'+`#5P"#'OB!78"`'P`'4M@"O.`",#B%63`"&N@%
M4'B"'\@#;>B"USN%-ZB!4Y"%3\"#/)@^1<@H%Y@#6"`"'<Z#]Z.",H@"/JC_
M!S_H`5:88ZQ8AAC8;E)XO][.@4^(@QJ8`2EPA38@A23H@1=P@G"(@1>H`5>(
M`U'XAE=`@CB8AS"X`N&Y##^`@!E@@G+H`@A(@B=P!2SP!44P@B8`!3>(M,E1
M@BF`!5$@!FM0!Z)RMFA@VWJ\%R>J#U=,5!'*U-$+"E=-AZ\3K-*8!`YX"!IW
M;,B>!TV0`&-(!TI0`7M@@5N`!DN`A%<8!D+8DURHAA$HAD'(@$A5`4$X@0EH
MA&[H`&:0QP\8A`_`!F08QF;)A6M(!`>(A'3@<A08A&G(`&M8!PS0;"?<5&C(
M`#]@!VH0AFA@GR^!P:%;CTNTAFC`!5,LB'P`0GUP_X=B,`:8S%/ZG88A+36"
MD`?31;V#:"2"H2`+X3AZJ,9*/)-Z:"QE<(`1.!-E4(9F*(0(:TG,\2E]^``,
MF(82Z``I90<3BCFC.(9W"(1BB)="2`!"8(K(9H^`V4C@F@=[:;H0<FE_.9-*
M(9:!.V9&LC!P?&GC_%=660<#00I[P#@Q(42Y/@AC/%#E;0J/^Q,2208G&I*\
M^H:@'F!O4`=+`(%DT`4G<();:`-(B(=D&`9DT`036`2'H`=N8`8<2JU@2`9N
MF#D(@85D,`;X!6QN^(8&NKI*=P=^P,?4VD4=VH=UF`8W8;IS6-UX,;KA>2`0
M0KOAN8I;V(4P>`+>GH)2B/^!'*"!72B%),`#PLN%4O`"8K("&E"#4V@$6["%
M;P@&9H"%4A"%B.V!5.`%,"#C4_`&9YH"ZX8!&QB%4AB",S@#*H#6>O@"&Y#O
MKMXM@_`%&'`!4WB$'(B9"`P%(X`"&;@#5S`%';`-(#B%<("`""",S'"';9@#
M"J"`&LB#6)L#*?"$(G`!'.`&1GB"*<@!*BB%3JH!P0B%/WA-)1"#)-"&3.LO
M>I!E<*B*]3@M9-B*>?"\]VF':6@/F`*=B.FM7UU&<["`9CB(<BB&?H@&=I!F
M#\@M%,CU$3"Y0X"$;8@$9,"`0J@'87``9W`*3"B$2,4%7>"%=,@`3(`'0_"#
M9=C_@'7,-D*0`V)X"9BK!G'(@A)8AB8GAT/8@'1X+V(`"'V%5NR#5T^=OGO<
MZNF+5X\<N73ER%F[9BW:-'3P]-&K1T^?OG?KMBTK=X\COH0)Z5EKMJ_>/)`G
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MU>"E4\<PYSOI;&,..>5P8]E0'D643C6@*970.N$\F%-*]`AFU#T(8K@62`S!
MDLP?4CP!A1))Z)$'&4F8THH2/=0@S2UQZ`&-(SGLD4H<G9C"""S4@9(*'IZ4
M(D02TJP"ARCW))+#%'!PT\423]PQQ1%3>)&$%:?@`P84K!SU)9A&85/B+H\8
M0<846Z0BA0TY=()*$>QLX<(3I>BS3`,V?#,-*-J$LP\V,+Q@1#S\;.-)',B8
M8H,,U)0S!PXY>,&.$:E\P44<5__0,H447B@Q13>N@',/8]S`XXTVW7SSSFCK
MU(//.]UXPPXY&^7#D#C7J(-..FDU5`Y8]:03333LX//9)"S<0TY,Z5TB@BZ-
M$"+,!*U4$PD(Z60@3#?=(.<!)(V<4`\SW23W#DS<Y%)-!H4D<\(M]E@P##?5
M5+/&+=$8@PMUJ\"BS38E''+(/;VN\8$TWN!2US#'((,,>],88TPUS%Q#++$+
M>J76-^V(4Q,YU8@CSF+ZK+,..XS1XTTTU^`$DH4`4K/;4?0T8QD],3VXSX,3
M4EA44QPMQ9!228&D#`<9'&)9/M;@PLXE@L1SR#KNO%-./.F\<TX^V]!#33'?
M9,&-)I7_O!-3/9IP8($F,K%TRRWYK+.,,-R`Y!E(Z;PR#5#3W$*-/N4L,TQ5
M7ZZ#C#%R@?393,Y-K'A.VYRF#SG#*+/15]N(,TTNQGA%:C[Q.+W*+?&`)!)(
M[6#C#3:O"+-83/E\5L_)!E+SS</=4C-,9>EXHPXWZA#3B"TB@&."%M_H@LT&
MCK!SC0:1W-.-,'`C@U,\W,CW#5C4W'),--YPPWLT%ALH$3?'5*-9-=;0G%,]
MY6Q#SCODV,W:K?OH5+A1YY`#YCO:<91\E(,:\/@,/?9A#&TH(@E/F,(4='`'
M3\"`!Z;8!1YZL`0U]`(4I8`&#D:1BBG<812\T$4SZJ$,7>RB_Q-E*(4KGI"'
M:YB!%990PA*J`(U0&,$%<2A%#:0@!2B("!7\",4>O/29,#%13$20@2M4H0,>
M+($(>#!##J"`@T^<0A%*Z!0.2+$,&[R@"+CH1"A@T8HCZ(`/-J#"*RH!AE"0
M@@(S>((N(,$(,!!!":MPA2>>(`E3K((44M#!%+C@!6ZL`ASM8,PZ\,$.7+Q"
M%^5X1V2L,0V1U6,CC$G',HQQC7J,`S)@V89O;K6L<$R#&MSP"B%<-TIK#"($
MS-#'-Z31"$ATHQ7?6,,$%I&,5>0B&=X*@0-P@0M'O"(:ZKC'.J8AC5:\P@25
M.(8(D@$.$:QA&O"X11824@YI)`,7QO^`!C2NH8(#3$,=NGA%.;*0!2UHX!#U
M:,<XNE$-<O@/%]A@ATC:P0[>W&,>O;H'?ZS!,EQ0XW?P,`BI$@*/:DQC&M>8
M!U,$^)5U$(<;D5%)P:;A47W,PVB!*<J%'%04C\2,)Q;Z2%*4$I:8,&,$"3A$
M,%;#GW(P8Q#W$,0A[%&";FP"$/D(P39N08AN)(,:';G'-BJA`0=4HD/S28A'
M2$4/4P[E,^WXSSR^<1+>T..C0%DB2,KAJLLPY"23\<8]\K$/>^0$'E<S!RDQ
MF9##T&,<Q,#&1R*:$/8D@QGJB$<^[!$64BT+&<)PG^0"](Z'[I54\$`HJ>KA
MG.5XPQK((`3_,BYA@E9,X"[?P,<AV#`-$%BB&L2(1CK8,0YF+",>!E%'-X;A
M.F]<-A[,6,X[DH&,;D0C&</HQG#7T8YY+%<G\>C&-M+#DM]\Z1X.,6M.F'64
MN&X#NV--!VGTT0I>/&*(4)A"$G10BCOT(`^@@(44C``$/O#B%:"X@1KV((4Y
M2*)!,M&')<#`A2MTH@<_X`4KM/&%^.;!%*#@`A1(T84G/*$*59!"%(S()E@T
ML<,_,P8$7%`*5>"`"$18@@R,<`HVS<$5;F`%$HA@@RIP8P<O:$`,YP".;2RB
M%0`6A3Z;,(50"(H*X$B$%IH@A59\P;Y$0%(<B)#>)"1!"L<@A30N_PL6>*`C
M&Z\H'5890@YC(",;V!CKR20&WG2LPQF7!%\UZF&/F-&#',7M2G46\0$ML.%_
MZ0!'+F`AK-PF0PNZ:(4NJJ$.X2A5%Y'(!3>(P:]CZ"(9EXC$,-*@A5N,IQ$=
M@`<S1'`+>A0C&;IXSSVQ(8YC`.,5B'X%,JJ!GW3,(SV;40<\YL$.=?#:&UNM
M]3K&\0YKH'(8TT`&.5P64=XP!"8%;&@\/E)6I-!CV--PU7_^PQ%RN,JD)C7*
M9SQS(9_I9"@I]=D[!%.,%"B`!8<XANEV\@YWN",8[F"&,O+AYKR=Y!R:6($#
M.O"*SZS#'O:`S%!.!IK"O00H^+"L/=`Z#_^P%,UGC"E*7&67DW6,QB/:AJ9:
M9Y+8G81$K7)AQT`3\MQD)*,?VS"X3EP5%F'Q=!G,F)]FFM.<:M2+Y<S0;2Z\
M88E7W$,%EU@$",#AC&I\`^EM:(7>I/$-F=SC&LD@!C.HP>9X?*,<STE(.JB!
MC&T@P^:JZH9U%9N3YS+C&][`6C6VD8ZV'DOC@?E/NHUB#J&PIB@F`9.V<Q(+
M;RCB"%5(@A)XD`164($'[G4%*RA\`U28HPDT`$(J3''J>[RB&_K`CSZF48I4
M=$(&-^A%/;Z@!"BH`1R,<,03;C"+(R2A"@_T0A5DL8\K],`5??<P$T\"#1G8
M@+PXD$(5B8`#5H#_00=SF$,H'@$!'G@!%_%P0P.,P`H")\*I'[&,,CR!!R[\
M(08S&,7GAT"$&-AB#HLPTR=<@00E?%'`7=B&(WC^C6>^`]?>D(9)@,5,G$P]
M>,,U/)*T8=0]&`L]*`,U,)WI?`4^O`I-I$-$,(,PP`(L0`,\4$,T((/WM$<T
M4(/4*40RY`)UZ,=&U$,W0(,VC.`V[$XWO$+0A4LY@$,\D,,@:,$:+,(T60(N
M$$<U9`.O(0,Q:$,U!$B]$$,N"9<Q:*!UY`(Q6(>^&(,W)$,T5$,WB)0[I`,Z
MO))`(01O/-0ZT,/%7(Q&,$5@;97DQ-9`$91;0<3_=(BYQ112U$,^!`U;_W45
M3YQ$RLB9P6'7!%Y<X&#""5C`!:Q`)6C",<S=7JD<`3E#,&S""6B`!)1`(YP&
M9J$+-.C"U!T&1]S#-R2#6*7$2<R<1X#$.915P:3#[,!&_;#9?\%,-W@%6J55
M>FS#`:&+/>"#VMT#-D37*8(&;XR#6OU.6/3?2=B#_%`#-5C#1(#%4&3/$M4#
MNG326FA&)\&&/?3?*RS"-Z3#!QS#!V1!-!"#)>2")3Q`*V25:2R#<-0+-EQ#
M,R2#W)VB9F!A/V3=,A@3L*P#-V2/N7"#*Q&#?GP#.;1#.V@(N4$'UW3($IU$
M7WU4QD&%AA@%[9C5NH"!%TC!%#Q!&:2"&8C!#?^\@39T@1M4F`Y8030@P0O<
M0"KD@2UT0RQ(017`%Q/H@C60@B>``0Q,WBL8`1=,P1NT6"L,`0_@P2?@@4U:
M21EX`CTH@@V<`O`!'S8(@8@Y@HDEP1+D`!6X`@XDP2E$PBGDP!+HP'W`PC%`
MP"B`01%(01C`0@)]Q#SX@B)0@1'D`1[H0'T9`R@021/8PBK$@A)TP2J$@1$(
MI1)<&#*P@C?LGT-T$O=TX-SQQ'\@%$T@FS4R!JG46E",$\]Q0T=T!&M4&SU\
MQFVL0SPL1SRL@SJLPV4QUCHP`S-40S2H2S1\PS(<&S9H@S6`UTE,E!'BPBT@
MY#5<4CT,W3<P'3R<1S7_V(<EK,(J$,-F\`=;P(/_B4,T$*';:<,W:,,U8,-[
MN)TW\!9FI8-8Q8,WU`,[T(,XE*<UF`:SL"?,/9P^2(0U,,-NQ%7$X<-EZ0,\
M#$?)(`6!.MR#?,82W>+=%(53?`6ZJ,R7>`2VE8/:<8,P5,()F(`'6(`'=$`(
M?$`(A$`&=``&2$`&?``;7%.'`(L`<L,MX`*"O$H9&L/>)$1*V&?*W:%F+<,R
MN,-7X.%]@H\U]%W.W,//#:G0I)5CO<,V`$,EG(8U\F(Y3,,R$,A:Z<,X')ME
MJ`4Y7-LQ7$(RD(I#W"<L:,(TI$,XB)U%$$8TZ!HT&<M`01-_/-1$K`,YE`LD
M_S@",63!)0C#!Z#'/LS#,HB`=L2#/6Q#<]S",-R"0IWB:B+#;W%=-_1C,IPI
M6ZQ#.GC+*[%%<\Q,NMU&7'75?UDCL9G51S'+1QV+1,YAS7076IW$NH2"E5A!
M%>A!%!@!$^2!(\@!-$A!$DP!'<!#..#`@;U"(O#"/>S#+.2`#42!-(2&*3@"
M-(2!#>C!/D1"B!P!*!`#(\1!&$C!'9Q"1[Y!)TR!*XP#[_E>57;8+Q`!!)""
M*AB!%"@!%^2E*TA!#9#")5!!#H@8,C2!*YR#&]3`&WB"$)%")#C,-%0"(^R`
M%'Q"&.0`*<##*CB"*73!$.0`*-B7$B`L&'S1$83L%O]00RM$@ZK$0WL6H$&V
MPS74"CO``VR2PQNR0S)HX3<,`W*&Q3C4PS=``S$,P\WA6F7*&4?HAG7=@SVH
MQ?C<)C4<P_<DAS!,@V020RL,`RS@PGZ`5ZPXXRLDPSR\PS%8E*2UPGI^P_[M
M6@%&0X_@`C=XP\_:(W(9`S$80[%<@]GNW]EF`US!0SO``\KRFF:08"X1PS)<
M`S6$ISBT0[61RCOXHE9Q&T6P(F-AQE=80]C.G;;A@SR80\\0Q=W0@U*`+OSH
M3U=-VTDL!T5BR$F8SH%\A5",0S#$KB$4PB#$$MP$#S2]!YNQ@VI&E(&4PXTF
MA864@S44#CY@FTIX+F^@PS7_,.Y_4HXU*.!*4$Y3W<:%S$TQZ,,)>(!4*,,V
MO`,F]08T.(,X(0.%4@.9R5R'7,,K`.&JH$M"6%KV=D0ZL*PV;.`UB`,U+`,R
M7(/A.D>GKL<S,,-MUD(;W(,EB``Q"$.8MD,SA`.V.($N$&<T8,,WK.:!-$=L
MMH/;XL(P"$.#(-07=L,QF`I"Y58QW`)TL9GB8$:P,!:;<8,Q"B!34&[\H`4H
M+@6`.N)1Q`]=!9X^Y$(W*$)'5H$7I`(5,($7X`$LU,$N@$$45$$7W,.P/H$M
M:`,KS&0^Q$(.Z$`4@`,_*(HK5$,<V,`GZ(,Q@,$6/($:N0$TT!X3?((G4,$;
M>,$4_YS"/OB!'<C"NC*1_F!#&$Q!+CB"$7B!(DG!*1A!#N"`,R'!&XC"+8#"
M`ZU"C36`>SD!*]""*VQR*9""&I1"&#2`%73#*L2!)$@"*5#!%"A!-N""#Y""
M(W2"@"7!%DC!%E@#+#`#,3RF-:H#C>(">X9,*8&7-;8F@*I#-)#3D#*$A6B/
M-$3#)S7'"%[#,K1M)[9",JC/.1;7[6(#+F#S/23#+>1'S78+=GH#8>`'K*GG
M*US"--R#.4P#-)RC.9&33F;#!^J'0^Q?-<R*=$Q#%4Z,+YR3SZ*3?9C3<QK#
M,$2#"QKDB^:"-$B=-:`#6`Q4K?T/[=CI_A+#R8)%8A'02?^0@S`@ZCA8%F\D
M!6_LPX6\"NE^KDKAS[E]!/B*!*X%GF<<R]H]%6.@[,NFG&)9%]A]@]^:;2UF
MC4B4`VGN%4.HM,,-1<_0CMJ9FV!E%F,=AC3&#-5Y[L8]Q1I``C"L`"240#&$
MP&G>PS-A%?CJ4S_+%%W=)Q**IS(<0S=H73%X3229`\'Q7#I(TJ[`P\O"0T`B
M5,H]!(")P"NP04G@0@:Z`C2L@A:T@1R`0U-%@S5XA%Y=C'#I<C]G#4%VBT=]
M$C(`@S`0`Z):%V`/%SAHX7Z@@V]XRW#-Q]\E1%L3!4)IHU8GB$;<ME7]Q[<%
M<34P@@-Q2AQT`1Y$$!_L`G&K<A+_>((S(($+G%X<S$$_P$(3T$$V5!@O0,,/
M*0(,T``J0,.G[($74$$K0`,5/($7=$$JV%ZG<`%5*@(9V$(?A\EG_$(,N``I
M@((25$D8E,$N+$(2\(`K<$$#2$(QK,(6!`D>0#0.-$`HB,$7@$$G\((B@(&%
MFT$#/`$XP`(CA$(B2`(T5`,6R(`J7((.@($J8,,6;($2L+@44(,K(',R_`YX
M:<\VI,PZ;&'+?HPVQM9)S&.]!`])F0,W;`."3%Q,U%HV<#`W]`@W8$,M@D7E
M5`-C)$,S)0,Y2</Z=)(Z9,,SSW,T\"\6)H,&CB`S((,WM,/^<7`U7`,TM$(K
MX`(X1/1M_Y8#8-M61#S3/:W#/""S-V0#-&3#"V8#,;1#-2!A.?2YWF*-V<8#
M.*0YS!J$6EV,,+1,R[(9[<P=Z"P@5V`#-K"JP^G:C1Z&\2*</LP91MW&.;3T
M@LJ$ML%$1*GAU8!4*C*66FEC:W;#G+%9+JF#-X"#G1\6?ZC%U3Q2AA!'A]`:
MZ+8#.=BG3#P<\'KN(,8634ACS#UBLQG$[`RCT*C`!Z1`"&1""4#""$#'55N(
M`/+&@%@#VFFZ9='#.:C#./Q%!4_,;4J.:CI$._`YRFE&>UX#?S![FF,#;(F#
M%FA!+MSO%!I#H%T!+"R")5PP;I$Y,F0J86B#-K@M,5R#-]A61O]7@P=2PRMH
MG6:\64DL1D%UTD/5`WJL`]8`!^UH66S?,#>\C^Q$1EC8#^"5@X^6V\6]`CET
M@DU2`1=\T3=\012,@B*<0BGL`!1`02OLG@T``2]4P2DL!K?H0RPD@SU@`QU\
MPB?80`_L0C@<08G@`2[0P2Q,F"R(`A%`D!7@7B_00Q/T`%7.=W6AL0SD0"FP
M`A%(01F(01XH`@[H`"JT0P[X0#=\@2*D0BC$01PHPL4T@0S`@`N\0`W$`0S`
M``14P`T8V6]WPA>``BE\`1QT0PT,03MXPA%00$\>P19P`1B$032L`H.``S%(
M@SK8.5C8EFU9@@I,C#@`-LK91#$PQ#K_G",Q)$,XG$,Z_(3D`$N"T(,[=`UT
M$7MKYG@U!&%A502Z8`;;,73GY"98C$,\`#0TN`(U=4,]F,-3U.(VK-`VK(]S
ML%PTO$(Q+'0Y'`.7,4,V9`-`3!/'KINW;-BR95.G3=V]>-7`<7-73YTZ=OK8
MP6/G;9XX<>FX&4.&3.0T9-GJD:-WKUZ]>_K6:;1&;9RX<AA=XL.G;U\]?3I_
MRM.);QZ]G_J0ZJ1W#E^]>4B1TML']=X[>T;U%?7I,E^^=_?`OF09-AZ\=/#N
MG877TF5+?=_`5:P([QNZ=/7@K5MW%VDU8Z_((<7[[ITP8=.HSG.Z,RG4<MRP
MO=/[DB<^>D_%_X+EQHR;OGPN/5_SUGF%)GT=;AVZP$P?-UW,ND%U7&V;/GK,
M<%F[1^_8L':"9>M[66ZOM6VW<%';MLW::';MUI%#1\[:-&74NDTK5XU=NGCQ
MO'.SAU<2FWXBF-W[MOX;L5?4B'E39P]L/(?=J*6[MX[>-6O=T.'L+*I^LJ:<
M=)Q9IZW@&'PIGW7>*4?"<NBAQR>PA*-*LG)`D^TE>KQ)1S9\*$L''V*J4>0)
M*Z:08HHG3HD#"E?8<(6+)'@X)1YN8*F!BB^\0,43UG[:Z191[HB"$2.``,>=
M6*YXPHA<\F`E#B]XF4.*)ZJXPXLH4)$GC!]D8=#,,\U\R9@8<MCE$?\CO/""
MBV58F>&)7*[`XQ18X/A$ED[B^&068\;!YY0?:'A!T1>"H.$'5.*!!AI6/'&E
M%%`Z`8-2/!@IY@LJ2F%%##/,X*(+;DCAQAMXN"&FH&JJX;"<>]@8Y)`0HGEE
M&/G8L::=00R,IYZR8*%'!3;JN26#-<JAIIQQ[IGGGG'*88>-#SX8A)IDK"$G
M&F*BX2992U[*))-SRF'F&&Z^@><27.KY!BQRDOG&FVBHN6>81:+!99H3)`CA
MF!..T6>:++H149]%0H!G&Q,TF""++*+)!AI?H#$&FERJ28@88JCA!A+?ODGG
MED:\@>::04S(PI=76C9AA5ON:F><>=;IKA[_O9!JQS]CJO'FFFPN`FN=HO9)
M&A_)>OII'7R8HH>_>Q@#*B>LIBI*N);>J5`XQ13+",*O,@3+I?'884<=>.+Y
M)IZ<V=EOMV\J0L>;;X)6)YMV+7H[)I:FN26PC.#1IYYEBMFFJZRV\@DHR^@I
M1Z2\6,HG*JP$>VF;8=+39ZV7J+FXGD!(8$$0?3+)0+A++DGF$D$"`2000RK!
M99A;,#D$.4L.B>062P)!I)%#(#&D$$,F,<201FBO9))78+D$DD.8KP222AJ!
MA!)+*N'>DDM>>4433&K9A/5:6-?DE0T.T00$$PB))))6P!<&$TU:@:0678*Y
MO1CT#S&)05@"&*\(_\8K;G&+3&CB$NH[1C&0T3]A:$(3F;@%`R^X"7_<`AC"
M,)=AEA&,8]PB&,6PQ@DY9#:QU.,=V[B)<.YA.:2\I![6,`IC@E,.<]@B14_8
M@A2H8`4\V&('-R`%*41AA#&\`1JFD(8YFE"*4C3!"WS(1=I8N`U<:*D*HKK#
M/5I!#3:\H0IQ@`8LW)`#/)#""E"`PAN\,`54[.,*/6"%9]"41S/M!!LQ<$$K
M'I$$+BPA#K$(PQ@\$0L8/"$.MH@$'D+1B4YX(E2Y2%PYM!&'+L0!#Z(`AS2^
M,0Q8S`(4H8#%$1D!"E:$P@@0T,4K0/$(9(!!"6%0PA:XT0KYK.H;QB`&+O]P
M88RSK.,#60B&)83Q@1.PX1`.Z,`E#@&+9:0!$I!P`"/TP0Q2=&,-(EA$,FYQ
M`DA<0@6#X`8UAH&+:"@+$A^`A"-`$0UA#&(0K(N$"2X1/3:0,`4G,(8&/J"/
M:D1B#2G0Q1H(T8I;0$(+6JB&-430@6[04P0?.,0R!#&.Z9%#`8>`AS40@)Q;
M".(5EAB$.(+A!T(D0QB->(0Z++&&5ZC@%J_0PC`$\0%[:2$$X0A$"2AQ@!:4
MH!''$`8DJ'&-2DQC')J@Q#;680UG3.,:UQ`'?PP7E7<XQ2=9%<Y.FJ(8<T!N
M-PQB3`QY\I)VM$,QXXG03\C1#GBLC1WKN,=S5@+_%GQPR$+>V(A\U.*Y>J1C
M'.OX1C?HMA[1R,=N?\T+A`:+F><HK!ZSPMP\GA(<G"GH&G&#$(:2`E9]$,9"
MUUB';;SSDA9NHZLO,8<*+C%:%_:C&\H`1C`V(8Q;1&,9[K#M-)(QPF0,(WR8
M($0C&F$)2FQO$YBX!":^EXEAO!(3XJ/$)BBA/4Q0HA*'V$0EK%?-Z35B#6Q8
M`R36D`8M3(`-E.@F)!:QB#0<MQ')J^8B&D&(-+!`!80XQ'$/,8CNQ@X1A%!>
M(0+A7T0(`KF%.,2##U$(00B"$&L0A`H$L085;%C#:UC#(/HIB(F%X!:R84<]
MJ.&L=\#0+4"!R36>0@_+_^4#A_2HQCZ(08XK_<$,:K##*+HP!2!H`Q=22((.
MI,$,)GCB&KC(P1AD$0<JC$(4MG`%+!31B2=XXA,Z>$(W6N&%2.AC"TN@@B1R
M$8<D@*$4<9Q"&6'$CRWTX!1ZM'-P=@(-)?``%8HP@A1XL`PA/`$5CP"#&:"0
M!%+$PQ-O."(=6.$*4K@#&..H1R.,PHQ*V(-SVIP%*>!@"D8DPA'U\,,6-AD'
M4B1B"&Q`1@RX8*IML((<ZG#;SMJ1C%:X`BWD4(8@5E"(1DS@!,H<Q"L<\(%7
M*.,8*BAF-UJH"UV<X!8A>.4P("$!+4A@$_HX1BT.H8%&G"`+S90$-"31A@J+
M0/\#";R$)=(P`1&$`!(DZ.=AD=L!04C@%N^^!<NND0[44"Y;Q30!P"2P!G$&
MZ`%:R`+,LO`!$YB`=RAH!`BR$`)"9*$1'6BW(%B&B"S@@QT?>(932E""#W`@
M$"J`Q,0DC`(.8"(#6DA&-ZZ!CFM@R!XJB8<^^'(7&1((0T9Y6EAK@V>7L"1S
M9O/).PI'X[OL9ZNMI>%N?)*1G65$+0X)"S?*`8^YMLL;WJA&.KY!N(HL_2O2
M$HR"9@BA$QMNJV*Q'-7PX0[+^41!'"+15QWC#J.(Q7"G=0C@!UN59L2P'N,!
M+5+R88]O'.A"*A066FBX$7:0(QOHX$XYKD&.:DQC&LW_&`<W(#2.<VQ#]=9(
M1S/@09QNF"4=S(B'[;?ACG<D8\SZT$0;D&*?=*0C8?3A1CK<D:YN).,=:$\*
M5EAHCWZX@Q^4P5!*AN4.NQ)>CZ`=/-OHLIRIE<T>PK&<9:QQ#9_8@Q\,F@<W
M"I>+:.3A#GBX0Q4\@0TG].`&O'`%#_``',"!%$I!%&!!'>+@!?9@%N:`%TB!
M%Y(!%DHA%4)A%I+`!GIA&4AAC:9A&TB!"?A`'[K@!FC@%$#!"NS@#N8@"DYA
M'$!A#^YHZ.[,SF`A#+A@%F*!"(J`%R(!"3XA#L#`"'C@#J;`"*"!&.[@$SH!
MDD!A$?2!'ZX!"[8@#ECA"YH`_PRR`1_"`0Y801$8@0_XP!.0(18H``^88`N>
M@!1`(0YTP!10X0ETP`VZX130#AP^9QWN91>B`1O.(0V"H1OD30302Q",@1HR
M(`0$`1#&P00FX!5:PQXTP00@81PXH,#2@1`F(!+2P#2VX0260Q].X'4<0!(N
M81$(X0-$(`U"X!X6C'VZJ0V8@0368!/F*@T:0>/6(!U"(`26;0U>@@,,01]>
M1P7.H1#28`T^0`L\;`1NX1A\80+@8!%:0>(<X18Z`!(*801$0`2JX1`R@!!\
M3P.$(7C8)POTH1U,H!CT81PV@+S\@!+^P0&ZK9G\8`,XX0-:XOB^X1UP1H72
M81VXX?\ETH$<%&0KQ*,>+"1:&N\EX,$J9J@>FH(=PD%!O`,O8H(P6`*RV,%"
M]&(O=H8_+`2LVB$=Z`$C%2->UL8A[*.RS@(OX.%NV*$:7C(;UN([&O(=O((9
M;L&N[&&K,,(:BN$NV.+$P,(>?LXVNF8=1F_%[F$\P&I!"N_G4,]L5HP>XL$=
M%$8]CA*/\&)``"\KUB,=9J*P!K(:E@_UUF(N;'(]JF4[HL$DE.$U6$`7CJ<6
M0B`-'$#AAN$2Y.`6,&R:TJ`-GFO8#@X01``$VB`-=($;:B$P)2$+&.H$&M,=
M"&$;**$0+B$$5H!X^&$2*,$$UD`81L`/`B$_MN(>Q&XO\&7_&$[(&LZ!'$)O
M^/Y1..B!)(=O'=JA.M`N5AKO*)NR)V$((/$B.(8.'MJ!'>;AYUHA&D`!#/#`
M#)Z@%%[!"J)@#K1A")A`&EI!%$K!%1@A#G;A&^"@!CYA17C`#K2!"7P`"/+`
M"G;`%M+!%)`H#DIAMZZ``EQ!$:8`#V;!%:@`"KQ@#Z+`%>3L!UQA!F=032``
M`F+!#ZA`#8RA"`94&["@"6Y`#=Q@"7#I%3C)$R`I%XQA29+`"ZK`"*8`"JR@
M"(R!&1X!DCR!#O+@%)"A"("@"I@`!]Z`/T%!"KI`&YH@#(K@&$R!'=9C;<@!
M[>Z&&W`!G%B@`^8`'%+`FP[!@$Y@_Q"2H0-8`!+8@!"X(8&L(0,T@1DV0!A*
M0`*.404TH!+6P1K)`?6RH!(R0>*V]`-0`!`$H1*PY16`;0VT@`W$M!(TX"PZ
M8!$F8!`Z(!DRX!)*(`14P"<T00*R0`,@(028(056(`TLX01,H!$X8!CTX1H<
M0!K4@1F421`<P00ZX`,FX`-`X!54L9P^8%E"8!`<H`1.X!JPX1!:H!%$8%-+
MX`(,(0M$X!`HK`0>00LJX0)B(F=*4K#@KB7$@AQHSR?*@3`BY.?NP1SX0^S`
M`BOP81_@@1[RHTV]0R,&BQSBYL18:!Y`CSA:@OA0#R)WHK+0XBONX4"&SRSD
MHFWH@EWV1O\^#H)5U*$LP*XG[U487B$@Z^X>T.$OHJ&N\(*%MDI!/+(>V.$:
MHB$79L4A:5,QUF*T9J4<AH$:=&(X@8ZE[,$>MH$8I`$J=B(>L`$:JL'J]&$;
MDF%F6V(DZ6486F$8J@$[[)!NQ&6PS`(UNT&=&L\>+D$"*@$0$.$8.B`?5,`>
M.B`0!.$$3N`>%L$$T@`5E*D1C*$`V$`$(H'=DD'AZB&]:@$2JG08LJ`.)``2
M9D;EXD$0T<L<1B`+-.$8!6$3-&$<EH$<3F]6[(,AKR$OA@]7L2$:F$$8CF$;
MS@D9N&$:L&&MZHKI#`<AQ<*NZJ$=U.$8J`$T$/(G**-SK0$=,E+_'UI!&AC!
M"^[O"6R!$5S@!W*!&)P`%72!%$;!%$0A4%SA&^K!$8Z@!FB@>)_@!H)@!F3`
M"GBA'%Y!#4^!%4`!#V#!R5PA&9C`!HQ`%MR`";P`#Z)`%.AA"VA@%(X"0>V,
M&)C`"J0A$G[@%#[0"O*`%W!A%4S!"JC@#J0`#K3A&V"!$>8@$LJA"/#`=>?`
M#:S`#;K`#?:@"QPA'AB!%$S!%5JA%>#`"_(@#N@S5(@A$IC@":Z,#MS@&UR!
M\]9C'8B#&Z0A:+W!'3[IL/JA',!C'W;D'<#.&H#NYUJB&WA!%^*!^<KA&,"A
M&X8A&2"$&Y)!/_!A'/2#&QQW38^A&X(!_YRJH8A?81JZH1OB01C`3!?6`1=&
MIA^2X3BZH=_Z01W2P1Z4H1%NX1XTH;9ZXQTD00[`X1:Z`2)?`1RHH1HX:%UN
M@1HDP122X8I;(;@&0;>N@7Z(01B&0>?8X14.P1+@89UN81O>XQ4:`2@C^1HX
M@5W/8O@,AR5\`O,RLBKBIBIFJ"KHXQWL0VHN`H^HXB78`1WH:OMV9K2^(B]"
M>1[TPW#<;H92N2V@53:[#BW4@F_H)B,JPC[405SJCO(*9R60@C@@Y"94BSZ>
M[BNV@AH00V)C>>FJPB>6KQWH@42Z:OF@K35TX1OR82H$(QU"IJN@8EN8;VM<
MHAQT(4S/J1ND0?\;^!GLB&/XAB49<B$95+(-^D#=-N&@XB$-&CH-!N$#UD`8
M4S$5=0$2ZF`1J"$$VJ`-#B$>@@$2O&T3SFL-#*$>Y*`.ZB`-TN`2$E,7"*$6
M0EH?UB`QTR`9V@`2VA@A"2*+M3BU.B1#OOECRX8R/$0V/K):"6/&8'F&V*9:
M[5D?..84Z(`.U(`/I.%04($7=F`4>,$6)E@63$$6>*$7M$$;[L$:&$$-^L`'
M;J`/@(`.3"$>U$$:H*$4>N&K4:$4)$$;VBS2?.`.P*$5--@,JL`6]D$1@*#.
M9!!]&T0?C($(AH`75L$+0J$)B.`+C"`.6@$+;H$*IH`*O$`)C(`1L@'_%G2A
M&7QA/]F`%$)A!^B`"D!M"K8@#(0A'DQ!%W`AOII`D^!`1;%`$B"A$;I`"D)A
M%>(@#Z+!%+HA%Z1!)O4!'7#A%6R!7>)!BT/I=I)ANZMU6`S#&L#C*-_A&*+!
MH$<KC:^;I4RK5:(!+9X#-@=9$\(%-K2X&QB('%!3'6BK%72AD,$"\YAA&#3!
MFE]R5CS';=!8'2A"7LS"KX[SL)(!'932K[K!UB("&]#A&_ZU(NJC)3HO'58,
ML;@A&M2A&HKT'HYS^-3!<P_K'UNB7N]"+%UB+78&(:%NZ6"";+SB'8YT/(ZF
M<Z.E*FBY[.3CKL9F+^ZU6LR"&O3U^'R"($M2_S_V0^Q>/%_C@7#8IF10DUVZ
M057$[A_S0E@N1#`&:\7L@R?<P1Q<$C3B86,EPQU(5S`DXZC]INJ8#A_R0870
M&"RZ0EY^0H92-A[R'&?.89JW05C&(BR^`1GD!34A'#Q")KBJX1B0(1F6M!NL
M`1C6`!P(0;\T(!*8869"0'H0:N(LH0[`(0T.(0T0`,-"(+W:0`6L[1[8=KXJ
M`1$N=;[`@05:6A,0K!;<(0U6@!`JH1LP(0U*H!`(03]<0LK?9CNXX9RX(1ZH
MI3<S!%HE=L8^(Y6'+U;:@1S(81MPLBGS?#P69VN.+RR$0T1:H1O8X`ZZX`FT
M`0[<(!5:84>E(`YX0?\:3($/4.$41L$63J$7=&$<]*X;P($9D@$<].$<Q@$:
M4N'*1H&24H&'5J$)?H`.<H$1Z(`/NJ$+R,!U>X$?G.`&=J&I'?M,HL&/9F$5
MI(`6[J`&I$`'%.$78F$:H`$'$BT,>$`*MB`65`$)8B`)+F45NB`4OF'45H$4
M9AX&%&%2O@`,I.`(ML0(I"$95F$:_J`)MJ`(P.`3Q``,J"$6JD$;]AT:L$$=
MB$'^&A(>W$%8O@$:P`$@+9TS<&,8TJ$<UD8C[N$:B.$L:-FT[H$<B&$:Y*,:
M<"':F0'ML^$:,H886L*T\$+M82$=/@8:A@$_EI1SK94>E$$8T,)B!S9BKSO_
M(]3&&[`A[9797O*F&D!ICX-&&@Q"&ZIA<;%!&^YF1\I.'48#'CS/Q+\A&H`W
M9PKB8O=&&^("C;_C'4ZYZE9\+>"A&LRA**'U*RXC+/`!A5E9E,5.;(9%[)KY
M;GQB)83E*\"#+C9"(6YMQ=)!'2P#8B^/;1Z"KH&W:-'NQKVAPKU!KL"N7*.Y
M0@"BFK5T[^K5NW</7[ER]-X19(?PG;MXY,JY6W=/WSUVY.:E8Z?OX+UNV!`F
MU&<.G\9T]])I?!=29$9[]O2%3&BP7DAR]!#B0PCO8#UX+N_!@\>-&SIX[\81
MC,>.'3R(]C#62T>M&[=US*@E[9:NF[MC"[<U#,8-_]XZ;NFXL8'4S)FX+*_8
M(;NFSMN[6]'JC8,73%F]<O>VE5NW[M@Q9MR8W8IGCR`S9I<T48O6C5V[>`?U
MI4L'+]XW:EB[;4N&#!DY<EW+I=NVKARY=>2L;=MFC5NUW8>%YANJD9X^E?7H
MK;;W[EX\D\KUN:JV*,>4.;:*V'$#2@J5*5&Z?",U1T^I4J=.\8)'KAVL1=OT
MX7*D#MFY=Z[JCSH5ZI,W8UO*4+$RBAYEV*!+)&18$84MYXC!@RDV/0AAA!).
M^"`L7%2Q2R);>.'%)Y\8<<0.1S`A3C=/)*'($5(0P<,,-O22C"]^X`'-*B!,
M$\L7KHC"2Q,-&)$$%&6(8?]&#7D4@PT2<&PQXAM[="+%%IV0DPLWVGSS33;0
MP))+-M^$ELY$]8CVS7)7P:-.4M00$PTST2!#C3?(>---+L3D%4V>T533&#/I
ME/--/>I(-50UZA"%3SO7>%.--LET<TTYW'SYYS>?P7-/0P@=E!QHH<&C%9I$
M>9--.KM=(PV6I*JC3C974@,-G]UH`PTTV$2C#:[9\&FK.M=DXV6CI&H#[*]8
M:H--.^WLELV@U:2#W%#SW%-/._.,B>8ZG`:USD?KM+,I/FBB$P];1D5%3E1'
MM55--MZ4><\\[)0#U5#8?,/JN]]XHTY&&[$S&#OJQ/,I4=](PV\Z^$KE#3<C
MO:O_SK[97!//:T,%!1$UK\323CU6Z;-.,J]8DU%!Z^A#%+V88JJ/.,\80X^F
M!WDCC3'C:'20.?58@TPX]R0'CTV*7J/339Y%LTW0Z_0#VSOSM*,1S\_&M-PZ
MQ.!2#53?M`1J,IZJ1<]@?,)3SJ&,'L9--V"5*9H[Z73KS3K52"H"-?>40\T@
MX+#*-TM'M;-.5&$W]`X[^*P#3C?5>',-.N5@&Q$[\5P639;?L*531@^236\W
M[["UC=J,=4,-,]=T0PXZ`+\-TU#K,&6/.S71,\]:LV4>4M#T!%[//M$D0\H8
M58!CAA>FZ'*%%T8(_X,I]K0BBB>CR)*')/H<,P<45>"1_T<54KC!BS[4,-))
M?I\P@@LVVX&!`Q1=>!)*%WEX(\<.=Z"R3RCB4<A__\/A$PLQ+*%&2!"#%Y30
MB5UL00](>,,0=I$,4RR!"%PPPA-X80Q?Q"(18(@#&!AAC"]\00J=\`,L-A$-
M.+1O17@HA2NV08HM?$$-;EA%*+@`!BF$01'=8`4WO-0J=GB#&*_`AC>B,8TO
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M>1LZ\DB.5QB#-@`#V#IP`0MN8'-=Y\(2FM3AQ]0(!2%M@08NR*&1D``L&9BP
M6SW,@9%U4`,9RX@'R!"BCV[<`A=EJ@8QDG$RM>B$&;@81CF.XK%Z>*,5JW#7
M-P3F1)'=XBC>H(<]N$&,C=[Q*&!A"UNZ8:EKQ@,<B60+/+9!C%8LXAM:L80D
M\)4-J:C_`QV'6A<[UF&->EP54XCIUZ%<941O*.PC*[LEJ*ZQ&ZV\[75'68Y1
ME#.FGW7F6MP*"4K"9A!]2/$S%2M'-;`(F@=12XH'.4HU^)$+:"#!"]H0A0Z>
M8`MND,(3<7C#&Z+@AEQ\PQ9R(`4M/)&,573!"G<HPQV><`<]<&$)K$@&+$@Q
M"D:4(A?I>(04JN`%*'B!$<DX!R.B,(=0Y`$*=-C'%6YP"O\I5T+X\$4,;%`C
M)2BA#%SHPBZD,`4=%,D3(%A%'G3P!D^40A5-P($9<K`$"."@"H[(@0U@D(0E
M*`$"L&A%*/#P`R:,PA*)B(0GO$`%5UCB%6%0PA:X@$-NY--+_UG*8RY:\0IM
M5"-/U4`KEDZGMFAHRU+Q\`9*V?&-:.`B&KYB53:HNAQ,,6,8QZA4-6REFV14
M`QG&$,:=0G/'5I:CF%)L23*&80PY=NMU\T!3Q=1"-GYI$1Z_F@8U<#'B81#C
MP:W`Q32L(0Q<($/$KL@%+HBABVM,XV5^A88TB'$-<N`B-XRAQJ-^]2Z23.,:
M=$8K-JC(C('LS!KM**40=U8-]*1C,(-^73T\$I)W&*>CG^D63:4"CZBRJAO+
MH8<7![:UH7##P\TRI%K>(8XO"8JF?R*C.D@I*'EYY4^D*F2K\-4-0P<E7?BX
M:CD*]SB#8.E+^-CE5;QQU71X8TR$V?_(S[AQZX\($6#<L$<]F`J/TA6$'E'4
M*SM(HY%[(":2'P4'43P)%4G-0Q_CN`4US+$I07D#%I8@L3?$L3AOY.(2T0#-
MG^Q1CF&\`J2CA(>AL/+M:TH#'.E(55*P9`UT:"$2WTA&/4[`47$<ZG)Y4<<Z
MS!$V2-=#BAJ1'+7$>)!X6`,:>_+&&*FEG(R\;932V`6Q<C-*=;B&("UYG5YS
M<A3-$>=M?P*'--I%Z:/H-1\VN8>S;3(O9G1#'U5RA1=:P0C2>@$6FHC#*7R@
MAS>8H0QSX$4\8.$);30#!WNP@QK>T(0J<,$,[V,"*>8AB5/D0AW08,04\!"&
M'X@"%K:X!AS_GL`#->Q"$4_H!3_`@-SE*OY!L<`!#[0Q0C"4@4.=D,;?.X$#
M6^BB&IW8PRC>H`0B[*$&;TC"'>;@A3?HX`Y4&$4/R,"#)$@!"550Q"CN`(U7
MS.$1B7"%$B2QB"]T80I3V$,9//&.5G#C7JJ2MR5@D:VV?(-6NX!&-JZ6BRXB
MTL/J\`@Z=I&+:)2+5-#8-)8BM@M<I&IQ[;(4M>#AC1\C@XQ#:97)_V@4SDSC
MRX/*BZ<$]5+/E@[HL"M7X@T2Y@A:P`9:(`=MT`8-J`5MX`1M$(%:$($4>`(.
MR`98T`9L(`>+\(`?R`9LX(`5N`B)``<IZ`B+<((LF`B-$`G`!WR6_P"#D1`)
MC6`)-`@)-+@(E@`).YB#K1`).7@)10AA.6B#D'`)F+`)E=`*EO"$$%8)EK`*
M0P@)KX`+M_`*6-@*PK"%7G@+85@+MU`+S"`RPV!04'8,-28,RN`,PG`,NJ`,
M<4$-P<`,Q,`,VQ`-MT`,RS`-Q%`Z;-(/C](/S!`7S#`.Y;`-TK<.Z/`GW7!K
MAC$4LE$-VF(1;O,V=W0-[4`V"3$XY8`/^_`.0<$R^9`ICZ,/[J`YJ6@/_-`2
M4602II@/\T`/GZ$Y&9$/ID@38A0/>5%D4Q$1H*$3NY-R4!,2W/<1X")&1`6)
MNV0-*N,.#9<%HW0/E=`&\``.[9`9Z]"+:?_!*3@C$CG!#F$S:`:!*2JE&>GP
M.]B`;``3$L*H+1>39KK1%MH0AVXF#5^Q$..P#>0P#M-0#M9`&].@.-U"#9CB
M+YUA;#:!#^.0*A$3--&P#*"@!ZG0"?8C!:*0"6Q`#*2@!EXP!6]@!52P"[S@
M<VY`!5[@"=+`"'#@"GE@"Y(`!UT@"KJ@CMS`"%10!6,`!IW@!:>P"&Y@##LP
M"E[0!;3P>;DP#E+0`[:P>,N5$=#@7KO@!TE@!IW007C@"M`@!UB0!&\0![$P
M#5H0!UY0`SLP!V[0=?4A"T?``V]P"K;0946`!U0``4:`!U@0"=P@#'-0"D4P
M!U@`#9ZP=AS"!5+_P`CQ0`K"YB5>Y"5>LD12\0XIAB_HP$S70`SO(@W)H`W:
M8`W9(`V<E$ZY`@T21CHQUPW*$13"QC6<T1*3`BYEPS?]\B?Q$$FV60UCTG^0
M]D\3]TF-V6K>$`E8``=RD(+'29Q80)QN``?*V08<V`9NX(#$V9P4")W.68)8
M,((+V(%MD`C/B046Z)Q?T`;%*0>*``=LT)QNX`9QT(%P\)SDB05RT(#1F8)L
MP)Q8D`@@2`B$0)SJ.8)8,($5Z`03N`81.`@D"((1>*`1F`9KH('&69X.>*`)
MNJ`/N)W;V0:+8)SI.0CAZ8`A2H(DV`80R@:+0`B6,`R7L`B1H`LLRI\L_[@(
MC+"",0A\/V@)1&2#IB`)D>`(D4`*EA`)EV`+*V8)1O@*K=`*EW`+FG`)R=`/
MPR"&8W@+2KJDNC`,W9`,8?@*PA"&6WH+NG`+6;JEN@!F9HH+NI`,<&B&T-`-
MQW`:D\%&U!"0U;"9R<`-U.!FR>!SNX`9:H,,:I,,TD`*(L`+WZ`+(8`9WX`W
M1(%L:Z$1ZS`MU%(<YIA7G`(PAT8H"N5'U-`.2"16O0B,$0(9"^$.DQDQ])(V
M?((8;4$8&(%-@U80V88S&3$4PA8IH#%&^D`,V#`'5(`'G^`&>"`%=L`'HT`*
MT\`&N55V5?`$>>`&Z\4(N^!?72<-NL`(H``+C/]0!35`!Z>@"'.0!U1@!GM@
M!:V0#'*)"E5P!U(P!Z=`6;M0#D=P`T[YE,OE7#1@"Z"0!$@@!6`0"ITP!ZOP
M#;X@!5T`(I9`"ET@!;T`![O`#:P`"G'0!*^@"W"@#7BP!8K09=P`!WDP!T;@
M"::@"F+P!'&0!-J`#'$@)7B`!TT@!?^Z#:O08?A2<9!I2/EG#]IV%`-#,/^"
M)OB2'HADLYQ86!]W,BAC$`C!5H)R*`0C*A4C5>P@1TC11VE!1AXV%:`1%:P"
M#W(T,/`G88T2"1%(G<C9G.IYG&Z@G!RHG"3HME?@G%@@G118G!28"-HY@M.9
MG/:9GEH`!VY@G/3YGHG_D`AL,`>!FX(22I]JF;B*"P<H>*(=&KF#$+E*:@J+
M\`HXZ`B7T`JPD**DT`9":(.10`@Q:`F'<*1L`*1PT*.-``FL*PF-(`F7T*,V
M**0Q.`@<*@>1$+F+H)[`VY]L0`@LJ*!M0`BMX*2$(`FZ8`MLL`806*)ZJX`+
MN("0L"66X($=2(*[FYZ6H`N60`C02X$**`?02PAA*KX06J+<VX&#8`FXH+U[
MV[U[*P='*@?C6X+[RX$-6`?(^X3DZX`)"KU94*(0N@8)O*$:6IXD"@(3(`EM
M,`%8L`A=A`X.L6E5A1'H0`XH!XS4HA%!(47D<&C:DAP9T1,)^2<OUC#;,`[6
M_T`/^Z`/\;`-^4`O.YMR1J<<YA(4(=$M%V-(Q8$SR9$SZ<!GI90Y;:43$@D'
M;Z"3>>`*8/`#0/`$54`*]/"Q5O`#=O`$.T`%C``.W(`+K8`*ND`*3G`*NR`*
MKM`/X>`)6Z`$Q3<%*LD$/M<)17`$/W"RH4`'<9`';V`+Y=`%:I!<]ZI<OA`&
M;R`-HM4%<1`'I9"M?V`&H,`*;N`#.N`%1;`$G1`-L,`*I#!9A,D(K>`*H*`(
MBA`'\*,(N[`-PW`$1+`%75#%+E0*G0"RGO!?'=0)C$`-K1!)7LLJQ((O/[LR
MAQ(Q8(0F8>2:_W3"\J*KX\BI&Q=R;T-&ID8V/?M/Z_]"4\6\1!5W%`(C5=V$
M+V44,=6`#=K@"![X@1Q*@G"`H@U8O"?:@>?K@.F9@B':@";J@1P*O/N)@H>;
M",7+H75`G\#[!80P"/L)@O3Y@06]"`F="`G*T.R<H,4[OLR+T(;KSVPP#/R`
M"?ZP"?S@"_[@"_J`"<&0"<%P"X.P#<S`#[6P#?XP#L%P#.Z`"<S@#^]0"830
MALJ@#Y;@#+>P#9L0#,$@#/00#/V@#)G`#\+0#X>@"=:`"<H`#.?P#,RP#L+`
M#950#,N@#,K0"/?@@]1P"V]Z#)0`"8:@#,>PI9=0#HMP"<*0T"5U"\>@A991
M#*:[#!FT,=%0#,JPA6.*"Y7_H`F84`N-(*-#"@G`]X$$S;PM*@F:IU0L"`F,
M4+R0L`@]6@M%"'P<NJ'T20AM,`?T*8-"V`@%?;Z$0+CT"9]U$+TB&((/.-!M
M``(B``)U,`>+L#A+1`T`=<PD?":4FCE"`1J/\Q?G*!+#(1P@O+.DB!YY=F[S
M($?"YHA'EP_+@</7L@X%<55'&QH5L7';M@T788LWH3F%A0_$P`ZE\`9JH`96
MD`?:@`5YT`5T4`1)N@MQT,AS(`HJ.P>=H`B)\`95D`?2H`9TH`9YD`>K\`K7
MH`AXT`5@L`6V<`O(,,A3P`=<,`K&<`5[D`=Q,`JY8`^BP`>Z8,B'#"30<`5&
M0*Y'_S#'8'"81V`&1:`',:L*[/`*5]`)I-!!CHQ@G=`)PJ<(>=!!>@`'I%#!
MNU`&3#`'4H!#8L`%>&"4,,YV20`*Z6`)'18/0"5&68(I?/41^(`/5&5DRL$V
MN=.S5,09WE0/M:82,8,/):P18I1_G-&+N@I0%4-%8T(P$-DO1C',`'44@8Y(
M7K5$7H0.PLF`[+P(6;`&NRL'A^NAQLF=%OC9;9`%ZNF=VOD%!)RA)PH'W@N"
M(RB"(GBBXWN^Y[N=^4OJBQ"YE`Z@7<FA@Y"@$>T'$.W.<!`)OJ`)S5`)UG`)
MEO`,M_`!@F`)Q5`+)S`,RW`._M`/AN`,:P`)SI`&D)`/EO\P"%`M#,50#,^(
M"9IP"\J`"8C0#(6`"><`#./@#\X0")=0#,Y@"2=@@X=@#6L0#,!@#2J0`N-`
M">;`#)AP#)JP#<(0#()`%\5@`H10#LK@#O>>"0FZ#<&`"<T0#.:0"9C0I9?0
M#&Z8"9O@#L#0#];`#,H@#/YP"_>@TL++ZN<KHXMP")+@V/G+@@7]V6O`@L4K
M"8<@HXS0@02M\KQ+GY#0!H?`T/"<ZJS^@,A[Z74`@B%XOEH@`@PM"087**+"
M+T%Q#P"54OIP+6^#<CE1."%A43^Q$9BR585#J481%%JU:009#3^G&Y:B-M7`
M5*>4I]9`#NF`8=6@I\P@*2=C:*;_",*T2@\`HP[[X`KB\`4$?@=OD`>[L`I-
M``>@\`.ZH`7#P`A>4`J>95E28`9*X`558`1>$`=FL`-JH`.3QP1Y4`JLP`A?
MH`BWH`6@``9R\`9/\`6\P`B595EO``[AL`5`<`JK>.(3$@LQD`.YD`NP$`VM
MH.NO!<E7H*VDD`ND,`6!"P:PX`B)X`BK(`IP,`?B.@=@>0IGK`BD@)Y!KI>L
M\*YOX`5X\`>AH-^3__JKH`Z6P#4%<12)[F'*,8H,"1#Z[JFK=R_>O7L%[ZVK
MIPYA/'@((^+#IZ^B/HP6*QJ$&"]>/7CP#H:,:#`=O'403X:L!S$BR9/K.*8#
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M!1NV49NPPM+O.?W:Z`]`NO3#+ZRG%I0++*CJ`%".J`"LB\()Q?^""K\*Y7!#
M0J,"Q(\7;=1AQT1XU/E&'7W8:>>>=T(B)QV9$A((H8)TBJ@@D&1*9QX>2UJ'
M'79PO`>?>O+9D9UZZEGGI'+6X2:=D]2IIIUKKK$F'76HI`DCA!:J*<R/!&J2
M27CVR669+Z1X`PP][H!#&T:4"&,,7G`!)YE%YH@C"1SNX"$/1FSA)8XGH,C#
M%%>HT,.(3ZHP@@M63"&E&V:RP2*.-]Q(YY0X1O'BDSV>D&:?+FYP19]\,G+U
M55AC934?<HB)!IZ,\KFHU7WBH2>?5NWA9IMM/BI'GHJ`I,<<<][)YZ!ZN"G'
M'BJOF:8<@=ZAAQMNZG&''GW<80C,=[;_B14A6=,%,TQ8[U'WHG-9?=5=?9JD
MIYYW,"KHU2;OH8=>?>LQ,TR4R&FG'4>.^@(HJN#``@NHW."JC2XJ)`L++;9J
MBJFHFEI**;;F:`N+H0`+,8Y%AL)OD*_*2HLHH%)F,&5'\F,$,$486821N=A@
MF2A'$GF$D,_86"222-H8)))7(#FZ#48B:6000B+)C#5"'+&DDDN<;@622S1I
MQ>A;&KDDDD$ND:258VYQ&A=I8&&C$5SDL"0S9I:QI)%;U@#F%DN&N4680;):
M1A==(KGD$C:&:06_:"`A))I7IAEF&#EL86:05YA1)AEFV&B%<F:2V088=X)I
M1A(V#FEDD<\@_Y3CD+"<%C"2_/13$+_/\$M0OZ5$7'#""R&<D"SDR:)P/^$W
M#"M#21C)9D43B1QRQW::_!&>=V2JAYUXZDWH'GOL87<>G-Y1"-QZS*D7I285
MPK?&(@5"<IV-T(<'2(38$<A5F=S('DUZ!T+,5\"$?*\=ZMA'-*:AB"J\H0QX
MR$,7XF"+:#B""E5@`AUTP8A/X.$+7BB%*VR1#5>(XE!/.$4K%,$+7DC"%4UH
M@AX^D0AKM,()7<`#%41ABU-XP0V?R`,>O#`%7>RC"#S@A;J<&"M@N6H?^MA'
MJW*E+BMF!%X8B6*N>.6J+LZJBU;,(A:?R,4RGE&-:V3C&2LB#$ML+?]LK[A$
M'"$1"4M$`A*0<`0D&M$(1[P.D*\;A"`3\<=%.(UHB?B,ZQ;QND2`AA!PB-TB
M'#$(R142-')@65U8M@;8)8(-HDQ$)^NB!9:ETG6I]%E=3JF%IV@!EH30@A.<
M@(6L:"&266##&K1P`E>^SF>/)-I]%D&6IX`%=@*"'2$&(4EGLD&78Z$0(>JR
MAEXB\RMKX&6`"*&"+(0%#HN`V.XD"8=!W$=ISUQ0[C*#NZ,E\I&26(0DY"`)
M>HJE#@4BA#WQ><]Z0J(.3JLG/O7S3[KX3BCXT=D][TF(0QC4GK[+CUBL.1=Z
MVK,-Q]SH0<."3W"L*"=,BL>7^@4/@;FK2"C_=1>ZV(4N,Y4/(:TZB#[,9R-\
M'`E<`+-(2_4Q#WP`M2+D*,B_<@JF`;**?"UUDD)N&B,BX0,:ZP#%'=[@!4^$
MX@Y[\$0N<A&)/90!"J.X@Q7BP`YM$$,:M@A%'+IP"EZ<HAMYT(,>5`@-6*@C
M#E/(@R3>0(5/E,(4VG#%'\S@"4^\(0YQND4X8G`#6[2QC6E\UQ-A>D5U\12,
M7)1L9SV+V<^&5K27E=5%\"$/*N)C'ZNU!S_V40]ZO(,?_YK';/%%CW24(TKE
M,,<XS'$.:^BV',$]QSG&P8UQ#'<;UB#6.,81#G*0PQKAF`:QEA$.R#1#&<<8
MAC"L,8UB+$,9Q2A&_S".<0QA!$,9Z;U%>Y,QC&,L`S?(N$4QA"$XZPA.<,GH
MQC!08]Y;`,,8N!#&+391"TW0T1*:J./B-A''L'$-PGO$XR8J`38]WE$2D+#$
M(9S&8:GML1&5P!TB1;Q'IS7"=7L\Q(-1#`D/_]$0LY,<(?[8B`U;`L6@D032
M7E?/35(T=T:K747'N;RQ/.5"S:RH?HRF/`K1\Y&0\(8Z4,2D?]TCB^Y*$D^/
MM,8F<;9=E"TM1DSK+G#-:XNO8A\]*L*^>N##&.'8ZQWP<(<\C"H/9=C#*:3@
MA2J,(@^DL`4I6A$*5I0"%*0H!2E,`411I"(/LBB%)URQ"U<H`@QYF((7O/^P
MBU#@P1.D`$4G//$)3^AA#[LP!R-$D0MYB5;6LZ9UK6U]:USG6M>[YO6KTDCF
M6%-15UK\54Y72P]DTX,?5.3';/E1CF;SXQS\,,<ZFD4/>Y3#'>-`=CG(40[?
M3MNX[G#'-M;!#W?\MAG]*$<WMM$/>+OC'-OX!C.8L0UFG*,?[BA',HS!7&YT
MXQC]N/=Z;J&+8R#C%;@13>EJH0OXXJ*]NKA%,-K;BO:VM\"XT?@MZ(CQ6A@X
MY+?`^"V&<9`UZ[J,*<<'L'N=I%@)PQR@B(,CL/(%17RA"YZ(0R?<``I&=($1
MQ"!%%TKQB3C$(11M]4(G0MB%/.2AYY[H!!A*4;K_.,P!%$:/`QBXT(E.-,&"
M;G5"+OCAA2\0(]B]9GO;W?YVN,=]7I]-N68W:Y%XQ<JTKFJYK,C(93!EL55V
M7_L374[K+)IO[K[N;+!:=7@UVJ.,DX>\W"V?+M56Y!SAP-\SM"2,8F!)'^GP
M."R(X0W*18,;K_!J)%S1"E?D`AJMB$0KH!$+W%FB%>(P!C)\L0I8P,(5VL#%
M*EJAC63D@AOG\`(15E7YRT=?^M.G?O6M?WW#/YY54_1L%(%-QLEO]HM7U#X9
MT>A$8(6Q_-AG?T:X+^LP0I'O\W]5%5W%#W1H(QU:;G___?]_``Q``10_>8$^
M7+,BPFN7_\D(G_J?PVO`__])P`%T.S)KN?+)AY<:/`S4(LS:HM7"B-5:+<'3
M"(J@(HNHHO0[OPE<019L01=\01B,01FTM?`KK<&K/RS2OAG<01[L01_\02`,
M0KC#!][H!UB)!W*P!UEQ%WBIO/@30BB,0BF<0BJLP@"D!T`(@1/(`$W@HGO0
M!`T(@1"XA2S:AD,P@4-PA_\1F%<0A$DX!P[$!$#0A'RQD7RHA<Q8!BO<0S[L
M0S_\0T"$%118@&30!TE8`&7`B$D@`$A0!T(P`$/`B&8X@`^`A"Q`@%J0EQ-`
M`$A8@PMH!GU9@0V@A!,(@6U`%T#@`$NX!`U@@W0(1%B,15F<15ID/WI8`!7`
M"/]ZF(!,P`@+(($;T0`1P`A!>(!\H8<'6`.,*`8"T`6,\``4P(A-,`!0U`</
M`$9]H`1JQ(A;>(!%6,!:#$=Q'$=R+,<SHH="$(9E1`!_P`@4*(3_$4:,6(-A
M!)<0,`&,,`0"2#-FP0A$Z(!ZT0<4V`",*(1HG")ST`!E-$>&;$B'?$A`K(A^
MD(`1>+^^"P0$Z$5]2`.`Q(@/P$=],`0).`=?<`97*08)J`1]V`8$@$=XF:)@
M2(!+@$B:K$F;O,D75$)-0(`TP);W,X<5,`!*T`=P"08#4(%@6`$'6,A;F``$
M0(`$B$:BU(=I[(`%`(0%C*))6``4>#^<_$JP#$NQ?+O_>[@$`5!&>FD5;C``
M!6"&*WJ%"U``<#H!C!"&`B`$?3@&`HA$?2@'"3B!3$`$">A"F.N'#;@`3!A+
MQ5Q,QFS,SNJ'`5!&>]@5>PB!"1@'O',5)]$'+<0(3"@`=Y"\,)S'#,@(%@@!
MO`,&"6"!97-,UWQ-V%3,BE@!#0BVBM@$`L"65Z&$2'27SM2'3)"`;E#"-1@!
MC%@!0>C+D)2`5L$'!(A$9-N'E(M-ZJQ.ZY1%>I&`-+BP3:`$.-2'$SB!>G,&
M93`'=ZD$`W#+6D``TUA)!"`$>L#-H<Q&!3@&C.B`-&B52BB!Z^Q/__Q/6'R'
M$NB`"?"`$5B!:AP!#;@`"T@`_PN(Q%9)@P3(@/>,M4I8@`MP`*ET%ZM4@0[P
M`'>(4`]8`Q4H!$-(@?FTOND$4!9M41<-K7%H!O+L!W-H38P(ADTP%U>YAW*@
M!)-D0'O0A#38A#3+2T-8@S0`A#18@Q2M/F4HTA>-4BF5TC<SP=#:0"<"&`.<
M4B[M4B\-P!75NR>2SB\M4S,]4S1-4S5=4S9M4S=]4SB-4SF=4SJM4SN]4SS-
M4SW=4S[M4S_]4T`-5$$=5$(M5$,]5$1-5$5=5$9M5$=]5$B-5$F=5$JM5$N]
M5$S-5$W=5$[M5$_]5%`-55$=55(M55,]551-555=559M55=]55B-55F=55JM
M55N]5?]<S55=W55>[55?_55@#59A'59B+59C/59D359E759F;59G?59HC59I
MG59JK59KO59LS59MW59N[59O_59P#5=Q'5=R+5=S/5=T35=U75=V;5=W?5=X
MC5=YG5=ZK5=[O5=\S==L]4I][5<@Y`=U]%>!_<$2'%B#/5B$35B%75B&;5B'
M?5B(C5B)G5B*K5B+O5B,S5B-W5B.[5B/_5B0#5F1'5F2+5F3/5F435F575F6
M;5F7?5F8C5F9G5F:K5F;O5F<S5F=W5F>[5F?_5F@#5JA'5JB+5JC/5JD35JE
M75JF;5JG?5JHC5JIG5JJK5JKO5JLS5JMW5JN[5JO_5JP#5N>L1U;LBU;LSU;
MM$U;M5U;MFU;MWU;N(U;N9U;NJU;N[U;O,U;O=U;ONU;O_U;P`U<P1U<PBU<
MPSU<Q$U<Q5U<QFU<QWU<R(U<R9U<RJU<R[U<S,U<S=U<SNU<S_U<T`U=T1U=
MTBU=TSU=U$U=U5U=UFU=UWU=V(U=V9U=VJU=V[U=W,U=W=U=WNU=W_U=X`U>
0X1U>XBU>XSU>Y&77@```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g70882kgi002.gif
<DESCRIPTION>G70882KGI002.GIF
<TEXT>
begin 644 g70882kgi002.gif
M1TE&.#EAJ`)P`_<``!L;'!04%@@*"QP=(AXB)2,D)"PL+"4G*BPM,BXQ-#0T
M-#P\/#4W.C`O,AX@(CP]0C\]2SL\?SE!/CU#0SM'13Y02D`^0D1$1$5&2D1+
M2TQ,3$='24U-4DA*5$I13DU34DQ65E!/5%-45%15659:6UQ<7%=765!13%U=
M8E=99DQ-9UU@7UUA8UID95U@=6!>7V%?8V)A761D9&5E:F9J:VMK;&=H:6UM
M<FIJ>&YR<VYV>'!O='!N>G%R;G-T='5U>G9Z>WAW>WQ\?'AX=FYP;T!`/S<[
MD3A*E#9-HTM5EU%;J%IFJ5QJM7U]@GEYA6%HGF9JJ6=LLVIVN'5ZJW9ZN&QQ
MK%]@FW=[Q6]YQ44[AGR`?GZ"@WV'B7R#O'J$MW>#K'R$PWJ(QWJ+TX%]?8!_
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MS::KY+6YYJZTYZ*=UKS`OK[!P[S"S+O"U[W#Y+/`\L&]O<"_P\&_R<&]V,&]
MX\+"O</#Q,7%RL;)RLC'RLO+S,C(Q\/$U<+%V\S-TLO,V\7*U\W1T\S3W-#/
MTM#.VM/4U-75VM79V]C7V]O;W-?8U\_0SL?*Y,S3Y=/4XM7:X]S<X]O=ZM;8
MZ=/3[MSAW][AXMSBZ]_IZ=WC\^#>W^#?Y>#@WN3DY.3EZN7JZ^CGZ^SL[.;H
MY^/E\N3K\^WM\NKI]^KQ[NWR\^SS^NWW]O#O\O'O^/7V[O3T]/7U^?7Y]O;Z
M^OCW^OS\]?W]_?CV]O#O[R'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````*@"<`,`"/\`^PD<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8
M,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`
M@PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-H
MTZI=R[:MV[=PX\J=2[>NW;MX\^K=R[>OW[^``PL>3+BPX<.($RM>S+BQX\>0
M(TN>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX
M<^O>S;NW[]_`@PL?3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@
MPXO_'T^^O/GSZ-.K7\^^O?OW\./+GT^_OOW[^//KW\^_O___``8HX(`$%FC@
M@0@FJ.""##;HX(,01BCAA!16:.&%&&:HX88<=NCAAR"&*.*())9HXHDHIJCB
MBBRVZ.*+,,8HXXPTUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGD
MDU!&*>645%9IY9589JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGG
MG'36:>>=>.:IYYY\]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKI
MI9AFJNFFG';JZ:>@ABKJJ*26:NJIJ*:JZJJLMNKJJ[#&_RKKK+36:NNMN.:J
MZZZ\]NKKK\`&*^RPQ!9K[+'()JOLLLPVZ^RST$8K[;345FOMM=AFJ^VVW';K
M[;?@ABONN.26:^ZYZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_``<L
M\,`#WT/P:/L,E+!%"T_DS\%P[?/,--"8<T["]ZC33\,;*ZQ/QQOGL_'#!'%\
M$#\"\8/R7B9OU/*SU)3```=K#*'Q,W<XY$\QP^!QR09Y'*3.,PE10XA!"W.<
M,"9$]P.,P2!'G73""7\LT#Y);ZSQU1MSK([&^]RSS\-4(RV0/R8O3/+("D?-
M]4$OE]S0RW%G+5+<`UF-$MYEO_^-]]LZU?W0W_4E',0N_8A`!"/$7#)-&XR0
MC(@0U#PSQS/FX($&`\`0<X(/Q>1S"2+W/)/'.H5HT,\DDUQM#B;F-+)!/Y1`
MT\\TP'R<,##FA)TP(L_X\\P)U.QCCD#J&+P/.@)E+-`Z`N'3SSW23[_PXPE-
MP_HBDP`C1-'#D%Y0PHL`$_4S0B2<AR4'X?S0/7D0TX\ZT#N43\/$-#W0-(PL
MDLD^P-"?.:C1/*A))&NE0]O;,I8TL;D-9%03&>"N1C6[]4T?#<.;U3*8$,'-
M32&$0U'"A'")Q`$##7/``Q%LP(A_](,6-?B%'3JP!0S\0`.+$,$DA$`$.`@A
M$#5`PR3_MK`%%"!B!FR0@0;0L+$?J$$$0!`"#5"0ATN@H`8^$`@>9*"#._A@
M'34@H0]\P(!BU*`&P(A#"43PC#;(@(0U4,,TAE`"1`CD$3,@@C#84`(TJ(,-
M+QB"0.9XAWO@H0:(0,0&JH&)"TRB#=,00NL>X8-E"$0(0O!!&Q9!NSE`30XV
M0,0ZUA&_2Q3A'HM8`";V@8CD`<-\Q1#!):#W#/FIXQ(`)-H^B.$/3!A@&OU@
MPQSZ,;&!W(,8"9O&\>ZQ#A^80WC]J`0F^O%,@60"`&PP`1L(P4E@ML$'"1L"
M^\Y!D'LH+QYRBUX_[F"^?IRQ(-28Q"(2T0_=Y<&`"`&&#4HP_X=+M&YA>AN(
M.7)6$#948V.+P&?'%J&!$MQS$1)<I_*.5Y!UX,$A(9S?P^Y!"Z0I#7`<%,CH
MP"80<TSC&1BC:,=(MH_MP>Y^4@,92_NQ-H+0KVLX->8ZL#;!Y_C`?#8()AXN
METGH\8$-JX-`(MX`!$+\@PC`B.(BZO"#8O0C&VH``@D4L88:L``(:>A'/!"1
M!@P`00V5:$$C@&#'$T!/!$-`P1;4H(8\#,$'WY.!#V0P`Q[D(!IL:$,-)#8!
M($Q@"R98G$#ZP(4/".$%S[`!$:I8`X'H501HT``P@BA$//``&&P@@A`Z$(@'
M`(&3_<C#'&K`!Q\4`@-D@('![C`$-O^@`0W?1`01B,"&"U`"!4&P`1X4T+IJ
M,*`-0UB$7A%Q@AK,H0<OV*P-AH`'$PAD"$/X9@F(=@\AP(`-F*C!"XHA@QHP
MX!%"D`$;)H&'&<@`#0^[A`;4D0DB+`(3>3#!"^:@`1$P0@1"N`$&Z-D/3)"`
M!M30@0CLV`]$:&`(ZU"##:@A@LJZHP&+:(0(RB<#&)S`#RKP`7<100TAY*"=
MD40#,/M1QW\D4@1L,$<UFJ`(?"QB#M.`PR6<<0$\R.\.<]B'"(!1"S2P8!^+
MX&0Q"G$\'0Q!'RU@`RWB<0E:A.,#B/B&+2R`CF`@3B"$"`#1UD&+=?R#&N$8
MFL&F04!_4$/_'6_NQSH(N(]U:*P$YEN'!E#:CW\`4P8E'%O7ZN>\^1D0#6<4
M@<$,Y@,VB$!C)[1>V^[A`P,L(`\W(-I&Q\<W8LX!&-.TVT`P<8*.9?0X:)#?
M$/)AAT3F`0TE`.8SL%B#+<1!#2C<APWF@%Q!X,$.0YB##EJ@B!8L`@@ZX`(<
M!-&/<"`@$#3X`1#JH`@,S$#',DB8#.A0!V!40@#F:+0-S'$"(:`A$(\@PC?:
M<-M\`*,#=:A#("91`Q$(9`8Z\(`0;`"/QTYB&I7MQPG(D(<M]@,-0KC#(@@Q
MA&((@9]JN$0C9J`&@2"B$&W81W5W+0-WI'82ZL!N/Q9A`Q^H3@AN_\``']#`
M!X("0P;N%($F`7F/%Z#!KM_[IAPLSHC*3JX?Q!"D.6K`!D1^;PC?B`,<:(`'
M'Y2`Q58%Q@%*$`!U*)((_;`Y(S:[AD:80`CRZT<Q\""".UR@GP+Q`0EH`0<9
M:&$(0F"$0&K@AA^0`PUXO800'$&'3&3Q'EI01`EH08.$T:+I6"?F&J>1B>SZ
M(!-QP,`D+"#L'%0`$3+`PZ[QF@<MM&$%B'Z$"$Z0!PV\P&!Y6($@9*"(/`!B
MC4)H`0M84`<1S`$#.Y#&QJB+5!C(@`1Q.(`B]CH$8/C`!O1^@0AL8(-GR*".
MB!C])#1@1W5<P`1#F'4))G$!-"#B$C(01O\=V&"#-4!#!C;P7@F<V0]J:,!@
M`6R#$(#1!D1,>`@7N$,Q?)`'HRU"[B/4.N55`].`"#5P!\.C.6.P"+0@`S)0
M#?MG!^8P3-0`:\_P#)4@!(]09)[4,90@2UI``_`P:T@%'<JS:/Z0@IBP8NVW
M2O<0",\`#\P#@?0##[VS"':@#Y!P!]30#H\0#X+`!>CP,9>@!HH`#,)0"S\0
M"/@`!S\`3/I@#FH@!-,P#\.$")EC<^8P!#5`#(J`#HE`#'P@`_TD;9<P1M_3
M#V-D`W>0!_]013Y`!,/4#W/@`T,P"5GD?0DW"420"7:`<%IP"6F`!A\@$(R`
M!GB0#W/`!C[`!V[_(!#K]0RV-0="P(@^0`@BD`DRP`ATX'T"X3W],`2XA0F8
MYP_"90>9,&X_X`-,U`^,4(?F<'/$Y$R(X`.,X#."A`:8L`)U0`-P\$[1M3JJ
MXP.+H%L^H`XVL$F70'>+0`P[\'191P0F4`F7H`4PYS2!(`-#$'%Z-TUJ>`=(
MA7`GA0>JH`K54%GW4'](-0,BHSFP-CV9X`_#P$^30`P^,$0>$`=KL`\G$`<_
M%#3[]F9$H`8:<`?[L`4S$&QV8`/U$PA`0`0Y<`]<6`S`H`,1&0@$%PTT$`?'
M0PP*8`,<8'S]X'F/L`PF0%LU`'=XMP\^,`U$\'QM0`1H,`R90%M6E0Y/_X<&
M&,!\1#`$F$`&;:`!;``('!!;0H`",/!8U8`'=D1>T]-@1<!'/F"`+X`)F-`&
M)2`$"[`(:*``*G6/_=!\;9`Z/D!Z-6`.;G!7F/0,:T0$ZU<"_G`'X,@(>4`$
MQ$`,+%!'6[,Z-B`#=Q`'/J`#U9!0T=$RHM8/^1!1!:$/'V,U>I,V`440`54U
M]012!5295F,P^A`/'L=,"C,-+)4PZ%`_`D$-P+1H]V`.&J.::(,)R`!TC[`U
M]S`-[N`/&B.&Y%!2R:,.Y\`&Q7`/;X8'C+`/SI`&D0`-!#0_1#-+:7F7^S`-
M6C`'_D`+1#`)Y-`ZMX,'F*!)8J,/A"`#F5`-1/]0`]70.HQ@!V]'"+3`"#G3
M!D1CC]0D1,20!T)0!/4(#9FP"&Y`!C80-/W``SW0ASH01P*!!D.@`\5``W?8
M!G8@$$U`#&>$B,0`<'$`"?LW/6UP!W#P#X47EF<4<'NE>80P"<LH`UO``'$@
M2$(P!L0H!&#4=#[`:W-@`^1G@*@H`O4#!(K0#Q\P!W!P!U/X</>P!MYU"8KP
M`'9$=)0F?Y.0C)-0#2]`"UPY!]WC`Z9(#39P1OV#!OZ4!S5@57JVA2(@`^6#
M1G@@E`8`#!I`"7?@!O,77O<P!SEC?41CB<&`AW=@`B9`#/1G`S6)/E[9,37`
M22^@#H1`=I&0!WDP"<7_8`*>-0>8H`XB0'V,P`@RX`]M,`GKA09:X#2/<`<:
M8%7D8P(^0`V-*DB7H%+,P5.F!D$3A#9JDTX1Y#<*@S%5TS=M8Q#*@U%JD3:G
M-@TV0`:"9!#I0!#3@#$LV'X&,V<;`S7+:C[F=#OFX$+KP`_[H`[H(#:$A@G`
ML#5(=@>C]#7C"`S,B@YX`'(H10SWD$C^\$R8,`?%@P=#@#L2]`S10$R.,W8;
M(`2_^0S4P#T\@`;%B@D&,YB3(`-%P#3!]`*,L`XK!&K^`')W8`Y"@$.+8*J7
MX(F4=@*(,`TF(`+%D`GSEVI"X`]#8'M#)P*8@`?JP`C8B0DB4';KT)?%B`@S
M_UE>F="D][BHWY,P4G9PZL"H7IJIBS`\O(4&)B`#P+`(*3EKDD4-1,!.>:!7
MBV@#[VIXM44-F+`(18=&[50=U-!."4-O/Q41YJ!0!/$T#A&T%!EV'!.95U,,
M+M0WL/HV"D1!"Q$V`@&WG`8W(?5`XQ.X@-M3A)M.($1,C("V$>%`9E.X@4LW
MM%H0-640DVN8!K$(>*5+'80\K-@&$V0R9#.XQO0P^0`UHN:L8&,WZT!1<"9I
MU+13[7<\"?,/24,V"U,Z8B,RTR`_0L"R"5-,]U`-:),\6#-+!69F%X6W_I`Q
MW?J4JTH(_&IU+GH/C)!<`^%^6IM%.2L\CH,)U.`/C/]D3O'PG!H`FL%#35^#
M4B=P"2[4K@;C#M"3K!1;`/Y%4VZC#FA@0,2@`2AP`OHCN(.S3G*'"$<S=R5D
M$"N8JYO+J@=14Z%IMW-SK)WFO+/9N(<Y#<-0/.H@N].3NCV5@A5407CK422#
M01DTJZVZ06ZS#S#EJH]9F?^`3SS%JARS#LD*NLUS-1+$P-;Z00I\N`!LN'`C
MQ/U0#M[*'I'4!AM@J0@W!YG%23X[3`DC6"^`!R]0L4/`L!O`6<^`"8[&M#*9
M!P:`!C$;"2<@`B:P?V\4"09@!VR@`7,X$$50#=10!$1`.G.P".5&"P"@/S+0
M.D6+"=0W:_S7?/;7H/):#>C_@P;E*7:J6@,`T`]X4(+K``!8QS'F8`.[-`G,
M1`LD]3J]8P[/<`__D()[*3&TNZMF)F=@4TW),SWU<\H#,0FUJ*J2VV!?&Y8'
MY1#_L``F<`'@E;Q.TXJ5<Q#3(`+PP!#'>A"=LS^Y+!"+X`P1T4Q6U6><%`^)
M^Q#K8$D+\3K)21#/<`D&4PS<E0D4M0[,<T"U.L):L\/-LY<#4;E!/%.,J\!4
M0S(*A*NL>@^3JQP4BP<;,`>,@*5!Y;(=8[,;<PD+8`[D\%[[0`3W0'07A0,I
MX`ZC,P>)L`!\4`(F8`?J<`)MT*@690>%0`8A``-]@`D+0`BG%,\*0`V6.@DF
M,+-#_X!#Q7`"4.,.10"[YB`"NH!7SF4"=E5VPL4(3F>@HE@#%):</LNQB%""
M]4>`4<,(;.!^[Y4'!6!5#Y,')7`"Q,``(O!-EX`)3/0P0M!]:+`(2\E0VR<#
MZ^L$)N`&B]!'O"`"-X`,>?`"D'0!/1N*,H#&/'`/A3`#E\`("Y`)H45A[&0"
M->`/5!TU%`LZFU6"U&1=ZF`"NW`)P[`&<K`(&-`&F"`$-=!&N-0Q829WP)`'
MT]0(A"`\B``["I"L_>`.CP0,,!VT,.=/\Q,,,E#-TZ/9_>`-XDP0YE!":J``
M6[,.`E`)Z'`!QH-2[J`/TF-2TW,QQ7H).1`/RTI1_'PUR?_XM0DC#!<P`H'0
M2.5;`Q?P=Q)`V2'3/+[:N$@3:_:;,.!HOPLQ#00F4J]Y-OT`#R<`ST`,W_.3
MALTQ"0LP!PO`E$'7!GP$Q7*F`9;@!C*P!F[`!D(`83*P#F3H`Y?P`SQ`"3.`
M"$&0""$0#(UP`Y-@#HN07I4E!R9@`W20`FA`"=,'#(C`,08`TU18J'@6?8OP
M`B!S`N:3"8@FR39P"=20!\_`A?MP!S6`7#8W#+60!SU'V>'D<`R0,_>@`#)P
M``7<,9F:2&'YQSAU"?QU!TST`J\V!+8C$&T0737`"+-6`^J@:YS$"`S`!R:0
M69:P"PJ`")L5BN.)#@IT!XSP`L[_@&@+4--]!-`G*T0V0`PQ>0]P"<YHT'U=
M?0@+\P\7@-Z(4)<H8`DFL`8;0`M]1`@:$$I)4P)8Z7Z+P`&"D`(W,`8V@`8R
MP%SZ,T)HX-5HP$>$T(?[-`=#$`0*T.9T.`094`<@0`,[FC#4T`(_T`02MC\F
MD`/+``2-6L5"<`YR_7!760*UC@*7X`$U@`?[]Z6P5C_/`#3_VW[+8`XS\`%=
M7`-/)P//L`@&$`<K)03:!`POKC^6D)0`=^LEP+*W-0TX=P]W4`*QC0:13K$-
M$,<"06^88`<R<)?\1`@'(`UD4`/!``-I$(&K\P(&`.!'!0W>AP^U6$*3,PW%
M@`Z9\`\3_X,&YL,(#P<=P#`)U*":J9F.G&SI]^0.;L`']_";EZ`.P,`(&B`$
MTD`--0`'[H`(C"`'.\`(CC.S5DL(]P`,>E>)S1C14TD0^?`"ZW`)>'`/&O!@
MV02RY3L0:OK7$%H")3"BQ)!JL%9R`.T#F.5/;+`/63T''(Q&Z@``A#!V6/=R
MQ4S?@$ZF>"5WR'/@&Q!8_6`"ZE`$]M8\B)!#EW@'F30-.70)Q3`$([`+=G`)
MF<`!.8M%WR/:3,13=L`(6"<'')#UAEP#M"Q&_9`)0%X"B@GE/S4$,N!`ZR`"
MYM#;T(MU34`&9'!P:3#68W2]"T`#"Y9%3N`$.-`'AY0.]=>*"_]#;B-7#`98
M1ST71NAW<%KMBD/``&G@!#F@N77P/3,P!T&3,,3@!HU``D#0!K@$!$VP!4``
M!P!A8X@0(<]D2",3)T^_(26TU&CC@UH_BN;L(#JQCV(_??W,D:!$Y!^Q!3;Z
M"1F"Y@Z;?AKOX1$B@I!,<RW[S5'#`<V,2R*(H40S<,$E'S6&`"O11L.0"S`F
M^6ACTU^_&C[PB*A:0L2B136FS1GQ8PTC#&PND/&!:,&]C1X-3*K19`0?$8BL
MEJ@A@\BD!IA*R("QM`8;$6T-'T:<6/%BQHT=/X8<6?)DRI49:W2,N=]43(OT
M?3ZL6:,[P_[8[O.W+Y\ZQNJFM7R&KM__M']MIRU:UT_=)76F5^]3=^+.1$R7
MS)F[YYI8B7\V7FNDQOK9NF+$<O>K1NR936(U^N61,8W:ZXULB""B1JP?HWY6
M;?;#D]2<#1O/)FD00@U&>#DA^"PJX0=+9K"!F#E.<(.8J#:BQ0<T_.'C$CM*
MR(,-8,R1H81%&!F"CQ-,F`88-NXHQJ8V9/"!#33RND>C^?KY!R)$^!A"!#>B
M$@*1E-`H@:U^T%BD'T!TJ`,/$@;A`H^NUA$"DZ.>T:P&1*24R01$T&A#"#OF
M@,&2$9#9:`$T,,@AD1P*TVB1%J!IH0XA;'KFAWY`P`"//)Z9@1@!!`GDO$MX
MJ,8$<]`0@@UT_ZJ*`X],:O"QGV>*,4<#C?*A")T'U.BGA&JF+*&]$DI8`(3-
M^@'F`B$VH.6.!1"QJ88T4!""AV?>%$*&.2Q!1(9]\EC@S1<$PF0.$=:YLB7,
M:J!FCA(8P806-FQ8:1(4@EC#CD8PN(01&/*X9ZVVGAFB'Q0:X>..A=CP(<=%
MVKC@A1(0D0"1/-[-U#)[[\4W7WWWY;>Q?30#K<70,/OW/8+SV:>C?Q?6J&&*
M"-:L'WX*%OBPU!RF:"I]^#%VHX)#N^3AP_*I`9A^*E8LXK;PJ$GDE/M9Q`>5
M*1V5(H$_9NUDETC3366*>M/LF=0JJJ:E=?:9CBIJ%C%YHTNFN>>>2?\:!:XB
M<]1!PXX%JG'QGF*^NLY12M4A!B8/YA'D#'Z@?.8?8##QH=%G2MX')F+,P6.?
M-H90!YFT3H/9AT6><2.'9=JBPP9HJ`GY9Y.I0>0>'DO$8YUU=)"AF$7(*80>
M3(`1PH:G?2B0D$:GD4&#28!A-4T&9,CC$A-L\$?8!2>9A#L14++#AA<:Y\<$
M-&S`Z1DT\F$#D1($'T)O1GP0X05,:I`2#QB$0Z/$J7P8!I@3:IA$"!]4?X&'
M%VIP0\5T:[BD*@TNN6-4:KS;P8<@,$%#G;2,6ET!3!;81PV"@@D4^6`:)>I7
M`A6X0`8V,('%F,B]D..RB/E,9!AKR<6F0L'_#%JP@BY[V`9#8QC1($:$B:F@
M!1T8F7O0XF*3T<@D$)$[R-RC#6S`!$<20YX5(J8C'BO-"=L"#YLUJBW^8`TQ
M&F<3=6A$'93:!P\/LXZ632-G&7-&U(9F&D<5C2TM4@<P<O.,2["E&-N9PW8H
ML@ZV/`,82`3&1&@S#&HDQQSKF,1VJ#&)W;PI8Z]91R&*<8^CO682IO/'-/Q1
MDW/@P62:ZP<FXM=#2E;2DI=<##4&J0Y]P,,=\!!&/O(QC>T,(1/ZH,;8D'.=
MH[6$B(L@1#\09I,AJ`<R>%L,'B)HDTGDL!]W*($*VW*</)P#,0OS"-4\LHY%
MM`R(;;E'&4=",&@>_R<3C`C9-'CHFH=1DR+_H-H^.*:1$Z)&G`Z;RK\VB)I[
MB%`S-ZM9"'W$L(*EL(0@3"$(\8&/MJAS5*@Q5CW?<\&.D9`C/J.FPB[XL<T0
M;"I"M(DPGPFQT*SS9>]ABQ`U`U&/J5!EWBPH2%'(F*AATJ0G16F_8MBK1<C@
M'G#(`P.&L`5A#2$0>%!$'`3("!FP@`@V*$;O"O("&=Q!6<`8`A&@@0<;7.`U
M@Q(<(=YW,KO-$!-N8,`][%"02Z`!#>X(7PGVF`=UF",/-J"A!BRTB*^$#!B,
MH,8=;#D8MA)C$M/@HS\PH<9^B"`Z9:0(NNY*MGN80S;F>,YZ\B"X%Q`CH__.
MK$$)YE``-%P@#YC('6L089)^X/!D;<%//+OY&,T4`QA>)01[;$*-8*F'H3"B
MX441<P<T'"8336NFS28A42`28R+"/.!`*4*-IO&+8-28RCJN^$'=)/9AYN!H
M/V&4V(]]S*(@[-C'?'3=@144A.G,V#$[ZLY^4E.D*45O>M7KF&F4@`S`T-4<
MAJ"%3,D@$_<H09](L(42"*$2BT`$(M;`@1KEH0W?`,(='L&!&I!``S;`;TV8
M:HX3,$!F,&-`&TY`C`?`@("9P,KYYE"5(4QB*R*0P0N&\*P@464.!LB#!O#@
M@SMH``T:.!%%?$"(-B!"!#4:PAS:4`,1F.P>,I;_054T,@<9X.$^,I#!0'YA
M`Q,T3@;FV``B?O4":NP$#RWY'##[X>.]$B9Y"JC!,TJ@$ANT&!@B".8T:G"#
M8K0!!G-;2*Z`,8V(C/@<Q(#!(NY!&%H0X0:TP,0T3``X0BC`!D00PCWDC%L#
M_.-*N\G#'1"AZ2\7`PUJ7$<>!-V`+Q_GCNWQP2[V@0ASV,<<&N(AX^*!#\>N
M`QB860,1:K(/8K#F.([:1R4RT,33:`03K$+':7)6TG[$HR4_5!E;V+`+P_RC
M!$04PA(30XR%M*48,GB,411H/.&6>S$1$T)M#;.+%MN!VA1A]4;6H>[UUMO>
M]UX,)@IA`\`$HP5<:$$T_V@@A#;H0@=PT`(16+<%8`2B$+1%:X`)@0X=Q$$1
M+%"P&L#MG._4E@07L.6$+B$'?US@!^2`2EUT9!^(_`@-,N"Q=R:AVC8L@@CJ
M`+>)AX`AJN0F#\48`B+<4(RXV6`#0JBR+%7$D@ULAQ%WP,.,Y[,/'Y3`!C7X
MLIK[(3HB2`X-$A#""42("06\H`#NR`,1\F<#-CB2#3G20%HH`FD-5(,(B\C#
MC9]A`W8=*`TV]JH0[H#T&Z=!!CPU\$8X4"*-\)3@1,A##8C`@*(M0@.6'\Q2
M1+"BT.%!`C-H<;H<I($<$D(.`[D/#/B.!^71&$4:D,TT<G"#)K"A`8F#@0\H
MDO^'(KP`[R:8`2\:\(,XD,`&PF#`".Z0`VKD@54-GX$&1&`.LZ#A$1I``3%`
M,(,<E(`$Z!!"!NYPB07D80@H*-4:D&+`EU]`(VSH_1E_P(9U``$(CP!"(.QS
M"1OXH";36(`A8`3MF`96N0DBF`8T0`1B*(!BF`0T,`>BVX5(D`-R`(8\P`-_
MJ#,Q8@-&P`QB<`-,D)HY*(9]B!G.PAM!<Y&?4P?6BR8[``9U@!)@(`V\$2,%
M8!7$DH::6(,@R`1UH(5GP!MUL))BF`IUN`-U0`0/U(AI8!EUN"8CPK<II,(5
MHH8;$()SD)8Y4(0$R`%BL`,#J`$\B@9%((%&J`1J$`;_9+B$7?`Q-`"&24B'
M.GB$'P"&&FB!90`"JVNC%+N2IED''P@R/)@#-*`$&-`RK/LT0L`#(F@#%+B$
M(6@#1L@2&:`A!00WF",>!`RF%R`B31,"0F"#]KD'&UB6-G`M&S`_:CB!W$"$
M-IB#._`*DZ@!&["#1<@F<!.!2:`=M;,!3,A`F\@$^BJ!2]@LEA""-<`$8E"1
M2X`;<%N'$WBYT+$/--`]&<.#-A`!1KB299@$.Y@;#9"#K&D#J@NPSRH9FX";
M3ZL&(L,#-IB(\&$#]GF>DRA`;AL_&_@R?>B1.QR"IZ*/$.`!,L@$:4"?4/0(
M[PB/V5"#+;B!'^`%1+``.7"I_WZH.6)HJC8P`3KX@7A(`#3@`#@``GU`@1R8
ML==0A!Q@@730R.:9!A)XAET0`1*(!@18!JS:`G<(C#PP!T+X`0*1A*2(NW\4
M`;;P*D3XJ1MX@#4(`4K8`!I0@"%8`WVL@?B9AO<1GK9CB7NH"QFP@0*X@[10
M`!&`,VC1@!F`@:1H@Y\"QJO3@/CQAS58@[+`0?SP17@;`AP[&1MP`T*H@;.:
M%SFX`3NX`6B8@7[`A[>LRA)0#SZ0@Q(@@D((@1$X/39X%EA,"A-@CVD8`J9`
M@]>8AA<0`B(X$!_0O2I$S=3LH46`@]T+$H"A"-#8B)S!F7[(AIIP!RB1-R-K
M%',H(_^V<`<9O`=@")(F0HX"9`U/4X>7`(99>@92Z@<FF9IJN`=BV(=;FXV?
M,S5B\(?T@(B<&;^KH`6*>(8!)`9&^(<<`H9BJ!4U"H\[8`078H1G(`P#I`A:
M8`_0681B0)>ZP(1B8(1%L(&@T+U)V,H:6`0T$($VB(HUL,9G2!%")(8`X\]"
M68-$2`-UJ`%&H#<98!V*N`04L8\V0(,U\`J/D`%$$()W?!.OR`-@<`,#$X()
MZ(A"08.SBB`;DP$''9S!F`,?0"I&.8&:F`,,J`,2R(%A:`2>8`.-$`)&*`93
MI(0Y2`0(>X!&J`-%D(%O&(%I8``_HH0<0`%\"(0`O(<[Z(#_97B$#J`!?,"`
M;U"$#MB"?I`!!4"&^Y@#X)L$&&"6/%@($ZB--J@%:N"!&Z"#0LB$&4@'$%"$
M+8F(9XBZV:!%73"!"ZB)>^";!<`[_)D)8_0K/H!$.8`!:MB%!=@!C[`L-,B=
M?;`#,CC+&O`'$0"YO:.(13@5DZ`&W:,&#?`'8AC(?I`#0G"#(@B29[B`]1@"
M__.(#IB!JD@$._B1O=$]17N)VD*=N1&"UV"$%GU+:7@3WE+-<!57R-B'?6J)
MY?28SY#-9SH,A4D8$T(H@_JL$0(ACHFHC8`B?Y%7E9F8Q/`'$5J$.1"M1*+7
MJ:`&2=0]<\J'?S`'76B)%AF:0[)$_V.AA=Q0ATD`IWL`)W50!W=(!',`#N"X
MAPB*4JRQF6F`+G50+D1HFGTH!EN[`\3J!VK8AZMY3F#``]GH![1C%<?2".M`
MAC^[FDOHM1\%AC)B!+8PS"UX!+;:ASF`%HH`AFJ@!EK0A1E(@V!@E3L`@3B@
M!AH8@43HAPUX!/)\!#K`ATBXA*NH@UH@@1:HA3C`APD("W,`6SIP)&#8`%=Y
M0!_SBLCBK#8HAFI@@T+`@!K8A1G0!SB8@;N[@R%P!M:+S@O`B_8X@6\:`G]8
MK*,HB-V1Q5UX!AA8T?#@T"&X.A\@@B$(&7IH`![0"1F`AP7-B]-\L,I5AQ<X
M$1^`6@&=2O\H+``?T5VTXKA^N``WV`%+I(-]$`(R<(,2\$L34(<Y8`DYRX,Y
M*(*%4#.X88,[\:-Q]=[O;0Q,L`1J>`:>.2;-P(=L^"$.$IED<QAUNH=\O=>.
MPJ"&JIE]F*?YY:A\`B@2BE<@`B_$D+3P(F#Q^I=%8)G,<!0@85<8PH[?"M?U
M/3=YU2$VZ)'$T`>VR&":20<2`-EF<Z9DH@C2F`;2^`=%PJ=A(`?$;`G?>MC-
MV"#?7(=_\%!\;8E)4`_6*,#C2")"**M]((>KX4GXB*UBD(,R@I*:X$8?24!@
MJ`V/R(-R\`<[F`1_X,M@Z`<:L0D;RB&:)<]S0%EU6&%JJ*-AR-;_&4;9DWG.
MFL,,$1'"XP3?.)9C;[N`#7F!J#$B@5'6?:@#?P/7?G"#9CB,9P@"Q+C`PTB1
MT'%8R)B$-OBBP8LM1Z$%[HQ.6QJ919"AI[DB<C4,J&G@C;@'?2`8*7Q7&)ZH
M@!HM[&*H_YU?5*9@?"(O86)EZ;HG?>TG8."K@8*VPW"F/R8MR*"&+QLIBY$N
MJ6"N5E;@DS%`<_A'>OUD!\:N.9;F<=4(\5RLGW@!!((;]BF`XF2`.O@`%EB#
M>Q""&K"E*4&#=4"73UN#(5@$==@;8T2&-/BJ2"0&`5TC/&`$<W"T#9B#HG4Z
M:MNCL`$&]=```ZS%Y5`/DYF#\TD.0JBM_V=HD2\ZF9D0`:+`3AA1IZEHE(<Z
MHC$K!A(I9IMXNV<>:8WXT$3JLM8H+A&:@Y`AI^)B#`1E7Y>Y$)'Q!]/9B$S@
M(7=`&=,H+%OJWQ)"C4O0G(P6J8X83A&:((MYAF!XC7,`'#P>+6BKF'L:&EI^
MJ'0*X(TJKX`:ZG_M)HLB:M$0#7L5J',Z+U0^:_8MF!?RIPPJ8'.;YKJN0DCM
M"C@@@J(X36"X`QD8'O(`@EKHTAH0`KSHE'XH`E@<@B*@@Q%@!!2HA`W8FT5(
M'!.X`4FTU55Q`XJH`1/-@P6-`1E`%R&8@SQX`1'``PTH@4R@"&5Y`48@O9/1
M@-Q(#BCKL17CQ?\-<#Z\``8BP(/:8HLVR)T:8&US4!:6_=*&0`2_$($0.0%$
MH(7(P80-$)P"W``94FV1V>L0%=@[$)VV>$"V>D=M:NA28P",>-%(0H2<^8KS
MO-P-^8=0@]!,J*.=50!G]"U66X=,P(U\F(1U:#1U*(82T20GPF7=J(8V$$)B
M<`<K$C3J@!ES^(>)\('M,`=4\@=RJ(%JR!UGVF3=6(\%J`'+0DR:X2BS0(U/
MNV`)[H=)4``?V``[@`,PF8J)?5J=;8LB@.G%L&]0%H$208-=H@AG")?(>`:^
M<D+%8`1+T*Z.]A@1ZK4>\H>P:;MJVPU?LNLM1\U+2(-'H($A:P-,4*W_&?@!
M&&B"&F@9(0`&%E#>_CO'OB('3!`!F9F!1$"#>V"!^^N'1+B!&WB&9:@!.%`#
M#U!`W3")89"\.@MMD]B'#;B#-A!%'\@=_"(;@IL(G,LHV;8#$6"#%<O681BR
M1=@P-"B`VM`(!AX":N`Q$\"#&/AT=;"#AB"([MB=_ONJ3U=1/&"?25B`B1T5
M+'D!C)!%1!!FCJ@0X="`.4BW>2RU$JCN>8D/R:.($SCH7+&+)@L*@L`+MHA&
M4W]<K9B#!5`Q=A'%UC8!#=D`&]`('5&=X2F!4B$"#8`T1\(*-/#OW<$$#6"$
M3]D"U%T$">@E/(@R1>NO-8JLWTL*7!0!%B@&_S6@E]F(K%*IK74X`$KX,35(
M!_EJG'K4%EUX!C[P@40@LC:HA@)HA$"X<(HHAJ-SE'0A+AL(!GC(DGY@`(&=
MBGPX`),I@6+0D4OPATDP@<*8Q/40`M;`FOB9!&XIACF(.VI@@T6(JP+TP(I@
M`V+(A%J(0-^4AF%(CG1`AF:@!G.`!F<@SFZYA&>8`ZBYA$;(C>+H!V(`AGC8
MA]6Y94'S!Z/>B&F@!=;0^G68/H\H`&!H(3LRC[]N:BY7?'M[FV40!.DVW<;9
M`1Y``;QKL5=T9"'HBL&@"!1KLQJ(AY%G@W-@@:Z0@1'8B2W0@2WH@#@``3R8
MI*(:`EZ_!(+(`Q,@A/^S@KI)L%5PVP?I$3*)Z/P\-VS20X1Y)#AC1(.]6'LM
M8(#MT`AW;@^S6I%+L%5F,8$[<,1,0`=W64*O&C3BKI#:(@9,0(FV$(+(NP?3
M%%C=[(=TV`(X^``\>(1[J,5[P`0ZT(TA:,?VH.SC!XA^_2;YN'.)30UJ]VKX
MN-</C8!)`N^AF9.G7YXA&P@M>E:#F`A&A^R@$5$#T9!^^_H1<X-!B(U^=V92
MLW%/1HU%>-0)03.IQ)!I:*J9N*?(#05$;8KY2,FF#9&;Z&3ZZ"=#2"$\B-#4
M4/0M$(,A"M3UXP((&`LAB/KE@U$,!;@</R[@6+`2T8(7&VK>J!%,PXT[=FK_
MR*@S`0@E@3787'AF(I*-%"7(A#!Q$HT)B1,5%.NGU@`B$T3:N)&!9L@%/$7P
MP.NWF$T>$T-@VI#!AE$;#7#FO"!B(I-*&SXR8E)'C,@:9,7.[?I!SM("-\QK
MU``F`I$0&1H(B4!!ADZ-(7ALU(":H88Y@?VF^3`AI(T"'^FG*1`Q:<V"$'BI
M]:.FX5(--@S!PP8EV,"=#7BHMR"##3KX((012C@AA15:>"&&&6JXX8+P.*1>
M>OW<XX]`^SBDCT/F/%.B"(N0T\\Z_;B#SSSZK*,/,)?H\PT+B`#33RV/3*,.
M6?V8DP<F]SASSS3/W`/,$-28`]LZ<J"QXGIHH*'._R4?FB/$21C)P$@QDTS"
M7@G%9#*$%I<0`LQ%*Q%22S]LJ%,(+5S-A`DM*[3!!AL;$$$,(C8(H8L()3!R
MQQ!S%".#;#Z\4,,E/SZ$DCHU3$*$@(@0TX\P"K"A`1Z+F$/$5B+8(=`0:%3U
M`AM"S+'60W-H<,=K[Z&!!TQXR#!-/^H(A\@S!]C:QIN4SK$`&DH-@0@F*0FD
M@1PSL'$#,#(@@@<P#6F04Q[J^(`&(]VV>HD,]WPPR0=]`,%42CVE),(__?#:
MSPL^(#(K&C0@8PX/&3!2`UE#7#)-":CVXX\)NZ#0SP\<P+!(&B3:,<0_%Q`C
MQ`UNJ#-#=;18!DTC+=1A9/]\J<G0#R(<F"!'$"8@8HX()ORX4C\,=(9J3#8L
M,`PU-8A`R!R,2-N/".FA8<,DA4Y#R"2$"%%"&VTTQ,@<+-4@D!"1G!D3/C](
M<\D/EJ0S@G)\Y.$#4X2B0>TBR#0A!#0/R7"(%H'H$*YZT]R!A@R+O'!'>IFB
M@<D&3<#`QQH"D2,$&UF7<,(TD[1AAX]HJ,0AYYU[_CGHH8M>X3XX:\A(O0OJ
MP^#J_2@2#X;\@&ZZ0/[@O)+IN=-^3WJEKP>LOO^L1`Q9U*S(^TKF7++/-+3T
MPPBMZMRCCC\Q/H/(/L4`VP\PBDCISCT*(5)(C"PMPM\S_FR%9;>3J,/(.F@(
M$;[_#\`\HPXPVT]RL#]L^#`),J9A#F)<X@6+F`8UQ"4$:EQ"/9:`@1W(<0D3
M\*$:Q:#&(O:!B$D\`QCJF`0FCB,"8,@!#Y-8R`^:<`D?+`(8>!!!&Y[!AGV@
M(44U*$$F+H$)3+BP%B/X0"6FAH>5%",#)"#&'3[E&DK`81YNB$0-<)`UEEUD
M$3YH`S":$`01H&$:B\@#&[:0AAFD@659JP89\#"$$[@A"&D0@EH\(H0\7*)\
M/JC!&6P`C!)815Z+L=HB:O`A'Y!ACC7(0Z&*$<CHB`".-?@'(12T#ALP@@@E
M0$0-]D$$1I"!`VA`P1I@T(P%.`,-/T`$4(3@@P6PH0AN_WA3$-@@!T9DAQ&+
M$`0>&H")8CBD#1?(@PTP<8<#`.<9A/#!!E!`"#=<8@?`HL8++D:,&T[#:'C(
M`RW:L+G1<;.;WOPF."EDCO3X@T3JN8?P2J=.@:##',#:!XEL)R*VJ$<?]NQ'
MZ^QY3WW@0R7XH-T\MUDBW\%3)?G0G4!5L@]^^*Y$ZC'10,L9(9S)TZ$*61!`
M(911A[+.F^:T4$&_Z8\/M0X?4]%'0],1T@4QJ:/3.(>(^`,BF6[.=_<T1V=*
M)$^'``,-9+"!.OWQCWL((S'!<L@^U,$&.YB`&NF865)'JHYJ7%0EEV#$/?:1
MGO04`Q/FN(>/_&$.G/V#6_VXQ/\<W,F[2Q!C#EY5$9.VMT(.&J\?TB##)-SA
MACND8Q?TZ!(T9"B$=%@"$TK)WSB#$3\VW$.-Q"@&)<U1@N350`@$U-9*[@$F
M8%!#!FO8!Q\:"`^)H*$$'5S'.KCU#'-8*IRN?2UL8WNAE02B@0[M(",(D5"!
M>``!"Q`",BXB$'4$02#A6$:#+J$#?((NJQ7BY4,OL8A)Y.,9VTMJ[SBJ71']
M8Z@/S=UW:[JPAJX4H!3]J(-N]U`&-72@"S)G>S$J7X=N%+RR9>]\NZF./Y6/
M0IADQ'TK=(]ZF(,>&F)MD2QT#RP%N,$.?C"$-=1"/LC@#BM1@P8FH8$%KN-/
M9-&'!U;_I`%&[&)*B/@+'9#!"`S$`Q&4*)T^<A"`;_3C&9A0"&*[U)]/K>,9
MZYA&C-2!)2+MXP7;$\@Z$HP[AVB`P=,PP!`L@X<&RDF;S\MI>A'!!D3X@"R'
MVZV#BB&M<C4HO@M:Q*=<&#JM:I1!J+V$\GS`8-,A-;VX>RB)DNQ>&`'9'/#M
M!T-S1Y:0WAEW#37G/3X$SXK6="7ZB`=YS6D[W:FW=0K=[D3"NUZ(:M>^FX/O
MA];+4=/Y0QJ3,+!X-]IH6K"!RO(E;^W,2U#=3;K,"OTHK".LZUWS.D()*L$E
MFLRR_UU2E2+8@.;V48$4B&`,NF"#:4(0A!+0@0-QN`$:,%`#_V!Y1`UUB`<+
M9+`!/"@`DQI`@RXTL(%%E.`%&O"!"*HA@Q+\300:R`0#;L8RDV1+'43($[U-
M\@+^3.,%Z[%/,=I@J#ML8`W%6$`>"`)@L+H#$^M`1";:@`<4D,4')9C#.LS1
MA@PZ9!)S^*"0RV4./)2`&-28`Y`GL0@1$0(3_<#$S#]8@A^ADAAJ_4>(GO&+
MZ>TB1M2PN3_R9Z3T`0,>CNF/,QY:C/E4HQ__F,95,(%O&0R#)0XAQCKN40*8
M.JD_(1+1BY(Z%8;>X4<'W1PPYC"'H8AWO>9(5Z<EM`C=$OI!]V@#6:IQASWO
MUG>+&+PY--<@=13C$K3R485\G(<C"?^;O65W4"9D,(0$0T.Z=3M')"!T!SBV
M@1$T%5$Q&$PAWM$*0L#(AZ@GVNO9TY[V*Q&"&A_RJ3N,?"U$D$$>-([/##BB
M!G=@#PR>MX,?],,'<VA#,&`@A!C-`0`7(*/F?,`&8"#"`$3P@0U,D"`?^$,&
M7S+!M]H-#$SX@`C]1<0%&#$-!JCC*@UY1M(T5>,%U,``S\B#"/C`-'!`&PA!
M,91`#2".$.B65>2!`61"PK#!'=B$9Z!!K,B`#VB`+IQ5`,K`H,"$U0#@(I!'
M"90$JKA*'MQ!HOP-&FS`ITR"`K1!#0R%!'+/`O``^PD!$3"<#^`!K\A`,?Q2
MK!`!(6@`9(7_29WD2R;4QD^4P&_EE@9@$1YL@!!,@@THB@$00QN<`!M@P@+8
M`%F(RPELT`9H`##\A`;PQQP``QOH`B-@3AX(P8H\PQ72`C640)<920VLPQ#(
MP#/\Q!#XPR10ASD$TC-,T,Q-P@7(&4_D@3EA1S4P@CJ8`R:<4![0VSVP@?O@
M`1I0@S_@P1VL`R:P`6HA@@@HR#-(`)D(4#]4W20P`,M-PCH<$!+)U/M\RB4L
MSS00PP+803%8@@$0@I/HPC3L`S#P$F?<@_LX5&@``PJLQ2[X`R9P!3!DCQ`$
M"XF$R/`0P08XPZT@U30X!/(0`U+Y&8SPQ]M-@P@4PUI(R>^PE$V$_X]`#`F#
M,(D_`(L_5%7M[2,_!A@;9((0[$,,]4,QU$#-_<,<R4\#W8,&J,,_;,"^D($=
M!&!#V,`B$`$>U`$#;&`-Z((_U,`6J,%/M(&9A`2OY,$B7*0ZB,`Z5)8/Z%`-
M'&)35$-!*9()`*`YN$=5(((&Y$,PL80)N`8B,`+5N(9:[(.A%(,N^,`URL0"
M^,`%%(/\(`(1U$L>[$*F&-\0_$AI;46VE$H)K(S1C-ML$`,Q-,5*P!L:%&`_
M8!'+L$$_E,`BH`$1;%5X8`*I\(`08(([H$`DY`$'<!D5#0X;#(%P5$4_4$X_
MU,8,ED#_,$*SS('_5`4ESD$1],3#<04AW/^D0ZP#[XG`'&0"+536/YQ!U1&"
M"C(E'FC<E0P$$4P#0TP"9!H)Y*SA#<T!'_``"B!#";Z`$+C'M@V$#TPC^)7;
M0"RB".S`)&C)N+0!#]Q!^VD`&RB`'?2@#:0@8-3`&YF`S5$#Q+U`14Q"2F""
M?6C`$(Q!&XR!`FB+2O@`3K!!"&"`'5B`"5#G&!#"">!!(;CG&#3"&%@`PUT"
M#,C`"=0+B<B`S=T>#/!`(Q`"&1`"#$P*,="!--`##+@/-*R$.ZQ(#72`))R#
MU0P!)AS`-2V-AKW',-C`#K(!-13#'"@`SO&DIN`ATHE(&R#*"TR9")S`IY#(
M(L@`>7#GT@C!'1#_PI3T(Y(F:3>-2(RL`\ZLEHA(3TKB##G6V$LMPJB8RCW0
MPCU,%PN92$X10RTPRCJNR!R8P"(LA`U0PPE5XR1,B08L@E=5@^/-@?D-A`:,
M4!N\@)$-@0BP00WE`7]0PS6N0T&T%53B@<7EQ!`,`1$0@4!4PPL`0U"^QR3,
MC[T(R"3`1G!60P\.T0'\PL#`A@P,8B2AP6/Y#R>.RQPT0A6Z!<L`FPCL`[,(
M!#!`Y[CL71ZD@278P`B8(AZ0WT:8@!H!ZK8(Q#IFWI8Q@DT,01X@TGL@A#F8
M8@NNY26(`";@03%4@AGV`RUH0!Z<0![H`C`0`1KL0QY4W3TPRP*0Y!S)_^%`
M9(TJ]9CF?(D0_,CD!!8'S$!;WM&B",',/<_@W=!3=`8B8,#>%0/(3-,>%@,`
MREP<+J8)K`@AR(`EV($-N`,BZ!;6><:/;D!GG.4B7&,/W*<,-M`TG,"TU,`8
MR($(U$,/9$(/!!(BY$$F[<,P3.08C,$D6$`AG(`T+(Q5).@T;,`<U(`<%`(;
MR,P]Y`$9$`,],,<U-H-*J0,Y:,,,S!PT:,#1:DD_8"FI7&,-G`!3$H$03`-:
MH0$PJ-**`,.&,5@FXL$99`H1.$/(;0X:$,(E&"`:?)$&4&4>,*"2#B[A/I@;
M\$`>J!J@`1J)+`,-.!^8S5:2(%EK6%WMG!V>9?\:-?P`5-C./83=.K#IA_".
M4#$/Z`Y72HI(Q*G'IJ:'DS8)1310,1`!,)A#DH6<#P"8_TSBLZ0(EW6&#=C6
M?M40,&@**JW!Q:4!'PQ#`P4KX>0!,O#&!A+D#<`<&Q!!F9R56PT#+9P))IA`
M192E"6'2'012<!*#])$+;C%"OH0([;+H)6`.'@"+80GDP"#H>K0!+9"''<CA
M,"Q5$S!`=98>P`J$AM4`'L@!>42=-L#`&I31G_*$U`3.$#C?L=J&H_*`#:!!
M(LR!$)QB?S``NVF6"`B$?\C!'/S#SB[5O"V,0=:`"9!!TEK`/^Q`'O"L#=Q!
M'EQH$%B`&[@'$<+`LXW_`S7<10G<@_81P>$1@ASLK,$(01JX02)<@AS00"($
MK5TE0C_`P"Y(@QN(0)VVP3U<`")`9%TRY1HL0J%,(Y>-[+T"`R,PPK>,U,*0
MP5:T)-O00G'`GMJ.+#"$GRE2`QI<0((5KB$?LH2HET#=#GCMSGAMTT:MCCL<
MV8,46NQY#JFI,26WF2+GUYVI!'IU\B676:C=W,JH&B*XFGRA5T!],AU[<D`I
M&HF,+J[5RR<7\C95U$K0\=?)5%*U8F=(SSZD@UJ(P#2@;?6DSCT0PX]T:6LA
M0R/$R%>)E30"@S^H0]NI`[`48R3U`RNP`3GLPRNY@U71$48`F$"T$/68Y3CP
M_TJ(=-8B^$,AC8,EU$,SG,\X``,T3$,SP$`AZ`(/T`$Q,$(F6"$C%*)ZL)SF
M9`L;-`,O6((T``XPT$,0P``T6,(Y%$*(-$-B9((VL\*CR&%GJ%(J7\`+)(D0
MO$"9@*92$0MD^<`TP70>=)T@#D,F7!S#$H,=W$4U#,,D8%!S@E4)(S)1%[5&
M]=,E*(*H9=1*9`,\Q+.#K$,:W$`=S,,ST)0Y()>(.!?.H-0]T8[BE@Y7JP>)
MJ%=FE3)8YQJI03(\X<Y'X=I[492HR=.AE9E$U12CP9JA[?(BTU?=C=HH1VYZ
M53+HX$IK=8[B8L@SO$"=Y9>#)?:&.,0T;I.B+759K_]$-<1(1HU(A%0/0::A
M48<V4;_<--RJ.NP#)<B`%K#,BE#B:>\BVC+7"#0"]A;.D@A$)#``*@5O`R$7
M(MP`.3>!%E-R/-1+&U1=A7PD+CM(-=RJ9D!V/[B!ZCW(/ZBMD<S`"?S8$$C$
M2EPJP=G<ZM7L3J2>>CP#@\&>1LF4.SE(1;$R?JG#C\'UJ\GUI<G>4A/>IC&U
M)9?(ZL27JGG:8&_7/N2#>]M7(]?.?.FW8U<R=#=X@TS/?9G.,V"9:%?XX(H`
M"2@""O"`$_S`%G0`'(R+??B`QS&""!"!20Q>/VQ`(QB("#P#&LS`#0C$(Y"`
M/LR!#31"3V$`#30"`\RV"=S_@!R<FT`0@PF4P(@JB$R81(SX`[PIK(+,P>3\
M79=!E@02`37D@0S0P@<3RZ;\6!ZDL$!@PJS$:UIEZSJ0@R1NSC,`&!HP@$.D
M]+T>B`:DAQRW`1]M0$R43H^118^M!)"M!P-`9N[^"+"@@2/V0VA"<GKD0XJ4
M0&OH@D2TQBP_!'\@I"WC%XE@$B$XQ)_1`H5#R/XD,C`[R#T4`S$H.4!1`TU!
M-X,0J8@4(G?_F;T$B)$.D4"8@QM,1']M#C4H^26;66`+%7KY@TZ4PX(,`P(!
M^NEMT],8%F>)HU^72*#)]Y,6"6<+U.>&E.VP,EV;@_0(3WBI%Y$LMX6?^^S-
MP#.X_T$%Q($.5$"+`<$'3"9H7M$=/,,0/$-3ZL`RQ,3HA4`:8`!9-$("Y,`!
MQ(,':TX+P$$=:(/\/%!."$0QP,$*V(`-*!'O*8!$%"TF%$$&9IT(?+&!:`FX
MZN7?FD8;#`%#8!(;&(JTG+AI()NVX"'+$8$&U,L!,N40\!%!+@`'Q81U%T0_
M:,#%2<LZK&<)L`>QLL$!=,8=LI;S`0,9B(`,M$$1$"L,',T^1!EVK(.D:\`+
MM`&T8`)XJD-I,8+1KH<"$`,`6IDZ](`!$8,,7,`:(,(BT((7L1LA](`/[$)X
M"`'&8!(MW-V:DL<Y2015K<W460TQ/`,>$$^S?/8BB,`=\/]'2GY((\F$S54#
M(A0#(^!<`V%"I\\CS`$#`/`',7P+VY`%"&T.Y4N6S/G#)5##,%Q`ETP^0?+'
M2@R!`!`<,)Q#/IX#_ICPB@@9D\S',ZR$E*##!FBV"]\1'S')/HC`VE@=K!?Q
MI)$%,9#!>DZ"",B49R]:]<SRZ*X.0]W<K'S*AU#/G5T"'ZU4A-C!IK+!D7VR
M0Z3#K,0)NN__[)6`.00"0-"X4T<((A]H;"`2@J?$I#EM$%T2`HQ(OWXU)M7H
M-T>(C6)X[O4+I-&''3MK?*2K@0:/.2$^$`%C<T%=/X,B2A`AUF^?C)F3^E$K
MH4Y!GC8EV%RL46,.(C;%/`(3D=3_QI!);BXPZB>C!C!J-BS*F`;L0HE^/H;<
MZ:?KPB(>T_JUR;-U(<]^EQ:@&=)OXD5,_3;<*X;&(C41_89L$(&FAH]+%J<9
M$%%@W1HT,A#[R+/.1I['%O>5&`+,Q#U$>&K\(T($=1X3;(2L>^:C6#]U0S"5
MN'?A63]SC,Z8L'$ISY`A;"8!NRRB6)M)/O`0070'T0(9)A#)N-.FS1R[YC0B
MRLY(R!@\:#")4-.AC0)@_9[5N'1A$@HU-FC,L.BCD)H2+!"Y8`L/VM"`#0WL
MV(`(H-01(8T:"BDB)&)$:&,%'8281(8B\+#(!B$N84$1(>;PP80;BABB!#1@
MJ"&$'<ZQ_\V')MS89X,A,"!#`3N"*.&.2VR`89$/2A"AAA*^8<$$/H0X805&
M#-AIGWZ(N<"B=:`9H@9,;)B##:D46`0/`PM!@XQ$["+#G'Z*T&`,SDRXQ`X%
MYJCA!43FV*`$<Q:I@1`\\MB'D0+;F,:.J?(X08@II\S$ATE$,,$<3"ZH(22+
MYI@FMO,N:0,-N-89P@;&\`!F"!#%],ZB55EMU=5788U5UEEIK=766W'-5===
M;RTF)(6F4<?3::CQ@9%]+K&*F&?,(68LBS"9`ZA+B"&D2XN*40L:.Q9!A@\T
M-)@$DW4F000-(4Z=LDX:\,"SGWL^+&$8WS3*PP<?@&E,OAJ&6/]D#N6*(<8&
M#=KP`1,AY%J1"#8N@<JB"H?(0S<?2D2D!ALP.:,F1N03P4N+[AA"@Q*+*>&9
M:1`9XI+#)A&BL`O6D8$Q3"RF!EL3XF(##3=JH$8(^=2180ZM0OJGY1K$0H.0
MBK3DPV":"2.&-MO0`XNY?H!!R@01UEEDAS;L``:8-IYAK(UA?)AFCFH&*P$3
M.0B99)H[FOK.AW[R6&0S(7JXYQ)$.EA$C2W4\JV-2^ZN000@XMC"HCSRI8&+
M.FCHQP9JT(`'(C5J$`9K#?HA8X8;"MLB#T2F.6$#'XB8JQ\3A,@`C6=$F&$=
M1F;0CX@A"LED!#G<Z6<7!5`(H1#2:S#_X8Y$&`@"!@ULL.$'#J#A>HL:4D##
M!Q&>6<2&U%;-;545\^`*#S(L=<J$,<EA8`2>I%&'!W+N@<&<,=S`@(X;:L!#
M'3N(((07+&(2%]@`(TJ0EWM8)0\(\X$Z*&0#6DS)(L^A6$:Z\HR03&DA!2#$
M]AAA&;@8IAHO`,8+GD&($J#%#HBP"Z]@&$,9SI"&-;3AK2C8JAS6:H?O:A4_
M5J6.'PSA!Z!9U3Z>D<-IA"0?Z[#(/R[A#PKZ@R?`6%.SID2,2?A#BOF@(B8X
M`(Q["&9-U=K'/^[ACS7U0S11[,TS_#$)-JBC&GE;U1W2-@VX]&,=*]I'OH"Q
M#K7DH09KHL9G_R)3$+R5`!&36*,YU**.A5#C.1L@!#'4,0=BY`$-U7B7$&2`
M"$:<0`;#((()3'*'292@!M,@@@A.TR&^).(HB[K+"5B'"1F48`Y$`(8,1,`(
MAMA@$D3P@3GFD,)D]0\3DZ#&'.:`!D38S')<600;IM&&.RRE&#EP0QK4($MU
MU*`X6YF#?11A$43D(0U`4`,K3)`/$CQ#".;@#AY.`(1^G&,$BX`!BPI3@AP(
M0B@'R<-?^K&":>1#!GC0`A`0X88?Z*<&=^`!(A:Q`&=83@[.L`$9@M`,$:"@
MD1I81'9Z((="H``9*\@'$'AP@TAD!V47FX8YJ+B."U##'#`XU246T?]0,@A!
MDD<1$^TXD(Y]J,,<,S"'.G0CA#6@(!B[D`$F%A&#<W7E$B<H`3"NR89G8,P-
M;1`"81:1B3EH8$U3*J80:#$-$=C`'\^PV92JL0`A,&`1O#.KS8CA,B*`!V%$
M&&H>9'E#Q2Z6L8UUK`Q[Z*H=1E:RL1H&(IQ(V<=.XS.SFM)F8)A#RD9V-A:A
MX@:/F-J8V6L?%)P2(];81(NH@XIJM)Q:@M6/?\!E'Y>ZASKV04W(3&-*U%!'
M,7!&#9O=`Q/`-6YO?]N/:337'_?H[3JFD0=J3L.1ZE#'/=:Q#T34)AM<D,8Z
MG&B12UCQ+O.H@QH>R0ATN$$1\8B&/HCACFG_J-$<:%`#.OJA#VK<X!+XJ$T_
M\K%>=,"#&/\8`AK2VV#X/"(:Q`C$`MC`BWY@PARGXX\4$3&A1A0""!A@A#/V
ML0;Y3`,MR*A$.B;QQVRDP0:+:"XP+I$)1BPB'Q8Y84-"A1%$8`(3Q?@9,>A0
M`CQ0`AAV:$0_H$&.0GQWCGEPAO.$.0Q=R``F-]A`S]C@@QH08Y>:],$:GI&'
M%YRU!"#22#^J(4QBF(,0=SB!"*+U1!M,PP2:PL0=L`GGN=3S7$2P@1WP<(E=
M/);1C7;THVF(#@"S:A\"A@9/7/NNWE1Z54OD24WZP8_63K&U^AAC@'W8VO!2
MFE&MY0D5*8UI3$_V_X5&-.VM:YW:7+_*U?V`M:VMNRHN9IHG_["+J&6=;&23
M8Q'&EF(/74OL!(-ZU['N]:IZ3"6$QIK;L7)V9:>X*GWP&L&O&K==SNUK68U6
MAZF=$AYD,(2-PHJ"(>'S^I(-*V3O(]NRN@<\3'LI7>M6A[UFU*J4NJISU&0&
MBY[2.:84W=[6-KW4V,<T9!E93PM<UF/L+;8G'A+V_AK2)3?YR4L^;A])-[V(
M@$,<:N!J[Q9F!O?`Q[M"4H)EP(<PK9+BJNY!@D?T8Q+/&,(5DS)P5XUE$<"`
M=]);]8S>*'8?>.B-.\S1V5;%>1'K,,>!-7W$GP<1M;32[+4K^VOTVAHTJO]>
MZJ\/#FY6#9OMLD;[Q]MM$7X@N^T%[W;>@2[L===J&L8&O*O,`0R2_QWM2C^\
M9EV%CYN_NN^5AP\]ZAZK'"Z^LBCW_.=!'WI790`/=RA2;YQ`@D4\``:%V,4-
M2E";=6B@!6IX1@E,5H-:Y$`".:!&#>H9/6,K0@2)+H#-%L,5[2Y":GB8DCE@
M<XY(_``9SV"##"YPB4DLX`[-QL,B[C$)0MQ#!'>[`]C!:GAW.!-K[TF\.?YA
M[#W^HS;;_ZX,,L'6HJ6W'WE!1$,6@>"J009"@IY\R"XJQ89R;/"`H7#J3F*,
M`_&T[E6,"PWNRMV(#B@L0C!B)1]`1%8F@1B::8W_9F7<G@$3=NLS*,L<>@@3
M``Z'-&_@IL0?R@'RGJ$FXJ[O1"T'IV0=0&VR6NL<I(&XU$&#W@4;0"T=D"%&
MU.&FKJ08<)#57LC5]H&*6FOLEHJ"X`$'S\C5HJOOP&L*16\,R;`,744?QDT-
MGJ,?_*4?%*$.)B$-SF$&-&`-9``LI$$'W"$'6J`8GD$&A&`%\(`6M"`G9$`&
M-*`VGN$#O"$'%*$&G*@&,D$$,J(C=BD/:@(M$($/%D!QT.`"3H4']((1%@-=
M%,)(1J4C-.`]BJ4$P&(K2H`[;$`&2+$&B&`.\N`9*L(<6$D(#L0W&J"`T,(<
MQ$PK7N<2R(\1A*D$0JG\_]I@$1B`8X@`+JI!..YA-F1@$1BC;(1@+/I'%Z%#
M!H#!R/!@'1CC$GYQ`SE);G1FA":!/`AA2M3A3W3*!Q8`K.Y@OZ0I#XK`(ER"
M#L)O"%R(C;9)"-2B.:AI'5`#=82`&AAA`XAN#@R/&"!L$@P`P+#!$HHA$V)L
M$1@A_%1HFJ:!$7H#Q_C/NZ*K$O[O,HC!B8C!9M"!BJ9A`](+N]2!`8K!V-9A
MN5C0ZR!#X.YAC?YAJ=K*NK[+UT*"#>Y`!C++M4)B$0I``VR&\Y1N!FT"**;D
M;W)M&.Y@']S!'<BA'^A!':"AM=(A'6*$%[2!'(IL'0()!E^E>\;B'XC,'_"@
M&/\8H3;0X1(8P?!,2P-<!_+,<#`)$]+&30MH2IOZX1&VH`[P`!]@H`0(Z#&>
M(0?B`0=XX!FR9@A$(!.>00=80)7@S<?``@W8``BH:`B(82A"9G;:8`B<J`0>
M(T$0@0X$$AA2IH%^203@0F]>P`:><60,1KH0PBS4X01"0BRHX00T`@WJI%_Z
MP:*V`E!DI!@LI3$T('G"0@2XKQBX8A]T!@WVH0;,Y1,)`>!4A`2*X06*H3A*
M@!JX0@2$0#XW@`UJ8!$:`ER$0`-,#Q@*PF6F!!ZT@`V*;P/R8"<R0@-H@0,>
MXRA>`#:T$1$J9$6<8PA@("PX@A01:$WNLW]\0`Y$8`W_%L!FA,`.L*,X6*!.
M+@'W*F(FV>`6<>8>5(`.F!,&)F$(9@`.[J`U+R$[,08G#F-*1*D-%F0%`,$#
M1(8#9.`2/D`$K$4=A,D`2A*8`F2%J($&/J`.X&`!C@(P)=0&UH06-$`#R&,"
M+F$%[E$+RF*N)D$Q=*D$!A03RD:Z%`<U-,``L$H&[*`8%H`0B&YDM$<1IJ$Q
M4N@^L4H(&@)1*TAFB&$$'D,Y>``8]H$2-/(2R,$-AL`D+"$1#(2[[$"2H/,N
MQ)$0ZDE3<A$1U$%N%D$(BL$<(J%3&H`8B,$-..D.2/(2\(`8\$`@IP$-`N8`
M,&X.XJ@-^*\PC?58&>VD@$$#_X8@)/IK$:AA'6+B2'J#&@0A'N@@&$Q``]),
M&'9IR%R1$7IN'WS@$`UP(T#I'J)I.X:``>"B?#1#-.P`#>R`SY@"-PY"+Q@@
MWCZD."QC30C!!-#@,/PAF-C`!ACA@VK`.D,%=+!&+"3S;NX!(TI@'0[BJPI'
M4L9*.1X(#]B@#2["8E)H`S1(`W;5!DI@&E;U;J9B$>Z`$K?C#HQN'>:3$&*"
M".Y!FI+B^60`$+X*#KZ*Z)8",0+P7I`C0]C@8+=#'*.S0^X!,P;E;GS`9MB`
M&(A@'2(!F.QE38A`4!B!#;2`!?"@*;+1A<CC+-"`,.#!"OA!"YSAH-J@!;@`
M#OK@)?_ZJA_48`8*##,L8AETH`5:P+_00`L"03]T0`$P*5(V0H5R3BU*2!]4
M,Q!RP#@H@0:"03D(Q@0"4`WR(!Y:``1JP62\0096H!HV0!U\X$/X;`X<2@T.
M(A-\0Q!6(`/J8`UF8!$TP`<V`"&,C0W<1@&V0`*(0&8Q@0%\@#E]0`.FP09\
M`&3-80-Z"C4N;1@0U66`@0=LX`7N`&5YX0;60`[8H!`TEP-L((PX('B$P"`5
MP`=P;Q':P'?_83$N8#_%#!FD8DW8X#PFX1$0P0,R00W:0`1T`3`W8!&:MRDD
MA@T$$UD9N(%C:-0"K(>"+=:.L@?72+EJ[1_>LMYND(_.(2C_"8&X?&T1'F-6
M>2J\Y(:I(.@>G.,>\E?J+H$8`X6/T`!R(.-..&,.S(%\`W"=[((A)L$MU>D.
M="'\P`-A,04NYJ#I;E0#Q&,C?NDY[R&P?&T((B&`T_8N+N;/F%<\T@R22F0T
MV$"0M%'[X.,$V&`+%$$+LG'#SJ4?T(,-3V4P=*$-=J%U5*DQMFE-?.!@,\(?
MNM$FH@-*#W97:P(VE.P$YH`$&.%1^ABW2H!C#*(?X,$%]&%A[5,'@$`+PDD'
MAJ`1[N8'XD`-XB!EUV@!U(`&:J`2@&`&M"`'^B$'2"!L+B9?,$%YXT*[U`"6
M:8"-=QD(B"$-`@'0&&F:^B$.9B<%_UH`'A:6%F@@!_CL(I1L>=L@#FC@'DS@
M`GKL$&1`#58@#QIH3(IA$B#"(MK`ZC*`?_6V'X!8&WW`91HC*<B!9?"@#8SM
M#GY&#GCB!%Z@2%IF8A=A%^Z`$)SX#LB`,/8$,?[&!+Y6!)C+8L9S/A,A#9K!
M#3K3EKY/AS$!#50/#;[E'OH4<M+V!@^"VASXI%&:5]AM@<4-I35+(:]$!$C0
M5CBN58ZCD%CE'OC!"&<-;]H@E.R"&#QI'S!AC_@-T[QB[N((*X'A$>Y!'XK.
MB"*.@I*#C_8A':2+$&IB$J8EL_#@+YS(')R5PVQCMTKEB50)'80A$(H!'G0A
M5=%@C?SS&?_6H3;P@1+PX1GLP0_;H`YJ01B@`1B&@1K>0QB>`6B'8`[J0+VB
MH1:(X1LJ81$"H1;T@1*HP9@.J<U<^#W0051H`1'R01%H@0AB(`X6(1NB@088
M(")$(R0`@0'BI`[BX1DT0`1J@1'6X0RJ3@@68`5T81&T`!#@N"(6,P-H@`8H
M`1T1ZP6&@!$&$A$6NUQ+I03"Y3+P0(XN0`;(Y@6,[:>)(;@^RP2@PYS7*6R&
M8!_X@`4-HH&$(!'T&0:HUIEBH"#PX'M:1G>)`<>"``\L6B&THAB&0`NXBQ%H
M(,S,91_:X!SR0!?8(*A*(E`R88]2>L(I'%9XRC<DW"Y$.+5@[>#_>+#2THC8
M:,W@+&+<JM#7@-#6J)#OJA#R-.L+&<_Q;HV")L63;.49$NU2*"@?&`6(_NY5
M8$T?6#KS<$U7SFY5)F_P[,(*R8V**H$%?D`8,%BT<@@-#X]5>JS26LTN%F$+
MAJ`2WN7$Z\`8@>ZISXV*YF`O6JO'Y.H"S6'5D%*ZAG**0H+!IF0:>N.X:F)9
MQ=HW+J4:S$$S02.N=-S5JJL?TN$2&H$L[\)F;@ZX>"(DUH$69)(-7`@9J0$/
M?B!&+&$GS`$N\H&N_8''X8$D\\'8NB?/^Z$8)-7>:KK"87W"2R`2^H$-U-PN
M]L$$,LM6W&'H5B707B6;R"U6`GW8?]PB_\AC:M4A`*\D`(,MT\YA)]0MUZ+-
M-HHULD1\@D4KTF?PYVA-\%#\B'J+WXAMVGUNU(XZW*.-R<7.M!B%R;FH[ZQR
M\5R+R44<`ZEAZJH]!]&MUM!]VK><"HG:<W;(!WNZQ&WMS5ME&J3$YV+%QUDE
MW5AE':1=JOVQ6&=%,*8.!NT*Z"Z!%JIM5OQA&A)A`F/]Y%%^!B@A+LX*.-75
M!V@BS7%,ID'&![0H!S"!&O(6`:8A$)H@&BYA)-O`QC>,$8)!;A!!,QGAPLTA
M\;RBZ_PAQ/(`=,1FJ2[!9MA&TVJB&D#^B!J@)&*O0S2(&J22Z)SW4K+%-R*N
MIKUH57`QB3UK(_^\(X?6H0:HJ%HL@JA@!:@ASQQD"1@T\%6D8E1>W=&H(0#S
MH?ON(.=97>`@/5>,B]Y:Y1XDG*7OH1RF7>+;K=C?);W*?>UEK>DSC>3<@5%8
ML.Y.+=_\X1_ZG-PI[\K%W>)5/-D:;]?V;N\L;P-1J_91OO<=V#'Z(0TX,S[0
M@AIB8`ZB9T62SEJ`01$FX`8F0`L^(!!88!G@X)G5T*1>0+TJ2@02^P(0`3A%
MX`3X8NJ'0%$$Z$Y\MZ].8!%$@`A>@!:REQ#JQ#%P(O#[00,X3`0NX4]$P(D!
MXH2(.WE*+#I10UT_3'@(:<CSK(8-77CZX3'GXT4U8#46$.IWKP$Q1"7_$/7K
MMP]-C6F31#SK-Z<(FF?3?"`R)T/=$!N+3IKP<><9L'Z([O6;QH!(OW5#YEAL
M,ZV8NV?$%DV;<X<8,#:8%N(IMJ_?'0WW2IJ[^0_/LV>(U*W#<VE?L47F^DWJ
M>7+:(G7J+DT[^0S3NG_4P$[;ATYAOQH`^NEB4*/$)#QH)JF;1FWQRVE&W9X\
M:>Y?/W^*]QT0<E*=T7M&^XD&N8\:&Y!&:V2^IZ\?O[`HA5RRX6_T2=Z?]_%6
M5^3.R38F/W\.?M('L<_%%,A8Y_RDO[`V+AWUD=TN-2&MG_=;U*"$!FJ$BJ&$
MZ;U?L;_%^_G(\S[\\/W.B>^[%]8EZUP"G7_._QGUS"3]X*,?2L0U"&&$$DY(
M88467HAAAAINJ&%83?0T!!HV]-/&0/W80`01A$PBA'O]H(&?(!3T$4<:=4P#
MQ#(SI)"#&BSN4\-R74V"!A[`Y%$1)AST,\0=B"SBPSHEV"'"(I/X0`T:"[#A
MPSUMV.#4)0KDH4$C-@CQTF<;U&!`'E*6<$\>/'19@I-SE&04(S6(2`L>%RQ"
MBPS[^(#&3R6XY$-%^\APAP_FB/`7&RT2(4(-8<TA!")"$+H!'D+`:--)(N!!
MZ$PO1,?($--XF@<:1'S:ACEVX'$'&R*P0<@)7][)!@,G,7(",38@(H,/,K2Q
MP")%^+!(#4.<L(@(-O_48"L1FVE@@P]L'#"4.D344$,@&LB`APW3"#&4.340
M,<DD&L"(R!QH%)*)#S;@4<(E=?A`Q"/%#D6B"#(`LT$)84U2`G!DMO&,P)?D
M(0(:ZT3&AAV8U.##)`=D`J40-=G0E3H&+*(!H>J@X<,S^$8BXC27O(`')@8$
M5]9;-DW3!AOT'#S$!>1@$D26&B`R#1M$7&*.''/<0TL;!^BRU"+KM)KF`H@X
MFTD_C;"1F45#],-&#<^8,\D<6?)D3A&+/`/52>XL(,(^_PAQASG`H$&-&VTL
MI<4D]Q!"QB1M##6''/?\`Z@Z"Q2#B#0H[?+,,'0(E8D<R!3SC$WJL,(+(I3_
MW%,V-<BLHTY=')Z.>NJJK\YZZPT6@X&S-8'-B!#97N+#$).Y^,RT3>2P!1=S
MY.%."4*PH$:3S4Y\$C`V:9#S)<[?*0-)C#`R"1O33'E'$6W8R\8&WS.5<^8E
M8,)&NR*@UMH%TP#S@O,EG#N$#_[4<,<<S\RA0#5V15DBQI5`4NJH@1!JH(LV
M:``F%;E'#?+@%!L,XT3>L<$+TM2&K'R+$8BXA!MVH`Y@*.A^8B&2!A1TCR*(
MP`!LT%X_>'")>R"B#?Z(%R+R`(Q+S"%(=Q`!(_H!)Z(8``W5H(4($H@&8*2D
M2"(@2@WPX$#<L:$NB/B:O7KBCWO,80@/G(0YT(`(_S(((3B3N$#)B)$'3"R"
M#'-8`QKF4@)M/>,";-``'D[@0G^091(F>`&`%B,#!@!##1NXA"X.<`=&R(!)
M)<"#/_A`!&K8@0-H@`$P-""$!L0$#=,IRS-.,`UGB6`(,JB2[5A@K/&@003N
MZ,<E@J2#)C"`!AJ00SKZ80X-O,P.11""!L)F`T*8`!,V**8,3%`"@GF'&,7R
MP0%/<KX:+$(&B[B`#\A"%`:4<AHJL<$D7C`$-PR!2V1:0R-.PH<X``%]GT)#
M"="`!AF$@`YCJ($)V'"!0ES@@'EX@0CR<`E$H.$2)L@$'7JR#D38@0UNH,0:
M;H`&.TR##R5@!#0N8;0,3/^"`6@0@A`8@8>*N&ZD)"VI24]:H;!,8Q>MV4=P
M[':28@S%.)^I2C_4P0=SY$,A8[L#)N[!%\[4)2R8\)@YS*&0*JIC$D,8QCJF
M4;I[$(,1(*,&H(!2#0+1PAP%25`-](<Q:`P4)7FHRQTF@0E,S`%Z12$$+="@
M)W/UHT^$\`$9$&$O3'"1#9D;%B/L!;",#6%3S7/F'-1RDCRT!PULR(-O\&"'
M^N%%!'.0P:I\M9`A^,,9/FA#&X9`AQ#9H0UW(L0=T(`)2^0!."UDPQPN$!;'
MYJ4&U\N#+E8%KLK<!PTX600B-J"@8I2@&#X(53\NB0@;L`$8LP-`<TPPB8BP
M80W_C"`$8X7`AB&T85.#@Q8<K(1*D(A`AG$\R3JJMX4?U$)<.21"B$A4DGW@
M(9Q;:`$0:M`2M18#$XT$20EZUP\AE$":R;T'#7R@B#B<R@TJ.<DC:H`/Y"'`
M$7;H@"7Z08T@D0$-,V`%(EH8T3;L0\!H:,0:2M"/86)86^T"SV*(.^(VU.`2
M=Q`-'FI0'76X00.$`)(/@+$(-K2!&(D0`AU.0@(:;,"CYB"&1^W3!CM$8@-W
MX$,;T,`D<S0!!HCH\G78P`@B0(,030`),/9WY0^I@R<#0D0ZGG$'-7R`#6C8
MQQ"J001'H73/?.ZSGS?$FP?5)T*"?I"@&W1H#!$'.I]A_XU\3,>?%Y&!"-CA
M37"F(9JP&(<61J'&7^!ANFFDB1KE`9`ZBL'H:=#B/]NAS7]`1PQ_8`<3J,X+
M(R8XA[W=5#'F2*AW@'$'/+P%:9AQ"S6>L8]I5*-93>Q'Y-Y3C"$`H]?_X!(T
MQK.(>P!#JM%NRZ^2>>R3W$-2DRB&.>[1E1)D1AV("`Y#@`$,8F!B$IFPQ"1L
M,`1,@'01)<C#,FCP`;P@HE+/R$-8@&&2>&QA"[<"A@WR189]4D,&"X@9&D9`
M@T;``1%WP#<P2E"2DS1E-FRH!+CRA^X?M`"C,I#VU_H1#1I0@P%JH($:6(""
M2)RD!CQ`P2YL@(8YC!:,:UA'&__XL`/?"$$:1'!/D^>`UI<'G3Q#H$0-<G82
MRL`$1H08PHU],.]6"2$-:8`!ADT0CWCDP+$EZQ(>B$`&8/#@!T-PK#M@\`PW
MU*Y)X)E#)DX0F";P@APW70"9Y%`(<NR@"628P3GU<0$M_!,-_PB2"1:9Z#]K
M?O.<)RE-B]/J_&@Z.P;:SX-RTY_PH#X_^C$THBMT:4;\)?.=GY`YB`!I"&E[
M0IGC9.>MRWI"__$]K8$'.IPS&`=96A_[T(<YXH%+[.2#&L$IW4GT00QX+,BE
MU!#-,[H&DG4`*#CK4.(?B5&+?L1C$MA1ATL74XMT7(+YTGN/.FBA$'-0`A]`
M94UGCNO_'NEP#YRQ#^YW&.Z`';A$#'6!#OZ@%Z;C&?=`:FQA#L/P#*HQ#<00
M&(V`#"`1#-EP#O)'"#5`"/"017;P0^I`![IP#^80&_<@@'Q@!^M0%Z1S9D/`
M"T/0@0LQ!\!`#N>&#.X@!WQP?FW@1=/@#]0'=K7'A$WHA*FC:3X@&JLW:!,2
M&PZ6)KS!$B=1&%7H'/Y`%ZF7':'A',]0#&"Q#IFA:4;Q><&G?*-G:>(6>C3U
M'_SA4G-H>F[8'\$Q>B`AAFU8AWKXA:)':,41:*07>H16($O1AWDH'*/'#^\1
M%HQVB.%1B:M'AXF&>I68:)7((/V`B=KA;$.A#_H0B:/1B9$F_QPHL0[FQHK$
MD(`HP6B,IHJ?80Z,T!?Y%V[)!@SGT`_2\`BL(!\&I!#OMR'W8`=+`2"G2'K.
M086?<0E?0WM/2(W5R(27<#3/$`W94`LBD`.)H#4_<&Z!4`?Z\`QL4`U-)E7[
M,`F*@`_/D`B70`T;4!=```?$,`_NX!?`0`)'D0,S<%QU,0WTH0Z9@0@'H!`#
M"""CIQ`U`#`85@!$\`(RH%9^J`[VTP_5X!07PH<O\A+3:&BT-XF(@`G3$2',
MU2`B=!)>9%[@P@-YD`GEX1SUXAOL6!Z7T$JX1(N?T1?A,1\N8HG]D`^[D28<
MX@_5()/B1A__T%)!*7I`51]91(GY</\/VV$<Y9%Y85&5QM%\_,%\8AA\AZ9I
MZP`=I#$<BR:63GEJ87%_V.&`2`@2D"-N?3A\:=F&JFAI8EEHTVB-?>F7FW</
M##`$ME`#B@`,,T`"=6!S^X0,0B`#+0`'*2!@>#4Q=U`"$Q`'-)`#&H`)%_`2
M/]`!'B!0+U`"<U`'=X`""0!7`E,,![`WCW(K[B24I(D&;5`,U8!6$>,#(F`"
MTS$-"\"4)W`)N6D"M'`")W!8"I`),H`?G]$HE($&ZB`$1$`,EJ$5`28$<W"4
M^>9*+7(.;4`(-70'1T(-\(`(`/,/DX`(GD8/+3@$0^`=^Y`@@Q$80,410\$9
M+7@."D(+/\3_$:8C53`S#3/`DB'T&D`W#56R;=.`'>?3@@M`.O2Q%`4I`JH!
M$G\A!(F`95JIE0HA!R%3`^LPB3))BY-HB6R@&/M!7-&!%Q6RHJ.G`\K!:-0P
M6.XA!%@T(1T4'44)BOTA-J%W.(W&&XZ6'7@P>]3Q0_V0!^X1'(A5BY\!9.%Q
M!_FG<^%1-!<2%HL`E&YC!P_B#\60"4"Y#NLPI4[YEV>*IGNV#X1@`W;0!)?P
M;T$2!T(0"380"2.@!HCP`RP@%GPP!!=Y0$(0"%N@#WF*9?T`!-%`##[``_V@
M)W4P`^LP"3_P2Z4Y(D2Q-\XDHQLP!-1`!&=6+KU6`\3@*4MA`")P_P"8<$GJ
MA@9K,`0143LB``/Q>1(:P&^+\`*+L%HFD$0S9A]TU@;&HP!ZP@;ED@=$T`;(
M>0*?0DH,L$P7D`<R8`.X63&^<5,'I%P:X'5TI@'3@5^9H!*;\F'@<@$R*029
M40)<5`T2\7*=%4J+@`?)]2[V4@.8H`"3(`/X91<R(`1E1`0R\`PJ,3Q_!1+2
M2@0U\0)S\$\@<0(RH#W&@A>,\)*+0`B(P`BTH%W;4[$WN@C$T`-DP!*)4AVO
MV@-6X@/Q<1*8X`-NH`YM0`1W@`YS8`)!<@]WT")K`#U4D2G/P`,.V0\R4!*<
MP09X@31I.$U"00S$0`0-\!+FD*'G\:H@P?\`Q*`.5&L.F/$/P$`-ES$:`Q@/
MX[$+)X%O)G$5YO`]ZL`(&C!3/SL$Q7!JCU:067$2R>47_C`)OW`.)G`/S6`'
M06`7G&8W^[`.C-"*EJ"%7J0.SX!_9#FFCO$,52E^=M-CE[`9.E0,SI">]R`$
M;O!3&7@/ZS`,)IFFHTNZK:,.QM,":@`$0"`$'Y`&*(`(07`#,+`&1*`&E4`#
MS:)(EKE#/M($\_!1-J`0.1`-ES"=LJ$#<V`#CX`&/V`"C#`'RKN20K`.-G!E
M-[4(0H!'ET`(>1`ES_`"YI"]1[$`^[!=#;-(>-`&:Q!@C6";;&`#Y5$"TJD.
MA)`S:!`L&^!B0F#_#K]02G;@O5^##`O$1W@@#6S@#P=$&0K"$>O0`S9`-GEP
M!]Q)ICW@L-/F3$HZ%"R2!TAB'R*0._91&@'V$I:"!^%C.V'A`Y$!'OQ"#<1P
M90EU0[G$6_U`#!&#K_LP7!WG`W.@*4M1`_^0(A5!*-.!#H*R*0@!'M2@`'BP
M`!$A`NMP`:]%&<2T#KKP1':$,W9`1X["`D\4,08P5$0Q!QA@!R`S0#<Z(M-P
M&L#0!FFP79>`!T50!T+0`^Z1KU]"!&@`7"22!]G[`GA5`W90/4_\LR)0!\W"
M!HO4#QPP';@Z$_?P#!K@=&R(#K_92&'Q*N>3KZ4Y!]K"`.X1%M)*+1`L_P)U
M@3L*D!F+8`*;\G8FL,`C$`)H0`<#<0_$Y0].-@0P`"TW)2FEJ0$&-`1.>Q-Y
M@`A^Y'5)T5&-=`DBT&_74P,.N\)Y@#!/-+/)5+K9K,T<`F?J$`_8XP[4@`CN
MP0AVH!K1*X%Z0@UJM6V,90[(5@SK0`AU(0P2:(8/1!49AB7\]48*<JU5\@P]
M\0\/9P<W;`(!C4G"!@P_I"X@002($#-"P``=?`\#Y2P^,%R'6@/F,`3KT"S@
MU$0+D*1$<#O9.0?"PD7@I")LX`S1F0?%"A&N9"X&9`<F`-%H$+:3L`"$S`;%
MD"5"@`DPX"*50@WSDUM#0`PFD(&\(03^4P-Q(O\'8'<'W.$=(N#&0VM=;:`.
M><`'+1(M>W,)_+8GBV$[*E&L6!9*^V"]VJDM0[$.+^`/KF(0#%T$#X,3`+L!
M57%#P(`:^$H,E]!(_'H!\-0/_C1PBS`'OG@2:^`#(2`OFHM:Y4"SK]19DX`[
M`@4#=I`&0B`,_;`%EL&;C&";N*0!@?PUE$H'X%$"TW$)<+!P%5$"=0$#*(`,
M_@`#)H`,'($:-W$>Q7`)-C(#17$B"94'>$0M&+T8M&H;174',+,/XLL&1>`>
MA+`(T&`"*-`/PZ!<,#`,YK`&)C`#M;`/TF`4O^!,=H,:ZX`I&K`&>\$#D\`#
M,(`-K`!7)9#`0M`&YY7_"271!HQP#XA]O4HZ"6Z0,?<`M.IP6H*XS0O.X!22
MEG8AH588:7?9C&YHEG5H'"*:'?[0:G4H!'9P0;0A:_<00[*1&@58@"0N%5(R
M5!Y-"S?5@QCF!N(7XTBH#O3P5&!V$O_P#/0`BT(@;-1`#77A#U<&#-!`.L%0
M$]$)&--!+&>V$=UQ%;PQ;0NA;;?X`O$Q"9EQ"9@P#--@!^]$#/=P6YP++G61
M8=*F((Q`#`:45BK);OO@)G=":Y8")'5B#A;DSW?@+)-0L?%"*)?`"",F`VAP
M5OB6!P]4`H1@/(UU"3*&-[J&`DU0`H4P!]*9"34`3KBT)Z6)";N0!L:#`8DP
M_P=IL`S]H`;@!-$'E";$R-XSL`:3T`1.DQESX`8,$`@E\#TH`0,BT@2#Y0QT
MX%AL4`#^T\HSD`-UD`8,@!T0#%<UP''R`A0*D%9&H>L9`PP!4!?J0&4*X!Y8
MT>8\0`?X_>%"P`=K$`1V@`B%X`8'QP,>8[QVP0`'X0:-<`XP<`\!P`=+883#
M!0/X+263P`C.S`:5DS,GZP9`+F1&*"U:]*=)V>`1O^"9F(=<Z2`3/ARA.&BC
MEQMT^*00TN&5B(@G00SC>3IA_?$2#R%$8@.B^QSY8![9P902\AKE\0]LF7N'
M88C40!Q255/^D[A7"7[^@`G3=ZCJ(-["@2!`R1)5"?\;#^@.[O!\_>`..002
MEMT:GD$,=$`.1D$.U&P4T1#C9:,8T+`/F6`'`U@ZTT`0"R"0$CP-PB`$I^YL
MDMR*TF0.0FX316T4,*P<'_<9+,*2-*%MZQ`$>9#+%;T&ZG`.0\`#46$4ZZ"!
MGZN&M<-<71^V!RURD^!DC'`Y_W`)Q6`#4RIC5#$-Q)0)U%!N6XW4)9XY/*KR
ML;_-RT8A^C"F+J]Z$3(-.>E*K\%Z'B^)((%4[H>4%R]Z[M<?7GJ5&U\<,+_A
M&(^*K1>4QFBF)[$;>Y9%-,$A?)E2$N[]@9:(A3@<._D9I>B%TI]ZJ/>)?_@9
M]/`IRI$=FRAN$7++OX\FX='_@BCA#N?@I:E!HA4.$/T$]MM'L%^C'P3Q#:DV
MT*%!AP4'2GPH<=J]AQDU;N38T>-'D"%%CB19TN1)A^K,[0O7[Y$(8NKZ01O6
M+QXQ?-.(%<0WXE$-<_GZK9NFS^B^=?W.N>N7CZE#+=/ZZ<,W9U(@CA0'5HM!
M"%.;#9@TTGK6)IY&B8B>Y1D",>)$@=-D.EP'#Y&Y?O[@WJ$F4*M;MQ+U$BRH
MMZ!@P@+]293V;"`\8@0']R.6])Y4@_LH&IY<\)ZYP8<59]RW.*_F?O<P^@LM
M\9YIOZ/?$A:*&C;JQ(0+4RSMNG!LB/IFPX;H#Z-#PU-U5Q2-=I]P?)^3:E8-
M6+-6_]P32[-69UB=3,WK9*I;YRRTW^3GM0\\5VQG\LP#]9K6;)BWQ.PH]>_G
MW]__?P`SFD2(.F0`)H4-?)AA&1@XB&.(#QY)@04U^D&'`4$TH`$(:$CX@))^
MHF%@!C4^T`$?(#Y`8PY,ID&DCDMN($$02M1@P)PA?,!K'R%,0&,18,RAY1(;
MV-#E!5H6N8`18G#D*P\[R%&`D4O60:0-:JJ9`Y'C^@$&F`TJ&>J.2NYYAA%@
M_L'KF7\$VF"2>X(LR(8[7KC#O'R*2:H?/*99)[)[BE$GGWORV4>=9S!222!S
M9,JGG(&$D*I-Q=#)2RB!,&HC#X.J><&@ZDK0I1]JA,CKN/_))`-NRQH`VZ@Y
MNDS=2(@]0_)GCLD06>2A:=@0Z)E)/MH'C3OZ,0<>-C!["!,;?!#"G$7P$H@O
M@HHYKB!,@@UIFF('6L.9AXK1=ITVJ\D$CVN)TK:C2?H::!U:B'F&&+GBPNR>
M2Z1"1EF/S'&,HG46<7<C?Y35ZI*Y-#)'V@`;=OAAB",&R1P9,*B`!C4JG(&#
M&H3@X@9UA/!@"Q*$TZ$6'_#)88L4-NQ'&`SP>8`&&6;8(AP;:IB$&#=NL(,"
M-821H8\Z<CAA@U8O\:$8&6I@$HU)2B@"CR':8*,---#P`1$\'MFB`S16R$2+
M.6I@PP<9A*BA6(Q\P$.&R!1!XP+_/$H8PLXVICEA(!'NX.&,%V02@0\?AM"@
M&#2:30J--DK0680:%D'C$EHP<:.&(181X04@:ZBAF#:*[$>=!3`1P@9.^R&D
M!D3FH&6=3"ZI`0TV3*A!+&HN(&(.<QQ_9H@!2T!C&B)JF,8''P:CQ@<;S!&B
MA'O^68"-"WQ81!W:YR)$"&J>*48M3$QX9AT9,@D?DSFHP7R?26QPK)\73@@$
MF$OZ$>N>-88`=I]+[IE#B&*\X$<"88,(\&`._[6K!NK`0PT(X3]@]&,1NXH+
M&XKQC`,XI@1LJ$$;ZO>/.[P/#:TB@A`01HQ+[$,&/GB&.A3@O6+HI1C68L6.
MO/2,0PUE_R;J(,8":#$7/$#C'OOXQV<6T3]:8.0?/N!!)@ZE#FJ4`!B$Z,<S
M\.*OP9BI'S9X8%Z>X0]:C+!^I5E'0=3QFA-(10AXV),5C9,:8TD+$VAXS>BD
MX@]S_*,TTZ!4:HAH`YF4RH[]R(-4]O0=@]Q.8HMD9",=>1(9[``(++"%J5#@
MLT90`BAJT,$E$-$/?+3@$3QPQX;20`E%].,2*.A'!1[Q"#<`X1XZ\`$FOC*#
M1URB!#.@01T4`80A(((1_9A$&_J!AB%@HBQY`,+NQD`&1.0!#T(@PC[,`0<=
MC&!#PF"#$,0B@@NL@Q$^@*/UT(`73&PA`V@P%1X842`JZF5%Y/^$VC&5=H\[
MV`%R(G",]=+V#.85@PC`P,0B,%&#&["!#10K@53FH($\0.^8C&C5!B+C@\C5
M`!C3R-'"VH`(8)B*:>H8@C>I@8(V^&`.SS@=&DPP!QD,K`;5D%P)ZG</(60B
M!LY(6PE6J,H-:.$$I/,!,"!:@CSX@!%#0,8XA7""1>B"`4)0@$QL4,S\R:X?
MNWA`'X)1@WL,X0Z9PX0!#]>/-HB@;(SSP8K(@(82($((0]C`(A3@JX*(8`A]
MTT!2BE0#&Y3@?S;0@$-+D`D?#.@.=L-<8!&A`30LH`:16803.`"#$>!E;BK-
M@SILL`@-O(`1&NC!"Q:C-3:LXVHGJ,'_'&Q`ISOX0*\61-Y>$>$&#FI4`S:0
M@4!>4(+MO8!S<D`FUWA0OT640+2(<-PD%N`8L,#@$G8HWATXY8/8RB!8P+C`
MVCCZ.6;9@!HFL%U!@$$$(A#C`C`0`B(6P-,2X.$.H-5`)J@A@Q)0HX$*B,PC
M_?M?`#<2&,_HWC206Q46+",1Z(!'#E@0P7VH81&,B`=?8%""8E1Q"_V80PF$
MX`XA?,`$Q=B`#8#1!D64@`5U0,0E=`",&M1R*+RU`28V4()%%&]M>9CO?%N'
M-@VP@`96:P,C%N$CM9D#$6C0!5Z`]ZQ^B$`+PA/"/N9P"4(4P!T[Z4=KAQ#%
MOHAU"`S,\2+8_]AE.>BB!&O0Q1TPAP<\Y,&`/L@#(:91`B(4`Q@YH\8=ABB$
ML4:Y+U,LP=)TP0,?J*,8UKL$&OI1#!OX`YF7H-CIVH6\26`"&.1$1T%T1`S/
M[4@(DZ`GL;+5#^9>PL\*F-P++C&)/&"":_U@A`Q<-`0TB.`2<Y!)JW0EA")D
M>!I]X$$A3*7070&T'VP(UH_N40(1F$EXB9ZB#1`!/!M(Q!PB.":N]8*'8A@/
M$S((BQ27O0$(+;N6^"""#::!ASF@`=)Y`%<C>#""?LQ@5XP0@9G=<`_,17#/
M4<;+#$:0AWMT$Q.,P%J-12!.&0P!>)01`C!.4`)"ZO4?T>Y'$&:`#/\:Z+D-
MP$"##.S@9K'`F1C,,X<NB9"4-NS,FWDPP21D`"7'S8Z8IL*O$*Y&/Q,P0A<`
M'P<QR7&)(?`AX6UHPSTFX;E)L"$/YL@:$8:@!G(*H;\!YGK7O?X?X50D-L]1
MSD#N`0^_A!V!`@&&"?HQ#4L5A,`#F<8^IA'!3!TT3HY1<CK@2!WCX*$O3-H'
M.JQ%S&)UYXQ8,M9G"F*.F)N#&G:/4QO6@7%54@/4M/@5D/S1)!AW"QC$*"DU
M0C>):K36'&[(G"Z&X0],4*-XP\`#$>P@$-?=00941#6=`=J#2UQBA8LH!C6"
M]0PYL`_&-=`%2(4@`T000VT+-\=0:>TX8O#_6B#.&B8>GE[C?OQ#"'2>Q"30
M<*7V"G-8@&U#34W7++V40/[^F$01!"([$XS5!U(D@@]8C]9@$0)&,(?922FI
M8PL;8`3&60-(,P>\>X&Z*00?P(@E<[=%F"M$\`$U:HL2J(-`N`,T"`01L`%M
M<`-$<!K0<K1H(H)\"Q9$N`,&6(,T2`2SP0,[&*%U$`&9\($T$$`R:(.%<QHV
M6(`2F*,8^ZA%.)NG*X%GN`&)4P<-P`=:6P,,4(%F(#T9F`,3B#,?J!\[L`-D
MD#AB6(0A<+=CVJ@A6+,+,#T`N(>:P0.Q6(29FATT`(;B(P9$J(9U@+1S6`=D
MP(=,&(++Z,*%`0;(_ZDB\J"=.3"?2"NJKWM$2(Q$M%`,_$@-^&B.P[B.29P(
M?HD(Q(@/RH"+V0B,K'"(+O$(@"L&:\H+TNB(SB`(3%F/463%AV@3B5`'S\"(
M'!J[6JR5ZAB*N5`'7!$(1)J,7\2(:5`6'L(4U5`'8-B'ZG!`:-P'LC"6`<P+
M>!BP8_HD@3BU,W$,/%038T$[N3"3>["#1?@,?,*$>UB'R;D':EB>N.A"4BF(
M=6B7.#J>87H[J6@Y:G`1&!@"<G`':G"ZD$(#F9@&:A`XJ:B&S]H'._@!/M(:
MG:`_C("!79`#2=&39P`&BGJ=-JBX*E&;9[B#T5,:.YN$?5B$@G"#SZ(T(?_!
M`Y6RPTQPC-%K.6*(N(2KG]C[AUT3@N$QAV%2'R8TEAHH0G7HOP'#`QY8AV=X
MANOAH4E`@6`@!T8PE99SLSNXNT,AA.5APJ@I@5J11+(L2TC4(H]8ARY!#:2X
M%H,P%,+0Q8;A#93X"V@4%K$C";H$#K,4B;\P"7/P@;%\F,_P#V&H@1\(AI+X
MR[]$!A@X1>282X_(CX>`S,E4#/7(%%29B#I22^3PC;X,3=&4&'](&(PH!FZ3
M#XT`@F5X.T<;"$08&/EH@:28!AL83=+X2]RLRUEL)-VT#KX$B;UTE8ZP2XTP
MBM3PN]PL1;]@2[IL%(BH1/S`#>D,SM'(Q4K4",__A!75%+OA+`A^$,6PRPV"
M"$]1;,[?L,[=7$_V!`E_X(&;PX0+")9I,`#DF88Y(`)N)`8;R(%E^`$BJ(-:
M2`!BZ*9BT+0X$()'>`8UZ`-BV``U4`1H*(%\X)J$:4\,S5`-9:0Z:HIK&2+9
MR)2)2!62*$U4+".!R(<^VE`6;5%)+(AQZ@<9$`%?Z8=JT`!_\('?$H(-T(O(
M$88?N('L@X,:6(8\6"$\J(,."`864(0M<(*O4809T`(MT!H?(4X7S5(MW5)3
M-#NT(X@N6<N$48<5)8FUXXAV#,:"Y%(V;=-%DL,MDH%]?(;;["860@2A&`)B
M"(<<:`%T"(0MV`(BZ3\[_YB##6,!(-@"(`""$M@'.,@!+2B20L@$-ZU42[W4
M_UI+R\143NW4CKB'/-`97<`[SQJ".5B'TYD#@2"&$J`!GID!-("&&N@#/&.#
M14"$..B')FB"'`""0$`!()B!2D"#1RBI3'L?3TU695U69FU69P6)3?W0E#@.
M<S@+?-`':I@.B="'/"D*=R@&J<"(+QF*37U6<SU7W-3-WS3%<AT)(FK7YD17
M>0VP=3V)[)Q7?,U7DU#1AOD'$B4(,BW.RZA7X2R&_ND(:J`T?5W8T218AGU8
MB$6/`-G%RD2'?^65P3R)IZS78LB$3HQ8D`U9D1U9D@T)A_V'C"U9E5U9EFU9
M]O]T6)-U69F=69JM69*('O^`V7>!UY"X!VW0V8Q`!YZU6:(M6J/%5,KCCWV`
M2V.Y4(V`QZ&=3&E`!J<UV=$#VJ/-6JW=6G,%45>,VH\P!VU`"7GA6K,]6[1-
MV_V@3+4%6>QHQ74=3HX8SU=I6[O]5*Q=3ZT(T^F\6T^]V*TUSKP41;GU1%D$
MQ;[%1$P$#NH\7'=EW,%5SYR5W+QMF':D5DKAARXA#X'XASYB6_9$%'?YDZ10
M!UK(,&,IAC+U6S:=`W=B!#9@!$287=IEA#NX`SR8W2VQW=DMA$A@A$0PLO++
MA$D@WO*[!$Q`7DW+-/H)OB\AAB\!AFHH!N)SCWGQ'F+_&(;HM</GM<-J((89
MNMYGJ(9GF(;RC<=D3$9SF(:%$0_RB!YX^`XR50WZC0?Z+90A&B)"T0Q^T$36
M#<V\?:-,P8\N(9?.M93.7=W=+(ASN`1W(88F>[M)N"F"`MO_;4^`6P?6N%_C
M4`U_<(?O^`?R.*.%40=I.(=S,`>B6!CU95\79F&%)-^G'%]Y&=_1,UCNW5[D
M783B181)$*9H(H39M8,\F`,>RX,\8(,Y<(,\8)RK08,UL)H5J;-"F*])N(-,
MX&'FO80O&54N!@9=2%X[#+Y7*RA-RQ9=F038Q=T[((0Y<-W<E2;7E8,[>$$>
MSI9,H(5AT#/NO5YB((;O!61Y_QGD`0-?]WBU3,OBXDW>2=`%6IC@Y-4T+N;B
M>;D@0![?&7[*9*2&]?473E[?9`3?9Z"%T;-#/;L$@Q6&0'[*>&1E/VG?=5B'
M1HEE64YA65Z';'7?6%X83?;D>/S'3EZ81CDC$3ZC^Z7?^KB.[8#&U5@,^ET,
MXYA&ZBB,?%B,I67F(6(-9MZ'_B5<[KQ,KZN5@"6(%F(4AKE@+KV'2)-9Q/@-
M0B&48YY?=/@.69[G6UYA669?859A]A6/71[A6TYA8=[E@09E\VWE&;YD&09D
M\B6&+,%D4(;A?TS?\E5(\WU*A\9>Z-4%Y`V^3,L6'O9A8-!B*CG0.YB$"YHA
M.T0&[O]%95(F9>2EDN2MG$D@A#M@`S20+T5L8H5:D3;`K2VY$MPE!$88W@F;
MW4F8($;(8ETQLPG"73Q@NB+&`ZFS&B&8`X7"`S0HXCLH:ED[WB])7C*&:<KQ
M8>(EXCN`XSB#LY/CL=S5!3RX!&+0M`NJ!4SX8_<(ZR/*EOFR:=JEW9/VX4SS
MX3.>!.XUY#]^AF$8DDQ;A"V):C:`LRO9ZD*074:X;!X.:5U!YP4F`@O^#\;,
MS>KDQ61.#/^-C[VLW,?E[/_JC>:TYD*Q9F4^E6.N;6@V%*]]B^F$1FU>VM>H
M[6:D7WPP9F0&[OLE;O$X[C-R!W*A9[5LQC,*8?DE4WKNPUC_%FAU$&CVC6[W
M_8Y[(&%C8FW1#"O`G8@:'I^UY,P++6W#)0[KH,OLA%G5[@^"G6_F%,Y-A!7&
MK%?J+-SSS$3T$(W\>-O>_&^XF,[.T&_Q-HE[P(,%#TUXJ":/4(<:,``&V+^/
MG0D&X+S4^!%5U8AG</"/P$<&*F]CX49BY);*W4._S,M5?#M*T0H!EG'PN-=,
MK`VS8US!)<Z^_4S"C=Q9)/#HQ,OSK-OBE%PL!?*V56UUN+T'-\M[\('Z[@?]
M[+(:`()XN`0@J`3A"(0%:/!3Y0$[6`/GN82*G@9WH`1!(`8X[(=EN(-:P`=L
M*98VJ(%@4`<3:!%_*(9=.(=%>.X]_V<#?W!D&<V#79F&:CB4[AF*1#&[W^X'
M6D@TC&A'S23/TI!+@U@'&\"(9'D([VEC6C2(9T!QSG0(8MC'H6ADO$ORC`"C
M:1@F&:<U%@Q1CI@&6ND'9SB3516+_/:+N_L2$5@7A_@'>]`(*6P*2A`.BNC(
M]RE?@J#;(8_.6,]+O:!T?9#;0T%==36C@3D,SXS7'V]QOT"@>S7R`'^[[GB(
M]8W+7XP8=Q#Q)R=+=9!RD(`^^)&;.AB!)I@`O'`J)9:!-2@$P+K*MM*!&5"$
M"9B!$Y@#$4"$%I@#!FB)8<"HG/:<QZH!&="%!:":&##5;+&!N"8"#6`NU+&Q
MD9<M#;B$#?\X@6'2BS;+P)#2`!D8'N4"'9G'BW4PII/.&:%DG;"2`1/0"R9Y
M'MYK`PT80J"@A;CZE>+M&'58G?%1J46KPTD()F(X@$E02`%4LB&HG]')@V<Q
M'40HB&FX`&#8H%UH<'0AB`T`*3:(($;``W7`S_>A1D1`U;V!'R(0`4:PHFI0
M!S0Q"&"`$RN)96"0,_>`K`P;/1L-!A7Z!6+J]BHBAG/H@$HPI`A:LO!.8FJX
M]@MZEV?<!V+P5W0H9_;-T8)<NTFG!KVX1VXL&+U8%('(@UKSUU-9#VPA)X,P
M=#38NL\."3;8M=$YCG;GB+E#JTZD!@V`L'[`-4ZQ;VB%]WB/Q+#_PLL7^"09
MB`=*``(12-"6,+\:8!,;$()&X`!3P9H:^`#(<3,I]X$-,!42:`G(JP$1R(/R
MM8&V.&)SD(`YX!PA$`*`L(,&&)L2=_!,\E'CTCV%Y@CED5'C6;^*ZX38$)&'
M#9I[9'R8$&*B!+$[>?J9J]'/1QL1F"Z5P+.AC1!S+^[U$\)(QC,6.!>QN3.'
MD)`2:`P0ZS<)30U$0O)H\`',!Z%+-6#D02,"41LT/O(0JL%G2(T3BS3XZS>$
MS1H?+^YHN-1OW8MB-O+4F+/APIR*)2;E&:)A45-&)81<6->/6`E$-?!6)#+G
ML8E%<VSXZ-@/DPTT>&S4J(%82`U&=VJP_Q&":(@/.VUP_/D[!(T,<_WV]<LD
M`HBB#$!*%$/#FA&:OOWNR+`!;%$)$DGAU3":YX4,1D5*#*$EP@>C!I,VV!#2
MC]&S-B\8`=.@`5%%VCZHE3`A=YV"-28T"'FF0<2E.=,8(9*);9B(8`,>%6TP
MQ!`GU&#.'"(LPD@QS[#1#R)W`(-',9=HA0DB%RSB%3#]J,.&.6NLPX8-)>2!
MAPBW$4/$-!4YI4Y%<M30QC23](/.-+8=MXB"//9CQU;/F#.5$&C<IHXZN.T#
MSS\5^;,.;NI,8V,_]VAYCSE:5A1F1?<0(J:99Z*9IIIKLMFFFV_"&:><<]))
MYSU"X-:F$)GT4_]#.I0HLH5PZ/3S2!N($.'#&F[<0<8-=Y3PS`]Q;`'$):"I
MHP,B:O#!03K]Y,&!8&W,(4<;)4R%"!KJB%",&OY<P!-&I-G!AAT^"+%(,37X
ML`\A;`"#V3I`:B`#&AH4@^<02Q*3R0OJW,'D-"HM1!@1-0`SR1Q,RF`C&XSX
MT"=.B"""AZXU;,7&C!P*<<\DP/HPAP^*K0$,,&W4H$XF-=RQ2!XV])-($7V)
M8*,-/YK0ZQ#S267'-$.T(4,>1+9!#$<B"#%,/]JM9MLB9<9K7(M#Y!04)B7,
MD59Q_?"A0&`U3$)-&Y/<P<8<0@BASCW$H`$;&]1<4-"(%3&FPR4LK`3_C&/K
MV5Q1'L5,HP4)/GQP(#!$]'/)BRYB/02D;3R37PW_J(1)'EN]4,(TE[!GH5Z3
MH$Q1/VCH4H(Z/JRPR+0^3'.'"3#,C48>U)A0T1"+D,$S'B6P(4(;;+#!YS/+
M%H%OL1+5>H(,X?9SEP*?G<`Q&O[<HQ4CU1"SCQ`\$F.".C6@T48_P%`#Y&$U
M`(W34D1@0M`:;9SDY32X^3/-C%M.@U.22=TSS3,VJH.DFM#66;WUUV.?O?;;
MPWGWF_O@=L\]N+FC")#W$+K((ONH<XXZ_["1E#GQ?(G.,Q35K@@;"^"T#AJ$
MW&\(>?@'<1:1)*40H4S%H(8Z=$$+(;2!&I-8_P0QJ.$#GF#B'L"XA`]L<`F=
M5&02(C0@(NYQAVHH!!-L4`?-MC2$SA!&")B831O,80.)5.0.D\"3#W27ETD4
M(UHU&`).+I$5=0!C#BV!&6BD<@G#R,`$R4+#!WT`,9(5K!_R(L(=?*".(6""
M1")@!`"Y0Y9%5&1U&VC<(C*#F3NT`2=V42)QTOC"?L@!#_WBPP84,XDA$,4'
MD\!##3#QC!(`"&)SF,,B\&""&CB!#&Z(Q`L6D1]JX&:0,&!!#517$#Q<``]I
MD%T_V("(_A@(6(OQ@3E\H`'_;6XE&-I`'MIPJ7Z4P!QML$,-JK$((CR#$0=:
MQP80\8)+`.,"I/3!+__[<8,.6&):$V$#"L(%`\'9L"+,%,(Z\#`93,Q!'0O0
M0)A*8`,BK$<&F&BC._`B0AHIH`8+N)0_5L"(-F2"$3=#!#'>@XA&](,7-P"5
M:LPQA$S(I1\R$,(=^K$!&X6(#9<`#!K((+M]F,,<4#)'6DAT/DS,:!_3H`:5
MI)>F?QR(>RI=*4M;ZE(ZM?(V+VW3G7R0TCKE"4WBJTA.<4(,Q>2T'QVEDF+$
MQ(_;<!0EMKG',_I7C8[>PQ_Y(!&5J(&.>^AC2\"P#?BBNB5_/`,8-HK9/W3F
M#QG,@2(_\L<^$%$,+_6#&OBXC?I0(E(M$2-+_Z"&/_"`!YSLHZG](88_[BG_
M4B$,K1^67,<ZCO>,2<R(&LF;H5S2TD6F^@"D.F,$-=8Q#..MHP:%,(<0Y-`,
M7DCB&3)`Q#1ZU0]HP$Z"^P!&<-#`3]I6Y!DU(,(YKB:$D"Y.?2]@`RW8,T%>
M/0,102GE"=!PCA?>X1G;H8@_6()8TORB(G;@PX'H(`D4H``8SM(`,>1P@P?<
M`1'^2(H6&;&(>Q0B9H[)#1JG:@=&_K4&)FC1CT##I[CB;@CD&)L0JE$#0EI%
M*NIB1$+14(+W#$%BQ""96K[5IRD5@\&@640;#C6GH+I)'7:8*8E+;.(3SRFF
M;=H'6V\#I7UXE7C^(%V86#P^F>842A6QT8OSQ-8<_[M8J&AB\6V&"CXJ\51,
MX/MQF#K:8B4+-4]`KG&4DWPF$*<)R\68JI2I;.4OHYC$8!TR3X=JIJE>&2=?
M-=.1S:2.M,"X(E^J,:%NH^8I^T-+BC&'"8(``QV#N,56\K),QT2.0C.6S($E
M'9?V43LAL^])@75'/_XQ/"RE!;!;4K(Y%*,S-;OI'D"5DSJ,$^93HSK5++W(
M];"\&/>:V4Q-C9,YB$$,,(6IL1691IW#I`X@Q<G5_=`'EO\!XO'%&LF%5O6'
M"<UF-P45R,)^=IN9;>)@'KH?^3"'FD4=IAMO"=?-%C5[U;0/=U#:3.9PQO%8
M2@U@/&/::7+'3:UM[WOC^_],,96W8FT0B$(-81G9$"0\T!`(=RQ"#<\0!.,*
MX0QPHEL1DU!,-`[PC'4PHJC[V)`^T!$,VTPC*>`2JSI(RE2EM"LG<B%I")E$
MC:C"&3?_N'.E>9K3M"2;2D*`<]9T,0E@.SO?0A\ZT<4$:G`'>=/8"RS0=3J-
MN9II';-N*34P$8PYE;KH6M_Z3/VWXF@AX!$R2(0:6C`'-_S`!T#8@@&<0`(T
MH,`--2`#!UB@!C7D@`",Z$<V&*`($.3`!$4<`@KFD(,1S"`]0\S*0&10`HCX
MX"\:L`$BW-!&T>"F/__:PATR00A,9")11&!Y&S8P!UT4@3W/X`LC7H"(NX4'
M@,7_6(TS`C.-$FS%04/8T6S^T49?)I3KPA^^2OE==.-?STLY9],Z3D+\YT,_
M3NIP_IK0`<$.P(%)E5B!/MPQ`G008P(VB`<(]E$(-I`!#99P1P:0E@9%]",<
M3K@#UC[`HV7,@04TP!TP:O""?-R!"`B'*:&$$2V`7]W#$-B!$,03`TR)"@%#
M'DC`LDP>&@C!`IA(/^S*2EA116#""=S#`<C`!N`,-43%2Z`!&PR#B[0!'GC%
M9"1+#1!""Y*@(55#].%@#JX8\JE)/BR?G(":N=58$+X4#^Z8&^A@$B;A-#`)
MFQ"#`C`"!EQ""ZC!%K1`&OA`#@`!$#2!#/0#$:C!#*3!_P\TP25(PPTT01R`
M`!KA0PLH0@HL`PLDQ1`0`1R@@`XT`AOD0:2@@0G$#D>$C>3EP6\)@;S$`";T
M$,KQ"P,\@@F\@`;4`#&T@0GL'2V0#%,D5"9TQ`$X12%VC@\4PPZQ@0O*0(?Q
M08>QAQ#TD&70`K\HX2O"XD[AE!%FF:B)&T_!0YGY6M.YE).\28G`8C`.GRZY
MB2\1`SY`0R#DPS0@@C/@0QUDPCX(@SZL`Q\$`C7LPL6!WR(`P0-00E;502U,
M`@LD%#2@P0_`S0>XP3TL@`T00BB^GE9P&`1-P@TE5S'\2TIEV+6P`#7@02;@
M`2840PD003'<AH.52QAES4D(`?\=,B&ZP(U&*)$J'DIG!(L0X`$;K(.V6*!J
MH)$P@N3PK<,MVAF;B!H1?EA&%968,-IM_(-&;0DQ\")+B5KRN,DYF%I(ZN2]
MG4.]P4E6R0D;R,`/I!N;Z,B6)&*6.5O38=2SD0-7(4\_P,/1"54Q_(-JW=!B
M\%4N3HB-/`.E[4B>D8@&-10Q4`0M[F1:JJ69<`F:T)A%3,EMV"2)[0S+M8DY
M'`A:KN5>7L\Z-!3R=9G-'1EN9)64$1MN<!N55=NP`>4^\,.+@1E.-1F885E/
MZ1.P!9J5Z25?<N;6_6!(HJ2:X&5GDN9+F0/U:8^P3=FRH0E0*B64/1MLQN:*
M79ELUF;_T(69JW599BY;F]W<;`*GDFUF:5I/6^*@+"K=F83F7:(F<3HG]CB(
MG-B0"&#`'#3."=Q!)2`A,=P4'\#.IW21U3S";=S!3*8)7+W)DX7)H]&F<`IF
M9#YG?#(;^PSG<*J:2,4;2DQ=R>%$]*C9C_#47*+):,IG@<)47L*)EVS`'=`#
M"%S",N0#'0C`/>B"%_:#('1`ZSQ"_FG-'0`!`/3#-PA`&`7F2!';RU7$+G@A
M@/:#^]Q&MMT#I:4!,FS)D<T!B9Z)D=DF:^*@>*%$)&2")<S.)#0C&]R`#!")
M.N`!=R@%-"Q"$*A?S7A&1:062OR<)0R#09J#058$)1S/!S%"_^GX0+R@6/A,
M0O")"5!"747HPS<\FCX<IIA5SV<6W3U0@]Q,`S``U4@IST_=!C6PG`:1I)PU
MH8$:ZIN<)IVT0%)DP`BP0"TD`@20P2XT046@`"M4!#YT@&U\PPV\P0%L0R4$
M`"^<23'(``ST@2"@@!;@!!XL@#38P`P@@QM@0`A,`QF,`!_P@@EP@#.(P!#0
M`0<@83]$@B3@@`BD5#K`@`DT@QN,P"7LP@UXZ@PTPQO\0!K@@!O@PQK\@#0T
M@A.X@7V>&&[@R&*@`!H(@#HLP@]4D@CP0EY51&A0`QH4PPP4P@U8`C+<SP9$
M(FX\``_T`QT4@"6,@!P<P&9P#CX0`/_63$(E&<1`8@O2D9@ZE(`\7=1MX`.A
MJ$%2T`-AG@,/X`$M],.:BNNAZI2:50F:)>:6#)JC=5M^IHDY%*K)TBR:]`V=
ML,#5?<`CU$(\N$$?]($85L0,8&H^+(,($,HZ$,$6X,`;_$$*".E<$$&%F`,;
MS``/]$$*W$$1H8$;\``/O,$.F$,31`(BD,$,S$$C6(*MZ((%-,'0D`$/I``T
M9%$?X(`Y],$/8(,3\(`<R,$;]`$98$`K<``=\$`D40(/A$`C\$`B\&C16=)B
MV(`=0,`;4((<_,`EF$`B9$)_V@#[O-4,,$(39`)A]4G;X%('[`,/C``EI``?
M6(`=<%!%!$+_'6S!/2A'I<W(C9X:'H@'EK#6)!"'##Q"`BA"'W!`NZ1!"*A`
M("S#([``$$!#$YA`(3RNB97L>2[GC@J?S-;L]^I;F<P)"XS(!P#"(@B#&B`A
M`%"8(J"`.>1`(*C!#\"##]BN(FB`#G"!XY+((O#(&'0&^>*!`9#4)$PM(TW%
M/:2!'=C`&L"`&UQ",7#$+J@H#,Q5&V1&/VC`C+B!',R-[-"A!"'")/S`#GRA
M/T8B+I5`P#84\85(/R###:S.''"`8UP"!T3")$"/2EP"B-2`D#`83MC`7^[#
M#P0!(=`!&S`'&V!"431A<WAC#H@L^_2#+:U#"7QDB4TI;KS'#,K`_Q8L0QFB
MP#ZXP0:@03K0P!`\PB34`0G4P0Q`@PG0`XF!3_:^"7JJB?CTE/"10W.";\V:
M`^K&R3"<P^QDQ2.,U&+,"+'A`1CV0SRH`1$(`3X@@SF4;BU`PYG0@@]H@?K8
M`!M0&C40P2\D2A"Q4#VF(`4]PR*82D4-`6X<PG(U2%R]@`@0P@NUH`0M0B;\
MCC_T$B,M%`;[`UA<[]!)%S4,`1_004,!`(Y8PN<F&1J@0=4R`A$XQ5SAAD'P
ME`T00P'00ALP`L:\5P"0##'<P#/@`0M$2TXP"1-;B-R,25&]V8Z-B9;,7$EV
M%97D29=HD!>6AP]PIQOH%AAB`N`@@@*P0?\^+-0AL``AN4%?V("F%?-BRLE+
M3F8]?]OV)JA)34]<>@G,:AV!_C'XWJP=UXEKLF6>P*28Z(R5N:C-;<D]9+*+
MM1BHF0-%J,,PW-B,Q>B;>=IB\(B5^.+S3<)C+`9%+!`P[`C2W0,AR8$_Z,*[
M@=HDL%=;J:LZ3,@DP)MBC0@U",-MO-Z_S$$1P;.8')!BS0@Z[-WL?"1G2>5?
MQ57;9,)'UM`JJ44):``P<`86XTL=").*U``32L0=<`8:N"/\Q=&6O-?LM#`_
MD4C*/9;3C(@_V(&-4(/XWD'4WL&,!'(F\<@^L`%.$\*4/%'U8)1&QS25=)KP
M,>%(_S$SMIJ\#:;_CB4=2B<9D14:\<!T;E<;15\OG7K942EA8'(/B!DWFR8G
M;D*9;K=TS,79LLDBN*G9\U@$3C1/D_2#3>8#7Z6%?^8#\>SSCA65.<0E.H0/
MD##0;90#;NA:7''5K.V5G`'),TR)H^'&G;[VS+JVR08R^)JT\&VF7DY;R5("
M(?R1$!Q"H:4%+1`#(ICGT*G#)1"V%I%+SOT#D938/JQ#:")GFOS:2F5O:^WW
M]\+V?X_XB=.)(-G-.C@#`%T")FC`OJ#!#A$?(C""!LQ`/SA`&B`3%=U#'B0"
M/>B0#3SX2HGEE<5E'D\=J14#D*P#7^V8ED1/7&[XFSP,BAOJ?0LREG.Y_XGE
MQPK[Q3/,`2(4P0X1`GP`N%I,@PS$^`&TA1#PD@GP`91NP)U@.(D)J)@DVII(
M'6J?9S'0:&#I-/*PG#E@PE*9Y9M0@TIT>8$FEV3Z-IR8>*.#9`W<0U-D`DWX
M+B.P`:]$UPL0WWO80!!@@!$/P1RD@PPL0#`D@K&L1)E,^I`MIY]W>)PTSW\>
MCTB-=S&D6V<I.LG$.J4+WS.(KZ0+^['3)AKP`:C`0?0P,1->`C$,THAQ'6Y(
M%"'P`D+9@0Z=9B*@@310PH'(0+G1<5J&#;([YRH7,YK\`S`,@U(O#Y<`EIIA
M26=)63[<P\PE>9K\8+2Q"8C9-KI;FP0I]WCDXO^:2%FD0UNPG<F\KGL_?$K5
MHA@\=(GQ!7N-'?R:U+J9(+/`ER8UH)$1KOD!J*/XY;46``XC.!\1-,`%O`#<
M+$8.(`(#)(`)M!MM3@.7OF9%L&>8`)"V+=O,Z3#W-IF=RDU/W<-;(3MQ%SR+
M@0^7Y39\RLF4*?QMNB5D.IN=<A5:$AM.&0^52*Q.%7GRP>N:F,/PB*9X>'QG
M!A/#]T,.I(,^B,`ZI`40!(`Y1,(3SP&,`<.(9L,(!(P)*/P]``A3$<+0"*52
MB.PS8$)2$`,M<`F@]\,)9)`.XP;E#8]&):8/($()8`+TZ#Q*',^7*/0D:(Q&
MM241T(+E2_FQXT%9ATG_@R^&VI/(')@#2;A)*QG%CU_$':RDG/V^4*$!_@!0
M%M/4'9C9GB.\]0!WEDU#457YFOC#RK+4>L$^FYD#BJ;)N5_\VN/;[-$)"DR#
M/DQ`VA"#&OC`#RS"L/K``[#();#&T11*CK/EG.E"&VC`'#Q8RGD%'K!Y.`,$
M&Q.TSM3(@\:&#$PB\BSP@:A?/QDU2MRQ<:_$NGXVYI2H40.8CQI"]O5[5F,(
ML#8B:DQ:0(B8$!.3B`PAQB!/)FE":F2R"#%B4*%#B18U>A1I4J5+E9I[MJ_8
M-$2(]CU#5&):,4;KUA&BUF^7D'[$7JR;9$G=)40:[A$KILY<IF>T@!5;U*^D
M_PTVTX0L*I9'0XT;]S*9BRAC3K]+SR+Z`^"C7QL`Q2[M`S:MGSIB_OP1<PH,
M;[])`D"GW<B&:6K5JUFW5KKN7E*X2*F)=7T;=V[=NWGW9JJU=8EL^F3\BQAC
M4B0$=P[CB<B($+`$+/HIFA$Z:+$+J!<)T3!GDL'8>.;X&"*$T)!^1(KAD3&D
MS31&B,X\L\'^L%T9:-J@B9BGF!+N06.(!=#8(#8?-/"!#1DNN:,--NZ80P9J
M:GA!AC9N(`:-.40@<(B6?!N11*9*N@0-?X00PH8:RF/D!4PT*`$--C0P[!+4
MGA%BB!Y,R",/.XC(@\4\;!#!!!]B:)&Y:6KH9QUBIO_Q@0@BUKCPA3PB$N$0
M'H0HX:Y_-D!0!@T0(42$B8BQ00@?T&!@"`ULBFB--M13T`Z/L#-JGY)*_!/0
MW<SQ+]!"#3T44=R(N8NU(30JH45&\KAK`:!JV$`(-!!!S8<2^KGC2:+\*6FB
M&M#`PXX-#,.#P3GF8(0(?\AHHP0B1J+&#D2&*&2.E2(J85,\GA&`F(B$N&2(
M`=FX`!$T8D,C1EW)N8/5.1#Q89U,_?*A/39\N*018/(HP<]$S;WMDL3:B.\9
M!ON1`XV*YF`#DXB`$8L8']J@1I<VW%@$CQNJ46<D?^9XAA%&[NW''!L4<V@(
M(!>I`Q$1%(D(/!/Z*>9)=5[_Z'#>.8@@EXT&VI!(@\L^Q,P<!4Y8`)@G]QF"
M4:3V02>H<I/R<Q]_CM+YW*/NH28V*`WKQY]S\HG(''/\7`?HHXH1*^J@K;X:
MZ]N`861/IN[91Y]UII%F'#]'+4D=RH!1)[9[VC[:*'7LF&2=9PZ.:)VUY[C#
MJ7V@F2:/.:89>)II,)D$CS:@B>@2(4Y^1H2@@$$$F'N*,8=5H-9!0PA@@%GG
MDF(0N<.J=6K;\$Q,\JT!1<=]SAIVHXC9CP@VJ`&&C75%F,2'/)K-!&\1%JDA
M$#2FF:1&1'J=(_%8A:CFCCLFL:V&'YSY(0T?[)"0ACO68,"P.0BQ`?F3X1'A
MF0(N__'ACD[Q<8.#'\PI001@GK'HY#9\`(9S'Y[)PR!(B\@T?*8.C3",&J-Z
MAL_0\97,:"0M/ML'-4IB#J(QK&T)S`S.]C&-HL6.8<1@S#VF08RV<:4?_WC&
M)2`X#;@E91HG`^$,:5C#K1U*'T6IVL]&9`/0[)`H/./3ZXBH#KR\L(8@!`8>
MIJ$.?ZS#'.JX`RT4TX:VP*U=3>H@,:A1.'^<YQZ@J<8ZR%$X!^[C#C"8PSV>
M,8UG1*,6UEE&1*BQE2&@P3CWP(0>VT(-8E2F&,]81`F`@0EJF*-VF`&&80R'
M"1DL8A=`Z<<])N$S<Q2#<9A91QZ,2`PM]0,8EYAD&PQC#O^J]",37.L'(EB6
MA]@`8Q(1:0-H9IBV`TZ#@BE\1FSV@0Q":$2%F%G*.9R31&,>TURP[!IK@(B;
M9BY3@#H42DG\(<QI*N69R-2F;EYGL];DT)G>W)F?^!'$>\RF)/OX6D3RT2=_
M_*,:7=-9-F.GLVZZ+2CK7,HZBKE-?_Y3-\H$Z$`)FL0^#>6@T(P(T,J5SH5>
M<Z'X`)H^*#K/J#ET3P[=84,3:K/7E80,F/#9/=A@ATGVHP847!H>C!C$@HX(
M<R^5Z4R'4DB%TA2G.=4I0/?1-+Q-@PU/-(P/W-"/:0`#?8JYRS[^\<&=ZL8<
MB7GJ5(]I4ZI>%:M9/9<Z_11&*W[_A55\8$4:@'`'*;%A".X0I59O$U.VOO5<
MH;Q-GRS:&'K"%:]YW69M('<'&=Q@!!PPP1#(@(?SA`XU=]5K3!6K5\<NI21R
M;>PW#07.UDS61"Z%'4<?^E#.XD5G_!!B9V^:L\YB]K%%68,%X^,.:>QB$>:0
MTC#P0%):IA:&4L7M;G&#B7JQIAC(2QZ4V+"I260B0IB8AC#Z\0W&N,9/T(";
M.83)4(PVE+30I&8W,[J/I77THII-#4/%R\.@$%&[?!HB0M7;&-[FIH('3`HR
MVEFBJB44A;HYIV_<^E[_JF82L60-J""WO\PLH@@_H(4&UF#6.Q2@'XW80FGW
MQ-V@X.&V_U,1(#&`\@P9+H41F#2*/_#@1\H0Q2^AH06CGA'/:0I!DDG!`SF4
M@HC8J$.52IF$83Q3R0FNHQCK0(0=&!$;Q.&!B6R85%7FD(=)E*0:H,D'+4P7
MI4E:$XH1N8?"0'F)76`"M8FZQ\`0BMV<<16BI@U-1S6KSH6.ZK1QYJ93\3D4
MMQEF:`YT)C6*L32A/4.^22%'/_];Z*10(I:*+0DBQ#)+[)3@*QI8Q"74\8@$
M+*(6:DA->&K@R1H`!1&B8UTU?"(#1MQA`Q$AQ`7NT>2C*GD?S;K$-,CS#Q/`
MI`;/)48$)XT'$RR"9D>#7B&RD@>IG(`0]QB"IS)S!W)0HP`BOO_$)$A8S7,$
M]VN`>PL)U:%<RP%ZCV"BQCH6`>3G'H4!Q9HE`)@CA&+LKP2ZH+9)3,``3%0L
M9JZR@6]CTP8(FR,`DXA1`*@KLWZ80&/3H)WT2K"!-6IS&C9X@0V*Q>9,R!=M
MDYC#;8DR*`D*Q1RT(`;R+-P:-N@"OK!AI].(<@]SC%2$^GT&QXMR220>Q1S,
M,?3.CX*)M:8F-HSN!QI^WH\2,.8$_)%*(VB0!CHD94>@X=\"&#$C`5/$!_/C
M01M,P+'$120\XY*!2.Z@*3[D001L$!X1A'`'$;2!43Z8Q`&&\78A+4)?ZNF'
M>83`B-YMIP1LR%2H1O)I5:U2`VB(A`S_8BB$(LA`".9X@7G,:H,AW.`A`+`1
M>TH@@Q=,`A$VT(`-8DP4#<0S#Y<XDCD`U+DAN%"`?)!!/[HSH#R4W1Q%NX,!
MNAT`8H!$`368$AU%@CG(P(,QB-!2F`_U@KO<^R[`@(9AI\$L7:"!:WD8`AWJ
ML@@?$F,(/IA&2?"`"$Q4HQQJ(8(E$%$$8&3"!FCK#Q3K1-TU%(N'F"`"A;?Y
MS'W`(S6F0>=XC@`?RN=6@Q%Z!3520B@T(-(\:!_8@!*D00`2ZRA^CXIJ8"46
M`1.@)2)\X`+\PP9^8`[48UVD:A+(($00@1%J0!UT`3[4SG?\P09\@"YL``W(
M[P6&X`(880V4_X\1&D'9(L)1$*$&G(-S&$$=T,!W,D-C[,0VIF0([`,=M$]+
M'(<1AF!JV``/G@1:F*,&]N=),@$-[*`&S`$3F,TH-H`QY"`!+V$_BB$E9"`/
M0,-G\F#V)F$#1$`#(D,&6"DBV,`&[``-1&!])J&X?,`V[N`%1&!3"`$O?,8.
M/BR[ZDD$CD8=(B</Y&`$Z(!C,D$&VB5"&,$-F*<,:21B($,BS&$(+N$2B$#2
M;*`_&`&M?$8.;:!%"H$C-*`-%L":C.(>+D+-V`NA/LC,[&J9]"F)IL&D"K``
M2V(2J$BQ(BX':0]N]F$.C*@&-&`#T,`2AF'H&B$UPJ\$UH=&(H+T:O\`!=B@
M$?C`.9SL#$&)",)C"*YE'6C!2.Z@!)P,'9AP".8`#33`9R[A`HAA`6H#&`81
M$UCQ`S'G6N;@.Q#!'(1`\/"B!#"!?1Q&-/"`)6H`[]RD'^:@`?9!!O9!""Y@
M'33@)-AG'SA-+`@!QO:M#6S#*(!%'10",FK@`-JE`T&K)-C@!5:).<JQN-P+
MQCY$[FH`$X"@'PK`-EZ@_#YM]F*F'W(GHUJ*,RI1*TND!&()16:O!G8A$U"`
MT5*P'\9E&-2!$.P`#V#`#1(/$W1!%3-""R_A(R(C8B9!^WPF)-8`!6:@)85@
M=[!%*4*Q-=2AI9#BYO+,-=2!&A)S->K,**;_`1*9SQFU:A%H;K,6:I<R@QC2
M20,^$Q@L*O?P0ATLX\F@QF<X+(J^YA],AQC8H*7N02.^!FH6LF<.R&E<[DPR
MHJFF`<CP1@AH`2J8)E-D"PT6(>;R1C0F"#0P$A.>X2G8X`R(H5BJ83%$0`?:
M`#*)XO<^#1T@0C[,(;9H3IE.3'0N(9[\A&X0X1DFX7Z(`1+5HA^H`37.$AD8
MP09,()Y<<4_4`2@.)R+*S:AT[A)HR=@R`RB(H9@H9Y+8``"9<RR>Z^(F::U\
MBQA*@$)B9@AL8!'(``?O@`]Z!PT$KD86H0DX@`Y,H$0;YS#,H0UJ8#^>1`CP
M0`A<A22&[D-VH!#R_\0(@0T:?HL:?HL8J"B%Y&ZM&,%(=PQI[L"([H$0&.AR
M&$;`K"(B9HYMB(&6@.$KRL@UAE3`5J.#<LDHJ*'T+M/04FR@UH$14$YH>J-J
M)-,XB:!FAE&A[DN]2BXBT,"(X$R<X,N]F$*T0F,=C,-.3VJ2#/4T)VDVBZ8T
M\V%178YIC&B"WB8BT,%02[.GF(9E,$$C0"<V>"$2,B.*MF(L=N&<+.,2T"'W
M$#,B,"$Q0DP=:`P>VJ*)#D@=,C-7&8$#+B</B,:!S(&6W(AQV&`=7,Q^(F)*
M_>$2V@;,\.(?T,9(!>E**Z<J\.\2OF(=NC,UU.$9;HXI"H<VF,,RT72J2O\B
M,_FOO&Y*H_POGXJ!:-SH21<"+US.,"JU78KF'P@H,UIJ'8:@3RCUH-RL),8#
M-(QC-6.)E]@L4)'Q4-GI==S&B;"#KB+1'^KLH.Z!NSB*,S2J'P;5;31VFM+)
MG2IV9/GA;!8JH7*(KBR,O-*,8D'+M-RI7J^I8V663\PFB(ZQM(1('8`'9G$V
M*`K!1:2)O>S@N?P4HC2*B#9V*]MKKMKKNA[6J,[47'D+78LN4!J+$6#@`EQB
M`UZ`&FR@""*G'Q)A`18`$QCA!&J`#0X`,Z;!5L`C,`RC&!R@7X:@`TU`;'5E
M4F1`!##A`N3N'$UB$E9"AOPA7CSG!>;@']ID#FK_(+C8#JU6R8=HS7C6]3)U
M9AV42R0(#6^*H1A^*&@U]VG5BV%5%K(85M&J!BZRM1^@P2V"B"LP@Y[D]#86
MM6&=2C7,]&IY#LG4]5PRH4"N9>@>Z1YZ("+N(!-FYTF:A5#DA@@<D1=+J2^"
M+TWN;5+<H`C8@`C&ENA$P$-+PA*,I!IL`#.FIQKBQ4E`!1,VX",)(?#0P`?$
ML#SPP#_*];\6@1&$8!+2`0^DA!KL\U_0)U1J2']UP^<NP&$,Y!G00;E`*9Y(
MR`<,-2F&YMQN@XV>B]N0IHT*UH.8XGY^M]!*(@]`=X;,A"$@0PC^D!8XX#_@
MLW[-0<ER%!$NP`W@=Q',_X1A3D4#;-0&J($6)@(BD_,>#.(2=*&%8P-6_4,(
MON(.(((0GF0.;K1AU.$^J,%X+F$!8FDFLY50`H6B*`JK2D)RDV5/#Z<0G6S_
M\.@9^X$,S($#,``:#D`.R,`$4,((6X)H^H+_W$%*="-O,&D?'-,PX*&0>F;F
MP+4H?)>$"\U:A-=<4&3C0`->T8`(FI%+J6$2=$$O[L$'KG,,UD57T(`Q9@81
MR>!PJ2%'AH`0M&>/V(`6S"-$EF9R((*4&*9^T8"79:`8]@);%'%'CJ<\V$!3
M&.%_)!E-4XH,^(:7%Z')C/`@]HYW=ZX&T@$&>``%>"#\'-!(WG,#(&(.ZA0I
M]/^4F;95RZ`&+[KH4JFAG)8BF1/XD66J)%X%F<QYG!KCG7'W'G#&9_+A8@U#
MM/J$A."I:-P,4?L!'3"#C=3A'_[A8B'5B=C&;58(,=F&D><Y(O!@$8Y8[M:A
M)F)&"'8D7P`UJX0`_!:!"&AA'HG@&?``1F`,(N1.IZ#!:C7:L?*`:_`Y:\!+
M:-],NQ**9WKFI*[+78V6J$_77-/)9R2HJ?=AH#LKJH2V8(MF4G[ZS"H1H^3)
M:/_4O5*7:L,)$2=)G336B4J"G;_&473JI949IY^JGF_ZK9E)HYGX/J/)6#3B
MB8,"$T1'!@Z:K(<B'WQ`!"#%J:K&1F&H.]5!-FF/$9C_5*G'8JD:@U][0U*7
M@H3<VIB>X:[G^K'N@'0]6[35JUGMIW\_$Q%,8`XVA]KF0)3V(2,VXA(L`0\^
M0P&&P<.(AG*((<3D`FE@U'@$:1HX<&@`D18PP1V*@-JHS1\V.1.*IB)$XY8$
M0)0NH-/@8A&@,9ZR(E=MMQ]$H`!B@\_4X0)^T5SD&78\;+3UZB=S;+W?^Z%,
M8%!LA-$"QP?D5P,JQ0`(.;:'8`V*H`O;``_`I''_L%(V8%GP4(!8L!].X`\#
MTB7:!`^*@%M.`!ALQ088@0'P0`'88*U85%\NT:@`0`C^00-\1P[:5@[LX$AN
MN`9"8`;D@([8+EM-P`;P8`&0_^&]J6$`X?NMBA*]?=R_;.`?$B<Q:L`$.I<-
MYO>5!4@&-(((3F4]5'E%_&,F%\E1?,!C_.0.N*8L0L),(",YS0,97'D!R@,-
M(-%6C)0-W.!)1&1V&$3`;=0-[B$$(B<->2`R4N"4[(`!-(`(VH!K\G6S@OQ<
MJJ$9A3RKZCE,%5VT?2931`!_^Z%&:T`$&(&7N_Q)?$9_1$9Y-J)$68?T;GP2
MJ$'\L$5C(L(.[B+)344&RH[2K64?02+#\X`-"(&S!?,#VR"(2Z!8\LT`@.$?
MR8`/L+GK``A@Y4`DU\$?=B?.\4#C&,^!V"@B')-I'&@V3.)>BX&7BJ%@%^?*
M@'&A+/\846^FFI/H&4S*T!T=A#1%L]F=`-72,S"#'/P!]$B(#8@!^18*2M<`
M,36B<"RH'S!A"`8F]Y["A(K%9\35VT^BW!C#@OP[;=C(!V)K_-KG:#QG=@0L
M+=!0'8"!&'BA&>B!%:#!38;T;'_@+G+U58M!9*S"<YA&E58H(K2TYO$//O%"
M"!C:QJ"DF*2BY4HS48-B8J'D,;6I)(H!#N`]J]A@LID>ZJ.>*73W'_PLA;KJ
MW-']9-9=ZL][Z!J]Z^>YF<!Z[.W+JZ'V:><ILC.CIYKU*-ZI[+,J-L-^ITJ4
M[N^>`$LB)2CR(8#!'Z3!)#'Z+''F9W27-92QAC@$[V<JA^S_GNL7'_(!:AJF
MT$S:Q9A/`!&ZV-+MT[U%Y1D`\/"SS)@\Z=TC/VOTUJ`L:V15W_1;OS6\[Q[2
MA2(7(0]00`AL_00^X`Z&YZ;$M37JAEM!J!AZW/61OA^XH!)*_T_(F!B+W_F!
MBST4PB!DH`1*8$7JX`-`@$%IDKTWAER??YO4(+1CYQX>P;*`@8.H81F>(1\X
MN:NG@=RAY)8$UBB$GNBM?K2.46>O":KIJER4%B#\[>LW<&"_@P?Y&=RWT"#"
M@PX?'A0(\:'#B`@Q9I3(L:-$C1Y#BAQ)LJ3)DR@1WGNA#AB;:>J*7<)D[AFU
M2X'N"7EV$F3*GT!+$D,4M*C1HTB3_RI=>E)+):9(+PD(U,\=,1_3\A6+4VM2
MC:']J*WKIPYFOVG5^@TI=O">LWZ(T`RL0?2@NG[W"@[,8XYL/T+`$%$C>-%B
MR('^.!83LO$AFFDC^7T\.`G8P6+`\)1<E-;G6<C])O%\J$[:HL$>!T["9%(=
M(42C^ZU+#+6V;93$QHZ\9]DDQH@.S7F^_3,P\>/(DRMG6J?W<I)MT#`68J,$
MM1HRA@"K(X+1HDDO;!2+\>)Q#;IL4%-GL^C"6BT;AE#S0836$$*7B'I_QD8&
M)A%H8#(-'C)4,TP)0YB320V3''1)&T(L@A4M/62B2S7F+-(//YB<<8DN9U#3
MAB[V$(+'7?_]U."#AK^<48UDTU#CSS3EX($)AX?XHV`/K/U3PB(E3`+9)9G<
M,\Y9]@RUSAEC%///0=1,PA8T<_R#1QL'`0,,-8OTU0\P1`QQ2#7^^`,,:&=9
MED<;PO4#C7!W/4G,:-/(P`A,P-QC@W//];D40QL5I,]P'=UCSCT$&=J6.@:M
M@Z:?*!73(*&05FKII2BQ81FERKFS@`P7+$)$/VRLV4\>B.`!F`\^Q*3%$/X,
M0<P=-0@QQV#WX,%&#7.,<4\//3RCRPDOW"/"KD(,D<D=9&!"2']"9(+'$'P-
M,00B=N0A0AMLJ94'(WD0(L0O=YB`QR&+8&GE(3$@<L8)/?PRQIK_8QQ$UQQX
MQ/#N78C`UD8-)V2220DQ4,NN+OW\4\,E->!1`QIXG-'&"NK4P(809\AP1QM#
M:-:/!GC8<(<-^;9QQD%LH*'!'2(\B0D1/=1PAAUV"*$!PM,,P<8,>&B0<AYL
MO'"E.4+<,80&#4[C0[@FK/@"(YA&#16G$*W34%MMDH6BU"(5XS'78(?-]4!M
M7#)V/W@(08T0(M@P#1&(#`$-$7?,@4;<-3R#2`WU)BL#A&@,1LP%=\B`!AKK
M$"'>)"<P)@(BAU!CQP'3V&J"$)=G<L@04+]00C&(S`%,#24@.L0TDR!RR1!H
MM+'!=1I`YHX-;HP@QQG%D"''">4\8\-!_S:L0PD**#22X%^92(-&,6NLT48/
MD2#B`SZ+9()7V6C\8X,-YE!CPQ#WM&%N/Q(_DPEC_OS>AN']4&=]/V[D,6H)
M/#WHPS/#-%%#&C-8I@X;/BC!&A"1OACX@QBM>YKB;$`4<Q"!/6BP`3'R0`RQ
M6?""%AS()>9`$`QZ\(.V(9O9P"8@V6!"0H381\TP`0R]4;`:M2(&:S"!"1NT
M81)=ZH<YLM,&3,!`!IF)@1"`D8=^8*(&-AC'-&K0CSED0@1$0,,E?,`(8J@H
M#WAXQB7NX`/JD.T9F&`$,*A#A`WX@SH'F<8"VA""0I`A#VN8`1O60`.J]",[
M06C$#-;@@R=-HO\$-L@#'\B``48(80N7H`/;S.:/$A`"#0Y$A!!\@(@US.%Q
M0A!"#>H0C$L4\1XRT$D>:F`'&5S"!D]J`\?Z88+!Z,(&-X#&+H20!CZ@(2V7
M0)H,DG4^'UQB@)@(P!E;QYIID`P/C#A/&Q;Q#-V`\)G0)`XP.!C-:EK3-_UH
M`Y^X5B;#+,0C^FA+1=KB#HCD91_J0!2@S'$7O>@0,O<8"SHA,Y!\D.49B,G'
M/NYQ#W_<HR7IM,'[^F$^=OYC&H@8"R4H$4ZR3"(MU$!$7P:R"$P82@YLP0D_
M$=&@@Q!C&NNX!T_NH"%I:/,<TF,!/MP!#R\]8T8'W$EH^@*-9^#R+O?_0$0Q
MZ+$.9YB#5X@*'QKFQ`8VP$,=0YA#/NY1074(H0V(^D<QGF&..1#A&<3`H9>N
MR=6NGH06=NB@5\?*U35L$U/`Z0=M.E(8M8ZS-E3K"#6H&36-_",/X^I'0\G*
MU[Y>4Q=T]:M@,]@/LQ+FFX#J8&(K4IC%BK4QO^'(<.(:5\DJA39K#2'5$-L8
MCRBD)'MUZV10HA')#/:TU1P(,.[P6-2Z]E)H0,9KG]/6;XH54`4AB&1RFUO%
M(F8?X>0M;A/"$.#Z%B*T<6<W#TN8YKHSL<-M;F)XNQ&*1)<BBG5N9PUCV;=Z
MM[6S#2]*+O$U\9I7.6DP01K(\-0VL,&]<ZA;_Q[PA8<[W`$1BT`$(S(QB?[V
M%Q/^S02`,7&)2P!#)@8&1H&U=.`#$V.JQ`#&G";\#&?$B!K3R'"&R3$-<WC8
M'.LXASK2L0YUF/@?_+P'BONY#X'<8ZFVS>QY9TSC:U(*))'=[CB_B0G65K;&
M0":).EBXBTG,1,):PHR"=P&,7;`0P/[%X2*^DU]&](L1=R`$(>X[A_EV&6A%
M14/*5/E4,><!8D]-V1Q4B2H[F`B+<L"#G.4\ASK7>;YXF*\<V("O.C]5"&@8
M`JM8-00BU&`(@&;=X>;;AB]WF0Y8Y$-]XVO?^UJZ7_<]\QRZB(<YN*$->&7=
M4U44:`BI4I7O9<.GN__,!CG3H=-UMF]\Y\"&.Q3U#GD&-:WSP&LLXD'2];VO
ME?NE7_SZ%\I&+O"1E7V)_O(WR@1N]DQV8>!B%./!Q,CV,VQ"C6YGV!P:CI%/
MMSV-;4]UV]+PMH8_S.X/K\/=ZRBQB4W\SW3.^Y_Q+C$_U1'2>*;SGRGFIS_/
M^=R%("HC/OGQ1];:V['.*L@0CSA<?ZM/?JZ8G_%6QU'3,6][FSC?_(YWNSOL
MX1A=F!K;WC:VL:UD!C,XPL\(QIRP"F%K2SC"F+D$+72A8`)#^83]941_%\&(
M84]YP#]/72:FC,-,]&O+B,!UW>S0Z3QD*\R'`S4:YA#UN!0[#]^Q,@Z-C5__
M_!(]ZO=%.[YZ?;C61:?M[M49A/*`ZSZW.MAX"!VN2U7G/-<9U&1X.Z)]\-ZW
MMTXZ8G:OKO(@!_IVN=.=;H.NHN.#1C\UBH+V`:*MM;2LUUK6;$#$?-%NWSS;
M86.URCJU;J`B&YR'"#YP?29918;#93+K:TB9[0]7>6O]@-!#.(^*@#])06=2
MT5D_'.M8EP:W`UJ@$H^^41J[XT`5E[&]O4CVLVM;B'2?L6_5B,*E3_[E.':[
MC;5NBP.^;W>DV,3P<,?'0_KO?^_[_OR>=XC/4>)WMQO<(R<6[P83\<9_^>9A
M_@=N)/=MZH9ASQ`C-M%A$8AAWM9M%HAR*3=SUO8,_P=7?A[X@3\Q?D7A&><W
M$B18?9W55K>U@MP7*"WH3MGU6)R55@@'7C+(@CBH8R"X@SS8@S[X@T`8A+<A
M@D)8A$9XA$B8A$JXA$S8A$[XA%`8A5(XA518A59XA5C(5^<G8]=G@BJ($#*6
M%)25A618AF9X7D1XAFJXAFQ8A<201691#8A`#/DP#?LD&NI`"[UQ4/?@?C&Q
M#]/00NL@)/!087%""XCR@'B!3^K4<(XB&\UT%NIT$-V3&.K@8>UT<--P#F%A
MAU6S#^\64@91%O^T5?M$#0.!<GFA5B1F#O[48<55&/<`#Z/E6.N`#PDC'/[@
M3'Z1,(QB$0?7@7CQ$8BB#_\HUH;(F(RHY0-HX`,RP!,UD`?`\`\-0`V%8WR7
M\"1H(`)XL`AYT$6,@&C%@&@,(@(G,!9(M`B%4`(E4`UL4`)YX`;3`#'\X5&U
M,@<\0`C4L"N55PS!(`39X091)P)=-!0:4DHUD`FNAP8$@0:\0@PPD#+K0"1#
MX`:KTVID$1<B8`?#L"V9T`;^P&L&L`9W`)"+\!AX(`=\(`3J($7.2!3$<"=R
ML`C[0`B-1BJ,H`%#50(+8P.&,Q"$X)$EP"W]0`Q8T@8ET&PE@`B-8`YXL`%<
MQTQSX)/"`)!UH8Q8F95<A0:3@`;6T0\YD`?2@`D-4#TUL`P.DR?]X`,UH`%T
MX0/_>+!$D"0$HC<49*!6)]`&ZV`#(K4`;$`64G0!1+`(C-$/ER`"Q,`P6O0[
MUR$I)3!$9#`&UM@E&C`$.G0"_;`(&Y`'#/,E#%D#Q4`(YG!#;6`'/M!";E`,
M);`/[I!)Z@!'Z4$,!J`+<C`-,'!'-K`(\*`+)K`\-:``&GD)YF`VSZ``+I$'
M^^"0(I`-&U!?0G!FU%`+-0`,%R!2,I!-:&`'Y,`O"D`-,K`:):`(#\('0[`.
MRX`&H?("0@`-WV`#&**5\!F?'C000]`&S]`&@T$#DQ`/-Y`"0+`,EP`#.;`%
MR.`.^(`=B%``=@`-H;8&YK"-)7`JC*$.R(`&0;`#^P`-_P;`D.J@!G,P`1T`
M!W!`B:,C!TU`0SZ`%S:`#,#P`R9@G$)0H:R%`IKA/6["`3<@`C/$6ESY$N]U
M+3*`!Z.C`%"C#F[`D'9`!C^P"!5:`W1`#B:@)P2I(2)P)B@@!#]0`PP0#GC`
MD%=1`X5`%&B0!BV0`RR@"#?``G;``D(P"1K@E_W`""F*"&VCE_U0`@E0"<M`
M`H@`#2S@!B69",@``FK@!!.`!RB`2"T`!&<EGX[ZJ)6"!XBB!C,P"6D`!X'@
M!DVD!H$0!UN@!H(`#?W0C"*""&V`"(70!&0P"7*P#WC@#(N@&163.HMP!V@P
M1HC@!FE##<)``UK`"/L`#&C`"O]HL`:10`Q#<$1LP`=WL`9V<`YND`:C211M
M>A!HL`AN0`:GP43FX`/$,"IX8`YLL`Z6@`>GB0F90`Z6^0QH\`.'TPAK,`S%
M@`QK$`3N,`+]\`,W`!IM$",CD)H,$`=]L`@S8$3`<`-K(`>48"MS@`*ATZE;
MD`;:L`MNH`X\(!LUL#95>AE"(`PSH`BUH`-JL`Q`H`:3H`7+D`,SX`TEH`8Y
M\`W+L)Z/`JDT6[/'P44R(`,^@`()\`$H@``,0`-;T`);P``LL`4)P``B*QU=
M-@="H`"+8`,(T``\4`AL(&I8-`8*P!X8``.4H#*=!@2(H`A;``,:@`B[0`8C
M0`D[T`#_>4`+FXD,-7`#EB`'EI"M:#<)0L`&1K8()@`$C6`'E\`&EC`,XL((
MS\`(H%,,WP$PH*8+=D`-%/L#"$`'=J``#"`'C9`(;[`+.[`+A>`&E5$,A;`+
MK("JO)`&R.`$(#`)7+((E\`'?+``:Q`'=2`(CZ`&!Y`"CV`!1=`$<T`.;4`+
MZH`(%S`'Y@,31G8/<[`%%7`)=4`!?*`(E:`($\`#BF`+DZ`(*W``+4`#""`"
MY$`-PFBSYGN^09$8)P``)W`!"U`!(+`!#_`!%?``#)``"?``"I"_%X``!M``
M"5``!V``12`"1:`!(K`!&+``#;``"H"Y!]#`#6``"O```[P`_P=P``I``!FL
M``L```!@``A0``A0!`50``K0``C@P!D\``-0````PP%0``X0``$``!,,``-P
MPP$@`"<,``)@PP!@PP'@``90`#9L`#&<P0PPQ`R``#L\PSH<``-P`$1,Q"XL
M``2@PU8,PCX\Q",\`%L,`!EL`%6,``X`PC#LPP<`PT,\PS!\``EP`%6<``2P
MPQQ\``0@`%Q\`%!\`"`,`#.+OEX5AH0L<0,A`JPU&?@P$,'5#_@0#_N@3]]%
M$LD5B_Z`#_<0R?N&8NK@?O)V8OQ$#_RT#Z3<3_QD#^PG?_-7<M0P#A>H<L3@
M#+GA*")F#N3@8>2PR]*08>DV#<B`#/\I5PUS8FW$('/R.E5*-G//(,S/L`S1
M,"?#,`S(<&W5+&%*IH?1]F3!8`E&)@PUQ:O`$`W+0`W0@'+F;!//``P%@!J'
MC%9HP8$YB'`,P87>!%G)Q5WO[%4K(UK[C!SJT,[_?"G3L`$V0`1H`APRA@:T
M:(,DD2$A`49%V(?:Y4ZE7"ANY6*K:!$&(1`M1A"4W-$6P7`N.(PH>(.5C'X<
M03@./58_9EM?"!PQ[5V(U5#=IX(XW4$485T$@5TLR%GF4`"#/-#+\0RCHAI"
M0`O$,`.L85/W8&!L(`?K(`3%,`WW,`W_,`<=M0^I,PUS0`N&>2O%FQL/%4_E
M-@F'@D`,F8;_XC40=U!$(H$)'-1P';%:D%02U$`(0($&/&$.C<H1T_"5)5$3
M;-4/&P`U1(T<YN``0YW8R$$-W'@)SR`#R."3)=`7Q"`$ET`$<BT"9&`WB[`.
MF!![&&`]TZ``B7#0%W!$>>`5,(`!6*39&\.30>J06,+6X948=^`>4^4#<^!4
M=F!,BP`,&T#5F/`/V0:8-6`.5\%"W[A5Z]`ZZP`,/D`+_\`&D7L)\X&?75D7
M-<G7Q?#6ZA!1#,`3F/``ZW`'!X8'R"#:=W")@D$@H1$,^%`,C(`HPN%AU,`(
MZC"5H0$,,G8!5^G8MA'4C4W@M_$,3&1$EDD$)0#6`^$#L6-K,X`&_VMR)HA0
M'GG`&L6`)2>`W?&E0QKP>#8B`SRP""=@!VS@-L005D#HUFC`1?!X`6N``I?@
MEPL0?%&[X=H1&@;PJGDI`H%@-!-%4'B@GCXY1F=;"*PR!P]#21K0%^H`!X#$
MED0P!C[@IJZ4Y1=`#+16`VVPD6B0LZ(W7R@`(`PP!!&>U[L-0-*1,B(`UPBQ
M`7J-VPC.$>9`.7=>U`R)L1V#*FZ%"->)`FD``V@@N^>A7V=604;9#W`S!ZO3
MI=E97W^Y,I/M'4`#,=V#@]B5?7HA7)_>TZ&N5H"2S]<7B[AUZHB%ZJ>N6-/E
M?2V8&&!7#,Z8.GP@CPT0"8M09_=`/Q>`)?]G02N+,)TGE`?'DQB8@%=Y(QU$
M%.,U\`+!^EXIPA/5T`9C8`,O00M_,^W]0`O2&%:`MC28,-7:;F698`+NN@8_
MX%8^8`Z,L&FC2I<LN3;9M0'64X+8%!3?-UHZ=F,X-L^.M5B$,A"?E8.3Q5W[
MWEPHO7T,KT,%4.1'8>?FRV*)@0Z(H&*3N$^R$0G-\,E<K0LMEG=8HT.<V0_%
M,*Y9;0<'%19W09C$X`\7HPYM`#7E"X(<Q3R2Y`.DFZ]K0)<Z6>D:8I@!9$A)
MM4%H,`Q![Y6U0@A#H,@K7E2$J9,<-`0\,0G%#9?79N%M<`&B.ME3-@V/@VAS
M0#3@(C3JF+"FV4'_>^L#7+26=F/A?.;/&Z`A=#T9-*COYI?2'&%:^8X2?&]9
M"B?Q&W(6#[_GRB%^)''W*6B"'7$H80%H@(9XD!_Y;T=HDS1\*O)[731HFK=Y
MJ%8J5)=EQ49L_4)E1^=?A.`=2U<]JT]T`C,)SU9@++1@U79@UD;,U8!56#46
MI7PFP[@/5:U#;$$-EXT0UT86P@EPT\`'"#$)Q+`/YG`'?;$(+[\.NQXD!!%2
M!Z$+:`T/_<1O.E40']47)P2`@)C9Q/`/PF$'=*`H=L$&EW`/@P%2>6(KK;4`
M06_X2V$.`+!5^G]!`+&OWT"!`PT>1%@P(4*#_M2I.[=NG3J)YLQ-NSAM_QHU
M:AJI/>/XK%@Q8B.)$0-V"1,PEL"&U2K&$F7,D2TOW<24$],DE9,R(6+$B!`B
MH(CNW"&*:$Z>HW.(+F(T:=$DJE.G7EJ4:1'017>F,01KL-BDL&7-#@36!I'"
MLVW=OF7HKU\1LG#MWL6;5^]>OGW]3BM@SN]@PH4-'T:<6/%BQHWOLNVG4#)8
MR`<5RHU,\&SER@8Y6Z;,L+/`!74=GT:=6O5!:@X$KX8=6_9LVH9'B_:L>6%N
MWIXA[Q-8D*WDX`<QUT9NEV[FY,V=KY9+K<"ZY]6M7\>>7?OVQ@P6]9,K''A!
M?^$)FH\L//WZ?>B!:WZ?.7[PXO77R\</G[GZ]/_JQ<.G[[[B=!N.MP)UZVVW
MAO2BY@#JN(,P0@DGI+#"TQ:XQ$(-(9S&P0T_!#%$$4=L3H$-?""BAA2'8%$(
M(="`T<4VT&BC#2':8*-&-_)`8P@7?7PQ2!C1R+&-//*88RD\YK#C*$(.P2,H
M1*+$(P]">)011C9RW!*/.^;`P\NDG@**D:Q\0@23KIQ:A!"AMD*D33>ARBH3
M.S.A*J=),%'IDE^*^467EE)*Z1):#/WE4%UH&=2D8JIY!M)GIGEFTDJI.:E2
MD8`9::1A(OVTFI`\\L@<3`I0AT155V6U55??RL,&&V1X00892L`55Q%,$$&#
M$D0X00,.>NU5`Q%$T%7_UV.//:'8$SC08`-I-;A@@06*L#9;!AI80%H%KMV@
M66"7U:!<8\W5X(0+RI7VA`TNJ%8!!A3X=MYL%Y#@@F\WB+:((B0HHEIL&;"V
M`7H9,*"!!A*F]P`#OEW@6VPC+H*!;;_%F%YK#S#88'J_;>``C!=>`&$#'#X@
M904,>/CACU<V^&$`BCCN59MOQCEGG1'KS+K?^N%G/.#RD<N??":S#+/V_+FG
M::?O^2?J?]2)^B%X_O'GGW6:9MH>KIEN^A^HFY[H'WBHGBC5G==FNVVW'0N/
M/KG!\R\__H2V&[^>%Q+(O`#YBTQI!$,;B)_[0'L[<<479[QQQT7<.\'!'Z>\
M_W+++\<\<\TWY[QSSS\'/7311R>]=--/1SUUU5=GO;#Q"!H0\,,'S"ORUF_'
M/7?=;;Y-OX0*K'LR^V"?'.G>]I9=<MN3)WQWYY_7#IA)*N$SIYM8BFF878AY
MIB21JN&T).XSC?09:#CB2"/U+6)?(HH>@O\>=>3GVNGY\H.^=-MQD[UNP1%W
MB_``&#@""8@Y^OG/>HKV-P'*)6C$NUO^('>)1"`B$(%0A%&\Q(<^W,$.?+!#
MDHZ$!BRAP44F1.$<3@@C0K!!"(AH`YB2%*8Y$*(.89+#'.2P)#8<"4EWR,.2
M[)"''N*(2"]BPQ!HY(,M"<$'*.QACN30PS`=:0YWP/]#",&$E#L,A4Q%V<H=
MA(*(#UH0*7A@PQSHT(<^"*(0A%A$(1;1B$@L(A*1L(1**'$)2_2QCWNDA"5X
M80E)4"(2K&!%(BRQB*GTL1%TC(0C*!%(/O+I>I=H24T&Q9*;,"(F>]H)52:1
MDNJII"4E(0GWJL$]374$?>C;R"MAB9%ID`,C%V&?.=9QCO?-;WY/<QK8@/FT
M?=Q#F$W#AS^`<P^AC<=H<V->6/:GE\](T)I]V8<Z%.*.=11H?L1SQSUPHYN:
MN:X?S"Q/0>CGM*TI\WWR.Z<VX7F/K>UC:Q2YQT72MQ%^<B^5SQ@&IGA1$DX!
M0QBLN,0P@E$+2R"#%Y0(QB7_D,$*8NR"%PJ]Q"Z`P0M66*(8EJ#C)"31B$50
M`A&$Y`,C$,&'1;`T$F9:1"*D0D>HP#0HC-"*2L<$%"S.02UH7,-28)0'1`C!
MIU[*`Q^.`L0DS6%+2-*1C5!(AA@)@44F]($/AN`#,EC5!S>:$9'0X`,<L8%(
M;5B#$8>4(R&PX8D]&D(-Y%J#K-)UJT/(0QOP,`8>6)$-8?(2%HD2ID,0XHI3
M<BJ2MD0&)5IUJS%"8PRW]%<L(L4H.V5$E)C2PCO4R(E:=5%6QZK$(:4!K6&=
M$8_0L!0V=!8-51J2$TUHU15R*8I$/-)?J^0#'](!#['-DI&RV$.EW($/8>KB
MF"Q[_Q2@X`$1XKPFA8IQAQ^@P0V4Z`<*B/`,0J#A'C=``QU*,`=_K`,&KWW!
M$"Y!"#P`8PX^4$`P^H$&#0##!B4@RQTTP$1S(**ZQ:@!&@I!#3>8`P]"R$,Q
M$-'7.P@A0\70Q3-,98Y)=*08(:1.I<SQ#'5@@@UKZ0>E^M&&1:B##8OX!QXF
M<0^B_&.4]U@$,@BR#L$\A!;?_$<QU[&+<_3#'>[(ICIJ,1!XR'@?SD@5.=QA
M#FVD8R#T,`@YU.&.?IR#ROV82#_44>,>Y_,@VNR'.:Z<F_80!+H+ND<^1O0>
M9A:SF,-\VB^;EIE\_$-ROEFF,?/Q-+/)#WY_OB?\).(.JO\]9"(5D4BB::S+
M7+;/(M2@\302K<M=+IJ6&\D(-:3A2I"T4E.7RN4M^4D-:'2O4L5`!DT*2BB4
M``,DU$`&*RE%ODN9^B2/ZAXQIAG=YU"B$39P@Q,FH8\<+*,?)M"`-.1@!Z-^
M91TH<.L0VF!8$0CA#M080C\P<0=U",$&)#PG&\SA5DS4H*UN*$8>A$"$1?C`
M#M+.Q!V`,80Y4*,?B-B`O#4PB1KT,$6,$,P+A#")"UQBO&W`Q(AM,(PSV($(
M9+@#$9PH!QM@`A$:*.H)ZO(,-L@`&/UV"B+Z@8=IV"$&5(VC"#B.AAH`HQ]:
MN$`;W%"#'Y#!`H5HA`**L0->K"'_5?AP@P;L0/$:;/F)B&#1(M;-B!((P1P"
M840-/HA?;1/!'R5``R)D8`=,P%870S!'C^R`B!K<82?[T9O>@E=`X\4'[9OA
M==R=MPA,S*$?A+`!,$J`B$FT(0UV:`099A"$1M`3#95B8B:$``PBL($<1.@'
M,>IM0KT.9`[WF`8BS&$#:M2B!BK!+WYAA(=,Z((::*CPO?D@`CQ<X$8^6NTT
M]F&.!6@`1C80`DH(T8]>S>$D&A"5"-A0`T3X0!W$`.(DK#209\S(!R)H0S^`
M<8>1IV,.)>C'(DJP"!NT0023>`8C^N&#O>>A'Y,(`AD:80XRF.,!<G@#="<Q
M#$8(009#_\C')<B2X'T07QUS8#?JV`<T.#^,$PPT,`!B,*M+D#I,4`#PHP43
M\`&Z,H=+`+M[\"ZYVPODH2;EN;-Q.I[!H1W`(4'0V#4-3(Z5&(AU8`1&681B
MB(QU"(9A@(8."B<[^Z6.2+1_((:!N`1$(`;9RY!^H`;YD8@>#+LV`(D*A#1J
M6`1R>`86K`$\B+P*!`9SN#5@"`:M(@9JH`7N4H<]:2L:RX2T8`,^F`1KN\*Q
M&((XF9(\8`0[&`:)P`1BF`0RP`0W08,?!!,AV)%)`,(\D`.EB[[#ZX<YF`0E
ML@,W(`<Y:(0^0(,;F(-I((8%P(0=802!X"Y&^+!)N`,VL`,\8/\]";LW7>"1
M'G0'-(@X1,B13$"#10BO-O"!OC.!@6.Z1;B'-C@S%.3%7G2,.:LF:3H@N!/&
MYK$+^>D=L&":@T#&-DN5=;`S\!@(?Q`,&LNGIN$P^%"'KS@G@GB&=-B'9Q"G
M>WB'@2"'8FB::BB&7S((2O&'2NF':J@&?T`)D=`R"9NS932'8M`E:C"''",&
M6MB:?`*&1:`&JJ"&(?3%A61(V#"<R8'(B/S`QVB5$U0--VO(C-1(#;1(LWA(
M!7F+`P'!`<*?C33)DT3)E%3)E63)EG3)EX3)F)3)F:3)FK3)F\3)G-3)G>3)
MGO3)G[2<!!I&D!1!H#3*HT3*<0K&.QO_P;3;!WU`._N02C+S':0YD/=HNZ@\
MH&@JH(.`RJ0$R\7!!YH0!I(`AELSM5.KE&!8)6"0E$KAGE>BI49KG[1QGX<@
MIGT(FM<A'@(:RK#$G+K9C0BBG:VT#*Q$'!(T')%TN^2)H+[\2\"\BWO8B4O0
M"E$"Q*APPZ3@H31JK1J!D;!2HB8B(:/H(3(((B[ZDBVJ+$1XDLPB!$*H+"0)
MDRYQ*B,)*R*)HK*JD2S"@T)8DC$:.T:X@ZF($T;"DZJH*:GPHJ$X(Y7B@Z2`
M(S.1BJG($Y7@$V"@'F`0%$,I%&!8B470/ZH@3D`DBILZ3NJDNTNZB>MA"8T"
M!IA("?C<)$PB_RA.&89'\116<H9*49^.J"5R:+1TV#*+6!^+6+2'(+0_4X>S
M^26Q`29E.AIEZH^F<;-GLM`V"Q#)Y%#L:*9F.J:Q*30&Y:5$.P==>A^+H`@#
MQ25<4A^-*!_Q026<V!.>J%&JP!/KZ1/LO(0]"J4\P4S,?(KC\I(JPH-INZ(E
MX2G9Y"G7/(HE@=)07)(D*9(<42VKTI(L$:LU\"'6PBTBBJ(MJ1$;>3VKFJNM
MHBLB\('WHI$\>(3DZJ)`D$WC`A.B<,XO01(B6I*Q<J&Q^JJO>I$9$52S,I(T
MP@,^F"$96@HB"J$VD(.QJA&MRJH;,%-SRRK0(H.P(M0\2*N\"LT<@?^1M`*M
MNKK4%PG-3ZV1+4FK'CH2(RHK-^C-0'TBQ_*1-'*J'0*3P"(*P7(N*OJK11VJ
MI_(2-P"3H7"N\]Q5XL0#.$&$(&HA\>M0O/`;H!&@XGB@J1Q&A5C,:'T,O1P>
MN)B/9:(/HAD/8Q(:<V4F.(NSIC$T0TNTAV`T1%NT>*6T%6VT2P-0CR"UC_BT
M\IF4]+F4C^"(4B,&2$&U53J)6T.E[W&43NFT?NW73"&)5+K/8J@%72")4^-7
MD*"45X-8N$38+BS8CN36TVG*KOP9!$%,`UI9Q$P@E[4;_YC*_RC,OU%9]H!,
MOB#9DN79G@7+G25)B<Q9HJ0,H)U(GT7:I%7_VJ5EVJ9UVJ>%VJB5VJFEVJJU
MVJO%VJS5VJWEVJ[UVJ\%V[`5V[$EV[(UV[.EC<+LRYH-6HOL&:.E2;A%V[G5
MD!(T01-D3`/"GZM,$+X-P;YM"[FEVZA5AZ`@SZ!@).L4)958%$P:%&+(3TAA
MI8T]-7_*-59JI7VZI5S"2W2`T/G9,V5:V<&%G+(0R;=#70!"F@=2D+<=(,&5
M3'7(436)"L.EDYHR$_04"N<Z+B1)K,2ZD:[:*DFEJPFL`1N8*[E"WA>H@<<:
M`B*(JZXZ512*$12"/=+B@3/8JJYJ7HD+$B)@7B&8JZ\B`RMEDB#:H27)H4-M
M*J>H4S`9(CY@KZ-@_P.5"L7E>HK,Q!.K`-)(Z(D=Y5'_59-)4"FML`J=L"3P
MQ"3'W23LF=B3<$N4:#57N\^$]1Y3TUQ2<=%0,]!I0(:0R&!_I,M<NLMV!;1U
M6%`3IHBT08>F,0>H@=!_.!H+[0=R/=EA9*8`$LHU(]T-$8A=3)KVB#-?*F$:
MJX@.W@@)^S00SC1*T==:@\M;FUC'[9.=N%A08HG*O`21,(E3J@E-&A3]^U$Z
M42F<.L[Q=-Q:$&,=%6/E7(1'D`KB5"G99*\HN5^D<`JD:!/F@BFNT"DO"<4=
M8D56K=Y`[1$A6`-83:W;2J-"98,IFI%'SM/0A+VL(@(BF)47D)5:L96ZDO^!
M`',L0\[-&T&A$[(KNI(KXY4!66G>L:(\,16K(F*#'3$KLVJKV0*2'JE>(S$A
M("+6)*DLY'(NW\*1()H1-!(20V6*I=BIHM`I1K`BQ1("/)C`K$)>K/JVK0I4
MU"J2L1*YJ-U0!!*(:]5+I1&>K)3*WE';H_U:MJ!0=-J'/<LS<7HS]ICGL(%A
M>GK719M7B:`G>OJE@(;00X.(21MA%C6'%2W"%:ZT2J.T@^9@]CE179*T(XYH
M]MG<N?0(B:"4BY"PC+@(`7W1I^MARCE!YIFF<^:;M.O*U%U;PUR[_A':D"SI
MFK9IQ8%=U%C*F^;IGO;IGP;JH!;JH2;JHC;JHT;_ZJ16ZJ5FZJ9>E9QVZJAN
MR)V6ZJJ6.TQP-WC(!/0(6JOVZFL"!@;`!!N8!!,`AJ\P!V#(L&E0!UH0)V*0
MAJFMCVT5S!MVW:_>R&D0`31`QP7H@1,H!O&5`48X`#M``XE;!!$8`K7!Z\9(
M6<%\N_^A'<$A3+5S#\!576*,II0U"\X66\R;`Q%`A!X8,4;`!#0H@1-[!OP:
M`JS.`WI^6B?$BB`-I9VP;??DE)'`8'[2Z'M%T%YZ5[&A"`>=FK'AF@DU)KKQ
M&ZB&6LZ6#-9E.PB2[MDIQF)TNZVT2@(!GG#]UK<[04S`OA\9,2$H`48X`>>:
MAA(`!B`$A@OX#N;FR4L0_RL7P5);+B)2'BK5FBQ/'9+^[F_:HF\6N=3B%=_C
ME15;L942N!59L8'T@E[O93EI*R(M$508@3U#GJVORF5#K1(M"BP[((0/4BFH
M*).A2%Q&\J+B7*X0ZJ*A<),R(0JIH`0=Y21=,)1B8."8D!ZIJ-&IT.+KT:29
MD&*XO%Q;$XE*<8;\[!Z$#88CCTN/E27UL26ZQ(B/7C2.Z&"0%E!%6V$3_@="
M\[-U<AHYNP=X<!JLR5!C*@^CH=#W@,KK)IU[P(,A$+=+N`=G``8>0020Z(<[
MJ#AH>!%N;-IB:@[Q((]S8IKR"-VT85=U0(<19:85OE=U(`=+2^*/R)3<QJ17
MX_\(9T`?3H\E?L44\=%Q6E@)[-R3K*"3ZC1MQ1TE!":E\?1QQ0VEKB@*I8`#
M)Y%2`BZN19@#S;PI.%DJI4`$WUK4*A%3L\K4WR)E-`+%*TJ2'/*@/,V#(0)3
M&"&"&/DJ3)8K&>@!&ZBKV<)2+/41Z74LT<JJT(HK&U#3&M!D%5%>;C>W(&$K
M'!'4W"I4(I(JST(1'[E4$\HK29[2REJJ.28*IQBCHU"WV*)>'PHBIC`*+A*3
M.29.8E^$,#&A&K@!'K"!']"J"T^#-%B#62;60@V3-(#6P"5&K.T;=NX-M>8-
M1K"S\,O6R`M#(`8+^F/K2Q"(#@.+2;`!*L2-2UB'KGC_#:)U"\8&CP=A1K<H
M)X-@^@[4F6DZCG'&RG)5\Z?9,^/6YU]ZL[.9FODY-$O#Z"R72Q'N\A<F<U\R
M0N">:'WJB(==0G/`\HPF%7T-"8@E!FA`AE@C!F00E4GI6&@@_`SN:+=MVZF]
MAZ^BAB?R!S>P@=>&D6+P`>K;A1+8O:*Z!\IO@P8AA'UH@V'0MCFP`7&JA@NX
M@W4X:W5PN7M0`(?+`UV(O#EX#0[S1W7("A,HOD401T)(ZV)X#U%\AA<@BR`,
MLVZ3MT78@$GH06*@#KKOAQIH!")4&X5@ZW/*X7YX!O,K"&*0`>P?B,4_LSG+
M#.I8!.X_&C9#`WGJQC,;W4-__X;O[X=+\(%S6J:G[PQ$F`9"*(:$ZT9*`(AB
M_0;VV[>/($&#_>XQ6G@08<&$!#,1(W@/V,"'$2%FA*B1(\B0(D>2+&GR),J4
M*E>R;.GR)<R8,F?2K#G0G`%B/FQLP%,"49L\&RZ)J"&BT(8:DS)=*$&D30T?
M<TI,*N&CR"(9C$0<?*8!$9$AA.[X6'BA:HT+7F=HN->O#243=_@,P7.!T0L;
M,C#Q0*-!!**!(@3^VR>DAH9+)824J(%FB`A"<^[(H.I#QJ4-<X"9\#$-X:(:
M,H")$-&&F@P3>`8^\R'"L^AG@F4,N9>H1IYI)1@ADC%ID@8;D]!0`]:FGSHT
MI-&40/^#Z04A3'S@G:;MKRHB8C6$4$MZYY*-.^J(!>['2,.D9R+0J&.,YQX;
M'\4*M`F]X=DD=:1K^$,SYR$Q0\RA3AX^3.(/&T,(,1`\>/PP33%HL+$/(T(T
MA(D/SBPRS"5MT/(,`-38-.)*'WE$(D<FTN1/1P/QTP\_+\:((HTUVG@CCCE2
M4Y8&/@R!B`__+!)6/R+D\6.$_I4PAQO*7<+&'<\4<0<:;2SH@SK]%%.6#<`(
M(81L_=1`S1"&X;%!&QJ(6(P-)<B0!R%Y@%E#/W,$)<0EBZ`Q4`G5+$0-`S9\
M5=8<F-1PQQR9,'8/A(B8Y@,Q)9R`54?&73"'#_<(@<8DT]S_,9`/BU2#AA#`
M3'+</B)0(P0B#4!&V30%"+&!G-64@`<>>2S2SSHUS,&="/](D.80!N+1Y1U$
M$/$,(YGTAH8-YM@PQQQHX"'$)/U48\,SCM+2!AHF`/,"&QK,\8P-E_C`!AJ7
M<-=&&W=`)4*V_2R"B`:,7(!'#4`5.-`T=O@`[A!ML/&3#(B$9T,-F;S0A@V8
M*!!FCA5;?#%$+[J(,<<=>_PQ3>;L.4>QQ-C@0PU;]E,EGC:PH51XA*@QR2)S
MY#&'#':@08L,=VPP$#%%;-6/#2;TDT^1B`P1CP^9T%OF0`6<Q\8B\4U")[QY
MU'`)(G,,5.`T7]K`2!N8R%`G(3X@_R+$(CZ40$QH9PQ!*H9LM`',.EG>\Q-@
M@7V)B:<#M3N-W=,`L^<]=.(QQP;RWL&&.@L@XE@>]XB@S@5E(2<5(COVHP`B
M+V!BAPBZ722#$/L0(\00)A3;CP]WY+8`"2Q.4I9Z_=Q>E@^FPC#)$*W=@<CA
MTU`+/+P8]9/'RV[DT0\;0A0#WT#`1!_4)<]$=4_H;$#OVX)W,&*#BB";?S[Z
MZ:N_/OLAW7,0,`(E_-DZ!V&"D3F8K*/E)/>8HXXYIF$.6JR#$)?H!WD$@AQ&
MW.$S1+!#/UBDBT5,[Q+J4%>]^H&W84R#&L0P%4:`08MB3,(<Q#C@0*82F-:@
M81K9BA`C2/^(GV<TYW9CP,/A@-&8O1WP'FA`@P\ND:TH7:9>U&@,&VA8`]EH
MJA_$$P(1V-"A?A0K#TZSP6ILL"=>"0$/BWC&$%86O754I4ZL"Y`/A+"N-Z$.
M#<YXG@\:TH]_;$H(OQ)")GS@#R'(J2Z(2)#VS,8#-ESK#FFXVT!DL`@C>8]5
M/EI0G6K0!C+,P09#6$0)V"`<&ZQ!"&U@1!CM`!P_M:^4ICPE*E.I2I50PRTT
M6ITKT^?*?"CD??]PRR7V-Y`L^8-%![D'.A"B#G6XQ1RZ[`<\]O$^?^!M(0NY
MA%ON(1NO5&0@_[BE/_[!FF#>PY74,,<<IX=`<]SC'\2X!XN>\0+_<%J3&EWY
MC#G\@8Y]/$-$]R#&9XBA#FH40QW_>,8])E&,AY@#&,\`8#_<68U+N&,@_L"$
M!8%(C%3A0434R,,ZJ#&-BA1C'9@0T2I#*M*1DK2DJ2Q?1UA$$I2"Y",N10A+
M82J1@Y3O(RI5*4TWTJ*=ZE0CP-A52!2BD!8]9*@(81%O4M32C?%4(C+5Z5,)
M0HO/!%2E)KTJ5K.JU:URE:LFBFGZP*K4J#H5JD3M*EK3JM:ULK6M*!*K6^,J
M5QS!=:YVO2M>\ZK7O:8/IWS]*V`#*]C!$E8DHNH'.:>1I<(RUB4R@DE=.?+8
MQE*VLH"-!P%8T(\2W*$$!Z0$-/;1#&1,_V,7\.3%/<BQ#W<<T[*$G=$^?&F0
M%QV$'_Z@;4:,6A"-Z?:IC\6M:X,K7+4>!!%;H`$Z0+`%"@0B#6@8P24LT-D2
ME``8(=B!&VH`#3<T)++#_2XJ7RI3FO(VIP8Y;T=ZZ]2<)H2]0V4O5-T;$?E&
ML"#N+>I\YWO?F6XDMOPM*GPU(MZ1P!>\:/U!&B!P"34(8PN7F$$_^``$.O1C
M06AP`P=NL(-+H.$&K36P7B_!!TL@PA",<$0B^B")1"3"$(EP1",H(0E+2*(2
ME[@Q*W@Q#%8@8QC(^#$QB/&,(3^C&L5P1C*>T8QG0./'1.Y@/:FAT6\*T!Q6
M7D?>_C=,>-SR'O_#[":8[Y$/?/32E^\;")AGZET0LYFQ\*-3)5J`ACH`(1!$
M(,8/Z+"&?=!)*C!`Q!KZT8`]K;G-63W()/@0B43PH1!]H(,<6`SI/LCA#2<N
M!+7FH`A%-"(1F6`Q)1S!B$6,>M2D1@0A$$$'.ZQZ<<YC%QO8]:4O*>A+/E)0
M&H7`ACSDJ@USP`,B\&`'/-P!5\,F)+%SQ<=<D0H--[/2#TD%+F?[9PT&H];P
M[H6(8&^[V_>:@[81(3Y$&>QQ[,H#O/QC,V%/Y@[%%C<CXHV(4W<[V,5^]^+R
MD(<J_;`-UF9>4)@WAVWC(=5X*(2I%T%J>1/B7O%>A+/J;>I,2"+&E+#_!"4N
M/HD;7X(5K-C%+H+!BV($8QC.0$;(>;$+9$!#Y,,81C"040QD-(,8T*#&,YPQ
M9"EW<!H^_WD`-4J.9DB#'.2`QC2D(0UM:`,:T)#&-+1!CJ)/P^A&%R`YK&S,
M=9PC'>E0Q]>__C]VI$/J2S>Z-LR1]:QKW1SI.$?7S7$.N:NCZV!/QSN^K@XL
M=YT>Z:#'.^CACGO0H_#XZ"8^#K\/?*#WO`JA!S[J08]Z))[QCL>'?>WK>)H*
MU;R+%VI(@''`?3Q"&(K($S&`<(>"[B-;F#`'(8B`D2`HT-"V!QE*%=++?>0#
MS+T'\S_V/LQAH@/+>U_'UJ>1-^.S%LM5%J#/_W$^C2$'N?K5+P;V@:%]CG,<
M&,0HAO8_J/WQDY_\NN"X)7ZS%-YX&QB\N1<A&"'$16#B-XSXC<+AG^IM#^\.
M=N"#ON4*\^2!',C!',B!&TR:&_R:'?Q:`:X:I='!&R3@&P1!&@"!$SA!&NS`
M#_!`!TY@$UC;K]W!(M@!(D0<(O`&^^V?L$&:'#P:&:R!&[A!$S0!#Y!!$P1!
M$Z1!$PC!&^#@#LH@`LH!';@!$18@$L[@!+Y!&OP`&3@!#]S`#?#`#LP`#.#`
M#>#`#^``%`9!!CH!&?Q0!J;!$SK!&C2!$S3!%-(`#?``#L``#,S`#+CA#9!!
M!][@#8;A&J0A&CJ!#O]FH!S"H1S.0`J@0`K`P"%VX`]D(1GP(!.N01I4F@R^
MP1J001@^X1IL(0_`0".@Q(!9U4"`1Z'=WE7M0ROE5D$<DRN=F3+YDJ=DB7]9
M1#^0@S:QHN-%D)D!E#+M#WKYS_O$%BTI4VP9Q#)U7E/A8E"=R%F1(C.658O@
M%.=M7C1V'C$B'CX(WN!!WCUD8^$-'S'1PRT-WN<=7N+M`^7=P^$-WCU('I@1
M4TEP7GK%8RV-8C.2E#DLP#K`PS,H!#7<0&I1@S^PPO[0PS2X!3Q\A@G8`'+0
ME#L<Q!#HA/+L`SNAF38A4VRQ04--PPE\A#K0B5F9A(FH`_%X37UE7AM\AH#_
M$<0P/,](K(,/^(F5,<)GD(3UK,,]X(%L3,,6J81&Z,,L*@]\)(P_%)H_Z&-Y
M])1330,M=),%9=XS8$)$N,.0L1-^Y=>`Z=0]8$)%.A5"`5@_%%EZ'80YB,A[
M980TH=.,J!0Y155*>EY&K"4\9EX]SF5:48,"`(,/$(%"]L,E7,`B7`"5$$'O
M:,`0\$`Q%`4P:(#";0<T7``9#(1B^L`+E``US(%I#$2O5%=5V``U+,(TN,8"
M'`0UB(:M+(8Z#`$17`(U?,4BQ,`E0(-@+M8O$`$>[`,>$,&G](,S-$`FF``1
M0"6[Z-(02!(]"<&G>,GW04HU3$,>4`PF,,(]S`$#_[A%&_B`G$!E`543`*D#
M0%T")E"%%AT4(W#G(K@2/4$3,P&#/YA#1Q4#_:@G`BG<UV"&(HT38@'4,X#3
M/;@38A6D0#S'-`1&,8B(.E2#>1:$6YQ0#51#'!W38D3$,SP&+41$.;"(EZ'B
M0)P#/2S$,2G3\IP-@^#7KT0$BQ`#&T"4`47$.B`")I!D2!#"8M670-4`1H!B
M3)E(&U`,26@,2/"H2?BHCY(5000I4SFC2!`I77Z7.L21]\A`3N;!)"P(NIE`
M)6V6H[3!:0(#`[3!">2!T1Q$#4S#$)C#$.2!!A#"!:S)!;`!,(C;I>B:$)C#
M";@%(DB.>E0#$=`"4/0,C?_2B@F8J1WLSSW(P##PP"2(P"7(P&<<$2W@40\@
M0@F(`"01`1#9P;2\`"/<BF]<@*)J0`W(T23(`+MTUD!LBAU0UR740`EH`#AM
MR58D*AK,`":HT0LHC1#T2!CU`R:\1KOX!5[TP`:@@:H000U51KW``#CYPSW,
M30D4PYJFT=M\R=8HP..L@51L`'ETUFAL@`T0P?ZP*,EXR20,Q1#D!3AA#J+X
M`R%D`AXHQT+`@`FT4`W@!AM\9CG00204A3K`P)SJJ@R\P&%J#B)0*3$0PCXT
MW`)PYB*8P"(0@@)<0F(*B#K8C`$@0O9H@`D0S@OX@"[-&\.@T+RBP0D,`838
MP!C_1%-UXH$YW$JJ>N9CJ-$DW`$UQ-XSF.@=<$\0?622[FQ(K4.M^D`^O,"B
M#H&BW`,#(,()M`$1],,+9,(DV(`:?2<FD&`/U%<-Z$1[L('HL`=R8!(:1(6Y
M*$AY&DT_3`,A;``A+(B=^``A'`HC.,,%%`,C$,,=1$S9T@E0+.W5(E;*L(&F
MJ!&P#<00K$,U;(>]:,#(M($"X.T8E$<>0*6!""RJ&8ZP0@4[^<!EH`$A_!"9
M4$/7I!$BF(.HUH403`.WH,$"W($0_(,)W(,/^(4F18NI#,0Z%80.V0L9'(</
MM-[<K,R1O(6P#L=HUD#K-8:8[(IVB,`)-`D:>*MGW($"_PD!AD`/(_P*1JR#
M"%28"'B-#/Q`'S``&?1!"+A!"13"F/))S8J%'.W$+WC)LE:OR?B`!@`#)E0)
M\Q"""/C#"^`!&Q!"L=#"[<@`,:!!8/@#$:@1+7@D'\$`(<!+8RC`A-XC-?#`
M5%!#YER`EQ(#8,@`VV;.K@H!!F=.)O`L"9<4@IC#'&R-0^'!)`"#8:R!`>T*
M(S2J?"#".1A*<Z[&05`+)JA#(="M%MU$5,C+85S"W![&TMH+PR#"GB!"'A"!
M&YS!\/@#O9)-#V3+/=B`UA@*[,C&.I0`)K#!.G"*5!#"0-S`O-8OQ)A,?#"Q
MM>B,!@P$AMS!$&#"7KK+2=)""O\#14-I;QY4UZ&D#3%4;QHQ`@W]#R.@@3HM
M"9RJ0^M"1PU@PB*T@1/+$;J)+I`$2%"("3'83`VT!UF8`V"<@+I$R!!8SW!6
M&%3VPP(\<6IZ$IM00XX.A%+4P#J,#:9<[PGLT;3H;RTD@!T,`"^@@"7P`3#X
M8R)Y$!"`6P292@GH"3J(Q1Q\,3'@@0C@P1K\FAMT5A870AXHC6<0PPLL"+$)
M#K9TY$"P084\@[M@:G,B5@DLCW_\@V(N0KON@WQ$1?U!K0G8P1W0;U24L$"3
M5%5"A%4]A+(BQ#KX53P>S33XTBSZR3Y,@T8$$$(\`U75UY`IDUNL`S"XQ0A%
MA#IXYC[_9,E"%P0UG(,Z^,/^")$KF</&(59VE"T>*-\Y00@;@)2]M(&5A0E#
MN+#/M<9J``Q&5\-X3`,?=%0'$0/.7<1-Y"<F:$=VT((_T$+KW0,F84+BY$&,
MXL$'F/$S]$S^]`.\KD:FOMX!B>TZ;`8PH`;D[`HPL-,P4,/YK4.0(4)^O-Y`
M+,(Z9`5Q_!2!,@#;+FO/W,,8Z*265"%YJ!1X5-<B3&@_J*X/:(\DD4;P6*8,
MC&8>#`,>&(P);,`TG`&V$(,)("H>7(<<%5MY#@&+Z-"87,(<C(\,\*(&G$"I
M/(\0:%&+CK$LL\%PE$`>,,+K1L@+R`![#C1RGY)&@")!0+2*_]#C6S$CEH;$
M4$8W1*R##)AGC"($/:C(,''$6MZ#+EUH0NF-6WAH_2R$*R%?5%6W>18D@N8#
M`3F4#%!U1-S#)5#E*I8M)AQ$]I0M(\16,"4W@1?X2HT53['458I$3;E$@1UC
M0V/EC1JI,E(X4B+$?BX5@94(3S8X654W0E1305?X1E0W<QLXBJ>XBN,>^BSX
M@:\XC,>XC,\XC=>XC=\XQT"W3.@X1^B#3R+$C_^XQ_BDC_=#D!/Y0!0YCB\Y
MD].$=_5DA$,XB5LX7ZE7C?!XDV>YEK>9CZ=D1RAYD0LYD$-$F!NYDHN$F(/$
MCPO8/A!YFG/XEL<YDQO.">V"]HU0_/]@7Y!1W_<%&?9%M>@!@XUI'_@5`RWD
M.?@)F935T\^M@P!]PS>8PS=@F=8I7T;5DS?\7)6%@]9AF?$=7]X,TRT%GY=Y
M6:CG8_&%`SJL>CP,7I?=PSR,V3PD7C[H`^?YN(_/0Z[/`Z_/`SS$`Z[G>K"#
MN9GO0SP8!#'=`SR@0SRL^K*W`SQ$.SK`0Z_G@[7'PYCI0ZUK.Z_'PZ_'@Z]3
M.[7WNCZ`NZZ_N9RGNXP[I`)`10WHQ<FTB0Q4AEZX2:26!@E\P`6P``E<``AD
M0`:(@`9D0`6,@`9X0`6`P+]7P`5D``4P`,%O0`9<``5(``54O`1,P`5LO,5?
M_,-?P`9LP`3_3(`&:'P1+,`"%,$%J+S*9X#&;WP1J/P"7,#,T_P",,#&S[P'
M`/P'`/P)?(`&;(`&#+T'B,`'>,`)G(`'@(#RED;#Y[L$+/W25T#"5\#2DP`)
ME``()#S6DP`(E``+R$#89\`*E$!3F(`&E("^N[P$4+P&7,#.-_S.#[P'>(`&
M8,#!_WL&@`#"RSW"__O.9\`'\/W.?\#1,_T)9+>ZL_CB5SD5\8%*#'N8NWF;
MN_FPTQ*1YX.O>WNT+_NOKX,[H,,YI/JRYX.WUWJT][&7#1\ZA(.J<WJE3T,Y
M])S/!5``30,\K(.WDQ/R(=^559WMFT/-UJSU$4,`"<,R?,,T+`,S_WB#-TC9
MHN/<SA6_]E4#/Q&#S#$U1O=^[U]9V_T<->C<]%7#SNV<\EF9`(6#SR&?-Z#_
M6&K4)!0!EC=^3.B65^ILNL__QQS$#3S/>4<00.P3V&]?OW[Z"AH\*%!?0X/[
M&NH[J)!B05TU@%%;1U%A0W,4)1J$]\P@M6H3$;796)&C0G\).:K[:+#:1V3W
M**[#V>^?N7O$8'*\A*>CP9`M@W*LQJAE4XY'G4:5VI):D:13L6;5NI5K5Z]?
MP88-NXZ(CR'4*`*;^;"?6K%OX<:5.Y>K/X-VZ>;%6K#&'8)ZHQ*S`6R(+G/$
M@*DK1JPML6<FGMU+]^W7NDO]`LU))^S9"_^#<X3<D?'OWCIUQ-3]FV;N&;U[
MQ?8)&;8.6C]RTOJMFV,'G=T-1`$0._=1'9Y@.B\-F9/)7^1[/@NV02.DC;][
MZNY5\Z=NVC^2ZDBB@8V6N\%B)="PF4-MVK-]JZ?IC,]6:]*"5YO:);8`<'__
M_P$,L*!B-%B'$2+V0>2.>S:8HQ]&,.F'FDDN`*:8G0+,4,,-FS+'!R(F><8'
M(=;B,"Z^_,*/+HDD0H<%--91!)$7-'!#A!(FT6("0&I8`9DY:*#A#@F&$(*8
M$S)0AP>TAL#.G"&&80.-$GS`0P,[-FA#"`/F>.&,&C30!880+K'A@CG8L.L%
M(8`Q`!,3?%CD!1G_%AFB!D1J8&.2.T1@@Q`%AN"I!G_P*4:(:6H@!(8\T#"A
M44:$:+`$-FHH@9A*)^F'&`T6(::(-FPH`9@.,BA""#08*`&O#`MZAC\388U5
MUOZ`(:(??T181`@AB,BU#1$XE0&-!0Q=:=9CD?VJF#;4D:$&8M!P,-FO"K+!
M+P[OF28/'QC)`QA@:F"$F#L8.>&.2H9X1LMBYBQA"T2'\&<(6OH1PA]$>$AW
MCCOLJ*&-8JJ1080\+D6$C05*2"&$$4Q8I!A$%,*#.A_8..&%#8J9!),V3K`C
M/3Q*T`T/8H389YU`V9#!!W-$@-2'2\Q!Q`8?["!&!(V%*$$#-!9!@R!@_TQH
M`Y%GX$`!#D0">02-&1!EC,/]IHU:ZJG[H<6&?NZIX1)&3Y"!&&=]T+*?-H"Y
ME>JSI4Y("#9L6&>20%5$6Z%JKV6UG_.J\6$.1-#(8X@[1/2ARCRT0,2LO-4@
MQ`=@&.%@DL7[00-P&81@I(88T'@ACV=$&$*&.9Z1(0]>^>`A"#IX8`,/.4CR
MAY`V2KACB#;8*`$1.W;5&XUH!Y,2&#3^Z4<&6HIAP`=:-"AA#,;,.6&1=<RA
M1H-IGO,A#W^F4:<?@]71H`T66$!!C43B>$0(&H2Q@:2G7Y7;_??U>J8(/!4L
MP0T;YI"..F!>8$0#8/"@/60EQ#Y-*2!;[C,WH_\0)(%_H8\"6>+`"!*0(Q2\
M2MQ@4A`\U*`?-8B9#R080;D5)`:$B$H&,S@W_.R#'Q!,"!YR18UA"$$!;""&
M.8"Q+D1<0@B(F(0YSJ.N3##*'"_`B3I\((.,:(X1-K`#)M9AAQ+@P1(Q0P0?
M\``$<[2A!MJ2P1!_!HP=$F-VTYC9#-$PB44L0A?#T$`F@/&,2>"D,SZ@ALP(
M@0@B#(,]0B#$/30&HV\-P1SK<(LY*O4,1``!"&BXQ#`H80M%T$`#1($)5)("
ME:AHLB50@]\G02F6?3"B#9/8#B*&9HY)J",/A-@',=B`"'.L08`$68=IU)%+
M76+G'KWTY4L:^,!0#A/_&`'P`2(6<8/!#+,I>0HAAZ8A@Q<($(,&&9<U(;8J
MJ<0-*15L"H:$Z<`+FNTOV#'(=<ZYCKB%I"!SV`@GJ965@GB2F?6TIUX068,:
M[&H((]K=KDYUJG\.X9\"1<,:=H<&@@JA2$,@@UEFY@-]"JX&-M!G#<Q2I#2T
M(0]KR`,;5'<'/.1QC8A@A$E1>5)&+.*D(C5I'EU*")8B$Y4LG<0E,'%33%P"
M&),`!D\MI(MB!'42.N7I4"\!U)]BXEL6(L9BD/$,8E3C&5*M:E6G08VJ7F(1
M$;H$8];Q#&A4HQA7O:I6J9'6K$Z#K=,@ASG@6LBXFD,FM\P>]+A32/BTE:UO
M_X7>.H:3RW6@0Y?W&,C:O#F)-F`"KG=<4#^*`XWLV6$2U>#./:K*4F_D`SQX
MN`0RT!`9:LS!,9"%95G700USI$&KJ75&/ZH!.H*H<1W(M,LZ\*"6;.7C&?&H
M!![,<8[XT/5AST`&(Z:!B4Q``Q'3($@U)M$>?WQ$,ON@J_;,@8EBF&,[]X!&
M,;!3U5SVHZH*22MVL`./]T"Q']1#1S[600Q;N,,Q]XBC1.YQCGU@9QF3J<4S
MW$&+2^CW-#^]Y0]]\@UX8,T<P0!G/,#9%&)<X)X5MG`(*2C!:G:3(/[(!T%\
M&>+KZ/*6<=TK>[*J5;-*5<555>LSG.'B%3^C&L28JO^%BC%48`CX6SB=!"4P
ML<:<JE%C1;T$\7[:U*0J^:='IL4D&)$)EC)BI2:]PQT4<0=$C!01A&#$'1:A
MQB%#.<Q0SH0:";$^CL#R#E+*PT?7T`;IN&%U>4"EEN\`4Y%>><O[VO,<UH"'
M_,EA;7,@J`_0L%$V"&%?@L[#'![M!C2I)Y8OZ:"#D@*,"Y`2#VS@@!MP,@01
M%$-B>)@$>@@!C`U@`M&D)40/X@"$&]C0<#;`1!X^X@,3W$$\;1:HNH@"FB'T
MT@1$H%0F<*(E@WE(&")X!@L^M\%3`V,.&IA$#?*`"3JEK$G]((*QTW.93'"`
M<[J($!HVL`@?_&,296'#(MK_\`(BR&`2Z]#`,SZB1U[SD!HF8/40>C"-$Z##
MVDKKP#00,80\5)0Q;E@`'1@!@Q9LH1(="`07B#"#&TRC9R=@-!IJH`8A*`TM
MKY,!X"(SC4<@@K?.]68Q*'QAF<^<YC6'"S=!F<`V$*4E]QC"-.#$Q3S@A!IW
MF`0>8#"-2=C!+)A@P)G%6/0V"&D+0G@&(Y9UB4D4HQ^72/7L]M:/T>EF$?U8
MQ#WN0(U[[%P./E@0VK/[Q[T=@!%:$`(MB+`"16A!"]%8A#G6I@L;3$*6DT#&
MV/2$)X-H00*76$$.RM8&.K7!O@D@!C4`H06"B@`89.F'3\1S]6=X5@)<:,,0
M?&B`_UK)H!+?"$0AD4$Q-#@W#RA@`0WJL`5!Z,,.RW"#,!;A!FHL@AI0W)W9
M_:4%<_QCI3801!Q(`(@>R(`%E;"!TUK".9MOG_O=US`$%1B4%7JS(N)OX$!<
M.$$1.N6`WS_AAE#T3`\!@Q"TV)5;\L`'R;5A#HBNA@A\0+'00(P@30L600M(
M0%P6`1%`@Q'*YLIJ8`X0C@T*X<T8`4W.`0_P)+_V)FP2HQ_BS`?D`!%V132T
M(!#0@`O80`*$00*(`72&X!<F`0W,X=%4PN<4Y!+8(#>T@`M`(!!R(%/Z9AI6
M9A$D`!'B(`,()Q`4@/A,0*OZ85^H@Q'6@`?:H`560!!J`/\(XJ`$U$`+V.`;
MG"`8Z$]TT(`<ZF4"(($"=.`1-"`:MJ`6MD`8^N`1>H8:&($:IH,8MD`-*N$`
MGB//\,`)M(`!M.`1%N`#!"$&`DC\[D8#O"\2)7$2*?%L"D)8ODGMU&$=IN$2
M^.`CI@%P?&(1.N\]3N(9U.(?YH"J7@,/U*`8YD`'UP'7R(L0;,P<IH$8<(T:
M@&N-9H@Q_.'-1&0.Z$@(BH$:%H<D=FH?)!`>V``>:*$<+@$>2+!GLHU."((-
M?.`9IJ%LIH'KZ@`8O($DRB2/`G`9\""T#$5/;*!.KJ\?S@$-\&`:T"`3B,$?
MA"$0^@$0*J$?*F$13N,;@.$>A,#_IZ@AQS1%$=:A$AYA"!8!'Z)++8`!'="`
M*5@!AXIA"'P*'1#!'>YA#NID$>``#6@!^#+&(3.E)8`!$BNQ)5WR)6%2+T[E
MF<("_<BO+;3''Y`!_>")_2HHA<X)@0JBA3[L_6[R)A,"(3B,_<CA/AIH)WH2
M))P"DVZ2&HH2_'Q2U6)R*[FR*[V2)68R^\2#&NRB(.(CM2B"&UL"+X#!!]#P
MG-8G*+2I5;`#*(0))YZGF];!'?H!'MBC)?@A*>[AM?H!S#B"Q:P#-9Q&[3@"
M>FR#K0Z#&(H*O.[!'>A!&M*A&9Z!^/I*O]IC$5#Q>9)K+]TA&LZ!$EI!'_`!
M'>*#'#8"_Q??`:[.H1_<@1KV08UBQC'<(!CZ@1"J03Z*X0Z@ZQ`BS"!6\BN1
M,SF5T_N(H`V^;ULF@5/NH!@6(5$N`2-RB]?:`!HVQV`081_LXD;P4%R`88TJ
M:SUDJ1^0`0^&3ZI\0":<$Q,0@1KR@!K:@!)RPP"(8:7"S!.GP88L`9D@8Q&<
M@8T4R;`\:QCL8!K(P&?P0.&^Q:>*P5SN[1Y,H!@&T$)Z:D*H08Q\AF]D``\N
M``\H1VNNPQR"X!S(86V@P2=JH!!Z*3V^9E=D@`QJ(!,:00A2H`9@@`[&I@$8
M@0W*Q@W>C=XBH>M$I09F)P]X@`/60`@0"@U.@!K89EXP:@=5DO\EEW-+N;1+
MX:<@K.>9GL$-$*'8YF`!GH$'%(#^;&!F$&$!S*4`;``/!.<OVI+51$`(."!/
M/&<1;$`&2&(1!F8-VI$-9,*5H)0-1``-$*TM-L`.1,`.8.!OZ*`&&H$1Y,`$
M;,!.-FA-,J`$;@4&."`-8*`&QH`H/"@*B>`".`#D;L"#U*$&]%!PI(D(%*`$
M=`83;*`TVE0&W$`^,50CK>,"UH`-\N!F$"$8G,`)R``12D`&,*%2Z(\-R,`$
M8@?:4@`_T8`#?J`$G$L$6.`19N`';"%R-B`3L*U.["1/.`@32B`-&`$-;""/
M_L%G6.(XO31?]75?905,G;,E#$VB1L3_!PCAV_CF91@J=VS`6Q@AW;!CYVI@
M`]R.H1#!;QA0;_J!#2Z`8(9`&V_)CJ:C#4Q@"##!0=8@$6S@!U!/`^P,!A9!
M#IH`!E!@#5!@1O#`#HA``PK)!$)`$.R@`WQ@#?I!#@1M#OA``U)`F?3))V)'
M""X!#6XU#Q0`3UX`#8A@(T1'!+H,0M@$#;9#H@CJ>7P@!=[`"1)!U"9!&,(E
MC=R@`7AA%YK@`GS`L(:V!!JA`=1AAA`A!5B!`QPL3DJ@9#!A!]&`#X0@#W($
M&!B`&,8`CM"@9)\)$S:`)OFU<BWW<FO2V_*@*=:!#J*GI^YA$88+$4["'/#`
M-,@!$2ZD/#'!_[DRTFW`*[7H:A$JA+'N9AYQL6015'7G,P]6XQF:@[P0@1@N
M@1&&(1.V00Z0X1(*`1H8@;DN[QDB`0]ZB0XF0;+(B.O404^FP1UNBO`>AC%^
MAQJ@@19HP1+<H*R*(0]XC2"VJQBR"JZVBQBNXZLX;@@2`1BDP1G`)4`'K_/F
MH-.@0;@J`1/08IXFP1T&DAOWX?6D`1WN`2U`\_.<BS'P+0\N8R"#,\CFH$3^
MXA*T%'-%>(1)>)LZ:'-Q;BG#HA@809M,9/SBPC$Y)(6+8BY`N(1Q.(=S6'2:
M`AEY2D0081B22QU4%PV$1AW*<PB"X=K*YF3"C!IN"!%8Z5`4`XG58?]P^2!O
M)-,&IL$?%N&5=N$%&%`&Z(H0QD$[R@88Z'$2B*$]R"$>%R$8VN`2]($.,F%[
M#J4)Y*`MH$$:XF,8#"(3AJ`8HC%C<*UX+R^MI.$TUL$9%.09UB&6S&$.N&Z4
M,L4<M$P@;JH@.)(1X,J^)+@-<.,ZJ$$76-.YPNI6L&,8T(&!J-(GU\^;,$$$
M=+B6;7E?^<*2%(A1!3D`@4%11V8!<FH(TF4(-(`0AF!F/F(-=B@`'<D`=F&*
MWNT"U($!4"D/%B$/["!6I5@=#.`9FE,(J*$$VN`.=N$"BH$X'31H^8`%;B`.
MV-AV)F`+M@`.V(#_T``1,C4(_/0.UF`&,,'_7OM"!&"`C*+E6;5Q$1KA#BQ@
M%VR`!_"`#Q[`'/9A8#P&!L!#`W:0;[A.=N:QZVY`$5#@>6KH'C2@N:+02"Y`
M&&B@"?KA!W90".!`$48`':)2+F:9<F]YIWGZ)2]16C@"&.Y@#GA`"'IST6R@
M86TH?\CA5_I$\LJ&1&3F$BKV`OIE`70%8RHE8[1E&T<$KH2E!B"U6]Q!I$Y@
MCIFQ'T`F@DD`"##@J4X`#[0``]Q@"Q2C`(C!$GY@!&R@&$9@".A@!E#@6FJ@
M;])%&Z$URVR-%\@``=9@#3!@28RZ,"_!#?JA$9!!'?*Y'R;!&,?&N7!"&$@@
M#>[@$>[A`?Q"`\ZB_Q^&@2A\(!U&H`GJX`86=!@6H1)R8!D"9!).H*=]^[=]
M6GCLX)GXI@9&2@BLIQK6I,VH[1EVAQ"&(0_<8`#QN"Q.A0W*1`A^P09ZR`0R
M00C6J!C4@QHJASWF(&BXZ!)*8`X`[0YVAHRHM"\4X0>$@0.&`1B$%@[JH`[Z
M@`WL0$ORX`+(H!!XP`V"8,`YX.PZB'YK@`[4`W<JUHG*%.2$@`Y@X!DX2*TO
M00Z8@AZ"[%EX#1C2@?_8N.OB(!#BP+\[1],\N;T008R>80N(X`,"H0D001KL
MX!GJ@`]N^BU::!)HF8:!>\B)?)@NL6YRPI.UAQ3OX1\X$6N>8Q]&AB!DPO_4
ML"86M^<2M$<FVL)U?6(3LT5(?Z>)Z:H&\4`^5V,?J.$2AFH2U*X.'L$=_+(T
M/@(:6#,=4(FSY6`UW.%"Z&&`S8$<Z.`]"F)PH^<?'N:/O.P9"F47S@$U`%E"
M<#$1Z($<R.'=3N/=\(T-&&$3TV$U*@%2MNC*MA%KX",;U@$>@F$-2&(=D,$6
MYB`:^+(_"N+4BOS6<=W""B)V=!J6YT+(N8*=N$(P]X(K9#@K>MPH%\@_"B(3
M@CS7+PP\H?V6"T*,BWTK'-&$?9TEVB^<EA+8O2G#AOV!5.3\M-U$%@%4P7W:
MTR;\8KG7V1TY2X`I7)C(T>F<"`A#@N<N%LP@_F'_W7W=)K6I.`W([-0]WNT)
M$YQ6,;""X!$>.4T`8MA='?#B.13B'NS"'[8#Q):/P6SS+?9K+4J#('JB++-'
M*VS]X9EI%S@`&$J`I3[O&4A#M4QK'_ZOE_8!X['#NJ!<Y5VR($R`*:9]$PMB
MNC8B6\BR']`!D@UB&G1A(]3A+]\"LUP.>[3'NMSC5JBAEJ;B$F+.YT$)&6:`
M#YZA&=B`731`"$+E!)QA#O1I$0P`WM2!.H29"$J`%A:0G,`^$L-3Z*'=TOQ=
M(=2AW_<++YP\(1R^*ZRKXE?"9'9B'_I]*@:$EO<>E.@QXOOO$O)&!G"K#73!
M#BZ`%LAF;HE`(R?!`-`-_]XKO^9.@"D`?O6E9E-@_WWX(`CZP0Y^X*.0R7/\
M`30&+UB*H0;4868RYF8,U5C^`OV<4OW"*=N5??9_O1]RA=UOJ2ZX"RXV'BQ,
M0RJ0!_KEYA[6H`98YX=^A0<6P1_*$P]&QQP&$+GW92!W13XSY?6!6\B[W?D9
MJ."5'X&27\-@`O`!8E^_?@)/+!J(,*'"A0P;.GP(,:+$B10I[O-G[I[%:1HK
M,CP'K:/'?L^H-10X:</(E2Q;NGP),Z9,B).&U`!&<*`_C0()YDMX;UU"=7<0
MX3%ZQ\Z=I4N/(F+T=!*C29@F7<*$Z=(E8)=V`:,%+&PQ8,6(/2-F]FRQ9VQ+
M$O\;JQ9M6[;4V$*;AA>ON;U\S:U3!UC=.7/G[MU39V[:WG5^R4TCE]@OX;_K
M*@-.!]CPOWN;[\$SK.Y?OGT7_?DC;?C>1=6F3_?,.3.V1'_]1$R2C3NW[HC[
M%+^.:,XD3'/.\+$L^1"3AMW,FSM_CKOG3VK3$E[LQT\@:=@Y7]\+&U8K5ZU:
ML98?2^M2L6#C=='"!,Q\UDGT%TU:M`A1)JF(GO9GA`<>;N`QQQIMY#%'&VC<
MX913C,Q!R!US+(444GDP.$<>:TR8!QL^H(&&$$,,X4.)([91PQAG"`$B&@J"
MJ"`;;+C(HHMMV%1"#6@,(8,,-NA@0X]#$/&A$$:N6&/_B$:VR"23;-S(HI$^
MU%"##T*46**(,![881X7SH''A1A"Z"6-+I:)1H9HV)$''IGD=,)MOT%'9YUV
M>C0G1+^I]A`P(MP):*""#DIHH3+ER=!HANVTSSWN@!888/^H\U=0ZJ1V3SZ8
M_C-II'XQEIAB>BD6&:E[F2I97Z$&-PTU=3G3EEG(5/-,67(!4U<Q=5'7DP:W
M&0ILL,(^)%`Q?PZ+;++*MJ0=0K\]>Q)WK_4TK77=#=3L=MQAZ^QSB"X[*`>8
M@$MNN0C=HXU`]YBC#K;K:(214/VL2UL_U/6YW+?F[LMOO_[^2R>B<^K+D*_;
M`HPPG>8\X\Z\9@UD#C'M[D/6_T#K`(,.0<1D(M)"DRR7<,@BCTQRR;EM,*[)
M*L>&&$+F--R/.M/T9$[&_?BC3D_4$(,H;9@<NW+00@]-=+\:T%)TTL`"4\+!
M2C\-==12NR30!KI,C35S`ET"=-9>?PVVU!<4$_:@`@/5<;*7-$UPV6Z_#3>Y
M%R`=-W3[F///0),.M&Y',K==Z"4RU$UXX88'>P%.@!\>T^+)"H0)VXQ/3GGE
M,U5-C.6'KZUYYYY_#M'<H`.Z$TN'Y09YTZ.OSGKE&^#4ND5I4[1NNRO=\\SL
M,DUB0NR^_UZV0$1<`CQOCB]TM^X2)89Z/[P[77STTJLL4`V_3@_U)))CSWWW
M"0LD`__QWL=VO'7E>Z0]]..OS_ZP-8Q[?OLRJ>-,.KIE,KC\^N]OJ`\I[_^:
MTNFM(^ZPW4O($0P#7JX?BWB!^O@'P0C*IGK_TY]WZK6/G^A$>1ZAAP)ELP@;
M/%""P0K.O,S!+=CHBUHD?%KUQ+<_?>@C(C-<ED`8(<(6@NL9)1#!$(K!AF[I
M!"'3@%W\="@R\,'N;4?$#C_X82TH8HM:,I2'<?!A#5EPHX8(T0<XN,B2?1@P
M'?3`5CIZPJ=YB<0P#T&$`YN(Q.8@X@?]@`\FIJ$@8#"B#7>X!R+8$`Q&B,`L
M_^`*&Z@QB3OX@QCRBB/U^B&#)6;MB=HZB4"DF!!^V,-9A\'_!SKJ]8UM=",4
M?G`%*D[I"EQ@HQ_H^(,G7/'%A,Q#&7"$F#;JT0]Z-$,;`Z$'-(2R#\8,)!\9
M(<C.&@)%1(BPEHZ<8,R&(`)$`$,(-5@$$=`@`F"8(!-W0(,&,M&&`#W#!B=`
M`QMD8`(A4*.1S329#13G-4SRYHGQ8,<[SJ$-2@Z$':H(12A,(8Z!0"(4HIC%
M*&(1BU2(`J';Z$<Z-!&+7%A#'@GY1C1@D@YR#`0?T$!A/\PA#8'X8QJV2XRZ
M=!4M98ZPG7;*@TE*X`,VV&`=F;A2/](TA#R4X#Z(N`,U;+(/*K$!$2P-VCM7
MZJ]F200?X,#&8,XQIVNXXABDT8<R__S@3U3`3"#.6(5"4R&.&;8"%JE8A41S
M$0M9I.(4W>!'.J8@"UGDXAH5S<9N*JD0[SA$((2H`5*+^IQ%E`!$`,($&DQ`
M!B'THPUL.($;:G`)'TS"!C$=PCH,FP>R>/2O>E(JMZC%PA1J:SO9<A9IM$,;
MT*H0@RP<;6M?.T4AMM9:VPKM;`-(V[R"<;:RQ9,04^BT%TCR<4]$'FF*^Q!\
MW.,=@"%(3_BQ#E2$(A760$4W<J(/?)2R%_;KQS%2`8M8K((;";$&++QJBNOV
MP[RK,(4M7%&*5*1B#Y]8A2;U((KX6J.&^K`BN?#@5V8"5B;FN$3._-$?$2Q"
M(^O81S$P<?\/?P!#'?%9%TH.\HR\[>0PE*(492SS%TD=QA^:,HRF3)./T]PL
M(?4:,&Z.2B[D,F2&R'6'-5KQ"E/Z4P^E*"5!])%!@6R#NOT0ARNLX<1XH*(?
M^'B'/:!HC>FF@JZI184I4A$*3>!B(*TPA2ENT0]NC$(4G>"$)E9!FE#4MQWS
MV,<,\;&-=]RCN\,2R!V6Z6)A%0,/U\MM7A<R#1F!R$H^&,*5J$2$&B1:!E5*
M-)6&Y.@A&2E*:,@#B`P$(C:PJ`UI4%`;VD`$:D[)2C4@D9$,72/&/DD.79K#
MA,!$H?X@8A&$.$I3>IH'7!-B0GBX`R$((>O\+"(355E$5K*B%:O_D&<LQ.#*
M),)"'_*8ASQ<`0]9BE$-N<RE)&PQ2UFJ;>VQ#*-6W3Y+6UQ5DE:)BB_4*,8T
MO,T676W;+"@$7^:$]>;G.NL=KT!%CEWA!V7(8Q]2=`451#$*4&AB%*L@JRQ<
M@0]XV`\5Q]B&*T+A"G588[[7P(<[\H$*<40C'?:PAS^LL0E1B`(5K_'%*$K1
MB2ZX8B"V"(,I<#&/;*QB%=;H^3MHLX<PK&(>Z&A'/_*1#VP8W3C*`G">$38P
MZ]0KM<XE;:,P=9C.F*91.$,'ISQ,J53MA3IXV56LT(+V9HLEW,$82S&*<8E:
MQ`<\\*%/5:I2GT4P8N^%0$2$).1J`K$A_TQY@,JLJX*(^D@ED;/.#U3VKI2>
M]IH/MI[#4/&0"`#)NJ=3L<]][I.)O1N^I[M&D*ME]&DW6+I->&B#'`@!%0H-
M/D!XL,.K9Z0@4YO:!T2R`:KS<!T9/`/?XK!&+*QQC'<DQ!E96((9C!"%4XBB
MK*\XQT!<885<8%D3H#"%**1/A6WD0Q^ML((H7F&&*XQB%IO@A"?\0-%]Z&$5
M?C@&ES<Q"DZ(P@_*'P@JQEQFJ3`0VM`%H5`*\&`[EY03I:!_K^`+KA`/^H`.
MW&`-Z!!63><#G/5TWB)@_3`-M$$,'J5BZ_1G"3$7Z]!B)2@:&T@UD#1\P((/
MMW!EWO=RRH`=8?\6`4L0!=#G?IX@"E`0"M=W!"I7!5)`!>X'!E=`!<S0#_I@
M!>:7A$8(!5AP!9\P!=;7#WN@"3)W?530"5?0"9\04`+A!SZ(<*%@'-)@<ZD`
M1M?2"J+@"5(64/T0#ZW@"JL0#\A"&W,08"RH,A>@6)%T#YG3!K.6.<)!4OW0
M8`3!!@JP`#YP`B\X+PKQ$WA`-E%W,W,@$G-"&]/`"("F"Y?P*XN`A;6U$.MP
M$!;A,O7&$'/R#.P41L#5$PMF+=2`"`6$"!TA$(EA1,RR$,('+/I@#7M@"K,P
M"V06AK>0'>>0!$=@!$;0":+0!6`0!EA`!49W"T8`!F!`A53@A51@C73_-0])
M4`5Z4`55X`K=T`M54(6KX%^AX`58(`H#D0U4``9BP`E4`&90]`>AX`F:0`6?
M8!S?4("M,`]YJ!!0YGVI8`JP8`W&(0^J$`NX`%4Q\0\IV(K'@P=$X(<K(P(,
M<`_^XP,*]@(B(`3`D`<;D`>3(`(V,`U"@$*T$4[]P`$:\`+FT$!Y@!!S$#YW
M``QM(`-"H#V#Q#1",`P`,&OW@`>+D$V"E3)M4`#JH%,>E0<7P)1L,`V+8`Z(
M(`0O^`Q"T`;W$%F8H`Y"@`=;F0[AM`S@!`SD$""7<`>YDP?$,PEXL`[8!#%2
MX8D4]@_F``_$@`CJ8`)V,(E:T0_`D(LX^1;/_V`.$'8/F/`,^/`,P"`49^&!
MSU`=C5D"&G$IC+$/F(`(-2!(?&`2`C%8(G`)0C$-M$`MZY`[)$$VZL"8]V(.
MPS40P&@HX'"'H@`+I.";H``&4-`PXI`$\0@%<9B/2A@%MM`/T)`$81`&WE@&
MH;!SJQ`+[<*,5*`)4#!SM`$-4]`)\I`/\-`/H5`%5!"$_?`.GR`%46"$8`9T
MH/`)2E@&%'4.4N`)Z&`/YD!PR"40XD!0L*!RJ,`.3(8*8-67,*$.Q;!9K0@/
M'\@;_4`''(F1'8DPZC`$BS`$;6`#<]`/'W()3Y*!Q;``-G`!0>0:-Q5$(E`,
M=^`#%X`&"W"))<`&Q/^`!C60!\_@6`B"!HN0!T5`"#Y@"3[@#S)0(KJ@`#6@
M`!K!"#[`"$.0"3D4FI/`(D/`!HR@`&Q`-LZ#!X.I`39P"6U0!'PF!`@B`GB@
M`7G0H2(@IF@@`S,P`1+P"!M@`S7`!JI#!PW@331:`[9X!T7P`HA0`G<P$$-@
M`VS`E#<J!#3*`)EP`D-0:24`!Y>0IF0@J$(@6'5:#"\@!!JP-4(P!Y*E`'E@
M`HP`4R)0'?M0!&BP`5/R#%,21`Q$IVCPE2<0"290`HPF`N90`B7@H0HA`\)1
M**T0"["P"7H0"E/`?9T@!<:@#^&@!&$`"E[P!WM0"IX`!EV`!4NV#DL`"F'_
M4`K[$`]/5$-0%`U)\(5Z8!P$UP^.4`4/US"K``57X`<$%P]Z``9+4`58D`H"
MD0]_\`F><`58T`7*)P]=(`JW@`ZEF!/\0`Z],`K^)`H-UYVH(`O6@`T?=#O%
MP+`+@0_3\`P5NA![F($62C+_L)E"L`!/\J%H8%A7<@^,<`*(T*,1AA!DH).;
MR3LB<`<E,'R/24UNZJ%VJ@O`4&ESH`!X,`27,`3^8`-H,`R+8)5AV0^ZX`9L
M0#PBT"Z3,`?V00QE2@Q\^"N,X"%M@`DU,`?#$")46@/[P+5!!):30`UHL`\D
M(`%:0`.(T`;\,`1%,1!X(`3J8`/40$WJ,&ML0`3%_R`$]V8"F8,@_5`#-D`,
M4#$)#>`#+U`,,L`&/WE3-4!21#`$^[`(/H`'D*L1]Q"Y+[`F7>LG_7"2`^&D
M?F43&F`3?QM$1/`,;/`">>`#]X`&TX`&A`"C?M4MP5HH_`!RLD`*5`!QX/`%
M!P<%J*`/\+`$8A`&7@`/\Z`/XF`%4H`%4Y`I4M`)8B`+.6$/,I0=^H`*1\`)
M5?`*SC40KV`%5P`%UJ<*22`%H>"O5"`%59"$7E!&_A`*8M`%41`%74!1\N`%
MT6D-XB`.W8`-ZKA*_9`,5.`)S/L)X45P=Y@*$PP3[M`V`B01H:J!)JLL^]!'
M_^`#Y@!JC$"X<U`-H4FFB__+!N1)&X@*N?L0>SY0`D*!LFC@`VG`M400346K
M:7/``)/@`XA`)"+@!JDI`WF@6(HH`XR@([]:#!WZ;#'%"$(0E`-1`W:@(XQ%
MHWF@`4"`!C0+`G>@6"R"")&E#HP&N#5Q#V?@=/W0>M/@`U\)JC:`"`GR(;\:
M`VQP")2EQ/Y3%%Q#I<!F`GB`N1O*!QJ:@7?0!B?9.X7*J2]@HWP0I/<P!+`3
ME!F(HT.0"&CPMXBP#ZCF`Y7<#T-`#3QP"#*P"*9<O-51*/?P":G0"56`$,R@
M!&(@!9H@0U7@!5X`"C?8#Z4`!;M\1L\9!JK@$*6P!'M`!70U$%#D#%4@"E.P
M9;C_0`5Z0`4"80]>(`9>H`E7L`GAP`_^H`E8\`E5P`1A0%']<,[(ZH6;$`JS
M0`5+%F;XI0G<L`FF@`KDE0P,:<T=>"C],`=#L&(FG$2<1!"Z:#MLM">K<707
M$;((\0^Y@Q%H4*=JM!G%T&"`L0[5T&$?10MY,Q`24PV84"_WX&[ODACW8!\=
ML0Z,8&#%@`B,(4WW@$AH,`%K82^,B0X\4PS>,`>"()O]0`OF@`<"P18+ZIK3
M,`2Y.`="`+)$]5%IX@^30`3FX&YPQT`UP!9^3`R/BA-"0`;K0#;54&!"\(D"
MH6XAJ"MX,`R'Z5&3H*7.HPX:>F]L(;I&>P</5D>&&V@N_[L0)6#+A/(/H9`+
MG:`'V+%)WHN/QO$%3"`&H@!%M&$-RRP%#:4$40"NW0%%E%0*\;P)\XP0_I`.
M[Q`/QG$:VJ`']7`1>A`&7:`*4-`%8&8/72`%J/`%2^`%=M4/7B`%R<`/L>`)
MI9`.XR!=`_$.FS"MYX`*G!`+W%`/KK`)1';-'N$.,#,2^T`-&IL0*.+0)D,P
MU<(L>,`&#0HLE6`#=Z!!T>$2U)"*^Z+8AN(.>R`+8;`'3M0/?N`%H:`'!;H'
M4@`*HG!)_'`-5G`*6&"#4+`$81`*(EN>3/`):-C=R(P0]K`/X+`)[@!%!QX%
MMT`%4=`*_0`/"WP+>B`%7F#-YO^9#.OE!:8`9*G@!WP3"IPP!>"P#50@"_5`
M#ZYP4*YP7"-Q#ARQL9+X9W*0@0A]W@!CX4,$7.:S4A7:-M<1+?`K$#.$5R7H
M9R486F`.YJ35BK&U5Q'Z+>63WX5RKZ:@"5YP,P07#M?@#>\2X`BN!_R@#YID
M#E5P"E7`G%.`V56@$?50#^0`#8[0+JH0!6`@"OA`&_Z)+?S`#JO@XM\P$'JP
M!$M@#5,0!4&(#EZ@!*NP!\)M@^6)!;+@"Z$0D*LP"V:0GONP!V#P!,:0A9P@
M"<VP#:$`"]#,$N0@#2S!UK#8+;P;Y8SS&F#Q%XM-+`J!055^$;0XYC&CB56.
M[0.A#HS_P$Z#@>81NC#W\&S_4-%3+DQ_!3@]@9'_0)YX=2DJU!!M3BCX\`7Y
M%0H--1!MZ`?RN`>8%`Y5\*U(%MR=H`13``4&'`5+D`1T90Q2\`G`SN$*00]Z
M<`5F@.^&$`5*P`V<W@5>%(^M\`GQ#&;]D`I,T`G::0:C0`5FP`FH@$O^,`I=
M@([]X`IE,`I_@`VH4`K\+$\KX3C5SA!LT(?)/C68<`<<<0>,(!(\(S&NB0EV
M,%F(\"?4P`BAD15KA$+3@`[34`T$@1RRJ4!'(0/%D#'^0`TI:,:]H6$S\U'N
M32FM?`&V0PUYD`E!)!`J#>W`90Y8VZ1/>[H$(11^!SV+0*A0_\X060F:#&$#
M3.X0)>#>@#)#?L"0GZ`'V,!TW;(*4G`*7V!7`H$-!R<%O1#@2_`)46`%!CRP
M4@`%UL`/J^#.JF!`*I97UF`*4Z!>KI#Q.::OZ``.A'X+JA#:J^!_44`%4U`*
MKY`*1^8+W"!2608&[_L.H3`*4X`*>Q`*KT!1/8\GT#*R$R$00M_01`\UYC`B
M-B"F/B"L,D`,"T"V-J`!HAG%&D`,7RH$?WH"L?I1)>`/5O*H1]&K4@\0)43L
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MW5(B1A7P+ISVX+-:F!^_4)["&"J(:I0H/:)DQ:+^>/?B>]K2%:1'CB`];><*
MPIMVE3%!/`_MG^??W_]_``,4<$`""S3PP,3,">L%6H3PX9GJ%J'IA3S.,.<.
M0N;`I`U,3$#_!(\\BAFFANJF,:$?!PG91P,-^L'$!B'Z.8R@.S`IX1X\:KA`
MB`4\.@F/2W01H@@B8O2G!)HP,:D?&S"AQ@8T%JF.&#0NR0,8(630D9$E&6GC
M'F`N\.$"/(8P9X@[#J+%AR':4`>8.=C`*4<A-)BC.AJ'T(":#<R!R`<M9)BC
M2AZ$0*.&.80HIHU+:BBFNA(F86.K-DY(=!$T$&'#ATN&(8(8OX3`Y`XA;*C!
MS<1>\!/!`1]3IHI32BD%E$XX^4*5S0A:!8I3I+@%E55*D>(*U8[IIY0CPHB"
M"B6:C4*X5OYI10E-,+M*G9/ZN4<=B-"Q1HI5[%G'FDVB0.4>*J)H_P4;**)0
MYA8FQ/BM'V/TF"64ZA(+I1,P_"@(FU%DH:R;4)XR3\!SH&''*G*:H8X>9&*:
MIIK]%".H#1)9U7ACCCOV^&.0=R,(F`W0$.%#!:0D:)T":#$`$R&F80.1&EY:
MY`9&,+5$%QM*O``8$PRMI`89@,FCAI)$H&9)-O"0H1\VA(B!ECG\/&D.1#3(
MV@<=[LE#A$48(>PD'S*IQ@8B,IERB$46(6:(&AB9`YCJ$*EJD1<PP;J-?;82
MH@8LA;A3"!/R$'2.&O*8XU&H[O`AQAG[D0&13*BY0X%GA$!D$F#0\(?/DB"J
M01W!?&BCY$NFN1*-DM1!@QI@,O&!CQV.KO]AF'RA,F'5D$76QY%53#&E"UHY
M`6.5=S:[)0E00/ED6##$"`,4+Q:^Y0@Q0&&"B2B4L((*+UKI1YDEJ,_&O&Q-
MLN<ZR-)]Q:1LO)!BE'Y&P<(/9J0(8YMKI-`$WWX@8PJ@"$7%H.('3G2A%`79
M1R@FDXI8A,(C^S!@?]SA#HBD`X-6T8U,N"6R?K3A:17L70E->$(4IC!`_LA$
M(:CQC#8@HH-6><8]BO$/:NR#&N8PVR*>P8@A4(,8TW@35!91`T2@H63K,`?2
M8-</1#RE(,5@`Y<L,0Q$%&Z&EWC&$(C0AFD08@-X>(:I>%>-%YB`&I,@#$'N
MX0-$$(,<DRC&07C_MXX:O&`2-V$#,:24*:Y0@Q#/Z`$1$,>&/$QB;C!Y7744
M28A^^(!WB_#!"Y[QC!/T8Q%_*X8=GG*!23"P'R(@RB)*1H0[9((>1$`$%0_"
M"!G(8!)MP(,&_M:&9[2R,/X004Q4F!ATE.(4L@C#)TYA"E!TX0\8Y,81FB<*
M,.BO"V$`@QYTL[Q.*&L/JEB%*WRQ#7GT`QQ4$(4FDG$PQ3CB"E0`(#>\\+]^
M^.$*J7#%-,^1C2B,(A0G&6<G0E&/Q!`D%)P0Q2;VP8]]]$*?$$P%.'[)F,=$
M+7</I6A%+7I1`Y&P(.G3Z'DTU)_]I&^7$/D'`RMVCY(B9A_^L(\Y*O:/_Z?L
MHSY0L0]!U/$4=:SJ).;@UB*D"!66[L<</R6(7JI#BQ?L1P:8X-8ZVGB2FUH%
M&$]Y1GVX]0QBW$,W.2G,/43P4XPZ(CRP$$7P-K$)*'#G&JGI0B=&0;PN4&$*
MMRC(-ZS0B2F(3Y00<4<5.@$*7ZA4&]_4#2K`T*^":&,*5]##/EYA!DU\@7CA
M`$?Y0J$;?'R"%*8XQV;P5)U9F&$44^B@.<ZZBEB@`AH%0>=%YZ`?C,96MK.E
M+8$Z2M/'K)2"&KMM"J_2VP%E0A>%H1B"*I:/$GPPMOK@ABKT``9.A&(49C!#
M%=QACR>$(0R<&`4G/,&)*URV(/CPPR:\,!N$$O_$/GT817BM<AV"2.,+9>#$
M.XY%A3"@@B#O\,(5KN"/;FB"$TF@`BC>(8XEC&(/)\''*(ZY*@.&@@J>V$3Z
M4L&)6$00&Q.U*(T>4EL0AUC$*9R&G_814XCL-G<LM<H^2KI;-ZKW*O<X"8Q5
MW&(<[U7&[_VM27J\8XADZ\8T30Q'<YQBQ-0X=R2L*9*=K&..[<.KRKWHP;2!
M"BI<8114,`,4L.$/*(!A$YJH@I9%D8IVY`N!5#"62OMAB#)TX@L8/!@JRC"+
M6<2C'Z](5P'[P=].F,$?Y/`K*&:AB7>@@YSB=4=XJF":=SB#'-SPA2^XT0]4
M1.$3UH0(P6:1BE!<NK;_B./PB$U]:E3_AR"3J`8B&K11Q,0#$0@5)2+:P`@J
M%^89=6$<5%H;9,5@(I0'JBJK_M&54O<'$_DHC#H@A,(ITY:"*WT'*J3`"3WH
MH1O\6&PGH'",;:@#'R+MQQ\^T8E5)/L592"%%S9<$'O$TPRPF`6W>E$%,Y2!
M.O?X1$'3X0_1CH(49F`'/+QPS'"FHPK3I4(JS$"%[E[!#`MT!!0F0QWVS**L
MJ[A&LA]ZDDVE6N0C)WEAW,:&/7ZE`7?00`SN<(\\`H,0ZWC&(C!GDCSXP!*$
M\,$#FL&+($1B&J@DQ!"*`0<-%(,:BR""+LPA!#`6A!IMN,,^+O'R?ORC;?L`
M_P8N$7&'==AA$O\(2A@Q<0]D>-(<D\#$)1:Q#W6XS1_`D*$0V)`O=&#"([M@
M'#'`GH]BO/P94I8B-1!ACI-!R.WY,`<P:-$/=62";FO,UCKNX=)U-.E1TV!J
M,2[0CV?0[2DTAL:C[C&-&1KH'R;(-48WLQE^_&$)FJ""-?0A/S%T@;7Q=@RF
M-1$&`*I7E,T8H!A*@8^#\N,>4]A$)\J@FUY`X>$+P\<7.N$)^8SY$^8]AS\&
MN`ETF,0+!*5"^5,!"TY(AJZJ2$(YE;L/5T#P%N(`L>,\7G+\Y[^BJ^;#!DPW
MA$P0@D:AAA>(DV+P@1I`!Z[P`0Q:AS@I`3SXFV9@`/\T*((YV``X40H[&`)"
M@(,:P(13*8LV*`@?X#D\@`%DRQ(1L(,2H)D\6(0[L`,1F`0%V)2O,9PA(`JB
MV8DDL@$38`0-:`,T,)0@PPD?8`0%""5U&`(Y^0E#&8)IT!S0*P$?N`.6D(%?
M>`$;8(,TRAL;\($-6(02*)*"0(-G*`)B:`,-D`$8F`2H.YD-L`01$('74@>L
MF<.D*(().I![N!'9T@978`5\T`?86ZM/8((]Z`<O8()BF@?JV`]7$050T(-?
MLZD!`@4J>(Z"<(0I^(0K(*U^2`8HP`).2`<*FH).T`.'0H4N2`5/F(+U<*!-
MZ#A^V(,S2P51>`5\:(=2,`7_<2!$8["X3]B@@@@'5W@'>9`'SP*0=3B)>]B/
M#I*R&?N@>Z"&U".RG+L__=M&;C2A>PC"(A"<68*9>X"14%J+>\":&`$]&4B3
M-A""(4"&(H@$/A!"F#L4#)D$'Q@<&^"BUA&!?B`&'N`;@MC"F1F"?A@"-&"$
M"&Q!(;B'%T`)C,@#-#`31J"[HU%(N[F'-EB#4"HJ(H"B*C2)>TBBDL&#?FB)
M0_&312"#?GB2?B""1<A!A0R]!2B!?B@$$4($(B`(0D"#$\B4&KB'.\B4.1`!
M/L`#LH"Z_$"#26$#-C!#C;F'$V@]%7J,=)`P5=P'SYJ'\I$"+S@-)0@#+Y@'
M@EC&_WYX#%30!%!X@GMX!W8X!W8@!V>8*538@ST(@RI0!6PH!2@8A4_0A%30
MAWW(!BC02W*PBBD0!2H(!LC8!%CX!"^(!W[P`U'X!/0JA4_P!%Q<A7E@A_/C
MAMQ@ETX0!>7B!WRXAG:`A_`+$'>(B6WIH'M8AZM8!RFZ/((PATOHM<(@"#GX
ML&X,3N$\H1J@$EK`A&=`)$9`!S1`HQ\DA#3J(B4AAI)!%$18@YE$@S;(A#R@
MA@4X%$PHF_!$I+:!AJH(H3;P@47XDH(`D40:0<UAA!+8B*+LASQ`!!M`!/6T
M`S0P!SMP.UM;!#RPM7-@`UIZ!C^!R$7)`V2CA@L0##3`@_\^5`<%N).`]`$;
M(1$VJ`$>R!$PNH2P@)G\L(3S?(8#``8`P!(H(@(&0(02`"+'V2-U<(!)6(0Y
M<(F860>K=$T-X)V',H]LT`13\(1TVPQ[B(<G\`0F\`-]V(/F`(5Y6`Q5Z`)/
MH(+8J((J\(3)^(2%B9\N^(10\`(NXP13$(4OH"O>,`-2J`)K,(D]@(5-,`UH
M:#@PS0=^2(53"(4V[8=!V(3S,P4(@@4(6H5;T(=PV`196`7Y@(J;^@=F"Q!U
M2*G9K,T/DJF4XJF"N(<A8HP(U,;A_%10S2AM><9LF08(\8=G:*I5F89B<`>M
M8J*XLZJ`G`13M$:96@2MXI89N\C_?J#-3,T9W%R'?_"':B`C<_"32V`$$3"'
M:A""9_@'E,H,K=*0G/('<S#5Q2D(:!@"8,BIM!`"8CC6?2",P:B.SJ&&'#*'
M9Y@#1B@&8O@'=:4%1/@J('H\DP"&>S@[PJB&3HHA<V"$=<@/PI@$=5`'C*$%
M?$T=!%F''HVM>/"#"2N%>3!+?;B&\ED"?_D")!`#+T@SQ6@%,)!$*@"#3Z!2
M6#"%4'"H?2B%[QH-5!`>X2F%\..'=-`$QDR&M+1,3WB.<Y@"6?"$3V"V5PB%
M3<!93`L%64A:U,JP8[B&2XL'=I"'=^!*C+HM_"@)<@M5K=U:KF4,1!""\_P/
M<[C&W<"#_]`!J2%`$U3S*K+])8+P@R0(@U/P@G`@1"\(`S%(`E,H-R0@RW#@
M,(*P!C#P!$WX/9L5A?3S@FTHB';H!E##A7"X!EDP!5S@!@RRAV]`!5'P!%JT
MS%!XGSV+!5F8%V3HA55X-W`0AV[H!G1HAT'$..OX)7]H6X]"2.#J6MS-W0"Y
MW8X1ONK(EJQU,U6#BF$ELH""BM/SW=X\WHVJ&-[]#W58`!^MJ'QXAU(0!8X-
M`U/X`R^0'B2@JT'HVR]87)72!V8HIFR2'E`H4T_P@C;U!T)D!3^@/W%0A51@
M!W1(3'_(!W&(!5C`!G[P!W"X!FO(!I-X!WJX!\(\2WVX#O;QA__5\C7K>%Y6
MN;P=70R"R`/;U5T.[F`/_N`"^8<^<;U^T`=K2(7L(<ONO5LI2#-5Z-LPF%Z(
MT`=PV`/GT=(P\(0A53#Q\0=TD(=D"(55Z(9;&`1<,`=TJ#QW($RT_`]_F`9?
M<F*M^IC32RF0@IJ2H&`0WF(N[N+A5`<-`*O]$Z=5^(0PP`(L$`,QD`)PV0QC
MD`(Q^`0QAHIJ6P55<`5<P(5;X)]KV(;$3$M"%(=L8(9M8`?8W1@M-EZ/D3(`
M>8QW]%0OCF1)GF22NX<1EJV*#5,XIA4OF(Z"<`9/N`55^`8,;@=')$3"3(Q?
M,Z%$KBV"B$I(IF19GF5:QJA>HBU\<(7_4+#9DUV%-,-*<##DCO(L\R"(508J
M$WK4$"O8_A#"):EE:(YF:?XE2Y;ABRK,8UB.;GC$`*G$XE6I5E8U9O:/<`80
M=,@A$&*=:5YG=F[G*#L!:ZY:?PC>@FAB_WA&Q3AFCM%1Q9@A;&$@VNT8*.X/
M-'`#=SYHA$YH_OC&>(XM?5;HWNV'IHAEB*YHBYYD,+[@BY:V?FXR!DJ?@"8(
MI]QHDB[I6:9*C3;IBYKB%LN6;=DH?M:65=D+C9[H<E9IG,[ID?O&E-;I7[+-
M3+6\@F"B3!U;F5@5THEB(MM'GVYJI_Y4,+;BI]Z_S`AJB(C4@L@'?Y;-.4:R
M(;B3FYYJL1[K_Q-":;+F6J8.Z[->:[9&$#`.:)^FY_PC"*9N:[N^:Q52!Q&`
M:R^.1GSFPT^E:Y14:[PN;,-.#+WF:RYFY(+X![4>LL3X:XJFJ,?P@<$^;,S.
M[`)9A[W6[/RK`3N8;,\>[<Q>AQ-0;)7.!\)&$!;;*XJF:T0@;=F>[00Q@8?.
MZ=ETVZKN!Z.&O)_ZZWM8C]T@&TBR9]H^;LQ&O-5F9Y:F*;E.,646YSLJK:7I
M!_B@AZ/N#R1";NX>;<1[;IUNY942$+A+L9;JH'10KG-`;8*H@:Y8[NZ.;XA6
M;OD.L>VN;_QN:W(XD;-V,9,"(9`1:HT:Y^.U@??.;P0?:_HFZ]-S;?_&F%TJ
M/M;&4(<=8@P#3W`,GVIJX.\/#N>7WEUTT`U_*`>^9CSX1EX$;8QU\"&+24DN
M.?$,C_%(I@82N.O>@O&N$ID++DA(DG$?-VEJP$G@PO'%!O`H>[+E[0\;>/$?
M;W*+=@8.!]7]J"GEW0^T[+'WFJ@;\UTLAS51$CZ"H&>-:K(=VX>A<B-J>`IW
M.`?ACDV3N%8GF[9\T8W\%&TGO_-()HAGN)%S4(=M\7.MRE7="'1X^`=H+=B;
MTE%$1ZEG#/36-G*+DNQN9&G<'*]*_>=X(/#=D$D\[_2#)@<.$`$%6(`+N``&
M*/4+4("YN``1*/4-6(`%*`()4`!:/P`#,`#_!3"``LAU`UB`45<`!E"`!E@`
M!F``7R?V6"^""]@`$5B`#=@`5X?U#5"`(B@"6"=U:R_U4W=V:(?V4C^!#=``
M$3B!.4R(.=2`<)\+<=>`$V"1<=\`@2@!$P@)&>A"&[AW&UCW$GB!$FAW%M&`
M>9]W$3`!A6!#+=22>Z\!A4\C(AAW$]@`<+_V"R@"=*]X%MEW$YAW@1@"FGF!
MR<D#@<C/&<"`<)R$<"\!0K`!9A>!BX]WCR\!+9$!`'@\(O=TF^]&?#@'<X`&
M*'ZA2Q*B:T57:BBQ$C.''8+B:^UY=+TDIB>&2W)74"D&8)AZ8+B$ML.$JL?Z
MJ2>&J9=ZJ4?8NJ`%_UT0-F%KF[;)!$9@!$1@A#M`!$*P@[9?A+4W>T2H^[5W
M^P$EA#L84#R8`\69@S:`2K^/2B%LBHGP^\//`ZA4G#Q0_#9X_,*OR#;(00WN
M>SRP@P%%A+"I^[;?>T3P^[Z?`SR`2M8)_#M@`[_'^SI0>T1(!$0H!+?'>Z6\
M?,1O?,'/@S90'#SHZ9OO?=__?>`/_MGRZ!8O_B6+\R?K\B]79"K_+##7EJ`2
M)26;-NK'D_$6OM96,3#_K>W/,>UW_O\N\^5__N[_,?`',NU7?N%??]^7]&BT
MXGU0YIIG?_JO?_N_?_S/?_W??_[W=&]5<8"XUV\@P8(&#R),J'`APX8.'_]"
MC"AQ(L6*%B]BS*AQ(\>.'C^"#"ER),9]^PJ>;"@PXSUJ*Q6J6T=R)LV:-F_B
MS*ES)\^>/G_2O)>2H3J"^UY>7&>.X3YS,H%"C2IU*M6J5J]BS:IU*]>N7K^"
M#2MV;-6A.//YLXB4+-NV;M_"C2N7XE&=]]9"5$=M+M^^?O\"#JQS'[5_#(4B
MW/=THF*\#]=-6BIX,N7*EB\#WE>483ZS!1T_5)>6XKUGH#&C3JUZ->O6KE_#
MCBU[]L;3)%,>'7V7-N_>OG^K]GQSW<K=`]6]M`U\.?/FSJ<>%;X0N<9SB\UM
M1GYRW[3%S[^##R]^\E"SRL>C3Z]^/?OV[M_#CR__?S[]^O;OX\^O?S___O[_
M`QB@@`,2B%*!!R*8X%S2&<2@@@]"&*%-QBUTGH078IBA2`YJV*&''_9C$H@C
MDEBB0\29F***)-Z#(FFCK1BCC/;=LQE%Z^0SHXX[\MBCCS^J9B&00Q(9'F((
MY7@2A44RV>1LV`VT#SK;_9/2/>9PZ*266Z)6GE%9<AFFF&.26::99Z*9IIIK
MLMFFFV_"&:><<])9IYUWXIFGGGORV:>??P(:J*"#$EJHH8<BFJBBBS+:J*./
M0AJII)-26JFEEV*:J::;<MJIIY^"&JJHHY):JJFGHIJJJJNRVJJKK\(:JZRS
MTEJKK;?BFJNNN_+:JZ^__P(;K+##$ENLL<<BFZRRRS+;K+//0ANMM--26ZVU
MUV*;K;;;<MNMM]^"&ZZXXY);KKGGHINNNNNRVZZ[[\(;K[SSTENOO??BFZ^^
M^_+;K[__`ARPP`,37+#!!R.<L,(+,]RPPP]#'+'$$U-<L<478YRQQAMSW+''
M'X,<LL@CDURRR2>CG++**[/<LLLOPQRSS#/37+/--^.<L\X[\]RSSS\#';30
M0Q-=M-%'(YVTTDLSW;333T,=M=134UVUU5=CG;766W/=M==?@QVVV&,G;"/9
M@A)C]MEKL]VVVV_#';?<0_*S#S_\1#F0/B$.A'="V_U=D-\+#2YXWQ&!.?=[
M=_\GQ#A!=2/D=^%Z]^/X1)-?KOA\^T##"C+\9-.*,L3T@TXKK<2#CS;]N'-.
M/-$PPTT_ZL#CS3;KG(-.B/@,=`\\^22)CS[Q3(G//?&TLT_J\?2C#VYZ[^U\
M/SDV_SCFE&N^>#_DH!+/)?.XHDHVWHA3RC6NM"+.(/HLTPHXJG#C!SC&9/-,
M*-:`LPH[SA@S$#2V@&,0\_C&+<1Q"UO8`AVV@(3[;*&,5C!#'OTC!S3Z<8L+
MMB,:K;A%,*+Q#7V(`QG-V(<_D&&2;.P#',J8QCRR%Y]WO.(6U]#'+5;1BF_@
M0A4A4D<X2J$/9LCP%O)0!3AN`8Y^M"(;_6`&*EI1CX'_7,.(I6#&-YAQ#57(
M0QSZT(<JVC&/5<CC'*J(1ROZH0UH?*,5^@#'$95QC7[8XAO9L(49C5$/1W!C
M'\-8QQB_T<+Z<"X=;E,,.TH!#FL44![*J$2(\B'&?D0Q&ZFX!1:-<<16;*,?
M^$"%-?J1EFM8(QO64(8KK*&/:ZS"%D49HSY*<<%KR.,69HR&-+!1N8%,PY;(
M8`<RIJ%)5G##&LXX!S;V@0UD9&-O\!F</K#1"VRXHVWGD,0YDF@+55SC&N@8
MA#5.)P]#KD(9S"@C*L2AC$PF<2"W4"+>G,F,9.!C#[@`1S?T,8AOX&,0\IB'
M+>3Q#5O@PQ7]2$8VYM>/=.Q%_QK2Z(<QMI&,9/2#'>FSACI@X8M\N,,=MI",
M>+*TCV.<HQ_44!O9S/&,D*IC&]E@!C_0<0MFS$,?VS#&#-$1CGYPXQWL8!XS
M0KK$D.)M'=`PQ^J2L8UXJ`*"TS.&\&1Y#V3T0QF]Z.<^7&'5I6PCD\^`1E7_
M=PY\U*(?QW"%.FZ(#"&%9Q_(..(^O)&XKQ7.<HZS!][VMAU^;%%O=AM<W?#F
M#[S&M'(ID1Y!4A<B?KP#'W@3D3]RA`]PQ$,?_'B*0.*QC7`H$SSF,(=UA$./
M=&3#E_K`A^[F9I:W[@@=UK!%-MC!#"46A!W+.$=F^[$8U+IP1MDXX-[P<8QW
M$(0>RO\8+$'(@8QPR..6N1W22<@1#%NL!&_N.`8YHJ0,<$1/'^>0QS[.80QD
M,*]OUUMNC.[1BZ(0UWG:,`;]]!$-)8*#&6S<1CO400]L6(,;:,6:,DTB'+^!
M241YPYY")@<YA3QO/>:(1O40HHYZD$,8Z'"'-I"A#VBP`QN#D*$\WB$.7(3W
M:]R9\`?C\8]IY.,>T(CF[/RAE^VDQ1^C]<=V[C&/?.@#':+I!U).&R*SI`6W
M['''+4)<VX*@HQ+8$`<WN.&*T&53'"'-ABMX%S9J3",>837'_\R!#><.)!C/
M0(8Y%LJY?2R#?>A`!C0N7(MX+.,9SS`',HB1#'0L0RC-F-W_,/IACF!``QWI
MF`<ZSB&-:6C#'8@69(B<D;9^A'0?VC#-.I"A#7RX@QS4&$J+$*..9VQF'SE"
MS&[NLJ0HV6C'(1H-X/CFZ@8U1,@6.8<K#AB.;[`X(?A@+W[;C(]MW&(>V3C'
M-7!A9;`](QWZ$$8\LI&-/!M#&ECJ!R^DT0QH;,88T5A&.Y:!#BN.=G7,@`8^
M\!$,>EA2%=%`AR2Z>VYM:.,>L&/M/I+ACGNX@ZO448<TW#%,9."#'M*@!YM7
MC`]D_*,8SR!(,5Q"#7,4PQPNX3'IJ$$-8FQV&O>8QC12HHZEF(/C3IFS2SB^
MCH\_XQ_KJ,9*UN&/ZBIZ'=.8\[3O_^$/8(":QSS>>&%ZIR1_A+PH3O&O0%*R
MCDTS!1WRT,<WH-$_A>P-,2?!QBWR@0]G9*,;J[!EV(!!#7U`]1S00$8ZZI$.
M5@B$%R'=A@G-V(IPU"(;XF"O.>(!U6`8`TN6((<QV.%&%<:#&<9P!M^AH0UP
M!,.6P\@&<8[8NG[0HQC.F(;AL4&/9&B#'.MEASZ",>FEG&3._9!S4>YAF!81
M5<X#*89B0JWITD23,`N]!SZRX0Y]F,,=Z@AI=0="#8%?::0MZD<U_A'\I5#C
M&[Z<ACKRP5$T0GH=Z7CY/M*Q%'6X8^'?4$<Z\I$."V66'+Y,C('TH0S@]N,=
MUHB%*]*!C_\0*S=KY$!.,?R<#%9L@Q=C/XG:I:'YDZB#+>@#:]E".IS#,)Q#
M,,`1.+A#.D!4-ER#"@F1,BB#/#B#,Z0#YYQ#/6B#H=$#/J1#,.`#-`#7.O29
M/V##`:X#.3R1.6#7#]6#,ZS.0(C>,S"?2/G2.?!;Q$'5/BR<4PR$/\R<H?%.
M]D73^VT#.+P#A;%#N7'4"C9%.KB<RHW>R:U#,0A$.C##\JD#=S3/:-%7.X0#
M/=B64!1%EJ7#-)R#`=;%1"3>@$&=,2370%W#.R0#-I`2<`W%>$U-7=P%&:H#
M"X8(&::#-.!&3#EAY30?CJ7#EZ4#&:(#//`#/-R#/(!#$6:@G]'_7O690S.0
M0[ZMVT#<FR8)4CJX0TJ00S2D0SP($CT0QTEPG,7Y(#$`P^E%TXH!@\3YTC,\
MQ3F<8CI`PS/D&SJLF#=PF3O@PSHHT\;US3\L%#'4R%W(Q#.81$LL7SB@PX6A
MPY7HS3S@@S6(0VOYV3X$G!F=XK/)G#[\`TG%6C#D6N0,1#0\W>PP6#\X`S?$
M`S8X%*.]VG+)6OQ!7:PYCX_U3G&8@V-HQF881TK0PY6P&#ID0V0YVY2DA#^\
M!#_P3A?:G,YUX0XYQ5*D8>P5G?+D6&)I`SV@UTD8SSZX5XY]PT%2A/413HC,
MD"?A#3-`%4'X`SCL5CN`PQ]939"-%N\(_T3NZ>`ZH@,^G,-*`([=^!S?'%G\
MX98R125$$"3Y,06L$5BK/8Z!&`6"1<Y)9!8?0H]%X,-"-40535L_S--`V(,]
M$`25'8-^70W`M0(Z.(4VL`+[M`(V8(,O9,,9)0/^$(,W],,RK`,_!,/P8%(V
M?-\WE!:/@1PU\,,S9$.*"82*38-DX`,VDN,T2$-Q'$>(*(7P])=0G(1%%IWQ
M`9FI;9$[1)9)8!3UX(:``23?\(YM]N-N?N54%-.))`,T9`,^<$,[5,[@W(,Q
M=$-R^:+5F`/?N0-X8<-P#I09'0.N(0/NK%<T[`,J+*$RL`,Z8,,[*`,UL!GU
M\)@A,H,R#"<^;/_A0JF#,_3#)6Q&H?U0B\AG/TQ#6O`B\J&#TLW./I##.<38
M9OG9.JS#PNFG9MA@ZI@#,U"#V''90CF#.AC?85Y)Z7GA/0P#-%A?-*S#-UB<
M/DB?GPG2?D+:4.&#/2B&56@#1S5$/+@#.+0#1`4A/RA2.G2#\!">U=Q#,IQ#
M,F2G+0@G0_V:,JQ#/"@#-A"4/G*#,9S#.QF#BJV4.;2"-0Q%/`0#.[!7FAWF
M,OB2.O@2E@T$.N!33@X#+(8>F3X#\1"#M>FG3Y6.:"AH-:0%,:#D.33#TDW#
M-\3#-TA#-IS5/BB:9$3H,A24#LX@--"#V&W1,KA#.$P#,S!#/P3#4@S_`XV5
M'33,G(=:Q3M4D$,HDY*^7=_D`RJLPCX8PS&@`SG\X]#@PS#<)S$,9RW(E#Y,
M`S)LXS*P(I16DS8P`S#@`S9,PRD25+Y!`XW-#E0M6*"-H#14$)?M0S%L1D;I
M0_W=0WY2PYV&7#](0S1@&C>2PV*<W#V03C\0`P!:FHHQSS>\%^.%`ZB1H1H.
MA#FP@CB`@RW8'38LE"$:%VU%@S9D0SO$SM6=`SE\&82=@V/B'59@`XPPA//H
M@R7R#D:N`BY<`P1VTM9$W7&PI"8I14>2*#E^WSI$4XMD)&(<9%HPHSNL(S&8
M1GS.GS0\P[DVTD%50[+B$O-AR6:M0V0*Q,D1_\2%CI0YG*M:F1XU-H:?=4<F
MVE:N%4,^A$,TF-13">&5+(7JX$,];(,Y.*`!LL,Y))M02$,Z`*.<1@7C7*JH
M$MA`@`,NB,,\(-(<QHUP'%EF^9AN_EA"^`/$-A9!'$E_*<1&-DA&O<3?#BX)
M^<.%VIQ`B*DZ)%:(N%]WE>/._1CMS8Y5!&GBZ(,[+,.Q50X(X<(MQ,(;D5>L
M_<:KUH3F/41T9L-0^4/%A@,X?!@LG>YL\%5#6`YT;`]L,80YO$.AX0,[L,,S
M^<(V_)`XW.Z/-,,3,00_#(,=<E(GN4(O^((@W4)5+N^*"&CK[EHW=),6.90^
MB-+V]HC91H1190/;Y?9JN26#]IIOBGQ<1,1#,C@>3&[##,:OCJ@81-B59Q`>
M6>XOB5"CX4C$/=[F`*<(:&+$22KPCC2#,Z!?1.S-=#XPC_@;.>@A1"2GZE[P
MA?`=?OF",8@E@<V#*<[.,>35!^_(4<3#/=02<$6//"BE,4`#D_8#-K`5"\O(
M[MY#*UQG/\2#TSV43VT#-X2#[_+PCDBL/MSADMT#]>25.=R",BPQD5085Q($
M^B;*J5VQEGCQ%XNQ?=S-[H[Q&:-Q&JOQ&K-Q&[OQ&\-Q',OQ'--Q'=OQ'>-Q
E'NOQ'O-Q'_OQ'P-R(`OR(!-R(1OR(2-R(BOR(C-R(R]Q0```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
